sampleid	sample_name	run_prefix	experimental_strategy	cgc_base_name	filename	analyte_amount	analyte_A260A280Ratio	aliquot_concentration	cgc_id	cgc_filename	vital_status	gender	race	ethnicity	disease_type	data_subtype	tcga_sample_id	cgc_case_uuid	sample_type	cgc_platform	gdc_file_uuid	primary_site	age_at_diagnosis	cgc_sample_uuid	cgc_aliquot_uuid	tcga_aliquot_id	reference_genome	tcga_case_id	investigation	days_to_death	knightlabID	data_submitting_center_label	tissue_source_site_label	country_of_sample_procurement	portion_is_ffpe	pathologic_t_label	pathologic_n_label	histological_diagnosis_label	pathologic_stage_label	PlateCenter	PlateCenterFlag
S13722.58cfa82de4b0c9d6adf6a502	58cfa82de4b0c9d6adf6a502	3d9f475186150ea055fddf25af7bb7e3.filtered.	WGS	3d9f475186150ea055fddf25af7bb7e3	3d9f475186150ea055fddf25af7bb7e3.bam	64.35	1.7	0.08	58cfa82de4b0c9d6adf6a502	3d9f475186150ea055fddf25af7bb7e3.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-EY-A1GW-01A	F8AC5FD2-11F2-4B3A-A3A6-FF1A6D8E1CAE	Primary Tumor	Illumina HiSeq	b2829fb0-5912-46cd-a87b-e2dcbb14192d	Uterus	73.0	22CB3D87-7FAB-419A-B071-1ADC6B810719	EC31E921-0782-4F77-AC23-4190AF1E61EE	TCGA-EY-A1GW-01A-22D-A13L-09	GRCh37-lite	TCGA-EY-A1GW	TCGA-UCEC		s4407	Washington University School of Medicine	University of North Carolina	United States	NO			Endometrioid endometrial adenocarcinoma		A13L-09	False
S13722.58cfa82de4b0c9d6adf6a4ce	58cfa82de4b0c9d6adf6a4ce	2258e57e8e0af9db6969a1da86177ca7.filtered.	WGS	2258e57e8e0af9db6969a1da86177ca7	2258e57e8e0af9db6969a1da86177ca7.bam	62.02	2.08	0.08	58cfa82de4b0c9d6adf6a4ce	2258e57e8e0af9db6969a1da86177ca7.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A03L-01A	1174F6E4-FFBE-4E59-A000-8D861C968369	Primary Tumor	Illumina HiSeq	e374014a-934d-4eee-b1e3-53ec285ea08e	Breast	34.0	00F81E98-E5C3-43B2-9757-F769EC17F3F8	8F558713-F32B-403B-AEDF-C79EFEB41C67	TCGA-AO-A03L-01A-41D-A19H-09	GRCh37-lite	TCGA-AO-A03L	TCGA-BRCA		s6617	Washington University School of Medicine	MSKCC		NO	T3	N2	Infiltrating Ductal Carcinoma	Stage IIIA	A19H-09	True
S13722.58cfa82de4b0c9d6adf6a48a	58cfa82de4b0c9d6adf6a48a	142ba22e796cab1075278cd533a287c8.filtered.	WGS	142ba22e796cab1075278cd533a287c8	142ba22e796cab1075278cd533a287c8.bam	93.54	2.18	0.07	58cfa82de4b0c9d6adf6a48a	142ba22e796cab1075278cd533a287c8.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0L9-01A	7B9947D5-E86B-4006-8890-EA5209584A88	Primary Tumor	Illumina HiSeq	56ea48ea-3024-42a8-9753-85711f00712f	Uterus	71.0	53D0521F-10D6-4F70-9277-D99025A6B963	2B78DE4E-4C8B-4ADF-A058-3DAE797E7881	TCGA-AP-A0L9-01A-11D-A066-09	GRCh37-lite	TCGA-AP-A0L9	TCGA-UCEC		s4234	Washington University School of Medicine	MSKCC		NO			Serous endometrial adenocarcinoma		A066-09	True
S13722.58cfa82de4b0c9d6adf6a4d4	58cfa82de4b0c9d6adf6a4d4	406aecbc23505359850e57fbf05d5b67.filtered.	WGS	406aecbc23505359850e57fbf05d5b67	406aecbc23505359850e57fbf05d5b67.bam	85.32	1.85	0.08	58cfa82de4b0c9d6adf6a4d4	406aecbc23505359850e57fbf05d5b67.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LI-01A	E1E8DC66-467C-48A5-BE56-3DB4F665B9F1	Primary Tumor	Illumina HiSeq	626ae092-ba0a-4c13-b860-b407436bc53b	Uterus	67.0	981D9E3B-63C5-41E9-827F-7F1D268D62F4	DEC775C5-7D9A-4DC5-B399-DC4B7BA49D73	TCGA-AP-A0LI-01A-11D-A066-09	GRCh37-lite	TCGA-AP-A0LI	TCGA-UCEC		s5189	Washington University School of Medicine	MSKCC		NO			Serous endometrial adenocarcinoma		A066-09	True
S13722.58cfa82de4b0c9d6adf6a529	58cfa82de4b0c9d6adf6a529	4aa512860ab86fb3f56ebdc8fcd69ce1.filtered.	WGS	4aa512860ab86fb3f56ebdc8fcd69ce1	4aa512860ab86fb3f56ebdc8fcd69ce1.bam	116.74	2.0	0.08	58cfa82de4b0c9d6adf6a529	4aa512860ab86fb3f56ebdc8fcd69ce1.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LE-01A	DCFF8659-ECCA-4798-80A3-DD6E7642BA2B	Primary Tumor	Illumina HiSeq	b5fe9da4-e8c6-4c5a-ae7f-b1227dcafe8f	Uterus	57.0	9C4A32CF-DE40-4996-91A9-56F1C18D69A4	638E80C7-9A6E-4A32-A621-FC4168E72343	TCGA-AP-A0LE-01A-11D-A127-09	GRCh37-lite	TCGA-AP-A0LE	TCGA-UCEC		s4982	Washington University School of Medicine	MSKCC		NO			Endometrioid endometrial adenocarcinoma		A127-09	False
S13722.58cfa82de4b0c9d6adf6a542	58cfa82de4b0c9d6adf6a542	161c6ea1a81d271566d819bb40703564.filtered.	WGS	161c6ea1a81d271566d819bb40703564	161c6ea1a81d271566d819bb40703564.bam	71.74	1.98	0.09	58cfa82de4b0c9d6adf6a542	161c6ea1a81d271566d819bb40703564.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A18C-01A	66E305CA-8A16-44F0-B837-85E529B7AD55	Primary Tumor	Illumina HiSeq	358cf81d-1664-4a81-9bdc-eddc1d95f8f4	Uterus	72.0	37F209B1-C738-441C-B205-EAEC4E2ADE4E	6E599FCC-D79A-4E0F-B451-C20768C989F9	TCGA-BG-A18C-01A-11D-A325-09	GRCh37-lite	TCGA-BG-A18C	TCGA-UCEC		s5187	Washington University School of Medicine	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A325-09	True
S13722.58cfa82de4b0c9d6adf6a59b	58cfa82de4b0c9d6adf6a59b	63caf3c72c859d6a05579c2a05cead25.filtered.	WGS	63caf3c72c859d6a05579c2a05cead25	63caf3c72c859d6a05579c2a05cead25.bam	32.95		0.08	58cfa82de4b0c9d6adf6a59b	63caf3c72c859d6a05579c2a05cead25.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-GM-A3XL-01A	65CAC997-4D39-4501-85EC-4FCB328A8EB5	Primary Tumor	Illumina HiSeq	77d3443d-1bf9-4867-89a2-65cc8e10141b	Breast	49.0	FED3A891-21BE-4196-B9EF-0BF7C8F976AA	B27D75BA-5989-4200-BFE9-F1B7D7CF8008	TCGA-GM-A3XL-01A-11D-A22X-09	GRCh37-lite	TCGA-GM-A3XL	TCGA-BRCA		s6264	Washington University School of Medicine	MD Anderson	United States	NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A22X-09	False
S13722.58cfa82de4b0c9d6adf6a580	58cfa82de4b0c9d6adf6a580	2db39072c0d1914dea2d317877070812.filtered.	WGS	2db39072c0d1914dea2d317877070812	2db39072c0d1914dea2d317877070812.bam	81.48	1.85	0.08	58cfa82de4b0c9d6adf6a580	2db39072c0d1914dea2d317877070812.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0I2-01A	328DFCB0-B5AE-43F2-BC87-DAD0AB3DF9E7	Primary Tumor	Illumina HiSeq	1f31bdc1-69ef-49bf-8200-d73661b23c67	Breast	45.0	47436CE0-438F-475B-AC0D-1972D0C5285E	A2D9325E-DA9D-42F1-A360-328D17ED492B	TCGA-B6-A0I2-01A-11D-A12L-09	GRCh37-lite	TCGA-B6-A0I2	TCGA-BRCA		s5788	Washington University School of Medicine	Duke	United States	NO	T1c	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IA	A12L-09	False
S13722.58cfa82de4b0c9d6adf6a5a6	58cfa82de4b0c9d6adf6a5a6	5e03098f26dc684c1f21cc0094f04543.filtered.	WGS	5e03098f26dc684c1f21cc0094f04543	5e03098f26dc684c1f21cc0094f04543.bam	27.49		0.08	58cfa82de4b0c9d6adf6a5a6	5e03098f26dc684c1f21cc0094f04543.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-DX-A3U6-01A	6201394F-B70E-4F14-9519-FF9D5F06EB09	Primary Tumor	Illumina HiSeq	d62aa69c-0aa5-4eab-b882-d3aca07cdd27	Mesenchymal	63.0	ACEA4025-F740-4A60-AD51-EAF61964256B	DB650EFF-4E2C-4CE3-9124-7697B6E03359	TCGA-DX-A3U6-01A-11D-A29N-09	GRCh37-lite	TCGA-DX-A3U6	TCGA-SARC		s2341	Washington University School of Medicine	Memorial Sloan Kettering	United States	NO					A29N-09	False
S13722.58cfa82de4b0c9d6adf6a546	58cfa82de4b0c9d6adf6a546	0efe658adac35f9288ebc6e59891a34b.filtered.	WGS	0efe658adac35f9288ebc6e59891a34b	0efe658adac35f9288ebc6e59891a34b.bam	66.38	2.0	0.08	58cfa82de4b0c9d6adf6a546	0efe658adac35f9288ebc6e59891a34b.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A05A-01A	C350B53B-3C27-4B9E-8B57-D7B6A1205A1F	Primary Tumor	Illumina HiSeq	1e8db39a-fb8e-4aa5-8cce-962a219e02e7	Uterus	81.0	482153FB-E69D-4748-9CF4-E281EC141518	99696731-C88F-427B-975B-1D90013E63FF	TCGA-AP-A05A-01A-11D-A013-09	GRCh37-lite	TCGA-AP-A05A	TCGA-UCEC		s4980	Washington University School of Medicine	MSKCC		NO			Serous endometrial adenocarcinoma		A013-09	True
S13722.58cfa82de4b0c9d6adf6a572	58cfa82de4b0c9d6adf6a572	29d8acadae6e2c6643400b1090ef29f2.filtered.	WGS	29d8acadae6e2c6643400b1090ef29f2	29d8acadae6e2c6643400b1090ef29f2.bam	61.59	1.88	0.08	58cfa82de4b0c9d6adf6a572	29d8acadae6e2c6643400b1090ef29f2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A1-A0SM-01A	784DE7AC-8424-42EB-83D4-A1BEBAA42B97	Primary Tumor	Illumina HiSeq	d1b482b0-0e66-4620-bc89-bfc93541735d	Breast	77.0	289F5433-4834-401F-9361-EFC8E883E630	546B982F-60D9-43DF-9761-09369AFBEE2D	TCGA-A1-A0SM-01A-11D-A19H-09	GRCh37-lite	TCGA-A1-A0SM	TCGA-BRCA		s6111	Washington University School of Medicine	UCSF	United States	NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A19H-09	True
S13722.58cfa82de4b0c9d6adf6a5f2	58cfa82de4b0c9d6adf6a5f2	58c9640b867e208cc0db2f7a975b1c51.filtered.	WGS	58c9640b867e208cc0db2f7a975b1c51	58c9640b867e208cc0db2f7a975b1c51.bam	48.69	2.02	0.08	58cfa82de4b0c9d6adf6a5f2	58c9640b867e208cc0db2f7a975b1c51.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0DT-01A	74F31744-0AED-4633-BEEC-4E203315F0B7	Primary Tumor	Illumina HiSeq	4ac2ec89-0e27-40ab-949e-6cb716b4d9e1	Breast	41.0	EB11D414-2F0E-44A1-843C-ECACC7212E91	30DBE353-86D5-40ED-84C2-DBDDF7BEB17B	TCGA-BH-A0DT-01A-21D-A12B-09	GRCh37-lite	TCGA-BH-A0DT	TCGA-BRCA		s5480	Washington University School of Medicine	University of Pittsburgh		NO	T1c	N1a	Infiltrating Ductal Carcinoma	Stage IIA	A12B-09	False
S13722.58cfa82de4b0c9d6adf6a656	58cfa82de4b0c9d6adf6a656	801434f25120f36fe582c7906500e08e.filtered.	WGS	801434f25120f36fe582c7906500e08e	801434f25120f36fe582c7906500e08e.bam	21.21		0.08	58cfa82de4b0c9d6adf6a656	801434f25120f36fe582c7906500e08e.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A3KC-01A	2D29A4AC-98E7-4663-9DD6-5681BC32AC2E	Primary Tumor	Illumina HiSeq	449d2c68-674e-4e86-89ff-574170845aa1	Breast	55.0	8318A9A4-E78E-4DB8-97C7-2CC733D0C512	F9F04E42-63A2-4EE1-ADE4-9E5BB5C20CDD	TCGA-A2-A3KC-01A-11D-A20S-09	GRCh37-lite	TCGA-A2-A3KC	TCGA-BRCA		s5952	Washington University School of Medicine	Walter Reed	United States	NO	T2	N1a	Infiltrating Lobular Carcinoma	Stage IIB	A20S-09	False
S13722.58cfa82de4b0c9d6adf6a5d4	58cfa82de4b0c9d6adf6a5d4	5b90de51bbfaf67cf060a869713e0324.filtered.	WGS	5b90de51bbfaf67cf060a869713e0324	5b90de51bbfaf67cf060a869713e0324.bam	56.64	1.95	0.08	58cfa82de4b0c9d6adf6a5d4	5b90de51bbfaf67cf060a869713e0324.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-E2-A152-01A	A8015490-9740-45C9-8BD2-EB6D1BEEFC2E	Primary Tumor	Illumina HiSeq	fe904377-4375-437b-8774-c80f11c6e0ff	Breast	56.0	0EF32921-BB7A-4055-A6ED-E8CED5F824E4	8691C87F-2468-44BB-A670-3DCCD6DA33C6	TCGA-E2-A152-01A-11D-A19H-09	GRCh37-lite	TCGA-E2-A152	TCGA-BRCA		s6915	Washington University School of Medicine	Roswell Park		NO	T1c	N0	Infiltrating Ductal Carcinoma	Stage I	A19H-09	True
S13722.58cfa82de4b0c9d6adf6a624	58cfa82de4b0c9d6adf6a624	52a567ba68a991f7946cfbf0a1803a67.filtered.	WGS	52a567ba68a991f7946cfbf0a1803a67	52a567ba68a991f7946cfbf0a1803a67.bam	71.56	1.94	0.09	58cfa82de4b0c9d6adf6a624	52a567ba68a991f7946cfbf0a1803a67.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-EY-A1GS-01A	C10B2885-70EA-4D32-BC48-8B85530DF702	Primary Tumor	Illumina HiSeq	e36825eb-c127-473a-a3d0-8c56a941a1a6	Uterus	71.0	99540910-61A1-434B-9937-216DFAC5F719	0C39C03A-EC84-42C6-BE69-8E98BC7A9F5A	TCGA-EY-A1GS-01A-11D-A13L-09	GRCh37-lite	TCGA-EY-A1GS	TCGA-UCEC		s4236	Washington University School of Medicine	University of North Carolina	United States	NO			Serous endometrial adenocarcinoma		A13L-09	False
S13722.58cfa82de4b0c9d6adf6a6c0	58cfa82de4b0c9d6adf6a6c0	869d810ce565d6181a7a0471f851fd20.filtered.	WGS	869d810ce565d6181a7a0471f851fd20	869d810ce565d6181a7a0471f851fd20.bam	107.78	2.13	0.09	58cfa82de4b0c9d6adf6a6c0	869d810ce565d6181a7a0471f851fd20.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K8-01A	24118B8F-59FE-482A-AED3-7B1BDE1571B7	Primary Tumor	Illumina HiSeq	48423c41-27b2-43d8-8358-735f4bcd008a	Uterus	71.0	66184035-AF3E-4C2B-901A-0709C49DC54E	554B9439-7E11-43EC-8BC3-448C59100B9E	TCGA-B5-A0K8-01A-11D-A14K-09	GRCh37-lite	TCGA-B5-A0K8	TCGA-UCEC		s4415	Washington University School of Medicine	Duke	United States	NO			Serous endometrial adenocarcinoma		A14K-09	False
S13722.58cfa82de4b0c9d6adf6a6e0	58cfa82de4b0c9d6adf6a6e0	8acca8432df87fc66fbf834556f68a20.filtered.	WGS	8acca8432df87fc66fbf834556f68a20	8acca8432df87fc66fbf834556f68a20.bam	92.82	1.95	0.08	58cfa82de4b0c9d6adf6a6e0	8acca8432df87fc66fbf834556f68a20.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A04X-01A	733A2A0F-B37A-4B81-B49E-3C0F30D1EB37	Primary Tumor	Illumina HiSeq	055e605f-56b9-4ca6-8856-1f32ab8e34a6	Breast	34.0	ABFF5667-7EF4-46C1-AD34-CEABC27E7992	41F140B8-72B9-4AE3-8B25-6144D9F94D0F	TCGA-A2-A04X-01A-21D-A19H-09	GRCh37-lite	TCGA-A2-A04X	TCGA-BRCA		s6767	Washington University School of Medicine	Walter Reed		NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A19H-09	True
S13722.58cfa82de4b0c9d6adf6a728	58cfa82de4b0c9d6adf6a728	G14857.TCGA-73-4666-01A-01D-1931-08.4.filtered.	WGS	G14857.TCGA-73-4666-01A-01D-1931-08.4	G14857.TCGA-73-4666-01A-01D-1931-08.4.bam	375.23	1.9	0.16	58cfa82de4b0c9d6adf6a728	G14857.TCGA-73-4666-01A-01D-1931-08.4.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4666-01A	4C31127E-D095-4978-9DAC-35153C27F6ED	Primary Tumor	Illumina HiSeq	16906318-0783-402c-9f2c-b8e22348748c	Lung	52.0	5BAE2E45-6DBC-458C-A66F-702EB1AF7357	9FFCB7FA-424C-4F93-87A7-CE5E9053C613	TCGA-73-4666-01A-01D-1931-08	HG19_Broad_variant	TCGA-73-4666	TCGA-LUAD		s10758	Broad Institute of MIT and Harvard	Roswell Park	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IV	1931-08	True
S13722.58cfa82de4b0c9d6adf6a780	58cfa82de4b0c9d6adf6a780	G16920.TCGA-CZ-4856-01A-02D-2048-08.1.filtered.	WGS	G16920.TCGA-CZ-4856-01A-02D-2048-08.1	G16920.TCGA-CZ-4856-01A-02D-2048-08.1.bam	34.73	1.9	0.15	58cfa82de4b0c9d6adf6a780	G16920.TCGA-CZ-4856-01A-02D-2048-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CZ-4856-01A	FCECAFA8-8B8B-4AE6-81BC-73ACF05B211A	Primary Tumor	Illumina HiSeq	11912043-5f81-4764-94e5-b6a0218a906c	Kidney	62.0	6F6C9F00-D6E5-452F-BA04-F77B146B780B	A7293FEF-B5D3-4572-A38B-5DC4F8A67C12	TCGA-CZ-4856-01A-02D-2048-08	HG19_Broad_variant	TCGA-CZ-4856	TCGA-KIRC		s9935	Broad Institute of MIT and Harvard	Harvard		NO	T1b	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2048-08	False
S13722.58cfa82ee4b0c9d6adf6a7e1	58cfa82ee4b0c9d6adf6a7e1	G25784.TCGA-91-6840-01A-11D-1945-08.3.filtered.	WGS	G25784.TCGA-91-6840-01A-11D-1945-08.3	G25784.TCGA-91-6840-01A-11D-1945-08.3.bam	315.7	1.9	0.05	58cfa82ee4b0c9d6adf6a7e1	G25784.TCGA-91-6840-01A-11D-1945-08.3.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6840-01A	D5326429-9805-47F9-97B0-FBDA658E3F01	Primary Tumor	Illumina HiSeq	27c919e7-a635-4c6d-a12d-31d1ee814e12	Lung	59.0	AF744755-51EB-4DAF-9029-5CF88730B1DC	09BC8542-4EA1-4599-91B3-D606425B37E2	TCGA-91-6840-01A-11D-1945-08	HG19_Broad_variant	TCGA-91-6840	TCGA-LUAD		s11430	Broad Institute of MIT and Harvard	ABS - IUPUI	United States	NO	T1b	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1945-08	True
S13722.58cfa82ee4b0c9d6adf6a8c2	58cfa82ee4b0c9d6adf6a8c2	G35154.TCGA-CS-6668-01A-11D-1893-08.2.filtered.	WGS	G35154.TCGA-CS-6668-01A-11D-1893-08.2	G35154.TCGA-CS-6668-01A-11D-1893-08.2.bam	220.0	1.9	0.05	58cfa82ee4b0c9d6adf6a8c2	G35154.TCGA-CS-6668-01A-11D-1893-08.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-6668-01A	A5D3F3FB-6541-419D-B47E-720D438F1BFF	Primary Tumor	Illumina HiSeq	698a92bc-1d75-4e94-a533-d41f6a195e9b	Brain	57.0	C6784C8A-FA04-429D-9290-40BD95F2D94D	D414E076-DCB6-4EDF-ADEF-0ABDC57354EA	TCGA-CS-6668-01A-11D-1893-08	HG19_Broad_variant	TCGA-CS-6668	TCGA-LGG		s8320	Broad Institute of MIT and Harvard	Thomas Jefferson University	United States	NO			Oligodendroglioma		1893-08	False
S13722.58cfa82ee4b0c9d6adf6a950	58cfa82ee4b0c9d6adf6a950	G32522.TCGA-BJ-A191-01A-11D-A13W-08.1.filtered.	WGS	G32522.TCGA-BJ-A191-01A-11D-A13W-08.1	G32522.TCGA-BJ-A191-01A-11D-A13W-08.1.bam	110.16	1.93	0.09	58cfa82ee4b0c9d6adf6a950	G32522.TCGA-BJ-A191-01A-11D-A13W-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A191-01A	2501EE46-8D38-448B-8765-E9C9706CBBE8	Primary Tumor	Illumina HiSeq	fe7c5f35-ecea-4165-8fa8-7a178959b096	Thyroid	49.0	C92FC4E3-7A96-4000-A969-AA894CA58A33	64C2E6A0-2341-49C4-A6DD-656E7BB505DD	TCGA-BJ-A191-01A-11D-A13W-08	HG19_Broad_variant	TCGA-BJ-A191	TCGA-THCA		s11973	Broad Institute of MIT and Harvard	University of Pittsburgh	United States	NO	T1b	N0	Other  specify	Stage I	A13W-08	True
S13722.58cfa82ee4b0c9d6adf6a95a	58cfa82ee4b0c9d6adf6a95a	G23063.TCGA_CR_7385_01A_11D_2268_08.1.filtered.	WGS	G23063.TCGA_CR_7385_01A_11D_2268_08.1	G23063.TCGA_CR_7385_01A_11D_2268_08.1.bam	289.7		0.15	58cfa82ee4b0c9d6adf6a95a	G23063.TCGA_CR_7385_01A_11D_2268_08.1.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-7385-01A	9F89510C-ED07-471F-B35E-7C87C237B9FE	Primary Tumor	Illumina HiSeq	0d321573-5651-4eb3-9f8c-a11f802e5e92	Head and Neck	42.0	4C4A6867-BABE-4032-A639-A9B31CDDDC6C	6BBD66DD-EFEE-4D6E-B02F-F88E98526B82	TCGA-CR-7385-01A-11D-2268-08	HG19_Broad_variant	TCGA-CR-7385	TCGA-HNSC		s15605	Broad Institute of MIT and Harvard	Vanderbilt University	United States	NO	T1	NX	Head and Neck Squamous Cell Carcinoma		2268-08	True
S13722.58cfa82ee4b0c9d6adf6a9f6	58cfa82ee4b0c9d6adf6a9f6	G32526.TCGA-EL-A3TB-01A-11D-A22D-08.2.filtered.	WGS	G32526.TCGA-EL-A3TB-01A-11D-A22D-08.2	G32526.TCGA-EL-A3TB-01A-11D-A22D-08.2.bam	42.57		0.07	58cfa82ee4b0c9d6adf6a9f6	G32526.TCGA-EL-A3TB-01A-11D-A22D-08.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-EL-A3TB-01A	A09D0BE0-FD41-4B30-B488-9A9F2ABEF8E7	Primary Tumor	Illumina HiSeq	3b8dc42d-2715-4480-a0f4-7595b3520131	Thyroid	47.0	11671156-4BBF-4A3C-B074-7D6C27EE4FEE	0567D3E6-6278-4D0A-81AE-C084D73C6DD3	TCGA-EL-A3TB-01A-11D-A22D-08	HG19_Broad_variant	TCGA-EL-A3TB	TCGA-THCA		s12084	Broad Institute of MIT and Harvard	MD Anderson	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A22D-08	True
S13722.58cfa82ee4b0c9d6adf6aab6	58cfa82ee4b0c9d6adf6aab6	G32450.TCGA-FD-A3N5-01A-11D-A21A-08.3.filtered.	WGS	G32450.TCGA-FD-A3N5-01A-11D-A21A-08.3	G32450.TCGA-FD-A3N5-01A-11D-A21A-08.3.bam	30.45		0.08	58cfa82ee4b0c9d6adf6aab6	G32450.TCGA-FD-A3N5-01A-11D-A21A-08.3.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3N5-01A	A658BECF-3934-49F2-9E74-291DCA61D4BB	Primary Tumor	Illumina HiSeq	3519f8d9-0eab-45e8-b398-5ddc469243cd	Bladder	69.0	66559B5F-AB2F-406B-9EDB-0F5085EEC7C5	418A3DEC-96FF-4719-BECB-E1A8260CCE2F	TCGA-FD-A3N5-01A-11D-A21A-08	HG19_Broad_variant	TCGA-FD-A3N5	TCGA-BLCA		s2677	Broad Institute of MIT and Harvard	BLN - University Of Chicago	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A21A-08	True
S13722.58cfa82ee4b0c9d6adf6aade	58cfa82ee4b0c9d6adf6aade	G32461.TCGA-BT-A3PJ-01A-21D-A21Z-08.1.filtered.	WGS	G32461.TCGA-BT-A3PJ-01A-21D-A21Z-08.1	G32461.TCGA-BT-A3PJ-01A-21D-A21Z-08.1.bam	55.89		0.07	58cfa82ee4b0c9d6adf6aade	G32461.TCGA-BT-A3PJ-01A-21D-A21Z-08.1.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A3PJ-01A	CB664EEF-BE6F-44EF-AA90-6F6DA0E6440A	Primary Tumor	Illumina HiSeq	d7aa3a92-c61a-478e-af73-14d0204cba5d	Bladder	76.0	29D79B83-FA80-490E-A8A1-C51C9AD061FE	B73523D7-F5A5-4140-8537-4DF4D1ECF465	TCGA-BT-A3PJ-01A-21D-A21Z-08	HG19_Broad_variant	TCGA-BT-A3PJ	TCGA-BLCA		s3071	Broad Institute of MIT and Harvard	University of Pittsburgh	United States	NO	T3a	N3	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A21Z-08	True
S13722.58cfa82ee4b0c9d6adf6aa8c	58cfa82ee4b0c9d6adf6aa8c	G32527.TCGA-FE-A3PD-01A-11D-A21Z-08.1.filtered.	WGS	G32527.TCGA-FE-A3PD-01A-11D-A21Z-08.1	G32527.TCGA-FE-A3PD-01A-11D-A21Z-08.1.bam	59.24		0.08	58cfa82ee4b0c9d6adf6aa8c	G32527.TCGA-FE-A3PD-01A-11D-A21Z-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A3PD-01A	39D90499-8549-4DA5-B391-C421F18FACF1	Primary Tumor	Illumina HiSeq	afcdae7e-5422-4f04-a64d-6bbdf39605aa	Thyroid	17.0	A6C23CA9-E6F4-4A2C-BB86-25EF76076381	5BDCA282-C671-48FF-B32B-2380996016C0	TCGA-FE-A3PD-01A-11D-A21Z-08	HG19_Broad_variant	TCGA-FE-A3PD	TCGA-THCA		s12339	Broad Institute of MIT and Harvard	Ohio State University	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A21Z-08	True
S13722.58cfa82ee4b0c9d6adf6ab42	58cfa82ee4b0c9d6adf6ab42	G32525.TCGA-DJ-A13W-01A-11D-A10S-08.3.filtered.	WGS	G32525.TCGA-DJ-A13W-01A-11D-A10S-08.3	G32525.TCGA-DJ-A13W-01A-11D-A10S-08.3.bam	50.62	1.95	0.08	58cfa82ee4b0c9d6adf6ab42	G32525.TCGA-DJ-A13W-01A-11D-A10S-08.3.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13W-01A	3B48CC5E-3396-4DD5-893D-54B75B98B016	Primary Tumor	Illumina HiSeq	2a8caa63-ca28-490f-8b5c-13db08afd1c8	Thyroid	45.0	4DCA97A5-B0E5-4383-8CC5-B6FF07741647	0C18A8B7-BAD1-4AA4-A6DF-472F89D9761C	TCGA-DJ-A13W-01A-11D-A10S-08	HG19_Broad_variant	TCGA-DJ-A13W	TCGA-THCA		s12736	Broad Institute of MIT and Harvard	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A10S-08	True
S13722.58cfa82ee4b0c9d6adf6ac34	58cfa82ee4b0c9d6adf6ac34	G39020.TCGA-BR-4280-01A-01D-A290-08.1.filtered.	WGS	G39020.TCGA-BR-4280-01A-01D-A290-08.1	G39020.TCGA-BR-4280-01A-01D-A290-08.1.bam	252.9	1.9	0.07	58cfa82ee4b0c9d6adf6ac34	G39020.TCGA-BR-4280-01A-01D-A290-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4280-01A	E0916597-E489-45EF-A8F7-653A3C6591EF	Primary Tumor	Illumina HiSeq	82a3e711-b833-4607-8007-dd29e00eea85	Stomach	78.0	797D2D3A-F01C-4985-B27C-4E4C2838D34D	388A8875-C3F5-494E-8456-28BE8D3626E1	TCGA-BR-4280-01A-01D-A290-08	HG19_Broad_variant	TCGA-BR-4280	TCGA-STAD		s14679	Broad Institute of MIT and Harvard	Asterand	Russia	NO	T2b	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage III	A290-08	True
S13722.58cfa82ee4b0c9d6adf6b056	58cfa82ee4b0c9d6adf6b056	G41960.TCGA-97-8171-01A-11D-2284-08.2.filtered.	WGS	G41960.TCGA-97-8171-01A-11D-2284-08.2	G41960.TCGA-97-8171-01A-11D-2284-08.2.bam	239.3		0.05	58cfa82ee4b0c9d6adf6b056	G41960.TCGA-97-8171-01A-11D-2284-08.2.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-97-8171-01A	397D3F69-1453-4057-B177-8723EEC923D1	Primary Tumor	Illumina HiSeq	e34a02d6-fc08-42eb-af7c-d4b40644bcf3	Lung	81.0	84CB5264-6158-40EC-8B65-F96A4A7D6CE4	FA2C3620-7E82-4B12-B135-87986F0F2890	TCGA-97-8171-01A-11D-2284-08	HG19_Broad_variant	TCGA-97-8171	TCGA-LUAD		s10766	Broad Institute of MIT and Harvard	Washington University - NYU	United States	NO	T2a	N2	Lung Papillary Adenocarcinoma	Stage IV	2284-08	False
S13722.58cfa830e4b0c9d6adf6c294	58cfa830e4b0c9d6adf6c294	TCGA-BP-4781-01A-01D-2098-10_Illumina.filtered.	WGS	TCGA-BP-4781-01A-01D-2098-10_Illumina	TCGA-BP-4781-01A-01D-2098-10_Illumina.bam	69.07	1.9	0.16	58cfa830e4b0c9d6adf6c294	TCGA-BP-4781-01A-01D-2098-10_Illumina.bam	Alive	MALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-4781-01A	80C4FC5B-DC7D-4308-8C81-6E83625963B5	Primary Tumor	Illumina HiSeq	d6c662c6-17e1-4d7c-ab4b-9a002c00648b	Kidney	78.0	15423D9C-91C3-4FE5-9880-A28840ACB75A	FBF937F1-5F30-470C-8A77-46CD1C41E073	TCGA-BP-4781-01A-01D-2098-10	GRCh37-lite	TCGA-BP-4781	TCGA-KIRC		s8836	Baylor College of Medicine	MSKCC		NO	T1a	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2098-10	True
S13722.58cfa831e4b0c9d6adf6c480	58cfa831e4b0c9d6adf6c480	TCGA-CJ-5682-01A-11D-2103-10_Illumina.filtered.	WGS	TCGA-CJ-5682-01A-11D-2103-10_Illumina	TCGA-CJ-5682-01A-11D-2103-10_Illumina.bam	155.4	1.9	0.15	58cfa831e4b0c9d6adf6c480	TCGA-CJ-5682-01A-11D-2103-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-5682-01A	4C325EE1-9B8E-45D4-A0A7-E47EC1EAC402	Primary Tumor	Illumina HiSeq	5586870f-0a22-4bd6-b331-defce06a0f46	Kidney	60.0	3D38F604-E571-422D-B645-BF73A0348243	DACD4CC2-FC2B-4FBD-ADF6-C8A46AE69C91	TCGA-CJ-5682-01A-11D-2103-10	GRCh37-lite	TCGA-CJ-5682	TCGA-KIRC		s9450	Baylor College of Medicine	MD Anderson Cancer Center		NO	T3a	NX	Kidney Clear Cell Renal Carcinoma	Stage IV	2103-10	False
S13722.58cfa83ce4b0c9d6adf72e98	58cfa83ce4b0c9d6adf72e98	c7785537c59d3349dd69e0f8e87266b7.filtered.	WGS	c7785537c59d3349dd69e0f8e87266b7	c7785537c59d3349dd69e0f8e87266b7.bam	27.86	1.93	0.08	58cfa83ce4b0c9d6adf72e98	c7785537c59d3349dd69e0f8e87266b7.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-E2-A1LL-01A	2A84997D-CCEE-4F46-BEA2-752534F26416	Primary Tumor	Illumina HiSeq	85360168-d41d-4201-8416-2cb4b45fca0f	Breast	73.0	E57574E4-7E01-4E61-BD29-EE4EC63DDDD6	47312F61-5EF4-4F25-9320-8FBB4758790E	TCGA-E2-A1LL-01A-11D-A142-09	GRCh37-lite	TCGA-E2-A1LL	TCGA-BRCA		s5780	Washington University School of Medicine	Roswell Park	United States	NO	T3	N2a	Infiltrating Ductal Carcinoma	Stage IIIA	A142-09	False
S13722.58cfa83ce4b0c9d6adf72ee4	58cfa83ce4b0c9d6adf72ee4	d8812a052472972b8c4ec509bc9bec1f.filtered.	WGS	d8812a052472972b8c4ec509bc9bec1f	d8812a052472972b8c4ec509bc9bec1f.bam	70.78	1.98	0.08	58cfa83ce4b0c9d6adf72ee4	d8812a052472972b8c4ec509bc9bec1f.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A06B-01A	95E6D327-9AB7-45DE-9527-F5634B3995C3	Primary Tumor	Illumina HiSeq	4f89c64d-ad85-45a6-a62b-e78fcbe761b3	Uterus	72.0	A43F90B7-4A6C-423C-82DE-AD2C330AE0FB	55ADA396-0878-4724-8EBE-00DA367EED3D	TCGA-AX-A06B-01A-11D-A325-09	GRCh37-lite	TCGA-AX-A06B	TCGA-UCEC		s4974	Washington University School of Medicine	Gynecologic Oncology Group	United States	NO			Endometrioid endometrial adenocarcinoma		A325-09	True
S13722.58cfa83ce4b0c9d6adf72fd0	58cfa83ce4b0c9d6adf72fd0	b2efe67d968c5b6634b971bdef73c05a.filtered.	WGS	b2efe67d968c5b6634b971bdef73c05a	b2efe67d968c5b6634b971bdef73c05a.bam	60.09	1.81	0.07	58cfa83ce4b0c9d6adf72fd0	b2efe67d968c5b6634b971bdef73c05a.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A11H-01A	DEE43082-4AA7-4650-981C-A779E9FE7B55	Primary Tumor	Illumina HiSeq	f7538b9e-e9b1-41fd-b09d-9ef50a3553d5	Uterus	67.0	D78D2F6B-3EB3-4082-A7EA-F7B6202CDC58	ACCFC45B-EAE0-4991-A488-E217CDB46655	TCGA-B5-A11H-01A-11D-A122-09	GRCh37-lite	TCGA-B5-A11H	TCGA-UCEC		s4571	Washington University School of Medicine	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A122-09	True
S13722.58cfa83ce4b0c9d6adf72fd8	58cfa83ce4b0c9d6adf72fd8	bcbfebca137feee918342e841c0bb404.filtered.	WGS	bcbfebca137feee918342e841c0bb404	bcbfebca137feee918342e841c0bb404.bam	93.85	1.93	0.08	58cfa83ce4b0c9d6adf72fd8	bcbfebca137feee918342e841c0bb404.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A1CI-01A	FBA80122-D8B2-4D8D-A032-9767E8160F9F	Primary Tumor	Illumina HiSeq	47f4dbcb-cbdc-4e4e-a4b2-5080f3e683cf	Uterus	61.0	DDD2F9E0-0AA3-425B-9D74-74FCC638CB08	92126163-00C3-41F2-9CE6-7AAD5F621407	TCGA-AX-A1CI-01A-11D-A135-09	GRCh37-lite	TCGA-AX-A1CI	TCGA-UCEC		s4572	Washington University School of Medicine	Gynecologic Oncology Group		NO			Endometrioid endometrial adenocarcinoma		A135-09	False
S13722.58cfa83ce4b0c9d6adf72ee6	58cfa83ce4b0c9d6adf72ee6	daf008933258f806fa354a9618f801be.filtered.	WGS	daf008933258f806fa354a9618f801be	daf008933258f806fa354a9618f801be.bam	62.71		0.08	58cfa83ce4b0c9d6adf72ee6	daf008933258f806fa354a9618f801be.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2PK-01A	0809BA8B-4AB6-4F43-934C-C1CCBC014A7E	Primary Tumor	Illumina HiSeq	7109053e-8be0-4965-a5eb-a9bbab5ee53f	Cervix	43.0	5F613800-55DF-497F-A544-5B12CB9446CE	B3B3A27C-EE9A-42AF-A6D1-9AF5970A98B9	TCGA-EK-A2PK-01A-11D-A18J-09	GRCh37-lite	TCGA-EK-A2PK	TCGA-CESC		s1506	Washington University School of Medicine	Gynecologic Oncology Group	United States	NO			Cervical Squamous Cell Carcinoma		A18J-09	True
S13722.58cfa83ce4b0c9d6adf730f0	58cfa83ce4b0c9d6adf730f0	ed7c0d707af5e0862abe28d9bbea0aec.filtered.	WGS	ed7c0d707af5e0862abe28d9bbea0aec	ed7c0d707af5e0862abe28d9bbea0aec.bam	82.92	2.0	0.08	58cfa83ce4b0c9d6adf730f0	ed7c0d707af5e0862abe28d9bbea0aec.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GE-01A	A587E62E-430E-4F1B-82B7-6FBE856FDAF1	Primary Tumor	Illumina HiSeq	acd74d29-be09-40a4-b713-578d8469edd7	Uterus	38.0	20C3F64D-ACF6-45B3-9ACE-2F93B3A951C8	23CC70C4-B744-4FA0-A0DE-B25C0FDF212F	TCGA-A5-A0GE-01A-11D-A066-09	GRCh37-lite	TCGA-A5-A0GE	TCGA-UCEC		s4765	Washington University School of Medicine	Cedars Sinai		NO			Endometrioid endometrial adenocarcinoma		A066-09	True
S13722.58cfa83ce4b0c9d6adf72f94	58cfa83ce4b0c9d6adf72f94	f45f02f7da5f0692a3a5e6f53061ff05.filtered.	WGS	f45f02f7da5f0692a3a5e6f53061ff05	f45f02f7da5f0692a3a5e6f53061ff05.bam	103.95	1.98	0.08	58cfa83ce4b0c9d6adf72f94	f45f02f7da5f0692a3a5e6f53061ff05.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A053-01A	AF37D8F0-FEA0-47F6-BE0A-2FB55A5DA5C4	Primary Tumor	Illumina HiSeq	f5bf0f66-e1e7-424f-90df-9ec48601cece	Uterus	90.0	E1121A9E-BC27-44EB-A1AD-EB0AB10B7C3A	B77084AB-8148-49E0-B3F9-90F7D9EA1862	TCGA-AP-A053-01A-21D-A013-09	GRCh37-lite	TCGA-AP-A053	TCGA-UCEC		s4574	Washington University School of Medicine	MSKCC		NO			Endometrioid endometrial adenocarcinoma		A013-09	True
S13722.58cfa83ce4b0c9d6adf73120	58cfa83ce4b0c9d6adf73120	c4db7ecd250c14ade136a8948ac7149e.filtered.	WGS	c4db7ecd250c14ade136a8948ac7149e	c4db7ecd250c14ade136a8948ac7149e.bam	46.45	1.84	0.08	58cfa83ce4b0c9d6adf73120	c4db7ecd250c14ade136a8948ac7149e.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-EW-A1J5-01A	5D8ED961-A012-4B6B-BFFB-9468D3953646	Primary Tumor	Illumina HiSeq	17593e20-8cc4-4961-8ff5-871806aeed93	Breast	59.0	BF42E8CE-CD3E-46C8-92F9-EA5CDA443A6F	98BB3025-0637-4106-8621-12DF7B5D662F	TCGA-EW-A1J5-01A-11D-A13L-09	GRCh37-lite	TCGA-EW-A1J5	TCGA-BRCA		s6251	Washington University School of Medicine	University of Miami	United States	NO	T3	N0 (i-)	Infiltrating Lobular Carcinoma	Stage IIB	A13L-09	False
S13722.58cfa83ce4b0c9d6adf731a2	58cfa83ce4b0c9d6adf731a2	a8fa89810891a177c65d943664f1e99b.filtered.	WGS	a8fa89810891a177c65d943664f1e99b	a8fa89810891a177c65d943664f1e99b.bam	106.68	1.91	0.08	58cfa83ce4b0c9d6adf731a2	a8fa89810891a177c65d943664f1e99b.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-DI-A1NN-01A	944A102F-3475-45AA-9E30-4B92D1449F00	Primary Tumor	Illumina HiSeq	b518c962-e072-40bd-962b-f0eebac9aa3b	Uterus	63.0	5FABCE9C-0DFB-4B0D-8478-599FD181A84F	95E8D38A-122E-494C-A304-BEF4275FED7E	TCGA-DI-A1NN-01A-11D-A34H-09	GRCh37-lite	TCGA-DI-A1NN	TCGA-UCEC		s4760	Washington University School of Medicine	MD Anderson	United States	NO			Serous endometrial adenocarcinoma		A34H-09	True
S13722.58cfa83ce4b0c9d6adf73168	58cfa83ce4b0c9d6adf73168	f31cfe2ad0117626a14c5b0dea28c02d.filtered.	WGS	f31cfe2ad0117626a14c5b0dea28c02d	f31cfe2ad0117626a14c5b0dea28c02d.bam	91.48	2.08	0.08	58cfa83ce4b0c9d6adf73168	f31cfe2ad0117626a14c5b0dea28c02d.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LF-01A	748E38B1-2EAD-4A0A-8881-D640617B856B	Primary Tumor	Illumina HiSeq	edd786b0-5020-470f-a33f-28c99bef68c0	Uterus	82.0	902E2DD8-81E5-4949-A57B-92B3EFD86C63	460F7427-EBCF-404B-9E9E-E0278D0BCA95	TCGA-AP-A0LF-01A-11D-A122-09	GRCh37-lite	TCGA-AP-A0LF	TCGA-UCEC		s5374	Washington University School of Medicine	MSKCC		NO			Endometrioid endometrial adenocarcinoma		A122-09	True
S13722.58cfa83ce4b0c9d6adf73074	58cfa83ce4b0c9d6adf73074	f69f0ef802b7feefa79f55fe3e188902.filtered.	WGS	f69f0ef802b7feefa79f55fe3e188902	f69f0ef802b7feefa79f55fe3e188902.bam	35.42	1.97	0.08	58cfa83ce4b0c9d6adf73074	f69f0ef802b7feefa79f55fe3e188902.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-C8-A12Q-01A	A824B3BD-34D5-4CC1-A92F-F9D6AC0F1814	Primary Tumor	Illumina HiSeq	bb80680a-245c-421b-a3ef-198dc78bad1e	Breast	78.0	8867F07E-0993-4C9A-96DF-18E24801BA80	D8C6D4B8-F279-4EDC-AAA3-A1CC266AEC4D	TCGA-C8-A12Q-01A-11D-A19H-09	GRCh37-lite	TCGA-C8-A12Q	TCGA-BRCA		s6108	Washington University School of Medicine	ILSbio		NO	T1	N2	Infiltrating Ductal Carcinoma	Stage IIIA	A19H-09	True
S13722.58cfa83ce4b0c9d6adf7310e	58cfa83ce4b0c9d6adf7310e	c31801ffe0265e1332d28d053c9a4955.filtered.	WGS	c31801ffe0265e1332d28d053c9a4955	c31801ffe0265e1332d28d053c9a4955.bam	64.37	1.97	0.08	58cfa83ce4b0c9d6adf7310e	c31801ffe0265e1332d28d053c9a4955.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-C8-A12L-01A	441919EB-8C9F-478C-BDA3-8DE4F8295E8A	Primary Tumor	Illumina HiSeq	c12fbad8-2c66-4967-9bfe-6837f6d1e5d4	Breast	67.0	E3CF8F8C-8FE6-45E2-B786-7DB5590C08CB	D5372745-95CF-4572-A6E7-E7F5B796911A	TCGA-C8-A12L-01A-11D-A19H-09	GRCh37-lite	TCGA-C8-A12L	TCGA-BRCA		s5945	Washington University School of Medicine	ILSbio	Vietnam	NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A19H-09	True
S13722.58cfa82fe4b0c9d6adf6b62c	58cfa82fe4b0c9d6adf6b62c	TCGA-50-5941-01A-11D-1751_111007_SN590_0110_C003AACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-5941-01A-11D-1751_111007_SN590_0110_C003AACXX_s_3_rg.sorted	TCGA-50-5941-01A-11D-1751_111007_SN590_0110_C003AACXX_s_3_rg.sorted.bam	237.4	1.9	0.16	58cfa82fe4b0c9d6adf6b62c	TCGA-50-5941-01A-11D-1751_111007_SN590_0110_C003AACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-50-5941-01A	F3F024C2-52F1-400E-946C-398F5B72E6DC	Primary Tumor	Illumina HiSeq	f7c353bf-7be8-42d0-88d0-e89032718c2f	Lung	55.0	91719392-76CE-479F-BA05-E43BF0201CC4	666720AF-64D9-4A63-BE57-2B8E49E79413	TCGA-50-5941-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5941	TCGA-LUAD		s11128	Harvard Medical School	University of Pittsburgh	United States	NO	T2a	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1751-02	True
S13722.58cfa82fe4b0c9d6adf6b6d8	58cfa82fe4b0c9d6adf6b6d8	TCGA-50-5942-01A-21D-1751_111007_SN590_0110_C003AACXX_s_5_rg.sorted.filtered.	WGS	TCGA-50-5942-01A-21D-1751_111007_SN590_0110_C003AACXX_s_5_rg.sorted	TCGA-50-5942-01A-21D-1751_111007_SN590_0110_C003AACXX_s_5_rg.sorted.bam	168.4	1.9	0.14	58cfa82fe4b0c9d6adf6b6d8	TCGA-50-5942-01A-21D-1751_111007_SN590_0110_C003AACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5942-01A	75DD635E-8E0C-4C0B-B21C-20F77770218D	Primary Tumor	Illumina HiSeq	915fe8ed-278a-43fb-90cd-986d5c65e9ad	Lung	67.0	AED669E8-23B6-4786-9398-6BB048815DFA	8DC8F884-F58B-4EFA-AE96-C87AB7F6D991	TCGA-50-5942-01A-21D-1751-02	HG19_Broad_variant	TCGA-50-5942	TCGA-LUAD		s10794	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	True
S13722.58cfa82fe4b0c9d6adf6b648	58cfa82fe4b0c9d6adf6b648	TCGA-86-6562-01A-11D-1751_120403_SN1222_0094_BD0UKBACXX_s_3_rg.sorted.filtered.	WGS	TCGA-86-6562-01A-11D-1751_120403_SN1222_0094_BD0UKBACXX_s_3_rg.sorted	TCGA-86-6562-01A-11D-1751_120403_SN1222_0094_BD0UKBACXX_s_3_rg.sorted.bam	237.4	1.9	0.13	58cfa82fe4b0c9d6adf6b648	TCGA-86-6562-01A-11D-1751_120403_SN1222_0094_BD0UKBACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-86-6562-01A	DCD066BA-5894-453E-B1DA-82092858C3DB	Primary Tumor	Illumina HiSeq	71d960e2-40e8-4084-bcc1-5ebbefc183af	Lung	52.0	DE4BB1D0-8BD9-4614-85CA-C39D8C636BCC	3AB9FD95-4329-4DD3-823D-F2E050CBA3C1	TCGA-86-6562-01A-11D-1751-02	HG19_Broad_variant	TCGA-86-6562	TCGA-LUAD		s11014	Harvard Medical School	Asterand	Russia	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1751-02	True
S13722.58cfa82fe4b0c9d6adf6b748	58cfa82fe4b0c9d6adf6b748	TCGA-44-6776-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-6776-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_7_rg.sorted	TCGA-44-6776-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_7_rg.sorted.bam	142.7	1.9	0.15	58cfa82fe4b0c9d6adf6b748	TCGA-44-6776-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-44-6776-01A	C2A1DE2E-6451-4C95-8CE6-263F2B7E6EFF	Primary Tumor	Illumina HiSeq	bb5d193c-cc97-466b-9b28-bdbf5cf255e8	Lung	60.0	64FB8EBA-A055-4128-92CA-695A3A6F8EBD	5BC01EC3-A1C2-41BB-A9C5-95946A066FA6	TCGA-44-6776-01A-11D-1853-02	HG19_Broad_variant	TCGA-44-6776	TCGA-LUAD		s10660	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	True
S13722.58cfa82fe4b0c9d6adf6b8c0	58cfa82fe4b0c9d6adf6b8c0	TCGA-49-6743-01A-11D-1853_111218_SN208_0258_C054RACXX_s_3_rg.sorted.filtered.	WGS	TCGA-49-6743-01A-11D-1853_111218_SN208_0258_C054RACXX_s_3_rg.sorted	TCGA-49-6743-01A-11D-1853_111218_SN208_0258_C054RACXX_s_3_rg.sorted.bam	219.7	1.9	0.14	58cfa82fe4b0c9d6adf6b8c0	TCGA-49-6743-01A-11D-1853_111218_SN208_0258_C054RACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-49-6743-01A	A391D49F-A822-460B-981C-6FBE1868EE38	Primary Tumor	Illumina HiSeq	8b2cdd00-4024-407a-94a7-dbfe5eaa6cd1	Lung	81.0	5D7DAE28-FC9F-4160-83AA-122F999668B0	3B48B0C9-B9B9-4926-97CA-7232A360A0EE	TCGA-49-6743-01A-11D-1853-02	HG19_Broad_variant	TCGA-49-6743	TCGA-LUAD		s10998	Harvard Medical School	Johns Hopkins	United States	NO	T1	N2	Lung Clear Cell Adenocarcinoma	Stage IIIA	1853-02	True
S13722.58cfa82fe4b0c9d6adf6b6fc	58cfa82fe4b0c9d6adf6b6fc	TCGA-55-6712-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_5_rg.sorted.filtered.	WGS	TCGA-55-6712-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_5_rg.sorted	TCGA-55-6712-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_5_rg.sorted.bam	218.7	1.9	0.15	58cfa82fe4b0c9d6adf6b6fc	TCGA-55-6712-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-55-6712-01A	F17D3463-AF6C-42C2-A8E9-FAE45F69286F	Primary Tumor	Illumina HiSeq	fb1682cf-0fca-4bf1-963d-67a3a177fe98	Lung	71.0	EA75499C-7BF0-47BE-9B09-3C12AAA22F12	61ADB041-60CE-4263-BEB3-33A4DBBA217B	TCGA-55-6712-01A-11D-1853-02	HG19_Broad_variant	TCGA-55-6712	TCGA-LUAD		s11345	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1853-02	True
S13722.58cfa82fe4b0c9d6adf6b8d9	58cfa82fe4b0c9d6adf6b8d9	TCGA-50-5055-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_5_rg.sorted.filtered.	WGS	TCGA-50-5055-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_5_rg.sorted	TCGA-50-5055-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_5_rg.sorted.bam	853.7	1.9	0.17	58cfa82fe4b0c9d6adf6b8d9	TCGA-50-5055-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5055-01A	CC3D9750-7CE0-489F-86D4-8017B7EBED29	Primary Tumor	Illumina HiSeq	97723d64-755b-4f00-b641-95ad083c397e	Lung	79.0	68D19E88-7FBD-48CC-A09F-55C47BFAF6E7	323E338B-1BA7-49E2-811B-C1FEE673A926	TCGA-50-5055-01A-01D-1623-02	HG19_Broad_variant	TCGA-50-5055	TCGA-LUAD		s11008	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIA	1623-02	True
S13722.58cfa82fe4b0c9d6adf6b8f4	58cfa82fe4b0c9d6adf6b8f4	TCGA-A7-A0DC-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A7-A0DC-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_2_rg.sorted	TCGA-A7-A0DC-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_2_rg.sorted.bam	6.58		0.15	58cfa82fe4b0c9d6adf6b8f4	TCGA-A7-A0DC-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A7-A0DC-01B	CB9F5E50-F49D-4899-8895-9367AFCC1015	Primary Tumor	Illumina HiSeq	b8f1a569-bcd5-4da4-a1ea-ae76c98a5d91	Breast	63.0	00B54C99-C26D-423A-9871-2552C1603A9C	A253B105-73B8-4E33-8870-B31CCFB02847	TCGA-A7-A0DC-01B-04D-A22S-26	HG19_Broad_variant	TCGA-A7-A0DC	TCGA-BRCA		s6121	MD Anderson - Institute for Applied Cancer Science	Christiana Healthcare		YES	T1c	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IA	A22S-26	False
S13722.58cfa830e4b0c9d6adf6bdd4	58cfa830e4b0c9d6adf6bdd4	TCGA-BH-A0BM-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BH-A0BM-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_3_rg.sorted	TCGA-BH-A0BM-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_3_rg.sorted.bam	18.62	1.9	0.15	58cfa830e4b0c9d6adf6bdd4	TCGA-BH-A0BM-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0BM-01A	C2AEEE6C-BA10-4CF9-B560-C739580F7BF3	Primary Tumor	Illumina HiSeq	46f039c4-a705-4933-bf85-0e96e80e5024	Breast	54.0	5423B7F8-D2BB-47C8-9AF8-3D3E1276888C	FA99DD38-37F1-4B24-960E-617F92CDADD0	TCGA-BH-A0BM-01A-11D-A060-02	HG19_Broad_variant	TCGA-BH-A0BM	TCGA-BRCA		s6772	Harvard Medical School	University of Pittsburgh		NO	T2	N1a	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	True
S13722.58cfa830e4b0c9d6adf6be66	58cfa830e4b0c9d6adf6be66	TCGA-BJ-A3PT-01A-12D-A221_120530_SN1222_0111_BD12L1ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A3PT-01A-12D-A221_120530_SN1222_0111_BD12L1ACXX_s_1_rg.sorted	TCGA-BJ-A3PT-01A-12D-A221_120530_SN1222_0111_BD12L1ACXX_s_1_rg.sorted.bam	17.47		0.15	58cfa830e4b0c9d6adf6be66	TCGA-BJ-A3PT-01A-12D-A221_120530_SN1222_0111_BD12L1ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A3PT-01A	29C4319C-3EAD-42B1-810D-418DA8D515C4	Primary Tumor	Illumina HiSeq	0d7263bd-8ffa-4ba1-93c4-0444afd9b56e	Thyroid	51.0	8C112A5F-AE83-4B13-8E00-802382729344	EC6A8D75-A25A-4179-BAF4-53607841AC09	TCGA-BJ-A3PT-01A-12D-A221-26	HG19_Broad_variant	TCGA-BJ-A3PT	TCGA-THCA		s12747	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A221-26	True
S13722.58cfa830e4b0c9d6adf6be88	58cfa830e4b0c9d6adf6be88	TCGA-BJ-A291-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BJ-A291-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_8_rg.sorted	TCGA-BJ-A291-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_8_rg.sorted.bam	30.94	1.89	0.15	58cfa830e4b0c9d6adf6be88	TCGA-BJ-A291-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A291-01A	D4C68C1C-A3F3-4E0C-B555-D457378A1D24	Primary Tumor	Illumina HiSeq	bb0bf0e4-e29d-422a-879e-b8dc7f5c720b	Thyroid	56.0	D1612961-A709-487B-A4D1-CE42F0B9AA54	E28A1E8B-41A3-44C0-ADBC-6A203C92DDF5	TCGA-BJ-A291-01A-11D-A16N-02	HG19_Broad_variant	TCGA-BJ-A291	TCGA-THCA		s11990	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True
S13722.58cfa830e4b0c9d6adf6beea	58cfa830e4b0c9d6adf6beea	TCGA-AP-A0LL-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-AP-A0LL-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_3_rg.sorted	TCGA-AP-A0LL-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_3_rg.sorted.bam	106.84	1.77	0.15	58cfa830e4b0c9d6adf6beea	TCGA-AP-A0LL-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LL-01A	D17668C4-5D66-4E16-8B70-B54616581AAE	Primary Tumor	Illumina HiSeq	0ea2fbb0-cc11-44d9-9706-2523b9d268be	Uterus	56.0	488A7462-8348-422C-91D3-7D9F0C39D25E	0D29C555-7C7C-4BBB-A4C6-E554CC758CA7	TCGA-AP-A0LL-01A-12D-A101-02	HG19_Broad_variant	TCGA-AP-A0LL	TCGA-UCEC		s4595	Harvard Medical School	MSKCC		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6bf44	58cfa830e4b0c9d6adf6bf44	TCGA-AX-A2HD-01A-21D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AX-A2HD-01A-21D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_1_rg.sorted	TCGA-AX-A2HD-01A-21D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_1_rg.sorted.bam	115.02	1.84	0.16	58cfa830e4b0c9d6adf6bf44	TCGA-AX-A2HD-01A-21D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A2HD-01A	A8DEF1A0-A136-47F4-9AD9-60EBCF9B726B	Primary Tumor	Illumina HiSeq	b9d10df5-eb11-4976-b3dd-10e970fc715d	Uterus	69.0	5A2EDE97-0CF7-44D7-A789-92EE9BDA3D6C	C24E7F27-2155-4727-B6D8-8E5BC16D9197	TCGA-AX-A2HD-01A-21D-A17E-02	HG19_Broad_variant	TCGA-AX-A2HD	TCGA-UCEC		s4428	Harvard Medical School	Gynecologic Oncology Group	United States	NO			Endometrioid endometrial adenocarcinoma		A17E-02	True
S13722.58cfa830e4b0c9d6adf6c062	58cfa830e4b0c9d6adf6c062	TCGA-B6-A0RI-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B6-A0RI-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_3_rg.sorted	TCGA-B6-A0RI-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_3_rg.sorted.bam	78.5	1.92	0.14	58cfa830e4b0c9d6adf6c062	TCGA-B6-A0RI-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0RI-01A	BFD55808-DDDD-44C3-97D7-41600497B992	Primary Tumor	Illumina HiSeq	9283f68e-d261-4afd-b0eb-0a29fdda83ca	Breast	44.0	973EE776-E287-4568-A43D-7B16CC0094A9	71542129-1393-4608-B81C-1767A5051763	TCGA-B6-A0RI-01A-11D-A060-02	HG19_Broad_variant	TCGA-B6-A0RI	TCGA-BRCA		s6273	Harvard Medical School	Duke	United States	NO	T4b	N1b	Infiltrating Ductal Carcinoma	Stage IIIB	A060-02	True
S13722.58cfa830e4b0c9d6adf6c134	58cfa830e4b0c9d6adf6c134	TCGA-B6-A0RG-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B6-A0RG-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_3_rg.sorted	TCGA-B6-A0RG-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_3_rg.sorted.bam	40.26	2.11	0.15	58cfa830e4b0c9d6adf6c134	TCGA-B6-A0RG-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0RG-01A	9B13927C-7357-44FD-8385-92AE6A656B7D	Primary Tumor	Illumina HiSeq	b38ff19d-a769-4388-81e2-03263bba7985	Breast	26.0	B98AA84F-5144-4062-BADC-32E89368D684	E71ED8ED-7371-4423-83C8-6075A6FC7C39	TCGA-B6-A0RG-01A-11D-A060-02	HG19_Broad_variant	TCGA-B6-A0RG	TCGA-BRCA		s5640	Harvard Medical School	Duke	United States	NO	T3	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	True
S13722.58cfa830e4b0c9d6adf6c128	58cfa830e4b0c9d6adf6c128	TCGA-B6-A0RE-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-B6-A0RE-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_7_rg.sorted	TCGA-B6-A0RE-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_7_rg.sorted.bam	49.61	2.14	0.16	58cfa830e4b0c9d6adf6c128	TCGA-B6-A0RE-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_7_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0RE-01A	08DA7C4C-3067-4BCF-9D7A-78566DF72E69	Primary Tumor	Illumina HiSeq	f7dd44eb-562f-4d27-8c45-5ec7fbf49448	Breast	61.0	270BE245-2239-4E96-A917-79CCA40868BA	D5CE279A-3A7F-43E7-894C-265E9504C3FD	TCGA-B6-A0RE-01A-11D-A060-02	HG19_Broad_variant	TCGA-B6-A0RE	TCGA-BRCA		s6769	Harvard Medical School	Duke	United States	NO	TX	N0 (i-)	Infiltrating Ductal Carcinoma	Stage X	A060-02	True
S13722.58cfa830e4b0c9d6adf6c1a0	58cfa830e4b0c9d6adf6c1a0	TCGA-B7-5818-01A-11D-1598_121130_SN1222_0160_AC1F13ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-B7-5818-01A-11D-1598_121130_SN1222_0160_AC1F13ACXX_s_8_rg.sorted	TCGA-B7-5818-01A-11D-1598_121130_SN1222_0160_AC1F13ACXX_s_8_rg.sorted.bam	411.0	1.9	0.14	58cfa830e4b0c9d6adf6c1a0	TCGA-B7-5818-01A-11D-1598_121130_SN1222_0160_AC1F13ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-B7-5818-01A	6E03B415-84A1-4B91-8717-1A41EDD4A255	Primary Tumor	Illumina HiSeq	9924779b-8261-4ea6-9925-28dd5a0aed8a	Stomach	62.0	FD97CDF5-0F7F-48A2-B5DA-5C5F56A89166	0EBF1A63-C6E4-49FE-B21B-AE46FF14261D	TCGA-B7-5818-01A-11D-1598-02	HG19_Broad_variant	TCGA-B7-5818	TCGA-STAD		s14963	Harvard Medical School	Cureline	Russia	NO	T2	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IB	1598-02	True
S13722.58cfa830e4b0c9d6adf6c136	58cfa830e4b0c9d6adf6c136	TCGA-BS-A0UJ-01A-12D-A101_120407_SN590_0151_BC0KKJACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BS-A0UJ-01A-12D-A101_120407_SN590_0151_BC0KKJACXX_s_3_rg.sorted	TCGA-BS-A0UJ-01A-12D-A101_120407_SN590_0151_BC0KKJACXX_s_3_rg.sorted.bam	125.71	2.0	0.17	58cfa830e4b0c9d6adf6c136	TCGA-BS-A0UJ-01A-12D-A101_120407_SN590_0151_BC0KKJACXX_s_3_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UJ-01A	FF82548A-F1BB-4DAA-A8F7-B3831B5843AD	Primary Tumor	Illumina HiSeq	094adbd4-f2af-42bb-9509-0dcfa2c6672f	Uterus	68.0	2EA1339F-A5EB-4552-AC13-858FA70E606E	15FDA615-0A79-4211-B5DE-F61741E8937A	TCGA-BS-A0UJ-01A-12D-A101-02	HG19_Broad_variant	TCGA-BS-A0UJ	TCGA-UCEC		s5221	Harvard Medical School	University of Hawaii		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6c1a6	58cfa830e4b0c9d6adf6c1a6	TCGA-BH-A0HB-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BH-A0HB-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_5_rg.sorted	TCGA-BH-A0HB-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_5_rg.sorted.bam	58.9	2.0	0.14	58cfa830e4b0c9d6adf6c1a6	TCGA-BH-A0HB-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0HB-01A	0C1023C0-D2CE-4940-8047-7642F1DC3965	Primary Tumor	Illumina HiSeq	c9a434dc-8ce3-485f-88aa-a2373f6cdfac	Breast	55.0	19193B8F-1E1B-448C-B934-93F25E60D45B	49556237-D73F-4DE9-B5D9-7169DB7A53C5	TCGA-BH-A0HB-01A-11D-A060-02	HG19_Broad_variant	TCGA-BH-A0HB	TCGA-BRCA		s6275	Harvard Medical School	University of Pittsburgh		NO	T1c	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IA	A060-02	True
S13722.58cfa830e4b0c9d6adf6c138	58cfa830e4b0c9d6adf6c138	TCGA-BS-A0UF-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BS-A0UF-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_1_rg.sorted	TCGA-BS-A0UF-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_1_rg.sorted.bam	110.21	1.89	0.17	58cfa830e4b0c9d6adf6c138	TCGA-BS-A0UF-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UF-01A	F77D7256-2CCF-42A7-9B30-332AC24CA812	Primary Tumor	Illumina HiSeq	33e84ef1-730b-4f0b-9967-bca62c9f631c	Uterus	65.0	C805F55A-322F-4A11-AE0C-4BBC365D1BD6	D1F78FB2-7BB7-4BF7-8EC7-E2E08F579A38	TCGA-BS-A0UF-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0UF	TCGA-UCEC		s5220	Harvard Medical School	University of Hawaii		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6c1e1	58cfa830e4b0c9d6adf6c1e1	TCGA-BG-A0MT-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BG-A0MT-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_8_rg.sorted	TCGA-BG-A0MT-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_8_rg.sorted.bam	93.28	1.98	0.17	58cfa830e4b0c9d6adf6c1e1	TCGA-BG-A0MT-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MT-01A	082E32C5-7F82-466A-B52D-A3293A8F8E57	Primary Tumor	Illumina HiSeq	3499ad67-e5ed-4030-9fba-fac9fa52f9c5	Uterus	64.0	91F629F5-6938-4F5C-BA2E-1F519CE6B255	23FB2C48-BE95-4169-BB10-00EA361C5687	TCGA-BG-A0MT-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0MT	TCGA-UCEC		s5217	Harvard Medical School	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6bf40	58cfa830e4b0c9d6adf6bf40	TCGA-AX-A1CJ-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-AX-A1CJ-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_5_rg.sorted	TCGA-AX-A1CJ-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_5_rg.sorted.bam	100.97	1.91	0.17	58cfa830e4b0c9d6adf6bf40	TCGA-AX-A1CJ-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A1CJ-01A	ABAF757B-F79F-40BD-96E3-E2C0F63061F0	Primary Tumor	Illumina HiSeq	f42806a5-e473-4ae8-bb1a-aa11fe2dde53	Uterus	59.0	72D06DDF-9FB2-4577-BFDB-B0E463105B4A	A4EE1BB7-59FF-4034-ABA1-9AF4F62B42B0	TCGA-AX-A1CJ-01A-11D-A133-02	HG19_Broad_variant	TCGA-AX-A1CJ	TCGA-UCEC		s5388	Harvard Medical School	Gynecologic Oncology Group		NO			Endometrioid endometrial adenocarcinoma		A133-02	False
S13722.58cfa830e4b0c9d6adf6c208	58cfa830e4b0c9d6adf6c208	TCGA-BA-5558-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BA-5558-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_5_rg.sorted	TCGA-BA-5558-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_5_rg.sorted.bam	252.7	1.9	0.15	58cfa830e4b0c9d6adf6c208	TCGA-BA-5558-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5558-01A	6A1AA50C-097C-4E04-8DDD-12D50F8A5AC2	Primary Tumor	Illumina HiSeq	4116c10d-23f4-49f2-bd5a-9b9466f08bfb	Head and Neck	65.0	EB749281-B3DC-43E4-812E-F5F5004A21ED	41737268-345A-4F87-B2DB-E184247E1396	TCGA-BA-5558-01A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5558	TCGA-HNSC		s15610	Harvard Medical School	UNC		NO	TX	NX	Head and Neck Squamous Cell Carcinoma		1509-02	True
S13722.58cfa830e4b0c9d6adf6c236	58cfa830e4b0c9d6adf6c236	TCGA-BJ-A0Z3-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z3-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_7_rg.sorted	TCGA-BJ-A0Z3-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_7_rg.sorted.bam	64.48	1.98	0.16	58cfa830e4b0c9d6adf6c236	TCGA-BJ-A0Z3-01A-11D-A13U_120706_SN1120_0170_BD1422ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z3-01A	331CAE6E-2868-4C58-9302-709A9FF7D025	Primary Tumor	Illumina HiSeq	ddae4f5a-aed4-4466-9434-23f6ed312d19	Thyroid	33.0	6BF032C1-B7D5-4B1C-BF41-C9BFEAFA5E7A	3D0982B1-944E-4C03-AAA4-F8FD4602D4C9	TCGA-BJ-A0Z3-01A-11D-A13U-02	HG19_Broad_variant	TCGA-BJ-A0Z3	TCGA-THCA		s12628	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	True
S13722.58cfa830e4b0c9d6adf6c2aa	58cfa830e4b0c9d6adf6c2aa	TCGA-BR-4201-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-4201-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_5_rg.sorted	TCGA-BR-4201-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_5_rg.sorted.bam	204.9	1.9	0.15	58cfa830e4b0c9d6adf6c2aa	TCGA-BR-4201-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4201-01A	8520654B-2192-46CF-9D72-1DDB885A7C55	Primary Tumor	Illumina HiSeq	359db0d8-a78f-4d9d-9a3e-9f1a04472df0	Stomach	66.0	B42CC87B-4BB0-433D-8AFB-CB314B8CBA30	FE12C75F-5A26-40A8-BEF0-742FAD4CD0E5	TCGA-BR-4201-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4201	TCGA-STAD		s14529	Harvard Medical School	Asterand	Russia	NO	T2a	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1128-02	True
S13722.58cfa830e4b0c9d6adf6c31e	58cfa830e4b0c9d6adf6c31e	TCGA-CF-A27C-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CF-A27C-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_7_rg.sorted	TCGA-CF-A27C-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_7_rg.sorted.bam	67.64	2.28	0.18	58cfa830e4b0c9d6adf6c31e	TCGA-CF-A27C-01A-11D-A16N_120920_SN1222_0151_BD1D5CACXX_s_7_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A27C-01A	7FEE9D6F-C0EA-43C2-89C2-66D965A077A8	Primary Tumor	Illumina HiSeq	ecc65751-9b59-49c3-a142-7a4c61174649	Bladder	52.0	EAD6792B-4E52-4C28-891C-6D8696873A13	1E553EB3-8C42-48A1-87A7-BFA8541CE568	TCGA-CF-A27C-01A-11D-A16N-02	HG19_Broad_variant	TCGA-CF-A27C	TCGA-BLCA		s2873	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A16N-02	True
S13722.58cfa831e4b0c9d6adf6c3b0	58cfa831e4b0c9d6adf6c3b0	TCGA-BH-A0H7-01A-13D-A060_130725_SN590_0233_AD2B3HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BH-A0H7-01A-13D-A060_130725_SN590_0233_AD2B3HACXX_s_7_rg.sorted	TCGA-BH-A0H7-01A-13D-A060_130725_SN590_0233_AD2B3HACXX_s_7_rg.sorted.bam	20.53	2.0	0.15	58cfa831e4b0c9d6adf6c3b0	TCGA-BH-A0H7-01A-13D-A060_130725_SN590_0233_AD2B3HACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0H7-01A	2021ED1F-DC75-4701-B8B8-1386466E4802	Primary Tumor	Illumina HiSeq	d5ab471a-88d1-4966-865a-f7fa29214fe4	Breast	65.0	69BFA6CE-ED46-4321-A107-347C49D68951	E0E60B71-1EFA-4896-B89F-D05974CDCF48	TCGA-BH-A0H7-01A-13D-A060-02	HG19_Broad_variant	TCGA-BH-A0H7	TCGA-BRCA		s5801	Harvard Medical School	University of Pittsburgh		NO	T1c	N2a	Infiltrating Ductal Carcinoma	Stage IIIA	A060-02	True
S13722.58cfa831e4b0c9d6adf6c3f0	58cfa831e4b0c9d6adf6c3f0	TCGA-C5-A2LX-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_5_rg.sorted.filtered.	WGS	TCGA-C5-A2LX-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_5_rg.sorted	TCGA-C5-A2LX-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_5_rg.sorted.bam	82.12		0.18	58cfa831e4b0c9d6adf6c3f0	TCGA-C5-A2LX-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A2LX-01A	B82F4C6D-530F-4B0E-8F33-995633CB254A	Primary Tumor	Illumina HiSeq	ef574f7b-2b69-4be8-83f3-cc02df579a0a	Cervix	54.0	41BEBEA3-11C2-4748-8E60-082CFB8E0251	F4772B1E-699C-4C3D-9E0B-1BD4634A7F36	TCGA-C5-A2LX-01A-11D-A18I-02	HG19_Broad_variant	TCGA-C5-A2LX	TCGA-CESC		s1175	Harvard Medical School	Medical College of Wisconsin	United States	NO	T2	N1	Cervical Squamous Cell Carcinoma		A18I-02	True
S13722.58cfa831e4b0c9d6adf6c3fc	58cfa831e4b0c9d6adf6c3fc	TCGA-CH-5788-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5788-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_3_rg.sorted	TCGA-CH-5788-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_3_rg.sorted.bam	257.7	1.9	0.16	58cfa831e4b0c9d6adf6c3fc	TCGA-CH-5788-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5788-01A	C039014F-821C-43D6-9D3C-914F9C8D98FA	Primary Tumor	Illumina HiSeq	8bd51d54-e1be-4a0a-bad5-3b8013692b90	Prostate	69.0	144E0265-C04E-4538-A721-94DEF2570486	ADB6611D-7A44-4FFE-A48B-FF8E24696B38	TCGA-CH-5788-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5788	TCGA-PRAD		s3595	Harvard Medical School	Indivumed	Germany	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c670	58cfa831e4b0c9d6adf6c670	TCGA-CS-4944-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CS-4944-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_3_rg.sorted	TCGA-CS-4944-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_3_rg.sorted.bam	18.0	1.9	0.14	58cfa831e4b0c9d6adf6c670	TCGA-CS-4944-01A-01D-1465_130808_SN208_0487_AC28U7ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE		Brain Lower Grade Glioma	Aligned reads	TCGA-CS-4944-01A	64CD17EB-C778-45E9-B994-02B68182E51B	Primary Tumor	Illumina HiSeq	c266d33e-c72f-4059-b287-2f1bbd6fd48b	Brain	50.0	F1AA24E4-BC7F-427F-9CEB-8CAAFABFE535	63B56E68-639B-483B-B777-EAD4BDDC112C	TCGA-CS-4944-01A-01D-1465-02	HG19_Broad_variant	TCGA-CS-4944	TCGA-LGG		s8127	Harvard Medical School	Thomas Jefferson University	United States	NO			Astrocytoma		1465-02	True
S13722.58cfa831e4b0c9d6adf6c73a	58cfa831e4b0c9d6adf6c73a	TCGA-D7-6524-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D7-6524-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_5_rg.sorted	TCGA-D7-6524-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_5_rg.sorted.bam	274.4	1.9	0.16	58cfa831e4b0c9d6adf6c73a	TCGA-D7-6524-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6524-01A	7EF3F065-1928-4A58-B5A6-76DDDB8488CF	Primary Tumor	Illumina HiSeq	67f702e7-84ad-4d23-90e7-03040d417e4d	Stomach	53.0	6F14723A-AF83-402D-AB98-B4ED29A93AAF	48540EAA-46FD-4C0A-9893-1FF69D205F79	TCGA-D7-6524-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6524	TCGA-STAD		s14557	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N1	Stomach  Adenocarcinoma  Diffuse Type	Stage II	1798-02	True
S13722.58cfa831e4b0c9d6adf6c7b1	58cfa831e4b0c9d6adf6c7b1	TCGA-CN-6996-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-6996-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_5_rg.sorted	TCGA-CN-6996-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_5_rg.sorted.bam	155.7		0.15	58cfa831e4b0c9d6adf6c7b1	TCGA-CN-6996-01A-11D-1911_120504_SN1222_0101_AC0UMDACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6996-01A	49B94421-FE82-4F24-8EF2-820674142418	Primary Tumor	Illumina HiSeq	533cea76-ea79-4b37-8e72-5626bc894990	Head and Neck	58.0	2C3790CE-A54D-431B-B76C-FA25441AA41C	5367CF72-E404-4203-AD7D-CF7663072EA7	TCGA-CN-6996-01A-11D-1911-02	HG19_Broad_variant	TCGA-CN-6996	TCGA-HNSC		s16180	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	True
S13722.58cfa831e4b0c9d6adf6c7c8	58cfa831e4b0c9d6adf6c7c8	TCGA-D1-A17K-01A-11D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D1-A17K-01A-11D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_2_rg.sorted	TCGA-D1-A17K-01A-11D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_2_rg.sorted.bam	56.36	1.95	0.15	58cfa831e4b0c9d6adf6c7c8	TCGA-D1-A17K-01A-11D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17K-01A	5C22C8D6-5805-455C-8E1C-E6B8006738E4	Primary Tumor	Illumina HiSeq	312dd86a-5fc1-4446-bfd6-fe867e3617f2	Uterus	74.0	CA213835-EFC5-4216-A762-A6B320B516BF	3E67F5BD-C5A6-4CDD-8D71-78038D316447	TCGA-D1-A17K-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A17K	TCGA-UCEC		s4617	Harvard Medical School	Mayo Clinic		NO			Endometrioid endometrial adenocarcinoma		A12F-02	True
S13722.58cfa831e4b0c9d6adf6c7cb	58cfa831e4b0c9d6adf6c7cb	TCGA-CX-7085-01A-21D-2317_120710_SN590_0166_AC0VNFACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CX-7085-01A-21D-2317_120710_SN590_0166_AC0VNFACXX_s_3_rg.sorted	TCGA-CX-7085-01A-21D-2317_120710_SN590_0166_AC0VNFACXX_s_3_rg.sorted.bam	262.73		0.15	58cfa831e4b0c9d6adf6c7cb	TCGA-CX-7085-01A-21D-2317_120710_SN590_0166_AC0VNFACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CX-7085-01A	2A7B4613-F908-4E78-98ED-857DCD7ED774	Primary Tumor	Illumina HiSeq	2a118e3e-c8f9-43b4-b1d7-4659e37a96ce	Head and Neck	77.0	A07E086C-1D2D-4D92-A663-ECD7EA4DBD73	57FA3BBB-D571-475C-95A2-AAEDFF4835FC	TCGA-CX-7085-01A-21D-2317-26	HG19_Broad_variant	TCGA-CX-7085	TCGA-HNSC		s16056	MD Anderson - Institute for Applied Cancer Science	Medical College of Georgia	United States	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	2317-26	True
S13722.58cfa831e4b0c9d6adf6c7f7	58cfa831e4b0c9d6adf6c7f7	TCGA-D1-A17C-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D1-A17C-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_1_rg.sorted	TCGA-D1-A17C-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_1_rg.sorted.bam	46.77	1.95	0.15	58cfa831e4b0c9d6adf6c7f7	TCGA-D1-A17C-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17C-01A	6F4F0CDD-8387-45D0-A9E8-EFCE6260159D	Primary Tumor	Illumina HiSeq	554e5953-4680-4681-a963-fcc940b3f448	Uterus	78.0	2D5AC7FC-BED4-4C7F-927D-9B44846324C4	99444E9D-219B-4653-9410-B258D28DEEB7	TCGA-D1-A17C-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A17C	TCGA-UCEC		s4801	Harvard Medical School	Mayo Clinic		NO			Endometrioid endometrial adenocarcinoma		A12F-02	True
S13722.58cfa831e4b0c9d6adf6c803	58cfa831e4b0c9d6adf6c803	TCGA-D1-A16N-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D1-A16N-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_2_rg.sorted	TCGA-D1-A16N-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_2_rg.sorted.bam	99.18	1.97	0.15	58cfa831e4b0c9d6adf6c803	TCGA-D1-A16N-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16N-01A	DBBBDDAE-D711-40F5-BD10-863735885B1F	Primary Tumor	Illumina HiSeq	0cea9a43-7170-4273-879f-084cb6e14196	Uterus	51.0	6D916A47-DCFF-4C98-9E88-348AAA353F98	133CBA56-19C9-47AE-AB5E-37FF35A7E71E	TCGA-D1-A16N-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A16N	TCGA-UCEC		s4263	Harvard Medical School	Mayo Clinic		NO			Endometrioid endometrial adenocarcinoma		A12F-02	True
S13722.58cfa831e4b0c9d6adf6c836	58cfa831e4b0c9d6adf6c836	TCGA-D7-6521-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D7-6521-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_1_rg.sorted	TCGA-D7-6521-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_1_rg.sorted.bam	131.4	1.9	0.14	58cfa831e4b0c9d6adf6c836	TCGA-D7-6521-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6521-01A	6DE6B8E2-03EB-4F32-B5A3-BEA73FC632B4	Primary Tumor	Illumina HiSeq	72a895e9-b1b0-4b79-a5e6-6bae340e8798	Stomach	65.0	C3D9FC3B-EF2A-4D02-B7A4-5D1463AD5EF3	0F49F6E2-C6C8-4F3E-8755-BAA962453E71	TCGA-D7-6521-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6521	TCGA-STAD		s14838	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2b	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1798-02	True
S13722.58cfa831e4b0c9d6adf6c82b	58cfa831e4b0c9d6adf6c82b	TCGA-D1-A17Q-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D1-A17Q-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_2_rg.sorted	TCGA-D1-A17Q-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_2_rg.sorted.bam	77.69	1.86	0.16	58cfa831e4b0c9d6adf6c82b	TCGA-D1-A17Q-01A-11D-A12F_120418_SN1222_0097_AC0M28ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17Q-01A	CA8DBBFD-8928-4E25-94C6-B875DE631BBD	Primary Tumor	Illumina HiSeq	77e56615-42dd-4c50-a518-cc93c3b80107	Uterus	54.0	B6ABEB01-B6EA-4AB4-AA00-AE16CFC88B7C	59FB249D-4C77-40B1-A557-98281869AC91	TCGA-D1-A17Q-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A17Q	TCGA-UCEC		s4442	Harvard Medical School	Mayo Clinic		NO			Endometrioid endometrial adenocarcinoma		A12F-02	True
S13722.58cfa831e4b0c9d6adf6c8c4	58cfa831e4b0c9d6adf6c8c4	TCGA-CN-5373-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CN-5373-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_4_rg.sorted	TCGA-CN-5373-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_4_rg.sorted.bam	165.7	1.9	0.14	58cfa831e4b0c9d6adf6c8c4	TCGA-CN-5373-01A-01D-1431_120420_SN1120_0134_AC0J8YACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5373-01A	546F01D5-AED5-4FB8-91C0-0FD5E0FDE935	Primary Tumor	Illumina HiSeq	22213a76-97e9-4565-8074-c3046269b70a	Head and Neck	55.0	9D73D061-F1E1-47BA-929D-FEEB6C191279	3FE7F18F-8AA4-4AFE-8AF0-256876F7E86E	TCGA-CN-5373-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5373	TCGA-HNSC		s16035	Harvard Medical School	University of Pittsburgh		NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	1431-02	True
S13722.58cfa831e4b0c9d6adf6c91f	58cfa831e4b0c9d6adf6c91f	TCGA-DK-A1AB-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DK-A1AB-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_3_rg.sorted	TCGA-DK-A1AB-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_3_rg.sorted.bam	43.47	2.0	0.18	58cfa831e4b0c9d6adf6c91f	TCGA-DK-A1AB-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AB-01A	F027D254-EC01-4882-A8A7-964AE90B7D49	Primary Tumor	Illumina HiSeq	a5005e15-2ada-4bf4-9a61-0febc81a99ca	Bladder	74.0	253F84AB-FCE2-4E2D-955B-0B8D13A9E4F0	D1F85B58-EBF8-4A73-A5E0-8DFE62CF1164	TCGA-DK-A1AB-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AB	TCGA-BLCA		s2707	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T4a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13U-02	True
S13722.58cfa831e4b0c9d6adf6c8f2	58cfa831e4b0c9d6adf6c8f2	TCGA-CV-5976-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CV-5976-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_2_rg.sorted	TCGA-CV-5976-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_2_rg.sorted.bam	135.0	1.9	0.15	58cfa831e4b0c9d6adf6c8f2	TCGA-CV-5976-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5976-01A	23062172-7361-4E61-8EE6-B0A613D72A24	Primary Tumor	Illumina HiSeq	ef7745ae-17be-41bc-a3a5-c24eeda89075	Head and Neck	50.0	EEF68956-D624-4CD0-9C48-28FAF052C5F9	2581BC16-0DEF-40BC-8A97-54A1AE577E26	TCGA-CV-5976-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-5976	TCGA-HNSC		s16041	Harvard Medical School	MD Anderson Cancer Center		NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True
S13722.58cfa831e4b0c9d6adf6c93f	58cfa831e4b0c9d6adf6c93f	TCGA-DK-A1AC-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DK-A1AC-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_5_rg.sorted	TCGA-DK-A1AC-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_5_rg.sorted.bam	61.12	1.95	0.15	58cfa831e4b0c9d6adf6c93f	TCGA-DK-A1AC-01A-11D-A13U_121002_SN1222_0154_AC1A3DACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE		Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AC-01A	36C14E9D-1863-4C55-BBBB-F8C9DD418932	Primary Tumor	Illumina HiSeq	befc5d25-55df-4a22-b4e4-25508f3935c9	Bladder	72.0	CD2FB6B8-5DB9-42B4-A407-A5B6F7B8665F	221E5DDE-BAB0-456C-87BE-DB54998FE197	TCGA-DK-A1AC-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AC	TCGA-BLCA		s2884	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	True
S13722.58cfa831e4b0c9d6adf6ca71	58cfa831e4b0c9d6adf6ca71	TCGA-DO-A1JZ-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DO-A1JZ-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_6_rg.sorted	TCGA-DO-A1JZ-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_6_rg.sorted.bam	91.81	1.77	0.15	58cfa831e4b0c9d6adf6ca71	TCGA-DO-A1JZ-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_6_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DO-A1JZ-01A	169F045F-1739-4B0B-9BDC-028AACA420F8	Primary Tumor	Illumina HiSeq	a349224e-f179-4a21-ae6f-5807917a484d	Thyroid	23.0	2EEB72CD-8A11-4ED1-87B0-3CF0C1BF1FB5	C69C86EC-D4E4-422B-88F8-AF3CE8B14148	TCGA-DO-A1JZ-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DO-A1JZ	TCGA-THCA		s12377	Harvard Medical School	Medical College of Georgia	United States	NO	T2	NX	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A13U-02	True
S13722.58cfa831e4b0c9d6adf6cb00	58cfa831e4b0c9d6adf6cb00	TCGA-EA-A3QE-01A-21D-A245_140124_SN1440_0178_AC2PL6ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EA-A3QE-01A-21D-A245_140124_SN1440_0178_AC2PL6ACXX_s_5_rg.sorted	TCGA-EA-A3QE-01A-21D-A245_140124_SN1440_0178_AC2PL6ACXX_s_5_rg.sorted.bam	67.0		0.14	58cfa831e4b0c9d6adf6cb00	TCGA-EA-A3QE-01A-21D-A245_140124_SN1440_0178_AC2PL6ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3QE-01A	A4E444B5-BBCA-4EF0-B92F-908D608CBB91	Primary Tumor	Illumina HiSeq	14055776-9bfb-42c1-a760-39fb0c8dba92	Cervix	45.0	36FFA53D-1404-49C0-B9C1-A3EB1ECBC6B9	80A263E0-9F91-48FD-B53C-7E2A25710BF3	TCGA-EA-A3QE-01A-21D-A245-26	HG19_Broad_variant	TCGA-EA-A3QE	TCGA-CESC		s1524	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T1b	N0	Cervical Squamous Cell Carcinoma		A245-26	True
S13722.58cfa831e4b0c9d6adf6cb04	58cfa831e4b0c9d6adf6cb04	TCGA-EA-A3HT-01A-61D-A245_140124_SN1440_0178_AC2PL6ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EA-A3HT-01A-61D-A245_140124_SN1440_0178_AC2PL6ACXX_s_2_rg.sorted	TCGA-EA-A3HT-01A-61D-A245_140124_SN1440_0178_AC2PL6ACXX_s_2_rg.sorted.bam	54.34		0.15	58cfa831e4b0c9d6adf6cb04	TCGA-EA-A3HT-01A-61D-A245_140124_SN1440_0178_AC2PL6ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3HT-01A	3C5B2452-014B-495F-B86A-F522ED84BC3B	Primary Tumor	Illumina HiSeq	e0e70b08-26f3-48d5-80c3-4836e9faa569	Cervix	68.0	8460C1E5-0029-4D66-AF11-373324347800	CE1A5984-E350-46A3-BF53-B32DEC8F8AF0	TCGA-EA-A3HT-01A-61D-A245-26	HG19_Broad_variant	TCGA-EA-A3HT	TCGA-CESC		s1182	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T1b	N0	Cervical Squamous Cell Carcinoma		A245-26	True
S13722.58cfa831e4b0c9d6adf6ca93	58cfa831e4b0c9d6adf6ca93	TCGA-D1-A16R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D1-A16R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_5_rg.sorted	TCGA-D1-A16R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_5_rg.sorted.bam	93.33	1.39	0.17	58cfa831e4b0c9d6adf6ca93	TCGA-D1-A16R-01A-11D-A12F_120523_SN1222_0109_BD12MPACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16R-01A	40F43483-B504-4EA7-AD24-40682B10CAAC	Primary Tumor	Illumina HiSeq	3574ade8-f6bc-44dc-94ce-8ea657978707	Uterus	39.0	F57EB4ED-4393-4DC3-9362-A4757EF8B21D	93FEF054-0782-4A27-A27B-22176874E805	TCGA-D1-A16R-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A16R	TCGA-UCEC		s4618	Harvard Medical School	Mayo Clinic		NO			Endometrioid endometrial adenocarcinoma		A12F-02	True
S13722.58cfa831e4b0c9d6adf6cb25	58cfa831e4b0c9d6adf6cb25	TCGA-E8-A242-01A-21D-A16N_121204_SN208_0442_BC1F7YACXX_s_3_rg.sorted.filtered.	WGS	TCGA-E8-A242-01A-21D-A16N_121204_SN208_0442_BC1F7YACXX_s_3_rg.sorted	TCGA-E8-A242-01A-21D-A16N_121204_SN208_0442_BC1F7YACXX_s_3_rg.sorted.bam	17.09	1.94	0.18	58cfa831e4b0c9d6adf6cb25	TCGA-E8-A242-01A-21D-A16N_121204_SN208_0442_BC1F7YACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-E8-A242-01A	4D9DE9A1-7DF1-412E-9F16-15DD51B4C5F5	Primary Tumor	Illumina HiSeq	0e5bb14f-1671-4b8a-9a38-e1d389ecd440	Thyroid	56.0	225B76AD-DB11-457A-9A77-E1F333895E5C	EA178797-16FB-41AB-B71F-3B397153CE63	TCGA-E8-A242-01A-21D-A16N-02	HG19_Broad_variant	TCGA-E8-A242	TCGA-THCA		s12378	Harvard Medical School	Asterand	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A16N-02	True
S13722.58cfa831e4b0c9d6adf6ca01	58cfa831e4b0c9d6adf6ca01	TCGA-DQ-5625-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DQ-5625-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_1_rg.sorted	TCGA-DQ-5625-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_1_rg.sorted.bam	154.7	1.9	0.15	58cfa831e4b0c9d6adf6ca01	TCGA-DQ-5625-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-5625-01A	53D9A130-4A3A-4491-85CD-9A44415A1632	Primary Tumor	Illumina HiSeq	33b84364-a81e-48fd-89d6-552802c7ff18	Head and Neck	52.0	74856E66-109F-4A68-A496-8FA66729FE1F	9641D13E-BE95-46BB-8330-6128EE15D47C	TCGA-DQ-5625-01A-01D-1868-02	HG19_Broad_variant	TCGA-DQ-5625	TCGA-HNSC		s16058	Harvard Medical School	University of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		1868-02	True
S13722.58cfa831e4b0c9d6adf6cbf7	58cfa831e4b0c9d6adf6cbf7	TCGA-EK-A2PL-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EK-A2PL-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_1_rg.sorted	TCGA-EK-A2PL-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_1_rg.sorted.bam	72.21		0.16	58cfa831e4b0c9d6adf6cbf7	TCGA-EK-A2PL-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2PL-01A	45CADCF3-EA98-4063-9255-5C18D6A5CBAB	Primary Tumor	Illumina HiSeq	ca898dd4-73fc-4fa3-8d2b-3d4f27be4736	Cervix	36.0	6EE33187-69A7-4328-9521-173CFCDE7A1B	2AC0C1AB-11A3-4806-82FE-08529AD8BBDD	TCGA-EK-A2PL-01A-11D-A18I-02	HG19_Broad_variant	TCGA-EK-A2PL	TCGA-CESC		s1187	Harvard Medical School	Gynecologic Oncology Group	United States	NO			Cervical Squamous Cell Carcinoma		A18I-02	True
S13722.58cfa831e4b0c9d6adf6cbd9	58cfa831e4b0c9d6adf6cbd9	TCGA-EJ-5515-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5515-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_1_rg.sorted	TCGA-EJ-5515-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_1_rg.sorted.bam	150.7	1.9	0.14	58cfa831e4b0c9d6adf6cbd9	TCGA-EJ-5515-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5515-01A	19CF56B2-A85B-43E7-971F-5680B9B1A67A	Primary Tumor	Illumina HiSeq	25dbfef2-277f-4974-a326-2747d9494a2d	Prostate	60.0	5FBA6E4A-3D7D-478E-AFA6-E66C816E7852	C124D41D-EBD2-4DAE-A344-8518DB3354A4	TCGA-EJ-5515-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5515	TCGA-PRAD		s4132	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cba8	58cfa831e4b0c9d6adf6cba8	TCGA-EJ-5525-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5525-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_1_rg.sorted	TCGA-EJ-5525-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_1_rg.sorted.bam	333.7	1.9	0.15	58cfa831e4b0c9d6adf6cba8	TCGA-EJ-5525-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5525-01A	554A7381-46FD-4301-B91B-5AF7F173C350	Primary Tumor	Illumina HiSeq	10ab041f-88f9-463c-873d-508073d1672b	Prostate	67.0	351AF15C-B213-4621-8BCB-3F4DDCF72553	333DDE15-F4B2-4301-A6AC-59C7F4CD6639	TCGA-EJ-5525-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5525	TCGA-PRAD		s3602	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cbfc	58cfa831e4b0c9d6adf6cbfc	TCGA-EJ-5506-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5506-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_5_rg.sorted	TCGA-EJ-5506-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_5_rg.sorted.bam	238.7	1.9	0.15	58cfa831e4b0c9d6adf6cbfc	TCGA-EJ-5506-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5506-01A	E5E4D3B6-8E58-4DCF-8F67-A00E656A8E27	Primary Tumor	Illumina HiSeq	bd66d4a0-aa1a-4bf3-a764-cb7292bc89b1	Prostate	67.0	9EBDA113-B0FC-4233-87AC-DAD0E7D033DE	CED987BC-B780-487A-A82E-2EB589AD3796	TCGA-EJ-5506-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5506	TCGA-PRAD		s3780	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cc23	58cfa831e4b0c9d6adf6cc23	TCGA-EJ-5503-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5503-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_7_rg.sorted	TCGA-EJ-5503-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_7_rg.sorted.bam	172.7	1.9	0.16	58cfa831e4b0c9d6adf6cc23	TCGA-EJ-5503-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5503-01A	AA252F78-EBF3-42F9-86AF-BB6E57345706	Primary Tumor	Illumina HiSeq	4eba210f-0895-487c-9b48-db8a8c629cc4	Prostate	50.0	627B9FF8-2557-4470-824A-B76A8BCD1E9F	68211C41-2971-4B41-8EEE-75FFB78175BC	TCGA-EJ-5503-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5503	TCGA-PRAD		s3782	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cc4c	58cfa831e4b0c9d6adf6cc4c	TCGA-EA-A1QS-01A-61D-A232_140124_SN208_0506_BC2PD5ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EA-A1QS-01A-61D-A232_140124_SN208_0506_BC2PD5ACXX_s_2_rg.sorted	TCGA-EA-A1QS-01A-61D-A232_140124_SN208_0506_BC2PD5ACXX_s_2_rg.sorted.bam	36.95		0.15	58cfa831e4b0c9d6adf6cc4c	TCGA-EA-A1QS-01A-61D-A232_140124_SN208_0506_BC2PD5ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A1QS-01A	6F9D21C0-3B88-450D-A249-3E9BAFBA2DFA	Primary Tumor	Illumina HiSeq	c7f62ea9-e05f-40ea-9e4c-1771bd722b74	Cervix	46.0	8389C79E-164E-4462-ADCD-364DB3AFB463	109962B4-F4A5-4C72-B902-92516110FE7E	TCGA-EA-A1QS-01A-61D-A232-26	HG19_Broad_variant	TCGA-EA-A1QS	TCGA-CESC		s1361	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T1b1	N0	Cervical Squamous Cell Carcinoma		A232-26	True
S13722.58cfa831e4b0c9d6adf6cd09	58cfa831e4b0c9d6adf6cd09	TCGA-EX-A3L1-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EX-A3L1-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_6_rg.sorted	TCGA-EX-A3L1-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_6_rg.sorted.bam	44.57		0.14	58cfa831e4b0c9d6adf6cd09	TCGA-EX-A3L1-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EX-A3L1-01A	F5D90810-8C4B-4CED-9360-383E42CB54B3	Primary Tumor	Illumina HiSeq	73141d26-4c6a-46e1-ab5f-b431f2f35c23	Cervix	32.0	89AD6395-973B-4011-BFBD-6759209406BE	6F24A0BE-76D7-4388-B73A-32BE2E902470	TCGA-EX-A3L1-01A-11D-A245-26	HG19_Broad_variant	TCGA-EX-A3L1	TCGA-CESC		s1530	MD Anderson - Institute for Applied Cancer Science	University of North Carolina	United States	NO	T2a1	N0	Cervical Squamous Cell Carcinoma		A245-26	True
S13722.58cfa831e4b0c9d6adf6cdb6	58cfa831e4b0c9d6adf6cdb6	TCGA-FG-5963-01A-11D-1703_130813_SN1440_0161_BC29ENACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FG-5963-01A-11D-1703_130813_SN1440_0161_BC29ENACXX_s_1_rg.sorted	TCGA-FG-5963-01A-11D-1703_130813_SN1440_0161_BC29ENACXX_s_1_rg.sorted.bam	7.3	2.0	0.13	58cfa831e4b0c9d6adf6cdb6	TCGA-FG-5963-01A-11D-1703_130813_SN1440_0161_BC29ENACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-5963-01A	68F550CA-3A33-45E4-B1C9-14F99E543263	Primary Tumor	Illumina HiSeq	11f814ba-95e7-4824-ab33-1e14947dcbd5	Brain	23.0	41C647E8-6A53-464B-9EFC-78547C514519	166F687B-F395-4AC7-A06A-78826A0722E7	TCGA-FG-5963-01A-11D-1703-02	HG19_Broad_variant	TCGA-FG-5963	TCGA-LGG		s8148	Harvard Medical School	Case Western	United States	NO			Astrocytoma		1703-02	True
S13722.58cfa832e4b0c9d6adf6ce58	58cfa832e4b0c9d6adf6ce58	TCGA-FU-A3HY-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FU-A3HY-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_7_rg.sorted	TCGA-FU-A3HY-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_7_rg.sorted.bam	37.56		0.16	58cfa832e4b0c9d6adf6ce58	TCGA-FU-A3HY-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3HY-01A	674E010C-7AD4-4DC2-86B0-284CD4560633	Primary Tumor	Illumina HiSeq	30d23ada-985e-43b1-9cc5-9e3931905b07	Cervix	47.0	A5879A60-AA8B-4DA0-904A-9FFE2968418C	0FD6C08E-8B41-422F-A6BA-1234E6596ADA	TCGA-FU-A3HY-01A-11D-A245-26	HG19_Broad_variant	TCGA-FU-A3HY	TCGA-CESC		s1531	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T1b2	N1	Cervical Squamous Cell Carcinoma		A245-26	True
S13722.58cfa832e4b0c9d6adf6ce96	58cfa832e4b0c9d6adf6ce96	TCGA-G2-A2EC-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_5_rg.sorted.filtered.	WGS	TCGA-G2-A2EC-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_5_rg.sorted	TCGA-G2-A2EC-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_5_rg.sorted.bam	18.46		0.18	58cfa832e4b0c9d6adf6ce96	TCGA-G2-A2EC-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2EC-01A	28E25FFB-8B0C-4839-A735-ED7B78E3213A	Primary Tumor	Illumina HiSeq	0d4b7559-34dc-4690-a8e9-144698537cdd	Bladder	58.0	2DA969E6-9A63-4C03-8347-01A51496C224	09ED2111-236D-47C1-A82D-7919C8EEA5B2	TCGA-G2-A2EC-01A-11D-A17R-02	HG19_Broad_variant	TCGA-G2-A2EC	TCGA-BLCA		s3303	Harvard Medical School	MD Anderson	United States	NO		N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A17R-02	True
S13722.58cfa831e4b0c9d6adf6cd7a	58cfa831e4b0c9d6adf6cd7a	TCGA-EY-A1GC-01A-11D-A13I_120516_SN1222_0107_BD12HYACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EY-A1GC-01A-11D-A13I_120516_SN1222_0107_BD12HYACXX_s_5_rg.sorted	TCGA-EY-A1GC-01A-11D-A13I_120516_SN1222_0107_BD12HYACXX_s_5_rg.sorted.bam	63.8	1.81	0.16	58cfa831e4b0c9d6adf6cd7a	TCGA-EY-A1GC-01A-11D-A13I_120516_SN1222_0107_BD12HYACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-EY-A1GC-01A	EBC25A41-BECB-4395-AE33-483A304B07D8	Primary Tumor	Illumina HiSeq	e6c7f95a-f103-4fbc-a123-91eefcfbf4c2	Uterus	62.0	06BE0E15-E48E-4243-AD8D-86CCA9DA68F9	C8E60958-98D8-4EE6-BAA1-DEEEECFF141F	TCGA-EY-A1GC-01A-11D-A13I-02	HG19_Broad_variant	TCGA-EY-A1GC	TCGA-UCEC		s4620	Harvard Medical School	University of North Carolina	United States	NO			Endometrioid endometrial adenocarcinoma		A13I-02	False
S13722.58cfa832e4b0c9d6adf6ceac	58cfa832e4b0c9d6adf6ceac	TCGA-FD-A3NA-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FD-A3NA-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_1_rg.sorted	TCGA-FD-A3NA-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_1_rg.sorted.bam	63.16		0.16	58cfa832e4b0c9d6adf6ceac	TCGA-FD-A3NA-01A-11D-A21C_120830_SN590_0177_BD141PACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3NA-01A	14917461-DAE4-44CB-909D-42AC45AEF450	Primary Tumor	Illumina HiSeq	8c4c1672-fea7-4c17-a6d0-d4a0f3c04558	Bladder	60.0	7BD000AB-6F48-4A9E-98A4-EAF47D6E3C05	37789FCA-0C64-49B7-A704-572A19BD2645	TCGA-FD-A3NA-01A-11D-A21C-26	HG19_Broad_variant	TCGA-FD-A3NA	TCGA-BLCA		s3114	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A21C-26	True
S13722.58cfa832e4b0c9d6adf6cf46	58cfa832e4b0c9d6adf6cf46	TCGA-G9-6371-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G9-6371-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_7_rg.sorted	TCGA-G9-6371-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_7_rg.sorted.bam	59.4	2.0	0.17	58cfa832e4b0c9d6adf6cf46	TCGA-G9-6371-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6371-01A	D5C43A14-21AB-4178-AE33-2D8B7BAA256F	Primary Tumor	Illumina HiSeq	46c365e2-d78e-45ed-8356-c9ad57629c34	Prostate	58.0	2F91086C-ADCD-4A79-96AA-58819AB28A57	570A6B67-7527-4F71-B37F-5D9102648470	TCGA-G9-6371-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6371	TCGA-PRAD		s3798	Harvard Medical School	Roswell Park	United States	NO	T2c		Prostate Adenocarcinoma Acinar Type		1784-02	True
S13722.58cfa832e4b0c9d6adf6cf7a	58cfa832e4b0c9d6adf6cf7a	TCGA-G9-6499-01A-12D-1957_130412_SN590_0224_BC1YMJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-G9-6499-01A-12D-1957_130412_SN590_0224_BC1YMJACXX_s_2_rg.sorted	TCGA-G9-6499-01A-12D-1957_130412_SN590_0224_BC1YMJACXX_s_2_rg.sorted.bam	62.7	2.0	0.14	58cfa832e4b0c9d6adf6cf7a	TCGA-G9-6499-01A-12D-1957_130412_SN590_0224_BC1YMJACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6499-01A	ACD5CEEF-C5CF-4E95-9394-C50FDBC70C8D	Primary Tumor	Illumina HiSeq	db7d4277-9d52-4996-ab7f-5e6ddc01c234	Prostate	66.0	424FB9D8-F70E-4A36-B895-A766176EEE7C	24062AD0-10DD-4BFB-B805-CA18C57D1FA0	TCGA-G9-6499-01A-12D-1957-02	HG19_Broad_variant	TCGA-G9-6499	TCGA-PRAD		s3459	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1957-02	True
S13722.58cfa832e4b0c9d6adf6cf82	58cfa832e4b0c9d6adf6cf82	TCGA-G9-6348-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G9-6348-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_7_rg.sorted	TCGA-G9-6348-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_7_rg.sorted.bam	59.4	1.9	0.14	58cfa832e4b0c9d6adf6cf82	TCGA-G9-6348-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6348-01A	8AD78C4F-C84C-4F9E-88C9-42A05EB65498	Primary Tumor	Illumina HiSeq	32ce4cfa-ee58-4c85-8e6b-9e7fd9bb6b8e	Prostate	68.0	A692E125-CCFC-4376-9CEA-2410511882BF	68D451D5-F3A1-46C9-BD28-05D71D2C94FC	TCGA-G9-6348-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6348	TCGA-PRAD		s3447	Harvard Medical School	Roswell Park	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True
S13722.58cfa832e4b0c9d6adf6cf7f	58cfa832e4b0c9d6adf6cf7f	TCGA-GD-A3OP-01A-21D-A221_120902_SN1222_0147_AC195DACXX_s_1_rg.sorted.filtered.	WGS	TCGA-GD-A3OP-01A-21D-A221_120902_SN1222_0147_AC195DACXX_s_1_rg.sorted	TCGA-GD-A3OP-01A-21D-A221_120902_SN1222_0147_AC195DACXX_s_1_rg.sorted.bam	15.89		0.17	58cfa832e4b0c9d6adf6cf7f	TCGA-GD-A3OP-01A-21D-A221_120902_SN1222_0147_AC195DACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GD-A3OP-01A	31DA07BB-6752-49A3-A7EA-5427C04A9458	Primary Tumor	Illumina HiSeq	e01f55a8-4fbe-4f9a-8617-ce0e6900f177	Bladder	84.0	C0773229-5A20-4451-9DB5-F757E34921AE	AB6D114E-DF58-4912-85F4-3C385CAA3749	TCGA-GD-A3OP-01A-21D-A221-26	HG19_Broad_variant	TCGA-GD-A3OP	TCGA-BLCA		s3125	MD Anderson - Institute for Applied Cancer Science	ABS - IUPUI	United States	NO	T4a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A221-26	True
S13722.58cfa832e4b0c9d6adf6cfdc	58cfa832e4b0c9d6adf6cfdc	TCGA-HC-7232-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HC-7232-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_4_rg.sorted	TCGA-HC-7232-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_4_rg.sorted.bam	168.3		0.16	58cfa832e4b0c9d6adf6cfdc	TCGA-HC-7232-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7232-01A	CE3585D3-7388-4D05-84C8-64E0883003B3	Primary Tumor	Illumina HiSeq	26e5268d-e95b-44da-ae7c-dfb6fe50a127	Prostate	66.0	0F4B7D00-1C4C-4634-A45E-10F8949ABB43	E847C3F1-CE33-494C-8D95-F82314C95F01	TCGA-HC-7232-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7232	TCGA-PRAD		s4156	Harvard Medical School	International Genomics Consortium	United States	NO	T3b		Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa832e4b0c9d6adf6cfb8	58cfa832e4b0c9d6adf6cfb8	TCGA-GC-A3I6-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-GC-A3I6-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_5_rg.sorted	TCGA-GC-A3I6-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_5_rg.sorted.bam	65.0		0.16	58cfa832e4b0c9d6adf6cfb8	TCGA-GC-A3I6-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GC-A3I6-01A	74CBB078-9AAE-422A-A7AF-DD29EBCA949E	Primary Tumor	Illumina HiSeq	ec0a1f1d-c6e7-4b4a-a296-02087e0b6586	Bladder	45.0	DB9442F6-38F2-4092-9E85-F5EC0C924025	8B23B777-2BF2-422A-8AB3-1DF94EE61690	TCGA-GC-A3I6-01A-11D-A210-26	HG19_Broad_variant	TCGA-GC-A3I6	TCGA-BLCA		s2733	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	True
S13722.58cfa832e4b0c9d6adf6d04e	58cfa832e4b0c9d6adf6d04e	TCGA-G9-6329-01A-13D-1957_130222_SN1222_0174_BC1RNEACXX_s_1_rg.sorted.filtered.	WGS	TCGA-G9-6329-01A-13D-1957_130222_SN1222_0174_BC1RNEACXX_s_1_rg.sorted	TCGA-G9-6329-01A-13D-1957_130222_SN1222_0174_BC1RNEACXX_s_1_rg.sorted.bam	41.7	1.9	0.15	58cfa832e4b0c9d6adf6d04e	TCGA-G9-6329-01A-13D-1957_130222_SN1222_0174_BC1RNEACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6329-01A	A08FD0A6-A89A-4ADB-B641-D4C1238ABB71	Primary Tumor	Illumina HiSeq	1971b9d7-8a67-4447-835d-23525622c037	Prostate	67.0	E004F38D-C874-4E03-830B-4E554EF3E274	46BEFA09-3AF0-415C-994E-330B07586058	TCGA-G9-6329-01A-13D-1957-02	HG19_Broad_variant	TCGA-G9-6329	TCGA-PRAD		s3796	Harvard Medical School	Roswell Park	United States	NO	T2c		Prostate Adenocarcinoma Acinar Type		1957-02	True
S13722.58cfa832e4b0c9d6adf6d044	58cfa832e4b0c9d6adf6d044	TCGA-GD-A2C5-01A-12D-A17R_120927_SN208_0432_AC188LACXX_s_6_rg.sorted.filtered.	WGS	TCGA-GD-A2C5-01A-12D-A17R_120927_SN208_0432_AC188LACXX_s_6_rg.sorted	TCGA-GD-A2C5-01A-12D-A17R_120927_SN208_0432_AC188LACXX_s_6_rg.sorted.bam	40.79		0.16	58cfa832e4b0c9d6adf6d044	TCGA-GD-A2C5-01A-12D-A17R_120927_SN208_0432_AC188LACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GD-A2C5-01A	5D54C742-5A8E-4C40-8D62-95E75E210AB8	Primary Tumor	Illumina HiSeq	27e88ee3-dcb4-43c4-9653-c55aa1851cb1	Bladder	53.0	2CD62676-762C-461D-B111-1F81E7CD5877	EEB315EA-D1B6-4F92-91B0-9AAAC7083D68	TCGA-GD-A2C5-01A-12D-A17R-02	HG19_Broad_variant	TCGA-GD-A2C5	TCGA-BLCA		s2920	Harvard Medical School	ABS - IUPUI	United States	NO	T3a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A17R-02	True
S13722.58cfa832e4b0c9d6adf6d188	58cfa832e4b0c9d6adf6d188	TCGA-HC-7233-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HC-7233-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_6_rg.sorted	TCGA-HC-7233-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_6_rg.sorted.bam	207.3		0.14	58cfa832e4b0c9d6adf6d188	TCGA-HC-7233-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE		Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7233-01A	E2B33861-2247-413F-B2E5-9BE3B604666C	Primary Tumor	Illumina HiSeq	b16d1760-889f-44f7-a1c1-1dfa3f31efc3	Prostate	73.0	848C2C7B-918E-4A09-BAD9-3B3D59BBC101	8262CCFE-6E66-412E-A8C8-E4FA91979764	TCGA-HC-7233-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7233	TCGA-PRAD		s3813	Harvard Medical School	International Genomics Consortium	Yemen	NO	T2a	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa832e4b0c9d6adf6d10e	58cfa832e4b0c9d6adf6d10e	TCGA-HW-7489-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_2_rg.sorted.filtered.	WGS	TCGA-HW-7489-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_2_rg.sorted	TCGA-HW-7489-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_2_rg.sorted.bam	56.0		0.14	58cfa832e4b0c9d6adf6d10e	TCGA-HW-7489-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HW-7489-01A	6957D45E-7CCB-457D-800D-C2A2037F4F01	Primary Tumor	Illumina HiSeq	e81e0ec5-b546-421b-a1ee-5adf17fd07c0	Brain	38.0	B4E032D1-B12E-4DC0-8978-899760F0A245	BBCC5F2C-08F5-424D-8A66-099084F3C47E	TCGA-HW-7489-01A-11D-2022-02	HG19_Broad_variant	TCGA-HW-7489	TCGA-LGG		s8578	Harvard Medical School	MSKCC	United States	NO			Oligoastrocytoma		2022-02	True
S13722.58cfa832e4b0c9d6adf6d0d4	58cfa832e4b0c9d6adf6d0d4	TCGA-FY-A3I5-01B-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FY-A3I5-01B-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_1_rg.sorted	TCGA-FY-A3I5-01B-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_1_rg.sorted.bam	41.37		0.14	58cfa832e4b0c9d6adf6d0d4	TCGA-FY-A3I5-01B-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A3I5-01B	52203FF5-57B2-4D56-8935-2FF1EB61D7B8	Primary Tumor	Illumina HiSeq	ed0cff3d-a985-40a9-b0df-ec57b3bcdd50	Thyroid	64.0	7AEC7C70-6A5A-48D5-A863-A8DB40D93097	C32A9B9D-B381-4492-9BBC-8F25B09D18C1	TCGA-FY-A3I5-01B-11D-A221-26	HG19_Broad_variant	TCGA-FY-A3I5	TCGA-THCA		s12119	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage III	A221-26	True
S13722.58cfa832e4b0c9d6adf6d194	58cfa832e4b0c9d6adf6d194	TCGA-G9-6377-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_8_rg.sorted.filtered.	WGS	TCGA-G9-6377-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_8_rg.sorted	TCGA-G9-6377-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_8_rg.sorted.bam	95.7	1.9	0.15	58cfa832e4b0c9d6adf6d194	TCGA-G9-6377-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6377-01A	007F9081-5093-4323-B4F8-CD510BF20705	Primary Tumor	Illumina HiSeq	126d92ca-d172-491d-9366-11555d88901b	Prostate	61.0	8F105D0D-0630-46FC-8168-DCBA11A5197F	811D74B4-6F98-4B1F-9ADD-CB949E4B5B20	TCGA-G9-6377-01A-11D-1957-02	HG19_Broad_variant	TCGA-G9-6377	TCGA-PRAD		s3977	Harvard Medical School	Roswell Park	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1957-02	True
S13722.58cfa832e4b0c9d6adf6d1a4	58cfa832e4b0c9d6adf6d1a4	TCGA-IG-A50L-01A-11D-A267_131120_SN1222_0230_BC29YPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-IG-A50L-01A-11D-A267_131120_SN1222_0230_BC29YPACXX_s_1_rg.sorted	TCGA-IG-A50L-01A-11D-A267_131120_SN1222_0230_BC29YPACXX_s_1_rg.sorted.bam	22.45		0.17	58cfa832e4b0c9d6adf6d1a4	TCGA-IG-A50L-01A-11D-A267_131120_SN1222_0230_BC29YPACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A50L-01A	9E54A27F-D0FA-4A5B-91BC-13E27FED2A3D	Primary Tumor	Illumina HiSeq	3e7102a5-f6cf-4918-83d4-8bc4a36d6eda	Esophagus	58.0	5B30B4D1-4FC6-4712-92B4-E3BE5131551E	62296F7F-6BE0-41E3-A2AA-27B3D1ACE0C7	TCGA-IG-A50L-01A-11D-A267-26	HG19_Broad_variant	TCGA-IG-A50L	TCGA-ESCA		s1815	MD Anderson - Institute for Applied Cancer Science	Asterand	Vietnam	NO	T3	N1		Stage IIIA	A267-26	True
S13722.58cfa832e4b0c9d6adf6d1dc	58cfa832e4b0c9d6adf6d1dc	TCGA-HT-7473-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HT-7473-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_4_rg.sorted	TCGA-HT-7473-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_4_rg.sorted.bam	122.7		0.15	58cfa832e4b0c9d6adf6d1dc	TCGA-HT-7473-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7473-01A	DBFACCB0-E8C0-48E8-9AEF-570267574822	Primary Tumor	Illumina HiSeq	0c3613f1-9a5e-42d1-a1a9-884cf56894f4	Brain	28.0	D302390B-4B66-48E6-92DE-612504B34FA3	A664FDA7-9BF1-4016-A16A-BCA75C6D139C	TCGA-HT-7473-01A-11D-2022-02	HG19_Broad_variant	TCGA-HT-7473	TCGA-LGG		s8154	Harvard Medical School	Case Western - St Joes	United States	NO			Oligoastrocytoma		2022-02	True
S13722.58cfa832e4b0c9d6adf6d1b5	58cfa832e4b0c9d6adf6d1b5	TCGA-HI-7170-01A-11D-2111_130607_SN590_0232_BD26R5ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HI-7170-01A-11D-2111_130607_SN590_0232_BD26R5ACXX_s_5_rg.sorted	TCGA-HI-7170-01A-11D-2111_130607_SN590_0232_BD26R5ACXX_s_5_rg.sorted.bam	96.3		0.15	58cfa832e4b0c9d6adf6d1b5	TCGA-HI-7170-01A-11D-2111_130607_SN590_0232_BD26R5ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HI-7170-01A	6394E00A-1F6F-4EA2-B885-373BBB59DEF9	Primary Tumor	Illumina HiSeq	4eefa9f0-575b-4039-912a-7c0e58f4e508	Prostate	58.0	70BF0C3E-0C06-4168-996C-46783752FA37	1C5E0781-5295-427A-B94A-062B2708B62C	TCGA-HI-7170-01A-11D-2111-02	HG19_Broad_variant	TCGA-HI-7170	TCGA-PRAD		s3629	Harvard Medical School	Fox Chase	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa832e4b0c9d6adf6d288	58cfa832e4b0c9d6adf6d288	TCGA-HT-7476-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HT-7476-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_6_rg.sorted	TCGA-HT-7476-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_6_rg.sorted.bam	31.7		0.15	58cfa832e4b0c9d6adf6d288	TCGA-HT-7476-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7476-01A	27D0D3CB-16C0-4BA8-9662-95917F665004	Primary Tumor	Illumina HiSeq	8eda6747-01ab-4378-b3c9-6f638de37412	Brain	26.0	50823838-03B8-4CD8-A40D-8439011C9B38	06ABBC57-F759-43B4-AD0A-3CEE74E012B5	TCGA-HT-7476-01A-11D-2022-02	HG19_Broad_variant	TCGA-HT-7476	TCGA-LGG		s8370	Harvard Medical School	Case Western - St Joes	United States	NO			Astrocytoma		2022-02	True
S13722.58cfa832e4b0c9d6adf6d578	58cfa832e4b0c9d6adf6d578	TCGA-V4-A9EM-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_2_rg.sorted.filtered.	WGS	TCGA-V4-A9EM-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_2_rg.sorted	TCGA-V4-A9EM-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_2_rg.sorted.bam	31.67		0.15	58cfa832e4b0c9d6adf6d578	TCGA-V4-A9EM-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EM-01A	711EB720-4CB7-48DE-9350-5C729BF9F0DA	Primary Tumor	Illumina HiSeq	f3dd06ee-2d71-4310-b226-e94b83da83f7	Eye	53.0	79658DC3-F2B6-4C5E-9BF7-2C0E440BA3BF	2A1955C2-F55D-48EF-A013-AA69288C3A0C	TCGA-V4-A9EM-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EM	TCGA-UVM		s233	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d57a	58cfa832e4b0c9d6adf6d57a	TCGA-LN-A4MQ-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_4_rg.sorted.filtered.	WGS	TCGA-LN-A4MQ-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_4_rg.sorted	TCGA-LN-A4MQ-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_4_rg.sorted.bam	35.61		0.16	58cfa832e4b0c9d6adf6d57a	TCGA-LN-A4MQ-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_4_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A4MQ-01A	33C0199A-BE0C-46D1-BB1E-889BFAEDF20B	Primary Tumor	Illumina HiSeq	beb51eaa-d60f-4bae-a401-293cb0ff9121	Esophagus	46.0	23CF07BE-97E6-4F55-A8F2-FF03CDBBA74E	4B6D7228-2E11-44F6-A1F4-DABF2085BB05	TCGA-LN-A4MQ-01A-11D-A28P-26	HG19_Broad_variant	TCGA-LN-A4MQ	TCGA-ESCA		s1868	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N1		Stage III	A28P-26	True
S13722.58cfa832e4b0c9d6adf6d5b4	58cfa832e4b0c9d6adf6d5b4	TCGA-LN-A49P-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-LN-A49P-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_3_rg.sorted	TCGA-LN-A49P-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_3_rg.sorted.bam	26.81		0.16	58cfa832e4b0c9d6adf6d5b4	TCGA-LN-A49P-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49P-01A	B64A5F5A-5913-432E-9D08-0FF67A8C6B64	Primary Tumor	Illumina HiSeq	bc96d005-85da-45f9-924a-a168644b49c0	Esophagus	71.0	4B768A42-B383-40A9-9A6F-511974E9E4C8	044EA190-FCC0-41BE-99F7-274A1DDA540B	TCGA-LN-A49P-01A-11D-A248-26	HG19_Broad_variant	TCGA-LN-A49P	TCGA-ESCA		s1760	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0		Stage IIA	A248-26	True
S13722.58cfa82fe4b0c9d6adf6b701	58cfa82fe4b0c9d6adf6b701	TCGA-44-6775-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_4_rg.sorted.filtered.	WGS	TCGA-44-6775-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_4_rg.sorted	TCGA-44-6775-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_4_rg.sorted.bam	237.3	1.9	0.16	58cfa82fe4b0c9d6adf6b701	TCGA-44-6775-01A-11D-1853_111207_SN590_0112_D09CDACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6775-01A	3C4FF061-D214-4D1C-8D2E-3034F207C252	Primary Tumor	Illumina HiSeq	c17b3c9b-e41f-48e2-9cde-facc8537afbc	Lung	72.0	7C606F64-69A1-465C-9F4E-2EB1EBEDA5D7	8B286297-0077-44ED-9093-6F13E2CA4EBA	TCGA-44-6775-01A-11D-1853-02	HG19_Broad_variant	TCGA-44-6775	TCGA-LUAD		s11454	Harvard Medical School	Christiana Healthcare	United States	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	True
S13722.58cfa82fe4b0c9d6adf6b8de	58cfa82fe4b0c9d6adf6b8de	TCGA-A7-A0D9-01A-31D-A060_130807_SN590_0235_AC29RAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-A7-A0D9-01A-31D-A060_130807_SN590_0235_AC29RAACXX_s_5_rg.sorted	TCGA-A7-A0D9-01A-31D-A060_130807_SN590_0235_AC29RAACXX_s_5_rg.sorted.bam	59.5	2.02	0.17	58cfa82fe4b0c9d6adf6b8de	TCGA-A7-A0D9-01A-31D-A060_130807_SN590_0235_AC29RAACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A7-A0D9-01A	17BAEF7C-D97D-4B98-AB53-503EF856523D	Primary Tumor	Illumina HiSeq	43dc32db-2202-486d-82f4-388e37224379	Breast	37.0	C144AE50-ED29-4E27-BBEE-FA81E79AC7DB	7CD9AC40-F6B5-4C68-9D9A-D57845B812DB	TCGA-A7-A0D9-01A-31D-A060-02	HG19_Broad_variant	TCGA-A7-A0D9	TCGA-BRCA		s5638	Harvard Medical School	Christiana Healthcare		NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	True
S13722.58cfa82fe4b0c9d6adf6b8d4	58cfa82fe4b0c9d6adf6b8d4	TCGA-50-5049-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-5049-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_3_rg.sorted	TCGA-50-5049-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_3_rg.sorted.bam	743.7	1.9	0.16	58cfa82fe4b0c9d6adf6b8d4	TCGA-50-5049-01A-01D-1623_120205_SN590_0136_BD0LRYACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5049-01A	9944F46F-9FA8-4E2C-A806-776BEC7F8803	Primary Tumor	Illumina HiSeq	16ea05eb-f830-4b36-83bb-989c8de99568	Lung	70.0	21B2F32E-CCEA-4B20-86D3-6647E99825CF	26ED24EC-1AD1-492D-B2CB-46314B47919E	TCGA-50-5049-01A-01D-1623-02	HG19_Broad_variant	TCGA-50-5049	TCGA-LUAD		s11457	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1623-02	True
S13722.58cfa82fe4b0c9d6adf6b896	58cfa82fe4b0c9d6adf6b896	TCGA-49-6742-01A-11D-1853_111218_SN208_0258_C054RACXX_s_1_rg.sorted.filtered.	WGS	TCGA-49-6742-01A-11D-1853_111218_SN208_0258_C054RACXX_s_1_rg.sorted	TCGA-49-6742-01A-11D-1853_111218_SN208_0258_C054RACXX_s_1_rg.sorted.bam	39.7	2.0	0.13	58cfa82fe4b0c9d6adf6b896	TCGA-49-6742-01A-11D-1853_111218_SN208_0258_C054RACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-49-6742-01A	21FB46F9-4BBB-441C-AF19-A687E9138344	Primary Tumor	Illumina HiSeq	eeeb9a6f-97a9-4db9-aeb9-c5afaf9d0153	Lung	70.0	F0A4AE58-D5BC-4AB0-B1CF-0D951EA91FC7	04467FAB-BB2F-4F26-AF9E-39C09D920A63	TCGA-49-6742-01A-11D-1853-02	HG19_Broad_variant	TCGA-49-6742	TCGA-LUAD		s10655	Harvard Medical School	Johns Hopkins	United States	NO	T2a	N1	Mucinous (Colloid) Carcinoma	Stage IIA	1853-02	True
S13722.58cfa82fe4b0c9d6adf6b697	58cfa82fe4b0c9d6adf6b697	TCGA-44-5643-01A-01D-1623_120228_SN1120_0116_AD0KRVACXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-5643-01A-01D-1623_120228_SN1120_0116_AD0KRVACXX_s_7_rg.sorted	TCGA-44-5643-01A-01D-1623_120228_SN1120_0116_AD0KRVACXX_s_7_rg.sorted.bam	672.7	1.9	0.15	58cfa82fe4b0c9d6adf6b697	TCGA-44-5643-01A-01D-1623_120228_SN1120_0116_AD0KRVACXX_s_7_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-5643-01A	27FCEEC1-3298-4CDD-A4E6-8F5CF34604F0	Primary Tumor	Illumina HiSeq	d7fc0a17-7a0f-4345-904e-dd40d39ebbc3	Lung	53.0	ED5B47C1-569F-492B-8D6C-155E3BA79ACB	98EAE374-5F58-4544-BB02-BF605A09AD15	TCGA-44-5643-01A-01D-1623-02	HG19_Broad_variant	TCGA-44-5643	TCGA-LUAD		s10778	Harvard Medical School	Christiana Healthcare	United States	NO	T2b	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1623-02	True
S13722.58cfa82fe4b0c9d6adf6b942	58cfa82fe4b0c9d6adf6b942	TCGA-A5-A0GN-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0GN-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_3_rg.sorted	TCGA-A5-A0GN-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_3_rg.sorted.bam	65.96	1.81	0.16	58cfa82fe4b0c9d6adf6b942	TCGA-A5-A0GN-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GN-01A	A2A2DBDA-D10C-49C4-86A8-61BAF6160CDA	Primary Tumor	Illumina HiSeq	7270b44f-635f-48bf-b3c4-8042b4557613	Uterus	65.0	F6F9C40B-1E58-47A3-B518-9694FB5FF2CF	41896FDE-677E-419C-B8B9-0171D6669A4A	TCGA-A5-A0GN-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GN	TCGA-UCEC		s4589	Harvard Medical School	Cedars Sinai		NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa82fe4b0c9d6adf6ba08	58cfa82fe4b0c9d6adf6ba08	TCGA-A5-A0G2-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_1_rg.sorted.filtered.	WGS	TCGA-A5-A0G2-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_1_rg.sorted	TCGA-A5-A0G2-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_1_rg.sorted.bam	104.46	2.03	0.15	58cfa82fe4b0c9d6adf6ba08	TCGA-A5-A0G2-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0G2-01A	4ABBD258-0F0C-4428-901D-625D47AD363A	Primary Tumor	Illumina HiSeq	f5289cfe-4208-4623-896c-ec78fb5f7dc5	Uterus	57.0	771811E3-740E-42FE-BE9C-FD485997EAAE	579C21E4-83BD-4DAE-B030-53E0930DEACA	TCGA-A5-A0G2-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0G2	TCGA-UCEC		s4773	Harvard Medical School	Cedars Sinai		NO			Serous endometrial adenocarcinoma		A043-02	True
S13722.58cfa82fe4b0c9d6adf6ba48	58cfa82fe4b0c9d6adf6ba48	TCGA-A5-A0G5-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0G5-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_3_rg.sorted	TCGA-A5-A0G5-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_3_rg.sorted.bam	83.98	2.0	0.17	58cfa82fe4b0c9d6adf6ba48	TCGA-A5-A0G5-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_3_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0G5-01A	4806D9A6-E65D-4A82-B422-1B287980A0C6	Primary Tumor	Illumina HiSeq	db20abab-2eed-4958-a741-e31199adb617	Uterus	73.0	FA7392E8-335E-4465-9272-4A19DC99412E	EDFD99A3-38A2-4E43-A3D1-B1D19EA818E5	TCGA-A5-A0G5-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0G5	TCGA-UCEC		s5382	Harvard Medical School	Cedars Sinai		NO			Serous endometrial adenocarcinoma		A043-02	True
S13722.58cfa830e4b0c9d6adf6bbbc	58cfa830e4b0c9d6adf6bbbc	TCGA-A2-A0EU-01A-22D-A060_130807_SN590_0235_AC29RAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-A2-A0EU-01A-22D-A060_130807_SN590_0235_AC29RAACXX_s_1_rg.sorted	TCGA-A2-A0EU-01A-22D-A060_130807_SN590_0235_AC29RAACXX_s_1_rg.sorted.bam	40.68	1.8	0.14	58cfa830e4b0c9d6adf6bbbc	TCGA-A2-A0EU-01A-22D-A060_130807_SN590_0235_AC29RAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A0EU-01A	C0427237-B476-4AF4-B664-7BD479922EA5	Primary Tumor	Illumina HiSeq	f8f8a691-8930-46b3-9cd7-1b8ac6895baf	Breast	79.0	69DBB2AE-3F19-4C29-9C24-810AE60312F3	7F0FA628-7A18-4E52-81CC-3E213C431D3E	TCGA-A2-A0EU-01A-22D-A060-02	HG19_Broad_variant	TCGA-A2-A0EU	TCGA-BRCA		s5489	Harvard Medical School	Walter Reed		NO	T1c	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IA	A060-02	True
S13722.58cfa830e4b0c9d6adf6bc7a	58cfa830e4b0c9d6adf6bc7a	TCGA-AO-A0JL-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AO-A0JL-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_1_rg.sorted	TCGA-AO-A0JL-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_1_rg.sorted.bam	48.13	1.89	0.13	58cfa830e4b0c9d6adf6bc7a	TCGA-AO-A0JL-01A-11D-A060_130725_SN590_0234_BC29HAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A0JL-01A	D5D8E76E-2F2A-49BC-BA0A-D51283611B16	Primary Tumor	Illumina HiSeq	b39a31b9-dd85-403d-ac11-d7b6dd2703a6	Breast	59.0	834D2E25-DA72-413B-BB0E-3BEB24D46472	A34C3F47-AD37-4777-A733-07AE8F4B4BFF	TCGA-AO-A0JL-01A-11D-A060-02	HG19_Broad_variant	TCGA-AO-A0JL	TCGA-BRCA		s5639	Harvard Medical School	MSKCC		NO	T2	N2a	Infiltrating Ductal Carcinoma	Stage IIIA	A060-02	True
S13722.58cfa830e4b0c9d6adf6bd78	58cfa830e4b0c9d6adf6bd78	TCGA-AO-A0JJ-01A-11D-A060_130725_SN590_0233_AD2B3HACXX_s_3_rg.sorted.filtered.	WGS	TCGA-AO-A0JJ-01A-11D-A060_130725_SN590_0233_AD2B3HACXX_s_3_rg.sorted	TCGA-AO-A0JJ-01A-11D-A060_130725_SN590_0233_AD2B3HACXX_s_3_rg.sorted.bam	29.04	1.87	0.14	58cfa830e4b0c9d6adf6bd78	TCGA-AO-A0JJ-01A-11D-A060_130725_SN590_0233_AD2B3HACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A0JJ-01A	BEF7B135-A727-45E8-850A-CC4CD56C49AA	Primary Tumor	Illumina HiSeq	6d955c96-b34d-4aea-961b-378e856ae8cb	Breast	54.0	008DAFDD-A3D1-4801-8C0A-8714E2B58E48	ED24B69D-599E-42ED-BBE3-5C4F59FABED4	TCGA-AO-A0JJ-01A-11D-A060-02	HG19_Broad_variant	TCGA-AO-A0JJ	TCGA-BRCA		s6271	Harvard Medical School	MSKCC		NO	T2	N1a	Infiltrating Lobular Carcinoma	Stage IIB	A060-02	True
S13722.58cfa830e4b0c9d6adf6bdcc	58cfa830e4b0c9d6adf6bdcc	TCGA-BH-A0H6-01A-21D-A060_130725_SN590_0233_AD2B3HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BH-A0H6-01A-21D-A060_130725_SN590_0233_AD2B3HACXX_s_1_rg.sorted	TCGA-BH-A0H6-01A-21D-A060_130725_SN590_0233_AD2B3HACXX_s_1_rg.sorted.bam	71.16	2.03	0.15	58cfa830e4b0c9d6adf6bdcc	TCGA-BH-A0H6-01A-21D-A060_130725_SN590_0233_AD2B3HACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0H6-01A	AEB6A3A6-B57A-4C53-90E6-E833777DD2A1	Primary Tumor	Illumina HiSeq	9c69c17b-33de-4bb8-be9f-7e0dcde9db0a	Breast	82.0	B2921C9D-C655-46F3-86E5-2FC2BED1ED33	57D73BC9-950E-42A3-B9FB-6045117112B7	TCGA-BH-A0H6-01A-21D-A060-02	HG19_Broad_variant	TCGA-BH-A0H6	TCGA-BRCA		s5963	Harvard Medical School	University of Pittsburgh		NO	T1b	NX	Infiltrating Ductal Carcinoma	Stage I	A060-02	True
S13722.58cfa830e4b0c9d6adf6ba9b	58cfa830e4b0c9d6adf6ba9b	TCGA-A5-A0GJ-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-A5-A0GJ-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_7_rg.sorted	TCGA-A5-A0GJ-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_7_rg.sorted.bam	92.8	2.11	0.16	58cfa830e4b0c9d6adf6ba9b	TCGA-A5-A0GJ-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GJ-01A	94817E78-78F5-4556-9394-610DF65605E2	Primary Tumor	Illumina HiSeq	d5b73d0f-c14a-4a54-a8e1-14bc027cfef5	Uterus	44.0	48FA5B7D-E488-4743-A7CE-ACEB9945F00B	A5D63CC4-892C-4357-B8A1-2BF50CF425DC	TCGA-A5-A0GJ-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GJ	TCGA-UCEC		s5384	Harvard Medical School	Cedars Sinai		NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa830e4b0c9d6adf6be82	58cfa830e4b0c9d6adf6be82	TCGA-BL-A0C8-01A-11D-A10R_120926_SN590_0181_AC19HCACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BL-A0C8-01A-11D-A10R_120926_SN590_0181_AC19HCACXX_s_1_rg.sorted	TCGA-BL-A0C8-01A-11D-A10R_120926_SN590_0181_AC19HCACXX_s_1_rg.sorted.bam	69.7	2.0	0.17	58cfa830e4b0c9d6adf6be82	TCGA-BL-A0C8-01A-11D-A10R_120926_SN590_0181_AC19HCACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BL-A0C8-01A	A6003B1C-56A9-430A-A5E2-B70AF3F81BDB	Primary Tumor	Illumina HiSeq	19df03d2-75d2-408e-86e2-482ddeed9736	Bladder	73.0	5FEED572-07C0-4DA0-8649-CA8F8682657A	AB020F79-BA66-457C-9D77-DDD87C799538	TCGA-BL-A0C8-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BL-A0C8	TCGA-BLCA		s2690	Harvard Medical School	Christiana Healthcare	United States	NO	T1	NX		Stage I	A10R-02	True
S13722.58cfa830e4b0c9d6adf6c02c	58cfa830e4b0c9d6adf6c02c	TCGA-BJ-A0ZC-01A-12D-A13U_120706_SN1222_0123_BD1488ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZC-01A-12D-A13U_120706_SN1222_0123_BD1488ACXX_s_1_rg.sorted	TCGA-BJ-A0ZC-01A-12D-A13U_120706_SN1222_0123_BD1488ACXX_s_1_rg.sorted.bam	26.88	1.91	0.16	58cfa830e4b0c9d6adf6c02c	TCGA-BJ-A0ZC-01A-12D-A13U_120706_SN1222_0123_BD1488ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZC-01A	6675C581-297D-44CD-B80F-AE7E53D48228	Primary Tumor	Illumina HiSeq	a470b305-96a5-43a8-b1f4-db15c7b0b4d5	Thyroid	55.0	1F945AFF-7BC2-40F5-87DB-92313E541243	0E4A0528-883D-47A5-B399-57B1B15EC412	TCGA-BJ-A0ZC-01A-12D-A13U-02	HG19_Broad_variant	TCGA-BJ-A0ZC	TCGA-THCA		s12232	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	True
S13722.58cfa830e4b0c9d6adf6c120	58cfa830e4b0c9d6adf6c120	TCGA-BJ-A0ZG-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZG-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_5_rg.sorted	TCGA-BJ-A0ZG-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_5_rg.sorted.bam	37.3	1.98	0.16	58cfa830e4b0c9d6adf6c120	TCGA-BJ-A0ZG-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZG-01A	A3810F36-D2B4-4A45-AD08-A4DBFB9D27AA	Primary Tumor	Illumina HiSeq	44c5a52a-3434-4e05-a510-33799f327c93	Thyroid	80.0	3AC025C9-FEC6-4997-8630-085750DC84E0	D030DC18-6E50-4679-8BF9-26A1DAEC8F79	TCGA-BJ-A0ZG-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZG	TCGA-THCA		s12101	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A10R-02	True
S13722.58cfa830e4b0c9d6adf6c298	58cfa830e4b0c9d6adf6c298	TCGA-BH-A0GY-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BH-A0GY-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_7_rg.sorted	TCGA-BH-A0GY-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_7_rg.sorted.bam	48.65	2.08	0.16	58cfa830e4b0c9d6adf6c298	TCGA-BH-A0GY-01A-11D-A060_130807_SN590_0235_AC29RAACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0GY-01A	7D9D3522-EC3B-4EFE-8C8E-C0E675276EF5	Primary Tumor	Illumina HiSeq	bcac7e1b-ddeb-43d6-ba44-db40336bf564	Breast	67.0	A7E71EAC-1768-4FC2-8EBA-1576D22E0F43	F5C72179-9BDA-4BC6-B006-93EB616804BC	TCGA-BH-A0GY-01A-11D-A060-02	HG19_Broad_variant	TCGA-BH-A0GY	TCGA-BRCA		s6771	Harvard Medical School	University of Pittsburgh		NO	T2	N1	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	True
S13722.58cfa830e4b0c9d6adf6c12e	58cfa830e4b0c9d6adf6c12e	TCGA-BS-A0UM-01A-11D-A101_120622_SN1120_0155_AC0WVLACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BS-A0UM-01A-11D-A101_120622_SN1120_0155_AC0WVLACXX_s_1_rg.sorted	TCGA-BS-A0UM-01A-11D-A101_120622_SN1120_0155_AC0WVLACXX_s_1_rg.sorted.bam	107.99	2.0	0.17	58cfa830e4b0c9d6adf6c12e	TCGA-BS-A0UM-01A-11D-A101_120622_SN1120_0155_AC0WVLACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UM-01A	A7C565FC-C711-4B63-9549-4CD74D1F57C2	Primary Tumor	Illumina HiSeq	942f9e1e-4e57-4325-a7d0-0a464cda140a	Uterus	64.0	6F70F18E-5C53-4F1F-A63D-62BD27039B8D	6CD1B997-3123-4934-A06C-14A5CF1BEBFC	TCGA-BS-A0UM-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0UM	TCGA-UCEC		s5009	Harvard Medical School	University of Hawaii		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa831e4b0c9d6adf6c39e	58cfa831e4b0c9d6adf6c39e	TCGA-C5-A2M1-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_6_rg.sorted.filtered.	WGS	TCGA-C5-A2M1-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_6_rg.sorted	TCGA-C5-A2M1-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_6_rg.sorted.bam	54.44		0.16	58cfa831e4b0c9d6adf6c39e	TCGA-C5-A2M1-01A-11D-A18I_140206_SN1222_0239_BC2RAKACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A2M1-01A	8911C80C-C903-48E4-AF5B-FFEDEF9ABC47	Primary Tumor	Illumina HiSeq	374c6310-126e-48e8-8b83-145f75714a4b	Cervix	37.0	065BB06F-5BB7-4F79-B374-97A3011F22AE	E2DAD681-2B26-43A0-804B-0F2DD17B1EFE	TCGA-C5-A2M1-01A-11D-A18I-02	HG19_Broad_variant	TCGA-C5-A2M1	TCGA-CESC		s1518	Harvard Medical School	Medical College of Wisconsin	United States	NO	T1b1	N0	Endocervical Type of Adenocarcinoma		A18I-02	True
S13722.58cfa831e4b0c9d6adf6c3ec	58cfa831e4b0c9d6adf6c3ec	TCGA-CH-5748-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5748-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_3_rg.sorted	TCGA-CH-5748-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_3_rg.sorted.bam	196.7	1.9	0.14	58cfa831e4b0c9d6adf6c3ec	TCGA-CH-5748-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5748-01A	0AF98331-9305-41E9-AF55-30390016D65E	Primary Tumor	Illumina HiSeq	02aa8440-93b8-43d7-a58b-6c4421e05321	Prostate	64.0	A499BF51-B137-4DA9-87A3-D1B1A0F04695	24A0496A-CA69-4AE3-BF8A-92289C738E9F	TCGA-CH-5748-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5748	TCGA-PRAD		s3413	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c3dd	58cfa831e4b0c9d6adf6c3dd	TCGA-CH-5744-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5744-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_5_rg.sorted	TCGA-CH-5744-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_5_rg.sorted.bam	249.7	1.9	0.15	58cfa831e4b0c9d6adf6c3dd	TCGA-CH-5744-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5744-01A	4E76DE8E-CB0D-4B83-8AB4-53BC67A7A9D3	Primary Tumor	Illumina HiSeq	b48809ce-93ac-45d2-b127-bf6ee8bd6870	Prostate	64.0	DCCEAF54-0BCE-4650-9980-9843ABCE0C41	B3198EFA-5613-4B16-BA05-4F0AACCCC00F	TCGA-CH-5744-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5744	TCGA-PRAD		s3771	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c3fe	58cfa831e4b0c9d6adf6c3fe	TCGA-CH-5792-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5792-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_3_rg.sorted	TCGA-CH-5792-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_3_rg.sorted.bam	61.7	1.9	0.17	58cfa831e4b0c9d6adf6c3fe	TCGA-CH-5792-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5792-01A	8A5F2D7F-835C-4726-B238-F82D6A7F25BD	Primary Tumor	Illumina HiSeq	1c4a46f6-fc5f-44b1-b30a-5baaa806e78b	Prostate	57.0	DA5F8107-7B69-45B5-8BEB-21D17B066CB4	5975F57F-2918-46C2-B59F-38FAA67A49BA	TCGA-CH-5792-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5792	TCGA-PRAD		s3933	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c440	58cfa831e4b0c9d6adf6c440	TCGA-CH-5789-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5789-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_5_rg.sorted	TCGA-CH-5789-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_5_rg.sorted.bam	148.7	1.9	0.15	58cfa831e4b0c9d6adf6c440	TCGA-CH-5789-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5789-01A	BE5411DC-3CAA-4B25-9B94-CE463E8E52B4	Primary Tumor	Illumina HiSeq	fc8da645-2fde-4ef8-9ee7-8b8101580793	Prostate	61.0	3C42EB4B-DB63-4F81-8D28-A439E932C716	1D569000-EA8E-4D54-A581-AEE36E66688E	TCGA-CH-5789-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5789	TCGA-PRAD		s3779	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c467	58cfa831e4b0c9d6adf6c467	TCGA-CH-5751-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5751-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_7_rg.sorted	TCGA-CH-5751-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_7_rg.sorted.bam	226.7	1.9	0.15	58cfa831e4b0c9d6adf6c467	TCGA-CH-5751-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5751-01A	721E76D0-4B1D-4E78-ADB8-1344B8030062	Primary Tumor	Illumina HiSeq	c152f07f-eb7f-464d-ba51-ce1b55777952	Prostate	68.0	6D8CE214-3A06-4F7C-858B-709A40EBBE25	FC06702A-2C27-42FD-A925-D0DB20C358E7	TCGA-CH-5751-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5751	TCGA-PRAD		s3425	Harvard Medical School	Indivumed	Germany	NO	T4	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c446	58cfa831e4b0c9d6adf6c446	TCGA-CH-5750-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5750-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_5_rg.sorted	TCGA-CH-5750-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_5_rg.sorted.bam	300.7	1.9	0.16	58cfa831e4b0c9d6adf6c446	TCGA-CH-5750-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5750-01A	DC40CF49-B208-4F59-B5F0-CFBDD02970B2	Primary Tumor	Illumina HiSeq	d0338227-feec-4f2e-bcfa-89c723bb89b5	Prostate	72.0	0386D0E9-7BD8-467F-BA97-A379C1D67A83	E1FEA0C9-E1D6-49C2-9DFF-9DC87F7776E9	TCGA-CH-5750-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5750	TCGA-PRAD		s3591	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c558	58cfa831e4b0c9d6adf6c558	TCGA-CN-4733-01A-02D-1868_120427_SN208_0287_AC0J25ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-4733-01A-02D-1868_120427_SN208_0287_AC0J25ACXX_s_5_rg.sorted	TCGA-CN-4733-01A-02D-1868_120427_SN208_0287_AC0J25ACXX_s_5_rg.sorted.bam	7.7	1.9	0.14	58cfa831e4b0c9d6adf6c558	TCGA-CN-4733-01A-02D-1868_120427_SN208_0287_AC0J25ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4733-01A	DEDD71B4-8537-4947-839E-90ACEDDD0893	Primary Tumor	Illumina HiSeq	c1887d1c-970a-4e8d-80df-a16844daef9f	Head and Neck	61.0	A1FD1C9D-C763-488A-8649-FF069F56D2BE	1CB41C9B-FB04-438D-A9FB-89D6186E0D37	TCGA-CN-4733-01A-02D-1868-02	HG19_Broad_variant	TCGA-CN-4733	TCGA-HNSC		s15880	Harvard Medical School	University of Pittsburgh		NO	T1	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1868-02	True
S13722.58cfa831e4b0c9d6adf6c720	58cfa831e4b0c9d6adf6c720	TCGA-D7-6527-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D7-6527-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_3_rg.sorted	TCGA-D7-6527-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_3_rg.sorted.bam	84.4	1.9	0.13	58cfa831e4b0c9d6adf6c720	TCGA-D7-6527-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6527-01A	CB622CD6-776D-4681-8A67-4ADDD61C66B8	Primary Tumor	Illumina HiSeq	d1534b7a-a5b2-4083-9736-d1ad62a97ad2	Stomach	62.0	8461CE68-3A6F-4343-8977-78448123F373	F91DFFCE-5185-4555-92EA-919E94EB9569	TCGA-D7-6527-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6527	TCGA-STAD		s14496	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N1	Stomach Intestinal Adenocarcinoma Papillary Type	Stage II	1798-02	True
S13722.58cfa831e4b0c9d6adf6c6a2	58cfa831e4b0c9d6adf6c6a2	TCGA-CQ-6223-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CQ-6223-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_3_rg.sorted	TCGA-CQ-6223-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_3_rg.sorted.bam	325.7	1.9	0.15	58cfa831e4b0c9d6adf6c6a2	TCGA-CQ-6223-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6223-01A	D9E8C707-E61A-4813-8DC0-2472E9CCF12B	Primary Tumor	Illumina HiSeq	d12d744d-5a58-4e30-bcb7-b8c033a8255d	Head and Neck	69.0	775DB365-3533-41D9-B635-582292B22700	6CE8A7EC-2730-49E4-81F0-47B03A54EA1A	TCGA-CQ-6223-01A-11D-1911-02	HG19_Broad_variant	TCGA-CQ-6223	TCGA-HNSC		s16038	Harvard Medical School	University Health Network, Toronto	Canada	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1911-02	True
S13722.58cfa831e4b0c9d6adf6c757	58cfa831e4b0c9d6adf6c757	TCGA-CV-7183-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CV-7183-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_7_rg.sorted	TCGA-CV-7183-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_7_rg.sorted.bam	7.43		0.14	58cfa831e4b0c9d6adf6c757	TCGA-CV-7183-01A-11D-2317_120710_SN590_0166_AC0VNFACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7183-01A	DE206681-3E27-4D4F-8669-AEFB12B5B1E3	Primary Tumor	Illumina HiSeq	f449ea84-f7cf-4a26-bc43-707ac56f0038	Head and Neck	53.0	0BFD11FD-B227-41EF-BD54-7BE877BCE5A2	C2030338-EFEF-48CD-B893-BBDB8D85456E	TCGA-CV-7183-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7183	TCGA-HNSC		s15652	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	True
S13722.58cfa831e4b0c9d6adf6c7fb	58cfa831e4b0c9d6adf6c7fb	TCGA-D7-6526-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D7-6526-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_1_rg.sorted	TCGA-D7-6526-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_1_rg.sorted.bam	423.4	1.9	0.15	58cfa831e4b0c9d6adf6c7fb	TCGA-D7-6526-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6526-01A	A28E57E2-9071-4558-856A-162F7A837380	Primary Tumor	Illumina HiSeq	0a9e4a52-46b9-4c50-9dd3-9418ed5569e2	Stomach	67.0	DDCEA84E-3135-445C-BA0D-62F686463797	737041EA-9798-4D2E-9C0B-371F533E058F	TCGA-D7-6526-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6526	TCGA-STAD		s15251	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T3	N2	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIA	1798-02	True
S13722.58cfa831e4b0c9d6adf6c889	58cfa831e4b0c9d6adf6c889	TCGA-D7-6525-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_7_rg.sorted.filtered.	WGS	TCGA-D7-6525-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_7_rg.sorted	TCGA-D7-6525-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_7_rg.sorted.bam	198.4	1.9	0.15	58cfa831e4b0c9d6adf6c889	TCGA-D7-6525-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6525-01A	82F9A197-040D-4C5E-89D9-D87A7AA0168D	Primary Tumor	Illumina HiSeq	03097d75-d0ad-4e1e-8a9b-5157a768cc05	Stomach	58.0	C1AC6717-828B-4289-9755-7C56A6FC1392	26A09728-CA75-4E29-A222-0826899E0800	TCGA-D7-6525-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6525	TCGA-STAD		s14493	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1798-02	True
S13722.58cfa831e4b0c9d6adf6c8a6	58cfa831e4b0c9d6adf6c8a6	TCGA-D7-6519-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D7-6519-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_5_rg.sorted	TCGA-D7-6519-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_5_rg.sorted.bam	266.4	1.9	0.14	58cfa831e4b0c9d6adf6c8a6	TCGA-D7-6519-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6519-01A	E37CAE9E-0656-4B89-B326-739A5CC859E0	Primary Tumor	Illumina HiSeq	66b2b99b-ac75-4068-9d05-34e6dbe9721d	Stomach	64.0	FA7426E1-FCFB-4B08-AD50-1D9E903A81FB	D7D0FD1C-F540-4BE1-A10B-160F59970FFF	TCGA-D7-6519-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6519	TCGA-STAD		s15249	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N1	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIB	1798-02	True
S13722.58cfa831e4b0c9d6adf6c902	58cfa831e4b0c9d6adf6c902	TCGA-DB-5273-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DB-5273-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_1_rg.sorted	TCGA-DB-5273-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_1_rg.sorted.bam	64.0	1.9	0.15	58cfa831e4b0c9d6adf6c902	TCGA-DB-5273-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DB-5273-01A	AE2DB022-EB4F-4B65-89B6-9FD4439DDEEF	Primary Tumor	Illumina HiSeq	844bcbca-fe48-4dee-be69-4cef2ac59e27	Brain	33.0	4BA48810-3915-4567-9D35-615DF00006E4	6F0ACC8E-2A73-4B08-AAA3-A29EBE61E6B7	TCGA-DB-5273-01A-01D-1465-02	HG19_Broad_variant	TCGA-DB-5273	TCGA-LGG		s8751	Harvard Medical School	Mayo Clinic - Rochester	United States	NO			Astrocytoma		1465-02	True
S13722.58cfa831e4b0c9d6adf6c90c	58cfa831e4b0c9d6adf6c90c	TCGA-DK-A2HX-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DK-A2HX-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_1_rg.sorted	TCGA-DK-A2HX-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_1_rg.sorted.bam	16.46		0.14	58cfa831e4b0c9d6adf6c90c	TCGA-DK-A2HX-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A2HX-01A	C728FAC9-5452-4759-A4ED-A366E0F757CB	Primary Tumor	Illumina HiSeq	17e4edb9-ac80-43de-a7c1-66edf1201ac0	Bladder	80.0	537F3FE6-4E8E-4570-827A-0F5CAB193BE0	4BAFEFB4-28D5-4126-B6B7-AE5B0D03F05D	TCGA-DK-A2HX-01A-12D-A18D-02	HG19_Broad_variant	TCGA-DK-A2HX	TCGA-BLCA		s2712	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A18D-02	True
S13722.58cfa831e4b0c9d6adf6c91b	58cfa831e4b0c9d6adf6c91b	TCGA-DK-A2I1-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DK-A2I1-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_1_rg.sorted	TCGA-DK-A2I1-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_1_rg.sorted.bam	37.09		0.15	58cfa831e4b0c9d6adf6c91b	TCGA-DK-A2I1-01A-11D-A17R_120927_SN208_0433_BD1D5JACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A2I1-01A	036B9681-AB58-4734-A8FD-E0D5D078BF5A	Primary Tumor	Illumina HiSeq	724308ea-3fa9-4762-9800-445a044e94f2	Bladder	73.0	F9BD70B2-6CDE-48E5-9F0D-55D86CCFEBA8	010259EE-2667-4B8E-BB20-0F75F53A64BA	TCGA-DK-A2I1-01A-11D-A17R-02	HG19_Broad_variant	TCGA-DK-A2I1	TCGA-BLCA		s2704	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A17R-02	True
S13722.58cfa831e4b0c9d6adf6c936	58cfa831e4b0c9d6adf6c936	TCGA-D1-A16E-01A-22D-A12F_120523_SN1222_0109_BD12MPACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D1-A16E-01A-22D-A12F_120523_SN1222_0109_BD12MPACXX_s_4_rg.sorted	TCGA-D1-A16E-01A-22D-A12F_120523_SN1222_0109_BD12MPACXX_s_4_rg.sorted.bam	37.7	1.95	0.15	58cfa831e4b0c9d6adf6c936	TCGA-D1-A16E-01A-22D-A12F_120523_SN1222_0109_BD12MPACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16E-01A	E70465F6-1922-4EB7-B646-8B01AD3CE77B	Primary Tumor	Illumina HiSeq	d5fd8d77-e4f4-4b13-b244-0dbbc2f74021	Uterus	73.0	58FC1E66-39C4-44D1-BDD3-338E0D833792	0651FC75-DFFC-4271-8832-2DB47C642804	TCGA-D1-A16E-01A-22D-A12F-02	HG19_Broad_variant	TCGA-D1-A16E	TCGA-UCEC		s4439	Harvard Medical School	Mayo Clinic		NO			Endometrioid endometrial adenocarcinoma		A12F-02	True
S13722.58cfa831e4b0c9d6adf6ca1b	58cfa831e4b0c9d6adf6ca1b	TCGA-DK-A2I6-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DK-A2I6-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_6_rg.sorted	TCGA-DK-A2I6-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_6_rg.sorted.bam	57.02		0.16	58cfa831e4b0c9d6adf6ca1b	TCGA-DK-A2I6-01A-12D-A18D_120913_SN208_0429_AC187FACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A2I6-01A	DE810AF0-4C18-4E8F-9836-F8ABC425E3EB	Primary Tumor	Illumina HiSeq	6567cd2d-a1e5-4226-9239-77c48c09c55e	Bladder	81.0	A536F8F9-3A68-4792-880D-387D78FD0C66	B791021D-173E-4B08-8769-A9F289818D11	TCGA-DK-A2I6-01A-12D-A18D-02	HG19_Broad_variant	TCGA-DK-A2I6	TCGA-BLCA		s2703	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A18D-02	True
S13722.58cfa831e4b0c9d6adf6cae8	58cfa831e4b0c9d6adf6cae8	TCGA-D7-6522-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D7-6522-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_3_rg.sorted	TCGA-D7-6522-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_3_rg.sorted.bam	52.7	1.9	0.14	58cfa831e4b0c9d6adf6cae8	TCGA-D7-6522-01A-11D-1798_130214_SN1120_0237_BD1TGLACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6522-01A	8BB3FACB-1933-4350-9F78-74537559E000	Primary Tumor	Illumina HiSeq	ac3cc7c3-e03a-4218-b297-d6c525338753	Stomach	58.0	825AE87A-69C0-44AC-A1AF-D1FAD7746C05	030D9DF5-48AB-46F4-AC23-F299A069191C	TCGA-D7-6522-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6522	TCGA-STAD		s15197	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IB	1798-02	True
S13722.58cfa831e4b0c9d6adf6cb0e	58cfa831e4b0c9d6adf6cb0e	TCGA-EA-A3Y4-01A-51D-A245_140124_SN1440_0178_AC2PL6ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EA-A3Y4-01A-51D-A245_140124_SN1440_0178_AC2PL6ACXX_s_1_rg.sorted	TCGA-EA-A3Y4-01A-51D-A245_140124_SN1440_0178_AC2PL6ACXX_s_1_rg.sorted.bam	30.33		0.15	58cfa831e4b0c9d6adf6cb0e	TCGA-EA-A3Y4-01A-51D-A245_140124_SN1440_0178_AC2PL6ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3Y4-01A	3AC62513-B5F4-4063-AABD-DAD08A1F56FB	Primary Tumor	Illumina HiSeq	32cd0b72-100c-4e6c-81f1-6be30738cafb	Cervix	40.0	FF97C148-76BA-480E-9456-5DD7D7238373	A7529CB6-2386-410F-B09A-62E10BAFF8CB	TCGA-EA-A3Y4-01A-51D-A245-26	HG19_Broad_variant	TCGA-EA-A3Y4	TCGA-CESC		s1362	MD Anderson - Institute for Applied Cancer Science	Asterand	Ukraine	NO	T1b	N0	Cervical Squamous Cell Carcinoma		A245-26	True
S13722.58cfa831e4b0c9d6adf6cba0	58cfa831e4b0c9d6adf6cba0	TCGA-EJ-5519-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5519-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_1_rg.sorted	TCGA-EJ-5519-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_1_rg.sorted.bam	233.7	1.9	0.15	58cfa831e4b0c9d6adf6cba0	TCGA-EJ-5519-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5519-01A	5313A055-C2D7-4CBD-A8C1-57AC85912D89	Primary Tumor	Illumina HiSeq	75f448c7-b10b-4c15-ae49-4eb217c65391	Prostate	64.0	EEE1828E-D25F-462B-9735-89CA2ECCC7E1	4C2E88A3-B668-40A8-B625-B6D7A48DEAF5	TCGA-EJ-5519-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5519	TCGA-PRAD		s3949	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cc40	58cfa831e4b0c9d6adf6cc40	TCGA-EK-A2R7-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EK-A2R7-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_3_rg.sorted	TCGA-EK-A2R7-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_3_rg.sorted.bam	66.58		0.17	58cfa831e4b0c9d6adf6cc40	TCGA-EK-A2R7-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2R7-01A	D7A75BF5-5189-4978-99D9-FCEF91C9FBD2	Primary Tumor	Illumina HiSeq	b998e76d-dff1-4454-abce-bbe7b5a6c398	Cervix	45.0	EE9A22DF-8612-4B71-AF3A-6B16C73197EA	9C763A04-CC5B-41E1-A5AC-2CB06B9E80C3	TCGA-EK-A2R7-01A-11D-A18I-02	HG19_Broad_variant	TCGA-EK-A2R7	TCGA-CESC		s1526	Harvard Medical School	Gynecologic Oncology Group	United States	NO	T1b1	N1	Cervical Squamous Cell Carcinoma		A18I-02	True
S13722.58cfa831e4b0c9d6adf6cba4	58cfa831e4b0c9d6adf6cba4	TCGA-EJ-5521-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5521-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_3_rg.sorted	TCGA-EJ-5521-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_3_rg.sorted.bam	72.7	1.9	0.14	58cfa831e4b0c9d6adf6cba4	TCGA-EJ-5521-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5521-01A	D44D4BCB-BEB1-4464-ACD2-9972751F5018	Primary Tumor	Illumina HiSeq	c9a43591-8317-4ff5-a2e9-33c98c6a6012	Prostate	63.0	9EEBD2EC-AF9D-493C-A006-A436C28D4CD3	83248990-416D-48F0-B6F4-59C4C7CEEBD8	TCGA-EJ-5521-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5521	TCGA-PRAD		s4134	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cc68	58cfa831e4b0c9d6adf6cc68	TCGA-EK-A2R8-01A-21D-A18I_140204_SN208_0508_BC2R1UACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EK-A2R8-01A-21D-A18I_140204_SN208_0508_BC2R1UACXX_s_4_rg.sorted	TCGA-EK-A2R8-01A-21D-A18I_140204_SN208_0508_BC2R1UACXX_s_4_rg.sorted.bam	58.64		0.17	58cfa831e4b0c9d6adf6cc68	TCGA-EK-A2R8-01A-21D-A18I_140204_SN208_0508_BC2R1UACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2R8-01A	D4510801-8CE4-4F10-8B31-25C0A39B5135	Primary Tumor	Illumina HiSeq	d050a7c3-8fe5-472e-bc71-4dff85991e92	Cervix	48.0	6B8E0AF3-1632-4FED-9A37-879EA013AE24	80B2C20E-8EFB-4105-8A96-A695FCFB73CB	TCGA-EK-A2R8-01A-21D-A18I-02	HG19_Broad_variant	TCGA-EK-A2R8	TCGA-CESC		s1190	Harvard Medical School	Gynecologic Oncology Group	United States	NO	T1b2	N1	Cervical Squamous Cell Carcinoma		A18I-02	True
S13722.58cfa831e4b0c9d6adf6ccf8	58cfa831e4b0c9d6adf6ccf8	TCGA-FD-A3SP-01A-31D-A233_120830_SN208_0424_BD1DKLACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FD-A3SP-01A-31D-A233_120830_SN208_0424_BD1DKLACXX_s_3_rg.sorted	TCGA-FD-A3SP-01A-31D-A233_120830_SN208_0424_BD1DKLACXX_s_3_rg.sorted.bam	26.79		0.15	58cfa831e4b0c9d6adf6ccf8	TCGA-FD-A3SP-01A-31D-A233_120830_SN208_0424_BD1DKLACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SP-01A	5F99DCFF-D809-4C87-8024-C9B30BD565E9	Primary Tumor	Illumina HiSeq	2da38f98-8b94-404e-99e7-7a8d58aa25c1	Bladder	60.0	3592A9C5-124E-428F-B1F9-40429C591429	9BE9B27C-A33C-450E-806D-7C791472DAE6	TCGA-FD-A3SP-01A-31D-A233-26	HG19_Broad_variant	TCGA-FD-A3SP	TCGA-BLCA		s3112	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	True
S13722.58cfa831e4b0c9d6adf6cd84	58cfa831e4b0c9d6adf6cd84	TCGA-FE-A235-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FE-A235-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_1_rg.sorted	TCGA-FE-A235-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_1_rg.sorted.bam	74.82	2.0	0.17	58cfa831e4b0c9d6adf6cd84	TCGA-FE-A235-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A235-01A	C781B49E-D08F-49E6-B774-7CFE4100E92D	Primary Tumor	Illumina HiSeq	7eafbe04-60be-48a5-8e8a-937b1dde35e8	Thyroid	26.0	377A0CBF-6A82-43FA-BC95-DADECED8916D	F3F4F8FB-6FAD-46B7-85D0-C591EB926DD7	TCGA-FE-A235-01A-11D-A16N-02	HG19_Broad_variant	TCGA-FE-A235	TCGA-THCA		s12528	Harvard Medical School	Ohio State University	United States	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True
S13722.58cfa832e4b0c9d6adf6ce02	58cfa832e4b0c9d6adf6ce02	TCGA-EJ-5524-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5524-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_7_rg.sorted	TCGA-EJ-5524-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_7_rg.sorted.bam	248.7	1.9	0.14	58cfa832e4b0c9d6adf6ce02	TCGA-EJ-5524-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5524-01A	4048C139-1329-4E6A-8D2F-C0AA104A68EE	Primary Tumor	Illumina HiSeq	bc7b862d-c88b-41f2-9061-6c4895d6b5be	Prostate	57.0	C197A81D-2AA5-4285-88E3-761798E2C190	4B173FC3-DBE0-47AA-8ACC-D36466B5522D	TCGA-EJ-5524-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5524	TCGA-PRAD		s3435	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cd7c	58cfa831e4b0c9d6adf6cd7c	TCGA-FD-A3B3-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FD-A3B3-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_7_rg.sorted	TCGA-FD-A3B3-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_7_rg.sorted.bam	42.39		0.15	58cfa831e4b0c9d6adf6cd7c	TCGA-FD-A3B3-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3B3-01A	4B5D873B-BFDA-482E-92A0-BF84C0F9032A	Primary Tumor	Illumina HiSeq	6b702a7f-ff83-4ff2-96a8-9da2f015ebcc	Bladder	74.0	769EE027-5ED7-4EC2-86B5-FE40F9D6FB5A	57731F40-BBEF-4C7B-BFDC-CE75DA6EB1EB	TCGA-FD-A3B3-01A-12D-A204-02	HG19_Broad_variant	TCGA-FD-A3B3	TCGA-BLCA		s2903	Harvard Medical School	BLN - University Of Chicago	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A204-02	True
S13722.58cfa832e4b0c9d6adf6ceb7	58cfa832e4b0c9d6adf6ceb7	TCGA-EJ-5522-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5522-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_5_rg.sorted	TCGA-EJ-5522-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_5_rg.sorted.bam	414.7	1.9	0.17	58cfa832e4b0c9d6adf6ceb7	TCGA-EJ-5522-01A-01D-1572_130218_SN208_0454_BD1TBTACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5522-01A	214884EF-A932-4FC3-B6FF-16CE5164DA3E	Primary Tumor	Illumina HiSeq	ee0fc9f9-f7ac-4f93-a066-2751ffaa3959	Prostate	51.0	8AC1E1E7-8266-48E0-8D4C-D78873111341	2312B3FC-1F68-43D5-8B19-D449089F153C	TCGA-EJ-5522-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5522	TCGA-PRAD		s4133	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa832e4b0c9d6adf6ce60	58cfa832e4b0c9d6adf6ce60	TCGA-GV-A3QF-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-GV-A3QF-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_4_rg.sorted	TCGA-GV-A3QF-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_4_rg.sorted.bam	21.58		0.16	58cfa832e4b0c9d6adf6ce60	TCGA-GV-A3QF-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3QF-01A	47990D5E-A0E1-4752-86F5-4F5B84E219DF	Primary Tumor	Illumina HiSeq	bcac19c7-1e8c-40ba-a577-39fce12db063	Bladder	79.0	6647C98E-7AA1-49E4-A067-D53AEBACFF9C	F7B433D0-F5DA-4E9C-9C32-A614FB4F614C	TCGA-GV-A3QF-01A-31D-A233-26	HG19_Broad_variant	TCGA-GV-A3QF	TCGA-BLCA		s2931	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO	T3b	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	True
S13722.58cfa832e4b0c9d6adf6ced1	58cfa832e4b0c9d6adf6ced1	TCGA-EJ-5542-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5542-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_5_rg.sorted	TCGA-EJ-5542-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_5_rg.sorted.bam	214.7	1.9	0.15	58cfa832e4b0c9d6adf6ced1	TCGA-EJ-5542-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5542-01A	5A92EC4C-36EE-4588-ACA2-E3303F29C7AD	Primary Tumor	Illumina HiSeq	45ba9a12-204e-4ab8-b544-61f2519b176f	Prostate	60.0	DFFC7994-E957-4451-A9DB-56D4560D6547	185234ED-0A19-490C-86D8-19762FB13C1A	TCGA-EJ-5542-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5542	TCGA-PRAD		s3964	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa832e4b0c9d6adf6cec2	58cfa832e4b0c9d6adf6cec2	TCGA-HC-7080-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_2_rg.sorted.filtered.	WGS	TCGA-HC-7080-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_2_rg.sorted	TCGA-HC-7080-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_2_rg.sorted.bam	398.7		0.13	58cfa832e4b0c9d6adf6cec2	TCGA-HC-7080-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7080-01A	FD50FF41-EC9D-4DB1-A673-36BA0CA1EAC8	Primary Tumor	Illumina HiSeq	4012de79-f9d8-4ee6-ab04-538482e6a66c	Prostate	66.0	E30730B8-81F1-49A8-8446-547B5C3CC730	CEF3C431-0329-4619-834B-DC57B33399A5	TCGA-HC-7080-01A-11D-1957-02	HG19_Broad_variant	TCGA-HC-7080	TCGA-PRAD		s3807	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	N0	Prostate Adenocarcinoma Acinar Type		1957-02	True
S13722.58cfa832e4b0c9d6adf6ced3	58cfa832e4b0c9d6adf6ced3	TCGA-EJ-5527-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5527-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_5_rg.sorted	TCGA-EJ-5527-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_5_rg.sorted.bam	188.7	1.9	0.15	58cfa832e4b0c9d6adf6ced3	TCGA-EJ-5527-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5527-01A	BA0C9096-5F35-4F0A-AE98-EE1A695B55F0	Primary Tumor	Illumina HiSeq	62c0aaa3-44c3-4b25-b1cb-8e6196d66189	Prostate	69.0	15A638FE-4DFD-4280-AD40-5E0D5FDE3812	AE85C536-0580-4A34-B686-161D337E7951	TCGA-EJ-5527-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5527	TCGA-PRAD		s3443	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa832e4b0c9d6adf6cf07	58cfa832e4b0c9d6adf6cf07	TCGA-HC-7079-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_8_rg.sorted.filtered.	WGS	TCGA-HC-7079-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_8_rg.sorted	TCGA-HC-7079-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_8_rg.sorted.bam	133.0		0.15	58cfa832e4b0c9d6adf6cf07	TCGA-HC-7079-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7079-01A	10FBE481-F111-4F88-AE45-4D67CB265567	Primary Tumor	Illumina HiSeq	5debd428-e42f-459c-8945-f3e0a3053b9e	Prostate	51.0	190EF71A-5B5D-4009-B707-68F10147CB65	3935531A-0F99-4617-A5B6-6774E74CEE5E	TCGA-HC-7079-01A-11D-1957-02	HG19_Broad_variant	TCGA-HC-7079	TCGA-PRAD		s3624	Harvard Medical School	International Genomics Consortium	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1957-02	True
S13722.58cfa832e4b0c9d6adf6cf34	58cfa832e4b0c9d6adf6cf34	TCGA-G9-6363-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_5_rg.sorted.filtered.	WGS	TCGA-G9-6363-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_5_rg.sorted	TCGA-G9-6363-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_5_rg.sorted.bam	313.4	1.8	0.13	58cfa832e4b0c9d6adf6cf34	TCGA-G9-6363-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6363-01A	B5B3871C-078C-46A7-AC50-EF916D4A6781	Primary Tumor	Illumina HiSeq	a64da28b-c092-4dfb-9503-06c15e566ac3	Prostate	64.0	65D588FF-58E3-4932-A7F4-25EF23C433D5	DBF42C34-D2E5-4136-83F5-093453913D5B	TCGA-G9-6363-01A-21D-1784-02	HG19_Broad_variant	TCGA-G9-6363	TCGA-PRAD		s3452	Harvard Medical School	Roswell Park	United States	NO	T4	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True
S13722.58cfa832e4b0c9d6adf6ceed	58cfa832e4b0c9d6adf6ceed	TCGA-FY-A3R7-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FY-A3R7-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_3_rg.sorted	TCGA-FY-A3R7-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_3_rg.sorted.bam	10.86		0.15	58cfa832e4b0c9d6adf6ceed	TCGA-FY-A3R7-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A3R7-01A	B983A678-B0AE-42C2-8F37-D6ECAF07413B	Primary Tumor	Illumina HiSeq	8f5f6e5a-6274-4d57-8dbd-2dc9d5bc3544	Thyroid	50.0	E85B6BC8-C182-4483-8F53-F312D5A545CB	5F86B67F-ECBC-477C-B72A-F41F104E03A2	TCGA-FY-A3R7-01A-11D-A221-26	HG19_Broad_variant	TCGA-FY-A3R7	TCGA-THCA		s12009	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A221-26	True
S13722.58cfa832e4b0c9d6adf6cfe4	58cfa832e4b0c9d6adf6cfe4	TCGA-G9-6333-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G9-6333-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_3_rg.sorted	TCGA-G9-6333-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_3_rg.sorted.bam	157.7	1.9	0.14	58cfa832e4b0c9d6adf6cfe4	TCGA-G9-6333-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6333-01A	64BF32C9-9466-404A-A147-E7A0B9E91E34	Primary Tumor	Illumina HiSeq	0e4674b7-f8ed-422c-909a-b2bfdf58ecf1	Prostate	66.0	98013499-4FAC-4378-9D7E-B3686003A4FC	F6373E03-914F-44B2-954D-E63DE95F89E8	TCGA-G9-6333-01A-12D-1957-02	HG19_Broad_variant	TCGA-G9-6333	TCGA-PRAD		s3611	Harvard Medical School	Roswell Park	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1957-02	True
S13722.58cfa832e4b0c9d6adf6cfd8	58cfa832e4b0c9d6adf6cfd8	TCGA-FU-A3TQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FU-A3TQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_3_rg.sorted	TCGA-FU-A3TQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_3_rg.sorted.bam	59.29		0.15	58cfa832e4b0c9d6adf6cfd8	TCGA-FU-A3TQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3TQ-01A	7218AA6F-3345-484F-A329-A3B6169A67C7	Primary Tumor	Illumina HiSeq	87ede4e6-17e6-4287-8ee3-cde27de3aa7d	Cervix	55.0	2F3BFFB4-2C85-4B72-9AF5-4DB9DC358AE6	7018744F-49FF-4F47-AEE5-07F0DEA5D7D3	TCGA-FU-A3TQ-01A-11D-A232-26	HG19_Broad_variant	TCGA-FU-A3TQ	TCGA-CESC		s1199	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2b	N1	Cervical Squamous Cell Carcinoma		A232-26	True
S13722.58cfa832e4b0c9d6adf6d00c	58cfa832e4b0c9d6adf6d00c	TCGA-HC-7230-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-HC-7230-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_8_rg.sorted	TCGA-HC-7230-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_8_rg.sorted.bam	142.3		0.14	58cfa832e4b0c9d6adf6d00c	TCGA-HC-7230-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7230-01A	03C66CF8-BC68-4EE1-A322-689A29B72262	Primary Tumor	Illumina HiSeq	40ad0094-93d2-45aa-a8b1-070359637c85	Prostate	50.0	B8BAC212-127D-4EEE-8647-3BDDC13C9415	CE9AA8B5-5CDB-42F1-A810-7F48FC241D20	TCGA-HC-7230-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7230	TCGA-PRAD		s3804	Harvard Medical School	International Genomics Consortium	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa832e4b0c9d6adf6d014	58cfa832e4b0c9d6adf6d014	TCGA-G9-6336-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-G9-6336-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_5_rg.sorted	TCGA-G9-6336-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_5_rg.sorted.bam	81.4	1.9	0.14	58cfa832e4b0c9d6adf6d014	TCGA-G9-6336-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6336-01A	59207BCD-F127-481F-B576-8716DA7D7D97	Primary Tumor	Illumina HiSeq	35e1082b-0264-4bb6-93d6-1d0e1b133135	Prostate	57.0	34C8B195-ECAB-492B-AED2-43ACFEDEF708	DB1475AB-0C9E-4D4C-B7F4-88DD8BB2F9B9	TCGA-G9-6336-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6336	TCGA-PRAD		s3799	Harvard Medical School	Roswell Park	United States	NO		N0	Prostate Adenocarcinoma Acinar Type		1784-02	True
S13722.58cfa832e4b0c9d6adf6cff0	58cfa832e4b0c9d6adf6cff0	TCGA-GD-A3OS-01A-12D-A221_120906_SN208_0426_BC194HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-GD-A3OS-01A-12D-A221_120906_SN208_0426_BC194HACXX_s_7_rg.sorted	TCGA-GD-A3OS-01A-12D-A221_120906_SN208_0426_BC194HACXX_s_7_rg.sorted.bam	37.3		0.14	58cfa832e4b0c9d6adf6cff0	TCGA-GD-A3OS-01A-12D-A221_120906_SN208_0426_BC194HACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GD-A3OS-01A	2A41B7D4-132F-4FB6-87B5-487C445379C7	Primary Tumor	Illumina HiSeq	2a801113-8404-4c17-9d60-508761ec1659	Bladder	54.0	C629CD55-54D7-4E31-AB90-955EBFF0B20A	80DBF776-1B0B-454C-9DA6-9688816A294D	TCGA-GD-A3OS-01A-12D-A221-26	HG19_Broad_variant	TCGA-GD-A3OS	TCGA-BLCA		s2922	MD Anderson - Institute for Applied Cancer Science	ABS - IUPUI	United States	NO		NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A221-26	True
S13722.58cfa832e4b0c9d6adf6d015	58cfa832e4b0c9d6adf6d015	TCGA-G9-6332-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G9-6332-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_3_rg.sorted	TCGA-G9-6332-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_3_rg.sorted.bam	156.4	1.9	0.15	58cfa832e4b0c9d6adf6d015	TCGA-G9-6332-01A-11D-1784_130115_SN590_0208_BD1TAGACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6332-01A	C46022F8-B122-4367-836B-EC1AE641A87D	Primary Tumor	Illumina HiSeq	91b58182-30c5-4b45-bf21-ee32128e4ad0	Prostate	55.0	30558AEB-76B7-4D27-99C0-E3EE21A00BD1	B9FAA261-1FA4-4870-B98F-60153ED7AD8C	TCGA-G9-6332-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6332	TCGA-PRAD		s3974	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True
S13722.58cfa832e4b0c9d6adf6d06c	58cfa832e4b0c9d6adf6d06c	TCGA-HC-7211-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-HC-7211-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_2_rg.sorted	TCGA-HC-7211-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_2_rg.sorted.bam	286.3		0.14	58cfa832e4b0c9d6adf6d06c	TCGA-HC-7211-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7211-01A	EC3870C9-4930-4AF7-B2EB-1E16C9EC9F14	Primary Tumor	Illumina HiSeq	c6d8e1f6-600a-4387-a51a-8812fee4f285	Prostate	62.0	79BF8C2C-470E-4BE8-8144-9C0B366ECADD	226F7F0E-AC30-4F20-87A2-EB8128402BE4	TCGA-HC-7211-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7211	TCGA-PRAD		s3622	Harvard Medical School	International Genomics Consortium	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa832e4b0c9d6adf6d116	58cfa832e4b0c9d6adf6d116	TCGA-JX-A3Q0-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_3_rg.sorted.filtered.	WGS	TCGA-JX-A3Q0-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_3_rg.sorted	TCGA-JX-A3Q0-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_3_rg.sorted.bam	42.52		0.14	58cfa832e4b0c9d6adf6d116	TCGA-JX-A3Q0-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_3_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-JX-A3Q0-01A	20280122-A66A-4C83-8F25-0B9D97558DC2	Primary Tumor	Illumina HiSeq	20d5be50-f8a2-406a-9415-bc65cdff0cad	Cervix	63.0	04FFDFC0-A73F-47AE-9014-73870B69AD91	A7EE4E31-77DF-470B-A748-87BB4DF76FD5	TCGA-JX-A3Q0-01A-11D-A245-26	HG19_Broad_variant	TCGA-JX-A3Q0	TCGA-CESC		s1218	MD Anderson - Institute for Applied Cancer Science	Washington University	United States	NO	T3	N0	Cervical Squamous Cell Carcinoma		A245-26	True
S13722.58cfa832e4b0c9d6adf6d153	58cfa832e4b0c9d6adf6d153	TCGA-FU-A3YQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FU-A3YQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_6_rg.sorted	TCGA-FU-A3YQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_6_rg.sorted.bam	36.15		0.15	58cfa832e4b0c9d6adf6d153	TCGA-FU-A3YQ-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3YQ-01A	6E01248B-C551-4F52-8066-CB2D26EB6394	Primary Tumor	Illumina HiSeq	104b02af-20c0-4d30-ba14-f5028b3a3ee4	Cervix	35.0	84A97589-63AE-4151-89F3-40F5AA9DE72E	5C95B361-B203-400F-B18A-8375849F5B84	TCGA-FU-A3YQ-01A-11D-A232-26	HG19_Broad_variant	TCGA-FU-A3YQ	TCGA-CESC		s1205	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T1b1	N0	Cervical Squamous Cell Carcinoma		A232-26	True
S13722.58cfa832e4b0c9d6adf6d16e	58cfa832e4b0c9d6adf6d16e	TCGA-IG-A5S3-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_7_rg.sorted.filtered.	WGS	TCGA-IG-A5S3-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_7_rg.sorted	TCGA-IG-A5S3-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_7_rg.sorted.bam	45.06		0.15	58cfa832e4b0c9d6adf6d16e	TCGA-IG-A5S3-01A-11D-A28P_131120_SN1222_0230_BC29YPACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A5S3-01A	DF0125B2-5278-4DED-B3B7-9FC829FE9F63	Primary Tumor	Illumina HiSeq	736bee98-6905-4aea-a839-1157081fd524	Esophagus	69.0	9595654D-B5F8-4571-A80A-BDD179881D91	AC4D24CB-89FC-4744-9227-4F65D8893F90	TCGA-IG-A5S3-01A-11D-A28P-26	HG19_Broad_variant	TCGA-IG-A5S3	TCGA-ESCA		s1827	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T3	N0		Stage IIB	A28P-26	True
S13722.58cfa832e4b0c9d6adf6d1a2	58cfa832e4b0c9d6adf6d1a2	TCGA-HI-7168-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-HI-7168-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_8_rg.sorted	TCGA-HI-7168-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_8_rg.sorted.bam	116.3		0.14	58cfa832e4b0c9d6adf6d1a2	TCGA-HI-7168-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HI-7168-01A	25D70934-01A5-45A2-9960-68D3058B6965	Primary Tumor	Illumina HiSeq	97c2b4ae-c671-4cf5-8b44-5c36e7e8fb57	Prostate	62.0	DD410832-95AA-4FA6-A2B9-3FECA6F70E1D	9FD5990D-22E1-4D64-996D-543BCD447500	TCGA-HI-7168-01A-11D-2111-02	HG19_Broad_variant	TCGA-HI-7168	TCGA-PRAD		s3633	Harvard Medical School	Fox Chase	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa832e4b0c9d6adf6d1c9	58cfa832e4b0c9d6adf6d1c9	TCGA-HM-A3JK-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-HM-A3JK-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_1_rg.sorted	TCGA-HM-A3JK-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_1_rg.sorted.bam	58.55		0.15	58cfa832e4b0c9d6adf6d1c9	TCGA-HM-A3JK-01A-11D-A245_140124_SN1440_0179_BD2DRDACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-HM-A3JK-01A	7C4CD55F-750E-4941-A9F3-0632A75D6531	Primary Tumor	Illumina HiSeq	cc4a29a9-d389-4d17-b8c7-53fcc5731b22	Cervix	64.0	88C6E5CB-D33E-4042-BE7B-12A081ACDAFB	EDAC7C77-CA42-461B-9006-F65E3EB6B7AB	TCGA-HM-A3JK-01A-11D-A245-26	HG19_Broad_variant	TCGA-HM-A3JK	TCGA-CESC		s1208	MD Anderson - Institute for Applied Cancer Science	Christiana Healthcare	United States	NO	T2b	N1	Cervical Squamous Cell Carcinoma		A245-26	True
S13722.58cfa832e4b0c9d6adf6d12c	58cfa832e4b0c9d6adf6d12c	TCGA-G2-A2EK-01A-22D-A18D_120913_SN208_0429_AC187FACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G2-A2EK-01A-22D-A18D_120913_SN208_0429_AC187FACXX_s_3_rg.sorted	TCGA-G2-A2EK-01A-22D-A18D_120913_SN208_0429_AC187FACXX_s_3_rg.sorted.bam	16.85		0.18	58cfa832e4b0c9d6adf6d12c	TCGA-G2-A2EK-01A-22D-A18D_120913_SN208_0429_AC187FACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2EK-01A	5DA1CB68-C438-4DDC-999F-90AED0C4BD7A	Primary Tumor	Illumina HiSeq	f98c8702-90e5-4e7a-ad12-d11a9af57bf5	Bladder	57.0	FF1691F2-DF11-4068-8D8D-A778F384EC60	8A75CF19-7645-489D-AAEC-5D9AD293C4B1	TCGA-G2-A2EK-01A-22D-A18D-02	HG19_Broad_variant	TCGA-G2-A2EK	TCGA-BLCA		s2725	Harvard Medical School	MD Anderson	United States	NO		N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A18D-02	True
S13722.58cfa832e4b0c9d6adf6d284	58cfa832e4b0c9d6adf6d284	TCGA-HT-7481-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_1_rg.sorted.filtered.	WGS	TCGA-HT-7481-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_1_rg.sorted	TCGA-HT-7481-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_1_rg.sorted.bam	22.0		0.13	58cfa832e4b0c9d6adf6d284	TCGA-HT-7481-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7481-01A	BFF37DE3-DC68-4E69-BDFC-8B524DD7774F	Primary Tumor	Illumina HiSeq	fbc2ca18-8dd6-41c3-9ec3-0189f96877ce	Brain	39.0	712405B3-14C4-4C26-9839-1749763D816B	AF69E75D-03C6-4EB0-A0B8-129BE37E30A2	TCGA-HT-7481-01A-11D-2022-02	HG19_Broad_variant	TCGA-HT-7481	TCGA-LGG		s8762	Harvard Medical School	Case Western - St Joes	United States	NO			Oligodendroglioma		2022-02	True
S13722.58cfa832e4b0c9d6adf6d279	58cfa832e4b0c9d6adf6d279	TCGA-HT-7475-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HT-7475-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_5_rg.sorted	TCGA-HT-7475-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_5_rg.sorted.bam	79.7		0.15	58cfa832e4b0c9d6adf6d279	TCGA-HT-7475-01A-11D-2022_130913_SN1440_0167_AC2A6PACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7475-01A	41456932-436E-4CDB-BFE8-97D089656786	Primary Tumor	Illumina HiSeq	13942ed5-f37e-4807-b133-369aab923f17	Brain	67.0	5E11FC94-CCDB-4E53-9A9D-5D7707157674	B59DECE1-1DE9-46D3-B5CD-0EFD8F453F8D	TCGA-HT-7475-01A-11D-2022-02	HG19_Broad_variant	TCGA-HT-7475	TCGA-LGG		s8372	Harvard Medical School	Case Western - St Joes	United States	NO			Oligoastrocytoma		2022-02	True
S13722.58cfa832e4b0c9d6adf6d558	58cfa832e4b0c9d6adf6d558	TCGA-L5-A4OM-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A4OM-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_1_rg.sorted	TCGA-L5-A4OM-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_1_rg.sorted.bam	36.8		0.17	58cfa832e4b0c9d6adf6d558	TCGA-L5-A4OM-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OM-01A	1A578AE7-5C0B-48EF-8BAF-7189DF703A93	Primary Tumor	Illumina HiSeq	2069622c-925f-4886-8005-9b8680ecc584	Esophagus	54.0	01EF1408-F028-4F6C-B09E-9BBB8D738704	081DEE66-D2A2-4FF2-94A1-6E3219D878D7	TCGA-L5-A4OM-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OM	TCGA-ESCA		s1842	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N0		Stage IA	A267-26	True
S13722.58cfa832e4b0c9d6adf6d630	58cfa832e4b0c9d6adf6d630	TCGA-LN-A49Y-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-LN-A49Y-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_5_rg.sorted	TCGA-LN-A49Y-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_5_rg.sorted.bam	41.86		0.16	58cfa832e4b0c9d6adf6d630	TCGA-LN-A49Y-01A-11D-A267_131120_SN1222_0229_AD2FDGACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49Y-01A	87FABA0E-28E7-4A7E-A7E1-12582EC68FAC	Primary Tumor	Illumina HiSeq	61d40e9e-a5c9-4e35-8e7f-5e08661da9b6	Esophagus	77.0	E443EA94-586E-4A0B-8330-55336AAE9A15	9AAF77BB-57CB-4073-BA2E-380B80303B0B	TCGA-LN-A49Y-01A-11D-A267-26	HG19_Broad_variant	TCGA-LN-A49Y	TCGA-ESCA		s1870	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0		Stage IIA	A267-26	True
S13722.58cfa832e4b0c9d6adf6d545	58cfa832e4b0c9d6adf6d545	TCGA-L5-A43E-01A-11D-A248_130115_SN590_0207_AC1H8PACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A43E-01A-11D-A248_130115_SN590_0207_AC1H8PACXX_s_1_rg.sorted	TCGA-L5-A43E-01A-11D-A248_130115_SN590_0207_AC1H8PACXX_s_1_rg.sorted.bam	40.6		0.15	58cfa832e4b0c9d6adf6d545	TCGA-L5-A43E-01A-11D-A248_130115_SN590_0207_AC1H8PACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A43E-01A	6969FE5A-5993-48E5-95C5-C5C7D3D08205	Primary Tumor	Illumina HiSeq	70d7fe7a-b9ff-4651-94bd-cc39c64b3657	Esophagus	74.0	5C8F603A-B8D3-407C-8E74-559C5F8C4D0E	2BDCF492-4741-430F-B1C3-ED029AD05FD6	TCGA-L5-A43E-01A-11D-A248-26	HG19_Broad_variant	TCGA-L5-A43E	TCGA-ESCA		s1916	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N0		Stage I	A248-26	True
S13722.58cfa82de4b0c9d6adf6a44c	58cfa82de4b0c9d6adf6a44c	023c722ed278d2ab1cbbeef1bfee4130.filtered.	WGS	023c722ed278d2ab1cbbeef1bfee4130	023c722ed278d2ab1cbbeef1bfee4130.bam	45.87	1.86	0.08	58cfa82de4b0c9d6adf6a44c	023c722ed278d2ab1cbbeef1bfee4130.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-E9-A1NH-01A	B2AAC45B-2073-4C7A-ADB9-769A4FDCC111	Primary Tumor	Illumina HiSeq	f57cf947-b314-4a64-a112-d09cc8045594	Breast	71.0	FB0B2D84-D982-4D3A-9803-36420F2E7E46	13C312EC-0ADD-4758-AB8D-C193E2E08C6D	TCGA-E9-A1NH-01A-11D-A14G-09	GRCh37-lite	TCGA-E9-A1NH	TCGA-BRCA		s6449	Washington University School of Medicine	Asterand	Russia	NO	T2	N1	Infiltrating Ductal Carcinoma	Stage IIB	A14G-09	False
S13722.58cfa82de4b0c9d6adf6a49a	58cfa82de4b0c9d6adf6a49a	1d2f2091a246a644d3f997d0edfd860a.filtered.	WGS	1d2f2091a246a644d3f997d0edfd860a	1d2f2091a246a644d3f997d0edfd860a.bam	17.4	1.97	0.08	58cfa82de4b0c9d6adf6a49a	1d2f2091a246a644d3f997d0edfd860a.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A0EY-01A	D67CD793-2931-429A-9084-2F3C4C8BE7AD	Primary Tumor	Illumina HiSeq	79cc669f-41ce-4384-ac00-fe94ad0c8cd5	Breast	62.0	2A3E4DBB-AAFF-4B14-BBED-F2D7CF0F8FA3	01658141-8398-4585-9F0F-8355DD9B0604	TCGA-A2-A0EY-01A-11D-A19H-09	GRCh37-lite	TCGA-A2-A0EY	TCGA-BRCA		s5947	Washington University School of Medicine	Walter Reed		NO	T2	N1a	Infiltrating Ductal Carcinoma	Stage IIB	A19H-09	True
S13722.58cfa82de4b0c9d6adf6a4be	58cfa82de4b0c9d6adf6a4be	16c5b03f7a162662f87a6ef4eb8efdb7.filtered.	WGS	16c5b03f7a162662f87a6ef4eb8efdb7	16c5b03f7a162662f87a6ef4eb8efdb7.bam	78.05	1.93	0.08	58cfa82de4b0c9d6adf6a4be	16c5b03f7a162662f87a6ef4eb8efdb7.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A05D-01A	F7E06A10-74CA-4F52-A944-B3F22C016998	Primary Tumor	Illumina HiSeq	4cb18a3e-36df-43cb-ab17-5ba82f2a7949	Uterus	67.0	5B19AF28-1179-42CB-A474-856EF2048D5B	82D2EA5F-EBDC-4907-A287-FE837FD6B59C	TCGA-AP-A05D-01A-11D-A013-09	GRCh37-lite	TCGA-AP-A05D	TCGA-UCEC		s4981	Washington University School of Medicine	MSKCC		NO			Serous endometrial adenocarcinoma		A013-09	True
S13722.58cfa82de4b0c9d6adf6a47a	58cfa82de4b0c9d6adf6a47a	36b47238be0497f388623d943762497c.filtered.	WGS	36b47238be0497f388623d943762497c	36b47238be0497f388623d943762497c.bam	64.57		0.08	58cfa82de4b0c9d6adf6a47a	36b47238be0497f388623d943762497c.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2R9-01A	00AD0FFE-2105-4829-A495-1C2ACEB5BB31	Primary Tumor	Illumina HiSeq	d25f9f12-7f03-4bbe-befe-f9250955975c	Cervix	58.0	7EFD873D-8165-40F8-A07D-69CFD68A491E	9FF21093-58D7-4B69-AADE-C242A383EA56	TCGA-EK-A2R9-01A-11D-A34H-09	GRCh37-lite	TCGA-EK-A2R9	TCGA-CESC		s1347	Washington University School of Medicine	Gynecologic Oncology Group	United States	NO	T1b1	N0	Cervical Squamous Cell Carcinoma		A34H-09	True
S13722.58cfa82de4b0c9d6adf6a4e6	58cfa82de4b0c9d6adf6a4e6	114daee2d5db94a8d315a300daafb728.filtered.	WGS	114daee2d5db94a8d315a300daafb728	114daee2d5db94a8d315a300daafb728.bam	20.16		0.08	58cfa82de4b0c9d6adf6a4e6	114daee2d5db94a8d315a300daafb728.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-DX-A3U5-01A	8F3F6F7C-4B50-467E-A6E8-D836735913F6	Primary Tumor	Illumina HiSeq	bee06413-ec4c-4545-b54d-d858d6a6e6e3	Mesenchymal	52.0	FB5C61D6-717E-4798-8306-86EB196D5609	3C963890-6E79-4B16-A4AA-BAC04938B4D7	TCGA-DX-A3U5-01A-11D-A228-09	GRCh37-lite	TCGA-DX-A3U5	TCGA-SARC		s2473	Washington University School of Medicine	Memorial Sloan Kettering	United States	NO					A228-09	False
S13722.58cfa82de4b0c9d6adf6a518	58cfa82de4b0c9d6adf6a518	143a9f78e15769fd3d037c291de40599.filtered.	WGS	143a9f78e15769fd3d037c291de40599	143a9f78e15769fd3d037c291de40599.bam	85.82	2.12	0.07	58cfa82de4b0c9d6adf6a518	143a9f78e15769fd3d037c291de40599.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K3-01A	79ECC142-8F6E-4260-A7CE-C8E2A6212C35	Primary Tumor	Illumina HiSeq	b48383ea-36f6-4edd-ae2e-04b235d472a3	Uterus	62.0	ED31DDC2-FEDA-496E-A642-0C4B5DCE014D	D12CFD8B-682D-41DF-ACF8-EE7F68A6241C	TCGA-B5-A0K3-01A-11D-A325-09	GRCh37-lite	TCGA-B5-A0K3	TCGA-UCEC		s5375	Washington University School of Medicine	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A325-09	True
S13722.58cfa82de4b0c9d6adf6a535	58cfa82de4b0c9d6adf6a535	4d34550076e0e5e5f628e1f2d531963f.filtered.	WGS	4d34550076e0e5e5f628e1f2d531963f	4d34550076e0e5e5f628e1f2d531963f.bam	58.16	2.0	0.07	58cfa82de4b0c9d6adf6a535	4d34550076e0e5e5f628e1f2d531963f.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A0D4-01A	75113445-D2D6-44A0-866C-C9175E6D214B	Primary Tumor	Illumina HiSeq	ac8422e5-dfeb-40c6-ab1f-dddd9f7fb015	Breast	37.0	ACE39EF3-1B5E-4AD2-A20D-62957E524281	2B000AF3-2C9D-4EAA-AF3F-8101B7425C37	TCGA-A2-A0D4-01A-11D-A314-09	GRCh37-lite	TCGA-A2-A0D4	TCGA-BRCA		s6624	Washington University School of Medicine	Walter Reed		NO	T2	N1a	Infiltrating Ductal Carcinoma	Stage IIB	A314-09	True
S13722.58cfa82de4b0c9d6adf6a53a	58cfa82de4b0c9d6adf6a53a	55d6e765b492c11513427738173a07b8.filtered.	WGS	55d6e765b492c11513427738173a07b8	55d6e765b492c11513427738173a07b8.bam	8.07		0.08	58cfa82de4b0c9d6adf6a53a	55d6e765b492c11513427738173a07b8.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-FX-A3RE-01A	7F9031DA-124A-4A38-83E6-878A50E58C24	Primary Tumor	Illumina HiSeq	41901beb-8e75-49c2-8bc3-a73dcaff36b1	Mesenchymal	65.0	8FAEDD92-D7FA-452A-8210-741118E516F7	CDBBD701-9C05-4F9E-923D-06039DD8A04D	TCGA-FX-A3RE-01A-11D-A228-09	GRCh37-lite	TCGA-FX-A3RE	TCGA-SARC		s2336	Washington University School of Medicine	International Genomics Consortium	United States	NO					A228-09	False
S13722.58cfa82de4b0c9d6adf6a570	58cfa82de4b0c9d6adf6a570	2d3ccd84c9564a9f00feb1379762746c.filtered.	WGS	2d3ccd84c9564a9f00feb1379762746c	2d3ccd84c9564a9f00feb1379762746c.bam	78.11	1.95	0.08	58cfa82de4b0c9d6adf6a570	2d3ccd84c9564a9f00feb1379762746c.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A2H5-01A	C88E3901-F3EE-436A-BA80-143C8EAB7D69	Primary Tumor	Illumina HiSeq	6b01cf12-3537-4e5e-857f-de5dd14c85ce	Uterus	67.0	44EB96B4-5E4F-460B-BC51-ADD38CBC76A1	CC19A480-9C66-4EE8-A0C0-921ACAC02689	TCGA-AX-A2H5-01A-11D-A34H-09	GRCh37-lite	TCGA-AX-A2H5	TCGA-UCEC		s5376	Washington University School of Medicine	Gynecologic Oncology Group	United States	NO			Serous endometrial adenocarcinoma		A34H-09	True
S13722.58cfa82de4b0c9d6adf6a4e2	58cfa82de4b0c9d6adf6a4e2	3868e1400ab74a5d31b7f3ace5862177.filtered.	WGS	3868e1400ab74a5d31b7f3ace5862177	3868e1400ab74a5d31b7f3ace5862177.bam	31.37		0.08	58cfa82de4b0c9d6adf6a4e2	3868e1400ab74a5d31b7f3ace5862177.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2RE-01A	9AA36AC2-8418-4109-A3C1-63CA8742BAAB	Primary Tumor	Illumina HiSeq	87fe03fa-225c-4d35-81a3-8b401d985fae	Cervix	26.0	7BCF54B6-3FFA-4014-92C6-51A7099E6F02	0D31A44F-1FC5-43A2-9633-36C4E650D3D2	TCGA-EK-A2RE-01A-11D-A34H-09	GRCh37-lite	TCGA-EK-A2RE	TCGA-CESC		s1162	Washington University School of Medicine	Gynecologic Oncology Group	United States	NO	T2a2	N0	Cervical Squamous Cell Carcinoma		A34H-09	True
S13722.58cfa82de4b0c9d6adf6a599	58cfa82de4b0c9d6adf6a599	6520482bf50a726c446002cb9b06ac69.filtered.	WGS	6520482bf50a726c446002cb9b06ac69	6520482bf50a726c446002cb9b06ac69.bam	27.61		0.08	58cfa82de4b0c9d6adf6a599	6520482bf50a726c446002cb9b06ac69.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-IE-A4EI-01A	C5E23947-253B-40D2-916A-277B2A580BE2	Primary Tumor	Illumina HiSeq	6070f836-ad03-4454-9395-d7c38f0949c9	Mesenchymal	67.0	1FE30A2F-22A6-4F88-9A3A-7A11359CC151	522DC834-8367-4F49-B93B-FCBA91A2DE7E	TCGA-IE-A4EI-01A-11D-A24N-09	GRCh37-lite	TCGA-IE-A4EI	TCGA-SARC		s2339	Washington University School of Medicine	ABS - IUPUI	United States	NO					A24N-09	True
S13722.58cfa82de4b0c9d6adf6a5b3	58cfa82de4b0c9d6adf6a5b3	551a836dfba4ddbf7b7859a2395b7794.filtered.	WGS	551a836dfba4ddbf7b7859a2395b7794	551a836dfba4ddbf7b7859a2395b7794.bam	30.4		0.09	58cfa82de4b0c9d6adf6a5b3	551a836dfba4ddbf7b7859a2395b7794.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-DX-A3M1-01A	B85E2156-D5AC-486C-93E1-86525EA41A64	Primary Tumor	Illumina HiSeq	bb1d2bd3-0664-4d25-a029-9fe225b91c2e	Mesenchymal	79.0	1AFCDB32-AE26-4747-A131-54E83DD84A46	72F0A49A-AEC8-47E5-846A-956C4DA1507C	TCGA-DX-A3M1-01A-11D-A228-09	GRCh37-lite	TCGA-DX-A3M1	TCGA-SARC		s2338	Washington University School of Medicine	Memorial Sloan Kettering	United States	NO					A228-09	False
S13722.58cfa82de4b0c9d6adf6a5b2	58cfa82de4b0c9d6adf6a5b2	6822184f0a41bd067261cf1591f0dbf6.filtered.	WGS	6822184f0a41bd067261cf1591f0dbf6	6822184f0a41bd067261cf1591f0dbf6.bam	34.66	1.95	0.08	58cfa82de4b0c9d6adf6a5b2	6822184f0a41bd067261cf1591f0dbf6.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A12H-01A	B5B99291-507E-4B68-A039-9A0F571F55DF	Primary Tumor	Illumina HiSeq	55b85b3a-3eed-4a89-ab63-56b85e180571	Breast	69.0	D8AFCB32-81D0-43B3-AD5C-E8C735710624	5A535C49-D42E-43C6-9D32-DC76F28D4F0F	TCGA-AO-A12H-01A-11D-A10Y-09	GRCh37-lite	TCGA-AO-A12H	TCGA-BRCA		s5481	Washington University School of Medicine	MSKCC		NO	T2	N0 (i-)	Other  specify	Stage IIA	A10Y-09	False
S13722.58cfa82de4b0c9d6adf6a5ce	58cfa82de4b0c9d6adf6a5ce	730dac4f2b9e3f7bc83f758dbd514583.filtered.	WGS	730dac4f2b9e3f7bc83f758dbd514583	730dac4f2b9e3f7bc83f758dbd514583.bam	59.62	2.13	0.08	58cfa82de4b0c9d6adf6a5ce	730dac4f2b9e3f7bc83f758dbd514583.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GG-01A	A8614C49-C7F1-4DE9-BD2F-4764B094D604	Primary Tumor	Illumina HiSeq	c4002956-bdc1-4b16-810a-ccf4b006d29b	Uterus	76.0	B5B941E3-F828-4091-B9B1-6B38D1493847	F7187888-F261-4A39-99B4-966FD7207117	TCGA-A5-A0GG-01A-11D-A122-09	GRCh37-lite	TCGA-A5-A0GG	TCGA-UCEC		s5379	Washington University School of Medicine	Cedars Sinai		NO			Endometrioid endometrial adenocarcinoma		A122-09	True
S13722.58cfa82de4b0c9d6adf6a618	58cfa82de4b0c9d6adf6a618	5c56d50bef568c9257651f615ec606b3.filtered.	WGS	5c56d50bef568c9257651f615ec606b3	5c56d50bef568c9257651f615ec606b3.bam	70.96	1.93	0.08	58cfa82de4b0c9d6adf6a618	5c56d50bef568c9257651f615ec606b3.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-EW-A1PH-01A	4DA999A0-EF41-4A0B-B1D1-446B39CC855A	Primary Tumor	Illumina HiSeq	877bbc2d-444f-44cf-8e0f-3fd2744c3f91	Breast	52.0	DD38BA60-656A-46F7-B22B-BCEE3B6D2F19	DF291849-4C35-44E1-B013-8F6B7EE36113	TCGA-EW-A1PH-01A-11D-A17G-09	GRCh37-lite	TCGA-EW-A1PH	TCGA-BRCA		s5951	Washington University School of Medicine	University of Miami	United States	NO	T1c	N1a	Infiltrating Ductal Carcinoma	Stage IIA	A17G-09	False
S13722.58cfa82de4b0c9d6adf6a60c	58cfa82de4b0c9d6adf6a60c	749ef764c5fcf5ac98cf3e0086566a41.filtered.	WGS	749ef764c5fcf5ac98cf3e0086566a41	749ef764c5fcf5ac98cf3e0086566a41.bam	7.51		0.08	58cfa82de4b0c9d6adf6a60c	749ef764c5fcf5ac98cf3e0086566a41.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-DX-A1L3-01A	9517413B-B5B8-4130-8BA1-D86D44ABE2EC	Primary Tumor	Illumina HiSeq	f5fa948e-2119-4b86-8bc3-7ef737ffdffe	Mesenchymal	60.0	19A45767-ABF7-4D53-B096-B59847FC47A8	18EC066E-8510-4921-9E35-45D85FB01E38	TCGA-DX-A1L3-01A-11D-A24N-09	GRCh37-lite	TCGA-DX-A1L3	TCGA-SARC		s2347	Washington University School of Medicine	Memorial Sloan Kettering	United States	NO					A24N-09	True
S13722.58cfa82de4b0c9d6adf6a65e	58cfa82de4b0c9d6adf6a65e	6dfdd72436bacf6a5f435146137eee03.filtered.	WGS	6dfdd72436bacf6a5f435146137eee03	6dfdd72436bacf6a5f435146137eee03.bam	8.01		0.08	58cfa82de4b0c9d6adf6a65e	6dfdd72436bacf6a5f435146137eee03.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-DX-A2J4-01A	F75D2589-FD7B-49A1-A1C8-0B4726B81F3C	Primary Tumor	Illumina HiSeq	ffc58c6a-5a11-4c5f-a5dd-b5082be0dc38	Mesenchymal	60.0	46E59502-D5DF-428B-BEEF-6AD1439B86C6	968929B0-6BFB-4A2C-BD4D-570BFCDB8A6A	TCGA-DX-A2J4-01A-32D-A21Q-09	GRCh37-lite	TCGA-DX-A2J4	TCGA-SARC		s2340	Washington University School of Medicine	Memorial Sloan Kettering	United States	NO					A21Q-09	True
S13722.58cfa82de4b0c9d6adf6a674	58cfa82de4b0c9d6adf6a674	4e9520d4069328bdb2c43937716bc859.filtered.	WGS	4e9520d4069328bdb2c43937716bc859	4e9520d4069328bdb2c43937716bc859.bam	27.88		0.08	58cfa82de4b0c9d6adf6a674	4e9520d4069328bdb2c43937716bc859.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-DX-A3U7-01A	EA3A524B-6EE3-4904-8924-29FCAA20985C	Primary Tumor	Illumina HiSeq	0c2d7c45-b582-429b-bf9f-ed279421c8a6	Mesenchymal	67.0	910CD9B0-5BBE-47E5-8F4C-A6E8AA580281	9E7B51FB-2249-451A-BF23-BB2A3D935928	TCGA-DX-A3U7-01A-11D-A29N-09	GRCh37-lite	TCGA-DX-A3U7	TCGA-SARC		s2487	Washington University School of Medicine	Memorial Sloan Kettering	United States	NO					A29N-09	False
S13722.58cfa82de4b0c9d6adf6a65f	58cfa82de4b0c9d6adf6a65f	5b233e3c073c9b60910bddaec0e5ed79.filtered.	WGS	5b233e3c073c9b60910bddaec0e5ed79	5b233e3c073c9b60910bddaec0e5ed79.bam	71.04	2.0	0.07	58cfa82de4b0c9d6adf6a65f	5b233e3c073c9b60910bddaec0e5ed79.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A11G-01A	D2AA7D70-A25F-4A9E-9D52-37E372461824	Primary Tumor	Illumina HiSeq	bef94a7d-d7f5-4172-9a0c-5b3dc033ca00	Uterus	71.0	FE5D8E64-98B1-4EA7-ADDA-F28D12349A7E	42DE1441-6F3C-4B4D-B8B8-AD91E4B1DBE2	TCGA-B5-A11G-01A-13D-A122-09	GRCh37-lite	TCGA-B5-A11G	TCGA-UCEC		s4411	Washington University School of Medicine	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A122-09	True
S13722.58cfa82de4b0c9d6adf6a6d4	58cfa82de4b0c9d6adf6a6d4	84cabc6d988c220d0be27b3d2d76db69.filtered.	WGS	84cabc6d988c220d0be27b3d2d76db69	84cabc6d988c220d0be27b3d2d76db69.bam	17.19		0.08	58cfa82de4b0c9d6adf6a6d4	84cabc6d988c220d0be27b3d2d76db69.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-IE-A4EK-01A	590FDB76-20EF-4F95-9783-7D80E7A25E5A	Primary Tumor	Illumina HiSeq	01fcfdba-18c9-4abf-84be-b5fbac48d25a	Mesenchymal	54.0	9963DA13-6EA7-48A3-A3DE-1C6A38F977B9	56681386-D407-4F53-AE4F-6C04437652F7	TCGA-IE-A4EK-01A-11D-A24N-09	GRCh37-lite	TCGA-IE-A4EK	TCGA-SARC		s2494	Washington University School of Medicine	ABS - IUPUI	United States	NO					A24N-09	True
S13722.58cfa82de4b0c9d6adf6a6da	58cfa82de4b0c9d6adf6a6da	917393fd54d541ee5bf939911e9e1142.filtered.	WGS	917393fd54d541ee5bf939911e9e1142	917393fd54d541ee5bf939911e9e1142.bam	17.01		0.08	58cfa82de4b0c9d6adf6a6da	917393fd54d541ee5bf939911e9e1142.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-MO-A47R-01A	8654C2B5-27D7-43C5-9A39-7FDEFD7A0324	Primary Tumor	Illumina HiSeq	1e530776-868a-4b43-ac6b-7e692691b675	Mesenchymal	75.0	3D38F7C9-00DD-47C1-8649-C50574953AAB	7A5D3B6B-BE5A-4E55-9255-32A069B8AF3D	TCGA-MO-A47R-01A-11D-A24N-09	GRCh37-lite	TCGA-MO-A47R	TCGA-SARC		s2492	Washington University School of Medicine	ILSbio	Vietnam	NO					A24N-09	True
S13722.58cfa82ee4b0c9d6adf6a8f4	58cfa82ee4b0c9d6adf6a8f4	G32456.TCGA-CF-A3MF-01A-12D-A21A-08.2.filtered.	WGS	G32456.TCGA-CF-A3MF-01A-12D-A21A-08.2	G32456.TCGA-CF-A3MF-01A-12D-A21A-08.2.bam	55.07		0.08	58cfa82ee4b0c9d6adf6a8f4	G32456.TCGA-CF-A3MF-01A-12D-A21A-08.2.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A3MF-01A	1E308B12-0590-4DAE-94D0-A539FCF25DF7	Primary Tumor	Illumina HiSeq	62e960fb-aaf6-4d7e-b15d-1b5136f6fa37	Bladder	34.0	E9889071-4C6E-4761-9D65-06C6B5989FB7	C66C92D5-DF65-46E6-861D-D8A98808E6A3	TCGA-CF-A3MF-01A-12D-A21A-08	HG19_Broad_variant	TCGA-CF-A3MF	TCGA-BLCA		s2683	Broad Institute of MIT and Harvard	ILSbio	Vietnam	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A21A-08	True
S13722.58cfa82ee4b0c9d6adf6a966	58cfa82ee4b0c9d6adf6a966	G35154.TCGA-HW-7487-01A-11D-2024-08.3.filtered.	WGS	G35154.TCGA-HW-7487-01A-11D-2024-08.3	G35154.TCGA-HW-7487-01A-11D-2024-08.3.bam	85.0		0.05	58cfa82ee4b0c9d6adf6a966	G35154.TCGA-HW-7487-01A-11D-2024-08.3.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HW-7487-01A	42251E02-B687-4BF1-A1B6-E3DD978542E4	Primary Tumor	Illumina HiSeq	efb882b9-fe40-4205-a704-5757740ee898	Brain	39.0	3040F10C-04E1-4CF8-8EAD-D74C856425C8	C1ABB741-4FCD-4161-B057-C7EFD619CC99	TCGA-HW-7487-01A-11D-2024-08	HG19_Broad_variant	TCGA-HW-7487	TCGA-LGG		s8550	Broad Institute of MIT and Harvard	MSKCC	United States	NO			Oligodendroglioma		2024-08	False
S13722.58cfa82ee4b0c9d6adf6a974	58cfa82ee4b0c9d6adf6a974	G32462.TCGA-DK-A1A7-01A-11D-A13W-08.1.filtered.	WGS	G32462.TCGA-DK-A1A7-01A-11D-A13W-08.1	G32462.TCGA-DK-A1A7-01A-11D-A13W-08.1.bam	35.04	2.0	0.07	58cfa82ee4b0c9d6adf6a974	G32462.TCGA-DK-A1A7-01A-11D-A13W-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1A7-01A	3ED614E7-F356-4D87-985B-D3BBBAE3BB40	Primary Tumor	Illumina HiSeq	7a0d461d-525e-4b3a-86d1-d6d3306fb405	Bladder	67.0	D68D16F7-6117-4D3D-8347-CF5CD3F23AE4	91F458E6-64B7-454D-A542-B0AA23638FD8	TCGA-DK-A1A7-01A-11D-A13W-08	HG19_Broad_variant	TCGA-DK-A1A7	TCGA-BLCA		s3070	Broad Institute of MIT and Harvard	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13W-08	True
S13722.58cfa82ee4b0c9d6adf6aa88	58cfa82ee4b0c9d6adf6aa88	G32469.TCGA-DK-A1AG-01A-11D-A13W-08.2.filtered.	WGS	G32469.TCGA-DK-A1AG-01A-11D-A13W-08.2	G32469.TCGA-DK-A1AG-01A-11D-A13W-08.2.bam	70.38	1.89	0.08	58cfa82ee4b0c9d6adf6aa88	G32469.TCGA-DK-A1AG-01A-11D-A13W-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AG-01A	F8C0A69C-DF53-4A0A-A30E-4424C0CE3DD5	Primary Tumor	Illumina HiSeq	9ef4c333-8532-4ab7-bd4b-ba1161f87a6d	Bladder	65.0	64668AA0-DDE5-4534-8CD0-378881E4A4E4	7D2A22EB-7344-4CBA-AD7D-94C3F9EF3D7C	TCGA-DK-A1AG-01A-11D-A13W-08	HG19_Broad_variant	TCGA-DK-A1AG	TCGA-BLCA		s2848	Broad Institute of MIT and Harvard	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13W-08	True
S13722.58cfa82ee4b0c9d6adf6ab22	58cfa82ee4b0c9d6adf6ab22	G32467.TCGA-DK-A1A6-01A-11D-A13W-08.3.filtered.	WGS	G32467.TCGA-DK-A1A6-01A-11D-A13W-08.3	G32467.TCGA-DK-A1A6-01A-11D-A13W-08.3.bam	85.12	1.95	0.08	58cfa82ee4b0c9d6adf6ab22	G32467.TCGA-DK-A1A6-01A-11D-A13W-08.3.bam	Alive	MALE	WHITE		Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1A6-01A	9C274536-3CA1-4F0E-93A8-1688074D862F	Primary Tumor	Illumina HiSeq	694693d8-dc04-4516-bc18-e8a9ccb24d28	Bladder	53.0	7AD1CD01-0EA2-4FA4-9B05-C280BD256546	DF8A913C-5160-4FC5-950D-7C890E24E820	TCGA-DK-A1A6-01A-11D-A13W-08	HG19_Broad_variant	TCGA-DK-A1A6	TCGA-BLCA		s2847	Broad Institute of MIT and Harvard	Memorial Sloan Kettering	United States	NO	T2a	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13W-08	True
S13722.58cfa82ee4b0c9d6adf6ab86	58cfa82ee4b0c9d6adf6ab86	G35153.TCGA-BA-A4IH-01A-11D-A25T-08.5.filtered.	WGS	G35153.TCGA-BA-A4IH-01A-11D-A25T-08.5	G35153.TCGA-BA-A4IH-01A-11D-A25T-08.5.bam	39.39		0.07	58cfa82ee4b0c9d6adf6ab86	G35153.TCGA-BA-A4IH-01A-11D-A25T-08.5.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-A4IH-01A	BD75D8EE-916B-4ABC-BF33-BCE6A4217076	Primary Tumor	Illumina HiSeq	dc2ac994-c455-4e1f-9319-2865614853ba	Head and Neck	57.0	F87EFB5E-24F5-4D2B-B6B3-987BBDA30E03	B537BC07-9998-49F4-BBBE-5B617152BFD9	TCGA-BA-A4IH-01A-11D-A25T-08	HG19_Broad_variant	TCGA-BA-A4IH	TCGA-HNSC		s15747	Broad Institute of MIT and Harvard	UNC	United States	NO	T2	N1	Head and Neck Squamous Cell Carcinoma Basaloid Type	Stage IVA	A25T-08	False
S13722.58cfa82ee4b0c9d6adf6abb8	58cfa82ee4b0c9d6adf6abb8	G32453.TCGA-DK-A3IL-01A-11D-A20D-08.3.filtered.	WGS	G32453.TCGA-DK-A3IL-01A-11D-A20D-08.3	G32453.TCGA-DK-A3IL-01A-11D-A20D-08.3.bam	32.38		0.08	58cfa82ee4b0c9d6adf6abb8	G32453.TCGA-DK-A3IL-01A-11D-A20D-08.3.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IL-01A	178B28CD-99C3-48DC-8D09-1EF71B4CEE80	Primary Tumor	Illumina HiSeq	092f2192-b2d3-48e8-be2f-f56c1febe40b	Bladder	79.0	59D6683F-5EB7-493D-8E8E-78B88BE2CD70	4838B5A9-968C-4178-BFFB-3FAFE1F6DC09	TCGA-DK-A3IL-01A-11D-A20D-08	HG19_Broad_variant	TCGA-DK-A3IL	TCGA-BLCA		s2844	Broad Institute of MIT and Harvard	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A20D-08	True
S13722.58cfa82ee4b0c9d6adf6abd6	58cfa82ee4b0c9d6adf6abd6	G32535.TCGA-FK-A3SE-01A-11D-A22D-08.1.filtered.	WGS	G32535.TCGA-FK-A3SE-01A-11D-A22D-08.1	G32535.TCGA-FK-A3SE-01A-11D-A22D-08.1.bam	31.42		0.08	58cfa82ee4b0c9d6adf6abd6	G32535.TCGA-FK-A3SE-01A-11D-A22D-08.1.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FK-A3SE-01A	AFB00CD4-E5DA-4251-86FB-532C3F65324C	Primary Tumor	Illumina HiSeq	e2561be5-1c52-4774-a3d5-2a7800d87c6a	Thyroid	31.0	D3CC158D-413D-49E6-8D23-3ED89FDEA94A	90883300-D4B6-45D7-AF9A-4E4CE4104500	TCGA-FK-A3SE-01A-11D-A22D-08	HG19_Broad_variant	TCGA-FK-A3SE	TCGA-THCA		s12216	Broad Institute of MIT and Harvard	Johns Hopkins	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A22D-08	True
S13722.58cfa82ee4b0c9d6adf6ac56	58cfa82ee4b0c9d6adf6ac56	G39020.TCGA-BR-6452-01A-12D-1800-08.1.filtered.	WGS	G39020.TCGA-BR-6452-01A-12D-1800-08.1	G39020.TCGA-BR-6452-01A-12D-1800-08.1.bam	409.4	1.9	0.05	58cfa82ee4b0c9d6adf6ac56	G39020.TCGA-BR-6452-01A-12D-1800-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6452-01A	27988B3E-CDE1-4F4B-82A1-6D8AD08DB8E9	Primary Tumor	Illumina HiSeq	e69add2b-1a4d-44e6-8186-3fb2163afa5f	Stomach	78.0	76144F2F-2498-430D-B33C-F000394C427E	C8E961B4-E324-40A2-89F6-736EC3845BC9	TCGA-BR-6452-01A-12D-1800-08	HG19_Broad_variant	TCGA-BR-6452	TCGA-STAD		s14524	Broad Institute of MIT and Harvard	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1800-08	True
S13722.58cfa82ee4b0c9d6adf6ad73	58cfa82ee4b0c9d6adf6ad73	G32529.TCGA-ET-A3DV-01A-12D-A202-08.3.filtered.	WGS	G32529.TCGA-ET-A3DV-01A-12D-A202-08.3	G32529.TCGA-ET-A3DV-01A-12D-A202-08.3.bam	16.24		0.08	58cfa82ee4b0c9d6adf6ad73	G32529.TCGA-ET-A3DV-01A-12D-A202-08.3.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A3DV-01A	B46D88E9-8477-4900-8DA9-5E7DBDED0653	Primary Tumor	Illumina HiSeq	6319fae0-343d-45e8-a507-cc9f7acf1b38	Thyroid	68.0	CE24FE0A-5C4D-4FBE-A02C-76345EAA2892	5DEEAA45-4C1B-4AB2-A487-93C548838F68	TCGA-ET-A3DV-01A-12D-A202-08	HG19_Broad_variant	TCGA-ET-A3DV	TCGA-THCA		s12343	Broad Institute of MIT and Harvard	Johns Hopkins	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A202-08	True
S13722.58cfa830e4b0c9d6adf6bb98	58cfa830e4b0c9d6adf6bb98	TCGA-A2-A0D0-01A-11D-A128-09_IlluminaGA-DNASeq_whole.filtered.	WGS	TCGA-A2-A0D0-01A-11D-A128-09_IlluminaGA-DNASeq_whole	TCGA-A2-A0D0-01A-11D-A128-09_IlluminaGA-DNASeq_whole.bam	66.88	1.91	0.08	58cfa830e4b0c9d6adf6bb98	TCGA-A2-A0D0-01A-11D-A128-09_IlluminaGA-DNASeq_whole.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A0D0-01A	324BCBA2-F6A4-45A6-807C-215BDFFCCA21	Primary Tumor	Illumina HiSeq	25ddf041-bc97-4ced-aa1a-cf0339d8c23b	Breast	60.0	7FD5702E-2D7B-4B79-B2D8-5CA4CA33CF65	71FDA5A9-7049-406F-9348-2C24F7DDF5F4	TCGA-A2-A0D0-01A-11D-A128-09	GRCh37-lite	TCGA-A2-A0D0	TCGA-BRCA		s6270	Washington University School of Medicine	Walter Reed		NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A128-09	True
S13722.58cfa830e4b0c9d6adf6bcbd	58cfa830e4b0c9d6adf6bcbd	TCGA-B0-5693-01A-11D-2103-10_Illumina.filtered.	WGS	TCGA-B0-5693-01A-11D-2103-10_Illumina	TCGA-B0-5693-01A-11D-2103-10_Illumina.bam	344.4	1.9	0.14	58cfa830e4b0c9d6adf6bcbd	TCGA-B0-5693-01A-11D-2103-10_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-B0-5693-01A	DB058EB4-9C5E-4226-92D1-DE24AEA83630	Primary Tumor	Illumina HiSeq	4a0c2db0-f10b-41b1-8aca-fcd712b7f672	Kidney	47.0	20A21A6F-F615-47F7-9935-B330B116D51B	FB194CA3-10AA-4DC5-8D08-619DDBD6D1B6	TCGA-B0-5693-01A-11D-2103-10	GRCh37-lite	TCGA-B0-5693	TCGA-KIRC		s9937	Baylor College of Medicine	University of Pittsburgh		NO	T1b	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2103-10	False
S13722.58cfa830e4b0c9d6adf6bdea	58cfa830e4b0c9d6adf6bdea	TCGA-BH-A0B9-01A-11D-A128-09_IlluminaGA-DNASeq_whole.filtered.	WGS	TCGA-BH-A0B9-01A-11D-A128-09_IlluminaGA-DNASeq_whole	TCGA-BH-A0B9-01A-11D-A128-09_IlluminaGA-DNASeq_whole.bam	73.41	1.97	0.07	58cfa830e4b0c9d6adf6bdea	TCGA-BH-A0B9-01A-11D-A128-09_IlluminaGA-DNASeq_whole.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0B9-01A	5A57DC25-D252-4B22-B192-4DE630D7002F	Primary Tumor	Illumina HiSeq	1a49cb56-547c-4a77-84e6-116bc406ba19	Breast	44.0	8137FFEE-BB4F-4E5F-B831-ACFC9C5585A8	CF599959-6AAF-48EA-8A15-8EF09163BAD7	TCGA-BH-A0B9-01A-11D-A128-09	GRCh37-lite	TCGA-BH-A0B9	TCGA-BRCA		s6770	Washington University School of Medicine	University of Pittsburgh		NO	T1c	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IA	A128-09	True
S13722.58cfa830e4b0c9d6adf6bdf1	58cfa830e4b0c9d6adf6bdf1	TCGA-AK-3428-01A-02D-2096-10_Illumina.filtered.	WGS	TCGA-AK-3428-01A-02D-2096-10_Illumina	TCGA-AK-3428-01A-02D-2096-10_Illumina.bam	23.4	1.9	0.14	58cfa830e4b0c9d6adf6bdf1	TCGA-AK-3428-01A-02D-2096-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-AK-3428-01A	9DA334ED-314C-4445-BA29-FFD9BB42403C	Primary Tumor	Illumina HiSeq	46d21c8f-8493-4886-82f4-91fd488b4364	Kidney	62.0	0B96A41E-6A0C-4FC6-8F21-8E5F992CE5D1	D01710F9-EFC8-4B5F-9E53-300B30F9219F	TCGA-AK-3428-01A-02D-2096-10	GRCh37-lite	TCGA-AK-3428	TCGA-KIRC		s9303	Baylor College of Medicine	Fox Chase		NO	T3b	N0	Kidney Clear Cell Renal Carcinoma	Stage III	2096-10	False
S13722.58cfa830e4b0c9d6adf6bdf8	58cfa830e4b0c9d6adf6bdf8	TCGA-AK-3454-01A-02D-2096-10_wgs_Illumina.filtered.	WGS	TCGA-AK-3454-01A-02D-2096-10_wgs_Illumina	TCGA-AK-3454-01A-02D-2096-10_wgs_Illumina.bam	28.07	1.9	0.15	58cfa830e4b0c9d6adf6bdf8	TCGA-AK-3454-01A-02D-2096-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-AK-3454-01A	28E9B6F9-AB6A-400B-A6A9-79095A443591	Primary Tumor	Illumina HiSeq	54d1e202-1017-4494-af06-5b5747b7201c	Kidney	84.0	74741322-3B24-43E6-9CE1-F267B0555F62	FD74DE4D-6973-4597-A541-E8A13D80AD55	TCGA-AK-3454-01A-02D-2096-10	GRCh37-lite	TCGA-AK-3454	TCGA-KIRC		s9731	Baylor College of Medicine	Fox Chase	United States	NO	T1b	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2096-10	False
S13722.58cfa831e4b0c9d6adf6cc42	58cfa831e4b0c9d6adf6cc42	TCGA-DV-5566-01A-01D-2104-10_wgs_Illumina.filtered.	WGS	TCGA-DV-5566-01A-01D-2104-10_wgs_Illumina	TCGA-DV-5566-01A-01D-2104-10_wgs_Illumina.bam	124.4	1.9	0.16	58cfa831e4b0c9d6adf6cc42	TCGA-DV-5566-01A-01D-2104-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-DV-5566-01A	4B2EC8AA-8460-440E-B75B-6B92AE7A3FFC	Primary Tumor	Illumina HiSeq	67e2d2b4-5d60-46c8-85b0-236331ed66a8	Kidney	67.0	58578D50-1E0C-4F5E-929A-C969C5346B05	BCF54C96-2B62-4E24-926F-D77576250DD1	TCGA-DV-5566-01A-01D-2104-10	GRCh37-lite	TCGA-DV-5566	TCGA-KIRC		s8844	Baylor College of Medicine	NCI Urologic Oncology Branch		NO	T1a	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2104-10	False
S13722.58cfa83ce4b0c9d6adf72eb0	58cfa83ce4b0c9d6adf72eb0	cea4bc4275e349522246f3666f7965b5.filtered.	WGS	cea4bc4275e349522246f3666f7965b5	cea4bc4275e349522246f3666f7965b5.bam	46.1	1.75	0.09	58cfa83ce4b0c9d6adf72eb0	cea4bc4275e349522246f3666f7965b5.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-D8-A27F-01A	1549DC64-3DAB-43FC-96E9-B07D520957E1	Primary Tumor	Illumina HiSeq	f4f2c07e-84b7-47d0-88fe-7032564a1ecc	Breast	40.0	7E9145F7-CCFF-4132-B2B7-9B992EEBEBF4	FC6D77A9-121B-48AB-A899-713C3D1319A2	TCGA-D8-A27F-01A-11D-A16D-09	GRCh37-lite	TCGA-D8-A27F	TCGA-BRCA		s6967	Washington University School of Medicine	Greater Poland Cancer Center	Poland	NO	T2	N0	Infiltrating Ductal Carcinoma	Stage IIA	A16D-09	False
S13722.58cfa83ce4b0c9d6adf72edb	58cfa83ce4b0c9d6adf72edb	df4a0a1fa966f237f85dc788514a4f3f.filtered.	WGS	df4a0a1fa966f237f85dc788514a4f3f	df4a0a1fa966f237f85dc788514a4f3f.bam	18.8		0.08	58cfa83ce4b0c9d6adf72edb	df4a0a1fa966f237f85dc788514a4f3f.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-EW-A3U0-01A	D9DC3B59-613D-469E-8B4F-6C5A557EB26A	Primary Tumor	Illumina HiSeq	107557e5-5611-4f30-9544-e8c315cb063d	Breast	61.0	549F03A5-3F91-4975-9EEB-AA062264A602	0448206F-3ADE-4087-B1A9-4FB2D14E1367	TCGA-EW-A3U0-01A-11D-A228-09	GRCh37-lite	TCGA-EW-A3U0	TCGA-BRCA		s6610	Washington University School of Medicine	University of Miami	United States	NO	T3	N1a	Infiltrating Ductal Carcinoma	Stage IIIA	A228-09	False
S13722.58cfa83ce4b0c9d6adf72ef4	58cfa83ce4b0c9d6adf72ef4	adc8fcb8e8a780076e27704767013d83.filtered.	WGS	adc8fcb8e8a780076e27704767013d83	adc8fcb8e8a780076e27704767013d83.bam	15.93		0.08	58cfa83ce4b0c9d6adf72ef4	adc8fcb8e8a780076e27704767013d83.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-DX-A240-01A	3608BFBB-2A92-4EC2-A330-BF4790A8B65C	Primary Tumor	Illumina HiSeq	d31b896e-0c05-4b82-9143-a039f927b80f	Mesenchymal	51.0	8ACAF190-5A0D-440C-9C9A-B9EABDF661BE	3DB6E6CC-1A06-49B9-834E-B6611CDE4C4B	TCGA-DX-A240-01A-32D-A27P-09	GRCh37-lite	TCGA-DX-A240	TCGA-SARC		s2670	Washington University School of Medicine	Memorial Sloan Kettering	United States	NO					A27P-09	False
S13722.58cfa83ce4b0c9d6adf72f45	58cfa83ce4b0c9d6adf72f45	e731bc4a6b242f2c3e68d238e90047f3.filtered.	WGS	e731bc4a6b242f2c3e68d238e90047f3	e731bc4a6b242f2c3e68d238e90047f3.bam	50.54	1.82	0.08	58cfa83ce4b0c9d6adf72f45	e731bc4a6b242f2c3e68d238e90047f3.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-DX-A23R-01A	B5F27002-4277-418D-90B0-CC5A2742692E	Primary Tumor	Illumina HiSeq	8611bde3-531a-4ac4-a742-255c5bd80352	Mesenchymal	55.0	05FC5924-07B1-422E-9D7C-7C0051F72368	35C797FD-CA81-4CEF-B6C4-7E3776F661B3	TCGA-DX-A23R-01A-11D-A26G-09	GRCh37-lite	TCGA-DX-A23R	TCGA-SARC		s2632	Washington University School of Medicine	Memorial Sloan Kettering	United States	NO					A26G-09	False
S13722.58cfa83ce4b0c9d6adf72f2c	58cfa83ce4b0c9d6adf72f2c	e886a9905c6ddb08a07cd12351b2978e.filtered.	WGS	e886a9905c6ddb08a07cd12351b2978e	e886a9905c6ddb08a07cd12351b2978e.bam	6.36		0.07	58cfa83ce4b0c9d6adf72f2c	e886a9905c6ddb08a07cd12351b2978e.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-DX-A1L2-01A	73D2E8EF-4E10-416A-845B-F48374E48ECB	Primary Tumor	Illumina HiSeq	f6170f04-5598-4fb8-9027-6176921b624d	Mesenchymal	78.0	901DFD62-799D-4E40-926E-22A5FD859B5A	4C59FB2D-21B6-4B09-8174-6102DE736E4D	TCGA-DX-A1L2-01A-22D-A24N-09	GRCh37-lite	TCGA-DX-A1L2	TCGA-SARC		s2633	Washington University School of Medicine	Memorial Sloan Kettering	United States	NO					A24N-09	True
S13722.58cfa83ce4b0c9d6adf72f9a	58cfa83ce4b0c9d6adf72f9a	a246b48a0a312eda5cafb748151a117b.filtered.	WGS	a246b48a0a312eda5cafb748151a117b	a246b48a0a312eda5cafb748151a117b.bam	74.65	1.93	0.09	58cfa83ce4b0c9d6adf72f9a	a246b48a0a312eda5cafb748151a117b.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-AR-A24Z-01A	9FEFBE7C-F66A-4940-843E-285CB7B392C1	Primary Tumor	Illumina HiSeq	1251c29c-8d85-4187-80dd-c459542e3080	Breast	57.0	5CDD3886-898B-4861-A748-D4164CE14A07	6C65CB6D-8C50-4C7C-BC84-EEEBE09FBE01	TCGA-AR-A24Z-01A-11D-A314-09	GRCh37-lite	TCGA-AR-A24Z	TCGA-BRCA		s5942	Washington University School of Medicine	Mayo	United States	NO	T2	N0	Infiltrating Ductal Carcinoma	Stage IIA	A314-09	True
S13722.58cfa83ce4b0c9d6adf72f73	58cfa83ce4b0c9d6adf72f73	f0f3dfb66995edcb514e1ccebc2c7e4d.filtered.	WGS	f0f3dfb66995edcb514e1ccebc2c7e4d	f0f3dfb66995edcb514e1ccebc2c7e4d.bam	61.2	1.96	0.09	58cfa83ce4b0c9d6adf72f73	f0f3dfb66995edcb514e1ccebc2c7e4d.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-C8-A130-01A	8CF54607-01CE-42B0-9BD9-8627EDD9F3B7	Primary Tumor	Illumina HiSeq	e70e14f9-ea63-4038-8a0e-5526391ea4fe	Breast	52.0	3BEA8456-DA16-4691-A260-5C94A83E2860	27F87D1E-2C32-4BEB-9677-62F7A286673D	TCGA-C8-A130-01A-31D-A19H-09	GRCh37-lite	TCGA-C8-A130	TCGA-BRCA		s6751	Washington University School of Medicine	ILSbio	Vietnam	NO	T3	N2	Infiltrating Ductal Carcinoma	Stage IIIA	A19H-09	True
S13722.58cfa83ce4b0c9d6adf72fb2	58cfa83ce4b0c9d6adf72fb2	a71534313dd3551e1b02d0eed8d54add.filtered.	WGS	a71534313dd3551e1b02d0eed8d54add	a71534313dd3551e1b02d0eed8d54add.bam	55.26		0.08	58cfa83ce4b0c9d6adf72fb2	a71534313dd3551e1b02d0eed8d54add.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AR-A2LK-01A	1B703058-E596-45BC-80FE-8B98D545C2E2	Primary Tumor	Illumina HiSeq	452eb1a3-2221-409b-a97e-f3266c5737cd	Breast	62.0	D6F5C34A-0F5C-4AED-977A-74A1E5D50915	7B0B60C7-5FA0-440E-937F-8D82119330D6	TCGA-AR-A2LK-01A-11D-A17W-09	GRCh37-lite	TCGA-AR-A2LK	TCGA-BRCA		s6746	Washington University School of Medicine	Mayo	United States	NO	T3	N2	Infiltrating Lobular Carcinoma	Stage III	A17W-09	False
S13722.58cfa83ce4b0c9d6adf730ac	58cfa83ce4b0c9d6adf730ac	ac2e74d430052ab39f0e2d8a23113736.filtered.	WGS	ac2e74d430052ab39f0e2d8a23113736	ac2e74d430052ab39f0e2d8a23113736.bam	33.01		0.1	58cfa83ce4b0c9d6adf730ac	ac2e74d430052ab39f0e2d8a23113736.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-GI-A2C9-01A	9F6BE944-83DE-42AB-8738-F0022F475E61	Primary Tumor	Illumina HiSeq	5f4a8fdf-00c0-4ab7-8323-d04f23a9e4a8	Breast	58.0	143FC27D-E119-48FF-A5EA-BD6AAFC0404E	5DBF3203-CE73-41E4-BF9A-32FC856F73F5	TCGA-GI-A2C9-01A-11D-A21Q-09	GRCh37-lite	TCGA-GI-A2C9	TCGA-BRCA		s5943	Washington University School of Medicine	ABS - IUPUI	United States	NO	T3	N0	Infiltrating Ductal Carcinoma	Stage IIB	A21Q-09	True
S13722.58cfa83ce4b0c9d6adf730ed	58cfa83ce4b0c9d6adf730ed	b2e10818826b4072c8f92e5b678b4332.filtered.	WGS	b2e10818826b4072c8f92e5b678b4332	b2e10818826b4072c8f92e5b678b4332.bam	76.73	1.92	0.08	58cfa83ce4b0c9d6adf730ed	b2e10818826b4072c8f92e5b678b4332.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0IQ-01A	01EEF340-598C-4205-A990-CEC190AC2CA5	Primary Tumor	Illumina HiSeq	7f45dc68-74e8-4953-8221-00c2ba51dee4	Breast	40.0	183A47B2-1B00-4A72-ADEB-F35B55692EE1	8956D73D-7E36-4129-8A3E-D4F3B43BAF0B	TCGA-B6-A0IQ-01A-11D-A128-09	GRCh37-lite	TCGA-B6-A0IQ	TCGA-BRCA		s6102	Washington University School of Medicine	Duke	United States	NO	T3	N1b	Infiltrating Ductal Carcinoma	Stage IIIA	A128-09	True
S13722.58cfa83ce4b0c9d6adf730e0	58cfa83ce4b0c9d6adf730e0	ee32938babfe9b6967e9a4c5f49435dd.filtered.	WGS	ee32938babfe9b6967e9a4c5f49435dd	ee32938babfe9b6967e9a4c5f49435dd.bam	84.77	1.86	0.08	58cfa83ce4b0c9d6adf730e0	ee32938babfe9b6967e9a4c5f49435dd.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LD-01A	1200C8B7-A058-4C01-BBE2-04EC09A65245	Primary Tumor	Illumina HiSeq	d3a5aa02-ef8e-4ad1-adca-1c4b867fe524	Uterus	63.0	649DADDA-5823-4B0D-B5A2-49F501ADC029	9D2671B9-BD30-4E3C-AA74-01E31DD2531E	TCGA-AP-A0LD-01A-11D-A066-09	GRCh37-lite	TCGA-AP-A0LD	TCGA-UCEC		s5185	Washington University School of Medicine	MSKCC		NO			Endometrioid endometrial adenocarcinoma		A066-09	True
S13722.58cfa83ce4b0c9d6adf730fa	58cfa83ce4b0c9d6adf730fa	c03fa22a7c8629afd7ba660ae443cddc.filtered.	WGS	c03fa22a7c8629afd7ba660ae443cddc	c03fa22a7c8629afd7ba660ae443cddc.bam	74.86	1.88	0.08	58cfa83ce4b0c9d6adf730fa	c03fa22a7c8629afd7ba660ae443cddc.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A04Q-01A	B5FBA77B-1F50-4E71-95B2-566AFBA4BDD7	Primary Tumor	Illumina HiSeq	77a8d1fa-9421-4333-b128-8a4b8fddfc6f	Breast	48.0	E17E273D-6F53-4419-9F0C-1E4E667C5257	03B8122D-02D9-4AD0-96ED-001C0D100DE0	TCGA-A2-A04Q-01A-21D-A128-09	GRCh37-lite	TCGA-A2-A04Q	TCGA-BRCA		s6903	Washington University School of Medicine	Walter Reed		NO	T1	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IA	A128-09	True
S13722.58cfa83ce4b0c9d6adf730c0	58cfa83ce4b0c9d6adf730c0	fd78ff5c667f21aef8657e218f7021a2.filtered.	WGS	fd78ff5c667f21aef8657e218f7021a2	fd78ff5c667f21aef8657e218f7021a2.bam	24.76		0.08	58cfa83ce4b0c9d6adf730c0	fd78ff5c667f21aef8657e218f7021a2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-FX-A3NJ-01A	7BAB6742-4E3D-4FCF-9B90-D3E0218B4D79	Primary Tumor	Illumina HiSeq	4031a13e-df1e-4608-8d52-01b9b1c04b9d	Mesenchymal	54.0	29FDA349-D725-4F69-BB11-95D5454400F4	408ED640-75F6-4346-BDD0-3B93C51ADAE5	TCGA-FX-A3NJ-01A-11D-A21Q-09	GRCh37-lite	TCGA-FX-A3NJ	TCGA-SARC		s2672	Washington University School of Medicine	International Genomics Consortium	United States	NO					A21Q-09	True
S13722.58cfa83ce4b0c9d6adf7313a	58cfa83ce4b0c9d6adf7313a	ff180684131876b77d5fa19e93aaeb1e.filtered.	WGS	ff180684131876b77d5fa19e93aaeb1e	ff180684131876b77d5fa19e93aaeb1e.bam	52.23		0.08	58cfa83ce4b0c9d6adf7313a	ff180684131876b77d5fa19e93aaeb1e.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-IW-A3M4-01A	0DA5EE6C-D012-4A57-9992-9D74937AAA5F	Primary Tumor	Illumina HiSeq	62a7d6f2-3b71-4449-83fe-da6beea65873	Mesenchymal	48.0	F854DB6B-57CB-4DA7-9252-B2ADE22C2675	6AA00162-6294-4CE7-B6B7-0C3452E24CD6	TCGA-IW-A3M4-01A-11D-A21Q-09	GRCh37-lite	TCGA-IW-A3M4	TCGA-SARC		s2673	Washington University School of Medicine	Cedars Sinai	United States	NO					A21Q-09	True
S13722.58cfa83ce4b0c9d6adf731b8	58cfa83ce4b0c9d6adf731b8	b063d293e0df48fc160fc08c84c39531.filtered.	WGS	b063d293e0df48fc160fc08c84c39531	b063d293e0df48fc160fc08c84c39531.bam	9.71		0.08	58cfa83ce4b0c9d6adf731b8	b063d293e0df48fc160fc08c84c39531.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-DX-A3LW-01A	2CACD9D0-8414-4F17-8259-C9D838597F39	Primary Tumor	Illumina HiSeq	0524db0d-7118-4575-ae31-3f7ebbf000c4	Mesenchymal	43.0	E25B5088-A3D4-4F3C-8335-308C571F6A30	9D691FA3-5C32-4B98-85C4-F6E0FD4C37E0	TCGA-DX-A3LW-01A-21D-A21Q-09	GRCh37-lite	TCGA-DX-A3LW	TCGA-SARC		s2460	Washington University School of Medicine	Memorial Sloan Kettering	United States	NO					A21Q-09	True
S13722.58cfa83ce4b0c9d6adf7308c	58cfa83ce4b0c9d6adf7308c	faba826f62de3e18afab489ceee4b813.filtered.	WGS	faba826f62de3e18afab489ceee4b813	faba826f62de3e18afab489ceee4b813.bam	6.41		0.07	58cfa83ce4b0c9d6adf7308c	faba826f62de3e18afab489ceee4b813.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-DX-A1KW-01A	CD73A55F-03C1-4DA0-9FA7-1AE4A263664E	Primary Tumor	Illumina HiSeq	1ac5c6a6-b264-4f58-b9fb-983c540128a7	Mesenchymal	67.0	4C93C0A4-73C4-48EF-91E0-40B2143833BC	63DB50D6-5EF2-44D0-9906-26EAE74ECF44	TCGA-DX-A1KW-01A-22D-A24N-09	GRCh37-lite	TCGA-DX-A1KW	TCGA-SARC		s2636	Washington University School of Medicine	Memorial Sloan Kettering	United States	NO					A24N-09	True
S13722.58cfa83ce4b0c9d6adf73082	58cfa83ce4b0c9d6adf73082	f56bc74c20a188c53b338d30ab71d4e2.filtered.	WGS	f56bc74c20a188c53b338d30ab71d4e2	f56bc74c20a188c53b338d30ab71d4e2.bam	89.42	1.98	0.08	58cfa83ce4b0c9d6adf73082	f56bc74c20a188c53b338d30ab71d4e2.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A1BJ-01A	7941D1C7-5319-4E8D-A15F-60B61CB68A9B	Primary Tumor	Illumina HiSeq	0990b367-e2b6-4b2a-8ca1-dd9efab1866a	Cervix	34.0	C7B95D35-7FE9-4C25-94C6-AE6D7416A5C7	43BE43CB-A367-4A74-94E4-973ACAFCF576	TCGA-C5-A1BJ-01A-11D-A200-09	GRCh37-lite	TCGA-C5-A1BJ	TCGA-CESC		s1344	Washington University School of Medicine	Medical College of Wisconsin	United States	NO			Cervical Squamous Cell Carcinoma		A200-09	True
S13722.58cfa82de4b0c9d6adf6a464	58cfa82de4b0c9d6adf6a464	459f50a1a35d272785306ecb71cc5754.filtered.	WGS	459f50a1a35d272785306ecb71cc5754	459f50a1a35d272785306ecb71cc5754.bam	39.58		0.08	58cfa82de4b0c9d6adf6a464	459f50a1a35d272785306ecb71cc5754.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-FX-A2QS-01A	2905CBD1-719B-46D9-B8AF-8FE4927BC473	Primary Tumor	Illumina HiSeq	8906cefc-240d-4590-8d00-1004fa85fd22	Mesenchymal	61.0	5402D273-3B02-4BF7-A0A4-625A59FED4CC	7D332CB1-BA25-47E4-8BF8-D25E14F40D59	TCGA-FX-A2QS-01A-11D-A21Q-09	GRCh37-lite	TCGA-FX-A2QS	TCGA-SARC		s2486	Washington University School of Medicine	International Genomics Consortium		NO					A21Q-09	True
S13722.58cfa82de4b0c9d6adf6a444	58cfa82de4b0c9d6adf6a444	05b05a3f284cf713011e4bd81b09ab5e.filtered.	WGS	05b05a3f284cf713011e4bd81b09ab5e	05b05a3f284cf713011e4bd81b09ab5e.bam	26.91	1.86	0.07	58cfa82de4b0c9d6adf6a444	05b05a3f284cf713011e4bd81b09ab5e.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0AV-01A	790FF5DB-B7F3-4946-AAED-305F66B1DD6A	Primary Tumor	Illumina HiSeq	b2a1b1a3-a780-4be9-9a65-8937ba5df3b0	Breast	52.0	DCE6CAC3-6C76-4574-B7A8-C7083B12F22E	9032B7FE-E38A-4641-A45E-67041668ADC4	TCGA-BH-A0AV-01A-31D-A10Y-09	GRCh37-lite	TCGA-BH-A0AV	TCGA-BRCA		s6450	Washington University School of Medicine	University of Pittsburgh		NO	T1c	N0	Infiltrating Ductal Carcinoma	Stage I	A10Y-09	False
S13722.58cfa82de4b0c9d6adf6a4a6	58cfa82de4b0c9d6adf6a4a6	3a96e8c557be05593e3dbb1fccbb73d1.filtered.	WGS	3a96e8c557be05593e3dbb1fccbb73d1	3a96e8c557be05593e3dbb1fccbb73d1.bam	74.02	2.18	0.09	58cfa82de4b0c9d6adf6a4a6	3a96e8c557be05593e3dbb1fccbb73d1.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-EW-A1PB-01A	88DB1340-E4BF-451A-87C0-6E9168296F5E	Primary Tumor	Illumina HiSeq	2ba1984b-043e-4cc5-8bc4-10b6c2915f61	Breast	70.0	DA9DC40B-0350-4B8C-8A7A-15100D5AEB90	9DDF2119-A222-4FA5-A9F3-0BEC7EEEA36B	TCGA-EW-A1PB-01A-11D-A142-09	GRCh37-lite	TCGA-EW-A1PB	TCGA-BRCA		s6454	Washington University School of Medicine	University of Miami	United States	NO	T3	N1a	Infiltrating Ductal Carcinoma	Stage IIIA	A142-09	False
S13722.58cfa82de4b0c9d6adf6a4b2	58cfa82de4b0c9d6adf6a4b2	1d839fbbdcb1971d9a0ef13b9f7a8b2e.filtered.	WGS	1d839fbbdcb1971d9a0ef13b9f7a8b2e	1d839fbbdcb1971d9a0ef13b9f7a8b2e.bam	69.79	1.98	0.08	58cfa82de4b0c9d6adf6a4b2	1d839fbbdcb1971d9a0ef13b9f7a8b2e.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AN-A0AT-01A	05506F4C-E701-4A9D-AE06-97F066AADE43	Primary Tumor	Illumina HiSeq	5285cd99-09bc-48e5-abcb-11230d5f40f0	Breast	62.0	B2905A3F-810B-4E74-AF5C-42D513D91746	F848B66F-BD9E-4FBA-AFD4-EB58848D1EF4	TCGA-AN-A0AT-01A-11D-A045-09	GRCh37-lite	TCGA-AN-A0AT	TCGA-BRCA		s6760	Washington University School of Medicine	Cureline		NO	T2	N0	Infiltrating Ductal Carcinoma	Stage IIA	A045-09	False
S13722.58cfa82de4b0c9d6adf6a50c	58cfa82de4b0c9d6adf6a50c	437fd4c58a0c6f406413c5f2b3073d0a.filtered.	WGS	437fd4c58a0c6f406413c5f2b3073d0a	437fd4c58a0c6f406413c5f2b3073d0a.bam	63.5	1.98	0.08	58cfa82de4b0c9d6adf6a50c	437fd4c58a0c6f406413c5f2b3073d0a.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-E2-A156-01A	F05D314C-5EC5-4E2A-B785-9A702716F111	Primary Tumor	Illumina HiSeq	3d9a2788-2bc3-4df9-bae7-fef37f6096b8	Breast	61.0	9D39F2CF-84B5-45BA-8C40-0A42D8F303B7	2DA2B745-068D-408C-9163-3B3A78D4AAED	TCGA-E2-A156-01A-11D-A314-09	GRCh37-lite	TCGA-E2-A156	TCGA-BRCA		s6622	Washington University School of Medicine	Roswell Park		NO	T1c	N0	Infiltrating Ductal Carcinoma	Stage I	A314-09	True
S13722.58cfa82de4b0c9d6adf6a50e	58cfa82de4b0c9d6adf6a50e	29084d88d2f33ba899ea13cb6d938384.filtered.	WGS	29084d88d2f33ba899ea13cb6d938384	29084d88d2f33ba899ea13cb6d938384.bam	41.07	1.97	0.07	58cfa82de4b0c9d6adf6a50e	29084d88d2f33ba899ea13cb6d938384.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AN-A0XR-01A	F51AF6DB-2655-47FB-9FFC-83A503A728EA	Primary Tumor	Illumina HiSeq	19e1e7d4-80dd-4107-98b2-6796fe22947f	Breast	55.0	6EDCDB8A-80E8-42A8-86FF-3950C1F3CB89	E7DC7492-3A84-49C7-8DEA-8F508B53DC40	TCGA-AN-A0XR-01A-11D-A10G-09	GRCh37-lite	TCGA-AN-A0XR	TCGA-BRCA		s5477	Washington University School of Medicine	Cureline		NO	T2	N2	Infiltrating Ductal Carcinoma	Stage IIIA	A10G-09	False
S13722.58cfa82de4b0c9d6adf6a52e	58cfa82de4b0c9d6adf6a52e	103f34ff20cea99f215bfb7393f043b8.filtered.	WGS	103f34ff20cea99f215bfb7393f043b8	103f34ff20cea99f215bfb7393f043b8.bam	45.75	2.0	0.09	58cfa82de4b0c9d6adf6a52e	103f34ff20cea99f215bfb7393f043b8.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A259-01A	3FC3755D-A3F8-4E2C-813F-FF124F2A75C1	Primary Tumor	Illumina HiSeq	767c5435-e3e1-4cdb-92e0-2b0961610118	Breast	70.0	EB2DE640-6C2A-4C8A-87C3-80F9FBDC3D9B	13D05F7A-E16A-40EF-9A15-21257DA2CF89	TCGA-A2-A259-01A-11D-A314-09	GRCh37-lite	TCGA-A2-A259	TCGA-BRCA		s5785	Washington University School of Medicine	Walter Reed	United States	NO	T1c	N0 (i-)	Infiltrating Ductal Carcinoma	Stage I	A314-09	True
S13722.58cfa82de4b0c9d6adf6a526	58cfa82de4b0c9d6adf6a526	54edfd331e278de330c2f6fc9d8b6e06.filtered.	WGS	54edfd331e278de330c2f6fc9d8b6e06	54edfd331e278de330c2f6fc9d8b6e06.bam	45.22	2.08	0.08	58cfa82de4b0c9d6adf6a526	54edfd331e278de330c2f6fc9d8b6e06.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-E2-A15H-01A	5580B21A-2CDB-4777-AD79-6E06654144F5	Primary Tumor	Illumina HiSeq	f359078d-7930-4e46-a5d4-3978f5434622	Breast	38.0	7CB99442-005B-4611-94F9-03AF195EC7E3	6D7F44DF-E9F0-4542-A6D8-D14EE7804002	TCGA-E2-A15H-01A-11D-A19H-09	GRCh37-lite	TCGA-E2-A15H	TCGA-BRCA		s5479	Washington University School of Medicine	Roswell Park		NO	T1c	N1mi	Infiltrating Ductal Carcinoma	Stage IIA	A19H-09	True
S13722.58cfa82de4b0c9d6adf6a53c	58cfa82de4b0c9d6adf6a53c	450a0ae734ab89c01b82ea2af8dacc92.filtered.	WGS	450a0ae734ab89c01b82ea2af8dacc92	450a0ae734ab89c01b82ea2af8dacc92.bam	75.68	1.83	0.09	58cfa82de4b0c9d6adf6a53c	450a0ae734ab89c01b82ea2af8dacc92.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A25B-01A	EADF8482-E60E-4307-ADB7-D5C3B9FA6CAE	Primary Tumor	Illumina HiSeq	372d2951-a381-41f0-88d7-72cc9da6b6db	Breast	39.0	2C619641-7849-4837-AB92-0DA80342B3E9	6E839EAF-1DBB-43F5-8846-C980E05540C7	TCGA-A2-A25B-01A-11D-A167-09	GRCh37-lite	TCGA-A2-A25B	TCGA-BRCA		s6761	Washington University School of Medicine	Walter Reed	United States	NO	T2	N1	Infiltrating Ductal Carcinoma	Stage IIB	A167-09	False
S13722.58cfa82de4b0c9d6adf6a47e	58cfa82de4b0c9d6adf6a47e	2c5b37c2fff4a62ce10d93452de3771f.filtered.	WGS	2c5b37c2fff4a62ce10d93452de3771f	2c5b37c2fff4a62ce10d93452de3771f.bam	52.88	1.88	0.08	58cfa82de4b0c9d6adf6a47e	2c5b37c2fff4a62ce10d93452de3771f.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A0D1-01A	084C6AEC-94F7-4090-8F3F-59FA9E89721A	Primary Tumor	Illumina HiSeq	6d37aa75-54cd-423e-987a-342e9a2def7a	Breast	76.0	12ECE355-F1D0-446C-84E9-0AED3E6D29F8	E5593865-5F8E-4A4C-B36F-73FBE64D66DA	TCGA-A2-A0D1-01A-11D-A19H-09	GRCh37-lite	TCGA-A2-A0D1	TCGA-BRCA		s5476	Washington University School of Medicine	Walter Reed		NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A19H-09	True
S13722.58cfa82de4b0c9d6adf6a574	58cfa82de4b0c9d6adf6a574	2cf824ff67beaee254d0025b0c57ecfb.filtered.	WGS	2cf824ff67beaee254d0025b0c57ecfb	2cf824ff67beaee254d0025b0c57ecfb.bam	23.2	1.82	0.08	58cfa82de4b0c9d6adf6a574	2cf824ff67beaee254d0025b0c57ecfb.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-D8-A27H-01A	0DCA98B0-F43E-45B6-9A02-00092C78678C	Primary Tumor	Illumina HiSeq	bdde252c-e43c-448b-8e22-1ff90c7c957b	Breast	72.0	B7542984-1410-45E6-B936-8333FF902EB4	6764E0A2-7A78-45C1-9189-6001C6518CE4	TCGA-D8-A27H-01A-11D-A314-09	GRCh37-lite	TCGA-D8-A27H	TCGA-BRCA		s5786	Washington University School of Medicine	Greater Poland Cancer Center	Poland	NO	T2	N0	Infiltrating Ductal Carcinoma	Stage IIA	A314-09	True
S13722.58cfa82de4b0c9d6adf6a471	58cfa82de4b0c9d6adf6a471	1076369c844452a633e3edce84850064.filtered.	WGS	1076369c844452a633e3edce84850064	1076369c844452a633e3edce84850064.bam	59.16	1.89	0.09	58cfa82de4b0c9d6adf6a471	1076369c844452a633e3edce84850064.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A1C8-01A	BAD34C92-1E64-4187-A0B4-061105FD13BA	Primary Tumor	Illumina HiSeq	37d56097-9e5d-4008-bbc9-5bd69910436b	Uterus	77.0	83E4DFB0-F240-476B-BC25-F9F52C960AF5	00DB4DC2-3EC7-4FF9-9233-D69C8C8A607F	TCGA-AX-A1C8-01A-11D-A135-09	GRCh37-lite	TCGA-AX-A1C8	TCGA-UCEC		s4403	Washington University School of Medicine	Gynecologic Oncology Group		NO			Serous endometrial adenocarcinoma		A135-09	False
S13722.58cfa82de4b0c9d6adf6a5b8	58cfa82de4b0c9d6adf6a5b8	61a02d82b4437f653c127eb3d3e0a78d.filtered.	WGS	61a02d82b4437f653c127eb3d3e0a78d	61a02d82b4437f653c127eb3d3e0a78d.bam	50.85	1.97	0.08	58cfa82de4b0c9d6adf6a5b8	61a02d82b4437f653c127eb3d3e0a78d.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-E2-A14X-01A	60DF7543-6DA5-4C75-943B-5800C1E08234	Primary Tumor	Illumina HiSeq	775348e1-91bf-4bf9-93e9-ff9f955b5a79	Breast	55.0	A7CC9298-D6F1-48EF-A93A-9C75FC0CB800	74039ACD-5ACA-4C65-818C-3B577D295BE0	TCGA-E2-A14X-01A-11D-A10Y-09	GRCh37-lite	TCGA-E2-A14X	TCGA-BRCA		s6116	Washington University School of Medicine	Roswell Park		NO	T2	N2	Infiltrating Ductal Carcinoma	Stage IIIA	A10Y-09	False
S13722.58cfa82de4b0c9d6adf6a596	58cfa82de4b0c9d6adf6a596	5f3d3040681cc587e66a46c6fe973f92.filtered.	WGS	5f3d3040681cc587e66a46c6fe973f92	5f3d3040681cc587e66a46c6fe973f92.bam	97.64	1.84	0.08	58cfa82de4b0c9d6adf6a596	5f3d3040681cc587e66a46c6fe973f92.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-DS-A0VL-01A	DFD30F94-19E3-4838-95DF-14A3763419AF	Primary Tumor	Illumina HiSeq	2c9bc14c-a6d3-4389-8360-024e9c04a5d4	Cervix	25.0	CDF4AB19-F243-4EFC-A5DC-8253CBE48845	E07991A4-0901-4ED1-8704-AA376565D862	TCGA-DS-A0VL-01A-21D-A200-09	GRCh37-lite	TCGA-DS-A0VL	TCGA-CESC		s1350	Washington University School of Medicine	Cedars Sinai	United States	NO	T1b1	N0	Cervical Squamous Cell Carcinoma		A200-09	True
S13722.58cfa82de4b0c9d6adf6a5de	58cfa82de4b0c9d6adf6a5de	6541447d40abf6e8944eb0fde79c5bb3.filtered.	WGS	6541447d40abf6e8944eb0fde79c5bb3	6541447d40abf6e8944eb0fde79c5bb3.bam	42.49		0.08	58cfa82de4b0c9d6adf6a5de	6541447d40abf6e8944eb0fde79c5bb3.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-DX-A3LU-01A	E786DE34-4C21-460F-89AB-008DE4347049	Primary Tumor	Illumina HiSeq	5f6336e7-c966-4e89-81bd-15a9523a893c	Mesenchymal	60.0	39BBAA83-8143-4E62-836E-1584B41B073B	7D734D06-F2B1-4924-A201-620AC8084C49	TCGA-DX-A3LU-01A-11D-A21Q-09	GRCh37-lite	TCGA-DX-A3LU	TCGA-SARC		s2489	Washington University School of Medicine	Memorial Sloan Kettering	United States	NO					A21Q-09	True
S13722.58cfa82de4b0c9d6adf6a5c6	58cfa82de4b0c9d6adf6a5c6	7abe99091880688658f0fbf83d4b2209.filtered.	WGS	7abe99091880688658f0fbf83d4b2209	7abe99091880688658f0fbf83d4b2209.bam	100.8	1.86	0.09	58cfa82de4b0c9d6adf6a5c6	7abe99091880688658f0fbf83d4b2209.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A1M8-01A	110CD100-5730-4873-9FAB-2AE6C8732062	Primary Tumor	Illumina HiSeq	bcb9d9ed-cd43-4eb0-a3e5-f667a80c20b7	Cervix	43.0	72FF7605-0905-4829-8B54-B76B45FBB0DF	07D20658-3DB4-47E7-877B-66536266EDFC	TCGA-C5-A1M8-01A-21D-A200-09	GRCh37-lite	TCGA-C5-A1M8	TCGA-CESC		s1167	Washington University School of Medicine	Medical College of Wisconsin	United States	NO	T1b	N0	Cervical Squamous Cell Carcinoma		A200-09	True
S13722.58cfa82de4b0c9d6adf6a614	58cfa82de4b0c9d6adf6a614	511a3675203dfa8034f97dbe11cc6195.filtered.	WGS	511a3675203dfa8034f97dbe11cc6195	511a3675203dfa8034f97dbe11cc6195.bam	35.64		0.08	58cfa82de4b0c9d6adf6a614	511a3675203dfa8034f97dbe11cc6195.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-GM-A2DF-01A	D6F7AFC0-1558-43AD-ACB1-2B5311ED2264	Primary Tumor	Illumina HiSeq	f577059e-baa8-4030-9baa-5857d30fbfec	Breast	53.0	66760E17-251D-4981-BB02-82C29B315080	7456ABD5-303E-4E6F-BF4E-47EFEFC7310F	TCGA-GM-A2DF-01A-11D-A17W-09	GRCh37-lite	TCGA-GM-A2DF	TCGA-BRCA		s6763	Washington University School of Medicine	MD Anderson	United States	NO	T1c	N1a	Infiltrating Ductal Carcinoma	Stage IIA	A17W-09	False
S13722.58cfa82de4b0c9d6adf6a63e	58cfa82de4b0c9d6adf6a63e	4904c28d460c5452fabb15e54e66ee71.filtered.	WGS	4904c28d460c5452fabb15e54e66ee71	4904c28d460c5452fabb15e54e66ee71.bam	73.92		0.09	58cfa82de4b0c9d6adf6a63e	4904c28d460c5452fabb15e54e66ee71.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-EW-A1PC-01B	F45210D3-9E66-4F5E-BEF1-5EE5547CC893	Primary Tumor	Illumina HiSeq	4ded0771-e685-45fb-99f1-4dc1212cc9fc	Breast	66.0	FB635F1D-5EE1-4E58-86EA-B1AADA2DE4BA	1C0E384F-7254-4AFE-93C0-B3FC6C6A7894	TCGA-EW-A1PC-01B-11D-A21Q-09	GRCh37-lite	TCGA-EW-A1PC	TCGA-BRCA		s5789	Washington University School of Medicine	University of Miami	United States	NO	T3	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIB	A21Q-09	True
S13722.58cfa82de4b0c9d6adf6a65c	58cfa82de4b0c9d6adf6a65c	4fa7ea559428c6a86aecf3aa8cb8acc0.filtered.	WGS	4fa7ea559428c6a86aecf3aa8cb8acc0	4fa7ea559428c6a86aecf3aa8cb8acc0.bam	44.55		0.08	58cfa82de4b0c9d6adf6a65c	4fa7ea559428c6a86aecf3aa8cb8acc0.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-DX-A2IZ-01A	6B189EFF-B919-49D6-8775-DBF32C9CCBBA	Primary Tumor	Illumina HiSeq	a3746833-4b30-4c7f-b95c-b534566de66c	Mesenchymal	60.0	B68F7194-1F05-4009-8ED2-58C5EBBCABA8	67BB70B2-B6F8-4AA9-80CE-48829F9FEC56	TCGA-DX-A2IZ-01A-11D-A21Q-09	GRCh37-lite	TCGA-DX-A2IZ	TCGA-SARC		s2488	Washington University School of Medicine	Memorial Sloan Kettering	United States	NO					A21Q-09	True
S13722.58cfa82de4b0c9d6adf6a678	58cfa82de4b0c9d6adf6a678	5ccefc1bca215bf54bcca30953e25fc3.filtered.	WGS	5ccefc1bca215bf54bcca30953e25fc3	5ccefc1bca215bf54bcca30953e25fc3.bam	87.84	2.05	0.09	58cfa82de4b0c9d6adf6a678	5ccefc1bca215bf54bcca30953e25fc3.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AJ-A23M-01A	D39DF936-4BC6-404D-9E1D-F6416CC5A34C	Primary Tumor	Illumina HiSeq	c45046fe-9086-4f96-bc47-68de65413b58	Uterus	61.0	ACBBC556-4E4E-4EBC-B408-55D69720A87D	96F337D2-CEC4-4484-87CD-AB2109D2BF50	TCGA-AJ-A23M-01A-11D-A34H-09	GRCh37-lite	TCGA-AJ-A23M	TCGA-UCEC		s4238	Washington University School of Medicine	International Genomics Conosrtium	United States	NO			Serous endometrial adenocarcinoma		A34H-09	True
S13722.58cfa82de4b0c9d6adf6a642	58cfa82de4b0c9d6adf6a642	56c4e1fd143ea68f16ed05f49f2cd315.filtered.	WGS	56c4e1fd143ea68f16ed05f49f2cd315	56c4e1fd143ea68f16ed05f49f2cd315.bam	29.64	1.95	0.07	58cfa82de4b0c9d6adf6a642	56c4e1fd143ea68f16ed05f49f2cd315.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-E2-A14P-01A	E4FC0909-F284-4471-866D-D8967B6ADCBC	Primary Tumor	Illumina HiSeq	6291117d-64a7-4c35-94bb-8e06275c498e	Breast	79.0	58BFE278-A80F-4722-B286-4D966214D244	74B57D2C-A83F-4798-B86B-A533975E4CC0	TCGA-E2-A14P-01A-31D-A19H-09	GRCh37-lite	TCGA-E2-A14P	TCGA-BRCA		s5629	Washington University School of Medicine	Roswell Park		NO	T2	N3	Infiltrating Ductal Carcinoma	Stage IIIC	A19H-09	True
S13722.58cfa82de4b0c9d6adf6a69e	58cfa82de4b0c9d6adf6a69e	898a39476e967ce15adbf5f7f4230feb.filtered.	WGS	898a39476e967ce15adbf5f7f4230feb	898a39476e967ce15adbf5f7f4230feb.bam	60.86		0.09	58cfa82de4b0c9d6adf6a69e	898a39476e967ce15adbf5f7f4230feb.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A2LT-01A	FB66B7F5-22CA-4D4D-97C2-30E6EDFFF781	Primary Tumor	Illumina HiSeq	f6c6e1bd-966a-4f96-b8ab-e8219607f960	Cervix	38.0	EEDE6958-96A5-433D-8823-503B58559ED4	0F6B355E-3898-4BE6-BE97-DA0C3840A4ED	TCGA-C5-A2LT-01A-11D-A18J-09	GRCh37-lite	TCGA-C5-A2LT	TCGA-CESC		s1512	Washington University School of Medicine	Medical College of Wisconsin	United States	NO	T1b	N0	Cervical Squamous Cell Carcinoma		A18J-09	True
S13722.58cfa82de4b0c9d6adf6a658	58cfa82de4b0c9d6adf6a658	56ee38b83bbac3302bd71fef66bd52a5.filtered.	WGS	56ee38b83bbac3302bd71fef66bd52a5	56ee38b83bbac3302bd71fef66bd52a5.bam	73.22	2.09	0.07	58cfa82de4b0c9d6adf6a658	56ee38b83bbac3302bd71fef66bd52a5.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JN-01A	B60F22AC-A659-4F33-B01D-820E86A9A5C9	Primary Tumor	Illumina HiSeq	4a8180de-0459-43a0-9e22-6a115e56912c	Uterus	84.0	684C6894-FD49-4934-8962-9628ECE734FB	8DD14F0E-8601-4AA1-864C-3C49E768CDD1	TCGA-B5-A0JN-01A-11D-A10B-09	GRCh37-lite	TCGA-B5-A0JN	TCGA-UCEC		s4410	Washington University School of Medicine	Duke	United States	NO			Serous endometrial adenocarcinoma		A10B-09	True
S13722.58cfa82de4b0c9d6adf6a6c4	58cfa82de4b0c9d6adf6a6c4	890d7ec2b62541e2e80696ea62529008.filtered.	WGS	890d7ec2b62541e2e80696ea62529008	890d7ec2b62541e2e80696ea62529008.bam	63.32		0.07	58cfa82de4b0c9d6adf6a6c4	890d7ec2b62541e2e80696ea62529008.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2RM-01A	C13215D9-26A8-4C8B-B4FE-5DA6AA3222AF	Primary Tumor	Illumina HiSeq	4bb49662-4b46-4288-a828-c518e6d697b2	Cervix	40.0	F0CA60FB-BD45-4F15-A791-0C5B1218D8EF	801E67C8-C506-410A-BDF0-856A66E974F4	TCGA-EK-A2RM-01A-21D-A18J-09	GRCh37-lite	TCGA-EK-A2RM	TCGA-CESC		s1168	Washington University School of Medicine	Gynecologic Oncology Group	United States	NO			Cervical Squamous Cell Carcinoma		A18J-09	True
S13722.58cfa82de4b0c9d6adf6a530	58cfa82de4b0c9d6adf6a530	11e9896c1184c4a8c38f78209b067bcf.filtered.	WGS	11e9896c1184c4a8c38f78209b067bcf	11e9896c1184c4a8c38f78209b067bcf.bam	31.82	1.93	0.08	58cfa82de4b0c9d6adf6a530	11e9896c1184c4a8c38f78209b067bcf.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TG-01A	13F31BCB-BEFD-4ED2-ADC0-DC9E9CE52B75	Primary Tumor	Illumina HiSeq	8a9ac951-0c3a-4112-8159-d585756fae14	Uterus	60.0	36E44603-A1EE-4A5B-9506-49A9358BF8D0	19DEF402-FB8D-4B27-90DD-CE9135A3C0A2	TCGA-BS-A0TG-01A-32D-A10B-09	GRCh37-lite	TCGA-BS-A0TG	TCGA-UCEC		s4233	Washington University School of Medicine	University of Hawaii		NO			Endometrioid endometrial adenocarcinoma		A10B-09	True
S13722.58cfa82de4b0c9d6adf6a708	58cfa82de4b0c9d6adf6a708	9e0aa323dd137c62bd3ba6626357862a.filtered.	WGS	9e0aa323dd137c62bd3ba6626357862a	9e0aa323dd137c62bd3ba6626357862a.bam	47.34	2.0	0.09	58cfa82de4b0c9d6adf6a708	9e0aa323dd137c62bd3ba6626357862a.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-E6-A1LZ-01A	9205C164-7975-421A-90C3-EDFE8DEF595C	Primary Tumor	Illumina HiSeq	d8f785e3-7de9-4e09-b830-5033e5eaa2f4	Uterus	76.0	62BFF77E-4FE6-4A9F-A867-345584608E7D	F7DCC2E4-1FC4-4B39-BC6A-720E66116D68	TCGA-E6-A1LZ-01A-11D-A142-09	GRCh37-lite	TCGA-E6-A1LZ	TCGA-UCEC		s5193	Washington University School of Medicine	Roswell Park	United States	NO			Serous endometrial adenocarcinoma		A142-09	False
S13722.58cfa82ee4b0c9d6adf6a8ac	58cfa82ee4b0c9d6adf6a8ac	G35154.TCGA-EZ-7264-01A-11D-2024-08.2.filtered.	WGS	G35154.TCGA-EZ-7264-01A-11D-2024-08.2	G35154.TCGA-EZ-7264-01A-11D-2024-08.2.bam	329.0		0.05	58cfa82ee4b0c9d6adf6a8ac	G35154.TCGA-EZ-7264-01A-11D-2024-08.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-EZ-7264-01A	FC3B7596-F515-446F-81DB-FED0154CA2C5	Primary Tumor	Illumina HiSeq	e0ea4522-35f1-40c7-92d2-5d1e7ec0cb63	Brain	47.0	EECBA415-5517-4265-8944-07AACBC679FB	00493087-9D9D-40CA-86D5-936F1B951C93	TCGA-EZ-7264-01A-11D-2024-08	HG19_Broad_variant	TCGA-EZ-7264	TCGA-LGG		s8329	Broad Institute of MIT and Harvard	UNC	United States	NO			Oligodendroglioma		2024-08	False
S13722.58cfa82de4b0c9d6adf6a76e	58cfa82de4b0c9d6adf6a76e	G14581.TCGA-64-1680-01A-02D-1040-01.2.filtered.	WGS	G14581.TCGA-64-1680-01A-02D-1040-01.2	G14581.TCGA-64-1680-01A-02D-1040-01.2.bam	380.53	1.9	0.15	58cfa82de4b0c9d6adf6a76e	G14581.TCGA-64-1680-01A-02D-1040-01.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-1680-01A	1AB7AD70-0F80-41D8-8EFA-3BAEBC8223CC	Primary Tumor	Illumina HiSeq	6b9dbd25-b2c7-4ba6-8030-e98c1c8e9991	Lung	63.0	0BDBE623-CF95-465A-917D-87DFB6A8618E	DD09C7AA-744A-413D-839F-E75E1825F9F9	TCGA-64-1680-01A-02D-1040-01	HG19_Broad_variant	TCGA-64-1680	TCGA-LUAD		s11313	Broad Institute of MIT and Harvard	Fox Chase		NO	T2a	N2	Lung Adenocarcinoma Mixed Subtype	Stage IV	1040-01	False
S13722.58cfa82ee4b0c9d6adf6a8b0	58cfa82ee4b0c9d6adf6a8b0	G35154.TCGA-FG-5964-01A-11D-1705-08.4.filtered.	WGS	G35154.TCGA-FG-5964-01A-11D-1705-08.4	G35154.TCGA-FG-5964-01A-11D-1705-08.4.bam	102.3	1.9	0.05	58cfa82ee4b0c9d6adf6a8b0	G35154.TCGA-FG-5964-01A-11D-1705-08.4.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-5964-01A	648252DA-DD86-48D1-AE75-4257E3142B0B	Primary Tumor	Illumina HiSeq	7c465b99-b3c1-44c6-899f-74975fb3d594	Brain	62.0	7BBFBDD1-4CB9-479C-8152-924D79E112F2	C6888BE2-4517-41E4-A801-9C915F24E737	TCGA-FG-5964-01A-11D-1705-08	HG19_Broad_variant	TCGA-FG-5964	TCGA-LGG		s8109	Broad Institute of MIT and Harvard	Case Western	United States	NO			Oligodendroglioma		1705-08	False
S13722.58cfa82ee4b0c9d6adf6a8ec	58cfa82ee4b0c9d6adf6a8ec	G35154.TCGA-HT-7695-01A-11D-2253-08.1.filtered.	WGS	G35154.TCGA-HT-7695-01A-11D-2253-08.1	G35154.TCGA-HT-7695-01A-11D-2253-08.1.bam	86.0		0.05	58cfa82ee4b0c9d6adf6a8ec	G35154.TCGA-HT-7695-01A-11D-2253-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7695-01A	5017C115-39B8-4C5C-8BE6-2CB298D7C641	Primary Tumor	Illumina HiSeq	0e08feb2-0a06-458b-a3ea-797020f9a68f	Brain	29.0	8B58DBF3-022C-4337-9FAD-5AE43B1B84F2	86386B36-2950-4479-B79F-4B347053C8BC	TCGA-HT-7695-01A-11D-2253-08	HG19_Broad_variant	TCGA-HT-7695	TCGA-LGG		s8538	Broad Institute of MIT and Harvard	Case Western - St Joes	United States	NO			Oligodendroglioma		2253-08	False
S13722.58cfa82ee4b0c9d6adf6a8e0	58cfa82ee4b0c9d6adf6a8e0	G35154.TCGA-DB-5278-01A-01D-1468-08.1.filtered.	WGS	G35154.TCGA-DB-5278-01A-01D-1468-08.1	G35154.TCGA-DB-5278-01A-01D-1468-08.1.bam	215.3	1.9	0.05	58cfa82ee4b0c9d6adf6a8e0	G35154.TCGA-DB-5278-01A-01D-1468-08.1.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DB-5278-01A	010AAC75-3BFE-4BF2-B866-AF0F2D92F125	Primary Tumor	Illumina HiSeq	6780f08b-966e-4836-9cd8-46b87be05578	Brain	17.0	11437143-41F5-4005-9124-4D6A4A2F0E2D	6847E993-1414-4E6F-A2AF-39EBE218DD7C	TCGA-DB-5278-01A-01D-1468-08	HG19_Broad_variant	TCGA-DB-5278	TCGA-LGG		s8101	Broad Institute of MIT and Harvard	Mayo Clinic - Rochester	United States	NO			Oligodendroglioma		1468-08	False
S13722.58cfa82ee4b0c9d6adf6a94d	58cfa82ee4b0c9d6adf6a94d	G35154.TCGA-DU-5874-01A-11D-1705-08.2.filtered.	WGS	G35154.TCGA-DU-5874-01A-11D-1705-08.2	G35154.TCGA-DU-5874-01A-11D-1705-08.2.bam	301.3	1.9	0.05	58cfa82ee4b0c9d6adf6a94d	G35154.TCGA-DU-5874-01A-11D-1705-08.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5874-01A	1CC53ADE-73C0-492B-A7DC-328269FD0E66	Primary Tumor	Illumina HiSeq	b0268c63-93dc-4e0b-b29b-217fd6028c92	Brain	62.0	3C7CE3D5-F9E4-4FAE-B033-2058446ED7F3	85D915B8-0184-4EC7-93AD-E9FFA2F5743B	TCGA-DU-5874-01A-11D-1705-08	HG19_Broad_variant	TCGA-DU-5874	TCGA-LGG		s8546	Broad Institute of MIT and Harvard	Henry Ford Hospital	United States	NO			Oligodendroglioma		1705-08	False
S13722.58cfa82ee4b0c9d6adf6a980	58cfa82ee4b0c9d6adf6a980	G35154.TCGA-DU-7009-01A-11D-2024-08.2.filtered.	WGS	G35154.TCGA-DU-7009-01A-11D-2024-08.2	G35154.TCGA-DU-7009-01A-11D-2024-08.2.bam	130.3		0.05	58cfa82ee4b0c9d6adf6a980	G35154.TCGA-DU-7009-01A-11D-2024-08.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7009-01A	01C4CA12-AC08-41DD-9E4F-BFB0971688A2	Primary Tumor	Illumina HiSeq	446ab57b-076e-4f55-b617-050e5f14bfa5	Brain	32.0	C7CA8FEE-BD73-435B-B351-216E5DC38726	4853FD17-7214-4F0C-984B-1BE0346CA4AB	TCGA-DU-7009-01A-11D-2024-08	HG19_Broad_variant	TCGA-DU-7009	TCGA-LGG		s8105	Broad Institute of MIT and Harvard	Henry Ford Hospital	United States	NO			Oligodendroglioma		2024-08	False
S13722.58cfa82ee4b0c9d6adf6a9aa	58cfa82ee4b0c9d6adf6a9aa	G32537.TCGA-EL-A3CX-01A-11D-A19J-08.2.filtered.	WGS	G32537.TCGA-EL-A3CX-01A-11D-A19J-08.2	G32537.TCGA-EL-A3CX-01A-11D-A19J-08.2.bam	46.65		0.08	58cfa82ee4b0c9d6adf6a9aa	G32537.TCGA-EL-A3CX-01A-11D-A19J-08.2.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-EL-A3CX-01A	934A58AF-0FFC-487E-9E95-FA7643B7D5CB	Primary Tumor	Illumina HiSeq	7466949f-795d-4b2c-99e4-92d507c8772e	Thyroid	22.0	C65B5941-3E1D-41C6-9458-CDE70425E7C7	D0A33FD2-085C-488B-B843-2CA97C85A5CB	TCGA-EL-A3CX-01A-11D-A19J-08	HG19_Broad_variant	TCGA-EL-A3CX	TCGA-THCA		s12337	Broad Institute of MIT and Harvard	MD Anderson	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A19J-08	False
S13722.58cfa82ee4b0c9d6adf6aa38	58cfa82ee4b0c9d6adf6aa38	G23883.TCGA-A3-3324-01A-01D-2229-08.1.filtered.	WGS	G23883.TCGA-A3-3324-01A-01D-2229-08.1	G23883.TCGA-A3-3324-01A-01D-2229-08.1.bam	602.9	1.9	0.05	58cfa82ee4b0c9d6adf6aa38	G23883.TCGA-A3-3324-01A-01D-2229-08.1.bam	Alive	MALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-A3-3324-01A	4FCA10BD-988A-47F9-8ED5-037C0D59D70C	Primary Tumor	Illumina HiSeq	4fa1626a-b369-4e9c-b908-528e1d550be7	Kidney	51.0	08CE626E-0734-4D54-BA3F-EA5702B886F3	BADA0A2B-88CC-4F38-9BE5-F4B698AE4DB1	TCGA-A3-3324-01A-01D-2229-08	HG19_Broad_variant	TCGA-A3-3324	TCGA-KIRC		s9154	Broad Institute of MIT and Harvard	International Genomics Consortium	United States	NO	T1b	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2229-08	False
S13722.58cfa82ee4b0c9d6adf6aa9e	58cfa82ee4b0c9d6adf6aa9e	G32455.TCGA-BT-A2LA-01A-11D-A18F-08.2.filtered.	WGS	G32455.TCGA-BT-A2LA-01A-11D-A18F-08.2	G32455.TCGA-BT-A2LA-01A-11D-A18F-08.2.bam	80.43		0.07	58cfa82ee4b0c9d6adf6aa9e	G32455.TCGA-BT-A2LA-01A-11D-A18F-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A2LA-01A	797A71EE-372D-41E5-AEEE-5AB3C4661110	Primary Tumor	Illumina HiSeq	baad6267-e92d-4dc7-a751-271da7ad3f53	Bladder	54.0	6ED52558-8039-4658-A245-78A29968CE2F	45A7949D-E63F-4956-866C-DF51257032DE	TCGA-BT-A2LA-01A-11D-A18F-08	HG19_Broad_variant	TCGA-BT-A2LA	TCGA-BLCA		s2851	Broad Institute of MIT and Harvard	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A18F-08	False
S13722.58cfa82ee4b0c9d6adf6aae6	58cfa82ee4b0c9d6adf6aae6	G32531.TCGA-FK-A3S3-01A-11D-A22D-08.1.filtered.	WGS	G32531.TCGA-FK-A3S3-01A-11D-A22D-08.1	G32531.TCGA-FK-A3S3-01A-11D-A22D-08.1.bam	22.44		0.09	58cfa82ee4b0c9d6adf6aae6	G32531.TCGA-FK-A3S3-01A-11D-A22D-08.1.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FK-A3S3-01A	785803BB-42A8-4AFB-B7B4-58C114894408	Primary Tumor	Illumina HiSeq	5c7965a4-3e29-4c83-87e5-2e23f356287c	Thyroid	43.0	F5EBEFBE-50FA-465A-A355-2C099941039D	15ABB2A3-10A2-4E04-8EB9-6EADBD976AF0	TCGA-FK-A3S3-01A-11D-A22D-08	HG19_Broad_variant	TCGA-FK-A3S3	TCGA-THCA		s12344	Broad Institute of MIT and Harvard	Johns Hopkins	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A22D-08	True
S13722.58cfa82ee4b0c9d6adf6aaee	58cfa82ee4b0c9d6adf6aaee	G32466.TCGA-H4-A2HQ-01A-11D-A17V-08.2.filtered.	WGS	G32466.TCGA-H4-A2HQ-01A-11D-A17V-08.2	G32466.TCGA-H4-A2HQ-01A-11D-A17V-08.2.bam	54.46		0.07	58cfa82ee4b0c9d6adf6aaee	G32466.TCGA-H4-A2HQ-01A-11D-A17V-08.2.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-H4-A2HQ-01A	CEDE5274-279D-4021-8ACA-5ECC4BF94D66	Primary Tumor	Illumina HiSeq	211fa39b-cffd-430e-b28a-b6624e81fb93	Bladder	64.0	CBEDC0DB-39FD-4661-9531-CC24D422FAC4	94108975-B7A0-40BA-AD39-E44CC62E8CC0	TCGA-H4-A2HQ-01A-11D-A17V-08	HG19_Broad_variant	TCGA-H4-A2HQ	TCGA-BLCA		s3250	Broad Institute of MIT and Harvard	Medical College of Georgia	United States	NO		NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A17V-08	True
S13722.58cfa82ee4b0c9d6adf6abeb	58cfa82ee4b0c9d6adf6abeb	G35154.TCGA-HT-7689-01A-11D-2253-08.2.filtered.	WGS	G35154.TCGA-HT-7689-01A-11D-2253-08.2	G35154.TCGA-HT-7689-01A-11D-2253-08.2.bam	66.0		0.05	58cfa82ee4b0c9d6adf6abeb	G35154.TCGA-HT-7689-01A-11D-2253-08.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7689-01A	D58B535A-6C95-43BB-AD88-0600E6447537	Primary Tumor	Illumina HiSeq	55583ba3-88d1-4c7c-8bf7-bfe2699d74da	Brain	58.0	80122820-0D29-4F56-BF14-AC5EEB6F2760	B95CD446-0FED-4DA2-892F-24B39D073AB4	TCGA-HT-7689-01A-11D-2253-08	HG19_Broad_variant	TCGA-HT-7689	TCGA-LGG		s8336	Broad Institute of MIT and Harvard	Case Western - St Joes	United States	NO			Oligodendroglioma		2253-08	False
S13722.58cfa82ee4b0c9d6adf6ad83	58cfa82ee4b0c9d6adf6ad83	G39020.TCGA-BR-7722-01A-31D-2201-08.2.filtered.	WGS	G39020.TCGA-BR-7722-01A-31D-2201-08.2	G39020.TCGA-BR-7722-01A-31D-2201-08.2.bam	454.7		0.05	58cfa82ee4b0c9d6adf6ad83	G39020.TCGA-BR-7722-01A-31D-2201-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-7722-01A	8D3E3D09-BC61-4D5E-B8D6-5AEE6CB488AE	Primary Tumor	Illumina HiSeq	2ca0a03f-9d9d-49da-98e7-b0ade46e5b18	Stomach	62.0	58038C32-1359-49EB-AAFE-2F44EC697F52	0FA9CFBA-0F49-47D0-AB54-9DD2144E0A73	TCGA-BR-7722-01A-31D-2201-08	HG19_Broad_variant	TCGA-BR-7722	TCGA-STAD		s14806	Broad Institute of MIT and Harvard	Asterand	Ukraine	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	2201-08	False
S13722.58cfa82ee4b0c9d6adf6af24	58cfa82ee4b0c9d6adf6af24	G39020.TCGA-F1-6177-01A-11D-1800-08.2.filtered.	WGS	G39020.TCGA-F1-6177-01A-11D-1800-08.2	G39020.TCGA-F1-6177-01A-11D-1800-08.2.bam	466.4	1.8	0.05	58cfa82ee4b0c9d6adf6af24	G39020.TCGA-F1-6177-01A-11D-1800-08.2.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-F1-6177-01A	C3CBA26E-38C2-4569-AFD6-6B045E604808	Primary Tumor	Illumina HiSeq	347b5bd7-20b6-4635-ae86-d43256011296	Stomach	90.0	0538EFDE-935D-4571-A200-B181AB622447	1D0617E8-2725-4411-B50F-E46EA1D43242	TCGA-F1-6177-01A-11D-1800-08	HG19_Broad_variant	TCGA-F1-6177	TCGA-STAD		s14962	Broad Institute of MIT and Harvard	UNC	United States	NO	T1b	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage I	1800-08	True
S13722.58cfa82fe4b0c9d6adf6b909	58cfa82fe4b0c9d6adf6b909	TCGA-A3-3387-01A-01D-2102-10_Illumina.filtered.	WGS	TCGA-A3-3387-01A-01D-2102-10_Illumina	TCGA-A3-3387-01A-01D-2102-10_Illumina.bam	180.4	1.9	0.14	58cfa82fe4b0c9d6adf6b909	TCGA-A3-3387-01A-01D-2102-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-A3-3387-01A	9DC7812B-C7A2-4DE4-BF6D-4C7261384A62	Primary Tumor	Illumina HiSeq	1abe0bf3-83d3-40d9-8e12-5729d760aeed	Kidney	49.0	413ED4FA-013A-4751-8F74-D54F6CF992C9	00BF0350-8C7C-4B9E-8143-13EA2DC1122F	TCGA-A3-3387-01A-01D-2102-10	GRCh37-lite	TCGA-A3-3387	TCGA-KIRC		s9302	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1a	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2102-10	False
S13722.58cfa830e4b0c9d6adf6bf02	58cfa830e4b0c9d6adf6bf02	TCGA-BP-4968-01A-01D-2100-10_wgs_Illumina.filtered.	WGS	TCGA-BP-4968-01A-01D-2100-10_wgs_Illumina	TCGA-BP-4968-01A-01D-2100-10_wgs_Illumina.bam	68.77	1.9	0.14	58cfa830e4b0c9d6adf6bf02	TCGA-BP-4968-01A-01D-2100-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-4968-01A	1E417B93-837D-4110-9090-239EB82C3E20	Primary Tumor	Illumina HiSeq	e2ce6973-54d1-4e7b-88f1-cb684419ff11	Kidney	40.0	8CD2BBCD-3CE9-4B57-99DA-895B82300AF8	AAD8C8D6-D828-4AAC-9CFB-CEE893E36850	TCGA-BP-4968-01A-01D-2100-10	GRCh37-lite	TCGA-BP-4968	TCGA-KIRC		s9162	Baylor College of Medicine	MSKCC		NO	T1b	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2100-10	False
S13722.58cfa831e4b0c9d6adf6c414	58cfa831e4b0c9d6adf6c414	TCGA-CJ-4639-01A-01D-2095-10_Illumina.filtered.	WGS	TCGA-CJ-4639-01A-01D-2095-10_Illumina	TCGA-CJ-4639-01A-01D-2095-10_Illumina.bam	90.64	1.9	0.15	58cfa831e4b0c9d6adf6c414	TCGA-CJ-4639-01A-01D-2095-10_Illumina.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-4639-01A	3E976301-4042-4AC0-8F01-EF2F1A8161A6	Primary Tumor	Illumina HiSeq	d3739e9e-1149-4ec1-bb8d-f3b495ed1b4d	Kidney	49.0	11B1DCA7-6FCE-41C0-9580-A28CCF83E55C	063CFACF-9933-4A2D-8921-0AEB76E12779	TCGA-CJ-4639-01A-01D-2095-10	GRCh37-lite	TCGA-CJ-4639	TCGA-KIRC		s9168	Baylor College of Medicine	MD Anderson Cancer Center		NO	T2	N0	Kidney Clear Cell Renal Carcinoma	Stage II	2095-10	False
S13722.58cfa831e4b0c9d6adf6c442	58cfa831e4b0c9d6adf6c442	TCGA-CJ-4885-01A-01D-2098-10_Illumina.filtered.	WGS	TCGA-CJ-4885-01A-01D-2098-10_Illumina	TCGA-CJ-4885-01A-01D-2098-10_Illumina.bam	75.7	1.9	0.15	58cfa831e4b0c9d6adf6c442	TCGA-CJ-4885-01A-01D-2098-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-4885-01A	5338D435-68FB-4F0D-A3E6-C843F703F75F	Primary Tumor	Illumina HiSeq	e9c31511-6628-44c2-a7cf-b25609056ad9	Kidney	64.0	A30B3254-3963-48D1-9710-7C3CAC0B1993	72C0603B-AD49-4E53-8164-2B69614BB743	TCGA-CJ-4885-01A-01D-2098-10	GRCh37-lite	TCGA-CJ-4885	TCGA-KIRC		s9171	Baylor College of Medicine	MD Anderson Cancer Center		NO	T3a	NX	Kidney Clear Cell Renal Carcinoma	Stage IV	2098-10	True
S13722.58cfa830e4b0c9d6adf6c2d1	58cfa830e4b0c9d6adf6c2d1	TCGA-B2-4099-01A-02D-2095-10_wgs_Illumina.filtered.	WGS	TCGA-B2-4099-01A-02D-2095-10_wgs_Illumina	TCGA-B2-4099-01A-02D-2095-10_wgs_Illumina.bam	660.34	1.9	0.16	58cfa830e4b0c9d6adf6c2d1	TCGA-B2-4099-01A-02D-2095-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-B2-4099-01A	1ADB05D4-E1CA-4EDE-81C7-FF24A243ABAE	Primary Tumor	Illumina HiSeq	5a0ccacd-ed1b-47b2-818a-592a0cf426ad	Kidney	83.0	E242ADB8-DB67-475E-A0E4-52A622666B12	252A1C43-F954-44D7-8E31-6BCD0157A05C	TCGA-B2-4099-01A-02D-2095-10	GRCh37-lite	TCGA-B2-4099	TCGA-KIRC		s9732	Baylor College of Medicine	Christiana Healthcare		NO	T1a	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2095-10	False
S13722.58cfa83ce4b0c9d6adf72e9c	58cfa83ce4b0c9d6adf72e9c	c7d4da3dbfd3dbc673a6cbab28c5999b.filtered.	WGS	c7d4da3dbfd3dbc673a6cbab28c5999b	c7d4da3dbfd3dbc673a6cbab28c5999b.bam	83.75	1.81	0.08	58cfa83ce4b0c9d6adf72e9c	c7d4da3dbfd3dbc673a6cbab28c5999b.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A11I-01A	F6D136C7-C250-4361-9FED-50F513959A40	Primary Tumor	Illumina HiSeq	290cd155-e6e8-450c-89ce-7688b88465e9	Uterus	65.0	56652DDE-33DA-451E-A1C2-6E9884F9915A	31BC44B9-35FF-43FD-8A01-A834F3B1CE46	TCGA-B5-A11I-01A-11D-A10M-09	GRCh37-lite	TCGA-B5-A11I	TCGA-UCEC		s4972	Washington University School of Medicine	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A10M-09	False
S13722.58cfa831e4b0c9d6adf6c862	58cfa831e4b0c9d6adf6c862	TCGA-CW-6093-01A-11D-2279-10_wgs_Illumina.filtered.	WGS	TCGA-CW-6093-01A-11D-2279-10_wgs_Illumina	TCGA-CW-6093-01A-11D-2279-10_wgs_Illumina.bam	112.4	1.9	0.05	58cfa831e4b0c9d6adf6c862	TCGA-CW-6093-01A-11D-2279-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CW-6093-01A	3F93D1CF-A307-4E29-9E6F-239E9FFAA179	Primary Tumor	Illumina HiSeq	1e7df335-e096-49e1-8490-8be7151ec2db	Kidney	73.0	13BA18EB-C94B-4F6C-AB50-2A98A8044CED	51206157-94CC-4702-8247-C98283B487AA	TCGA-CW-6093-01A-11D-2279-10	GRCh37-lite	TCGA-CW-6093	TCGA-KIRC		s9571	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T1a	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2279-10	False
S13722.58cfa83ce4b0c9d6adf72ea2	58cfa83ce4b0c9d6adf72ea2	c365daeccf937ff8ec5b164169f4beb6.filtered.	WGS	c365daeccf937ff8ec5b164169f4beb6	c365daeccf937ff8ec5b164169f4beb6.bam	32.61		0.08	58cfa83ce4b0c9d6adf72ea2	c365daeccf937ff8ec5b164169f4beb6.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A3XX-01A	53886143-C1C6-40E9-88E6-E4E5E0271FC8	Primary Tumor	Illumina HiSeq	c11a6c92-3f76-42d3-aa9d-e1e4c34f7cf5	Breast	49.0	0A1F4A81-38C6-407A-A33B-716A0F9A6B4D	C67409B2-AC25-42A0-8543-4636EF132FE4	TCGA-A2-A3XX-01A-21D-A23C-09	GRCh37-lite	TCGA-A2-A3XX	TCGA-BRCA		s5622	Washington University School of Medicine	Walter Reed	United States	NO	T2	N0	Infiltrating Ductal Carcinoma	Stage IIA	A23C-09	False
S13722.58cfa83ce4b0c9d6adf72edf	58cfa83ce4b0c9d6adf72edf	e4a6e1d5b4230f26d94ced982fad1af3.filtered.	WGS	e4a6e1d5b4230f26d94ced982fad1af3	e4a6e1d5b4230f26d94ced982fad1af3.bam	94.6	1.95	0.08	58cfa83ce4b0c9d6adf72edf	e4a6e1d5b4230f26d94ced982fad1af3.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-E2-A109-01A	F0787165-6F58-4D67-B510-928EEA2C4882	Primary Tumor	Illumina HiSeq	33884ffd-f43a-4cb9-beb0-9c0a7d6f3f31	Breast	64.0	710EAE35-A21D-4939-8414-D2AF4EA02FDD	3585E133-B3C1-4D90-B5F2-2B867E0AE0EC	TCGA-E2-A109-01A-11D-A10M-09	GRCh37-lite	TCGA-E2-A109	TCGA-BRCA		s5623	Washington University School of Medicine	Roswell Park		NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A10M-09	False
S13722.58cfa83ce4b0c9d6adf72ef8	58cfa83ce4b0c9d6adf72ef8	d9a4fed4943a3f61117cf771e1db8985.filtered.	WGS	d9a4fed4943a3f61117cf771e1db8985	d9a4fed4943a3f61117cf771e1db8985.bam	57.99		0.08	58cfa83ce4b0c9d6adf72ef8	d9a4fed4943a3f61117cf771e1db8985.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Breast Invasive Carcinoma	Aligned reads	TCGA-AC-A2BK-01A	6FA2A667-9C36-4526-8A58-1975E863A806	Primary Tumor	Illumina HiSeq	53c5c882-8386-48e7-b7dd-8815bcf6b316	Breast	78.0	B85BE663-EDBA-4E1E-A10C-D0297744A0E9	8E03E773-5557-4E78-889B-4710C515378F	TCGA-AC-A2BK-01A-11D-A314-09	GRCh37-lite	TCGA-AC-A2BK	TCGA-BRCA		s6750	Washington University School of Medicine	International Genomics Consortium	United States	NO	T2	N2a	Infiltrating Ductal Carcinoma	Stage IIIA	A314-09	True
S13722.58cfa83ce4b0c9d6adf72f7d	58cfa83ce4b0c9d6adf72f7d	e82f5efc1a18908b7a00b45b9bfd5e18.filtered.	WGS	e82f5efc1a18908b7a00b45b9bfd5e18	e82f5efc1a18908b7a00b45b9bfd5e18.bam	48.87	1.91	0.08	58cfa83ce4b0c9d6adf72f7d	e82f5efc1a18908b7a00b45b9bfd5e18.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AR-A1AY-01A	5FD9552A-C742-4388-940D-295D1107AE00	Primary Tumor	Illumina HiSeq	45a65b22-252b-4f92-bd7b-16a76d26c165	Breast	65.0	81FC993E-8F5A-4B3B-BEA3-4C4C2F5E4EF2	15F90EF0-831B-40A3-98BD-EC226A9E8B26	TCGA-AR-A1AY-01A-21D-A12Q-09	GRCh37-lite	TCGA-AR-A1AY	TCGA-BRCA		s6905	Washington University School of Medicine	Mayo		NO	T1	N0	Infiltrating Ductal Carcinoma	Stage I	A12Q-09	False
S13722.58cfa83ce4b0c9d6adf72f43	58cfa83ce4b0c9d6adf72f43	cee8053647191b1b4b10e3f58a90b606.filtered.	WGS	cee8053647191b1b4b10e3f58a90b606	cee8053647191b1b4b10e3f58a90b606.bam	83.38	1.91	0.08	58cfa83ce4b0c9d6adf72f43	cee8053647191b1b4b10e3f58a90b606.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-E2-A1LG-01A	EF4CBD38-BC79-4D60-A715-647EDD2EBE9E	Primary Tumor	Illumina HiSeq	c24e6791-401c-4b37-bfe6-669f050ea42e	Breast	50.0	B462982A-4DD0-425E-BCE3-0EB8F5527264	7CDBE0E8-F614-4F54-B864-FD6B39E8EF1C	TCGA-E2-A1LG-01A-21D-A14K-09	GRCh37-lite	TCGA-E2-A1LG	TCGA-BRCA		s5781	Washington University School of Medicine	Roswell Park	United States	NO	T2	N0	Infiltrating Lobular Carcinoma	Stage IIA	A14K-09	False
S13722.58cfa83ce4b0c9d6adf72f19	58cfa83ce4b0c9d6adf72f19	ccd535b1664251ecbc0fb70ec7dee554.filtered.	WGS	ccd535b1664251ecbc0fb70ec7dee554	ccd535b1664251ecbc0fb70ec7dee554.bam	17.51	1.95	0.07	58cfa83ce4b0c9d6adf72f19	ccd535b1664251ecbc0fb70ec7dee554.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A03N-01B	9435447E-D65F-408B-863B-6576B1D652DD	Primary Tumor	Illumina HiSeq	a198d001-d09b-4a43-9704-060db667151f	Breast	59.0	06B3E3CA-24B9-4E19-9E59-B51CC6D6735B	F8F749B7-547D-49FA-9DA2-44EED962B6FD	TCGA-AO-A03N-01B-11D-A19H-09	GRCh37-lite	TCGA-AO-A03N	TCGA-BRCA		s6749	Washington University School of Medicine	MSKCC		NO	T2	N1a	Infiltrating Ductal Carcinoma	Stage IIB	A19H-09	True
S13722.58cfa83ce4b0c9d6adf72fae	58cfa83ce4b0c9d6adf72fae	a67ab1214f8c6bab30f876560e45768a.filtered.	WGS	a67ab1214f8c6bab30f876560e45768a	a67ab1214f8c6bab30f876560e45768a.bam	61.5		0.08	58cfa83ce4b0c9d6adf72fae	a67ab1214f8c6bab30f876560e45768a.bam	Alive	FEMALE	WHITE		Sarcoma	Aligned reads	TCGA-IS-A3K7-01A	5A64F7E9-3833-4A3C-962B-13EB3E305C69	Primary Tumor	Illumina HiSeq	244fb4fa-4623-4468-acf2-601bb7f70990	Mesenchymal	63.0	7254C2AC-D8AC-4D6E-B444-4CB5F8A6EB36	AFEE5B10-3DFF-4E50-9575-BC9FE20C5DEA	TCGA-IS-A3K7-01A-11D-A21Q-09	GRCh37-lite	TCGA-IS-A3K7	TCGA-SARC		s2458	Washington University School of Medicine	Memorial Sloan Kettering	United States	NO					A21Q-09	True
S13722.58cfa83ce4b0c9d6adf72fc8	58cfa83ce4b0c9d6adf72fc8	b939c2720803667f3b27acd9d4596892.filtered.	WGS	b939c2720803667f3b27acd9d4596892	b939c2720803667f3b27acd9d4596892.bam	36.4		0.07	58cfa83ce4b0c9d6adf72fc8	b939c2720803667f3b27acd9d4596892.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-FX-A48G-01A	12BFD446-2EE5-4664-A492-C023D134F60F	Primary Tumor	Illumina HiSeq	1e67ee27-4af7-4e44-81ba-76ff196f16fb	Mesenchymal	56.0	CEEBA881-5A1D-4FDC-8C9D-D60B3FACECF2	CB5E1546-CDA6-4991-911C-F3DD9F1A475A	TCGA-FX-A48G-01A-11D-A24N-09	GRCh37-lite	TCGA-FX-A48G	TCGA-SARC		s2464	Washington University School of Medicine	International Genomics Consortium	United States	NO					A24N-09	True
S13722.58cfa83ce4b0c9d6adf72fec	58cfa83ce4b0c9d6adf72fec	f45b766a6494688451a4e74a68b954b5.filtered.	WGS	f45b766a6494688451a4e74a68b954b5	f45b766a6494688451a4e74a68b954b5.bam	31.78		0.08	58cfa83ce4b0c9d6adf72fec	f45b766a6494688451a4e74a68b954b5.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-HB-A43Z-01A	9C9B53E5-CDBE-4510-A839-4A3B5039681B	Primary Tumor	Illumina HiSeq	209a73b4-3820-4d16-9437-d67356ab9735	Mesenchymal	58.0	A6BBEE06-44BF-446A-8D21-550AA6E71960	16D33E09-2E21-4DA2-8E57-E78CE28C4408	TCGA-HB-A43Z-01A-11D-A24N-09	GRCh37-lite	TCGA-HB-A43Z	TCGA-SARC		s2637	Washington University School of Medicine	University of North Carolina	United States	NO					A24N-09	True
S13722.58cfa83ce4b0c9d6adf72f9e	58cfa83ce4b0c9d6adf72f9e	a10df74fe68e2f8902de76b1691f26cd.filtered.	WGS	a10df74fe68e2f8902de76b1691f26cd	a10df74fe68e2f8902de76b1691f26cd.bam	69.7	2.0	0.07	58cfa83ce4b0c9d6adf72f9e	a10df74fe68e2f8902de76b1691f26cd.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BK-A0CC-01A	2B865F8C-539F-4CB2-8F08-41709E9511E5	Primary Tumor	Illumina HiSeq	83ddf098-024c-49f8-80ef-b79b0b8182d5	Uterus	69.0	ED22CB10-EBDE-4019-9B6D-E19AB573CA94	E7D74D34-3255-4C20-90FD-B105E6E229C8	TCGA-BK-A0CC-01A-21D-A013-09	GRCh37-lite	TCGA-BK-A0CC	TCGA-UCEC		s5180	Washington University School of Medicine	Christiana Healthcare		NO			Serous endometrial adenocarcinoma		A013-09	True
S13722.58cfa83ce4b0c9d6adf72f72	58cfa83ce4b0c9d6adf72f72	ea57989a2a3017624491e77218b0f326.filtered.	WGS	ea57989a2a3017624491e77218b0f326	ea57989a2a3017624491e77218b0f326.bam	44.27	1.98	0.08	58cfa83ce4b0c9d6adf72f72	ea57989a2a3017624491e77218b0f326.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-E2-A15E-01A	0A2A3529-F645-4967-9A58-89EE20B8BB62	Primary Tumor	Illumina HiSeq	3b80e735-e034-4867-be5e-52500f523ab5	Breast	40.0	9992EEB9-901B-4A32-BADC-E9BE7C9BA4BA	92B515EB-4036-4DAD-9CCA-DFB59C2EF26E	TCGA-E2-A15E-01A-11D-A19H-09	GRCh37-lite	TCGA-E2-A15E	TCGA-BRCA		s6753	Washington University School of Medicine	Roswell Park		NO	T1c	N1a	Infiltrating Ductal Carcinoma	Stage IIA	A19H-09	True
S13722.58cfa83ce4b0c9d6adf7307f	58cfa83ce4b0c9d6adf7307f	b58386e952752d807a06a013a922b7ae.filtered.	WGS	b58386e952752d807a06a013a922b7ae	b58386e952752d807a06a013a922b7ae.bam	17.96	1.86	0.07	58cfa83ce4b0c9d6adf7307f	b58386e952752d807a06a013a922b7ae.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A7-A13D-01A	8785012F-F73E-4D68-87CF-1D804AF32782	Primary Tumor	Illumina HiSeq	3c8a206a-59d4-412a-97c1-9dd31cb9b7c0	Breast	46.0	79FC9ED3-4E96-4C0E-869E-1756CBDABB39	418E916B-7A4E-4FAB-8616-15DCEC4D79F8	TCGA-A7-A13D-01A-13D-A12Q-09	GRCh37-lite	TCGA-A7-A13D	TCGA-BRCA		s6443	Washington University School of Medicine	Christiana Healthcare		NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A12Q-09	False
S13722.58cfa83ce4b0c9d6adf730ca	58cfa83ce4b0c9d6adf730ca	fe1ba68c47fad6337f26bbdac35cbb2b.filtered.	WGS	fe1ba68c47fad6337f26bbdac35cbb2b	fe1ba68c47fad6337f26bbdac35cbb2b.bam	43.03		0.08	58cfa83ce4b0c9d6adf730ca	fe1ba68c47fad6337f26bbdac35cbb2b.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2RL-01A	61EB08D0-EA01-45E7-884B-AC3D6070172A	Primary Tumor	Illumina HiSeq	5848efed-18c8-413b-8a2c-9a63deec56ee	Cervix	32.0	DD3E80D9-0321-40AD-B963-25E2C94C6092	842DF341-D34F-4ED6-928C-EAF15BF7F667	TCGA-EK-A2RL-01A-11D-A34H-09	GRCh37-lite	TCGA-EK-A2RL	TCGA-CESC		s1507	Washington University School of Medicine	Gynecologic Oncology Group	United States	NO	T1b1	N1	Endocervical Type of Adenocarcinoma		A34H-09	True
S13722.58cfa83ce4b0c9d6adf730cb	58cfa83ce4b0c9d6adf730cb	fa894126e254827396a4f68e2b369bc2.filtered.	WGS	fa894126e254827396a4f68e2b369bc2	fa894126e254827396a4f68e2b369bc2.bam	34.01	1.86	0.08	58cfa83ce4b0c9d6adf730cb	fa894126e254827396a4f68e2b369bc2.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0DG-01A	0BC5744C-5FA3-45BB-87D0-70A02068B392	Primary Tumor	Illumina HiSeq	d1c980ac-6070-4a3b-8ff8-208b0f7897cf	Breast	30.0	3F104CF7-8DE8-4E77-8BAA-BAD1BBB493AC	EC4D4CBC-D5D1-418D-A292-CAD9576624FD	TCGA-BH-A0DG-01A-21D-A12Q-09	GRCh37-lite	TCGA-BH-A0DG	TCGA-BRCA		s6908	Washington University School of Medicine	University of Pittsburgh		NO	T2	N0	Infiltrating Ductal Carcinoma	Stage IIA	A12Q-09	False
S13722.58cfa83ce4b0c9d6adf7309a	58cfa83ce4b0c9d6adf7309a	be7bcf9d37d9e65a46acadb6e8e3450e.filtered.	WGS	be7bcf9d37d9e65a46acadb6e8e3450e	be7bcf9d37d9e65a46acadb6e8e3450e.bam	58.65	1.91	0.08	58cfa83ce4b0c9d6adf7309a	be7bcf9d37d9e65a46acadb6e8e3450e.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0BW-01A	5D1D00C6-FCAE-479E-AE1E-DE76EFD41D98	Primary Tumor	Illumina HiSeq	d87bcaa2-19f0-4c3b-8f85-8f47ed056ffc	Breast	71.0	DBEEDDC1-D149-46F7-91FF-D057F8C6BFFB	07B5141F-AC79-439B-883B-B0183BBE7FF5	TCGA-BH-A0BW-01A-11D-A10Y-09	GRCh37-lite	TCGA-BH-A0BW	TCGA-BRCA		s6253	Washington University School of Medicine	University of Pittsburgh		NO	T1c	N0	Infiltrating Ductal Carcinoma	Stage I	A10Y-09	False
S13722.58cfa83ce4b0c9d6adf73128	58cfa83ce4b0c9d6adf73128	c71bbdff2d8e43b1dd7f270bf112e2c4.filtered.	WGS	c71bbdff2d8e43b1dd7f270bf112e2c4	c71bbdff2d8e43b1dd7f270bf112e2c4.bam	87.89	1.88	0.08	58cfa83ce4b0c9d6adf73128	c71bbdff2d8e43b1dd7f270bf112e2c4.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A0J1-01A	EC7A9D74-8B3F-4747-8926-1739A016AB2B	Primary Tumor	Illumina HiSeq	4d43e1fb-f822-45ec-b3db-8b91f598ced3	Uterus	80.0	AC14E378-2DE1-458A-B8CD-7C60131AA927	950486AD-14F8-480A-B079-9CC3CD842090	TCGA-AX-A0J1-01A-11D-A066-09	GRCh37-lite	TCGA-AX-A0J1	TCGA-UCEC		s5470	Washington University School of Medicine	Gynecologic Oncology Group		NO			Endometrioid endometrial adenocarcinoma		A066-09	True
S13722.58cfa83ce4b0c9d6adf73184	58cfa83ce4b0c9d6adf73184	aa55b92d7a3d9eabf7f8c19d30f85566.filtered.	WGS	aa55b92d7a3d9eabf7f8c19d30f85566	aa55b92d7a3d9eabf7f8c19d30f85566.bam	60.12	1.87	0.07	58cfa83ce4b0c9d6adf73184	aa55b92d7a3d9eabf7f8c19d30f85566.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TC-01A	7B7D2D2B-ABE6-4F32-ADD0-3715096995D1	Primary Tumor	Illumina HiSeq	cfe5ac46-c8e7-4f91-a88f-bbbb286e9551	Uterus	69.0	C4C99327-B778-4E29-A111-75569AD38696	B0A83DF8-DD2C-4C1B-B238-9081D2C22258	TCGA-BS-A0TC-01A-11D-A10B-09	GRCh37-lite	TCGA-BS-A0TC	TCGA-UCEC		s4395	Washington University School of Medicine	University of Hawaii		NO			Endometrioid endometrial adenocarcinoma		A10B-09	True
S13722.58cfa83ce4b0c9d6adf73156	58cfa83ce4b0c9d6adf73156	a950fe8710031ec1f4934aa97d1d2437.filtered.	WGS	a950fe8710031ec1f4934aa97d1d2437	a950fe8710031ec1f4934aa97d1d2437.bam	96.72	1.83	0.07	58cfa83ce4b0c9d6adf73156	a950fe8710031ec1f4934aa97d1d2437.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TD-01A	FFAA98A0-2B69-46DC-AEE5-C5C3F2ABBC38	Primary Tumor	Illumina HiSeq	d09c860a-701a-48f3-bace-b479e65e7493	Uterus	65.0	8BB3A057-8958-4F62-AF81-976DA2E92DF7	712BA532-FB1A-43FA-A356-B446B509CEB7	TCGA-BS-A0TD-01A-11D-A10B-09	GRCh37-lite	TCGA-BS-A0TD	TCGA-UCEC		s5179	Washington University School of Medicine	University of Hawaii		NO			Endometrioid endometrial adenocarcinoma		A10B-09	True
S13722.58cfa83ce4b0c9d6adf73060	58cfa83ce4b0c9d6adf73060	a3d780740258da56025b3a939d1ea7d5.filtered.	WGS	a3d780740258da56025b3a939d1ea7d5	a3d780740258da56025b3a939d1ea7d5.bam	57.22	2.05	0.08	58cfa83ce4b0c9d6adf73060	a3d780740258da56025b3a939d1ea7d5.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A0YG-01A	C0892598-1F7B-4F23-9CD8-731F797753D5	Primary Tumor	Illumina HiSeq	64d3bdd6-809b-4c4e-bb57-71f60383b777	Breast	63.0	5006C942-BC9A-41CB-8674-2341B4E66230	4D409156-3A36-4C63-9AD6-B6AF34F27B06	TCGA-A2-A0YG-01A-21D-A19H-09	GRCh37-lite	TCGA-A2-A0YG	TCGA-BRCA		s6747	Washington University School of Medicine	Walter Reed		NO	T2	N3a	Infiltrating Ductal Carcinoma	Stage IIIC	A19H-09	True
S13722.58cfa83ce4b0c9d6adf731cc	58cfa83ce4b0c9d6adf731cc	c60fa4aad576f1b3b720d3433a80345f.filtered.	WGS	c60fa4aad576f1b3b720d3433a80345f	c60fa4aad576f1b3b720d3433a80345f.bam	13.75		0.07	58cfa83ce4b0c9d6adf731cc	c60fa4aad576f1b3b720d3433a80345f.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-DX-A3LY-01B	3505F91D-BC66-4732-84B6-18C5B32CA6B8	Primary Tumor	Illumina HiSeq	0f2523c6-fd2e-49ae-b8d1-eb4f0fd50867	Mesenchymal	66.0	A5697D2C-8E1A-42BE-8EBF-E57D6919BA65	DF4366C4-170F-4233-B577-A8EA277B069C	TCGA-DX-A3LY-01B-11D-A27P-09	GRCh37-lite	TCGA-DX-A3LY	TCGA-SARC		s2629	Washington University School of Medicine	Memorial Sloan Kettering	United States	NO					A27P-09	False
S13722.58cfa82de4b0c9d6adf6a48c	58cfa82de4b0c9d6adf6a48c	01e2ea9ed2554ea6df56ed963414b511.filtered.	WGS	01e2ea9ed2554ea6df56ed963414b511	01e2ea9ed2554ea6df56ed963414b511.bam	33.83	1.84	0.08	58cfa82de4b0c9d6adf6a48c	01e2ea9ed2554ea6df56ed963414b511.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A7-A26G-01A	5ED024E8-D05E-4C65-9441-EDA9930CCC82	Primary Tumor	Illumina HiSeq	f7140aea-8ed7-4d5d-adfb-bd360e319805	Breast	50.0	F0CF4ACD-6B09-4538-B58C-E86C623B6C71	36D1A85E-A09B-4537-86E0-EAF1EB03AED8	TCGA-A7-A26G-01A-21D-A167-09	GRCh37-lite	TCGA-A7-A26G	TCGA-BRCA		s6110	Washington University School of Medicine	Christiana Healthcare	United States	NO	T2	N0 (i+)	Other  specify	Stage IIA	A167-09	False
S13722.58cfa82de4b0c9d6adf6a4ea	58cfa82de4b0c9d6adf6a4ea	282e52fc396cb531fa21b3436906608f.filtered.	WGS	282e52fc396cb531fa21b3436906608f	282e52fc396cb531fa21b3436906608f.bam	35.31		0.08	58cfa82de4b0c9d6adf6a4ea	282e52fc396cb531fa21b3436906608f.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A3Y0-01A	174850B4-5EC2-462B-A890-89BD1716B3C2	Primary Tumor	Illumina HiSeq	f1452ca5-f44b-4f35-a5eb-a8b1f9c44ef7	Breast	57.0	CAA2D510-9024-4D7D-B0EF-80FA4BE1E2EE	D8FBB398-D1DA-4444-984A-22C8523625DA	TCGA-A2-A3Y0-01A-11D-A23C-09	GRCh37-lite	TCGA-A2-A3Y0	TCGA-BRCA		s6910	Washington University School of Medicine	Walter Reed	United States	NO	T2	N1a	Infiltrating Ductal Carcinoma	Stage IIB	A23C-09	False
S13722.58cfa82de4b0c9d6adf6a64a	58cfa82de4b0c9d6adf6a64a	7e4be797a621ce82629293065b38f858.filtered.	WGS	7e4be797a621ce82629293065b38f858	7e4be797a621ce82629293065b38f858.bam	13.63		0.09	58cfa82de4b0c9d6adf6a64a	7e4be797a621ce82629293065b38f858.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A2LV-01A	00BCA18C-B3D4-45A3-8F19-034CC40449A4	Primary Tumor	Illumina HiSeq	559f9675-671e-41a5-b073-7782ab8b5542	Cervix	36.0	CBAD0C55-915A-4F65-B040-57111EAD3BDE	3269608C-5DD7-452A-976A-31AC971AAC2F	TCGA-C5-A2LV-01A-11D-A18J-09	GRCh37-lite	TCGA-C5-A2LV	TCGA-CESC		s1354	Washington University School of Medicine	Medical College of Wisconsin	United States	NO	T1b	N1	Cervical Squamous Cell Carcinoma		A18J-09	True
S13722.58cfa82fe4b0c9d6adf6b720	58cfa82fe4b0c9d6adf6b720	TCGA-67-6217-01A-11D-1751_120309_SN208_0274_AD0R6DACXX_s_3_rg.sorted.filtered.	WGS	TCGA-67-6217-01A-11D-1751_120309_SN208_0274_AD0R6DACXX_s_3_rg.sorted	TCGA-67-6217-01A-11D-1751_120309_SN208_0274_AD0R6DACXX_s_3_rg.sorted.bam	282.4	1.9	0.13	58cfa82fe4b0c9d6adf6b720	TCGA-67-6217-01A-11D-1751_120309_SN208_0274_AD0R6DACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-67-6217-01A	108A71CF-B9DB-47CD-AA74-C03EC989B41B	Primary Tumor	Illumina HiSeq	cb2962fe-7f6e-4a68-871a-11d696bb5279	Lung	73.0	BC0FE45C-3249-46D7-8991-C6888F0B9579	565E717D-310B-4FB1-B79A-5F40FF12BBB8	TCGA-67-6217-01A-11D-1751-02	HG19_Broad_variant	TCGA-67-6217	TCGA-LUAD		s11244	Harvard Medical School	St Joseph's Medical Center (MD)	United States	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1751-02	True
S13722.58cfa82fe4b0c9d6adf6b674	58cfa82fe4b0c9d6adf6b674	TCGA-71-6725-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_7_rg.sorted.filtered.	WGS	TCGA-71-6725-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_7_rg.sorted	TCGA-71-6725-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_7_rg.sorted.bam	406.7	1.9	0.14	58cfa82fe4b0c9d6adf6b674	TCGA-71-6725-01A-11D-1853_120312_SN1120_0121_BD0RHPACXX_s_7_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-71-6725-01A	4B7CD595-E7F9-45A8-B736-A8C7C42D9539	Primary Tumor	Illumina HiSeq	9c1abbc4-5f6b-486c-a6a3-17a01c8783cb	Lung	48.0	83973755-FA6A-460A-A042-385B34698C39	1AD7566E-B9DD-43A3-94DC-96F525007EAA	TCGA-71-6725-01A-11D-1853-02	HG19_Broad_variant	TCGA-71-6725	TCGA-LUAD		s11554	Harvard Medical School	ILSbio	Vietnam	NO	T2	N0	Lung Papillary Adenocarcinoma	Stage IB	1853-02	True
S13722.58cfa82fe4b0c9d6adf6b92a	58cfa82fe4b0c9d6adf6b92a	TCGA-91-6828-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_3_rg.sorted.filtered.	WGS	TCGA-91-6828-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_3_rg.sorted	TCGA-91-6828-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_3_rg.sorted.bam	349.7	1.9	0.14	58cfa82fe4b0c9d6adf6b92a	TCGA-91-6828-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6828-01A	9536E32D-2707-48D2-A36D-08C521665BB9	Primary Tumor	Illumina HiSeq	94e2b6af-1f25-4698-9414-f3d916d26aee	Lung	70.0	CFE0F0E4-D8BF-40CE-99F1-2BF99CECA18B	2C0D4A9F-857D-4C6F-B616-304AB5922A2F	TCGA-91-6828-01A-11D-1853-02	HG19_Broad_variant	TCGA-91-6828	TCGA-LUAD		s10802	Harvard Medical School	ABS - IUPUI	United States	NO	T1a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	True
S13722.58cfa82fe4b0c9d6adf6b932	58cfa82fe4b0c9d6adf6b932	TCGA-91-6836-01A-21D-1853_120310_SN590_0144_AD0PNFACXX_s_7_rg.sorted.filtered.	WGS	TCGA-91-6836-01A-21D-1853_120310_SN590_0144_AD0PNFACXX_s_7_rg.sorted	TCGA-91-6836-01A-21D-1853_120310_SN590_0144_AD0PNFACXX_s_7_rg.sorted.bam	278.7	1.9	0.14	58cfa82fe4b0c9d6adf6b932	TCGA-91-6836-01A-21D-1853_120310_SN590_0144_AD0PNFACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6836-01A	0B31DBDF-0623-48E4-A0EC-017650DCEDA7	Primary Tumor	Illumina HiSeq	68fe0529-8b54-4c01-83f0-a5dc5097e2cb	Lung	52.0	49A0AB8A-F379-4394-ACCF-0B4B08D2DCC6	0D6B80DD-76A1-4174-9275-731B4A347213	TCGA-91-6836-01A-21D-1853-02	HG19_Broad_variant	TCGA-91-6836	TCGA-LUAD		s10669	Harvard Medical School	ABS - IUPUI	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	True
S13722.58cfa830e4b0c9d6adf6ba81	58cfa830e4b0c9d6adf6ba81	TCGA-91-6831-01A-11D-1853_120305_SN1120_0119_BD0REAACXX_s_4_rg.sorted.filtered.	WGS	TCGA-91-6831-01A-11D-1853_120305_SN1120_0119_BD0REAACXX_s_4_rg.sorted	TCGA-91-6831-01A-11D-1853_120305_SN1120_0119_BD0REAACXX_s_4_rg.sorted.bam	196.7	1.9	0.14	58cfa830e4b0c9d6adf6ba81	TCGA-91-6831-01A-11D-1853_120305_SN1120_0119_BD0REAACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6831-01A	DB0B9E63-4272-4F29-BF0E-1EC0FE79A9D7	Primary Tumor	Illumina HiSeq	319d6c8c-207c-477a-8254-30695b75f9e2	Lung	66.0	7B1D8B50-F3DF-4AAB-A654-C3810D8D576D	0D0D96AE-A83B-4C09-8ED9-4A568E816EFC	TCGA-91-6831-01A-11D-1853-02	HG19_Broad_variant	TCGA-91-6831	TCGA-LUAD		s10670	Harvard Medical School	ABS - IUPUI	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	True
S13722.58cfa830e4b0c9d6adf6be70	58cfa830e4b0c9d6adf6be70	TCGA-BJ-A28R-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A28R-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_7_rg.sorted	TCGA-BJ-A28R-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_7_rg.sorted.bam	82.3	2.03	0.16	58cfa830e4b0c9d6adf6be70	TCGA-BJ-A28R-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A28R-01A	524A39EE-8FA3-418E-98A2-A6A90E9C8064	Primary Tumor	Illumina HiSeq	122e0c7e-da24-4121-907e-8b913b4e4147	Thyroid	38.0	F4906B86-3971-4ED3-AC3C-69635311FB45	A5170F7D-F298-4330-8272-8DACFF7775A1	TCGA-BJ-A28R-01A-11D-A16N-02	HG19_Broad_variant	TCGA-BJ-A28R	TCGA-THCA		s11987	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True
S13722.58cfa82fe4b0c9d6adf6b8c6	58cfa82fe4b0c9d6adf6b8c6	TCGA-A5-A0GX-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A5-A0GX-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_2_rg.sorted	TCGA-A5-A0GX-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_2_rg.sorted.bam	89.76	2.06	0.14	58cfa82fe4b0c9d6adf6b8c6	TCGA-A5-A0GX-01A-11D-A043_120504_SN590_0156_BC0H68ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GX-01A	553F0CCD-4E6F-4AE2-9B39-97529EB3D826	Primary Tumor	Illumina HiSeq	cae767f1-aaee-4821-aa36-3ceb0b1756e8	Uterus	53.0	983A35A9-C825-4961-86C0-4C6133B5C9C1	FE0654FE-39AA-4993-8F36-768C7D829092	TCGA-A5-A0GX-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GX	TCGA-UCEC		s4989	Harvard Medical School	Cedars Sinai		NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa830e4b0c9d6adf6bd92	58cfa830e4b0c9d6adf6bd92	TCGA-BG-A0LW-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BG-A0LW-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_5_rg.sorted	TCGA-BG-A0LW-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_5_rg.sorted.bam	100.95	1.92	0.15	58cfa830e4b0c9d6adf6bd92	TCGA-BG-A0LW-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0LW-01A	68181BC9-AA8B-44EC-8601-564B30EA0561	Primary Tumor	Illumina HiSeq	89430da6-f21d-4534-8b48-c645836813b5	Uterus	47.0	6527EC31-1D41-49C2-93FF-11615A6CBA8B	5D88ADF5-468B-4377-B3E3-DF986C613D24	TCGA-BG-A0LW-01A-11D-A043-02	HG19_Broad_variant	TCGA-BG-A0LW	TCGA-UCEC		s5003	Harvard Medical School	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa830e4b0c9d6adf6bbf4	58cfa830e4b0c9d6adf6bbf4	TCGA-A5-A0GW-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_5_rg.sorted.filtered.	WGS	TCGA-A5-A0GW-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_5_rg.sorted	TCGA-A5-A0GW-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_5_rg.sorted.bam	88.42	2.12	0.14	58cfa830e4b0c9d6adf6bbf4	TCGA-A5-A0GW-01A-11D-A043_120301_SN590_0142_AD0LPVACXX_s_5_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GW-01A	5B6B9D0F-787C-4AE9-AFD4-DE7CE6C57A42	Primary Tumor	Illumina HiSeq	84e2e6bd-f438-45e9-9d44-2af82246e341	Uterus	46.0	E84D0533-E892-4C1E-9415-99F92AA9A360	3DCC9DC1-990D-4053-967E-B8E4EE752C4E	TCGA-A5-A0GW-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GW	TCGA-UCEC		s4421	Harvard Medical School	Cedars Sinai		NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa830e4b0c9d6adf6bfdf	58cfa830e4b0c9d6adf6bfdf	TCGA-BR-6801-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-6801-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_5_rg.sorted	TCGA-BR-6801-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_5_rg.sorted.bam	172.7	1.9	0.15	58cfa830e4b0c9d6adf6bfdf	TCGA-BR-6801-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6801-01A	24FED326-BDCF-4C20-A06E-7C1C3D6C9CC5	Primary Tumor	Illumina HiSeq	48843aff-35a1-472b-a298-6489ad1b7de7	Stomach	70.0	713F11EE-D285-4A3B-B421-1D416E5F8E52	FDD2EE8C-C74B-49B8-A530-8CC171C34804	TCGA-BR-6801-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6801	TCGA-STAD		s15450	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1880-02	True
S13722.58cfa830e4b0c9d6adf6c07c	58cfa830e4b0c9d6adf6c07c	TCGA-BJ-A0ZH-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZH-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_2_rg.sorted	TCGA-BJ-A0ZH-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_2_rg.sorted.bam	57.81	1.95	0.16	58cfa830e4b0c9d6adf6c07c	TCGA-BJ-A0ZH-01A-11D-A10R_120711_SN208_0414_BD13L5ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZH-01A	866CA8AD-ADC9-45D4-AD92-9F8F1A161DDF	Primary Tumor	Illumina HiSeq	488591c3-7ba4-421a-9fc0-36d0604c8175	Thyroid	52.0	01EE736B-F907-465B-9142-C50BE0A3461B	8B8B2852-9D53-4654-A37C-2749C0F264ED	TCGA-BJ-A0ZH-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZH	TCGA-THCA		s12096	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N1b	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage IVA	A10R-02	True
S13722.58cfa830e4b0c9d6adf6c1de	58cfa830e4b0c9d6adf6c1de	TCGA-BT-A0YX-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BT-A0YX-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_6_rg.sorted	TCGA-BT-A0YX-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_6_rg.sorted.bam	62.34	1.97	0.15	58cfa830e4b0c9d6adf6c1de	TCGA-BT-A0YX-01A-11D-A10R_120920_SN1222_0150_AC1927ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A0YX-01A	22473AD4-DF39-4716-B558-3C1409D5FA0E	Primary Tumor	Illumina HiSeq	71886c7b-a73b-4c00-9555-5fd61b5e1347	Bladder	70.0	DA614214-F84C-43AB-983C-D9D76CF2D6AE	DC052DFC-26A8-4393-8849-FA954913C622	TCGA-BT-A0YX-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BT-A0YX	TCGA-BLCA		s2867	Harvard Medical School	University of Pittsburgh		NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A10R-02	True
S13722.58cfa830e4b0c9d6adf6c0e2	58cfa830e4b0c9d6adf6c0e2	TCGA-BJ-A0ZF-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZF-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_1_rg.sorted	TCGA-BJ-A0ZF-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_1_rg.sorted.bam	67.32	2.02	0.17	58cfa830e4b0c9d6adf6c0e2	TCGA-BJ-A0ZF-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZF-01A	8BEEE000-ECAB-4A49-9C9D-BB8E677AE199	Primary Tumor	Illumina HiSeq	9bd9796f-01f5-45d5-837b-b0bece0995f4	Thyroid	54.0	83A66A9D-916A-44E8-A7E6-A1385DB504DB	14EE09BE-144A-4461-8F5A-A738CC5D955E	TCGA-BJ-A0ZF-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZF	TCGA-THCA		s12505	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Other  specify	Stage II	A10R-02	True
S13722.58cfa830e4b0c9d6adf6c319	58cfa830e4b0c9d6adf6c319	TCGA-BR-6705-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-6705-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_3_rg.sorted	TCGA-BR-6705-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_3_rg.sorted.bam	27.7	1.9	0.15	58cfa830e4b0c9d6adf6c319	TCGA-BR-6705-01A-12D-1880_121220_SN1222_0163_AC1HA2ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6705-01A	B14F2FCB-E869-475E-BC7C-ADAF6E7E636F	Primary Tumor	Illumina HiSeq	cf5ffdf8-e424-4a51-862f-816cba0c92e0	Stomach	68.0	DB8D0AC1-23B7-49AB-8BB3-44782156F038	F55A158B-F7DB-4786-9553-65DEBCAE80BA	TCGA-BR-6705-01A-12D-1880-02	HG19_Broad_variant	TCGA-BR-6705	TCGA-STAD		s15239	Harvard Medical School	Asterand	Ukraine	NO	T3	N3a	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIB	1880-02	True
S13722.58cfa830e4b0c9d6adf6c310	58cfa830e4b0c9d6adf6c310	TCGA-BR-6710-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-6710-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_3_rg.sorted	TCGA-BR-6710-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_3_rg.sorted.bam	391.7	1.9	0.14	58cfa830e4b0c9d6adf6c310	TCGA-BR-6710-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6710-01A	012E99FE-E3E8-4BB0-BB74-5B0C9992187C	Primary Tumor	Illumina HiSeq	e0e0146e-bf19-42c8-801b-c5a6ed564c5b	Stomach	41.0	25E9E880-4EA1-40CF-BBB6-0F961C735C97	999D0F8C-6A89-4753-AD18-F44304EA78F9	TCGA-BR-6710-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6710	TCGA-STAD		s15383	Harvard Medical School	Asterand	Ukraine	NO	T2	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1880-02	True
S13722.58cfa831e4b0c9d6adf6c3e2	58cfa831e4b0c9d6adf6c3e2	TCGA-CH-5743-01A-21D-1572_130104_SN1120_0209_BD1KP6ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5743-01A-21D-1572_130104_SN1120_0209_BD1KP6ACXX_s_3_rg.sorted	TCGA-CH-5743-01A-21D-1572_130104_SN1120_0209_BD1KP6ACXX_s_3_rg.sorted.bam	245.7	1.9	0.15	58cfa831e4b0c9d6adf6c3e2	TCGA-CH-5743-01A-21D-1572_130104_SN1120_0209_BD1KP6ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5743-01A	2DEE4BD8-B00E-4F8A-BFEA-5D8D1A068202	Primary Tumor	Illumina HiSeq	1c58f516-3239-499a-bbcd-f5a8d619d796	Prostate	66.0	6BD8573D-535F-4F6D-8EAF-60918B5DA578	EE5F51E6-F989-4380-A86F-29CBF50BA03A	TCGA-CH-5743-01A-21D-1572-02	HG19_Broad_variant	TCGA-CH-5743	TCGA-PRAD		s3588	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c3e6	58cfa831e4b0c9d6adf6c3e6	TCGA-CH-5745-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5745-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_7_rg.sorted	TCGA-CH-5745-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_7_rg.sorted.bam	146.7	1.9	0.15	58cfa831e4b0c9d6adf6c3e6	TCGA-CH-5745-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5745-01A	AC67D0DF-7DC0-4A1A-8B47-BEEC9B94DE86	Primary Tumor	Illumina HiSeq	c1d27dca-0355-41e5-a53b-0af94a125c6a	Prostate	68.0	BDA91E83-643B-4FAE-BFE9-B4660F3BDF02	780758FF-58EE-4B4B-AC71-DE15C89C4625	TCGA-CH-5745-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5745	TCGA-PRAD		s3770	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c404	58cfa831e4b0c9d6adf6c404	TCGA-CH-5790-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5790-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_7_rg.sorted	TCGA-CH-5790-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_7_rg.sorted.bam	285.7	1.9	0.15	58cfa831e4b0c9d6adf6c404	TCGA-CH-5790-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5790-01A	2B5EF82D-E137-43F6-BFEF-B202F20EE187	Primary Tumor	Illumina HiSeq	22e486a4-e20b-4211-b3fd-35f37d14e718	Prostate	64.0	5C8782C0-0B0D-4AFF-B996-423D214FF5FF	9BA30DBB-2730-48A1-94E5-10CCA134728F	TCGA-CH-5790-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5790	TCGA-PRAD		s3936	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c406	58cfa831e4b0c9d6adf6c406	TCGA-C5-A3HE-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_8_rg.sorted.filtered.	WGS	TCGA-C5-A3HE-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_8_rg.sorted	TCGA-C5-A3HE-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_8_rg.sorted.bam	43.33		0.15	58cfa831e4b0c9d6adf6c406	TCGA-C5-A3HE-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A3HE-01A	BC63DD2A-B8F6-4B30-A8D7-CE193BCD17F1	Primary Tumor	Illumina HiSeq	1d64c1f3-438b-4576-b2bc-74c1a26a2aca	Cervix	44.0	506D8B22-EE8D-4FB3-BB57-5CA79D6F5637	D0321E82-FF46-450C-AAF2-9FDCA2FF2590	TCGA-C5-A3HE-01A-21D-A232-26	HG19_Broad_variant	TCGA-C5-A3HE	TCGA-CESC		s1514	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO	T1b2	N0	Cervical Squamous Cell Carcinoma		A232-26	True
S13722.58cfa831e4b0c9d6adf6c412	58cfa831e4b0c9d6adf6c412	TCGA-CH-5794-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5794-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_5_rg.sorted	TCGA-CH-5794-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_5_rg.sorted.bam	52.7	2.0	0.15	58cfa831e4b0c9d6adf6c412	TCGA-CH-5794-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5794-01A	A80D3EE7-60DD-49BB-B049-9335AFC035F5	Primary Tumor	Illumina HiSeq	2cf518ee-af91-4cf0-a277-263170f71791	Prostate	65.0	D1A1CCFE-1215-4B34-94A9-C9765264F617	9D7EACBC-B476-4813-9215-AC0073382A25	TCGA-CH-5794-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5794	TCGA-PRAD		s3775	Harvard Medical School	Indivumed	Germany	NO	T2b	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c438	58cfa831e4b0c9d6adf6c438	TCGA-CH-5772-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5772-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_1_rg.sorted	TCGA-CH-5772-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_1_rg.sorted.bam	85.7	1.9	0.16	58cfa831e4b0c9d6adf6c438	TCGA-CH-5772-01A-11D-1572_130125_SN208_0450_AC1K3NACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5772-01A	ECF9F8BE-7830-4626-8617-694C68EF4074	Primary Tumor	Illumina HiSeq	97cf547a-bc4b-4b08-9f8e-c1986b18aa30	Prostate	63.0	068AC08D-1A9E-4C71-B436-4ED861A9DCF8	5C9AAB80-29D2-4D85-A9FE-99FA22222CA4	TCGA-CH-5772-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5772	TCGA-PRAD		s4128	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c44a	58cfa831e4b0c9d6adf6c44a	TCGA-CH-5741-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5741-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_1_rg.sorted	TCGA-CH-5741-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_1_rg.sorted.bam	214.7	1.9	0.15	58cfa831e4b0c9d6adf6c44a	TCGA-CH-5741-01A-11D-1572_130104_SN1120_0209_BD1KP6ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5741-01A	B3BF57D4-E31A-4740-B438-FA826FB79550	Primary Tumor	Illumina HiSeq	ae88c859-e075-4e3a-ba86-e6018e71fa98	Prostate	56.0	B22CBB75-E6E5-443D-AB4E-1CFD0079C69A	6AC2CA6C-FC79-4E5D-B08F-029A4AC2577B	TCGA-CH-5741-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5741	TCGA-PRAD		s3589	Harvard Medical School	Indivumed	Germany	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c50c	58cfa831e4b0c9d6adf6c50c	TCGA-CF-A3MI-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CF-A3MI-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_1_rg.sorted	TCGA-CF-A3MI-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_1_rg.sorted.bam	46.48		0.14	58cfa831e4b0c9d6adf6c50c	TCGA-CF-A3MI-01A-11D-A210_120913_SN208_0428_BC188KACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A3MI-01A	F1EBF96B-8DF9-4E59-ACEF-7AD433E40214	Primary Tumor	Illumina HiSeq	6559c325-d368-4f95-a2c0-df5efa895e3d	Bladder	62.0	A373568A-BBD3-4D67-92D6-96E8378065CF	86D4A4FB-47BB-4CD4-B481-CE9F815D38E6	TCGA-CF-A3MI-01A-11D-A210-26	HG19_Broad_variant	TCGA-CF-A3MI	TCGA-BLCA		s3273	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	True
S13722.58cfa831e4b0c9d6adf6c530	58cfa831e4b0c9d6adf6c530	TCGA-CH-5753-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5753-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_3_rg.sorted	TCGA-CH-5753-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_3_rg.sorted.bam	339.7	1.9	0.16	58cfa831e4b0c9d6adf6c530	TCGA-CH-5753-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5753-01A	928C48A0-68EE-4E28-AE83-9832E52850CA	Primary Tumor	Illumina HiSeq	971890ca-4817-4b12-b817-51caf2239fa3	Prostate	70.0	2BEEEBA8-47FE-4857-8704-E4C63E38C926	302AE7E6-2ADD-4556-8173-21EA12412058	TCGA-CH-5753-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5753	TCGA-PRAD		s3592	Harvard Medical School	Indivumed	Germany	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c531	58cfa831e4b0c9d6adf6c531	TCGA-CH-5768-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CH-5768-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_3_rg.sorted	TCGA-CH-5768-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_3_rg.sorted.bam	131.7	1.9	0.15	58cfa831e4b0c9d6adf6c531	TCGA-CH-5768-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5768-01A	F6C61A22-A711-416D-9E65-6A1B957E5B2E	Primary Tumor	Illumina HiSeq	98aa2eb7-52a4-424c-aa01-a574d0215ee6	Prostate	72.0	C4FF48C4-E953-4267-AB9C-3A09A97A88C4	9813DF8A-57D6-4D59-8534-3942B7FE672E	TCGA-CH-5768-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5768	TCGA-PRAD		s3420	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa830e4b0c9d6adf6c278	58cfa830e4b0c9d6adf6c278	TCGA-B5-A0K1-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_3_rg.sorted.filtered.	WGS	TCGA-B5-A0K1-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_3_rg.sorted	TCGA-B5-A0K1-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_3_rg.sorted.bam	82.72	2.05	0.16	58cfa830e4b0c9d6adf6c278	TCGA-B5-A0K1-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K1-01A	40A3ED98-3892-449C-B07E-7B7612BD997E	Primary Tumor	Illumina HiSeq	fb29a0da-eb80-43a5-be71-85cf2d58268c	Uterus	69.0	B514F636-DEE3-45F3-BB31-197CA6A171F1	D4814366-AEF2-453B-8DC7-A731B5E53FE8	TCGA-B5-A0K1-01A-11D-A043-02	HG19_Broad_variant	TCGA-B5-A0K1	TCGA-UCEC		s5211	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa831e4b0c9d6adf6c56b	58cfa831e4b0c9d6adf6c56b	TCGA-CH-5746-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5746-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_1_rg.sorted	TCGA-CH-5746-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_1_rg.sorted.bam	299.7	1.9	0.15	58cfa831e4b0c9d6adf6c56b	TCGA-CH-5746-01A-11D-1572_130103_SN1222_0165_AC1FBHACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5746-01A	618272C0-C2ED-4BFB-BB4B-404F0987F822	Primary Tumor	Illumina HiSeq	c4373feb-ceca-4bb3-9db2-6f9e94d29605	Prostate	57.0	54AD063E-68D9-4104-856A-2BD3905FA971	ABAFDCA6-6109-4686-A058-BDBEB9ADD1E7	TCGA-CH-5746-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5746	TCGA-PRAD		s3930	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c610	58cfa831e4b0c9d6adf6c610	TCGA-CQ-6221-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CQ-6221-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_6_rg.sorted	TCGA-CQ-6221-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_6_rg.sorted.bam	12.33		0.15	58cfa831e4b0c9d6adf6c610	TCGA-CQ-6221-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6221-01A	839B660C-98FE-4468-A2B3-408594350250	Primary Tumor	Illumina HiSeq	16de682b-970e-4857-821f-5a32d6b74f71	Head and Neck	79.0	65BAAE80-7FD5-40B1-B5FB-BDD013B70931	C90134BD-6F38-45B9-B82D-E84ACEB2E90F	TCGA-CQ-6221-01A-11D-2317-26	HG19_Broad_variant	TCGA-CQ-6221	TCGA-HNSC		s15637	MD Anderson - Institute for Applied Cancer Science	University Health Network, Toronto	Canada	NO	T2	NX	Head and Neck Squamous Cell Carcinoma		2317-26	True
S13722.58cfa831e4b0c9d6adf6c69c	58cfa831e4b0c9d6adf6c69c	TCGA-CQ-6229-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CQ-6229-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_2_rg.sorted	TCGA-CQ-6229-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_2_rg.sorted.bam	60.7	1.9	0.17	58cfa831e4b0c9d6adf6c69c	TCGA-CQ-6229-01A-11D-1911_120504_SN208_0296_AC0V09ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6229-01A	A091822C-447A-49A5-8C20-E329DF79599C	Primary Tumor	Illumina HiSeq	c3f7b43b-25d2-4df3-a85c-231a6708bf8c	Head and Neck	61.0	F01165B0-911A-45B0-BA7D-7CD0E723A2E4	4AF0777A-6FE3-49AE-B3B9-4AB077DDB007	TCGA-CQ-6229-01A-11D-1911-02	HG19_Broad_variant	TCGA-CQ-6229	TCGA-HNSC		s15631	Harvard Medical School	University Health Network, Toronto	Canada	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1911-02	True
S13722.58cfa831e4b0c9d6adf6c70c	58cfa831e4b0c9d6adf6c70c	TCGA-CV-5973-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CV-5973-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_1_rg.sorted	TCGA-CV-5973-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_1_rg.sorted.bam	115.0	1.9	0.15	58cfa831e4b0c9d6adf6c70c	TCGA-CV-5973-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5973-01A	8FC1F1BE-D2D5-4B3A-9973-F4D964018BEB	Primary Tumor	Illumina HiSeq	4965236e-7173-4701-bd61-0550f3451b03	Head and Neck	62.0	5078222F-B257-4286-A29A-BC1E395149BC	55E8AEAC-4C0E-49DF-8F57-605E7C820B89	TCGA-CV-5973-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-5973	TCGA-HNSC		s16193	Harvard Medical School	MD Anderson Cancer Center		NO	T3	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1681-02	True
S13722.58cfa831e4b0c9d6adf6c6a0	58cfa831e4b0c9d6adf6c6a0	TCGA-CQ-6224-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CQ-6224-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_4_rg.sorted	TCGA-CQ-6224-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_4_rg.sorted.bam	40.7	2.0	0.16	58cfa831e4b0c9d6adf6c6a0	TCGA-CQ-6224-01A-11D-1911_120504_SN1222_0102_BC0VHDACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-6224-01A	D86FD392-FA5C-4142-A647-440E6C32D478	Primary Tumor	Illumina HiSeq	e8b32a2c-944e-4b3e-a302-ffe9e9f8a3ea	Head and Neck	52.0	AD242EAC-A5AE-42B7-85CE-3E4D0DD308D6	3FAD44AE-89FC-4BB4-BA86-15A0EF7E2C3A	TCGA-CQ-6224-01A-11D-1911-02	HG19_Broad_variant	TCGA-CQ-6224	TCGA-HNSC		s15633	Harvard Medical School	University Health Network, Toronto	Canada	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	True
S13722.58cfa831e4b0c9d6adf6c77f	58cfa831e4b0c9d6adf6c77f	TCGA-D7-6815-01A-11D-1880_130111_SN208_0447_AC1JP0ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D7-6815-01A-11D-1880_130111_SN208_0447_AC1JP0ACXX_s_1_rg.sorted	TCGA-D7-6815-01A-11D-1880_130111_SN208_0447_AC1JP0ACXX_s_1_rg.sorted.bam	457.0	1.9	0.15	58cfa831e4b0c9d6adf6c77f	TCGA-D7-6815-01A-11D-1880_130111_SN208_0447_AC1JP0ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6815-01A	53086E20-A727-40D6-B42D-8030109B5130	Primary Tumor	Illumina HiSeq	aaa1a66d-814e-403e-bd88-38f4e3ea8c47	Stomach	70.0	B5F3D9A1-46B5-4A63-8F7D-9C993FE9340D	810C88A8-62F3-42C6-BBFD-A9D65E2A07A4	TCGA-D7-6815-01A-11D-1880-02	HG19_Broad_variant	TCGA-D7-6815	TCGA-STAD		s14497	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N2	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIB	1880-02	True
S13722.58cfa831e4b0c9d6adf6c768	58cfa831e4b0c9d6adf6c768	TCGA-D1-A1O0-01A-11D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D1-A1O0-01A-11D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_3_rg.sorted	TCGA-D1-A1O0-01A-11D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_3_rg.sorted.bam	86.58	1.84	0.16	58cfa831e4b0c9d6adf6c768	TCGA-D1-A1O0-01A-11D-A17E_120511_SN1120_0141_BC0VK9ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A1O0-01A	A98BBE29-8817-4380-A738-3C1BF9F8E0CC	Primary Tumor	Illumina HiSeq	30d286e0-9e60-48a1-81f4-b35d81af6da1	Uterus	77.0	E113E0F0-3AE5-48A3-A226-AD920F41259E	8DF3928E-65CE-4578-96A4-BA3AE51E764C	TCGA-D1-A1O0-01A-11D-A17E-02	HG19_Broad_variant	TCGA-D1-A1O0	TCGA-UCEC		s4619	Harvard Medical School	Mayo Clinic	United States	NO			Endometrioid endometrial adenocarcinoma		A17E-02	True
S13722.58cfa831e4b0c9d6adf6c74d	58cfa831e4b0c9d6adf6c74d	TCGA-D1-A177-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D1-A177-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_1_rg.sorted	TCGA-D1-A177-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_1_rg.sorted.bam	86.4	1.36	0.15	58cfa831e4b0c9d6adf6c74d	TCGA-D1-A177-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A177-01A	E8C58D8B-51D7-4599-AF79-469EE6F269DB	Primary Tumor	Illumina HiSeq	cf08e174-408a-4212-8caf-72692bcb55af	Uterus	70.0	97587FD4-0F6F-4AF5-AC0A-7328ABB40E9C	2F6D7D10-84AA-48A6-9B8E-9CBB257C653D	TCGA-D1-A177-01A-21D-A12F-02	HG19_Broad_variant	TCGA-D1-A177	TCGA-UCEC		s4800	Harvard Medical School	Mayo Clinic		NO			Endometrioid endometrial adenocarcinoma		A12F-02	True
S13722.58cfa831e4b0c9d6adf6c7f3	58cfa831e4b0c9d6adf6c7f3	TCGA-D7-5577-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D7-5577-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_1_rg.sorted	TCGA-D7-5577-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_1_rg.sorted.bam	414.0	1.87	0.14	58cfa831e4b0c9d6adf6c7f3	TCGA-D7-5577-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-5577-01A	2DC154AA-C478-404B-A92E-86ABCC8DBDB7	Primary Tumor	Illumina HiSeq	e417c8be-9c96-4e81-a2c9-ac3f23791347	Stomach	53.0	93BBD9FD-2385-46C3-AF21-E46C72A8A75D	8FCA6D2A-04D8-4A60-AEA3-298853E74752	TCGA-D7-5577-01A-01D-1598-02	HG19_Broad_variant	TCGA-D7-5577	TCGA-STAD		s14908	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N3	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIA	1598-02	True
S13722.58cfa831e4b0c9d6adf6c819	58cfa831e4b0c9d6adf6c819	TCGA-CN-6998-01A-23D-2317_120623_SN1222_0118_AD13T1ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-6998-01A-23D-2317_120623_SN1222_0118_AD13T1ACXX_s_5_rg.sorted	TCGA-CN-6998-01A-23D-2317_120623_SN1222_0118_AD13T1ACXX_s_5_rg.sorted.bam	9.03		0.13	58cfa831e4b0c9d6adf6c819	TCGA-CN-6998-01A-23D-2317_120623_SN1222_0118_AD13T1ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6998-01A	039788EC-1364-40C7-9E9D-13DC305674E9	Primary Tumor	Illumina HiSeq	d281a462-58dd-4303-9419-617fec3fcf35	Head and Neck	53.0	64C8DB8B-5D5C-4FBE-8996-4A7CB161D4A0	88B8B48D-51B8-4D46-9C36-E565A2582D94	TCGA-CN-6998-01A-23D-2317-26	HG19_Broad_variant	TCGA-CN-6998	TCGA-HNSC		s16333	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	2317-26	True
S13722.58cfa831e4b0c9d6adf6c858	58cfa831e4b0c9d6adf6c858	TCGA-D6-6517-01A-11D-1868_120427_SN208_0288_BD0RWBACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D6-6517-01A-11D-1868_120427_SN208_0288_BD0RWBACXX_s_3_rg.sorted	TCGA-D6-6517-01A-11D-1868_120427_SN208_0288_BD0RWBACXX_s_3_rg.sorted.bam	209.7	1.9	0.15	58cfa831e4b0c9d6adf6c858	TCGA-D6-6517-01A-11D-1868_120427_SN208_0288_BD0RWBACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6517-01A	EBE99910-E9F2-43DC-AD57-AC2F610B60C8	Primary Tumor	Illumina HiSeq	e84f34a5-8df7-4824-92d7-4f53b4bace58	Head and Neck	59.0	8C099F45-3FD6-4966-8CDB-CA4B9288B1A2	97962F6C-B2FB-4618-A5A4-7B376714EC62	TCGA-D6-6517-01A-11D-1868-02	HG19_Broad_variant	TCGA-D6-6517	TCGA-HNSC		s15655	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1868-02	True
S13722.58cfa831e4b0c9d6adf6c826	58cfa831e4b0c9d6adf6c826	TCGA-D1-A17U-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D1-A17U-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_3_rg.sorted	TCGA-D1-A17U-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_3_rg.sorted.bam	73.35	1.96	0.17	58cfa831e4b0c9d6adf6c826	TCGA-D1-A17U-01A-21D-A12F_120523_SN1222_0108_AC0VL4ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17U-01A	6397C4A1-0A29-4C2C-B8CB-CE73AF93DD0B	Primary Tumor	Illumina HiSeq	8d00983f-b836-41a9-a4b9-51c75b4452a8	Uterus	53.0	1F1945EE-4CF3-43A3-9998-1C4528C7A511	1B9EB26F-48E0-4EBF-9094-5013E3DF2FBD	TCGA-D1-A17U-01A-21D-A12F-02	HG19_Broad_variant	TCGA-D1-A17U	TCGA-UCEC		s4616	Harvard Medical School	Mayo Clinic		NO			Endometrioid endometrial adenocarcinoma		A12F-02	True
S13722.58cfa831e4b0c9d6adf6c8bc	58cfa831e4b0c9d6adf6c8bc	TCGA-DK-A3IT-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DK-A3IT-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_5_rg.sorted	TCGA-DK-A3IT-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_5_rg.sorted.bam	24.31		0.16	58cfa831e4b0c9d6adf6c8bc	TCGA-DK-A3IT-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IT-01A	58520C66-7688-435A-B09F-653B18768C41	Primary Tumor	Illumina HiSeq	276fd52d-8d51-4e03-85a5-a7f02ee03b71	Bladder	62.0	6B48DAE5-B757-450A-8248-65C2434A7AFC	CDBAE634-52F3-4165-A214-BB60BEC5D6C4	TCGA-DK-A3IT-01A-31D-A210-26	HG19_Broad_variant	TCGA-DK-A3IT	TCGA-BLCA		s2715	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	True
S13722.58cfa831e4b0c9d6adf6c98e	58cfa831e4b0c9d6adf6c98e	TCGA-D7-6520-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_7_rg.sorted.filtered.	WGS	TCGA-D7-6520-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_7_rg.sorted	TCGA-D7-6520-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_7_rg.sorted.bam	94.4	1.9	0.14	58cfa831e4b0c9d6adf6c98e	TCGA-D7-6520-01A-11D-1798_130214_SN1120_0236_AC1RPCACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6520-01A	3C573AF6-6298-49DE-8DE0-6A7F9CE9B000	Primary Tumor	Illumina HiSeq	46b79d94-56c0-4b23-955d-2395a50ecaf9	Stomach	53.0	7C162352-903E-4723-AF91-6FDD8E8EAD3B	F1CB7996-BD0E-4123-84E9-D359E5DB7700	TCGA-D7-6520-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6520	TCGA-STAD		s14494	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2b	N2	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIA	1798-02	True
S13722.58cfa831e4b0c9d6adf6c9b5	58cfa831e4b0c9d6adf6c9b5	TCGA-DK-A3IU-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A3IU-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_7_rg.sorted	TCGA-DK-A3IU-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_7_rg.sorted.bam	34.01		0.15	58cfa831e4b0c9d6adf6c9b5	TCGA-DK-A3IU-01A-11D-A210_120911_SN1120_0189_BD1D04ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IU-01A	F093F043-EFD4-4CBA-A87F-8CBB5C1ACD9E	Primary Tumor	Illumina HiSeq	346b87a3-0c3a-455c-b3c1-0fb96acd0f2f	Bladder	58.0	B9C39E8B-D689-499A-BC06-CE3BFFC9996C	8E8E8966-582A-45FF-96C2-EC0C1718C4F2	TCGA-DK-A3IU-01A-11D-A210-26	HG19_Broad_variant	TCGA-DK-A3IU	TCGA-BLCA		s3285	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	True
S13722.58cfa831e4b0c9d6adf6c9d3	58cfa831e4b0c9d6adf6c9d3	TCGA-DK-A1A3-01A-11D-A13U_120921_SN208_0431_BD1D5FACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A1A3-01A-11D-A13U_120921_SN208_0431_BD1D5FACXX_s_7_rg.sorted	TCGA-DK-A1A3-01A-11D-A13U_120921_SN208_0431_BD1D5FACXX_s_7_rg.sorted.bam	16.46	1.91	0.17	58cfa831e4b0c9d6adf6c9d3	TCGA-DK-A1A3-01A-11D-A13U_120921_SN208_0431_BD1D5FACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1A3-01A	C5B20CCC-523D-491C-8536-008E05C57212	Primary Tumor	Illumina HiSeq	0e78dec3-7b8b-425e-9cc5-489bf825e0ea	Bladder	60.0	954E46BA-514F-4708-AD3C-ECBF8CEF005A	DC0A234A-9177-4E2A-B218-212F1278B4A1	TCGA-DK-A1A3-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1A3	TCGA-BLCA		s3102	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13U-02	True
S13722.58cfa831e4b0c9d6adf6c9d5	58cfa831e4b0c9d6adf6c9d5	TCGA-DK-A3IQ-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DK-A3IQ-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_3_rg.sorted	TCGA-DK-A3IQ-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_3_rg.sorted.bam	22.29		0.16	58cfa831e4b0c9d6adf6c9d5	TCGA-DK-A3IQ-01A-31D-A210_120911_SN1120_0189_BD1D04ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IQ-01A	E44F60EC-66C4-45A2-A003-0A1FAF1D6E03	Primary Tumor	Illumina HiSeq	edc43d06-7118-46e7-894e-d40138b6d69c	Bladder	74.0	1E375786-DB8F-4A8C-BA1C-C6DD7DE1A9BE	DB940CE0-2357-4E83-AA19-AEA672A121D9	TCGA-DK-A3IQ-01A-31D-A210-26	HG19_Broad_variant	TCGA-DK-A3IQ	TCGA-BLCA		s2894	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	True
S13722.58cfa831e4b0c9d6adf6c9c7	58cfa831e4b0c9d6adf6c9c7	TCGA-DQ-5630-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DQ-5630-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_1_rg.sorted	TCGA-DQ-5630-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_1_rg.sorted.bam	374.7	1.9	0.15	58cfa831e4b0c9d6adf6c9c7	TCGA-DQ-5630-01A-01D-1868_120504_SN1222_0101_AC0UMDACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-5630-01A	91A712B5-A724-48D0-BA06-4F6857683463	Primary Tumor	Illumina HiSeq	865b23ff-32b6-41bf-8316-cde4e80d7873	Head and Neck	73.0	A0CDB208-E66F-4AD7-86FA-5077145A4A68	4C2960DA-103B-4620-ABCD-0EE586F39E0D	TCGA-DQ-5630-01A-01D-1868-02	HG19_Broad_variant	TCGA-DQ-5630	TCGA-HNSC		s16346	Harvard Medical School	University of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		1868-02	True
S13722.58cfa831e4b0c9d6adf6cac2	58cfa831e4b0c9d6adf6cac2	TCGA-DJ-A13R-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DJ-A13R-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_2_rg.sorted	TCGA-DJ-A13R-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_2_rg.sorted.bam	78.88	1.95	0.16	58cfa831e4b0c9d6adf6cac2	TCGA-DJ-A13R-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13R-01A	3E787A0E-B5D2-401E-B1E5-077376090B3A	Primary Tumor	Illumina HiSeq	84cf379b-0f45-44d0-b5e3-00a439bab300	Thyroid	50.0	27B0FF79-4213-4B57-B6E0-A393B8983D20	7B0104C8-1264-4580-94D1-C7C39D79C6E6	TCGA-DJ-A13R-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13R	TCGA-THCA		s12368	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage III	A10R-02	True
S13722.58cfa831e4b0c9d6adf6ca92	58cfa831e4b0c9d6adf6ca92	TCGA-DQ-5624-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DQ-5624-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_5_rg.sorted	TCGA-DQ-5624-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_5_rg.sorted.bam	98.7	1.9	0.15	58cfa831e4b0c9d6adf6ca92	TCGA-DQ-5624-01A-01D-1868_120427_SN208_0288_BD0RWBACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-5624-01A	B4A41682-4ACA-4F1D-BACD-66F5E6EC7466	Primary Tumor	Illumina HiSeq	72ea153a-e312-4f8e-8fa6-bd705df2b106	Head and Neck	43.0	39A74037-6C20-4713-A6AA-E972218EFF90	45F819EB-F6B5-4B82-9E47-060B2E111851	TCGA-DQ-5624-01A-01D-1868-02	HG19_Broad_variant	TCGA-DQ-5624	TCGA-HNSC		s15532	Harvard Medical School	University of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		1868-02	True
S13722.58cfa831e4b0c9d6adf6cb17	58cfa831e4b0c9d6adf6cb17	TCGA-EA-A3QD-01A-32D-A232_140124_SN1120_0291_AC2PHAACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EA-A3QD-01A-32D-A232_140124_SN1120_0291_AC2PHAACXX_s_2_rg.sorted	TCGA-EA-A3QD-01A-32D-A232_140124_SN1120_0291_AC2PHAACXX_s_2_rg.sorted.bam	58.49		0.15	58cfa831e4b0c9d6adf6cb17	TCGA-EA-A3QD-01A-32D-A232_140124_SN1120_0291_AC2PHAACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3QD-01A	9E2E29E8-D94A-499F-A98A-5B53B2C38F3B	Primary Tumor	Illumina HiSeq	d97f385a-fc08-43a1-9481-35f9ffdfcc05	Cervix	59.0	987E1913-A506-4A06-B247-9FF778CE552B	677FE002-1736-4263-B2CE-D93983F0BF95	TCGA-EA-A3QD-01A-32D-A232-26	HG19_Broad_variant	TCGA-EA-A3QD	TCGA-CESC		s1185	MD Anderson - Institute for Applied Cancer Science	Asterand	United States	NO	T1b1	N1	Cervical Squamous Cell Carcinoma		A232-26	True
S13722.58cfa831e4b0c9d6adf6cbaa	58cfa831e4b0c9d6adf6cbaa	TCGA-EJ-5526-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5526-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_3_rg.sorted	TCGA-EJ-5526-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_3_rg.sorted.bam	378.7	1.9	0.15	58cfa831e4b0c9d6adf6cbaa	TCGA-EJ-5526-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5526-01A	EEC48399-5660-4B25-8D34-191B54315C72	Primary Tumor	Illumina HiSeq	e57f50b5-06be-4be0-8b02-706bfb439f25	Prostate	56.0	4DBE4FA2-308F-4D5B-BF33-4C051F7DC537	4AC5F198-9558-42C9-8285-91D3F826E0E9	TCGA-EJ-5526-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5526	TCGA-PRAD		s4143	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cb9a	58cfa831e4b0c9d6adf6cb9a	TCGA-EJ-7317-01A-31D-2111_130422_SN590_0225_BD23TLACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EJ-7317-01A-31D-2111_130422_SN590_0225_BD23TLACXX_s_6_rg.sorted	TCGA-EJ-7317-01A-31D-2111_130422_SN590_0225_BD23TLACXX_s_6_rg.sorted.bam	61.4		0.16	58cfa831e4b0c9d6adf6cb9a	TCGA-EJ-7317-01A-31D-2111_130422_SN590_0225_BD23TLACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7317-01A	68FC3693-0910-4EE8-8997-99C6333B65F4	Primary Tumor	Illumina HiSeq	7c1cef2b-4606-4c6c-ad6d-b49ca86b9f74	Prostate	71.0	AEEA2F28-0766-42D7-9E6A-C14BEB03E692	B25F2F78-DB49-49DF-9150-DF43F23589A4	TCGA-EJ-7317-01A-31D-2111-02	HG19_Broad_variant	TCGA-EJ-7317	TCGA-PRAD		s3959	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa831e4b0c9d6adf6cbca	58cfa831e4b0c9d6adf6cbca	TCGA-EJ-5517-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5517-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_5_rg.sorted	TCGA-EJ-5517-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_5_rg.sorted.bam	52.7	1.9	0.15	58cfa831e4b0c9d6adf6cbca	TCGA-EJ-5517-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5517-01A	4B9AA301-D2E3-47F3-B724-A34F420B2B6B	Primary Tumor	Illumina HiSeq	add98c6f-07de-48db-b930-82504d0dd976	Prostate	55.0	B5FE6254-D1C6-4BA2-BD75-5CAF4FB2E2B7	62E5A068-01A5-40EC-8FF9-097D627127A0	TCGA-EJ-5517-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5517	TCGA-PRAD		s3437	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cbc7	58cfa831e4b0c9d6adf6cbc7	TCGA-EJ-7327-01A-11D-2111_130422_SN590_0225_BD23TLACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EJ-7327-01A-11D-2111_130422_SN590_0225_BD23TLACXX_s_8_rg.sorted	TCGA-EJ-7327-01A-11D-2111_130422_SN590_0225_BD23TLACXX_s_8_rg.sorted.bam	261.3		0.14	58cfa831e4b0c9d6adf6cbc7	TCGA-EJ-7327-01A-11D-2111_130422_SN590_0225_BD23TLACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7327-01A	E90AB72A-4BBB-4C37-B48A-8A1A85D79D04	Primary Tumor	Illumina HiSeq	fe462cbb-5d52-4a0e-8cb8-a7e6c0f39c7c	Prostate	61.0	992415EF-53DE-4C52-A538-07931E68182B	0FC53595-F61A-4171-B982-335AEE13CC85	TCGA-EJ-7327-01A-11D-2111-02	HG19_Broad_variant	TCGA-EJ-7327	TCGA-PRAD		s4145	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa831e4b0c9d6adf6cbee	58cfa831e4b0c9d6adf6cbee	TCGA-EK-A2PM-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EK-A2PM-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_2_rg.sorted	TCGA-EK-A2PM-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_2_rg.sorted.bam	43.27		0.16	58cfa831e4b0c9d6adf6cbee	TCGA-EK-A2PM-01A-11D-A18I_140204_SN208_0508_BC2R1UACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2PM-01A	085FB6D8-6265-484E-9307-8292386714B7	Primary Tumor	Illumina HiSeq	332b29bf-f948-4e2c-bf51-f768f819e9e9	Cervix	81.0	2E7F29FB-97DE-4EE0-BCA7-6A51C4C3E5CF	C32BE42D-CF78-4F46-B461-748796CEDA4A	TCGA-EK-A2PM-01A-11D-A18I-02	HG19_Broad_variant	TCGA-EK-A2PM	TCGA-CESC		s1195	Harvard Medical School	Gynecologic Oncology Group	United States	NO			Cervical Squamous Cell Carcinoma		A18I-02	True
S13722.58cfa831e4b0c9d6adf6cbdd	58cfa831e4b0c9d6adf6cbdd	TCGA-EJ-5532-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5532-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_3_rg.sorted	TCGA-EJ-5532-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_3_rg.sorted.bam	188.7	1.9	0.15	58cfa831e4b0c9d6adf6cbdd	TCGA-EJ-5532-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5532-01A	AE3A0C92-148D-4F1C-8563-06AC1050F53E	Primary Tumor	Illumina HiSeq	e7c833a1-c77a-4c65-b268-1db73a7028e3	Prostate	57.0	F32F7738-BAD4-40C9-B49F-084BB098A05A	E5F35020-2A9F-47B3-8271-FEF8E1883567	TCGA-EJ-5532-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5532	TCGA-PRAD		s3956	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cca3	58cfa831e4b0c9d6adf6cca3	TCGA-EJ-5499-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5499-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_1_rg.sorted	TCGA-EJ-5499-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_1_rg.sorted.bam	91.7	1.9	0.15	58cfa831e4b0c9d6adf6cca3	TCGA-EJ-5499-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5499-01A	FD1AA612-DF86-4D48-892D-2ACEBD76EA96	Primary Tumor	Illumina HiSeq	21f9da4c-83ce-44b4-b002-e18cd232ac6b	Prostate	61.0	22C4F5C2-1B1E-4212-8110-09DBD5CE10A9	0F4314C9-967C-4EF1-9CF2-A7B206E6129E	TCGA-EJ-5499-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5499	TCGA-PRAD		s3789	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cca6	58cfa831e4b0c9d6adf6cca6	TCGA-EJ-5497-01A-02D-1572_130125_SN1120_0233_AD1K3HACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5497-01A-02D-1572_130125_SN1120_0233_AD1K3HACXX_s_5_rg.sorted	TCGA-EJ-5497-01A-02D-1572_130125_SN1120_0233_AD1K3HACXX_s_5_rg.sorted.bam	209.7	1.9	0.16	58cfa831e4b0c9d6adf6cca6	TCGA-EJ-5497-01A-02D-1572_130125_SN1120_0233_AD1K3HACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5497-01A	DEE02265-D8DD-4379-AE08-72D72B03A570	Primary Tumor	Illumina HiSeq	453a9559-644e-46b9-8be3-7e4511448e7e	Prostate	47.0	317BE3B2-B7C1-4772-9E33-D55EB4B9FAA9	0B2246C7-CE2E-427D-BA10-4A2C942D0986	TCGA-EJ-5497-01A-02D-1572-02	HG19_Broad_variant	TCGA-EJ-5497	TCGA-PRAD		s3944	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cccc	58cfa831e4b0c9d6adf6cccc	TCGA-EJ-5530-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5530-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_7_rg.sorted	TCGA-EJ-5530-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_7_rg.sorted.bam	388.7	1.9	0.14	58cfa831e4b0c9d6adf6cccc	TCGA-EJ-5530-01A-01D-1572_130221_SN1120_0238_AC1TDEACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5530-01A	E4A755E3-4938-4321-B5A9-27A445036791	Primary Tumor	Illumina HiSeq	83b4e2b0-670b-441b-9b17-fa5c1da740c5	Prostate	61.0	27D61473-39D6-478A-A576-427D1AEDA01F	CBA52846-FAD3-4D21-8949-0105BD2AE713	TCGA-EJ-5530-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5530	TCGA-PRAD		s3961	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cd62	58cfa831e4b0c9d6adf6cd62	TCGA-EJ-5498-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5498-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_7_rg.sorted	TCGA-EJ-5498-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_7_rg.sorted.bam	52.7	1.9	0.17	58cfa831e4b0c9d6adf6cd62	TCGA-EJ-5498-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5498-01A	79EC7468-9AAF-4BB0-94C7-72BE4F497868	Primary Tumor	Illumina HiSeq	1ea5110e-6493-415f-ae21-019a8d1e2a17	Prostate	56.0	AAF0AF43-DAE0-4AA7-9D4C-6CAF1F039857	24F583BD-C378-4981-A661-97B8E39CE600	TCGA-EJ-5498-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5498	TCGA-PRAD		s3948	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa832e4b0c9d6adf6ce0f	58cfa832e4b0c9d6adf6ce0f	TCGA-FD-A3B8-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FD-A3B8-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_7_rg.sorted	TCGA-FD-A3B8-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_7_rg.sorted.bam	26.04		0.16	58cfa832e4b0c9d6adf6ce0f	TCGA-FD-A3B8-01A-31D-A210_120912_SN1120_0192_AC18ALACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3B8-01A	537CA5D1-5B26-496F-B7B4-05FEA7B46353	Primary Tumor	Illumina HiSeq	c0aadcb9-2d54-45c7-9585-575ed21ea52f	Bladder	56.0	9A27AA84-D541-4FA3-A798-D7559A5AE70C	582B2439-02F1-4E2A-9A4E-771603658FB5	TCGA-FD-A3B8-01A-31D-A210-26	HG19_Broad_variant	TCGA-FD-A3B8	TCGA-BLCA		s3296	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	True
S13722.58cfa832e4b0c9d6adf6ce6a	58cfa832e4b0c9d6adf6ce6a	TCGA-H2-A26U-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_5_rg.sorted.filtered.	WGS	TCGA-H2-A26U-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_5_rg.sorted	TCGA-H2-A26U-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_5_rg.sorted.bam	65.58	1.91	0.17	58cfa832e4b0c9d6adf6ce6a	TCGA-H2-A26U-01A-11D-A16N_121204_SN208_0442_BC1F7YACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-H2-A26U-01A	E61FB24B-613A-4B6D-BB2B-00CCEDBD3DBC	Primary Tumor	Illumina HiSeq	91b791c7-9ac1-4a55-bb8a-110046b81a61	Thyroid	54.0	A4240AB1-970E-4A99-989E-8968903E3A25	79850C4D-71D0-4905-946A-F309DCDDA59F	TCGA-H2-A26U-01A-11D-A16N-02	HG19_Broad_variant	TCGA-H2-A26U	TCGA-THCA		s12762	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A16N-02	True
S13722.58cfa832e4b0c9d6adf6cea9	58cfa832e4b0c9d6adf6cea9	TCGA-EJ-5516-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5516-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_3_rg.sorted	TCGA-EJ-5516-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_3_rg.sorted.bam	197.7	1.9	0.16	58cfa832e4b0c9d6adf6cea9	TCGA-EJ-5516-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5516-01A	1FD06207-54E0-4ABA-819C-C7F671871F39	Primary Tumor	Illumina HiSeq	80ba9751-2e29-4949-a07f-6e3542df8770	Prostate	49.0	84D2D822-204E-4031-AF83-E188BB72F3AF	7DBAAFC9-A93D-4FFB-9FF0-85FACD567555	TCGA-EJ-5516-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5516	TCGA-PRAD		s4136	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa832e4b0c9d6adf6cf48	58cfa832e4b0c9d6adf6cf48	TCGA-HC-7075-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HC-7075-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_4_rg.sorted	TCGA-HC-7075-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_4_rg.sorted.bam	242.7		0.15	58cfa832e4b0c9d6adf6cf48	TCGA-HC-7075-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7075-01A	5DD69C3E-9A3D-450C-9F10-10B4D6DAEEBA	Primary Tumor	Illumina HiSeq	7fee8465-32e2-4bef-bd48-102b2534003a	Prostate	63.0	1FA3E5C2-E415-42FA-AEA3-F6C84959522A	CFC425B3-7570-4FD2-8DB6-611EF4D627DF	TCGA-HC-7075-01A-11D-1957-02	HG19_Broad_variant	TCGA-HC-7075	TCGA-PRAD		s3811	Harvard Medical School	International Genomics Consortium	United States	NO	T2a		Prostate Adenocarcinoma Acinar Type		1957-02	True
S13722.58cfa832e4b0c9d6adf6cf86	58cfa832e4b0c9d6adf6cf86	TCGA-G9-6343-01A-21D-1957_130329_SN590_0221_BD1WHDACXX_s_8_rg.sorted.filtered.	WGS	TCGA-G9-6343-01A-21D-1957_130329_SN590_0221_BD1WHDACXX_s_8_rg.sorted	TCGA-G9-6343-01A-21D-1957_130329_SN590_0221_BD1WHDACXX_s_8_rg.sorted.bam	108.7	1.9	0.14	58cfa832e4b0c9d6adf6cf86	TCGA-G9-6343-01A-21D-1957_130329_SN590_0221_BD1WHDACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6343-01A	36B87D12-9F96-460F-A3B5-A4C08CBF5B07	Primary Tumor	Illumina HiSeq	e413f861-4cba-4bf6-a805-aff9ecf4eb3b	Prostate	62.0	084C6D1F-047E-4B0E-9034-3B0FC18D510D	CB58EB3E-4769-4050-BB51-AE248D0FABAA	TCGA-G9-6343-01A-21D-1957-02	HG19_Broad_variant	TCGA-G9-6343	TCGA-PRAD		s3453	Harvard Medical School	Roswell Park	United States	NO	T2c		Prostate Adenocarcinoma Acinar Type		1957-02	True
S13722.58cfa832e4b0c9d6adf6ce92	58cfa832e4b0c9d6adf6ce92	TCGA-G2-A2EJ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G2-A2EJ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_3_rg.sorted	TCGA-G2-A2EJ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_3_rg.sorted.bam	36.89		0.16	58cfa832e4b0c9d6adf6ce92	TCGA-G2-A2EJ-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2EJ-01A	C6227D39-D9E8-4E28-9E70-D7F720AB25E4	Primary Tumor	Illumina HiSeq	18abb4d7-25d0-477e-bda6-011263e96364	Bladder	56.0	FBAD20BA-EE08-4D46-825B-870126AAD539	8D99E3A4-DECB-49D7-9727-C5D7606D60DF	TCGA-G2-A2EJ-01A-11D-A17R-02	HG19_Broad_variant	TCGA-G2-A2EJ	TCGA-BLCA		s3304	Harvard Medical School	MD Anderson	United States	NO		N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A17R-02	True
S13722.58cfa832e4b0c9d6adf6cf1a	58cfa832e4b0c9d6adf6cf1a	TCGA-H7-7774-01A-21D-2317_120623_SN1222_0119_BC0WLLACXX_s_4_rg.sorted.filtered.	WGS	TCGA-H7-7774-01A-21D-2317_120623_SN1222_0119_BC0WLLACXX_s_4_rg.sorted	TCGA-H7-7774-01A-21D-2317_120623_SN1222_0119_BC0WLLACXX_s_4_rg.sorted.bam	52.73		0.15	58cfa832e4b0c9d6adf6cf1a	TCGA-H7-7774-01A-21D-2317_120623_SN1222_0119_BC0WLLACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-H7-7774-01A	EEAE67AC-C9E0-468D-AAD6-052501F7B982	Primary Tumor	Illumina HiSeq	ab347312-e135-4dd6-9be3-fa5fdebbcd68	Head and Neck	75.0	50F6615A-49CC-4E14-B5DD-54784B66C27B	B9B2B6F5-57EB-4DD6-8FE2-1E8669840DAB	TCGA-H7-7774-01A-21D-2317-26	HG19_Broad_variant	TCGA-H7-7774	TCGA-HNSC		s16209	MD Anderson - Institute for Applied Cancer Science	ABS - IUPUI	United States	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	2317-26	True
S13722.58cfa832e4b0c9d6adf6d036	58cfa832e4b0c9d6adf6d036	TCGA-FU-A3WB-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FU-A3WB-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_5_rg.sorted	TCGA-FU-A3WB-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_5_rg.sorted.bam	44.44		0.16	58cfa832e4b0c9d6adf6d036	TCGA-FU-A3WB-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3WB-01A	6868BA1D-B612-454C-8146-74AF2F573D76	Primary Tumor	Illumina HiSeq	39124a1d-9323-40ae-aee5-6fb32cf4a565	Cervix	43.0	0334B0B7-115E-40A0-960B-6A3365CDA3AD	52C1B6D6-A160-4FFB-945C-6FB3B29EFEF9	TCGA-FU-A3WB-01A-11D-A232-26	HG19_Broad_variant	TCGA-FU-A3WB	TCGA-CESC		s1203	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2a2	N0	Cervical Squamous Cell Carcinoma		A232-26	True
S13722.58cfa832e4b0c9d6adf6d078	58cfa832e4b0c9d6adf6d078	TCGA-HC-7081-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HC-7081-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_4_rg.sorted	TCGA-HC-7081-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_4_rg.sorted.bam	130.7		0.14	58cfa832e4b0c9d6adf6d078	TCGA-HC-7081-01A-11D-1957_130422_SN590_0225_BD23TLACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE		Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7081-01A	3DA2E90E-6450-4286-8C74-08DBECBFD788	Primary Tumor	Illumina HiSeq	f44b51c1-3e9f-49b0-817b-b31a58264c39	Prostate	62.0	D4EAA3C5-A0F0-4CD7-8B93-73DFB09B359A	AA4E666F-E577-4F00-82A7-EBC3B8739960	TCGA-HC-7081-01A-11D-1957-02	HG19_Broad_variant	TCGA-HC-7081	TCGA-PRAD		s3805	Harvard Medical School	International Genomics Consortium	United States	NO	T3b		Prostate Adenocarcinoma Acinar Type		1957-02	True
S13722.58cfa832e4b0c9d6adf6d0ac	58cfa832e4b0c9d6adf6d0ac	TCGA-IG-A3I8-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_5_rg.sorted.filtered.	WGS	TCGA-IG-A3I8-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_5_rg.sorted	TCGA-IG-A3I8-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_5_rg.sorted.bam	64.11		0.16	58cfa832e4b0c9d6adf6d0ac	TCGA-IG-A3I8-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A3I8-01A	7BF3F18B-A013-48D2-A743-26A57FDBE4C4	Primary Tumor	Illumina HiSeq	d45e0e39-36b5-4628-9dae-7a185f129e6b	Esophagus	51.0	944A68B7-51D4-4831-88D4-D647BE17BC13	3A1FBCCE-BAB6-466C-AE4C-AADC4E5D357F	TCGA-IG-A3I8-01A-11D-A248-26	HG19_Broad_variant	TCGA-IG-A3I8	TCGA-ESCA		s1621	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T3	N0		Stage IIA	A248-26	True
S13722.58cfa832e4b0c9d6adf6d0d0	58cfa832e4b0c9d6adf6d0d0	TCGA-IG-A3YA-01A-11D-A248_121211_SN208_0443_BC1H55ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-IG-A3YA-01A-11D-A248_121211_SN208_0443_BC1H55ACXX_s_1_rg.sorted	TCGA-IG-A3YA-01A-11D-A248_121211_SN208_0443_BC1H55ACXX_s_1_rg.sorted.bam	41.16		0.16	58cfa832e4b0c9d6adf6d0d0	TCGA-IG-A3YA-01A-11D-A248_121211_SN208_0443_BC1H55ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A3YA-01A	7AB6DE57-D659-47F1-A70F-1B67650E99D7	Primary Tumor	Illumina HiSeq	d20d3af7-3c79-446f-834f-9be861dc1490	Esophagus	53.0	AAADB48E-3C60-4AE4-B6EB-7B5F9C9D6544	A389CF30-6460-43E5-A895-6EBFC9555AF2	TCGA-IG-A3YA-01A-11D-A248-26	HG19_Broad_variant	TCGA-IG-A3YA	TCGA-ESCA		s1819	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T4	N0		Stage IIIA	A248-26	True
S13722.58cfa832e4b0c9d6adf6d0f0	58cfa832e4b0c9d6adf6d0f0	TCGA-HC-7077-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HC-7077-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_6_rg.sorted	TCGA-HC-7077-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_6_rg.sorted.bam	192.7		0.15	58cfa832e4b0c9d6adf6d0f0	TCGA-HC-7077-01A-11D-1957_130412_SN590_0224_BC1YMJACXX_s_6_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7077-01A	92252560-5984-41F6-A4B5-A3AA8654C0C8	Primary Tumor	Illumina HiSeq	bea10bd4-1049-4162-bb70-0bf5073199c6	Prostate	64.0	F3E4CC00-D6FE-4291-BB07-8E501E772CE1	EFC4EC34-58ED-40DE-8E0D-BCBA6320BF4C	TCGA-HC-7077-01A-11D-1957-02	HG19_Broad_variant	TCGA-HC-7077	TCGA-PRAD		s4154	Harvard Medical School	International Genomics Consortium	United States	NO	T3a		Prostate Adenocarcinoma Acinar Type		1957-02	True
S13722.58cfa832e4b0c9d6adf6d0f2	58cfa832e4b0c9d6adf6d0f2	TCGA-HC-7213-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HC-7213-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_6_rg.sorted	TCGA-HC-7213-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_6_rg.sorted.bam	408.3		0.15	58cfa832e4b0c9d6adf6d0f2	TCGA-HC-7213-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7213-01A	26EEFAA1-1666-4CE1-8CF4-F6FABFF81FD2	Primary Tumor	Illumina HiSeq	14482ee6-0af5-43ad-bc2b-c9574446f6b9	Prostate	53.0	0CB3DFFD-1521-4887-B19C-94DCD340D306	6D368C2B-4F13-4006-A487-7DB0ADA55C6A	TCGA-HC-7213-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7213	TCGA-PRAD		s3812	Harvard Medical School	International Genomics Consortium	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa832e4b0c9d6adf6d12e	58cfa832e4b0c9d6adf6d12e	TCGA-G2-A3IB-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-G2-A3IB-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_1_rg.sorted	TCGA-G2-A3IB-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_1_rg.sorted.bam	39.31		0.15	58cfa832e4b0c9d6adf6d12e	TCGA-G2-A3IB-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_1_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A3IB-01A	AF53D51E-0B5C-437F-A1C0-EC5F55C49364	Primary Tumor	Illumina HiSeq	f78443a3-8c1b-429a-93c3-fcd93f3c6d55	Bladder	66.0	791E4058-E872-4AF8-A431-F5782811F02A	80F634F1-C34C-40CD-9F9B-BBFC18E9DE6E	TCGA-G2-A3IB-01A-11D-A210-26	HG19_Broad_variant	TCGA-G2-A3IB	TCGA-BLCA		s2726	MD Anderson - Institute for Applied Cancer Science	MD Anderson	United States	NO		NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	True
S13722.58cfa832e4b0c9d6adf6d174	58cfa832e4b0c9d6adf6d174	TCGA-HC-7231-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-HC-7231-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_2_rg.sorted	TCGA-HC-7231-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_2_rg.sorted.bam	61.3		0.17	58cfa832e4b0c9d6adf6d174	TCGA-HC-7231-01A-11D-2111_130517_SN590_0231_BC24V6ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE		Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7231-01A	B182BDA9-3D9F-4958-96EB-BD6CC441830C	Primary Tumor	Illumina HiSeq	4b0f4fcc-c7c6-44bc-95d3-e693b0fbc7c7	Prostate	66.0	6AC7857C-5446-4297-95A9-5F2C11C28220	9826D5D9-D6D3-4216-9CA1-FE010711E13E	TCGA-HC-7231-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7231	TCGA-PRAD		s3806	Harvard Medical School	International Genomics Consortium	United States	NO	T2c		Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa832e4b0c9d6adf6d158	58cfa832e4b0c9d6adf6d158	TCGA-IR-A3LF-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-IR-A3LF-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_7_rg.sorted	TCGA-IR-A3LF-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_7_rg.sorted.bam	36.63		0.15	58cfa832e4b0c9d6adf6d158	TCGA-IR-A3LF-01A-21D-A232_140124_SN1120_0292_BD2F1HACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LF-01A	785DDEA1-399D-47D8-B2B0-39E95EAA24B5	Primary Tumor	Illumina HiSeq	aba44461-5b2e-40f7-9e8e-262aee825e6c	Cervix	64.0	B6A74A02-CD3B-4F0A-BB2F-F90C1D3F6D14	02D65CAC-E751-493F-A4FB-3DDB1400EFAC	TCGA-IR-A3LF-01A-21D-A232-26	HG19_Broad_variant	TCGA-IR-A3LF	TCGA-CESC		s1216	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b1	N0	Endocervical Adenocarcinoma of the Usual Type		A232-26	True
S13722.58cfa832e4b0c9d6adf6d034	58cfa832e4b0c9d6adf6d034	TCGA-GC-A3RD-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_7_rg.sorted.filtered.	WGS	TCGA-GC-A3RD-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_7_rg.sorted	TCGA-GC-A3RD-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_7_rg.sorted.bam	46.83		0.16	58cfa832e4b0c9d6adf6d034	TCGA-GC-A3RD-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GC-A3RD-01A	6A2155B3-915C-41B1-B730-32E55E0C1FBD	Primary Tumor	Illumina HiSeq	27573bf6-b72d-47e6-93f7-38d2887d8b32	Bladder	83.0	1C60F60E-A3C6-43A1-A56E-BA68801D2D90	C9E9DC46-2917-47BE-92DA-9C40C6F13500	TCGA-GC-A3RD-01A-12D-A233-26	HG19_Broad_variant	TCGA-GC-A3RD	TCGA-BLCA		s2731	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	True
S13722.58cfa832e4b0c9d6adf6d170	58cfa832e4b0c9d6adf6d170	TCGA-J8-A3YH-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_3_rg.sorted.filtered.	WGS	TCGA-J8-A3YH-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_3_rg.sorted	TCGA-J8-A3YH-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_3_rg.sorted.bam	48.6		0.15	58cfa832e4b0c9d6adf6d170	TCGA-J8-A3YH-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE		Thyroid Carcinoma	Aligned reads	TCGA-J8-A3YH-01A	A09B20B5-C187-4632-B996-0D5314A9885C	Primary Tumor	Illumina HiSeq	f6ec340c-1c9c-4c8d-9266-4728709a90e6	Thyroid	39.0	EFDAD0C2-A44D-48F8-A908-E8C9747E78B8	BF118D4C-A2DF-4617-92E2-3475E07D9BE7	TCGA-J8-A3YH-01A-11D-A23Q-26	HG19_Broad_variant	TCGA-J8-A3YH	TCGA-THCA		s12535	MD Anderson - Institute for Applied Cancer Science	Mayo Clinic	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A23Q-26	True
S13722.58cfa832e4b0c9d6adf6d655	58cfa832e4b0c9d6adf6d655	TCGA-LN-A49O-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_1_rg.sorted.filtered.	WGS	TCGA-LN-A49O-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_1_rg.sorted	TCGA-LN-A49O-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_1_rg.sorted.bam	20.64		0.16	58cfa832e4b0c9d6adf6d655	TCGA-LN-A49O-01A-11D-A248_130101_SN590_0206_AC1H8RACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49O-01A	3DF1B9DB-D900-47D2-839D-3900829CB2A9	Primary Tumor	Illumina HiSeq	e460c5ae-4179-406e-a1fd-fb7b1c7403ae	Esophagus	47.0	37A1045E-A566-4BC0-88CA-A54C5426A96D	C5253C04-01D3-40D9-85A2-155F9D0360C3	TCGA-LN-A49O-01A-11D-A248-26	HG19_Broad_variant	TCGA-LN-A49O	TCGA-ESCA		s1863	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0		Stage IIA	A248-26	True
S13722.58cfa82de4b0c9d6adf6a75c	58cfa82de4b0c9d6adf6a75c	G14083.TCGA-21-1082-01A-01D-1521-08.3.filtered.	WGS	G14083.TCGA-21-1082-01A-01D-1521-08.3	G14083.TCGA-21-1082-01A-01D-1521-08.3.bam	233.7	1.9	0.05	58cfa82de4b0c9d6adf6a75c	G14083.TCGA-21-1082-01A-01D-1521-08.3.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-21-1082-01A	0E2EE54A-51C9-4868-842D-A2A1C1CFB016	Primary Tumor	Illumina HiSeq	94c61492-d5ca-462e-84cf-6d6d690fe431	Lung	61.0	F091C76E-5D01-4F4B-8F6F-463C9F302930	1C3DF485-8E75-4378-87F6-C6463A520624	TCGA-21-1082-01A-01D-1521-08	HG19_Broad_variant	TCGA-21-1082	TCGA-LUSC		s10247	Broad Institute of MIT and Harvard	Fox Chase Cancer Center	United States	NO	T2	N0	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IB	1521-08	True
S13722.58cfa82de4b0c9d6adf6a750	58cfa82de4b0c9d6adf6a750	G14082.TCGA-21-1076-01A-02D-1521-08.2.filtered.	WGS	G14082.TCGA-21-1076-01A-02D-1521-08.2	G14082.TCGA-21-1076-01A-02D-1521-08.2.bam	423.7	1.9	0.05	58cfa82de4b0c9d6adf6a750	G14082.TCGA-21-1076-01A-02D-1521-08.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-21-1076-01A	220BE009-8F1E-4A77-AB04-3220B5F87EA6	Primary Tumor	Illumina HiSeq	f960f40f-32d5-4ab1-a88c-0e199b9d1969	Lung	54.0	22BE9844-4D9E-4372-A46A-B5C64480E5AA	504D4CB0-D2DD-420D-82E6-9EC14434A0FC	TCGA-21-1076-01A-02D-1521-08	HG19_Broad_variant	TCGA-21-1076	TCGA-LUSC		s10358	Broad Institute of MIT and Harvard	Fox Chase Cancer Center	United States	NO	T2	N0	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IB	1521-08	True
S13722.58cfa82ee4b0c9d6adf6a82c	58cfa82ee4b0c9d6adf6a82c	G35154.TCGA-FG-7643-01A-11D-A461-08.2.filtered.	WGS	G35154.TCGA-FG-7643-01A-11D-A461-08.2	G35154.TCGA-FG-7643-01A-11D-A461-08.2.bam	9.7		0.09	58cfa82ee4b0c9d6adf6a82c	G35154.TCGA-FG-7643-01A-11D-A461-08.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-7643-01A	B6F13250-31B3-46AD-B514-5A684F1094A9	Primary Tumor	Illumina HiSeq	ad52b277-d592-4ece-a72f-4d48f9394453	Brain	49.0	71F68BC7-2612-4D84-8948-5A06D30AF488	025B53E6-9687-4085-B5CC-3585CE87625D	TCGA-FG-7643-01A-11D-A461-08	HG19_Broad_variant	TCGA-FG-7643	TCGA-LGG		s8327	Broad Institute of MIT and Harvard	Case Western	United States	NO			Oligoastrocytoma		A461-08	True
S13722.58cfa82ee4b0c9d6adf6a826	58cfa82ee4b0c9d6adf6a826	G35154.TCGA-DU-5872-01A-11D-A465-08.1.filtered.	WGS	G35154.TCGA-DU-5872-01A-11D-A465-08.1	G35154.TCGA-DU-5872-01A-11D-A465-08.1.bam	31.7	1.8	0.09	58cfa82ee4b0c9d6adf6a826	G35154.TCGA-DU-5872-01A-11D-A465-08.1.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5872-01A	48607130-C09A-491D-882F-7D2591D13182	Primary Tumor	Illumina HiSeq	359efa91-062f-491e-805a-0130efb943eb	Brain	43.0	048550EE-189D-483D-B07F-B77F10278420	0BCE913F-C4A0-4CC6-9A8B-A223F00CBA11	TCGA-DU-5872-01A-11D-A465-08	HG19_Broad_variant	TCGA-DU-5872	TCGA-LGG		s8528	Broad Institute of MIT and Harvard	Henry Ford Hospital	United States	NO			Oligoastrocytoma		A465-08	False
S13722.58cfa82ee4b0c9d6adf6a8b3	58cfa82ee4b0c9d6adf6a8b3	G35154.TCGA-FG-A4MT-01A-11D-A461-08.3.filtered.	WGS	G35154.TCGA-FG-A4MT-01A-11D-A461-08.3	G35154.TCGA-FG-A4MT-01A-11D-A461-08.3.bam	24.05		0.08	58cfa82ee4b0c9d6adf6a8b3	G35154.TCGA-FG-A4MT-01A-11D-A461-08.3.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-A4MT-01A	E30F1994-3622-43D0-BEC2-6D7E2D9881D2	Primary Tumor	Illumina HiSeq	19c19563-8424-46b9-b88c-72e6dcc4ec23	Brain	27.0	18C49A42-5EB4-4A3F-9233-C2557EA684BF	1120B01A-0819-4C90-A1B4-C2B85108E786	TCGA-FG-A4MT-01A-11D-A461-08	HG19_Broad_variant	TCGA-FG-A4MT	TCGA-LGG		s8740	Broad Institute of MIT and Harvard	Case Western	United States	NO			Oligodendroglioma		A461-08	True
S13722.58cfa82ee4b0c9d6adf6a8d6	58cfa82ee4b0c9d6adf6a8d6	G23072.TCGA_BB_4225_01A_01D_2268_08.1.filtered.	WGS	G23072.TCGA_BB_4225_01A_01D_2268_08.1	G23072.TCGA_BB_4225_01A_01D_2268_08.1.bam	56.7	1.9	0.15	58cfa82ee4b0c9d6adf6a8d6	G23072.TCGA_BB_4225_01A_01D_2268_08.1.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BB-4225-01A	C1F50A22-38DF-41CC-A1F4-F7985504A7AC	Primary Tumor	Illumina HiSeq	e43130ec-f2f3-4984-8ba9-8f0e641acce9	Head and Neck	73.0	AC42070B-F4D6-47BE-96AA-A713D66A0072	81598359-24D5-4A8B-A6E6-7A6F94289119	TCGA-BB-4225-01A-01D-2268-08	HG19_Broad_variant	TCGA-BB-4225	TCGA-HNSC		s16163	Broad Institute of MIT and Harvard	Johns Hopkins	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		2268-08	True
S13722.58cfa82ee4b0c9d6adf6a8a4	58cfa82ee4b0c9d6adf6a8a4	G35154.TCGA-CS-6669-01A-11D-1893-08.5.filtered.	WGS	G35154.TCGA-CS-6669-01A-11D-1893-08.5	G35154.TCGA-CS-6669-01A-11D-1893-08.5.bam	11.7	1.9	0.05	58cfa82ee4b0c9d6adf6a8a4	G35154.TCGA-CS-6669-01A-11D-1893-08.5.bam	Alive	FEMALE	WHITE		Brain Lower Grade Glioma	Aligned reads	TCGA-CS-6669-01A	DC5BDD21-B23F-400E-BBE2-4C98A517FC9E	Primary Tumor	Illumina HiSeq	7069c071-1fef-4c6f-b741-c67ee56619bb	Brain	26.0	57FAE3BD-B822-4855-A4A1-AFDCC20F6071	218A9531-9264-43BC-8535-858D4CB0919E	TCGA-CS-6669-01A-11D-1893-08	HG19_Broad_variant	TCGA-CS-6669	TCGA-LGG		s8523	Broad Institute of MIT and Harvard	Thomas Jefferson University	United States	NO			Oligodendroglioma		1893-08	False
S13722.58cfa82ee4b0c9d6adf6a85a	58cfa82ee4b0c9d6adf6a85a	G35154.TCGA-HT-7602-01A-21D-2086-08.4.filtered.	WGS	G35154.TCGA-HT-7602-01A-21D-2086-08.4	G35154.TCGA-HT-7602-01A-21D-2086-08.4.bam	15.13		0.05	58cfa82ee4b0c9d6adf6a85a	G35154.TCGA-HT-7602-01A-21D-2086-08.4.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7602-01A	799E9106-E62E-4681-8861-137F474EE8B8	Primary Tumor	Illumina HiSeq	fdc7bab5-c807-4791-be95-6a588e86a4b8	Brain	21.0	0997BB1A-F0A4-4CB8-9714-5BAF9C391CE8	88395C0E-4AFE-434D-8B20-5A3EEF8B7F00	TCGA-HT-7602-01A-21D-2086-08	HG19_Broad_variant	TCGA-HT-7602	TCGA-LGG		s8531	Broad Institute of MIT and Harvard	Case Western - St Joes	United States	NO			Oligodendroglioma		2086-08	False
S13722.58cfa82ee4b0c9d6adf6a9a0	58cfa82ee4b0c9d6adf6a9a0	G35154.TCGA-TM-A7CF-01A-11D-A32B-08.4.filtered.	WGS	G35154.TCGA-TM-A7CF-01A-11D-A32B-08.4	G35154.TCGA-TM-A7CF-01A-11D-A32B-08.4.bam	11.46		0.08	58cfa82ee4b0c9d6adf6a9a0	G35154.TCGA-TM-A7CF-01A-11D-A32B-08.4.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-TM-A7CF-01A	033C1F48-9225-4159-B23B-7042272877DA	Primary Tumor	Illumina HiSeq	41c3ad23-569a-452e-8577-85a783c2a020	Brain	41.0	ABE68BC0-FE69-409E-851E-3CCF10C8AC94	979F7FD8-AB07-40A0-869A-D08FB8E598FF	TCGA-TM-A7CF-01A-11D-A32B-08	HG19_Broad_variant	TCGA-TM-A7CF	TCGA-LGG		s8116	Broad Institute of MIT and Harvard	The University of New South Wales	Australia	NO			Astrocytoma		A32B-08	False
S13722.58cfa82ee4b0c9d6adf6ab0e	58cfa82ee4b0c9d6adf6ab0e	G35154.TCGA-HW-7486-01A-11D-2024-08.6.filtered.	WGS	G35154.TCGA-HW-7486-01A-11D-2024-08.6	G35154.TCGA-HW-7486-01A-11D-2024-08.6.bam	21.0		0.05	58cfa82ee4b0c9d6adf6ab0e	G35154.TCGA-HW-7486-01A-11D-2024-08.6.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HW-7486-01A	55A67639-ED05-4143-AF96-A377BC5489EE	Primary Tumor	Illumina HiSeq	77a6b9b7-4a25-4784-95e5-98346720dcef	Brain	37.0	F0C5DF7C-53AA-4D90-8189-44A2BB55A696	67F88CD9-AB77-4227-A8D7-5512246F9772	TCGA-HW-7486-01A-11D-2024-08	HG19_Broad_variant	TCGA-HW-7486	TCGA-LGG		s8551	Broad Institute of MIT and Harvard	MSKCC	United States	NO			Oligodendroglioma		2024-08	False
S13722.58cfa82ee4b0c9d6adf6ab5f	58cfa82ee4b0c9d6adf6ab5f	G37566.TCGA-CH-5771-01A-21D-1576-08.1.filtered.	WGS	G37566.TCGA-CH-5771-01A-21D-1576-08.1	G37566.TCGA-CH-5771-01A-21D-1576-08.1.bam	30.7	1.9	0.05	58cfa82ee4b0c9d6adf6ab5f	G37566.TCGA-CH-5771-01A-21D-1576-08.1.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5771-01A	3ACD8328-76F7-4F43-9660-394B95748C3D	Primary Tumor	Illumina HiSeq	e5382b76-d2ee-4eab-b245-b0d58fda770e	Prostate	63.0	19C87DE2-7936-4277-8AA8-3942D36E7579	87E1FFEE-A8CD-4D75-937E-ED415CF43546	TCGA-CH-5771-01A-21D-1576-08	HG19_Broad_variant	TCGA-CH-5771	TCGA-PRAD		s3759	Broad Institute of MIT and Harvard	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1576-08	True
S13722.58cfa82ee4b0c9d6adf6a9fd	58cfa82ee4b0c9d6adf6a9fd	G32534.TCGA-DJ-A3US-01A-11D-A22D-08.3.filtered.	WGS	G32534.TCGA-DJ-A3US-01A-11D-A22D-08.3	G32534.TCGA-DJ-A3US-01A-11D-A22D-08.3.bam	47.65		0.08	58cfa82ee4b0c9d6adf6a9fd	G32534.TCGA-DJ-A3US-01A-11D-A22D-08.3.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A3US-01A	6EE95DC8-2BAC-4691-AFA2-8222E07506AD	Primary Tumor	Illumina HiSeq	dbbfcd8f-5283-4bf9-98f1-9211808bfed9	Thyroid	37.0	9F63C13D-6008-416E-9E6B-D4ED4210E569	AD874249-9964-4E48-AA3F-7E828EA28F3F	TCGA-DJ-A3US-01A-11D-A22D-08	HG19_Broad_variant	TCGA-DJ-A3US	TCGA-THCA		s12730	Broad Institute of MIT and Harvard	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A22D-08	True
S13722.58cfa82ee4b0c9d6adf6ab6e	58cfa82ee4b0c9d6adf6ab6e	G37566.TCGA-EJ-7791-01A-11D-2114-08.2.filtered.	WGS	G37566.TCGA-EJ-7791-01A-11D-2114-08.2	G37566.TCGA-EJ-7791-01A-11D-2114-08.2.bam	97.3		0.05	58cfa82ee4b0c9d6adf6ab6e	G37566.TCGA-EJ-7791-01A-11D-2114-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7791-01A	4FE004E5-49F9-4336-A690-6EBAD512C813	Primary Tumor	Illumina HiSeq	60424977-6a58-4b53-9607-4cf61abb2c55	Prostate	67.0	57ED8A64-46F9-4E1F-8550-CEF121A6BBC6	D32F41FB-0744-4A62-81F6-0260C4920049	TCGA-EJ-7791-01A-11D-2114-08	HG19_Broad_variant	TCGA-EJ-7791	TCGA-PRAD		s3927	Broad Institute of MIT and Harvard	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2114-08	False
S13722.58cfa82ee4b0c9d6adf6aba8	58cfa82ee4b0c9d6adf6aba8	G35154.TCGA-TQ-A7RK-01A-11D-A33T-08.3.filtered.	WGS	G35154.TCGA-TQ-A7RK-01A-11D-A33T-08.3	G35154.TCGA-TQ-A7RK-01A-11D-A33T-08.3.bam	15.56		0.08	58cfa82ee4b0c9d6adf6aba8	G35154.TCGA-TQ-A7RK-01A-11D-A33T-08.3.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-TQ-A7RK-01A	2F8C789E-BBD8-4753-A48B-6894C21162F8	Primary Tumor	Illumina HiSeq	4b48a880-f86b-4e8b-9d21-65c14ba90284	Brain	29.0	5793003F-E131-4259-91CB-BE9B65B0E523	EE20C616-5CA0-4B81-81A0-FE1551E6F760	TCGA-TQ-A7RK-01A-11D-A33T-08	HG19_Broad_variant	TCGA-TQ-A7RK	TCGA-LGG		s8745	Broad Institute of MIT and Harvard	University of Sao Paulo	Brazil	NO			Oligoastrocytoma		A33T-08	False
S13722.58cfa82ee4b0c9d6adf6abd0	58cfa82ee4b0c9d6adf6abd0	G35154.TCGA-TQ-A7RV-01A-21D-A34A-08.3.filtered.	WGS	G35154.TCGA-TQ-A7RV-01A-21D-A34A-08.3	G35154.TCGA-TQ-A7RV-01A-21D-A34A-08.3.bam	8.31		0.08	58cfa82ee4b0c9d6adf6abd0	G35154.TCGA-TQ-A7RV-01A-21D-A34A-08.3.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-TQ-A7RV-01A	5A3EDEB6-133E-4116-9F80-2485BD70754D	Primary Tumor	Illumina HiSeq	90057127-5744-4f65-853a-66561166dcbc	Brain	27.0	06D89076-34D4-496D-A412-F8C3B46A3A4B	33B54500-B50B-4368-8406-71015C43B929	TCGA-TQ-A7RV-01A-21D-A34A-08	HG19_Broad_variant	TCGA-TQ-A7RV	TCGA-LGG		s8124	Broad Institute of MIT and Harvard	University of Sao Paulo	Brazil	NO			Astrocytoma		A34A-08	False
S13722.58cfa82ee4b0c9d6adf6abf6	58cfa82ee4b0c9d6adf6abf6	G35154.TCGA-FG-8182-01A-11D-2253-08.3.filtered.	WGS	G35154.TCGA-FG-8182-01A-11D-2253-08.3	G35154.TCGA-FG-8182-01A-11D-2253-08.3.bam	58.6		0.05	58cfa82ee4b0c9d6adf6abf6	G35154.TCGA-FG-8182-01A-11D-2253-08.3.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-8182-01A	6A0BCF0C-FA4C-4119-99D2-F722B781D20F	Primary Tumor	Illumina HiSeq	de01f2de-931f-4b79-9abc-966eaee7ca0a	Brain	35.0	0CF6BE14-2F25-4361-ADE5-7E5B6CA1063E	2AEAAB9F-4459-4BE8-91E7-E0746CBD671C	TCGA-FG-8182-01A-11D-2253-08	HG19_Broad_variant	TCGA-FG-8182	TCGA-LGG		s8112	Broad Institute of MIT and Harvard	Case Western	United States	NO			Oligodendroglioma		2253-08	False
S13722.58cfa82ee4b0c9d6adf6abd2	58cfa82ee4b0c9d6adf6abd2	G37566.TCGA-CH-5763-01A-11D-1576-08.1.filtered.	WGS	G37566.TCGA-CH-5763-01A-11D-1576-08.1	G37566.TCGA-CH-5763-01A-11D-1576-08.1.bam	172.7	1.9	0.05	58cfa82ee4b0c9d6adf6abd2	G37566.TCGA-CH-5763-01A-11D-1576-08.1.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5763-01A	18E79A01-07A2-4CD5-B700-71D41724E041	Primary Tumor	Illumina HiSeq	ba68ecb8-6421-467d-b680-850c82a0b95d	Prostate	66.0	F4192448-E5B3-4A9F-8354-9FE28503017A	581BE6CF-9778-49C3-9C77-1316EAA78929	TCGA-CH-5763-01A-11D-1576-08	HG19_Broad_variant	TCGA-CH-5763	TCGA-PRAD		s3405	Broad Institute of MIT and Harvard	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1576-08	True
S13722.58cfa82ee4b0c9d6adf6ac26	58cfa82ee4b0c9d6adf6ac26	G37566.TCGA-G9-6365-01A-11D-1786-08.1.filtered.	WGS	G37566.TCGA-G9-6365-01A-11D-1786-08.1	G37566.TCGA-G9-6365-01A-11D-1786-08.1.bam	59.4	1.9	0.05	58cfa82ee4b0c9d6adf6ac26	G37566.TCGA-G9-6365-01A-11D-1786-08.1.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6365-01A	6845076E-E940-4437-8618-81DB4A447544	Primary Tumor	Illumina HiSeq	9cc69179-2c77-45b6-b3b1-0b1042756f81	Prostate	71.0	95D6E1D3-91C1-40E5-986D-1C5ABB33A03F	769E2AC9-A121-4B2A-A0FD-5F755B579811	TCGA-G9-6365-01A-11D-1786-08	HG19_Broad_variant	TCGA-G9-6365	TCGA-PRAD		s3412	Broad Institute of MIT and Harvard	Roswell Park	United States	NO	T4	N0	Prostate Adenocarcinoma Acinar Type		1786-08	False
S13722.58cfa82ee4b0c9d6adf6acae	58cfa82ee4b0c9d6adf6acae	G37568.TCGA-DK-A1AA-01A-11D-A13W-08.3.filtered.	WGS	G37568.TCGA-DK-A1AA-01A-11D-A13W-08.3	G37568.TCGA-DK-A1AA-01A-11D-A13W-08.3.bam	72.54	1.95	0.08	58cfa82ee4b0c9d6adf6acae	G37568.TCGA-DK-A1AA-01A-11D-A13W-08.3.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AA-01A	56D8A1B8-1268-4362-A7F1-77B76FBF1B59	Primary Tumor	Illumina HiSeq	0ff07006-7458-42f5-b1fd-d84db4c2f25d	Bladder	57.0	577700D1-C366-41EF-8A0D-E50DEEFB5E3C	804FFA2E-158B-447D-945C-707684134C87	TCGA-DK-A1AA-01A-11D-A13W-08	HG19_Broad_variant	TCGA-DK-A1AA	TCGA-BLCA		s3079	Broad Institute of MIT and Harvard	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13W-08	True
S13722.58cfa82ee4b0c9d6adf6acbe	58cfa82ee4b0c9d6adf6acbe	G37566.TCGA-HI-7169-01A-11D-2114-08.2.filtered.	WGS	G37566.TCGA-HI-7169-01A-11D-2114-08.2	G37566.TCGA-HI-7169-01A-11D-2114-08.2.bam	54.6		0.05	58cfa82ee4b0c9d6adf6acbe	G37566.TCGA-HI-7169-01A-11D-2114-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HI-7169-01A	11FB5853-8EEB-4AD8-825D-3EAAF3FA08D6	Primary Tumor	Illumina HiSeq	4ec05d23-3f9f-473a-b292-63ddb0e7d37f	Prostate	55.0	AEEF0836-305C-465C-A9CA-6C1825353AE7	E1FC4226-40CE-43B7-B92E-AA7CECD0CF4D	TCGA-HI-7169-01A-11D-2114-08	HG19_Broad_variant	TCGA-HI-7169	TCGA-PRAD		s3586	Broad Institute of MIT and Harvard	Fox Chase	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		2114-08	False
S13722.58cfa82ee4b0c9d6adf6ad30	58cfa82ee4b0c9d6adf6ad30	G49837.TCGA-43-5670-01A-21D-A320-08.1.filtered.	WGS	G49837.TCGA-43-5670-01A-21D-A320-08.1	G49837.TCGA-43-5670-01A-21D-A320-08.1.bam	559.0		0.07	58cfa82ee4b0c9d6adf6ad30	G49837.TCGA-43-5670-01A-21D-A320-08.1.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-43-5670-01A	7D905F8F-3967-4EA8-96C8-17B1B03FBEC3	Primary Tumor	Illumina HiSeq	118f7a8c-af7e-4f0d-a235-99c5487eee74	Lung	70.0	6B829F48-BA74-40D7-B92F-41A2A2B7D136	369C06F2-8904-49CB-99D1-DD297ED0CD0C	TCGA-43-5670-01A-21D-A320-08	HG19_Broad_variant	TCGA-43-5670	TCGA-LUSC		s10369	Broad Institute of MIT and Harvard	Christiana Healthcare	United States	NO	T2b	N0	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IIA	A320-08	True
S13722.58cfa82ee4b0c9d6adf6adb4	58cfa82ee4b0c9d6adf6adb4	G47088.TCGA-92-8064-01A-11D-2244-08.2.filtered.	WGS	G47088.TCGA-92-8064-01A-11D-2244-08.2	G47088.TCGA-92-8064-01A-11D-2244-08.2.bam	406.33		0.05	58cfa82ee4b0c9d6adf6adb4	G47088.TCGA-92-8064-01A-11D-2244-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-92-8064-01A	DC6CEECE-EFAA-4B9D-9E12-D35863D7A902	Primary Tumor	Illumina HiSeq	8a33c586-703c-4354-9bde-caab929fcc59	Lung	58.0	014AD75E-86D2-423F-B9D3-84657D459A28	0E6654C9-CD5E-4F94-A6D4-54F2BB16DE1F	TCGA-92-8064-01A-11D-2244-08	HG19_Broad_variant	TCGA-92-8064	TCGA-LUSC		s10077	Broad Institute of MIT and Harvard	Washington University - St. Louis	United States	NO	T2b	N0	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IB	2244-08	False
S13722.58cfa82ee4b0c9d6adf6adca	58cfa82ee4b0c9d6adf6adca	G39020.TCGA-BR-A4J4-01A-12D-A25D-08.3.filtered.	WGS	G39020.TCGA-BR-A4J4-01A-12D-A25D-08.3	G39020.TCGA-BR-A4J4-01A-12D-A25D-08.3.bam	25.07		0.08	58cfa82ee4b0c9d6adf6adca	G39020.TCGA-BR-A4J4-01A-12D-A25D-08.3.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-A4J4-01A	8A24F1A3-4BAB-4591-9676-7BEE01D096C1	Primary Tumor	Illumina HiSeq	2cdabae0-c924-481e-ad7e-bbe3f72f5c79	Stomach	39.0	5A5C4538-D75D-4DA5-8E8C-DD92766FEE50	2C316B7E-6A82-4BA1-9F34-D8BFCF82D41E	TCGA-BR-A4J4-01A-12D-A25D-08	HG19_Broad_variant	TCGA-BR-A4J4	TCGA-STAD		s14459	Broad Institute of MIT and Harvard	Asterand	Vietnam	NO	T4a	N2	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIB	A25D-08	False
S13722.58cfa82ee4b0c9d6adf6ae36	58cfa82ee4b0c9d6adf6ae36	G49837.TCGA-90-7767-01A-11D-A320-08.3.filtered.	WGS	G49837.TCGA-90-7767-01A-11D-A320-08.3	G49837.TCGA-90-7767-01A-11D-A320-08.3.bam	263.0		0.08	58cfa82ee4b0c9d6adf6ae36	G49837.TCGA-90-7767-01A-11D-A320-08.3.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-90-7767-01A	9DFF11CD-0784-4A60-9C77-43F8957D3DFA	Primary Tumor	Illumina HiSeq	667b4d6b-e888-4912-a5fd-74910e9b2f8e	Lung	56.0	609D3070-4B64-42EE-B071-42BE33DF7600	48F68F73-3AC0-44AC-BA12-B8889FCB7F38	TCGA-90-7767-01A-11D-A320-08	HG19_Broad_variant	TCGA-90-7767	TCGA-LUSC		s9981	Broad Institute of MIT and Harvard	ABS - IUPUI	United States	NO	T2b	N1	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IIB	A320-08	True
S13722.58cfa82ee4b0c9d6adf6ae5d	58cfa82ee4b0c9d6adf6ae5d	G49837.TCGA-37-4135-01A-01D-A320-08.2.filtered.	WGS	G49837.TCGA-37-4135-01A-01D-A320-08.2	G49837.TCGA-37-4135-01A-01D-A320-08.2.bam	968.93	1.9	0.07	58cfa82ee4b0c9d6adf6ae5d	G49837.TCGA-37-4135-01A-01D-A320-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-37-4135-01A	1F6B2ACA-7357-40D1-BA7A-99227D9900A2	Primary Tumor	Illumina HiSeq	00a52da3-1aca-4f65-b9ab-15fe28578557	Lung	68.0	5294476F-A200-453E-9D11-9C50F3C3FA5D	C48D7F4A-E98A-4077-A749-EB9F56F05B84	TCGA-37-4135-01A-01D-A320-08	HG19_Broad_variant	TCGA-37-4135	TCGA-LUSC		s10504	Broad Institute of MIT and Harvard	Cureline	Russia	NO	T2a	N0	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IB	A320-08	True
S13722.58cfa82ee4b0c9d6adf6aecd	58cfa82ee4b0c9d6adf6aecd	G37566.TCGA-HC-7744-01A-11D-2114-08.1.filtered.	WGS	G37566.TCGA-HC-7744-01A-11D-2114-08.1	G37566.TCGA-HC-7744-01A-11D-2114-08.1.bam	170.3		0.05	58cfa82ee4b0c9d6adf6aecd	G37566.TCGA-HC-7744-01A-11D-2114-08.1.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7744-01A	F6381367-142C-45D0-92B3-C1727D1813CE	Primary Tumor	Illumina HiSeq	8589d977-d1ca-42ea-975f-c3e664d57eba	Prostate	46.0	41E0D8F7-E104-43C4-B3BB-FD0B5CB3C7B2	0192D529-7340-45D8-A5F0-249CBB11CA19	TCGA-HC-7744-01A-11D-2114-08	HG19_Broad_variant	TCGA-HC-7744	TCGA-PRAD		s3925	Broad Institute of MIT and Harvard	International Genomics Consortium		NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		2114-08	False
S13722.58cfa82ee4b0c9d6adf6af08	58cfa82ee4b0c9d6adf6af08	G39020.TCGA-D7-A4YX-01A-11D-A25D-08.2.filtered.	WGS	G39020.TCGA-D7-A4YX-01A-11D-A25D-08.2	G39020.TCGA-D7-A4YX-01A-11D-A25D-08.2.bam	42.47		0.08	58cfa82ee4b0c9d6adf6af08	G39020.TCGA-D7-A4YX-01A-11D-A25D-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-A4YX-01A	2B4F014F-74E9-4DDA-A1AD-ABCBD124FC44	Primary Tumor	Illumina HiSeq	004a24e0-0e6d-4811-aac1-344ce1d54320	Stomach	63.0	DCFF683D-629E-4E67-9E9F-CE5752A2B276	A4C838DF-6AC4-455A-8096-8EC680064374	TCGA-D7-A4YX-01A-11D-A25D-08	HG19_Broad_variant	TCGA-D7-A4YX	TCGA-STAD		s14462	Broad Institute of MIT and Harvard	Greater Poland Cancer Center	Poland	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	A25D-08	False
S13722.58cfa82ee4b0c9d6adf6af34	58cfa82ee4b0c9d6adf6af34	G37566.TCGA-G9-6370-01A-11D-1786-08.2.filtered.	WGS	G37566.TCGA-G9-6370-01A-11D-1786-08.2	G37566.TCGA-G9-6370-01A-11D-1786-08.2.bam	59.4	2.0	0.05	58cfa82ee4b0c9d6adf6af34	G37566.TCGA-G9-6370-01A-11D-1786-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6370-01A	F947B0BC-BDAC-44E8-B5B9-FFAE4147740A	Primary Tumor	Illumina HiSeq	48541dbc-810e-4dad-a90a-5d33e6df1766	Prostate	52.0	644E1E7D-DFD1-4F83-82DC-AE0C7E010F6F	9689CB33-8AC9-4EE5-800D-3900769988AF	TCGA-G9-6370-01A-11D-1786-08	HG19_Broad_variant	TCGA-G9-6370	TCGA-PRAD		s3582	Broad Institute of MIT and Harvard	Roswell Park	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		1786-08	False
S13722.58cfa82ee4b0c9d6adf6af82	58cfa82ee4b0c9d6adf6af82	G39020.TCGA-D7-6822-01A-11D-1882-08.3.filtered.	WGS	G39020.TCGA-D7-6822-01A-11D-1882-08.3	G39020.TCGA-D7-6822-01A-11D-1882-08.3.bam	442.7	1.9	0.05	58cfa82ee4b0c9d6adf6af82	G39020.TCGA-D7-6822-01A-11D-1882-08.3.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6822-01A	E2AAABD9-F4BA-4763-A28A-C14D46A4BC5D	Primary Tumor	Illumina HiSeq	6bbb2709-a3ca-451a-82c8-996e619878b9	Stomach	77.0	C30AFDA8-FC63-4228-A9A9-42BCDB562ACE	1021B60D-F7B2-43B0-B2CC-F282D619D533	TCGA-D7-6822-01A-11D-1882-08	HG19_Broad_variant	TCGA-D7-6822	TCGA-STAD		s15097	Broad Institute of MIT and Harvard	Greater Poland Cancer Center	Poland	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IB	1882-08	False
S13722.58cfa82ee4b0c9d6adf6af86	58cfa82ee4b0c9d6adf6af86	G41960.TCGA-55-8299-01A-11D-2284-08.1.filtered.	WGS	G41960.TCGA-55-8299-01A-11D-2284-08.1	G41960.TCGA-55-8299-01A-11D-2284-08.1.bam	255.7		0.05	58cfa82ee4b0c9d6adf6af86	G41960.TCGA-55-8299-01A-11D-2284-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-55-8299-01A	2CD8EA73-CB3F-4B17-9B97-FA12EB03B85B	Primary Tumor	Illumina HiSeq	0900edf4-dd21-4cc0-a6cb-6de863318729	Lung	61.0	5D0ED8D1-6E84-4F6C-8E0E-0317AA8B0E3F	15E097E3-E468-466C-8E57-B59FBA90BBF2	TCGA-55-8299-01A-11D-2284-08	HG19_Broad_variant	TCGA-55-8299	TCGA-LUAD		s10765	Broad Institute of MIT and Harvard	International Genomics Consortium	United States	NO	T1b	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	2284-08	False
S13722.58cfa82ee4b0c9d6adf6b070	58cfa82ee4b0c9d6adf6b070	G8890.TCGA-60-2722-01A-01D-1180-08.2.filtered.	WGS	G8890.TCGA-60-2722-01A-01D-1180-08.2	G8890.TCGA-60-2722-01A-01D-1180-08.2.bam	179.0	1.9	0.15	58cfa82ee4b0c9d6adf6b070	G8890.TCGA-60-2722-01A-01D-1180-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-60-2722-01A	6FD72426-F6C8-47CA-A500-D5D3600B9B15	Primary Tumor	Illumina HiSeq	417178a5-e706-47ee-92d7-de1eb647b4fc	Lung	66.0	060717AD-F034-46FA-8E9B-94A9422E4666	96DC785C-8417-4813-8D15-C32B22D78B74	TCGA-60-2722-01A-01D-1180-08	HG19_Broad_variant	TCGA-60-2722	TCGA-LUSC		s9982	Broad Institute of MIT and Harvard	Roswell Park	United States	NO	T2	N1	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IIB	1180-08	False
S13722.58cfa82fe4b0c9d6adf6b86a	58cfa82fe4b0c9d6adf6b86a	TCGA-A6-2680-01A-01D-1554-10_wgs_Illumina.filtered.	WGS	TCGA-A6-2680-01A-01D-1554-10_wgs_Illumina	TCGA-A6-2680-01A-01D-1554-10_wgs_Illumina.bam	38.0	1.9	0.05	58cfa82fe4b0c9d6adf6b86a	TCGA-A6-2680-01A-01D-1554-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2680-01A	FF1407C6-9174-4BAE-A19B-D34CA71B898C	Primary Tumor	Illumina HiSeq	d43e0ed3-ab1d-486a-bbf5-91dabacf8220	Colorectal	72.0	D664F620-CFEE-4700-B00E-68B65387883C	2CDC4CCE-0877-4EC1-85F5-20C909912E65	TCGA-A6-2680-01A-01D-1554-10	GRCh37-lite	TCGA-A6-2680	TCGA-COAD		s13172	Baylor College of Medicine	Christiana Healthcare		NO	T3	N0	Colon Adenocarcinoma	Stage II	1554-10	False
S13722.58cfa830e4b0c9d6adf6ba60	58cfa830e4b0c9d6adf6ba60	TCGA-A3-3372-01A-01D-2094-10_Illumina.filtered.	WGS	TCGA-A3-3372-01A-01D-2094-10_Illumina	TCGA-A3-3372-01A-01D-2094-10_Illumina.bam	595.87	1.9	0.15	58cfa830e4b0c9d6adf6ba60	TCGA-A3-3372-01A-01D-2094-10_Illumina.bam	Alive	MALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-A3-3372-01A	11AB53C8-6366-4BC9-B60D-23E6ED2D1CAE	Primary Tumor	Illumina HiSeq	0dc73f18-4553-49e0-b22e-8bc863c7b907	Kidney	64.0	D3280297-5674-4AE6-AB57-8D820543901E	F64E9609-D75D-400C-A92D-D77FD54D6C29	TCGA-A3-3372-01A-01D-2094-10	GRCh37-lite	TCGA-A3-3372	TCGA-KIRC		s9155	Baylor College of Medicine	International Genomics Consortium	United States	NO	T3	NX	Kidney Clear Cell Renal Carcinoma	Stage III	2094-10	False
S13722.58cfa830e4b0c9d6adf6c052	58cfa830e4b0c9d6adf6c052	TCGA-B2-4101-01A-02D-2096-10_Illumina.filtered.	WGS	TCGA-B2-4101-01A-02D-2096-10_Illumina	TCGA-B2-4101-01A-02D-2096-10_Illumina.bam	138.47	1.9	0.15	58cfa830e4b0c9d6adf6c052	TCGA-B2-4101-01A-02D-2096-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-B2-4101-01A	CFC999AA-802E-4A0D-8B14-BE2B19FA2A17	Primary Tumor	Illumina HiSeq	06203d35-b4db-4e6b-9c54-14edb4129481	Kidney	52.0	A9947B6C-DBC7-4BA5-AF61-7647E11E2973	F3C1A125-06E9-41C4-9558-275A3E346CC5	TCGA-B2-4101-01A-02D-2096-10	GRCh37-lite	TCGA-B2-4101	TCGA-KIRC		s9564	Baylor College of Medicine	Christiana Healthcare		NO	T2a	NX	Kidney Clear Cell Renal Carcinoma	Stage II	2096-10	False
S13722.58cfa830e4b0c9d6adf6c07e	58cfa830e4b0c9d6adf6c07e	TCGA-B1-A47M-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-B1-A47M-01A-11D-A25F-10_wgs_Illumina	TCGA-B1-A47M-01A-11D-A25F-10_wgs_Illumina.bam	27.53		0.08	58cfa830e4b0c9d6adf6c07e	TCGA-B1-A47M-01A-11D-A25F-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B1-A47M-01A	072507CF-1249-4B28-86D4-3AB97822A74C	Primary Tumor	Illumina HiSeq	aa347261-ddce-4395-b3f2-84e8210d4d8a	Kidney	79.0	75658EDD-12F1-4BB3-BEA2-01C154CB6AE9	8FB7FCAC-6C1D-40C2-9309-B53821CBEF30	TCGA-B1-A47M-01A-11D-A25F-10	GRCh37-lite	TCGA-B1-A47M	TCGA-KIRP		s11581	Baylor College of Medicine	University of Pittsburgh	United States	NO	T3a	NX	Kidney Papillary Renal Cell Carcinoma	Stage III	A25F-10	True
S13722.58cfa831e4b0c9d6adf6c6ee	58cfa831e4b0c9d6adf6c6ee	TCGA-CR-6467-01A-11D-2266-10_Illumina.filtered.	WGS	TCGA-CR-6467-01A-11D-2266-10_Illumina	TCGA-CR-6467-01A-11D-2266-10_Illumina.bam	319.7	1.9	0.05	58cfa831e4b0c9d6adf6c6ee	TCGA-CR-6467-01A-11D-2266-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-6467-01A	89F91E36-FED8-4DA3-8A35-C761D6F65285	Primary Tumor	Illumina HiSeq	27f00d9e-af52-4af4-b29b-a75a506754a8	Head and Neck	59.0	5EF4D047-5A84-4E03-ACF5-02029D8A4CF2	EE963667-56B1-49BD-8896-E07B536D3014	TCGA-CR-6467-01A-11D-2266-10	GRCh37-lite	TCGA-CR-6467	TCGA-HNSC		s15769	Baylor College of Medicine	Vanderbilt University	United States	NO	T2	N1	Head and Neck Squamous Cell Carcinoma	Stage III	2266-10	True
S13722.58cfa831e4b0c9d6adf6c845	58cfa831e4b0c9d6adf6c845	TCGA-CV-5442-01A-01D-2266-10_Illumina.filtered.	WGS	TCGA-CV-5442-01A-01D-2266-10_Illumina	TCGA-CV-5442-01A-01D-2266-10_Illumina.bam	323.7	1.9	0.05	58cfa831e4b0c9d6adf6c845	TCGA-CV-5442-01A-01D-2266-10_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5442-01A	3C975B68-4A6E-4C97-A8D1-B9A427D4957C	Primary Tumor	Illumina HiSeq	53f0ce53-95fe-4d6c-930d-f8427c0c46ec	Head and Neck	76.0	698208BB-7272-4AD5-9CC0-909CB669BDAF	46D35B82-E1B7-4D35-BE5E-3A70FD47E421	TCGA-CV-5442-01A-01D-2266-10	GRCh37-lite	TCGA-CV-5442	TCGA-HNSC		s16336	Baylor College of Medicine	MD Anderson Cancer Center		NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	2266-10	True
S13722.58cfa832e4b0c9d6adf6d2dc	58cfa832e4b0c9d6adf6d2dc	TCGA-KL-8342-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8342-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8342-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d2dc	TCGA-KL-8342-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8342-01A	C689AE1D-4A6B-45DB-B4D1-6B34C5C61522	Primary Tumor	Illumina HiSeq	1f1d17e4-280b-4955-97a5-75180878dc8e	Kidney	45.0	BC04E860-2CB8-4D90-BC17-F3A4D6A09881	F38FC6AC-2AF8-4D89-A514-4E2C5FDF08DE	TCGA-KL-8342-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8342	TCGA-KICH		s16483	Baylor College of Medicine	MSKCC	United States	NO	T2b	N0	Kidney Chromophobe	Stage II	2310-10	True
S13722.58cfa832e4b0c9d6adf6d326	58cfa832e4b0c9d6adf6d326	TCGA-KO-8407-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KO-8407-01A-11D-2310-10_wgs_Illumina	TCGA-KO-8407-01A-11D-2310-10_wgs_Illumina.bam	150.2		0.05	58cfa832e4b0c9d6adf6d326	TCGA-KO-8407-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KO-8407-01A	151F07F5-1529-4FCD-912C-E55B2FF8ABEF	Primary Tumor	Illumina HiSeq	33c518fb-d4b6-4ec8-8125-6fd6c0032563	Kidney	42.0	24992BE3-78D6-4193-ACF3-F0A5AC959BB6	64F696A6-58B2-40A8-B848-FD775CD52529	TCGA-KO-8407-01A-11D-2310-10	GRCh37-lite	TCGA-KO-8407	TCGA-KICH		s16438	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True
S13722.58cfa82de4b0c9d6adf6a73c	58cfa82de4b0c9d6adf6a73c	G13228.TCGA-43-3920-01A-01D-1553-08.4.filtered.	WGS	G13228.TCGA-43-3920-01A-01D-1553-08.4	G13228.TCGA-43-3920-01A-01D-1553-08.4.bam	835.37	1.9	0.05	58cfa82de4b0c9d6adf6a73c	G13228.TCGA-43-3920-01A-01D-1553-08.4.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-43-3920-01A	9293E197-E38A-4E19-A7D0-1B45D1AD48BD	Primary Tumor	Illumina HiSeq	3281e662-29ac-4441-86e2-07a71d47196c	Lung	71.0	BBC07C89-5540-4217-AA56-3608539983C2	A762DD44-A8AC-4269-8163-BBF6D0F8D4B3	TCGA-43-3920-01A-01D-1553-08	HG19_Broad_variant	TCGA-43-3920	TCGA-LUSC		s10157	Broad Institute of MIT and Harvard	Christiana Healthcare	United States	NO	T2	N0	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IB	1553-08	False
S13722.58cfa82de4b0c9d6adf6a738	58cfa82de4b0c9d6adf6a738	G14681.TCGA-60-2719-01A-01D-1522-08.1.filtered.	WGS	G14681.TCGA-60-2719-01A-01D-1522-08.1	G14681.TCGA-60-2719-01A-01D-1522-08.1.bam	604.3	1.9	0.05	58cfa82de4b0c9d6adf6a738	G14681.TCGA-60-2719-01A-01D-1522-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-60-2719-01A	585E6487-B0A3-4828-8A06-46BEE01DFF74	Primary Tumor	Illumina HiSeq	f600dac8-9a96-4214-a398-c9e40ed580ec	Lung	83.0	DD32EF9A-246B-47C9-A0E3-60A110E9047C	EE6CC68E-8D2A-41EE-82C6-0FECDF7E6259	TCGA-60-2719-01A-01D-1522-08	HG19_Broad_variant	TCGA-60-2719	TCGA-LUSC		s10495	Broad Institute of MIT and Harvard	Roswell Park	United States	NO	T1	N0	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IB	1522-08	True
S13722.58cfa82de4b0c9d6adf6a763	58cfa82de4b0c9d6adf6a763	G13231.TCGA-60-2724-01A-01D-1522-08.3.filtered.	WGS	G13231.TCGA-60-2724-01A-01D-1522-08.3	G13231.TCGA-60-2724-01A-01D-1522-08.3.bam	508.3	1.9	0.05	58cfa82de4b0c9d6adf6a763	G13231.TCGA-60-2724-01A-01D-1522-08.3.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-60-2724-01A	A3E1AC67-A1F2-44FB-8343-A7E8239FC24A	Primary Tumor	Illumina HiSeq	fe7af73f-7704-440b-85f1-35dc1b30dea2	Lung	47.0	048E7EB0-57A4-4EED-A999-4E46D9FEF885	387C6519-6529-4074-A5AB-00F8052A5732	TCGA-60-2724-01A-01D-1522-08	HG19_Broad_variant	TCGA-60-2724	TCGA-LUSC		s10155	Broad Institute of MIT and Harvard	Roswell Park	United States	NO	T3	N1	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1522-08	True
S13722.58cfa82ee4b0c9d6adf6a8f6	58cfa82ee4b0c9d6adf6a8f6	G35154.TCGA-FG-5965-01B-11D-1893-08.2.filtered.	WGS	G35154.TCGA-FG-5965-01B-11D-1893-08.2	G35154.TCGA-FG-5965-01B-11D-1893-08.2.bam	86.7	1.9	0.05	58cfa82ee4b0c9d6adf6a8f6	G35154.TCGA-FG-5965-01B-11D-1893-08.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-5965-01B	2CFC07F3-A31C-41A2-A9E3-B708D2421A78	Primary Tumor	Illumina HiSeq	8e6db5b3-96e4-4a80-9604-99a9433a1bb5	Brain	39.0	93FBE6D3-2091-4151-9075-0ED2DD4B886F	0730868D-1FE9-4964-A0CC-A12A74D161E6	TCGA-FG-5965-01B-11D-1893-08	HG19_Broad_variant	TCGA-FG-5965	TCGA-LGG		s8106	Broad Institute of MIT and Harvard	Case Western	United States	NO			Oligoastrocytoma		1893-08	False
S13722.58cfa82ee4b0c9d6adf6aa82	58cfa82ee4b0c9d6adf6aa82	G25781.TCGA-50-6597-01A-11D-1855-08.4.filtered.	WGS	G25781.TCGA-50-6597-01A-11D-1855-08.4	G25781.TCGA-50-6597-01A-11D-1855-08.4.bam	12.7	1.9	0.05	58cfa82ee4b0c9d6adf6aa82	G25781.TCGA-50-6597-01A-11D-1855-08.4.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-6597-01A	0D66BF6C-EED0-4726-BD5B-3BF6D610B4E0	Primary Tumor	Illumina HiSeq	0e48684b-e0b4-4625-9f32-7e0331dfcefe	Lung	79.0	C5363830-3DB9-4C0C-AA47-B32FDC888C60	CD0AEED5-93A1-4287-8A88-FE6B7B5E3983	TCGA-50-6597-01A-11D-1855-08	HG19_Broad_variant	TCGA-50-6597	TCGA-LUAD		s11110	Broad Institute of MIT and Harvard	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1855-08	False
S13722.58cfa82ee4b0c9d6adf6aa01	58cfa82ee4b0c9d6adf6aa01	G23078.TCGA_CR_6487_01A_11D_2268_08.2.filtered.	WGS	G23078.TCGA_CR_6487_01A_11D_2268_08.2	G23078.TCGA_CR_6487_01A_11D_2268_08.2.bam	287.7	1.9	0.14	58cfa82ee4b0c9d6adf6aa01	G23078.TCGA_CR_6487_01A_11D_2268_08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-6487-01A	9AE5101B-6031-4AB1-BFCA-198C41AF3184	Primary Tumor	Illumina HiSeq	5efcbe11-0d48-4b66-abce-d78199fe8fd8	Head and Neck	50.0	027DEDD3-BD53-420E-B7F2-EB5B8C26BCDC	1DB83E80-BDF7-4D8D-8008-BD8406D641FC	TCGA-CR-6487-01A-11D-2268-08	HG19_Broad_variant	TCGA-CR-6487	TCGA-HNSC		s15606	Broad Institute of MIT and Harvard	Vanderbilt University	United States	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	2268-08	True
S13722.58cfa82ee4b0c9d6adf6aa8a	58cfa82ee4b0c9d6adf6aa8a	G32523.TCGA-DJ-A2Q2-01A-11D-A19J-08.4.filtered.	WGS	G32523.TCGA-DJ-A2Q2-01A-11D-A19J-08.4	G32523.TCGA-DJ-A2Q2-01A-11D-A19J-08.4.bam	41.27		0.08	58cfa82ee4b0c9d6adf6aa8a	G32523.TCGA-DJ-A2Q2-01A-11D-A19J-08.4.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A2Q2-01A	A00DA907-E527-45F9-9AFB-2FAD2C7B0940	Primary Tumor	Illumina HiSeq	a59111e2-1f5e-429d-bb7f-4e413ed0baeb	Thyroid	57.0	A2E3CA88-9FF0-44AD-8C5A-CA4C7B404DE6	565E656C-D5E3-4FE4-A10C-2E9CA1E498B5	TCGA-DJ-A2Q2-01A-11D-A19J-08	HG19_Broad_variant	TCGA-DJ-A2Q2	TCGA-THCA		s11972	Broad Institute of MIT and Harvard	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage III	A19J-08	False
S13722.58cfa82ee4b0c9d6adf6ab92	58cfa82ee4b0c9d6adf6ab92	G25790.TCGA-50-5066-01A-01D-1625-08.2.filtered.	WGS	G25790.TCGA-50-5066-01A-01D-1625-08.2	G25790.TCGA-50-5066-01A-01D-1625-08.2.bam	1182.7	1.9	0.05	58cfa82ee4b0c9d6adf6ab92	G25790.TCGA-50-5066-01A-01D-1625-08.2.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5066-01A	3199CFE5-3BE3-43CD-A36B-5CF2C7A9929F	Primary Tumor	Illumina HiSeq	a9a4ae39-4e53-45e6-b9c0-2df2afca64ee	Lung	72.0	478CC306-6AEE-4597-8834-1E5CF8B05A59	F5A97315-1906-4774-980E-0879C6AD368E	TCGA-50-5066-01A-01D-1625-08	HG19_Broad_variant	TCGA-50-5066	TCGA-LUAD		s10894	Broad Institute of MIT and Harvard	University of Pittsburgh	United States	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1625-08	False
S13722.58cfa82ee4b0c9d6adf6ac51	58cfa82ee4b0c9d6adf6ac51	G39020.TCGA-BR-6456-01A-11D-1800-08.3.filtered.	WGS	G39020.TCGA-BR-6456-01A-11D-1800-08.3	G39020.TCGA-BR-6456-01A-11D-1800-08.3.bam	282.7	1.9	0.05	58cfa82ee4b0c9d6adf6ac51	G39020.TCGA-BR-6456-01A-11D-1800-08.3.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6456-01A	1CA3C5E0-32B0-4467-8EC0-CA212E35D2B3	Primary Tumor	Illumina HiSeq	9830e4a0-d8b1-4166-8375-49851288cf1f	Stomach	74.0	53369A25-3BC4-48CB-9004-DA3507C4D478	C612570A-881D-421F-98B9-0E4563133744	TCGA-BR-6456-01A-11D-1800-08	HG19_Broad_variant	TCGA-BR-6456	TCGA-STAD		s14876	Broad Institute of MIT and Harvard	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1800-08	True
S13722.58cfa82ee4b0c9d6adf6abc6	58cfa82ee4b0c9d6adf6abc6	G32540.TCGA-EL-A3CV-01A-11D-A19J-08.2.filtered.	WGS	G32540.TCGA-EL-A3CV-01A-11D-A19J-08.2	G32540.TCGA-EL-A3CV-01A-11D-A19J-08.2.bam	15.76		0.08	58cfa82ee4b0c9d6adf6abc6	G32540.TCGA-EL-A3CV-01A-11D-A19J-08.2.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-EL-A3CV-01A	FB83F7D7-2182-4FB7-8E3E-8AD7F1FEAC72	Primary Tumor	Illumina HiSeq	bd9e1da9-58f5-49d6-b838-2acffb8ee860	Thyroid	40.0	7BC433ED-7908-4297-AA5A-E033924BCED1	B1753E9C-29D0-4955-89D2-949CDABD1211	TCGA-EL-A3CV-01A-11D-A19J-08	HG19_Broad_variant	TCGA-EL-A3CV	TCGA-THCA		s12727	Broad Institute of MIT and Harvard	MD Anderson	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A19J-08	False
S13722.58cfa82ee4b0c9d6adf6ac8b	58cfa82ee4b0c9d6adf6ac8b	G47088.TCGA-98-8022-01A-11D-2244-08.2.filtered.	WGS	G47088.TCGA-98-8022-01A-11D-2244-08.2	G47088.TCGA-98-8022-01A-11D-2244-08.2.bam	276.03		0.05	58cfa82ee4b0c9d6adf6ac8b	G47088.TCGA-98-8022-01A-11D-2244-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-98-8022-01A	ADC853B1-B8BF-488C-A1E2-E95603459B55	Primary Tumor	Illumina HiSeq	490e3546-83cd-4a44-a792-f1c2e1530f4a	Lung	61.0	95933B01-06CA-4F3E-8995-EB2AB01A2C4C	6962BC97-FBB8-4220-A600-E3C251E245CB	TCGA-98-8022-01A-11D-2244-08	HG19_Broad_variant	TCGA-98-8022	TCGA-LUSC		s10499	Broad Institute of MIT and Harvard	Washington University - Alabama	United States	NO	T1a	N0	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IA	2244-08	False
S13722.58cfa82ee4b0c9d6adf6ac73	58cfa82ee4b0c9d6adf6ac73	G47088.TCGA-85-8277-01A-11D-2293-08.1.filtered.	WGS	G47088.TCGA-85-8277-01A-11D-2293-08.1	G47088.TCGA-85-8277-01A-11D-2293-08.1.bam	270.3		0.05	58cfa82ee4b0c9d6adf6ac73	G47088.TCGA-85-8277-01A-11D-2293-08.1.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-85-8277-01A	8E6020A1-68DF-4D57-AD4E-33ACC0861FB3	Primary Tumor	Illumina HiSeq	b6b09fc0-6713-4047-8081-3b8224052fec	Lung	70.0	5600CB1A-D0F4-468E-B8D2-E431B77496BF	649F2C20-5B50-40A8-A6FD-9A51F3D5B9DF	TCGA-85-8277-01A-11D-2293-08	HG19_Broad_variant	TCGA-85-8277	TCGA-LUSC		s10075	Broad Institute of MIT and Harvard	Asterand	Russia	NO	T3	N1	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IIIA	2293-08	False
S13722.58cfa82ee4b0c9d6adf6aca8	58cfa82ee4b0c9d6adf6aca8	G39020.TCGA-HU-A4H0-01A-11D-A25D-08.1.filtered.	WGS	G39020.TCGA-HU-A4H0-01A-11D-A25D-08.1	G39020.TCGA-HU-A4H0-01A-11D-A25D-08.1.bam	42.83		0.08	58cfa82ee4b0c9d6adf6aca8	G39020.TCGA-HU-A4H0-01A-11D-A25D-08.1.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-HU-A4H0-01A	FE45EAEE-FF0C-4D52-B18C-04DC2D64D3B4	Primary Tumor	Illumina HiSeq	787fd694-c915-406f-a8a1-0ca998d01d93	Stomach	72.0	568CBF5F-86DA-4420-9C70-324D11B8E481	7116CC90-F465-4E7E-AA27-48A83ED258E9	TCGA-HU-A4H0-01A-11D-A25D-08	HG19_Broad_variant	TCGA-HU-A4H0	TCGA-STAD		s14394	Broad Institute of MIT and Harvard	National Cancer Center Korea	Korea South	NO	T4a	N3b	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIC	A25D-08	False
S13722.58cfa82ee4b0c9d6adf6acaa	58cfa82ee4b0c9d6adf6acaa	G47088.TCGA-68-8250-01A-11D-2293-08.1.filtered.	WGS	G47088.TCGA-68-8250-01A-11D-2293-08.1	G47088.TCGA-68-8250-01A-11D-2293-08.1.bam	242.3		0.05	58cfa82ee4b0c9d6adf6acaa	G47088.TCGA-68-8250-01A-11D-2293-08.1.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-68-8250-01A	7B982D5E-3A7D-40AC-BD25-6044C62879B6	Primary Tumor	Illumina HiSeq	c923eeaa-1b36-49b3-97b7-f64875389d5f	Lung	66.0	A6A1A05E-9126-45CD-B7BE-C1C342FAF5AF	71A2B4A2-88DD-4911-A67E-70B3309C4A12	TCGA-68-8250-01A-11D-2293-08	HG19_Broad_variant	TCGA-68-8250	TCGA-LUSC		s10252	Broad Institute of MIT and Harvard	Washington University - Cleveland Clinic	United States	NO	T1a	N0	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IA	2293-08	False
S13722.58cfa82ee4b0c9d6adf6acc8	58cfa82ee4b0c9d6adf6acc8	G39020.TCGA-D7-8570-01A-11D-2340-08.2.filtered.	WGS	G39020.TCGA-D7-8570-01A-11D-2340-08.2	G39020.TCGA-D7-8570-01A-11D-2340-08.2.bam	318.7		0.05	58cfa82ee4b0c9d6adf6acc8	G39020.TCGA-D7-8570-01A-11D-2340-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-8570-01A	1E1CDF72-820F-48A4-8FB6-89575D07CDE9	Primary Tumor	Illumina HiSeq	4b984072-ec9c-4924-a922-f7c4f5c2eacc	Stomach	44.0	E23E2A9C-5080-4276-8982-9CF078027A48	429AAD6F-816D-4739-BAA3-B0EBF2FCD501	TCGA-D7-8570-01A-11D-2340-08	HG19_Broad_variant	TCGA-D7-8570	TCGA-STAD		s14877	Broad Institute of MIT and Harvard	Greater Poland Cancer Center	Poland	NO	T3	N3a	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIB	2340-08	False
S13722.58cfa82ee4b0c9d6adf6aaec	58cfa82ee4b0c9d6adf6aaec	G32536.TCGA-EL-A3T0-01A-22D-A22D-08.4.filtered.	WGS	G32536.TCGA-EL-A3T0-01A-22D-A22D-08.4	G32536.TCGA-EL-A3T0-01A-22D-A22D-08.4.bam	25.01		0.08	58cfa82ee4b0c9d6adf6aaec	G32536.TCGA-EL-A3T0-01A-22D-A22D-08.4.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-EL-A3T0-01A	861F94CE-45FF-4588-ADDB-E1EA48878C2E	Primary Tumor	Illumina HiSeq	5c6477ae-68e1-4407-8f81-53f64006df76	Thyroid	45.0	913D384C-657A-4AE0-9E8E-E9BDB77D140E	54426B1A-E0D3-4D8E-9E81-2D8E6B153B22	TCGA-EL-A3T0-01A-22D-A22D-08	HG19_Broad_variant	TCGA-EL-A3T0	TCGA-THCA		s11975	Broad Institute of MIT and Harvard	MD Anderson	United States	NO	T3	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A22D-08	True
S13722.58cfa82ee4b0c9d6adf6ad22	58cfa82ee4b0c9d6adf6ad22	G49537.TCGA-BJ-A28T-01A-11D-A33C-08.2.filtered.	WGS	G49537.TCGA-BJ-A28T-01A-11D-A33C-08.2	G49537.TCGA-BJ-A28T-01A-11D-A33C-08.2.bam	61.44	2.0	0.08	58cfa82ee4b0c9d6adf6ad22	G49537.TCGA-BJ-A28T-01A-11D-A33C-08.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A28T-01A	A9D8F797-8A53-4BE5-B957-0F1F6D080390	Primary Tumor	Illumina HiSeq	e27094ec-2670-4ef1-a358-d36554e52da1	Thyroid	34.0	4CA4149A-E952-4A25-9163-8D4C15B09A62	1D97BA51-D981-4986-9F71-C2B6CB9961C3	TCGA-BJ-A28T-01A-11D-A33C-08	HG19_Broad_variant	TCGA-BJ-A28T	TCGA-THCA		s12218	Broad Institute of MIT and Harvard	University of Pittsburgh	United States	NO	T1	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A33C-08	False
S13722.58cfa82ee4b0c9d6adf6ad24	58cfa82ee4b0c9d6adf6ad24	G49837.TCGA-18-3408-01A-01D-A320-08.4.filtered.	WGS	G49837.TCGA-18-3408-01A-01D-A320-08.4	G49837.TCGA-18-3408-01A-01D-A320-08.4.bam	385.94	1.9	0.08	58cfa82ee4b0c9d6adf6ad24	G49837.TCGA-18-3408-01A-01D-A320-08.4.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-18-3408-01A	D4BC755A-2585-4529-AE36-7E1D88BDECFE	Primary Tumor	Illumina HiSeq	cea31b4d-7d33-4497-ae63-50688d12b045	Lung	77.0	EEFFADF9-2CCB-4937-AE1E-1D50ABA41C4D	24BADF07-8615-48A3-8D6E-45C3D783F18D	TCGA-18-3408-01A-01D-A320-08	HG19_Broad_variant	TCGA-18-3408	TCGA-LUSC		s10257	Broad Institute of MIT and Harvard	Princess Margaret Hospital (Canada)	Canada	NO	T2	N0	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IB	A320-08	True
S13722.58cfa82ee4b0c9d6adf6ad2e	58cfa82ee4b0c9d6adf6ad2e	G49837.TCGA-56-7582-01A-11D-A320-08.4.filtered.	WGS	G49837.TCGA-56-7582-01A-11D-A320-08.4	G49837.TCGA-56-7582-01A-11D-A320-08.4.bam	60.0		0.08	58cfa82ee4b0c9d6adf6ad2e	G49837.TCGA-56-7582-01A-11D-A320-08.4.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-56-7582-01A	B5E2CBDA-BBFA-4EF8-A9C4-CB978BEF9B23	Primary Tumor	Illumina HiSeq	0a8f41dd-07fb-47be-b963-8d807c40760c	Lung	83.0	1220E8B3-E16E-454E-BC49-60F49F9FE090	89C48E53-C8A9-4518-B3B8-509CDCAFF52B	TCGA-56-7582-01A-11D-A320-08	HG19_Broad_variant	TCGA-56-7582	TCGA-LUSC		s10163	Broad Institute of MIT and Harvard	International Genomics Consortium	United States	NO	T2a	N0	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IB	A320-08	True
S13722.58cfa82ee4b0c9d6adf6ad38	58cfa82ee4b0c9d6adf6ad38	G49537.TCGA-BJ-A28V-01A-11D-A19J-08.1.filtered.	WGS	G49537.TCGA-BJ-A28V-01A-11D-A19J-08.1	G49537.TCGA-BJ-A28V-01A-11D-A19J-08.1.bam	78.4	2.0	0.08	58cfa82ee4b0c9d6adf6ad38	G49537.TCGA-BJ-A28V-01A-11D-A19J-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A28V-01A	BED1FB3C-4459-460E-8190-29211857FA73	Primary Tumor	Illumina HiSeq	68b5668a-a719-42b2-99bb-d26c59c19b2f	Thyroid	80.0	4862B699-580D-4F2E-97A0-BD8918537067	19233FD1-5229-466E-ACF3-5882165758E0	TCGA-BJ-A28V-01A-11D-A19J-08	HG19_Broad_variant	TCGA-BJ-A28V	TCGA-THCA		s12617	Broad Institute of MIT and Harvard	University of Pittsburgh	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A19J-08	False
S13722.58cfa82ee4b0c9d6adf6ad63	58cfa82ee4b0c9d6adf6ad63	G49537.TCGA-BJ-A0Z2-01A-11D-A10S-08.2.filtered.	WGS	G49537.TCGA-BJ-A0Z2-01A-11D-A10S-08.2	G49537.TCGA-BJ-A0Z2-01A-11D-A10S-08.2.bam	89.84	1.92	0.07	58cfa82ee4b0c9d6adf6ad63	G49537.TCGA-BJ-A0Z2-01A-11D-A10S-08.2.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z2-01A	F9CEFFC0-D544-418D-B4A9-BD3C84E37026	Primary Tumor	Illumina HiSeq	b84e6415-1014-4d91-a469-879b108fa3bb	Thyroid	57.0	B06B7493-F38A-493F-8B47-61E0FA4D111F	2DD5EEA1-42A1-4E8B-99AC-20399CC7E15C	TCGA-BJ-A0Z2-01A-11D-A10S-08	HG19_Broad_variant	TCGA-BJ-A0Z2	TCGA-THCA		s12618	Broad Institute of MIT and Harvard	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage IVC	A10S-08	True
S13722.58cfa82ee4b0c9d6adf6ad47	58cfa82ee4b0c9d6adf6ad47	G49837.TCGA-68-7755-01A-11D-A320-08.2.filtered.	WGS	G49837.TCGA-68-7755-01A-11D-A320-08.2	G49837.TCGA-68-7755-01A-11D-A320-08.2.bam	35.0		0.08	58cfa82ee4b0c9d6adf6ad47	G49837.TCGA-68-7755-01A-11D-A320-08.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-68-7755-01A	3666BC65-8E40-409E-9A1F-41583DD6D978	Primary Tumor	Illumina HiSeq	2a201b20-3b01-4291-9e87-443bfb483c69	Lung	60.0	87D21E55-7F4A-4652-B7F7-1E64CB300FAE	84E601B7-DFA5-4CD5-9FEF-07F03967A0D4	TCGA-68-7755-01A-11D-A320-08	HG19_Broad_variant	TCGA-68-7755	TCGA-LUSC		s10372	Broad Institute of MIT and Harvard	Washington University - Cleveland Clinic	United States	NO	T1b	N1	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IIA	A320-08	True
S13722.58cfa82ee4b0c9d6adf6ad3a	58cfa82ee4b0c9d6adf6ad3a	G49537.TCGA-BJ-A0ZB-01A-11D-A10S-08.1.filtered.	WGS	G49537.TCGA-BJ-A0ZB-01A-11D-A10S-08.1	G49537.TCGA-BJ-A0ZB-01A-11D-A10S-08.1.bam	79.63	2.0	0.08	58cfa82ee4b0c9d6adf6ad3a	G49537.TCGA-BJ-A0ZB-01A-11D-A10S-08.1.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZB-01A	DC4D8468-6F34-40CB-A826-8D582CD86FDE	Primary Tumor	Illumina HiSeq	da7e540d-041b-4d8e-9158-52775a1aad5f	Thyroid	66.0	145A474E-D262-468A-8DB7-EE9F1B7CE0A7	ADD0B0F6-B4A8-4B73-B634-C3600DC567D5	TCGA-BJ-A0ZB-01A-11D-A10S-08	HG19_Broad_variant	TCGA-BJ-A0ZB	TCGA-THCA		s12221	Broad Institute of MIT and Harvard	University of Pittsburgh	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A10S-08	True
S13722.58cfa82ee4b0c9d6adf6ad8a	58cfa82ee4b0c9d6adf6ad8a	G39020.TCGA-BR-6564-01A-12D-1882-08.2.filtered.	WGS	G39020.TCGA-BR-6564-01A-12D-1882-08.2	G39020.TCGA-BR-6564-01A-12D-1882-08.2.bam	29.7	1.9	0.05	58cfa82ee4b0c9d6adf6ad8a	G39020.TCGA-BR-6564-01A-12D-1882-08.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6564-01A	AF1086CC-B330-4AD6-AE1C-3B5C7259949A	Primary Tumor	Illumina HiSeq	69520aa9-d9e7-49e5-a7a9-0b1e402a69c4	Stomach	46.0	B8355E52-D7A7-4711-BBA7-BC4D201741F2	2E66EB75-097C-4AD8-B2B3-9F5849DFD02F	TCGA-BR-6564-01A-12D-1882-08	HG19_Broad_variant	TCGA-BR-6564	TCGA-STAD		s15037	Broad Institute of MIT and Harvard	Asterand	Russia	NO	T3	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1882-08	False
S13722.58cfa82ee4b0c9d6adf6ad7a	58cfa82ee4b0c9d6adf6ad7a	G39020.TCGA-BR-8381-01A-11D-2394-08.2.filtered.	WGS	G39020.TCGA-BR-8381-01A-11D-2394-08.2	G39020.TCGA-BR-8381-01A-11D-2394-08.2.bam	329.0		0.05	58cfa82ee4b0c9d6adf6ad7a	G39020.TCGA-BR-8381-01A-11D-2394-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-8381-01A	AEF8D98F-7A1C-47F3-B5A7-A3CB299C70DE	Primary Tumor	Illumina HiSeq	8d5cdec5-779b-4ca8-a709-f2fbc527642b	Stomach	51.0	1DDC7F73-D793-4AE6-8A6A-851069892FAD	D6738C83-7B52-4224-846A-67BD085AAAB8	TCGA-BR-8381-01A-11D-2394-08	HG19_Broad_variant	TCGA-BR-8381	TCGA-STAD		s15170	Broad Institute of MIT and Harvard	Asterand	Ukraine	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	2394-08	True
S13722.58cfa82ee4b0c9d6adf6ad9a	58cfa82ee4b0c9d6adf6ad9a	G49837.TCGA-96-7545-01A-21D-A320-08.2.filtered.	WGS	G49837.TCGA-96-7545-01A-21D-A320-08.2	G49837.TCGA-96-7545-01A-21D-A320-08.2.bam	100.0		0.08	58cfa82ee4b0c9d6adf6ad9a	G49837.TCGA-96-7545-01A-21D-A320-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-96-7545-01A	4CA13C92-84B4-4EDF-842A-B20B7E713415	Primary Tumor	Illumina HiSeq	dadefdff-15a7-4c69-8436-344e649bc017	Lung	73.0	59F2654E-7F41-480B-B59C-F0DB373B7160	B7A7D93B-38A7-4FC3-A433-3BB0A8CB7C42	TCGA-96-7545-01A-21D-A320-08	HG19_Broad_variant	TCGA-96-7545	TCGA-LUSC		s10084	Broad Institute of MIT and Harvard	Washington University - NYU	United States	NO	T1	N0	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IA	A320-08	True
S13722.58cfa82ee4b0c9d6adf6ada0	58cfa82ee4b0c9d6adf6ada0	G39020.TCGA-CD-5799-01A-11D-1600-08.1.filtered.	WGS	G39020.TCGA-CD-5799-01A-11D-1600-08.1	G39020.TCGA-CD-5799-01A-11D-1600-08.1.bam	177.7	2.0	0.05	58cfa82ee4b0c9d6adf6ada0	G39020.TCGA-CD-5799-01A-11D-1600-08.1.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5799-01A	C991697F-77F9-412A-9BD1-0E47F7387CB2	Primary Tumor	Illumina HiSeq	4086df7e-765b-48a9-bece-369629691ae0	Stomach	45.0	A3180E0E-EB99-49DD-8252-5FEA05A9885F	EB59B79F-BD36-4BF4-83E3-2AF73BD1D30A	TCGA-CD-5799-01A-11D-1600-08	HG19_Broad_variant	TCGA-CD-5799	TCGA-STAD		s14602	Broad Institute of MIT and Harvard	ILSBIO	Vietnam	NO	T2	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1600-08	True
S13722.58cfa82ee4b0c9d6adf6ae76	58cfa82ee4b0c9d6adf6ae76	G49537.TCGA-FE-A22Z-01A-11D-A35R-08.1.filtered.	WGS	G49537.TCGA-FE-A22Z-01A-11D-A35R-08.1	G49537.TCGA-FE-A22Z-01A-11D-A35R-08.1.bam	78.59	2.03	0.08	58cfa82ee4b0c9d6adf6ae76	G49537.TCGA-FE-A22Z-01A-11D-A35R-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A22Z-01A	78D14F86-896A-4F98-9274-B2E8E387ADD9	Primary Tumor	Illumina HiSeq	d881881c-7108-46ea-92a8-1b1d9c915d5b	Thyroid	61.0	D206D300-E0CE-4A40-AF1F-45A685346A6E	8845FCE6-E2B4-4929-942B-57096B0BBAFC	TCGA-FE-A22Z-01A-11D-A35R-08	HG19_Broad_variant	TCGA-FE-A22Z	TCGA-THCA		s12737	Broad Institute of MIT and Harvard	Ohio State University	United States	NO	T4a	N1	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage IVA	A35R-08	False
S13722.58cfa82ee4b0c9d6adf6ae3b	58cfa82ee4b0c9d6adf6ae3b	G49837.TCGA-77-7139-01A-11D-A320-08.3.filtered.	WGS	G49837.TCGA-77-7139-01A-11D-A320-08.3	G49837.TCGA-77-7139-01A-11D-A320-08.3.bam	403.0		0.08	58cfa82ee4b0c9d6adf6ae3b	G49837.TCGA-77-7139-01A-11D-A320-08.3.bam	Alive	MALE	WHITE		Lung Squamous Cell Carcinoma	Aligned reads	TCGA-77-7139-01A	EE850103-6314-41A3-9734-8B520DE95B40	Primary Tumor	Illumina HiSeq	af2dee93-083d-492d-87c8-73cb962d49a2	Lung	56.0	48F646FE-03C6-4E7B-ACF1-9869E379443E	AD41F1F3-E38E-4418-9C16-52BCA5719F39	TCGA-77-7139-01A-11D-A320-08	HG19_Broad_variant	TCGA-77-7139	TCGA-LUSC		s10260	Broad Institute of MIT and Harvard	Prince Charles Hospital	Australia	NO	T2	N1	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IIB	A320-08	True
S13722.58cfa82ee4b0c9d6adf6ae8a	58cfa82ee4b0c9d6adf6ae8a	G49537.TCGA-L6-A4ET-01A-11D-A257-08.2.filtered.	WGS	G49537.TCGA-L6-A4ET-01A-11D-A257-08.2	G49537.TCGA-L6-A4ET-01A-11D-A257-08.2.bam	42.4		0.08	58cfa82ee4b0c9d6adf6ae8a	G49537.TCGA-L6-A4ET-01A-11D-A257-08.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-L6-A4ET-01A	E1FF7694-64E1-47ED-B0D8-34ACFB4FFEF1	Primary Tumor	Illumina HiSeq	1e492402-4405-430b-a336-e8043ef159c8	Thyroid	49.0	D6183BCA-9A4D-41AC-940D-0EAA23DECF56	546B97B0-AB82-42A1-BBD2-241523278EC3	TCGA-L6-A4ET-01A-11D-A257-08	HG19_Broad_variant	TCGA-L6-A4ET	TCGA-THCA		s12743	Broad Institute of MIT and Harvard	National Institutes of Health	United States	NO	T3	NX	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage IVC	A257-08	False
S13722.58cfa82ee4b0c9d6adf6ae8b	58cfa82ee4b0c9d6adf6ae8b	G49537.TCGA-EM-A22O-01A-11D-A17V-08.1.filtered.	WGS	G49537.TCGA-EM-A22O-01A-11D-A17V-08.1	G49537.TCGA-EM-A22O-01A-11D-A17V-08.1.bam	89.61	1.91	0.09	58cfa82ee4b0c9d6adf6ae8b	G49537.TCGA-EM-A22O-01A-11D-A17V-08.1.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-EM-A22O-01A	6ABC861A-376D-446B-ACEE-FB0F03A82C09	Primary Tumor	Illumina HiSeq	93872277-a7c8-4d30-999d-afa2db9d4986	Thyroid	75.0	AACF33BD-95CE-40FD-9828-1E78CBBB0E1B	13642CF8-9840-4A7D-A26A-95F65B2C70C3	TCGA-EM-A22O-01A-11D-A17V-08	HG19_Broad_variant	TCGA-EM-A22O	TCGA-THCA		s12087	Broad Institute of MIT and Harvard	University Health Network	Canada	NO	T4a	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A17V-08	True
S13722.58cfa82ee4b0c9d6adf6ae9a	58cfa82ee4b0c9d6adf6ae9a	G49537.TCGA-FK-A3SD-01A-11D-A22D-08.1.filtered.	WGS	G49537.TCGA-FK-A3SD-01A-11D-A22D-08.1	G49537.TCGA-FK-A3SD-01A-11D-A22D-08.1.bam	32.19		0.07	58cfa82ee4b0c9d6adf6ae9a	G49537.TCGA-FK-A3SD-01A-11D-A22D-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FK-A3SD-01A	63B01B43-A68A-4046-89B0-736BA4D08504	Primary Tumor	Illumina HiSeq	f713e001-9c18-4a72-a093-90bd147d414f	Thyroid	61.0	B48D226E-610A-40DC-B62A-6DB863A7366C	29578759-9CCB-4A24-B5B8-C45EBD4339D9	TCGA-FK-A3SD-01A-11D-A22D-08	HG19_Broad_variant	TCGA-FK-A3SD	TCGA-THCA		s12739	Broad Institute of MIT and Harvard	Johns Hopkins	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A22D-08	True
S13722.58cfa82ee4b0c9d6adf6aea8	58cfa82ee4b0c9d6adf6aea8	G39020.TCGA-BR-8373-01A-11D-2340-08.3.filtered.	WGS	G39020.TCGA-BR-8373-01A-11D-2340-08.3	G39020.TCGA-BR-8373-01A-11D-2340-08.3.bam	188.7		0.05	58cfa82ee4b0c9d6adf6aea8	G39020.TCGA-BR-8373-01A-11D-2340-08.3.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-8373-01A	60879669-96C2-4710-82E0-0AE9D0E5B242	Primary Tumor	Illumina HiSeq	cbbdb4e0-d400-45ef-bb4f-790b2cc9cb87	Stomach	65.0	4370B4F3-4FD7-4558-BF59-DAAE486BADC3	1F2A8889-4374-4037-BB56-0F20733380E3	TCGA-BR-8373-01A-11D-2340-08	HG19_Broad_variant	TCGA-BR-8373	TCGA-STAD		s15094	Broad Institute of MIT and Harvard	Asterand	Ukraine	NO	T4a	N1	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	2340-08	False
S13722.58cfa82ee4b0c9d6adf6aab8	58cfa82ee4b0c9d6adf6aab8	G23079.TCGA_CR_6482_01A_11D_2268_08.2.filtered.	WGS	G23079.TCGA_CR_6482_01A_11D_2268_08.2	G23079.TCGA_CR_6482_01A_11D_2268_08.2.bam	68.7	1.9	0.14	58cfa82ee4b0c9d6adf6aab8	G23079.TCGA_CR_6482_01A_11D_2268_08.2.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-6482-01A	468649E7-1525-4B8A-8AB5-DDB27DB5F022	Primary Tumor	Illumina HiSeq	47cd6984-3399-4fc7-a843-09a97b33bf4b	Head and Neck	62.0	92173F97-B46A-4950-8CD8-6729AB9522C5	7158C9FD-A633-4FEF-AA23-BD285F2A87A8	TCGA-CR-6482-01A-11D-2268-08	HG19_Broad_variant	TCGA-CR-6482	TCGA-HNSC		s15866	Broad Institute of MIT and Harvard	Vanderbilt University	United States	NO			Head and Neck Squamous Cell Carcinoma		2268-08	True
S13722.58cfa82ee4b0c9d6adf6aebf	58cfa82ee4b0c9d6adf6aebf	G49537.TCGA-DE-A0Y3-01B-11D-A10S-08.2.filtered.	WGS	G49537.TCGA-DE-A0Y3-01B-11D-A10S-08.2	G49537.TCGA-DE-A0Y3-01B-11D-A10S-08.2.bam	60.48	2.03	0.07	58cfa82ee4b0c9d6adf6aebf	G49537.TCGA-DE-A0Y3-01B-11D-A10S-08.2.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DE-A0Y3-01B	C31B3ADF-3FC6-4A72-83B0-BBC0F295B5E7	Primary Tumor	Illumina HiSeq	3c0140ae-22a1-4eff-8981-313aa5dd5315	Thyroid	60.0	3AE03B86-1473-409C-8118-A91A73A36F60	7DFCFE29-3900-4D7B-8067-60C51584B0B1	TCGA-DE-A0Y3-01B-11D-A10S-08	HG19_Broad_variant	TCGA-DE-A0Y3	TCGA-THCA		s12219	Broad Institute of MIT and Harvard	University of North Carolina	United States	NO	T4a	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVC	A10S-08	True
S13722.58cfa82ee4b0c9d6adf6af2a	58cfa82ee4b0c9d6adf6af2a	G39020.TCGA-HU-8608-01A-11D-2394-08.2.filtered.	WGS	G39020.TCGA-HU-8608-01A-11D-2394-08.2	G39020.TCGA-HU-8608-01A-11D-2394-08.2.bam	200.0		0.05	58cfa82ee4b0c9d6adf6af2a	G39020.TCGA-HU-8608-01A-11D-2394-08.2.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-HU-8608-01A	C6316FB5-99A7-4ADF-832F-DCE44DDCD3AA	Primary Tumor	Illumina HiSeq	58876087-e158-4469-af68-c91fe264ca8e	Stomach	70.0	E70FE3AD-F9FA-4097-B472-86606C241D26	A2EE5DDE-4342-4E78-88C5-3C9A8E10CBF5	TCGA-HU-8608-01A-11D-2394-08	HG19_Broad_variant	TCGA-HU-8608	TCGA-STAD		s15298	Broad Institute of MIT and Harvard	National Cancer Center Korea	Korea South	NO	T4a	N2	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIB	2394-08	True
S13722.58cfa82ee4b0c9d6adf6af1c	58cfa82ee4b0c9d6adf6af1c	G39020.TCGA-FP-7998-01A-11D-2201-08.2.filtered.	WGS	G39020.TCGA-FP-7998-01A-11D-2201-08.2	G39020.TCGA-FP-7998-01A-11D-2201-08.2.bam	278.7		0.05	58cfa82ee4b0c9d6adf6af1c	G39020.TCGA-FP-7998-01A-11D-2201-08.2.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-FP-7998-01A	B2E2D35C-7A79-4165-97A5-82D5C37D94F2	Primary Tumor	Illumina HiSeq	d124dc46-96b0-4101-b8a6-3e4ebf4862c9	Stomach	77.0	0A95BD32-539E-43F3-9694-A7D033A6FA84	172C9864-C26D-4E9B-947A-E8CE761E996D	TCGA-FP-7998-01A-11D-2201-08	HG19_Broad_variant	TCGA-FP-7998	TCGA-STAD		s15369	Broad Institute of MIT and Harvard	International Genomics Consortium	United States	NO	T4a	N3a	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIC	2201-08	False
S13722.58cfa82ee4b0c9d6adf6af4c	58cfa82ee4b0c9d6adf6af4c	G47088.TCGA-18-4721-01A-01D-1441-08.2.filtered.	WGS	G47088.TCGA-18-4721-01A-01D-1441-08.2	G47088.TCGA-18-4721-01A-01D-1441-08.2.bam	305.7	1.9	0.05	58cfa82ee4b0c9d6adf6af4c	G47088.TCGA-18-4721-01A-01D-1441-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-18-4721-01A	19F0CB8C-2E57-4310-967F-A9890F1605DB	Primary Tumor	Illumina HiSeq	cc99a2ed-feab-46b5-86eb-27fa81408f7c	Lung	74.0	1BAC4FF6-E35B-40F6-BBE4-705AB672D102	D2AB2555-7288-47A4-A80C-BF62D65B67B8	TCGA-18-4721-01A-01D-1441-08	HG19_Broad_variant	TCGA-18-4721	TCGA-LUSC		s10078	Broad Institute of MIT and Harvard	Princess Margaret Hospital (Canada)	Canada	NO	T1	N0	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IA	1441-08	False
S13722.58cfa82fe4b0c9d6adf6b8d8	58cfa82fe4b0c9d6adf6b8d8	TCGA-A6-6781-01A-22D-1924-10_wgs_Illumina.filtered.	WGS	TCGA-A6-6781-01A-22D-1924-10_wgs_Illumina	TCGA-A6-6781-01A-22D-1924-10_wgs_Illumina.bam	190.3	1.9	0.05	58cfa82fe4b0c9d6adf6b8d8	TCGA-A6-6781-01A-22D-1924-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-6781-01A	B54865B6-824E-4163-B759-21A6EACC98CE	Primary Tumor	Illumina HiSeq	bee0f5f3-5654-4349-b3dd-afe0b89cc488	Colorectal	43.0	F1B2CA40-F20A-42DE-ABA2-4F730D7CCC09	2182CE2C-5941-4B65-9419-FC7966D5E6D5	TCGA-A6-6781-01A-22D-1924-10	GRCh37-lite	TCGA-A6-6781	TCGA-COAD		s13354	Baylor College of Medicine	Christiana Healthcare	United States	NO	T4b	N1b	Colon Mucinous Adenocarcinoma	Stage IIIC	1924-10	False
S13722.58cfa82fe4b0c9d6adf6b920	58cfa82fe4b0c9d6adf6b920	TCGA-A4-A48D-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-A4-A48D-01A-11D-A25F-10_wgs_Illumina	TCGA-A4-A48D-01A-11D-A25F-10_wgs_Illumina.bam	21.0		0.08	58cfa82fe4b0c9d6adf6b920	TCGA-A4-A48D-01A-11D-A25F-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-A4-A48D-01A	925AE8FF-3200-4564-BE76-94DB0984B027	Primary Tumor	Illumina HiSeq	ca65f407-1de9-4171-8ae5-67e4d85f5beb	Kidney	84.0	4DDC37D4-35B8-4A5D-BBF1-6DBF0548852B	5ECC88F7-8391-4168-AF11-07A6BF9B3652	TCGA-A4-A48D-01A-11D-A25F-10	GRCh37-lite	TCGA-A4-A48D	TCGA-KIRP		s11850	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1b	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A25F-10	True
S13722.58cfa830e4b0c9d6adf6bad6	58cfa830e4b0c9d6adf6bad6	TCGA-A6-6141-01A-11D-1771-10_wgs_Illumina.filtered.	WGS	TCGA-A6-6141-01A-11D-1771-10_wgs_Illumina	TCGA-A6-6141-01A-11D-1771-10_wgs_Illumina.bam	315.4	1.9	0.05	58cfa830e4b0c9d6adf6bad6	TCGA-A6-6141-01A-11D-1771-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-6141-01A	58FACEDB-FCB8-4ECF-8338-2BFA4947ACEF	Primary Tumor	Illumina HiSeq	6fd83764-dbd4-43ec-bab9-c2950c46cf59	Colorectal	31.0	D67FC406-7974-433E-896D-57197ECED52B	00AA769D-622C-433E-8A8A-63FB5C41EA42	TCGA-A6-6141-01A-11D-1771-10	GRCh37-lite	TCGA-A6-6141	TCGA-COAD		s13355	Baylor College of Medicine	Christiana Healthcare	United States	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1771-10	False
S13722.58cfa82fe4b0c9d6adf6ba26	58cfa82fe4b0c9d6adf6ba26	TCGA-A3-3370-01A-02D-2099-10_Illumina.filtered.	WGS	TCGA-A3-3370-01A-02D-2099-10_Illumina	TCGA-A3-3370-01A-02D-2099-10_Illumina.bam	152.4	1.9	0.14	58cfa82fe4b0c9d6adf6ba26	TCGA-A3-3370-01A-02D-2099-10_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-A3-3370-01A	9F632FC3-2241-469A-A14A-CD537350155F	Primary Tumor	Illumina HiSeq	2bf569a0-5698-4304-b006-f61284e72aef	Kidney	48.0	1B2DF3FD-183C-4099-A387-5908C8B44F57	D7F1DB09-8BA0-4B76-BCD2-01C14165F0D5	TCGA-A3-3370-01A-02D-2099-10	GRCh37-lite	TCGA-A3-3370	TCGA-KIRC		s9563	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1b	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2099-10	False
S13722.58cfa830e4b0c9d6adf6bb82	58cfa830e4b0c9d6adf6bb82	TCGA-A3-3308-01A-01D-2094-10_Illumina.filtered.	WGS	TCGA-A3-3308-01A-01D-2094-10_Illumina	TCGA-A3-3308-01A-01D-2094-10_Illumina.bam	591.9	1.9	0.17	58cfa830e4b0c9d6adf6bb82	TCGA-A3-3308-01A-01D-2094-10_Illumina.bam	Alive	FEMALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-A3-3308-01A	3CBCA837-F5A7-4A87-8F02-C59EAC232D5A	Primary Tumor	Illumina HiSeq	ff863b55-b221-4580-b322-d2f1c9137279	Kidney	77.0	0B935ADB-0E19-4FCC-9BB0-B9D95872BCEF	68B7FDB1-22B5-4152-9E69-A41151640CD8	TCGA-A3-3308-01A-01D-2094-10	GRCh37-lite	TCGA-A3-3308	TCGA-KIRC		s9000	Baylor College of Medicine	International Genomics Consortium		NO	T3b	N0	Kidney Clear Cell Renal Carcinoma	Stage III	2094-10	False
S13722.58cfa830e4b0c9d6adf6bcfc	58cfa830e4b0c9d6adf6bcfc	TCGA-AD-6964-01A-11D-1924-10_wgs_Illumina.filtered.	WGS	TCGA-AD-6964-01A-11D-1924-10_wgs_Illumina	TCGA-AD-6964-01A-11D-1924-10_wgs_Illumina.bam	177.7		0.05	58cfa830e4b0c9d6adf6bcfc	TCGA-AD-6964-01A-11D-1924-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AD-6964-01A	5E7074A6-5011-4DC5-950C-41365DBC6D09	Primary Tumor	Illumina HiSeq	67abf892-45e8-4468-a1fd-8446401b3f55	Colorectal	58.0	4D16E41A-B100-4080-A759-1F62E54C1C91	42D20028-0DDC-4DAC-9F05-D674F8915F21	TCGA-AD-6964-01A-11D-1924-10	GRCh37-lite	TCGA-AD-6964	TCGA-COAD		s13536	Baylor College of Medicine	International Genomics Consortium	United States	NO	T4a	N2b	Colon Adenocarcinoma		1924-10	False
S13722.58cfa830e4b0c9d6adf6c046	58cfa830e4b0c9d6adf6c046	TCGA-B2-4102-01A-02D-2095-10_wgs_Illumina.filtered.	WGS	TCGA-B2-4102-01A-02D-2095-10_wgs_Illumina	TCGA-B2-4102-01A-02D-2095-10_wgs_Illumina.bam	142.77	1.9	0.16	58cfa830e4b0c9d6adf6c046	TCGA-B2-4102-01A-02D-2095-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-B2-4102-01A	BBBCE1BA-C739-43BA-B9CF-A4F746491AE3	Primary Tumor	Illumina HiSeq	08200438-3da7-446b-99d7-c23e7cbfb2b5	Kidney	61.0	0A187E9E-FAE3-4B9F-B6ED-23CF0FFCB39E	39C55051-E1BC-4081-962A-17205645DE45	TCGA-B2-4102-01A-02D-2095-10	GRCh37-lite	TCGA-B2-4102	TCGA-KIRC		s9734	Baylor College of Medicine	Christiana Healthcare		NO	T1b	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2095-10	False
S13722.58cfa830e4b0c9d6adf6c020	58cfa830e4b0c9d6adf6c020	TCGA-B1-A47O-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-B1-A47O-01A-11D-A25F-10_wgs_Illumina	TCGA-B1-A47O-01A-11D-A25F-10_wgs_Illumina.bam	16.46		0.09	58cfa830e4b0c9d6adf6c020	TCGA-B1-A47O-01A-11D-A25F-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B1-A47O-01A	6A6C1569-1045-4ED3-ACDB-5C45E47614CA	Primary Tumor	Illumina HiSeq	3b1d3bea-7b97-415b-ad61-4c84d3bd88e2	Kidney	54.0	EBADE9FD-DCE5-4EC9-A483-9F165823D9B6	CA2B9FE2-97E0-4D4F-AFD7-A5ACF638800F	TCGA-B1-A47O-01A-11D-A25F-10	GRCh37-lite	TCGA-B1-A47O	TCGA-KIRP		s11768	Baylor College of Medicine	University of Pittsburgh	United States	NO	T1b	N0	Kidney Papillary Renal Cell Carcinoma	Stage I	A25F-10	True
S13722.58cfa830e4b0c9d6adf6c13e	58cfa830e4b0c9d6adf6c13e	TCGA-B9-A44B-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-B9-A44B-01A-11D-A25F-10_wgs_Illumina	TCGA-B9-A44B-01A-11D-A25F-10_wgs_Illumina.bam	19.16		0.08	58cfa830e4b0c9d6adf6c13e	TCGA-B9-A44B-01A-11D-A25F-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B9-A44B-01A	B809C2F2-185C-496A-A1D4-589294443A1D	Primary Tumor	Illumina HiSeq	148c4a68-bab6-4ff6-bcd7-fc69c33bea94	Kidney	70.0	07C08E8F-4DCA-42E4-9954-C62C32FED225	88E35D25-D98D-4576-8EBE-1CD74010ECD8	TCGA-B9-A44B-01A-11D-A25F-10	GRCh37-lite	TCGA-B9-A44B	TCGA-KIRP		s11860	Baylor College of Medicine	UNC	United States	NO	T3b	NX	Kidney Papillary Renal Cell Carcinoma	Stage III	A25F-10	True
S13722.58cfa82ee4b0c9d6adf6aeee	58cfa82ee4b0c9d6adf6aeee	G49537.TCGA-FE-A233-01A-11D-A33C-08.1.filtered.	WGS	G49537.TCGA-FE-A233-01A-11D-A33C-08.1	G49537.TCGA-FE-A233-01A-11D-A33C-08.1.bam	92.7	2.05	0.09	58cfa82ee4b0c9d6adf6aeee	G49537.TCGA-FE-A233-01A-11D-A33C-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A233-01A	E70FEAFD-1390-4F4C-A635-DA65C1A7DAEB	Primary Tumor	Illumina HiSeq	d7f3aea8-ea8e-4400-b8b3-cc40582e70cd	Thyroid	18.0	76A6F76D-F33E-4B4A-B0EE-FB863345F194	473FE833-FCC6-485E-93D2-95E662C3EF53	TCGA-FE-A233-01A-11D-A33C-08	HG19_Broad_variant	TCGA-FE-A233	TCGA-THCA		s12224	Broad Institute of MIT and Harvard	Ohio State University	United States	NO	T2	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A33C-08	False
S13722.58cfa831e4b0c9d6adf6c41a	58cfa831e4b0c9d6adf6c41a	TCGA-CJ-4899-01A-01D-2100-10_Illumina.filtered.	WGS	TCGA-CJ-4899-01A-01D-2100-10_Illumina	TCGA-CJ-4899-01A-01D-2100-10_Illumina.bam	109.4	1.9	0.16	58cfa831e4b0c9d6adf6c41a	TCGA-CJ-4899-01A-01D-2100-10_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-4899-01A	900B5F21-E8FB-4A3F-B8E3-EF098716E508	Primary Tumor	Illumina HiSeq	ad992cd4-c4d5-4f87-b721-a2cbdf70f57d	Kidney	42.0	E2D40747-F751-4CCB-A45C-A60B06046DB1	9C181313-5B4C-41C5-9AD5-A5A86FE609AA	TCGA-CJ-4899-01A-01D-2100-10	GRCh37-lite	TCGA-CJ-4899	TCGA-KIRC		s9568	Baylor College of Medicine	MD Anderson Cancer Center		NO	T1b	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2100-10	False
S13722.58cfa831e4b0c9d6adf6c682	58cfa831e4b0c9d6adf6c682	TCGA-CR-5250-01A-01D-2276-10_Illumina.filtered.	WGS	TCGA-CR-5250-01A-01D-2276-10_Illumina	TCGA-CR-5250-01A-01D-2276-10_Illumina.bam	261.73	1.9	0.05	58cfa831e4b0c9d6adf6c682	TCGA-CR-5250-01A-01D-2276-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-5250-01A	9E178D80-FE90-4998-9DAE-726C4BECEEF7	Primary Tumor	Illumina HiSeq	486d7653-48d6-47cc-b04b-362d1b0e485b	Head and Neck	71.0	13AE9411-E63F-4093-A80E-8B64837C001D	29FC38AA-F367-46A3-A14D-A5F657AD0CAA	TCGA-CR-5250-01A-01D-2276-10	GRCh37-lite	TCGA-CR-5250	TCGA-HNSC		s16039	Baylor College of Medicine	Vanderbilt University		NO	TX	NX	Head and Neck Squamous Cell Carcinoma		2276-10	True
S13722.58cfa830e4b0c9d6adf6c2a3	58cfa830e4b0c9d6adf6c2a3	TCGA-B1-A47N-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-B1-A47N-01A-11D-A25F-10_wgs_Illumina	TCGA-B1-A47N-01A-11D-A25F-10_wgs_Illumina.bam	32.02		0.08	58cfa830e4b0c9d6adf6c2a3	TCGA-B1-A47N-01A-11D-A25F-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B1-A47N-01A	F1EC5A7B-0973-4C38-9908-862196DF9541	Primary Tumor	Illumina HiSeq	57987e56-d118-4f55-98c4-340866fcf3e8	Kidney	62.0	C5EDE5F5-35D2-4059-9F0C-6736ABC6F899	BD2CC59D-F5CE-46ED-BEB0-4C80B24CBE71	TCGA-B1-A47N-01A-11D-A25F-10	GRCh37-lite	TCGA-B1-A47N	TCGA-KIRP		s11855	Baylor College of Medicine	University of Pittsburgh	United States	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A25F-10	True
S13722.58cfa831e4b0c9d6adf6c6b2	58cfa831e4b0c9d6adf6c6b2	TCGA-CR-5249-01A-01D-2276-10_wgs_Illumina.filtered.	WGS	TCGA-CR-5249-01A-01D-2276-10_wgs_Illumina	TCGA-CR-5249-01A-01D-2276-10_wgs_Illumina.bam	213.73	1.9	0.05	58cfa831e4b0c9d6adf6c6b2	TCGA-CR-5249-01A-01D-2276-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-5249-01A	C7DF3466-B9A7-4818-883B-D0CD08483570	Primary Tumor	Illumina HiSeq	cef48339-6b24-4da9-b25d-55a64c71d0dc	Head and Neck	35.0	6697DD71-5A58-4862-B26E-EA16DCC383F2	C0812962-A345-48B7-AEC0-01336C2D1EED	TCGA-CR-5249-01A-01D-2276-10	GRCh37-lite	TCGA-CR-5249	TCGA-HNSC		s15894	Baylor College of Medicine	Vanderbilt University		NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2276-10	True
S13722.58cfa831e4b0c9d6adf6c456	58cfa831e4b0c9d6adf6c456	TCGA-CA-6717-01A-11D-1835-10_wgs_Illumina.filtered.	WGS	TCGA-CA-6717-01A-11D-1835-10_wgs_Illumina	TCGA-CA-6717-01A-11D-1835-10_wgs_Illumina.bam	201.0	1.9	0.05	58cfa831e4b0c9d6adf6c456	TCGA-CA-6717-01A-11D-1835-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CA-6717-01A	268C01B3-D2CE-44C0-A2FE-EA846A1253CC	Primary Tumor	Illumina HiSeq	da552d40-23e1-469c-9fe7-ff2904a35ebe	Colorectal	57.0	D412011F-061C-43D6-8FA7-F917DA658AFF	2DF02F2B-9F1C-4249-B3B4-B03079CD97D9	TCGA-CA-6717-01A-11D-1835-10	GRCh37-lite	TCGA-CA-6717	TCGA-COAD		s13038	Baylor College of Medicine	ILSbio	Vietnam	NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	1835-10	False
S13722.58cfa831e4b0c9d6adf6c81d	58cfa831e4b0c9d6adf6c81d	TCGA-CV-6433-01A-11D-2276-10_Illumina.filtered.	WGS	TCGA-CV-6433-01A-11D-2276-10_Illumina	TCGA-CV-6433-01A-11D-2276-10_Illumina.bam	207.03	1.9	0.05	58cfa831e4b0c9d6adf6c81d	TCGA-CV-6433-01A-11D-2276-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6433-01A	D5EEDFB5-4FA3-4A1E-AD0D-EA550B22A5BA	Primary Tumor	Illumina HiSeq	0fc542ae-619e-45f5-9496-dcf6f31f4c32	Head and Neck	57.0	47EC5010-4353-493B-AB28-C95BC2CB026C	0E6CA8DC-0F31-4675-95B1-5920576DAEFF	TCGA-CV-6433-01A-11D-2276-10	GRCh37-lite	TCGA-CV-6433	TCGA-HNSC		s15511	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2276-10	True
S13722.58cfa831e4b0c9d6adf6c88e	58cfa831e4b0c9d6adf6c88e	TCGA-D5-6540-01A-11D-1719-10_wgs_Illumina.filtered.	WGS	TCGA-D5-6540-01A-11D-1719-10_wgs_Illumina	TCGA-D5-6540-01A-11D-1719-10_wgs_Illumina.bam	473.0	1.9	0.05	58cfa831e4b0c9d6adf6c88e	TCGA-D5-6540-01A-11D-1719-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-D5-6540-01A	B08B5F49-9434-4653-9772-097EC29B2CA3	Primary Tumor	Illumina HiSeq	ea4fb044-493b-4e48-ac28-28ba39b8be21	Colorectal	66.0	201B6B48-418F-48A3-A568-6E851F85C25E	EC43C4B5-FB72-4A4A-AF03-10C2D05FF159	TCGA-D5-6540-01A-11D-1719-10	GRCh37-lite	TCGA-D5-6540	TCGA-COAD		s13396	Baylor College of Medicine	Greater Poland Cancer Center	Poland	NO	T2	N0	Colon Mucinous Adenocarcinoma	Stage I	1719-10	False
S13722.58cfa831e4b0c9d6adf6c966	58cfa831e4b0c9d6adf6c966	TCGA-CN-5374-01A-01D-2266-10_Illumina.filtered.	WGS	TCGA-CN-5374-01A-01D-2266-10_Illumina	TCGA-CN-5374-01A-01D-2266-10_Illumina.bam	384.7	1.9	0.05	58cfa831e4b0c9d6adf6c966	TCGA-CN-5374-01A-01D-2266-10_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5374-01A	D7641CA1-A062-4DD2-9414-447AF7311A84	Primary Tumor	Illumina HiSeq	3713f8c9-23d7-490a-bec2-99cb7ab55eac	Head and Neck	56.0	617DF1E0-B075-4610-B6D5-8850786FEA70	AB923DB7-54E8-4A50-B7FD-C2B4B300041E	TCGA-CN-5374-01A-01D-2266-10	GRCh37-lite	TCGA-CN-5374	TCGA-HNSC		s15768	Baylor College of Medicine	University of Pittsburgh		NO	T2	N2	Head and Neck Squamous Cell Carcinoma	Stage IVA	2266-10	True
S13722.58cfa832e4b0c9d6adf6d2f5	58cfa832e4b0c9d6adf6d2f5	TCGA-KN-8424-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8424-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8424-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d2f5	TCGA-KN-8424-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KN-8424-01A	8C9E1F60-1838-4AA4-A667-C1CEF7DDDBDF	Primary Tumor	Illumina HiSeq	5c114c89-2e86-497d-a02e-e309eee59dc0	Kidney	42.0	93B1AE00-43E1-466C-BBC1-8755CB1A1A0C	1E8AE8DD-74C1-44D5-A74E-BFDCE801C736	TCGA-KN-8424-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8424	TCGA-KICH		s16524	Baylor College of Medicine	Harvard	United States	NO	T1b	N0	Kidney Chromophobe	Stage I	2310-10	True
S13722.58cfa832e4b0c9d6adf6d300	58cfa832e4b0c9d6adf6d300	TCGA-KM-8440-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KM-8440-01A-11D-2310-10_wgs_Illumina	TCGA-KM-8440-01A-11D-2310-10_wgs_Illumina.bam	38.6		0.05	58cfa832e4b0c9d6adf6d300	TCGA-KM-8440-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KM-8440-01A	872092B3-D31E-44D7-BD03-E29F52F8AB5A	Primary Tumor	Illumina HiSeq	e0e06c60-542a-4e20-928f-7fed440fcd2a	Kidney	37.0	614E4163-7DA8-4F77-A58D-405B004BE3E0	CDF313C8-59F9-41C6-9BD2-F47CB4287DA5	TCGA-KM-8440-01A-11D-2310-10	GRCh37-lite	TCGA-KM-8440	TCGA-KICH		s16478	Baylor College of Medicine	NCI Urologic Oncology Branch	United States	NO	T3a	NX	Kidney Chromophobe	Stage III	2310-10	True
S13722.58cfa832e4b0c9d6adf6d319	58cfa832e4b0c9d6adf6d319	TCGA-KN-8429-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8429-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8429-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d319	TCGA-KN-8429-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KN-8429-01A	366219B9-FDE3-4D2D-82D3-15FE6245AA98	Primary Tumor	Illumina HiSeq	a527b958-1e44-4a4f-99e9-ba45c80bd326	Kidney	38.0	B802658C-4715-4878-97CA-99576F08AF6A	58C7E9C3-1345-48C0-A758-0887358B8696	TCGA-KN-8429-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8429	TCGA-KICH		s16492	Baylor College of Medicine	Harvard	United States	NO	T3a	N0	Kidney Chromophobe	Stage III	2310-10	True
S13722.58cfa832e4b0c9d6adf6d31d	58cfa832e4b0c9d6adf6d31d	TCGA-KN-8434-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8434-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8434-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d31d	TCGA-KN-8434-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KN-8434-01A	E1E15226-9F8E-4035-8F08-EB1FED57080E	Primary Tumor	Illumina HiSeq	46dd26b0-c7e3-4280-b67c-5141df9048cf	Kidney	65.0	F75DE9FC-5DE8-4CAE-B1E1-8C37D1915C17	24F887E1-CE82-40F3-9674-11102BD076C0	TCGA-KN-8434-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8434	TCGA-KICH		s16488	Baylor College of Medicine	Harvard	United States	NO	T2	NX	Kidney Chromophobe	Stage II	2310-10	True
S13722.58cfa832e4b0c9d6adf6d36c	58cfa832e4b0c9d6adf6d36c	TCGA-KN-8418-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8418-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8418-01A-11D-2310-10_wgs_Illumina.bam	106.3		0.05	58cfa832e4b0c9d6adf6d36c	TCGA-KN-8418-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KN-8418-01A	F3BA1CF8-AC67-4DA8-96F3-8680DC55F247	Primary Tumor	Illumina HiSeq	29118d80-8a70-4ed3-8742-d2c69bbeffb7	Kidney	41.0	D6F68966-D6A2-4B24-B1D5-15CB8F4ACB8F	9A90F951-AD96-4883-B97F-AC43395DAE5D	TCGA-KN-8418-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8418	TCGA-KICH		s16396	Baylor College of Medicine	Harvard	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True
S13722.58cfa832e4b0c9d6adf6d3c2	58cfa832e4b0c9d6adf6d3c2	TCGA-KO-8406-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KO-8406-01A-11D-2310-10_wgs_Illumina	TCGA-KO-8406-01A-11D-2310-10_wgs_Illumina.bam	131.2		0.05	58cfa832e4b0c9d6adf6d3c2	TCGA-KO-8406-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KO-8406-01A	9AA02D46-294B-4E99-B9EE-56EDCBFB5275	Primary Tumor	Illumina HiSeq	1980f1bf-6afb-4a53-97a5-f069b4200e14	Kidney	17.0	2141972F-8CA9-4E82-B410-B1E3BBB2934A	C29F6ED6-880D-4F03-977E-1087738E5E60	TCGA-KO-8406-01A-11D-2310-10	GRCh37-lite	TCGA-KO-8406	TCGA-KICH		s16408	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T1	N0	Kidney Chromophobe	Stage I	2310-10	True
S13722.58cfa832e4b0c9d6adf6d3d3	58cfa832e4b0c9d6adf6d3d3	TCGA-KO-8417-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KO-8417-01A-11D-2310-10_wgs_Illumina	TCGA-KO-8417-01A-11D-2310-10_wgs_Illumina.bam	186.5		0.05	58cfa832e4b0c9d6adf6d3d3	TCGA-KO-8417-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KO-8417-01A	0B77657A-0297-4CEE-B9F2-5DE72E182016	Primary Tumor	Illumina HiSeq	c1d96592-c2a1-4638-8ee3-0515f3a8c96a	Kidney	30.0	C6D5A991-4018-4D78-BF0C-4D240E7987B5	0C7AF04B-E171-47C4-8BE5-5DB33F20148E	TCGA-KO-8417-01A-11D-2310-10	GRCh37-lite	TCGA-KO-8417	TCGA-KICH		s16574	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T1	N0	Kidney Chromophobe	Stage I	2310-10	True
S13722.58cfa832e4b0c9d6adf6d394	58cfa832e4b0c9d6adf6d394	TCGA-KO-8411-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KO-8411-01A-11D-2310-10_wgs_Illumina	TCGA-KO-8411-01A-11D-2310-10_wgs_Illumina.bam	133.2		0.05	58cfa832e4b0c9d6adf6d394	TCGA-KO-8411-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KO-8411-01A	EE8C1919-17A9-4DF1-8AA5-79546621B23C	Primary Tumor	Illumina HiSeq	bcee9ae3-609f-4f6c-bf6e-9bf33233592d	Kidney	58.0	9E2CDD77-110D-498A-83E8-DF2E044303D6	9DFCBABF-2BC0-43A2-BDDE-D0B2AACA3F6B	TCGA-KO-8411-01A-11D-2310-10	GRCh37-lite	TCGA-KO-8411	TCGA-KICH		s16402	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T1b	NX	Kidney Chromophobe	Stage I	2310-10	True
S13722.58cfa832e4b0c9d6adf6d356	58cfa832e4b0c9d6adf6d356	TCGA-KO-8416-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KO-8416-01A-11D-2310-10_wgs_Illumina	TCGA-KO-8416-01A-11D-2310-10_wgs_Illumina.bam	74.8		0.05	58cfa832e4b0c9d6adf6d356	TCGA-KO-8416-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KO-8416-01A	0EC3CAA1-7C51-417B-A89C-18E9FCEB80C4	Primary Tumor	Illumina HiSeq	3f5f5abf-4e3b-409e-9e2b-c8543d51100b	Kidney	41.0	545486B9-EF3E-45AD-810A-F4594A2DB883	9D29543E-8601-4FD0-8E76-3DF3DE465CAB	TCGA-KO-8416-01A-11D-2310-10	GRCh37-lite	TCGA-KO-8416	TCGA-KICH		s16576	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T3a	N0	Kidney Chromophobe	Stage III	2310-10	True
S13722.58cfa831e4b0c9d6adf6c7e1	58cfa831e4b0c9d6adf6c7e1	TCGA-CV-7090-01A-11D-2276-10_Illumina.filtered.	WGS	TCGA-CV-7090-01A-11D-2276-10_Illumina	TCGA-CV-7090-01A-11D-2276-10_Illumina.bam	158.73		0.05	58cfa831e4b0c9d6adf6c7e1	TCGA-CV-7090-01A-11D-2276-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7090-01A	05FBD98C-28BD-41BC-AE60-16AC0C16C723	Primary Tumor	Illumina HiSeq	30e23a3f-f6eb-45e4-9d14-bddafc4fab6d	Head and Neck	39.0	E8BD9DCB-A9C7-4361-9724-24922A5E613B	A8041E86-071E-46CD-8FB5-7ECDC1AB0553	TCGA-CV-7090-01A-11D-2276-10	GRCh37-lite	TCGA-CV-7090	TCGA-HNSC		s15646	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T2	NX	Head and Neck Squamous Cell Carcinoma	Stage II	2276-10	True
S13722.58cfa832e4b0c9d6adf6d33e	58cfa832e4b0c9d6adf6d33e	TCGA-KN-8435-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8435-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8435-01A-11D-2310-10_wgs_Illumina.bam	134.0		0.05	58cfa832e4b0c9d6adf6d33e	TCGA-KN-8435-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KN-8435-01A	F2B58595-DEC0-4194-AB33-7C7DC6C058A6	Primary Tumor	Illumina HiSeq	28eaaad9-76f1-4c47-9af6-d8dc853ae96c	Kidney	59.0	B2D2BE13-C233-409A-A793-21D9CD3CFCE7	715F59DD-A80F-422D-988C-F73F4B987BAF	TCGA-KN-8435-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8435	TCGA-KICH		s16489	Baylor College of Medicine	Harvard	United States	NO	T2	NX	Kidney Chromophobe	Stage II	2310-10	True
S13722.58cfa82fe4b0c9d6adf6b687	58cfa82fe4b0c9d6adf6b687	TCGA-44-6148-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_6_rg.sorted.filtered.	WGS	TCGA-44-6148-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_6_rg.sorted	TCGA-44-6148-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_6_rg.sorted.bam	164.4	1.9	0.16	58cfa82fe4b0c9d6adf6b687	TCGA-44-6148-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6148-01A	8994C8C4-9EA0-46CB-B4A5-0055D7DA5BFA	Primary Tumor	Illumina HiSeq	e3f95d46-09ce-43a0-a2c7-581cb9fe8da9	Lung	60.0	C0FE5FFE-C0A3-4E62-AA55-2BC18788E505	F8A1C395-E730-48F9-BF82-E8931E4AF154	TCGA-44-6148-01A-11D-1751-02	HG19_Broad_variant	TCGA-44-6148	TCGA-LUAD		s10995	Harvard Medical School	Christiana Healthcare	United States	NO	T1b	N0	Lung Mucinous Adenocarcinoma	Stage IA	1751-02	True
S13722.58cfa82fe4b0c9d6adf6b80c	58cfa82fe4b0c9d6adf6b80c	TCGA-44-4112-01A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-44-4112-01A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_1_rg.sorted	TCGA-44-4112-01A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_1_rg.sorted.bam	452.63	1.9	0.15	58cfa82fe4b0c9d6adf6b80c	TCGA-44-4112-01A-01D-1103_120318_SN1120_0124_AC0HNPACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-4112-01A	68B86559-38B2-41F2-B66E-C3C2B628B14D	Primary Tumor	Illumina HiSeq	7c0e7b16-7643-4891-96de-63f2106bfb1a	Lung	60.0	6C206676-E511-4281-91F5-BFE91B3279A4	68185A4B-CC12-494D-99F5-84F5888A24F9	TCGA-44-4112-01A-01D-1103-02	HG19_Broad_variant	TCGA-44-4112	TCGA-LUAD		s10651	Harvard Medical School	Christiana Healthcare		NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1103-02	True
S13722.58cfa82fe4b0c9d6adf6b88f	58cfa82fe4b0c9d6adf6b88f	TCGA-73-4676-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_7_rg.sorted.filtered.	WGS	TCGA-73-4676-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_7_rg.sorted	TCGA-73-4676-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_7_rg.sorted.bam	216.0	1.9	0.15	58cfa82fe4b0c9d6adf6b88f	TCGA-73-4676-01A-01D-1751_120309_SN208_0274_AD0R6DACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4676-01A	195A5AFB-B79F-44D2-9D12-884487630C2B	Primary Tumor	Illumina HiSeq	a2b68d59-a4d4-4793-9e6c-72ccaf7c242b	Lung	45.0	22434A49-EB8A-43AC-8C08-AE6DCBE6FBB8	A79111BF-CB9D-4790-AE9F-6CB13C9334E2	TCGA-73-4676-01A-01D-1751-02	HG19_Broad_variant	TCGA-73-4676	TCGA-LUAD		s11465	Harvard Medical School	Roswell Park	United States	NO	T2a	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1751-02	True
S13722.58cfa82fe4b0c9d6adf6b8e2	58cfa82fe4b0c9d6adf6b8e2	TCGA-A7-A26F-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_1_rg.sorted.filtered.	WGS	TCGA-A7-A26F-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_1_rg.sorted	TCGA-A7-A26F-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_1_rg.sorted.bam	8.32		0.14	58cfa82fe4b0c9d6adf6b8e2	TCGA-A7-A26F-01B-04D-A22S_120816_SN1222_0144_AD16PUACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A7-A26F-01B	3B7B9C1E-A84C-47ED-983C-9E4B00CBF01A	Primary Tumor	Illumina HiSeq	4925c013-4605-47d0-9c97-2e8a69233aa4	Breast	55.0	29619D1E-E8B4-411E-BBBA-07F2CFB69E8A	A723DE1E-A9E0-487D-8D86-7AA4A062A1C2	TCGA-A7-A26F-01B-04D-A22S-26	HG19_Broad_variant	TCGA-A7-A26F	TCGA-BRCA		s6916	MD Anderson - Institute for Applied Cancer Science	Christiana Healthcare	United States	YES	T1	N0	Other  specify	Stage IA	A22S-26	False
S13722.58cfa830e4b0c9d6adf6bb7e	58cfa830e4b0c9d6adf6bb7e	TCGA-A5-A0GB-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A5-A0GB-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_2_rg.sorted	TCGA-A5-A0GB-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_2_rg.sorted.bam	52.54	2.0	0.16	58cfa830e4b0c9d6adf6bb7e	TCGA-A5-A0GB-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GB-01A	2F4458B6-3CAF-4E33-890E-A04722BADD1B	Primary Tumor	Illumina HiSeq	c4dd9407-812c-41b2-9953-baec8808ddbd	Uterus	65.0	130744CA-A9A2-4C99-8ABB-20FE76E0A955	A025733C-E300-4C47-B2EF-D9C978B58BFD	TCGA-A5-A0GB-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GB	TCGA-UCEC		s4585	Harvard Medical School	Cedars Sinai		NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa830e4b0c9d6adf6bc4e	58cfa830e4b0c9d6adf6bc4e	TCGA-AP-A05P-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_5_rg.sorted.filtered.	WGS	TCGA-AP-A05P-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_5_rg.sorted	TCGA-AP-A05P-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_5_rg.sorted.bam	55.61	2.3	0.14	58cfa830e4b0c9d6adf6bc4e	TCGA-AP-A05P-01A-11D-A043_120214_SN590_0139_BC0DYEACXX_s_5_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A05P-01A	3CB83517-78A4-47B8-8B1E-57E765DBDD2E	Primary Tumor	Illumina HiSeq	a12cb33f-6f29-4068-a6c8-3e20520bc2e0	Uterus	54.0	F51F7B0E-3EA6-4232-9DE4-A4DD63B23BB5	E08A6886-B019-4920-ACC3-73A4CAF18E3F	TCGA-AP-A05P-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A05P	TCGA-UCEC		s5385	Harvard Medical School	MSKCC		NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa830e4b0c9d6adf6bd8f	58cfa830e4b0c9d6adf6bd8f	TCGA-BB-4223-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BB-4223-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_7_rg.sorted	TCGA-BB-4223-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_7_rg.sorted.bam	11.7	2.0	0.14	58cfa830e4b0c9d6adf6bd8f	TCGA-BB-4223-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BB-4223-01A	05F01280-BF77-4682-A7A8-20DD0EAC77BD	Primary Tumor	Illumina HiSeq	e8bc6546-004a-4702-9289-b5c90582298e	Head and Neck	48.0	82DB742D-885D-4788-B509-474715AE183B	007F0F41-C370-45F9-8053-2C774ADDED49	TCGA-BB-4223-01A-01D-1431-02	HG19_Broad_variant	TCGA-BB-4223	TCGA-HNSC		s15490	Harvard Medical School	Johns Hopkins	United States	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True
S13722.58cfa830e4b0c9d6adf6bdc4	58cfa830e4b0c9d6adf6bdc4	TCGA-BG-A18A-01A-21D-A12F_120626_SN590_0163_AC0VU5ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A18A-01A-21D-A12F_120626_SN590_0163_AC0VU5ACXX_s_7_rg.sorted	TCGA-BG-A18A-01A-21D-A12F_120626_SN590_0163_AC0VU5ACXX_s_7_rg.sorted.bam	21.93	1.96	0.17	58cfa830e4b0c9d6adf6bdc4	TCGA-BG-A18A-01A-21D-A12F_120626_SN590_0163_AC0VU5ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A18A-01A	FEB3E930-3638-44B4-AC0F-A5DCB01FED76	Primary Tumor	Illumina HiSeq	cf06b397-1811-4a38-93b4-05f1457e9882	Uterus	74.0	8FD0971D-40BA-46C2-B3C4-8E48A3E6C122	518AFA21-9E19-49DE-A2A6-387828A10837	TCGA-BG-A18A-01A-21D-A12F-02	HG19_Broad_variant	TCGA-BG-A18A	TCGA-UCEC		s4789	Harvard Medical School	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A12F-02	True
S13722.58cfa830e4b0c9d6adf6be01	58cfa830e4b0c9d6adf6be01	TCGA-BG-A0M8-01A-12D-A101_120330_SN1120_0129_BD0UCLACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BG-A0M8-01A-12D-A101_120330_SN1120_0129_BD0UCLACXX_s_3_rg.sorted	TCGA-BG-A0M8-01A-12D-A101_120330_SN1120_0129_BD0UCLACXX_s_3_rg.sorted.bam	67.61	2.0	0.15	58cfa830e4b0c9d6adf6be01	TCGA-BG-A0M8-01A-12D-A101_120330_SN1120_0129_BD0UCLACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M8-01A	E055DB71-F3DA-43D3-A9B2-2F65DFB23D3E	Primary Tumor	Illumina HiSeq	f354958c-ea56-472d-b145-a7e2895af8e2	Uterus	50.0	9CFB7290-EF60-4FDA-ABD7-9552AE11E4E7	D45D62ED-7BC6-4682-BB4B-2CA6EBBCE717	TCGA-BG-A0M8-01A-12D-A101-02	HG19_Broad_variant	TCGA-BG-A0M8	TCGA-UCEC		s4434	Harvard Medical School	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6be06	58cfa830e4b0c9d6adf6be06	TCGA-BG-A0MQ-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BG-A0MQ-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_6_rg.sorted	TCGA-BG-A0MQ-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_6_rg.sorted.bam	87.16	2.0	0.14	58cfa830e4b0c9d6adf6be06	TCGA-BG-A0MQ-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MQ-01A	12D36A1D-9922-4311-BBDA-71F32AC2C03B	Primary Tumor	Illumina HiSeq	d1e9cdb8-f8a6-43da-9afb-28a6e6d72b6a	Uterus	71.0	3D1FA321-D2E8-4460-AE87-356AB1CA6281	08F01B17-0386-4C7E-B926-1736CEC043D2	TCGA-BG-A0MQ-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0MQ	TCGA-UCEC		s4253	Harvard Medical School	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6be04	58cfa830e4b0c9d6adf6be04	TCGA-BG-A0M9-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BG-A0M9-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_4_rg.sorted	TCGA-BG-A0M9-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_4_rg.sorted.bam	133.79	2.0	0.17	58cfa830e4b0c9d6adf6be04	TCGA-BG-A0M9-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M9-01A	4FD1CB59-6C50-4355-9D37-A341E1F4FAD9	Primary Tumor	Illumina HiSeq	633f3cff-14c3-45f7-b568-caa86760d863	Uterus	73.0	DC487BBF-555B-423B-B7C0-3E92DEFA5A79	3D712314-6FDC-41C7-9CE1-5F9BB85929EE	TCGA-BG-A0M9-01A-21D-A101-02	HG19_Broad_variant	TCGA-BG-A0M9	TCGA-UCEC		s4603	Harvard Medical School	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6be2e	58cfa830e4b0c9d6adf6be2e	TCGA-BG-A0MS-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A0MS-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_7_rg.sorted	TCGA-BG-A0MS-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_7_rg.sorted.bam	76.64	1.97	0.15	58cfa830e4b0c9d6adf6be2e	TCGA-BG-A0MS-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MS-01A	A798A8CC-4E72-4A8C-9E20-74A14DEAFD12	Primary Tumor	Illumina HiSeq	71c1fd79-298f-43fd-82ba-a1a2228aaa51	Uterus	53.0	EF7F78EB-314B-4CF2-B45B-810C84C6AA7B	463D0533-A168-4F50-8EA9-7812D01B5115	TCGA-BG-A0MS-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0MS	TCGA-UCEC		s5392	Harvard Medical School	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6be6e	58cfa830e4b0c9d6adf6be6e	TCGA-BJ-A190-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BJ-A190-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_6_rg.sorted	TCGA-BJ-A190-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_6_rg.sorted.bam	53.09	1.95	0.16	58cfa830e4b0c9d6adf6be6e	TCGA-BJ-A190-01A-11D-A13U_120711_SN1120_0173_AC0WN6ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A190-01A	04FFF86A-B6F5-4900-9E37-C1F0B881B160	Primary Tumor	Illumina HiSeq	a9f1f6de-8f02-48c6-a9e2-6cef21cd8438	Thyroid	55.0	2EB89D79-861E-41C2-BDD5-6F16D2A84B25	42FE4D84-B54D-42B8-81F8-92191723D057	TCGA-BJ-A190-01A-11D-A13U-02	HG19_Broad_variant	TCGA-BJ-A190	TCGA-THCA		s12234	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A13U-02	True
S13722.58cfa830e4b0c9d6adf6c16a	58cfa830e4b0c9d6adf6c16a	TCGA-BH-A0HK-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BH-A0HK-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_1_rg.sorted	TCGA-BH-A0HK-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_1_rg.sorted.bam	22.97	1.94	0.13	58cfa830e4b0c9d6adf6c16a	TCGA-BH-A0HK-01A-11D-A060_130807_SN590_0236_BC291KACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0HK-01A	24334AC1-28A3-4B61-B590-3F51E375B247	Primary Tumor	Illumina HiSeq	c4f3a9e0-4b45-4e06-9320-171c27d9e28d	Breast	81.0	8835B20E-9343-4266-A356-E0343C657130	B96AE5EC-0139-4B8D-8136-B5BFA7AF8987	TCGA-BH-A0HK-01A-11D-A060-02	HG19_Broad_variant	TCGA-BH-A0HK	TCGA-BRCA		s5642	Harvard Medical School	University of Pittsburgh		NO	T2	N1	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	True
S13722.58cfa830e4b0c9d6adf6c1db	58cfa830e4b0c9d6adf6c1db	TCGA-BB-4224-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BB-4224-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_1_rg.sorted	TCGA-BB-4224-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_1_rg.sorted.bam	16.7	1.9	0.13	58cfa830e4b0c9d6adf6c1db	TCGA-BB-4224-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BB-4224-01A	58574E35-8A30-4207-B127-59FFF7C87A43	Primary Tumor	Illumina HiSeq	44a7ef3f-57df-49e2-80b9-1f0dca51067f	Head and Neck	52.0	077ACD68-8C30-41A6-BB7E-5B014866B807	E2FF93EB-AE22-4C6B-B4D5-181B9393BC64	TCGA-BB-4224-01A-01D-1431-02	HG19_Broad_variant	TCGA-BB-4224	TCGA-HNSC		s15876	Harvard Medical School	Johns Hopkins	United States	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True
S13722.58cfa831e4b0c9d6adf6c3cb	58cfa831e4b0c9d6adf6c3cb	TCGA-C5-A3HD-01B-11D-A20X_140117_SN590_0245_AC371LACXX_s_1_rg.sorted.filtered.	WGS	TCGA-C5-A3HD-01B-11D-A20X_140117_SN590_0245_AC371LACXX_s_1_rg.sorted	TCGA-C5-A3HD-01B-11D-A20X_140117_SN590_0245_AC371LACXX_s_1_rg.sorted.bam	60.19		0.16	58cfa831e4b0c9d6adf6c3cb	TCGA-C5-A3HD-01B-11D-A20X_140117_SN590_0245_AC371LACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A3HD-01B	12427B02-6E3F-461C-B271-6AB230F628E7	Primary Tumor	Illumina HiSeq	475d850b-49e8-4f15-9f59-8d65bf9cf22d	Cervix	51.0	56AA88C8-AF6D-42BE-8672-074476F6575A	03576AE9-4222-48C3-A428-D85AEC400BD6	TCGA-C5-A3HD-01B-11D-A20X-26	HG19_Broad_variant	TCGA-C5-A3HD	TCGA-CESC		s1171	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO			Cervical Squamous Cell Carcinoma		A20X-26	True
S13722.58cfa831e4b0c9d6adf6c522	58cfa831e4b0c9d6adf6c522	TCGA-CN-4731-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-4731-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_7_rg.sorted	TCGA-CN-4731-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_7_rg.sorted.bam	31.7	1.9	0.14	58cfa831e4b0c9d6adf6c522	TCGA-CN-4731-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4731-01A	50E25A4B-2EB2-4770-9A2D-8922A1E0AB56	Primary Tumor	Illumina HiSeq	50e66965-d2d5-49dd-a113-8b1751d6f7b7	Head and Neck	63.0	CD4E9D8C-B1F9-486A-ADCD-BD4B77A50326	981D992B-B92F-4E42-AA43-FC48068648A8	TCGA-CN-4731-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4731	TCGA-HNSC		s15753	Harvard Medical School	University of Pittsburgh		NO	T4a	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True
S13722.58cfa831e4b0c9d6adf6c60c	58cfa831e4b0c9d6adf6c60c	TCGA-CN-5360-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CN-5360-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_1_rg.sorted	TCGA-CN-5360-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_1_rg.sorted.bam	449.7	1.9	0.15	58cfa831e4b0c9d6adf6c60c	TCGA-CN-5360-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5360-01A	5793879B-F663-4A10-9BD9-1ACD2E189650	Primary Tumor	Illumina HiSeq	56414402-7420-42b7-a93d-3d1f88308155	Head and Neck	68.0	0C00768E-8B13-4B8E-80FC-B344740845F1	7EE362C2-86AD-462C-B478-21255D96ED90	TCGA-CN-5360-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5360	TCGA-HNSC		s15883	Harvard Medical School	University of Pittsburgh		NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True
S13722.58cfa831e4b0c9d6adf6c718	58cfa831e4b0c9d6adf6c718	TCGA-D7-6528-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D7-6528-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_5_rg.sorted	TCGA-D7-6528-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_5_rg.sorted.bam	303.4	1.9	0.15	58cfa831e4b0c9d6adf6c718	TCGA-D7-6528-01A-11D-1798_130218_SN208_0453_AC1T26ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6528-01A	35496E4E-598F-4FFC-B11E-8EDAEB676079	Primary Tumor	Illumina HiSeq	478ea84f-df8f-4d1b-a7da-ab1ac7751e97	Stomach	70.0	DF817250-9A2C-42E8-AD90-0D9E13FE37B3	7DA37A25-E2DE-4193-AD71-2182B6DA5C26	TCGA-D7-6528-01A-11D-1798-02	HG19_Broad_variant	TCGA-D7-6528	TCGA-STAD		s14562	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IB	1798-02	True
S13722.58cfa831e4b0c9d6adf6c6c2	58cfa831e4b0c9d6adf6c6c2	TCGA-CN-4740-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-4740-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_5_rg.sorted	TCGA-CN-4740-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_5_rg.sorted.bam	78.7	1.9	0.14	58cfa831e4b0c9d6adf6c6c2	TCGA-CN-4740-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4740-01A	E37C83DC-C2C4-4E5F-A57B-39FFCF9AA3CF	Primary Tumor	Illumina HiSeq	c1580763-a5d9-4753-b80c-f8d5498a7494	Head and Neck	79.0	2311DEEC-8DBC-4449-BE09-FCD4E3BAFD87	9DD678DF-BCE7-46C2-8454-3DE815FB85ED	TCGA-CN-4740-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4740	TCGA-HNSC		s15884	Harvard Medical School	University of Pittsburgh		NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True
S13722.58cfa831e4b0c9d6adf6c774	58cfa831e4b0c9d6adf6c774	TCGA-D1-A174-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D1-A174-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_3_rg.sorted	TCGA-D1-A174-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_3_rg.sorted.bam	124.95	1.37	0.15	58cfa831e4b0c9d6adf6c774	TCGA-D1-A174-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A174-01A	FC7315B0-9F48-4206-B197-2268C0518EB4	Primary Tumor	Illumina HiSeq	6ec3f35d-55a7-439a-b179-8a4aebcab751	Uterus	51.0	AD5A9CB6-B3F9-4651-B6D1-13C78010BD88	D661CFB9-248A-49E6-B0DB-865CA257E8DC	TCGA-D1-A174-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A174	TCGA-UCEC		s4614	Harvard Medical School	Mayo Clinic		NO			Endometrioid endometrial adenocarcinoma		A12F-02	True
S13722.58cfa831e4b0c9d6adf6c778	58cfa831e4b0c9d6adf6c778	TCGA-D1-A17D-01A-12D-A12F_120522_SN208_0301_BC0VNWACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D1-A17D-01A-12D-A12F_120522_SN208_0301_BC0VNWACXX_s_4_rg.sorted	TCGA-D1-A17D-01A-12D-A12F_120522_SN208_0301_BC0VNWACXX_s_4_rg.sorted.bam	99.41	2.0	0.15	58cfa831e4b0c9d6adf6c778	TCGA-D1-A17D-01A-12D-A12F_120522_SN208_0301_BC0VNWACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A17D-01A	7DDEDDD1-B2AD-425F-94A2-9C476B959F2A	Primary Tumor	Illumina HiSeq	9d6f1593-568e-447d-b4f7-10048102ce8f	Uterus	58.0	9EC5A25B-9CE1-4FDE-9341-13DA39BC74B0	0F6ECDCA-5659-426A-8DAC-3211183597BD	TCGA-D1-A17D-01A-12D-A12F-02	HG19_Broad_variant	TCGA-D1-A17D	TCGA-UCEC		s4443	Harvard Medical School	Mayo Clinic		NO			Endometrioid endometrial adenocarcinoma		A12F-02	True
S13722.58cfa831e4b0c9d6adf6c7e5	58cfa831e4b0c9d6adf6c7e5	TCGA-D1-A169-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D1-A169-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_1_rg.sorted	TCGA-D1-A169-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_1_rg.sorted.bam	68.97	1.95	0.15	58cfa831e4b0c9d6adf6c7e5	TCGA-D1-A169-01A-11D-A12F_120522_SN208_0301_BC0VNWACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A169-01A	9A599F57-0E8D-4E1F-A181-791F5FDEADB7	Primary Tumor	Illumina HiSeq	43a5a914-7913-4e5e-9d2f-42fcec7bab2f	Uterus	63.0	9B36F264-55C3-4E08-A151-4B356871520C	B3A7C237-92C3-448A-A87E-8C8B1061A79F	TCGA-D1-A169-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A169	TCGA-UCEC		s4796	Harvard Medical School	Mayo Clinic		NO			Endometrioid endometrial adenocarcinoma		A12F-02	True
S13722.58cfa831e4b0c9d6adf6c988	58cfa831e4b0c9d6adf6c988	TCGA-DJ-A1QE-01A-21D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DJ-A1QE-01A-21D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_2_rg.sorted	TCGA-DJ-A1QE-01A-21D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_2_rg.sorted.bam	36.64	2.05	0.17	58cfa831e4b0c9d6adf6c988	TCGA-DJ-A1QE-01A-21D-A14U_120711_SN1120_0173_AC0WN6ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE		Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QE-01A	DCCBA97D-4E81-42FB-93B3-90BE68A034FB	Primary Tumor	Illumina HiSeq	b2380599-45dd-48d5-840c-f6e358db7169	Thyroid	62.0	E8BF40C4-8F4D-4032-B18B-D61A87A2DD1A	FB93D33F-510B-45BD-8E70-8FD3A0EA5DBE	TCGA-DJ-A1QE-01A-21D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QE	TCGA-THCA		s12635	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A14U-02	True
S13722.58cfa831e4b0c9d6adf6c9a0	58cfa831e4b0c9d6adf6c9a0	TCGA-DO-A1K0-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DO-A1K0-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_3_rg.sorted	TCGA-DO-A1K0-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_3_rg.sorted.bam	80.19	1.78	0.16	58cfa831e4b0c9d6adf6c9a0	TCGA-DO-A1K0-01A-11D-A13U_120706_SN1222_0123_BD1488ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DO-A1K0-01A	B7A01148-5BAB-4268-986A-A9CF7BCA967F	Primary Tumor	Illumina HiSeq	52d6a725-e64a-4e5b-88cb-c4845dc97057	Thyroid	30.0	C25AED9B-A1B7-48A9-8587-8D218F6A9562	7BC99883-45C3-4ADF-8761-40B4836552F2	TCGA-DO-A1K0-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DO-A1K0	TCGA-THCA		s12245	Harvard Medical School	Medical College of Georgia	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	True
S13722.58cfa831e4b0c9d6adf6c9b4	58cfa831e4b0c9d6adf6c9b4	TCGA-DJ-A13S-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DJ-A13S-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_6_rg.sorted	TCGA-DJ-A13S-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_6_rg.sorted.bam	58.89	1.97	0.13	58cfa831e4b0c9d6adf6c9b4	TCGA-DJ-A13S-01A-11D-A10R_120711_SN1120_0174_BD13R2ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13S-01A	8AA99F35-C644-4F91-9EFF-A5D3FAE758B0	Primary Tumor	Illumina HiSeq	a19c2149-887d-4a36-992f-2a0ebb46072c	Thyroid	19.0	17952842-3447-4A38-90F4-D25B90C3233A	3C630C3D-343D-4F9F-8067-43B66466D382	TCGA-DJ-A13S-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13S	TCGA-THCA		s12239	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A10R-02	True
S13722.58cfa831e4b0c9d6adf6cad2	58cfa831e4b0c9d6adf6cad2	TCGA-DI-A1BU-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DI-A1BU-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_7_rg.sorted	TCGA-DI-A1BU-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_7_rg.sorted.bam	88.64	1.98	0.17	58cfa831e4b0c9d6adf6cad2	TCGA-DI-A1BU-01A-11D-A133_120511_SN1120_0141_BC0VK9ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-DI-A1BU-01A	53245616-E095-4616-89BB-6062669122DA	Primary Tumor	Illumina HiSeq	1a6e5cca-d65a-40c4-b8ce-b7b282493459	Uterus	55.0	241BFB1F-5CF8-458D-B335-18BABF507E85	085C72D3-C295-4D9B-A5CC-08F76CFF2284	TCGA-DI-A1BU-01A-11D-A133-02	HG19_Broad_variant	TCGA-DI-A1BU	TCGA-UCEC		s4805	Harvard Medical School	MD Anderson	United States	NO			Mixed serous and endometrioid		A133-02	False
S13722.58cfa831e4b0c9d6adf6cb1a	58cfa831e4b0c9d6adf6cb1a	TCGA-E7-A3X6-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-E7-A3X6-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_5_rg.sorted	TCGA-E7-A3X6-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_5_rg.sorted.bam	39.5		0.15	58cfa831e4b0c9d6adf6cb1a	TCGA-E7-A3X6-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-E7-A3X6-01A	C871EA6B-FBD2-4E6F-AB29-F43F6E3DDCBB	Primary Tumor	Illumina HiSeq	548e206a-eaec-49d3-a405-664cf76d0e16	Bladder	70.0	554AE735-9991-4CB3-AFE8-4951490BD709	AE6DC0A6-7405-44C2-886F-E10BAD336295	TCGA-E7-A3X6-01A-12D-A233-26	HG19_Broad_variant	TCGA-E7-A3X6	TCGA-BLCA		s3291	MD Anderson - Institute for Applied Cancer Science	Asterand	Ukraine	NO	T2	NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A233-26	True
S13722.58cfa831e4b0c9d6adf6cc16	58cfa831e4b0c9d6adf6cc16	TCGA-DU-7294-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DU-7294-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_3_rg.sorted	TCGA-DU-7294-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_3_rg.sorted.bam	62.7		0.17	58cfa831e4b0c9d6adf6cc16	TCGA-DU-7294-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7294-01A	3F6FFB08-32A9-4555-BFD1-243B7F526105	Primary Tumor	Illumina HiSeq	2df0ab9f-8d32-40e9-883d-f5afad653272	Brain	53.0	C2D0A3C8-2354-475C-9027-5DF9523391CE	E6552DAE-BDEA-4945-9BA9-9C88D34CEBBC	TCGA-DU-7294-01A-11D-2022-02	HG19_Broad_variant	TCGA-DU-7294	TCGA-LGG		s8362	Harvard Medical School	Henry Ford Hospital	United States	NO			Oligodendroglioma		2022-02	True
S13722.58cfa831e4b0c9d6adf6cbd0	58cfa831e4b0c9d6adf6cbd0	TCGA-EJ-7125-01A-11D-1957_130221_SN1120_0239_BD1V59ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-7125-01A-11D-1957_130221_SN1120_0239_BD1V59ACXX_s_7_rg.sorted	TCGA-EJ-7125-01A-11D-1957_130221_SN1120_0239_BD1V59ACXX_s_7_rg.sorted.bam	118.7		0.15	58cfa831e4b0c9d6adf6cbd0	TCGA-EJ-7125-01A-11D-1957_130221_SN1120_0239_BD1V59ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7125-01A	ACA312AB-6DBD-4183-8B22-8F37834F3426	Primary Tumor	Illumina HiSeq	c476525e-5147-4afb-bed0-f9ad34226240	Prostate	44.0	08E17DE6-FE0D-4FF0-B588-1CF1AB03F594	4BAD4379-B8AB-4D28-968E-5729602757EB	TCGA-EJ-7125-01A-11D-1957-02	HG19_Broad_variant	TCGA-EJ-7125	TCGA-PRAD		s3442	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1957-02	True
S13722.58cfa831e4b0c9d6adf6cd1e	58cfa831e4b0c9d6adf6cd1e	TCGA-EX-A1H6-01B-11D-A232_140124_SN208_0506_BC2PD5ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EX-A1H6-01B-11D-A232_140124_SN208_0506_BC2PD5ACXX_s_3_rg.sorted	TCGA-EX-A1H6-01B-11D-A232_140124_SN208_0506_BC2PD5ACXX_s_3_rg.sorted.bam	47.39		0.16	58cfa831e4b0c9d6adf6cd1e	TCGA-EX-A1H6-01B-11D-A232_140124_SN208_0506_BC2PD5ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EX-A1H6-01B	1FE594D9-4240-49EE-8AFD-C7D16A377181	Primary Tumor	Illumina HiSeq	32948425-770d-4a87-8c3d-ade77ab0391d	Cervix	38.0	FE018D31-EEE8-4335-96A1-95ECEABFADF1	DD730721-CEC0-4034-B18D-588A200D4D76	TCGA-EX-A1H6-01B-11D-A232-26	HG19_Broad_variant	TCGA-EX-A1H6	TCGA-CESC		s1197	MD Anderson - Institute for Applied Cancer Science	University of North Carolina	United States	NO	T1b1	N0	Endocervical Type of Adenocarcinoma		A232-26	True
S13722.58cfa831e4b0c9d6adf6cd39	58cfa831e4b0c9d6adf6cd39	TCGA-ET-A25L-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-ET-A25L-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_6_rg.sorted	TCGA-ET-A25L-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_6_rg.sorted.bam	63.41	1.93	0.17	58cfa831e4b0c9d6adf6cd39	TCGA-ET-A25L-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25L-01A	4481D84D-109E-44A0-BCB4-E6E61BDCE796	Primary Tumor	Illumina HiSeq	bd558097-490f-4ee3-af4a-093fd4aebaf1	Thyroid	52.0	7D90939F-BAB7-4A39-8D57-79540142BB63	3490DBDC-8BFC-476F-BC1F-2D142365D9A2	TCGA-ET-A25L-01A-11D-A16N-02	HG19_Broad_variant	TCGA-ET-A25L	TCGA-THCA		s12524	Harvard Medical School	Johns Hopkins	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage IVA	A16N-02	True
S13722.58cfa831e4b0c9d6adf6cd64	58cfa831e4b0c9d6adf6cd64	TCGA-FD-A3SS-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FD-A3SS-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_1_rg.sorted	TCGA-FD-A3SS-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_1_rg.sorted.bam	37.16		0.15	58cfa831e4b0c9d6adf6cd64	TCGA-FD-A3SS-01A-12D-A233_120905_SN1120_0187_AD1E4NACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SS-01A	7B98B829-FDC7-4719-BEE9-C83F6154019C	Primary Tumor	Illumina HiSeq	23aab0ed-a2ae-43db-9050-527db1729aa5	Bladder	66.0	015E6B08-AB3C-4D1D-99E4-77B5E10BD7FC	315B09D3-D014-4EF1-9CAC-AD5F63F6024A	TCGA-FD-A3SS-01A-12D-A233-26	HG19_Broad_variant	TCGA-FD-A3SS	TCGA-BLCA		s3302	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T4	N3	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	True
S13722.58cfa831e4b0c9d6adf6cd90	58cfa831e4b0c9d6adf6cd90	TCGA-FE-A3PA-01A-12D-A221_120611_SN1222_0114_AC0WL3ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FE-A3PA-01A-12D-A221_120611_SN1222_0114_AC0WL3ACXX_s_1_rg.sorted	TCGA-FE-A3PA-01A-12D-A221_120611_SN1222_0114_AC0WL3ACXX_s_1_rg.sorted.bam	44.72		0.15	58cfa831e4b0c9d6adf6cd90	TCGA-FE-A3PA-01A-12D-A221_120611_SN1222_0114_AC0WL3ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A3PA-01A	10BDAFBB-831D-48B5-B9A3-AD374FC50235	Primary Tumor	Illumina HiSeq	0d67cded-ff5a-4b7c-bc1e-2bda8ee44700	Thyroid	16.0	D37BED2A-BF63-43E0-91D0-6C95E4CA2D45	DBD2621E-9F39-45C6-B9AE-67873AECA03D	TCGA-FE-A3PA-01A-12D-A221-26	HG19_Broad_variant	TCGA-FE-A3PA	TCGA-THCA		s12760	MD Anderson - Institute for Applied Cancer Science	Ohio State University	United States	NO	T4	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A221-26	True
S13722.58cfa832e4b0c9d6adf6ceba	58cfa832e4b0c9d6adf6ceba	TCGA-FD-A3B4-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FD-A3B4-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_3_rg.sorted	TCGA-FD-A3B4-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_3_rg.sorted.bam	41.92		0.16	58cfa832e4b0c9d6adf6ceba	TCGA-FD-A3B4-01A-12D-A204_121002_SN1222_0155_BD1ERHACXX_s_3_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3B4-01A	899F8D52-4C3A-4371-90EB-1F106001EDDC	Primary Tumor	Illumina HiSeq	54b70ff2-6c53-438c-934a-97fe2837620e	Bladder	55.0	6895A68F-0EFD-4B0E-8CF2-9195833DBBA1	7E975842-6EB5-4D66-A2F1-7EA7E8E989FC	TCGA-FD-A3B4-01A-12D-A204-02	HG19_Broad_variant	TCGA-FD-A3B4	TCGA-BLCA		s3111	Harvard Medical School	BLN - University Of Chicago	United States	NO	T4a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A204-02	True
S13722.58cfa832e4b0c9d6adf6ce42	58cfa832e4b0c9d6adf6ce42	TCGA-ET-A25J-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-ET-A25J-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_1_rg.sorted	TCGA-ET-A25J-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_1_rg.sorted.bam	57.24	2.0	0.17	58cfa832e4b0c9d6adf6ce42	TCGA-ET-A25J-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25K-01A	2F9ED09D-2626-4C23-BA47-1850D36F812A	Primary Tumor	Illumina HiSeq	970a6dab-c1e4-4446-968a-4b37d1506eeb	Thyroid	36.0	343311B1-D586-4F92-9984-32AF1AFB1F62	663173D3-A9EE-4E73-8444-52F01727BE6D	TCGA-ET-A25K-01A-11D-A16N-02	HG19_Broad_variant	TCGA-ET-A25K	TCGA-THCA		s12757	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True
S13722.58cfa832e4b0c9d6adf6cefe	58cfa832e4b0c9d6adf6cefe	TCGA-H2-A3RI-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_2_rg.sorted.filtered.	WGS	TCGA-H2-A3RI-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_2_rg.sorted	TCGA-H2-A3RI-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_2_rg.sorted.bam	58.31		0.15	58cfa832e4b0c9d6adf6cefe	TCGA-H2-A3RI-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-H2-A3RI-01A	BF193C4F-FBAC-41BC-B1AF-19B6CE856F0F	Primary Tumor	Illumina HiSeq	24a690e4-62f0-4e09-bbb1-ec78dafcf3cd	Thyroid	29.0	EAAE1A05-7D7E-406A-A02B-282A8B66F95C	5E15CB1B-B0D3-4FB9-9B30-3AEBE4DFC96B	TCGA-H2-A3RI-01A-11D-A221-26	HG19_Broad_variant	TCGA-H2-A3RI	TCGA-THCA		s12259	MD Anderson - Institute for Applied Cancer Science	Christiana Healthcare	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	True
S13722.58cfa832e4b0c9d6adf6cf94	58cfa832e4b0c9d6adf6cf94	TCGA-FU-A3NI-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FU-A3NI-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_8_rg.sorted	TCGA-FU-A3NI-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_8_rg.sorted.bam	36.82		0.16	58cfa832e4b0c9d6adf6cf94	TCGA-FU-A3NI-01A-11D-A245_140124_SN1440_0178_AC2PL6ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3NI-01A	DAC27C24-CDBF-4527-9214-178FDE3D098A	Primary Tumor	Illumina HiSeq	e3d152ec-0ab5-4fb6-b2ca-ecdb79e43095	Cervix	45.0	C75C6FD3-79EF-48B8-B3BD-D097EF2A73AD	90DC57B8-74B7-4FB0-9EE7-52A4264D395F	TCGA-FU-A3NI-01A-11D-A245-26	HG19_Broad_variant	TCGA-FU-A3NI	TCGA-CESC		s1204	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T1b1	N1	Cervical Squamous Cell Carcinoma		A245-26	True
S13722.58cfa832e4b0c9d6adf6cf97	58cfa832e4b0c9d6adf6cf97	TCGA-G9-6362-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G9-6362-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_3_rg.sorted	TCGA-G9-6362-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_3_rg.sorted.bam	385.4	1.8	0.13	58cfa832e4b0c9d6adf6cf97	TCGA-G9-6362-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6362-01A	F228EF91-ECFB-4D1E-8E6A-B43D2185270E	Primary Tumor	Illumina HiSeq	04834dec-1ae4-4a26-956a-f51c69d6c324	Prostate	57.0	1A626C6C-3DD9-4D87-BB93-CB2FEB82FBE8	A9B195C5-0441-4C98-8314-C50ECA082994	TCGA-G9-6362-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6362	TCGA-PRAD		s4149	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True
S13722.58cfa832e4b0c9d6adf6cfa8	58cfa832e4b0c9d6adf6cfa8	TCGA-GV-A3JV-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_1_rg.sorted.filtered.	WGS	TCGA-GV-A3JV-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_1_rg.sorted	TCGA-GV-A3JV-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_1_rg.sorted.bam	63.27		0.14	58cfa832e4b0c9d6adf6cfa8	TCGA-GV-A3JV-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3JV-01A	01EE41EF-1894-4408-9E96-A22A1F068190	Primary Tumor	Illumina HiSeq	8f626567-33e0-4b6a-974f-6b41b341c60e	Bladder	66.0	55072935-CD20-4355-897B-F60F77A18847	E5863D29-E61D-4EE2-B04E-FE61C9B9CA5E	TCGA-GV-A3JV-01A-11D-A221-26	HG19_Broad_variant	TCGA-GV-A3JV	TCGA-BLCA		s3308	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO	T3b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A221-26	True
S13722.58cfa832e4b0c9d6adf6d01a	58cfa832e4b0c9d6adf6d01a	TCGA-G9-6353-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_4_rg.sorted.filtered.	WGS	TCGA-G9-6353-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_4_rg.sorted	TCGA-G9-6353-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_4_rg.sorted.bam	144.7	1.9	0.15	58cfa832e4b0c9d6adf6d01a	TCGA-G9-6353-01A-11D-1957_130405_SN590_0222_BD21LGACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6353-01A	BCC94953-CE79-428E-99C1-632E42C1B9BC	Primary Tumor	Illumina HiSeq	86ec03a4-f08e-474e-b887-c5e06822b414	Prostate	58.0	4CBA0BA5-58C3-455C-9CD5-7D9428D27F8C	758712E3-95F1-4BB5-A83A-D01C4844122D	TCGA-G9-6353-01A-11D-1957-02	HG19_Broad_variant	TCGA-G9-6353	TCGA-PRAD		s3970	Harvard Medical School	Roswell Park	United States	NO	T3a		Prostate Adenocarcinoma Acinar Type		1957-02	True
S13722.58cfa832e4b0c9d6adf6d010	58cfa832e4b0c9d6adf6d010	TCGA-G9-6338-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_5_rg.sorted.filtered.	WGS	TCGA-G9-6338-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_5_rg.sorted	TCGA-G9-6338-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_5_rg.sorted.bam	218.7		0.16	58cfa832e4b0c9d6adf6d010	TCGA-G9-6338-01A-12D-1957_130222_SN1222_0174_BC1RNEACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6338-01A	2C48B1BF-4E49-4869-874B-F08787FA04B5	Primary Tumor	Illumina HiSeq	3c22fc65-7067-4d13-a148-5e953f3a7097	Prostate	61.0	21FC7F0F-FCB3-422F-AA73-0E09FD06DA35	BF3CC12E-1835-40C8-B29F-C685B828AB18	TCGA-G9-6338-01A-12D-1957-02	HG19_Broad_variant	TCGA-G9-6338	TCGA-PRAD		s3451	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1957-02	True
S13722.58cfa832e4b0c9d6adf6d020	58cfa832e4b0c9d6adf6d020	TCGA-GV-A3JZ-01A-11D-A21C_120830_SN590_0178_AD143RACXX_s_7_rg.sorted.filtered.	WGS	TCGA-GV-A3JZ-01A-11D-A21C_120830_SN590_0178_AD143RACXX_s_7_rg.sorted	TCGA-GV-A3JZ-01A-11D-A21C_120830_SN590_0178_AD143RACXX_s_7_rg.sorted.bam	63.92		0.14	58cfa832e4b0c9d6adf6d020	TCGA-GV-A3JZ-01A-11D-A21C_120830_SN590_0178_AD143RACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3JZ-01A	9CC92795-7A24-4875-87F0-3EFCCBFCC970	Primary Tumor	Illumina HiSeq	d4d5d34c-9665-4291-a3d6-14bc9b48f2fa	Bladder	55.0	449E18FB-CBC0-4365-AEEC-EDC6A6B276BD	5A651606-6D92-445B-AA0B-B73CC9329402	TCGA-GV-A3JZ-01A-11D-A21C-26	HG19_Broad_variant	TCGA-GV-A3JZ	TCGA-BLCA		s2738	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO	T4a	N3	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A21C-26	True
S13722.58cfa832e4b0c9d6adf6d086	58cfa832e4b0c9d6adf6d086	TCGA-HC-7212-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HC-7212-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_4_rg.sorted	TCGA-HC-7212-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_4_rg.sorted.bam	333.3		0.15	58cfa832e4b0c9d6adf6d086	TCGA-HC-7212-01A-11D-2111_130517_SN590_0230_AD24B4ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7212-01A	907B64D6-A26A-4092-A247-AC9AF444D1C7	Primary Tumor	Illumina HiSeq	4ff229a3-6637-4fdc-a3b6-079e28773187	Prostate	56.0	92888479-B534-432D-8F70-CAE857E0074B	9BF25BFC-4E07-4979-9169-F6CDADDB3A90	TCGA-HC-7212-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7212	TCGA-PRAD		s4153	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa832e4b0c9d6adf6d155	58cfa832e4b0c9d6adf6d155	TCGA-G9-6361-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_6_rg.sorted.filtered.	WGS	TCGA-G9-6361-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_6_rg.sorted	TCGA-G9-6361-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_6_rg.sorted.bam	19.7	1.9	0.15	58cfa832e4b0c9d6adf6d155	TCGA-G9-6361-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6361-01A	71D14304-CCB0-4A4C-B935-8C014CA75FD0	Primary Tumor	Illumina HiSeq	4fc66c05-8bf3-4a56-8bfe-6d20c3195258	Prostate	61.0	A369C190-964E-471C-878A-D8FADE7CF992	54B8E171-9BCC-469D-9315-114FE2C57DC1	TCGA-G9-6361-01A-21D-1957-02	HG19_Broad_variant	TCGA-G9-6361	TCGA-PRAD		s3795	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1957-02	True
S13722.58cfa832e4b0c9d6adf6d186	58cfa832e4b0c9d6adf6d186	TCGA-IR-A3L7-01A-21D-A20X_140117_SN590_0245_AC371LACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IR-A3L7-01A-21D-A20X_140117_SN590_0245_AC371LACXX_s_3_rg.sorted	TCGA-IR-A3L7-01A-21D-A20X_140117_SN590_0245_AC371LACXX_s_3_rg.sorted.bam	59.39		0.15	58cfa832e4b0c9d6adf6d186	TCGA-IR-A3L7-01A-21D-A20X_140117_SN590_0245_AC371LACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3L7-01A	66229DD6-C771-4455-A90C-C66FB40CF7FE	Primary Tumor	Illumina HiSeq	c50ab1fa-015d-4420-a67f-b023a5377b16	Cervix	37.0	F571523C-758C-4F34-A44B-F8E6A3EEBE0F	27168C7B-D67E-4B11-B5BA-A79FB523400B	TCGA-IR-A3L7-01A-21D-A20X-26	HG19_Broad_variant	TCGA-IR-A3L7	TCGA-CESC		s1211	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b1	N0	Cervical Squamous Cell Carcinoma		A20X-26	True
S13722.58cfa832e4b0c9d6adf6d40a	58cfa832e4b0c9d6adf6d40a	TCGA-V4-A9F3-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-V4-A9F3-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_3_rg.sorted	TCGA-V4-A9F3-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_3_rg.sorted.bam	49.28		0.16	58cfa832e4b0c9d6adf6d40a	TCGA-V4-A9F3-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F3-01A	E21D8018-8FE9-4C92-8B36-28D7D3F7DF2B	Primary Tumor	Illumina HiSeq	cae118e4-484b-45f4-b225-3d7297583648	Eye	49.0	6805D6DB-775C-4817-9F1B-5BE44AE2DA45	395ECE1C-9831-48BF-A933-A4A94566CD9D	TCGA-V4-A9F3-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F3	TCGA-UVM		s229	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d576	58cfa832e4b0c9d6adf6d576	TCGA-V4-A9EZ-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_3_rg.sorted.filtered.	WGS	TCGA-V4-A9EZ-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_3_rg.sorted	TCGA-V4-A9EZ-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_3_rg.sorted.bam	34.26		0.16	58cfa832e4b0c9d6adf6d576	TCGA-V4-A9EZ-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EZ-01A	39E494BC-7710-4F9F-98B0-0F509F7AEF1A	Primary Tumor	Illumina HiSeq	5c8725d3-7d4e-4fa4-9626-127c91f5ea5c	Eye	78.0	9FEE606B-30E8-4BD6-B4C3-E21EFE64870C	6C22A928-CD61-4D62-B401-A4BE19418177	TCGA-V4-A9EZ-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EZ	TCGA-UVM		s225	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0		Stage IIB	A40D-26	True
S13722.58cfa830e4b0c9d6adf6bc0a	58cfa830e4b0c9d6adf6bc0a	TCGA-A5-A0GV-01A-31D-A043_120214_SN590_0139_BC0DYEACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0GV-01A-31D-A043_120214_SN590_0139_BC0DYEACXX_s_3_rg.sorted	TCGA-A5-A0GV-01A-31D-A043_120214_SN590_0139_BC0DYEACXX_s_3_rg.sorted.bam	42.49	2.13	0.16	58cfa830e4b0c9d6adf6bc0a	TCGA-A5-A0GV-01A-31D-A043_120214_SN590_0139_BC0DYEACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GV-01A	5E3B981E-73FE-4CC9-8C89-B420E8E2F426	Primary Tumor	Illumina HiSeq	c99f6cb7-44cc-4045-a0f6-4fec580e964c	Uterus	67.0	339926E1-61E6-4256-A808-F931AA2C17D2	721D7961-15F0-4A52-8D2C-885278D3B579	TCGA-A5-A0GV-01A-31D-A043-02	HG19_Broad_variant	TCGA-A5-A0GV	TCGA-UCEC		s4987	Harvard Medical School	Cedars Sinai		NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa831e4b0c9d6adf6cd16	58cfa831e4b0c9d6adf6cd16	TCGA-FD-A3SL-01A-21D-A233_120830_SN208_0423_AC190AACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FD-A3SL-01A-21D-A233_120830_SN208_0423_AC190AACXX_s_3_rg.sorted	TCGA-FD-A3SL-01A-21D-A233_120830_SN208_0423_AC190AACXX_s_3_rg.sorted.bam	18.6		0.16	58cfa831e4b0c9d6adf6cd16	TCGA-FD-A3SL-01A-21D-A233_120830_SN208_0423_AC190AACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SL-01A	4570B6E2-D430-41CA-AAB1-CE4D14C36463	Primary Tumor	Illumina HiSeq	764ae567-a7b6-4d13-bef1-8cc55afb4524	Bladder	60.0	0A1E88E0-3593-40BA-86E5-751074885578	2BF89FED-C215-4893-BA35-2FE0C7DD5DD0	TCGA-FD-A3SL-01A-21D-A233-26	HG19_Broad_variant	TCGA-FD-A3SL	TCGA-BLCA		s2720	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T4a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	True
S13722.58cfa82fe4b0c9d6adf6b72a	58cfa82fe4b0c9d6adf6b72a	TCGA-49-6767-01A-11D-1853_120205_SN590_0136_BD0LRYACXX_s_7_rg.sorted.filtered.	WGS	TCGA-49-6767-01A-11D-1853_120205_SN590_0136_BD0LRYACXX_s_7_rg.sorted	TCGA-49-6767-01A-11D-1853_120205_SN590_0136_BD0LRYACXX_s_7_rg.sorted.bam	291.7	1.9	0.14	58cfa82fe4b0c9d6adf6b72a	TCGA-49-6767-01A-11D-1853_120205_SN590_0136_BD0LRYACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-49-6767-01A	6BFFE800-EC2B-4638-9333-97FE85DCD91C	Primary Tumor	Illumina HiSeq	759c1dd3-0f7d-4ba7-8c8e-c276faf0255b	Lung	46.0	708A8742-F6D6-411D-9340-2C6C25885D22	FBCE84D6-2880-45F5-BD6F-B079C33C353E	TCGA-49-6767-01A-11D-1853-02	HG19_Broad_variant	TCGA-49-6767	TCGA-LUAD		s11233	Harvard Medical School	Johns Hopkins	United States	NO	T3	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1853-02	True
S13722.58cfa830e4b0c9d6adf6bc46	58cfa830e4b0c9d6adf6bc46	TCGA-AO-A0JF-01A-11D-A060_130719_SN1120_0270_AC2CVRACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AO-A0JF-01A-11D-A060_130719_SN1120_0270_AC2CVRACXX_s_1_rg.sorted	TCGA-AO-A0JF-01A-11D-A060_130719_SN1120_0270_AC2CVRACXX_s_1_rg.sorted.bam	16.97	1.91	0.13	58cfa830e4b0c9d6adf6bc46	TCGA-AO-A0JF-01A-11D-A060_130719_SN1120_0270_AC2CVRACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A0JF-01A	F357FE19-5359-4662-8CE9-AA996132283B	Primary Tumor	Illumina HiSeq	031ab51d-07d0-4afe-a9dd-222889f5c32b	Breast	68.0	DDEE0B07-2771-40C7-BDDA-C1100958F0D8	BDAA1600-1B4F-4BBA-B4D6-A4D169B029D6	TCGA-AO-A0JF-01A-11D-A060-02	HG19_Broad_variant	TCGA-AO-A0JF	TCGA-BRCA		s5491	Harvard Medical School	MSKCC		NO	T1c	N1a	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	True
S13722.58cfa830e4b0c9d6adf6bcb2	58cfa830e4b0c9d6adf6bcb2	TCGA-AZ-4684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	275.02	1.9	0.15	58cfa830e4b0c9d6adf6bcb2	TCGA-AZ-4684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4684-01A	CAC80259-3A26-4A99-B0D3-13454068E6ED	Primary Tumor	Illumina HiSeq	bab439b0-f1d3-41c2-98dd-a660818851fe	Colorectal	49.0	37AD61EA-96D1-40F1-B77A-56408E4243EA	6731F782-4435-497F-9626-C0199DAE8A8A	TCGA-AZ-4684-01A-01D-1405-02	HG18	TCGA-AZ-4684	TCGA-COAD		s13391	Harvard Medical School	University of Pittsburgh		NO	T3	N2	Colon Adenocarcinoma	Stage IVA	1405-02	True
S13722.58cfa830e4b0c9d6adf6be13	58cfa830e4b0c9d6adf6be13	TCGA-BH-A0W5-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BH-A0W5-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_3_rg.sorted	TCGA-BH-A0W5-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_3_rg.sorted.bam	55.92	1.91	0.16	58cfa830e4b0c9d6adf6be13	TCGA-BH-A0W5-01A-11D-A106_130719_SN1120_0270_AC2CVRACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0W5-01A	DA9C10EA-C13F-4D88-8B94-A0CBC106D036	Primary Tumor	Illumina HiSeq	eeccc516-2d3d-4f41-a324-c90f92a6f944	Breast	77.0	050E66BB-438A-49D5-A005-7967A006B3F0	6C8B3A70-CD58-4BFC-9418-54182588CFCB	TCGA-BH-A0W5-01A-11D-A106-02	HG19_Broad_variant	TCGA-BH-A0W5	TCGA-BRCA		s5803	Harvard Medical School	University of Pittsburgh		NO	T1c	N1a	Infiltrating Ductal Carcinoma	Stage IIA	A106-02	False
S13722.58cfa830e4b0c9d6adf6bf16	58cfa830e4b0c9d6adf6bf16	TCGA-BR-4257-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-4257-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_3_rg.sorted	TCGA-BR-4257-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_3_rg.sorted.bam	106.9	1.9	0.16	58cfa830e4b0c9d6adf6bf16	TCGA-BR-4257-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4257-01A	DA112431-5579-4FD1-A230-9144B359B0E9	Primary Tumor	Illumina HiSeq	5e38d8b4-97fb-407a-ab06-2f002456472d	Stomach	79.0	97B44B05-97EB-486C-94DB-42838831DE0B	465E5E4D-A801-4BBC-9E1C-004C7718571F	TCGA-BR-4257-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4257	TCGA-STAD		s15048	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1128-02	True
S13722.58cfa830e4b0c9d6adf6bf3c	58cfa830e4b0c9d6adf6bf3c	TCGA-BR-4256-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4256-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_1_rg.sorted	TCGA-BR-4256-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_1_rg.sorted.bam	67.9	1.9	0.15	58cfa830e4b0c9d6adf6bf3c	TCGA-BR-4256-01A-01D-1128_130110_SN1222_0167_AC1JPDACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4256-01A	7B0D69CA-13A6-46E0-839C-E433BBEDE3AD	Primary Tumor	Illumina HiSeq	6e990147-2463-4d38-a785-6c76ae1dbc25	Stomach	80.0	61C7AAB0-51D9-4706-A37C-D5058007DAF1	30AF7950-11F7-43BF-9A1D-98A57F416397	TCGA-BR-4256-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4256	TCGA-STAD		s14396	Harvard Medical School	Asterand	Russia	NO	TX	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1128-02	True
S13722.58cfa830e4b0c9d6adf6bf72	58cfa830e4b0c9d6adf6bf72	TCGA-BR-4363-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-4363-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_7_rg.sorted	TCGA-BR-4363-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_7_rg.sorted.bam	264.2	1.9	0.15	58cfa830e4b0c9d6adf6bf72	TCGA-BR-4363-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4363-01A	66BCA2F8-F269-454D-ABE2-CE51A0704645	Primary Tumor	Illumina HiSeq	ab5af808-6239-48fa-ba17-b80aa3fc5e14	Stomach	60.0	06EC6231-EE0E-4C15-AF9F-5B9E5BF557B8	D62228AE-B0AB-4C31-9FD7-F9D48B140CDC	TCGA-BR-4363-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4363	TCGA-STAD		s14528	Harvard Medical School	Asterand	Russia	NO	T3	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1154-02	True
S13722.58cfa830e4b0c9d6adf6bf80	58cfa830e4b0c9d6adf6bf80	TCGA-BR-6455-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BR-6455-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_8_rg.sorted	TCGA-BR-6455-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_8_rg.sorted.bam	324.7	1.9	0.15	58cfa830e4b0c9d6adf6bf80	TCGA-BR-6455-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6455-01A	75A29059-4705-4A55-BC3D-F5923B24B358	Primary Tumor	Illumina HiSeq	719ee3a5-cfe9-48cb-9e48-e11e49bd217c	Stomach	59.0	59BD0192-A50B-4672-A17F-4DF138F58988	6C038E7C-8B03-4AB6-A31A-00C3C6CE6204	TCGA-BR-6455-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6455	TCGA-STAD		s14470	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	True
S13722.58cfa830e4b0c9d6adf6bfa8	58cfa830e4b0c9d6adf6bfa8	TCGA-BR-6454-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BR-6454-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_6_rg.sorted	TCGA-BR-6454-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_6_rg.sorted.bam	478.4	1.9	0.14	58cfa830e4b0c9d6adf6bfa8	TCGA-BR-6454-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6454-01A	AC2CBCE4-4BA8-42C9-AC61-70F42995588E	Primary Tumor	Illumina HiSeq	e344c34d-da8c-4145-8a02-b9ae248ca3a3	Stomach	58.0	E7D94421-7A3B-4100-9CBF-1B1F2EC07737	6F5506E4-8375-4F62-8B85-64FD729C6136	TCGA-BR-6454-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6454	TCGA-STAD		s14619	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	True
S13722.58cfa830e4b0c9d6adf6c010	58cfa830e4b0c9d6adf6c010	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_7_rg.sorted.filtered.	WGS	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_7_rg.sorted	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_7_rg.sorted.bam	106.93	1.95	0.16	58cfa830e4b0c9d6adf6c010	TCGA-B5-A0K0-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K0-01A	29C8F468-5AC1-4D6C-8376-E36E6D246926	Primary Tumor	Illumina HiSeq	e5550bf6-3edf-480e-9dc5-6d590e837e5e	Uterus	48.0	11C43948-E7C9-4436-A654-82FA8033B625	3296C785-7C20-487D-BAEC-C66022E77E53	TCGA-B5-A0K0-01A-11D-A043-02	HG19_Broad_variant	TCGA-B5-A0K0	TCGA-UCEC		s4598	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa830e4b0c9d6adf6c106	58cfa830e4b0c9d6adf6c106	TCGA-BS-A0TJ-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BS-A0TJ-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_6_rg.sorted	TCGA-BS-A0TJ-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_6_rg.sorted.bam	96.9	1.86	0.16	58cfa830e4b0c9d6adf6c106	TCGA-BS-A0TJ-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_6_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TJ-01A	F74DA4C6-4291-46D2-ABD4-7D7F6EF03B00	Primary Tumor	Illumina HiSeq	d9625d1c-df48-4532-994d-9ab3a3c8f8b6	Uterus	59.0	AC35307B-AC7F-49FC-A237-5E03AB2E2276	C20AA17E-3866-4864-A4AE-44ACFD746221	TCGA-BS-A0TJ-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TJ	TCGA-UCEC		s5012	Harvard Medical School	University of Hawaii		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6c1ba	58cfa830e4b0c9d6adf6c1ba	TCGA-BS-A0UT-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BS-A0UT-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_4_rg.sorted	TCGA-BS-A0UT-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_4_rg.sorted.bam	65.26	1.97	0.13	58cfa830e4b0c9d6adf6c1ba	TCGA-BS-A0UT-01A-11D-A101_120407_SN590_0151_BC0KKJACXX_s_4_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0UT-01A	E2B1D0DE-5221-44A1-8FAD-9708A3CADA14	Primary Tumor	Illumina HiSeq	ca5a88b7-6801-435a-aeef-b9ca9d963c17	Uterus	62.0	824D0DBC-293F-4893-A68C-24DEDD437EA5	12674687-D555-40DB-ACC9-7638F85D0661	TCGA-BS-A0UT-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0UT	TCGA-UCEC		s4608	Harvard Medical School	University of Hawaii		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6c13a	58cfa830e4b0c9d6adf6c13a	TCGA-BS-A0U8-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BS-A0U8-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_8_rg.sorted	TCGA-BS-A0U8-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_8_rg.sorted.bam	116.56	1.88	0.15	58cfa830e4b0c9d6adf6c13a	TCGA-BS-A0U8-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0U8-01A	FB7475DF-30CC-4316-B9AC-37CBEEB6BA2B	Primary Tumor	Illumina HiSeq	44c78212-4860-4cf3-bd54-0e8e150cd0b1	Uterus	55.0	E3E23393-8597-4091-A343-CD544111C63B	89AB037F-B001-486F-A7EB-37AF8FBD0677	TCGA-BS-A0U8-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0U8	TCGA-UCEC		s4261	Harvard Medical School	University of Hawaii		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6c1b2	58cfa830e4b0c9d6adf6c1b2	TCGA-BG-A0MO-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A0MO-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_1_rg.sorted	TCGA-BG-A0MO-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_1_rg.sorted.bam	37.97	2.0	0.16	58cfa830e4b0c9d6adf6c1b2	TCGA-BG-A0MO-01A-11D-A043_120327_SN590_0148_BC0LM8ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MO-01A	734EF97F-807C-480E-8DF9-FEAF041032D2	Primary Tumor	Illumina HiSeq	e165d17d-a860-4111-9ae9-3fb19605cd21	Uterus	63.0	7582CBB9-42D3-496C-991D-D76BEA4C434C	9AD06738-F4A2-47A8-972E-BF8C817326A6	TCGA-BG-A0MO-01A-11D-A043-02	HG19_Broad_variant	TCGA-BG-A0MO	TCGA-UCEC		s5215	Harvard Medical School	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa830e4b0c9d6adf6c167	58cfa830e4b0c9d6adf6c167	TCGA-BJ-A0Z9-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z9-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_7_rg.sorted	TCGA-BJ-A0Z9-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_7_rg.sorted.bam	75.83	2.17	0.13	58cfa830e4b0c9d6adf6c167	TCGA-BJ-A0Z9-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z9-01A	86F9ECA0-D1EA-4375-A6BC-055E44B3198A	Primary Tumor	Illumina HiSeq	2fcaeaf0-3a03-4b60-975a-31ac8afe58aa	Thyroid	57.0	AA8578FE-EDB2-4137-B363-FEB2C27D475A	B761F912-BDF6-4F1F-8CD0-0AE9DFC57A59	TCGA-BJ-A0Z9-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0Z9	TCGA-THCA		s12099	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage III	A10R-02	True
S13722.58cfa830e4b0c9d6adf6c258	58cfa830e4b0c9d6adf6c258	TCGA-BJ-A0Z5-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A0Z5-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_1_rg.sorted	TCGA-BJ-A0Z5-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_1_rg.sorted.bam	95.63	2.11	0.16	58cfa830e4b0c9d6adf6c258	TCGA-BJ-A0Z5-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0Z5-01A	0FE3B19A-F5E4-497E-92DA-32FF6C77B066	Primary Tumor	Illumina HiSeq	84ec4e2b-c502-4348-b6ce-ae4a912e603c	Thyroid	58.0	D17746B4-EDEA-45DB-9AD1-5EE4973F007C	0AB5F114-C3CC-4DB4-87DF-1B339DDC54C2	TCGA-BJ-A0Z5-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0Z5	TCGA-THCA		s12352	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A10R-02	True
S13722.58cfa831e4b0c9d6adf6c4f9	58cfa831e4b0c9d6adf6c4f9	TCGA-BR-4369-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-4369-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_7_rg.sorted	TCGA-BR-4369-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_7_rg.sorted.bam	161.2	1.9	0.14	58cfa831e4b0c9d6adf6c4f9	TCGA-BR-4369-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4369-01A	FE9A5FCF-FF99-4DD1-8CC7-ED9F4B9D952B	Primary Tumor	Illumina HiSeq	cbba5183-9ada-4363-8f98-bf406b64f6d6	Stomach	75.0	39B440B3-F888-488A-A0CC-D7410DC73093	7220D8C0-DF8F-4A72-8338-795181BD8A47	TCGA-BR-4369-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4369	TCGA-STAD		s14966	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1154-02	True
S13722.58cfa831e4b0c9d6adf6c3a8	58cfa831e4b0c9d6adf6c3a8	TCGA-CD-5798-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CD-5798-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_3_rg.sorted	TCGA-CD-5798-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_3_rg.sorted.bam	44.0	1.9	0.13	58cfa831e4b0c9d6adf6c3a8	TCGA-CD-5798-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5798-01A	E42F45C6-FD00-44CF-A210-C8803DA326A1	Primary Tumor	Illumina HiSeq	5b2c6e2f-0b61-49e1-bef5-6d7408918d47	Stomach	82.0	72855D36-60BE-498F-96E9-0F10DC05B3A0	F9D13E07-70F4-48F3-B49E-06984C9E39EE	TCGA-CD-5798-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5798	TCGA-STAD		s15455	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage II	1598-02	True
S13722.58cfa831e4b0c9d6adf6c4fd	58cfa831e4b0c9d6adf6c4fd	TCGA-CD-5800-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CD-5800-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_5_rg.sorted	TCGA-CD-5800-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_5_rg.sorted.bam	389.0	2.0	0.17	58cfa831e4b0c9d6adf6c4fd	TCGA-CD-5800-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_5_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5800-01A	EEB114EA-ECEE-49EE-A162-B3B7BC0A60CD	Primary Tumor	Illumina HiSeq	e62fc018-7ddb-4d26-b187-0781aa2ba772	Stomach	51.0	B23E2D58-E61B-4B94-B4D8-407418351167	5EF4C8F7-B17A-48DA-AAF2-EF2FA32619A9	TCGA-CD-5800-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5800	TCGA-STAD		s14753	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach Intestinal Adenocarcinoma Papillary Type	Stage II	1598-02	True
S13722.58cfa830e4b0c9d6adf6c31b	58cfa830e4b0c9d6adf6c31b	TCGA-BS-A0TI-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BS-A0TI-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_5_rg.sorted	TCGA-BS-A0TI-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_5_rg.sorted.bam	82.74	1.89	0.17	58cfa830e4b0c9d6adf6c31b	TCGA-BS-A0TI-01A-11D-A101_120407_SN590_0152_AC0C7LACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BS-A0TI-01A	DF857BC6-FD6A-4713-BEF9-6EE1301E5FB1	Primary Tumor	Illumina HiSeq	ea49ec05-391f-4ccc-8dbf-11ec80154839	Uterus	64.0	2F52C850-8E70-4EAB-88F3-D35DC55E385B	E1707EDD-FAC5-4213-BA50-2538F9F90EE5	TCGA-BS-A0TI-01A-11D-A101-02	HG19_Broad_variant	TCGA-BS-A0TI	TCGA-UCEC		s5010	Harvard Medical School	University of Hawaii		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa831e4b0c9d6adf6c548	58cfa831e4b0c9d6adf6c548	TCGA-CM-4747-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4747-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4747-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	541.0	1.9	0.15	58cfa831e4b0c9d6adf6c548	TCGA-CM-4747-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4747-01A	56EB96A4-D2C2-42FB-B26C-1A80012BCB8E	Primary Tumor	Illumina HiSeq	e66cdfc9-e0b0-4ca4-bbcc-9ae23d9d663f	Colorectal	47.0	D3DAA95A-19B5-4822-BCBE-35CEEC12FDF1	7E2021D4-E528-4EB1-A7A0-71D6BE77A71D	TCGA-CM-4747-01A-01D-1405-02	HG18	TCGA-CM-4747	TCGA-COAD		s13217	Harvard Medical School	MSKCC		NO	T4a	N1b	Colon Adenocarcinoma	Stage IVA	1405-02	True
S13722.58cfa831e4b0c9d6adf6c588	58cfa831e4b0c9d6adf6c588	TCGA-CM-4748-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4748-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4748-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	227.02	1.9	0.13	58cfa831e4b0c9d6adf6c588	TCGA-CM-4748-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4748-01A	CD845618-4CC4-49C2-9055-C171D4C24EE1	Primary Tumor	Illumina HiSeq	f3119dfa-63bb-4098-9ea9-874f04789d12	Colorectal	53.0	1A465792-4DA7-4D37-9352-73E76ECFF4D2	3E7170B8-B0ED-4077-A65A-B6E399719A93	TCGA-CM-4748-01A-01D-1405-02	HG18	TCGA-CM-4748	TCGA-COAD		s13392	Harvard Medical School	MSKCC		NO	T4a	N1a	Colon Mucinous Adenocarcinoma	Stage IIIB	1405-02	True
S13722.58cfa831e4b0c9d6adf6c605	58cfa831e4b0c9d6adf6c605	TCGA-CQ-5329-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CQ-5329-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_3_rg.sorted	TCGA-CQ-5329-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_3_rg.sorted.bam	687.0	1.9	0.14	58cfa831e4b0c9d6adf6c605	TCGA-CQ-5329-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-5329-01A	02DCC11F-4F0E-4C9E-8D96-D22D47BEEF5D	Primary Tumor	Illumina HiSeq	b54a3eac-9c58-453d-9db1-395601ae82ea	Head and Neck	46.0	D22E9B65-495B-4D42-926A-01BF2C436D76	63CE8A9C-2CC5-41D9-B24D-3FB88343B693	TCGA-CQ-5329-01A-01D-1681-02	HG19_Broad_variant	TCGA-CQ-5329	TCGA-HNSC		s15772	Harvard Medical School	University Health Network, Toronto	Canada	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1681-02	True
S13722.58cfa831e4b0c9d6adf6c6d2	58cfa831e4b0c9d6adf6c6d2	TCGA-CS-4938-01B-11D-1891_130919_SN590_0238_AC29TRACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CS-4938-01B-11D-1891_130919_SN590_0238_AC29TRACXX_s_1_rg.sorted	TCGA-CS-4938-01B-11D-1891_130919_SN590_0238_AC29TRACXX_s_1_rg.sorted.bam	19.7	1.9	0.15	58cfa831e4b0c9d6adf6c6d2	TCGA-CS-4938-01B-11D-1891_130919_SN590_0238_AC29TRACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-4938-01B	334F715E-08DC-4A29-B8E4-B010B829C478	Primary Tumor	Illumina HiSeq	8b9dc3cd-2c99-405c-8306-3b388ad5bdf6	Brain	31.0	99104139-6CB5-44F7-8314-A4DDF02DE7D4	7FE72196-9DE8-4A43-87F2-D2E8F74B0007	TCGA-CS-4938-01B-11D-1891-02	HG19_Broad_variant	TCGA-CS-4938	TCGA-LGG		s8553	Harvard Medical School	Thomas Jefferson University	United States	NO			Astrocytoma		1891-02	True
S13722.58cfa831e4b0c9d6adf6c646	58cfa831e4b0c9d6adf6c646	TCGA-CQ-5327-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CQ-5327-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_2_rg.sorted	TCGA-CQ-5327-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_2_rg.sorted.bam	234.0	1.9	0.15	58cfa831e4b0c9d6adf6c646	TCGA-CQ-5327-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_2_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-5327-01A	5A03E2B6-4C8B-479A-9036-9859AF031DA4	Primary Tumor	Illumina HiSeq	3482a15d-acdc-4fcf-86a5-b015e57faefd	Head and Neck	61.0	93D283A7-E866-4F23-81F7-942DEE5009B8	55F0F300-E472-4254-9BDA-76AD94EA8C13	TCGA-CQ-5327-01A-01D-1681-02	HG19_Broad_variant	TCGA-CQ-5327	TCGA-HNSC		s15638	Harvard Medical School	University Health Network, Toronto	Canada	NO	T3	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True
S13722.58cfa831e4b0c9d6adf6c526	58cfa831e4b0c9d6adf6c526	TCGA-CM-4746-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4746-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4746-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	516.0	1.9	0.15	58cfa831e4b0c9d6adf6c526	TCGA-CM-4746-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4746-01A	C0B8C55C-B993-481D-AEEA-9EBFA64EE20E	Primary Tumor	Illumina HiSeq	cba07266-002c-406e-bfb3-5fc3483bb04b	Colorectal	61.0	85991716-6807-4F31-BE63-BF80CEC40CC2	32AAA8D7-1ABF-4AEF-8067-BE801C95D30B	TCGA-CM-4746-01A-01D-1405-02	HG18	TCGA-CM-4746	TCGA-COAD		s12892	Harvard Medical School	MSKCC		NO	T2	N0	Colon Adenocarcinoma	Stage I	1405-02	True
S13722.58cfa831e4b0c9d6adf6c726	58cfa831e4b0c9d6adf6c726	TCGA-D6-6825-01A-21D-1911_120518_SN1120_0143_BC0VN6ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D6-6825-01A-21D-1911_120518_SN1120_0143_BC0VN6ACXX_s_2_rg.sorted	TCGA-D6-6825-01A-21D-1911_120518_SN1120_0143_BC0VN6ACXX_s_2_rg.sorted.bam	288.7	1.9	0.14	58cfa831e4b0c9d6adf6c726	TCGA-D6-6825-01A-21D-1911_120518_SN1120_0143_BC0VN6ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6825-01A	42BC2336-2408-441A-83B9-AADC9700F750	Primary Tumor	Illumina HiSeq	e785062a-dcec-4a1d-aa67-6089980c9e35	Head and Neck	73.0	D9E2F5AA-A6E2-491A-9DBC-E5D10B4ABA58	8B36C904-50A1-4B17-94A2-F9331A5FED1E	TCGA-D6-6825-01A-21D-1911-02	HG19_Broad_variant	TCGA-D6-6825	TCGA-HNSC		s15529	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	1911-02	True
S13722.58cfa831e4b0c9d6adf6c95a	58cfa831e4b0c9d6adf6c95a	TCGA-DJ-A1QF-01A-12D-A14U_120629_SN1120_0167_AC0WMBACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DJ-A1QF-01A-12D-A14U_120629_SN1120_0167_AC0WMBACXX_s_4_rg.sorted	TCGA-DJ-A1QF-01A-12D-A14U_120629_SN1120_0167_AC0WMBACXX_s_4_rg.sorted.bam	14.32	1.97	0.15	58cfa831e4b0c9d6adf6c95a	TCGA-DJ-A1QF-01A-12D-A14U_120629_SN1120_0167_AC0WMBACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE		Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QF-01A	FCA0C7D9-5E6F-4AA7-BA04-5DF2EB8BA398	Primary Tumor	Illumina HiSeq	267d7caa-22fc-41bc-8ea9-ee910a0ac510	Thyroid	61.0	E4B53CA1-D395-4FEA-A962-DFBD2B373A6B	FA0BE982-CE22-449F-9D2B-E688196BA8AE	TCGA-DJ-A1QF-01A-12D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QF	TCGA-THCA		s11991	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A14U-02	True
S13722.58cfa831e4b0c9d6adf6c7ff	58cfa831e4b0c9d6adf6c7ff	TCGA-D1-A16X-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D1-A16X-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_4_rg.sorted	TCGA-D1-A16X-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_4_rg.sorted.bam	91.84	2.11	0.16	58cfa831e4b0c9d6adf6c7ff	TCGA-D1-A16X-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16X-01A	22618073-4EF0-4C3A-97B9-90BA1CAA1D72	Primary Tumor	Illumina HiSeq	8f166eb0-a44e-4848-ae7a-4e174f470d5b	Uterus	54.0	6421D807-9BEC-4AD4-8B75-8F9DD594A977	E652FF84-B885-4245-86E5-70ADE972FD67	TCGA-D1-A16X-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A16X	TCGA-UCEC		s5023	Harvard Medical School	Mayo Clinic		NO			Endometrioid endometrial adenocarcinoma		A12F-02	True
S13722.58cfa831e4b0c9d6adf6c94b	58cfa831e4b0c9d6adf6c94b	TCGA-DJ-A1QO-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DJ-A1QO-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_6_rg.sorted	TCGA-DJ-A1QO-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_6_rg.sorted.bam	43.74	1.8	0.18	58cfa831e4b0c9d6adf6c94b	TCGA-DJ-A1QO-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QO-01A	F2AD720E-579F-4E2C-A3F0-17877CA91067	Primary Tumor	Illumina HiSeq	1ac10023-1615-4727-ac8d-23b842c19d3c	Thyroid	69.0	03811796-0ECE-4408-82F7-B449A631D2FB	9E0C97ED-7482-4400-B66A-72AB48BA11A2	TCGA-DJ-A1QO-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QO	TCGA-THCA		s12372	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage III	A14U-02	True
S13722.58cfa831e4b0c9d6adf6c9c9	58cfa831e4b0c9d6adf6c9c9	TCGA-DJ-A1QH-01A-21D-A14U_120629_SN1222_0121_BD143UACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DJ-A1QH-01A-21D-A14U_120629_SN1222_0121_BD143UACXX_s_7_rg.sorted	TCGA-DJ-A1QH-01A-21D-A14U_120629_SN1222_0121_BD143UACXX_s_7_rg.sorted.bam	51.98	1.61	0.16	58cfa831e4b0c9d6adf6c9c9	TCGA-DJ-A1QH-01A-21D-A14U_120629_SN1222_0121_BD143UACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QH-01A	F3C73DC9-6280-4619-A629-B575FDBDB0CA	Primary Tumor	Illumina HiSeq	0e84405e-6687-4f5d-89c9-c507d3c0bba0	Thyroid	58.0	B1775A45-D30D-42C3-91D8-53C662B4A974	31F3AA22-9E90-4FF7-872C-0EED3DB18545	TCGA-DJ-A1QH-01A-21D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QH	TCGA-THCA		s12376	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage III	A14U-02	True
S13722.58cfa831e4b0c9d6adf6cab0	58cfa831e4b0c9d6adf6cab0	TCGA-DJ-A13U-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DJ-A13U-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_3_rg.sorted	TCGA-DJ-A13U-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_3_rg.sorted.bam	76.6	1.95	0.16	58cfa831e4b0c9d6adf6cab0	TCGA-DJ-A13U-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13U-01A	8C5AEF43-341E-4A37-84EB-FD730EB957C7	Primary Tumor	Illumina HiSeq	c717fac6-b3b3-4335-8ee8-5862d742ea16	Thyroid	60.0	CD19D6BB-21A4-409A-A7BA-A4521A03ABD3	B80A7146-1AB2-49BD-A3B2-7F6650840195	TCGA-DJ-A13U-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13U	TCGA-THCA		s12104	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A10R-02	True
S13722.58cfa831e4b0c9d6adf6c9ed	58cfa831e4b0c9d6adf6c9ed	TCGA-DJ-A13P-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DJ-A13P-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_5_rg.sorted	TCGA-DJ-A13P-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_5_rg.sorted.bam	104.83	1.95	0.16	58cfa831e4b0c9d6adf6c9ed	TCGA-DJ-A13P-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13P-01A	CA95A11C-B54C-409E-B9A0-DA850945033D	Primary Tumor	Illumina HiSeq	5d993dc5-0dfb-4f12-bd8b-c21a2c64577d	Thyroid	52.0	EFAD8B07-B295-468F-A836-F94029AEC777	528EC19A-8218-4E8F-B1E7-8A149F54A6BE	TCGA-DJ-A13P-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13P	TCGA-THCA		s11995	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A10R-02	True
S13722.58cfa831e4b0c9d6adf6cada	58cfa831e4b0c9d6adf6cada	TCGA-DU-6542-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_2_rg.sorted.filtered.	WGS	TCGA-DU-6542-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_2_rg.sorted	TCGA-DU-6542-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_2_rg.sorted.bam	424.7	1.9	0.14	58cfa831e4b0c9d6adf6cada	TCGA-DU-6542-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6542-01A	CD69D509-A652-4257-A8D3-767296BBB4EC	Primary Tumor	Illumina HiSeq	4b6cb752-5ed6-42e5-aed5-c8bdc6b95945	Brain	25.0	D00791AB-AA9D-406B-934C-E6946A430BB2	6EF0AE20-9197-4162-9A35-E235071A83B5	TCGA-DU-6542-01A-11D-1891-02	HG19_Broad_variant	TCGA-DU-6542	TCGA-LGG		s8143	Harvard Medical School	Henry Ford Hospital	United States	NO			Oligoastrocytoma		1891-02	True
S13722.58cfa831e4b0c9d6adf6caa0	58cfa831e4b0c9d6adf6caa0	TCGA-DJ-A1QM-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DJ-A1QM-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_3_rg.sorted	TCGA-DJ-A1QM-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_3_rg.sorted.bam	41.49	1.86	0.16	58cfa831e4b0c9d6adf6caa0	TCGA-DJ-A1QM-01A-11D-A14U_120629_SN1120_0167_AC0WMBACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QM-01A	3597AF5E-65FF-40A7-95FC-DACC26CBCA14	Primary Tumor	Illumina HiSeq	e98815fd-cd95-4af1-af17-129186e4a00a	Thyroid	42.0	B4215B1F-3918-43D6-8862-380C35F891EC	A070BCA4-DDFA-4BE7-A635-69A2BA97FFE9	TCGA-DJ-A1QM-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QM	TCGA-THCA		s12243	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1a	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A14U-02	True
S13722.58cfa831e4b0c9d6adf6cd18	58cfa831e4b0c9d6adf6cd18	TCGA-ET-A25N-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-ET-A25N-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_7_rg.sorted	TCGA-ET-A25N-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_7_rg.sorted.bam	26.49	1.71	0.15	58cfa831e4b0c9d6adf6cd18	TCGA-ET-A25N-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25N-01A	EBCCFB5F-C0A8-4263-AAFF-B5DD83585191	Primary Tumor	Illumina HiSeq	2e9fb20e-cc3d-4aa3-a188-6695dc2532a3	Thyroid	28.0	0CD93B1F-1CBB-4C1E-A4F6-940F95C41683	1A00F009-28F5-406B-8F47-4BB9D55D25D6	TCGA-ET-A25N-01A-11D-A16N-02	HG19_Broad_variant	TCGA-ET-A25N	TCGA-THCA		s12525	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True
S13722.58cfa831e4b0c9d6adf6cdb8	58cfa831e4b0c9d6adf6cdb8	TCGA-FG-6691-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_8_rg.sorted.filtered.	WGS	TCGA-FG-6691-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_8_rg.sorted	TCGA-FG-6691-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_8_rg.sorted.bam	105.7	1.9	0.16	58cfa831e4b0c9d6adf6cdb8	TCGA-FG-6691-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6691-01A	E4D9B696-3311-44E7-9191-FDE56C080A00	Primary Tumor	Illumina HiSeq	b404ac67-1c7f-4b01-8038-7432d3d6e489	Brain	23.0	87800B98-1FD3-4A09-AC98-3125962BFA72	B4968770-4D21-4C51-9ECA-47E23D5C240E	TCGA-FG-6691-01A-11D-1891-02	HG19_Broad_variant	TCGA-FG-6691	TCGA-LGG		s8368	Harvard Medical School	Case Western	United States	NO			Astrocytoma		1891-02	True
S13722.58cfa831e4b0c9d6adf6cd82	58cfa831e4b0c9d6adf6cd82	TCGA-FE-A230-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FE-A230-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_2_rg.sorted	TCGA-FE-A230-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_2_rg.sorted.bam	73.25	2.05	0.17	58cfa831e4b0c9d6adf6cd82	TCGA-FE-A230-01A-11D-A14U_120629_SN1120_0168_BD1454ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A230-01A	B1D71782-2443-43F3-BD0E-8B7220515CB6	Primary Tumor	Illumina HiSeq	5aeaadf5-f228-4383-97ce-9048120f8b41	Thyroid	30.0	12FC3F30-08FB-47C6-92F1-009D961C1E94	001C6478-B20D-40D8-AF62-C45C64269129	TCGA-FE-A230-01A-11D-A14U-02	HG19_Broad_variant	TCGA-FE-A230	TCGA-THCA		s12389	Harvard Medical School	Ohio State University	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	True
S13722.58cfa831e4b0c9d6adf6cdcc	58cfa831e4b0c9d6adf6cdcc	TCGA-FG-6689-01A-11D-1891_130923_SN1222_0220_BC2DUUACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FG-6689-01A-11D-1891_130923_SN1222_0220_BC2DUUACXX_s_1_rg.sorted	TCGA-FG-6689-01A-11D-1891_130923_SN1222_0220_BC2DUUACXX_s_1_rg.sorted.bam	86.7	1.9	0.16	58cfa831e4b0c9d6adf6cdcc	TCGA-FG-6689-01A-11D-1891_130923_SN1222_0220_BC2DUUACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6689-01A	8D07B1E8-5D1D-4A43-B616-D29DD58CE5FE	Primary Tumor	Illumina HiSeq	9e07a7ab-1033-43c4-a4f4-49ba35319fea	Brain	30.0	D81C3F19-BBCF-4071-8BA4-CB8C505307D7	2FD05E93-48E8-460E-80E0-C3262EAEE72B	TCGA-FG-6689-01A-11D-1891-02	HG19_Broad_variant	TCGA-FG-6689	TCGA-LGG		s8144	Harvard Medical School	Case Western	United States	NO			Astrocytoma		1891-02	True
S13722.58cfa832e4b0c9d6adf6ce20	58cfa832e4b0c9d6adf6ce20	TCGA-FG-6688-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FG-6688-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_5_rg.sorted	TCGA-FG-6688-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_5_rg.sorted.bam	62.7	2.0	0.17	58cfa832e4b0c9d6adf6ce20	TCGA-FG-6688-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6688-01A	DADD7428-9E4D-4652-9469-AB521B88D529	Primary Tumor	Illumina HiSeq	3b45431a-1066-4467-bc8a-f1aa3342c5f0	Brain	59.0	8594744F-F317-4022-991B-21891DA7F80A	5977877C-7B55-4666-AC08-54FEF233FB2F	TCGA-FG-6688-01A-11D-1891-02	HG19_Broad_variant	TCGA-FG-6688	TCGA-LGG		s8570	Harvard Medical School	Case Western	United States	NO			Astrocytoma		1891-02	True
S13722.58cfa832e4b0c9d6adf6ce97	58cfa832e4b0c9d6adf6ce97	TCGA-G2-A2EF-01A-12D-A18D_120912_SN1222_0148_AC188PACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G2-A2EF-01A-12D-A18D_120912_SN1222_0148_AC188PACXX_s_7_rg.sorted	TCGA-G2-A2EF-01A-12D-A18D_120912_SN1222_0148_AC188PACXX_s_7_rg.sorted.bam	40.86		0.15	58cfa832e4b0c9d6adf6ce97	TCGA-G2-A2EF-01A-12D-A18D_120912_SN1222_0148_AC188PACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2EF-01A	2A142731-119C-495D-AD30-EB0B48BACB46	Primary Tumor	Illumina HiSeq	ac16538b-bd5d-496e-bccc-6f3374d226c6	Bladder	50.0	981F581E-32AF-486B-9B60-0C8F1047C879	CE2F4DE7-C8AE-4103-8084-5F783B1087A7	TCGA-G2-A2EF-01A-12D-A18D-02	HG19_Broad_variant	TCGA-G2-A2EF	TCGA-BLCA		s3118	Harvard Medical School	MD Anderson	United States	NO		N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A18D-02	True
S13722.58cfa832e4b0c9d6adf6cf6a	58cfa832e4b0c9d6adf6cf6a	TCGA-GC-A3OO-01A-11D-A233_120905_SN1120_0187_AD1E4NACXX_s_5_rg.sorted.filtered.	WGS	TCGA-GC-A3OO-01A-11D-A233_120905_SN1120_0187_AD1E4NACXX_s_5_rg.sorted	TCGA-GC-A3OO-01A-11D-A233_120905_SN1120_0187_AD1E4NACXX_s_5_rg.sorted.bam	11.56		0.16	58cfa832e4b0c9d6adf6cf6a	TCGA-GC-A3OO-01A-11D-A233_120905_SN1120_0187_AD1E4NACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GC-A3OO-01A	1FF60FD9-3CA3-43BE-92A8-8DBA2CD4D4DF	Primary Tumor	Illumina HiSeq	8c665767-edb1-4860-b26a-4171237962fa	Bladder	79.0	91E7F41C-17B3-4724-96EF-D3C207B964E1	67B2932F-8C9D-4D38-8791-D4D8AAB7F3B2	TCGA-GC-A3OO-01A-11D-A233-26	HG19_Broad_variant	TCGA-GC-A3OO	TCGA-BLCA		s3306	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A233-26	True
S13722.58cfa832e4b0c9d6adf6cf6e	58cfa832e4b0c9d6adf6cf6e	TCGA-G9-6384-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_5_rg.sorted.filtered.	WGS	TCGA-G9-6384-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_5_rg.sorted	TCGA-G9-6384-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_5_rg.sorted.bam	146.4	1.9	0.15	58cfa832e4b0c9d6adf6cf6e	TCGA-G9-6384-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6384-01A	A279D5AA-51F7-4E75-9E14-B206B97EC4BD	Primary Tumor	Illumina HiSeq	75df59ac-7525-45fc-843a-5210bd036dca	Prostate	53.0	1ABCBE00-5A6F-4E0F-A61C-D158545C2293	1F750885-56C4-4953-8D22-BC7719F57F9F	TCGA-G9-6384-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6384	TCGA-PRAD		s4152	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True
S13722.58cfa832e4b0c9d6adf6d160	58cfa832e4b0c9d6adf6d160	TCGA-IG-A4P3-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IG-A4P3-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_3_rg.sorted	TCGA-IG-A4P3-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_3_rg.sorted.bam	40.74		0.15	58cfa832e4b0c9d6adf6d160	TCGA-IG-A4P3-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A4P3-01A	6594ACD5-4D2A-4CC5-8CF8-4064E252C5F6	Primary Tumor	Illumina HiSeq	a5b7767c-9dba-49bf-8711-9a76a0ab0e4f	Esophagus	48.0	784021B2-5F94-48F9-9DF7-854B4FBDF802	84882FB6-6ED6-42E8-9179-90CE089C4664	TCGA-IG-A4P3-01A-11D-A267-26	HG19_Broad_variant	TCGA-IG-A4P3	TCGA-ESCA		s1826	MD Anderson - Institute for Applied Cancer Science	Asterand	Ukraine	NO	T2	N1		Stage IIB	A267-26	True
S13722.58cfa832e4b0c9d6adf6d374	58cfa832e4b0c9d6adf6d374	TCGA-LN-A49M-01A-21D-A267_131001_SN1222_0222_BC2CN2ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-LN-A49M-01A-21D-A267_131001_SN1222_0222_BC2CN2ACXX_s_1_rg.sorted	TCGA-LN-A49M-01A-21D-A267_131001_SN1222_0222_BC2CN2ACXX_s_1_rg.sorted.bam	23.64		0.16	58cfa832e4b0c9d6adf6d374	TCGA-LN-A49M-01A-21D-A267_131001_SN1222_0222_BC2CN2ACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49M-01A	B3E248B5-5D40-495C-BD10-90ECF0ED6A95	Primary Tumor	Illumina HiSeq	821eaabe-92ee-4e30-9254-77b2ce89ea42	Esophagus	62.0	E6BEF2C0-1C6A-4137-A099-920F1F811489	9C284314-4356-44EA-8087-E64F5A614179	TCGA-LN-A49M-01A-21D-A267-26	HG19_Broad_variant	TCGA-LN-A49M	TCGA-ESCA		s1862	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N0		Stage IIA	A267-26	True
S13722.58cfa832e4b0c9d6adf6d3ee	58cfa832e4b0c9d6adf6d3ee	TCGA-V4-A9ES-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_4_rg.sorted.filtered.	WGS	TCGA-V4-A9ES-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_4_rg.sorted	TCGA-V4-A9ES-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_4_rg.sorted.bam	57.9		0.15	58cfa832e4b0c9d6adf6d3ee	TCGA-V4-A9ES-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9ES-01A	C510A423-6AB1-431E-9248-D2AC91FDEDBA	Primary Tumor	Illumina HiSeq	0edc5349-7b58-4f3e-ae40-3c517bcc8d47	Eye	54.0	1BC52C96-A28E-4E9C-AD3F-0797234C5A12	B16AE1A2-403B-4573-A6B0-9CBB05CEA149	TCGA-V4-A9ES-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9ES	TCGA-UVM		s201	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3b	N0		Stage IIIA	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d4b4	58cfa832e4b0c9d6adf6d4b4	TCGA-V4-A9EV-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_7_rg.sorted.filtered.	WGS	TCGA-V4-A9EV-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_7_rg.sorted	TCGA-V4-A9EV-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_7_rg.sorted.bam	56.76		0.15	58cfa832e4b0c9d6adf6d4b4	TCGA-V4-A9EV-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EV-01A	DA6F0ED2-A6D5-4D87-823E-122EBD59AABA	Primary Tumor	Illumina HiSeq	463c617e-a31f-4ebe-9bb0-bdf35b3823f8	Eye	59.0	42BBB13B-DA94-44FF-A01C-4776A74AEA6F	A08A9A90-323B-48AB-89C8-4805FE59BC70	TCGA-V4-A9EV-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EV	TCGA-UVM		s204	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d514	58cfa832e4b0c9d6adf6d514	TCGA-V4-A9EU-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_6_rg.sorted.filtered.	WGS	TCGA-V4-A9EU-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_6_rg.sorted	TCGA-V4-A9EU-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_6_rg.sorted.bam	49.0		0.14	58cfa832e4b0c9d6adf6d514	TCGA-V4-A9EU-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EU-01A	DF685F8C-645A-47AE-A471-63BF1973A0AE	Primary Tumor	Illumina HiSeq	929aff65-5561-439c-9850-a5ce595efc28	Eye	83.0	2DAC7136-D3A0-4FFD-B22D-7F1F9B8B8E4C	4C43B0FD-D2D3-456F-AFDD-EC90DBBD5FBA	TCGA-V4-A9EU-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EU	TCGA-UVM		s213	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4d	N0		Stage IIIC	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d4fe	58cfa832e4b0c9d6adf6d4fe	TCGA-L5-A4OG-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_7_rg.sorted.filtered.	WGS	TCGA-L5-A4OG-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_7_rg.sorted	TCGA-L5-A4OG-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_7_rg.sorted.bam	40.59		0.16	58cfa832e4b0c9d6adf6d4fe	TCGA-L5-A4OG-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OG-01A	EB4AD376-4CC1-4D2C-9B93-AD2B082C77C4	Primary Tumor	Illumina HiSeq	cef87877-7e34-43b9-9599-f98660d7b833	Esophagus	79.0	E8E44C65-B4E4-4688-A217-206905E68A7F	04C91C91-E55A-4075-B08A-F80568BB4A7B	TCGA-L5-A4OG-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OG	TCGA-ESCA		s1926	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N0		Stage I	A267-26	True
S13722.58cfa832e4b0c9d6adf6d52e	58cfa832e4b0c9d6adf6d52e	TCGA-LN-A4A8-01A-32D-A267_131018_SN590_0241_BC30HBACXX_s_5_rg.sorted.filtered.	WGS	TCGA-LN-A4A8-01A-32D-A267_131018_SN590_0241_BC30HBACXX_s_5_rg.sorted	TCGA-LN-A4A8-01A-32D-A267_131018_SN590_0241_BC30HBACXX_s_5_rg.sorted.bam	34.22		0.15	58cfa832e4b0c9d6adf6d52e	TCGA-LN-A4A8-01A-32D-A267_131018_SN590_0241_BC30HBACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A4A8-01A	AA364B98-0097-43A4-976D-742FAA0276DF	Primary Tumor	Illumina HiSeq	fd30434f-5a9a-4128-99f1-85d8d06ead73	Esophagus	52.0	0C0582CA-A181-4EFB-8486-C4312B250BA9	E42ECB6E-825E-407C-9CC7-C153C8F40DDC	TCGA-LN-A4A8-01A-32D-A267-26	HG19_Broad_variant	TCGA-LN-A4A8	TCGA-ESCA		s1935	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N0		Stage IIA	A267-26	True
S13722.58cfa832e4b0c9d6adf6d5bc	58cfa832e4b0c9d6adf6d5bc	TCGA-LN-A4A4-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-LN-A4A4-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_3_rg.sorted	TCGA-LN-A4A4-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_3_rg.sorted.bam	24.3		0.16	58cfa832e4b0c9d6adf6d5bc	TCGA-LN-A4A4-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A4A4-01A	E89D7900-915D-4936-B1B2-CAC3670EA2F4	Primary Tumor	Illumina HiSeq	8f2d7e64-e129-494b-9068-ad15dcb9457e	Esophagus	36.0	C7A31A25-A496-4D26-A9D2-C42ADB22BB45	655BFF55-E213-442B-8C1F-A1A959E89CDB	TCGA-LN-A4A4-01A-11D-A267-26	HG19_Broad_variant	TCGA-LN-A4A4	TCGA-ESCA		s1778	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N1		Stage III	A267-26	True
S13722.58cfa832e4b0c9d6adf6d5d0	58cfa832e4b0c9d6adf6d5d0	TCGA-L7-A56G-01A-21D-A267_131001_SN1120_0280_BD2FDEACXX_s_3_rg.sorted.filtered.	WGS	TCGA-L7-A56G-01A-21D-A267_131001_SN1120_0280_BD2FDEACXX_s_3_rg.sorted	TCGA-L7-A56G-01A-21D-A267_131001_SN1120_0280_BD2FDEACXX_s_3_rg.sorted.bam	26.05		0.15	58cfa832e4b0c9d6adf6d5d0	TCGA-L7-A56G-01A-21D-A267_131001_SN1120_0280_BD2FDEACXX_s_3_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-L7-A56G-01A	70C5CE85-4022-46C0-8BD0-F5E9009DDF41	Primary Tumor	Illumina HiSeq	8e835c63-a680-469e-82b7-850d8f01da57	Esophagus	65.0	3DD6751A-6FA6-4365-8E5E-FCB3D17910F6	6AD8F7F3-2EEC-47F7-9176-B10EBEB78F7E	TCGA-L7-A56G-01A-21D-A267-26	HG19_Broad_variant	TCGA-L7-A56G	TCGA-ESCA		s1851	MD Anderson - Institute for Applied Cancer Science	Christiana Care	United States	NO					A267-26	True
S13722.58cfa832e4b0c9d6adf6d604	58cfa832e4b0c9d6adf6d604	TCGA-LN-A49W-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-LN-A49W-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_5_rg.sorted	TCGA-LN-A49W-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_5_rg.sorted.bam	22.73		0.15	58cfa832e4b0c9d6adf6d604	TCGA-LN-A49W-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN		Esophageal Carcinoma	Aligned reads	TCGA-LN-A49W-01A	DAF211F2-941E-4244-8CF5-D31492269443	Primary Tumor	Illumina HiSeq	30b9eb80-84d4-4582-aa2d-a826faadd2f2	Esophagus	73.0	25E6A27B-B015-4936-B57E-CF39DD5AF9BA	38678D1B-A9D9-4231-95B8-95D5AB4D64F2	TCGA-LN-A49W-01A-11D-A267-26	HG19_Broad_variant	TCGA-LN-A49W	TCGA-ESCA		s1772	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N1		Stage III	A267-26	True
S13722.58cfa832e4b0c9d6adf6d608	58cfa832e4b0c9d6adf6d608	TCGA-LN-A5U5-01A-21D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-LN-A5U5-01A-21D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_4_rg.sorted	TCGA-LN-A5U5-01A-21D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_4_rg.sorted.bam	66.44		0.15	58cfa832e4b0c9d6adf6d608	TCGA-LN-A5U5-01A-21D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_4_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A5U5-01A	656E3C14-1FC6-473A-813E-719753E7B408	Primary Tumor	Illumina HiSeq	d3861f7c-bb4e-48be-b15b-0c082a3b6ff5	Esophagus	57.0	945DA36D-32AD-4996-9D77-BE6D09B858F9	E9CE892D-BF42-4445-B566-A8D7AC73AED0	TCGA-LN-A5U5-01A-21D-A28P-26	HG19_Broad_variant	TCGA-LN-A5U5	TCGA-ESCA		s1682	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N1		Stage IV	A28P-26	True
S13722.58cfa832e4b0c9d6adf6d5e3	58cfa832e4b0c9d6adf6d5e3	TCGA-LN-A49U-01A-31D-A267_131001_SN1222_0222_BC2CN2ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-LN-A49U-01A-31D-A267_131001_SN1222_0222_BC2CN2ACXX_s_7_rg.sorted	TCGA-LN-A49U-01A-31D-A267_131001_SN1222_0222_BC2CN2ACXX_s_7_rg.sorted.bam	24.19		0.15	58cfa832e4b0c9d6adf6d5e3	TCGA-LN-A49U-01A-31D-A267_131001_SN1222_0222_BC2CN2ACXX_s_7_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49U-01A	931A50FF-3149-4C4A-9456-45ED3A9DD457	Primary Tumor	Illumina HiSeq	c075129e-527d-4603-9336-8b26a5ce10d2	Esophagus	62.0	9B3E9E79-52EB-40F7-87EC-E1CB360004E6	FF6F10D6-874C-4281-AB3B-79FF2440A901	TCGA-LN-A49U-01A-31D-A267-26	HG19_Broad_variant	TCGA-LN-A49U	TCGA-ESCA		s1777	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0		Stage IIA	A267-26	True
S13722.58cfa82fe4b0c9d6adf6b678	58cfa82fe4b0c9d6adf6b678	TCGA-73-4670-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4670-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4670-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	343.9	1.9	0.16	58cfa82fe4b0c9d6adf6b678	TCGA-73-4670-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4670-01A	1B354837-4925-4480-AC32-6B44D0957314	Primary Tumor	Illumina HiSeq	8e4449ab-641c-44ea-af17-a681182f7299	Lung	69.0	646402AF-BA5F-438C-AE63-213EBD58B16D	D2FFA731-14A2-4A83-964E-C9969080263C	TCGA-73-4670-01A-01D-1203-02	GRCh37	TCGA-73-4670	TCGA-LUAD		s11356	Harvard Medical School	Roswell Park	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IV	1203-02	True
S13722.58cfa82fe4b0c9d6adf6b834	58cfa82fe4b0c9d6adf6b834	TCGA-A5-A0RA-01A-21D-A101_120403_SN1222_0093_AC0L7VACXX_s_6_rg.sorted.filtered.	WGS	TCGA-A5-A0RA-01A-21D-A101_120403_SN1222_0093_AC0L7VACXX_s_6_rg.sorted	TCGA-A5-A0RA-01A-21D-A101_120403_SN1222_0093_AC0L7VACXX_s_6_rg.sorted.bam	85.83	2.23	0.16	58cfa82fe4b0c9d6adf6b834	TCGA-A5-A0RA-01A-21D-A101_120403_SN1222_0093_AC0L7VACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0RA-01A	AFD710B8-D172-4AC4-9973-E969DB1ED231	Primary Tumor	Illumina HiSeq	d644ff0f-6dc7-4922-a46d-3223823e8118	Uterus	68.0	4ED231EE-0E54-4AC5-8278-1061AD3972A2	01EFCC42-CCFA-4D41-87BE-CA8F1C551823	TCGA-A5-A0RA-01A-21D-A101-02	HG19_Broad_variant	TCGA-A5-A0RA	TCGA-UCEC		s5195	Harvard Medical School	Cedars Sinai		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa82fe4b0c9d6adf6b84e	58cfa82fe4b0c9d6adf6b84e	TCGA-A5-A0R8-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_4_rg.sorted.filtered.	WGS	TCGA-A5-A0R8-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_4_rg.sorted	TCGA-A5-A0R8-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_4_rg.sorted.bam	80.74	2.11	0.16	58cfa82fe4b0c9d6adf6b84e	TCGA-A5-A0R8-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0R8-01A	06D16B6B-9CA6-4CEC-A785-F27AA4323CEC	Primary Tumor	Illumina HiSeq	ed11d53d-5cbb-44e2-b4d2-1603cef4ec13	Uterus	81.0	5B5CC2BA-6A10-4279-A0AA-8DDAE94D56EA	289CE7E4-AF92-4857-9D07-7CF334C40542	TCGA-A5-A0R8-01A-11D-A101-02	HG19_Broad_variant	TCGA-A5-A0R8	TCGA-UCEC		s4420	Harvard Medical School	Cedars Sinai		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa82fe4b0c9d6adf6b86c	58cfa82fe4b0c9d6adf6b86c	TCGA-A5-A0VP-01A-21D-A101_120407_SN590_0151_BC0KKJACXX_s_6_rg.sorted.filtered.	WGS	TCGA-A5-A0VP-01A-21D-A101_120407_SN590_0151_BC0KKJACXX_s_6_rg.sorted	TCGA-A5-A0VP-01A-21D-A101_120407_SN590_0151_BC0KKJACXX_s_6_rg.sorted.bam	77.93	2.03	0.16	58cfa82fe4b0c9d6adf6b86c	TCGA-A5-A0VP-01A-21D-A101_120407_SN590_0151_BC0KKJACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0VP-01A	2DB0FB62-64CE-457C-9E22-DD05EF59F684	Primary Tumor	Illumina HiSeq	26cc510d-e8a9-4782-9488-478373dbc1df	Uterus	74.0	F1FBE4AC-F3FD-4609-9A2B-507820ABE77E	E23FE404-0449-453D-971C-6E940B546119	TCGA-A5-A0VP-01A-21D-A101-02	HG19_Broad_variant	TCGA-A5-A0VP	TCGA-UCEC		s4992	Harvard Medical School	Cedars Sinai		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa82fe4b0c9d6adf6b882	58cfa82fe4b0c9d6adf6b882	TCGA-A6-2678-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2678-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2678-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	493.29	1.9	0.15	58cfa82fe4b0c9d6adf6b882	TCGA-A6-2678-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2678-01A	3A785E32-7960-4C72-84C4-FB42C4DD86F1	Primary Tumor	Illumina HiSeq	31675676-aba0-4d34-a2dc-0356129ceaa2	Colorectal	43.0	20ECCD8A-DFAF-40E4-8128-D77AA41680C4	83E77250-E68B-4ECA-9592-4424151E0D79	TCGA-A6-2678-01A-01D-1167-02	HG18	TCGA-A6-2678	TCGA-COAD		s12856	Harvard Medical School	Christiana Healthcare		NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	1167-02	True
S13722.58cfa82fe4b0c9d6adf6b892	58cfa82fe4b0c9d6adf6b892	TCGA-A6-2681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	308.0	1.9	0.15	58cfa82fe4b0c9d6adf6b892	TCGA-A6-2681-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2681-01A	7D8EAB0A-E6C8-4449-9EBF-50C41DB94A06	Primary Tumor	Illumina HiSeq	eda754a1-3a13-47a5-8e0e-49ef1384646d	Colorectal	73.0	0537BAD8-0E85-4B05-91B3-FD965E96D0D7	BFF8CDA3-3C4B-416F-AF46-6811B139D670	TCGA-A6-2681-01A-01D-1405-02	HG18	TCGA-A6-2681	TCGA-COAD		s12860	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	True
S13722.58cfa831e4b0c9d6adf6c52c	58cfa831e4b0c9d6adf6c52c	TCGA-CK-4951-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CK-4951-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CK-4951-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	36.02	1.9	0.17	58cfa831e4b0c9d6adf6c52c	TCGA-CK-4951-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CK-4951-01A	2DB3C23D-C591-4EA0-B0A8-ED9C4343C80E	Primary Tumor	Illumina HiSeq	7dcee63f-adaa-46d6-a48c-750143760f41	Colorectal	79.0	EA9E7E8C-4151-4CFC-8631-5880C6F1A21F	C501681C-26B5-4385-AE24-BEC8FB230C51	TCGA-CK-4951-01A-01D-1405-02	HG18	TCGA-CK-4951	TCGA-COAD		s13040	Harvard Medical School	Harvard		NO	T3	N0	Colon Mucinous Adenocarcinoma	Stage IIA	1405-02	True
S13722.58cfa82de4b0c9d6adf6a6fa	58cfa82de4b0c9d6adf6a6fa	9ae1429cc5f7f8e4692281baf49e4ff5.filtered.	WGS	9ae1429cc5f7f8e4692281baf49e4ff5	9ae1429cc5f7f8e4692281baf49e4ff5.bam	55.4	1.9	0.08	58cfa82de4b0c9d6adf6a6fa	9ae1429cc5f7f8e4692281baf49e4ff5.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0RT-01A	4BF50455-9AB7-4521-A791-089F66D3B877	Primary Tumor	Illumina HiSeq	0058348e-638c-426a-9fba-b26a3143c45b	Breast	39.0	C2300B5B-43A7-43B8-8CD1-22FF7E89A21A	1BB3A1C7-4D7B-4FB6-B54D-E94CBD0E32AA	TCGA-B6-A0RT-01A-21D-A128-09	GRCh37-lite	TCGA-B6-A0RT	TCGA-BRCA		s5635	Washington University School of Medicine	Duke	United States	NO	T3	N1	Infiltrating Ductal Carcinoma	Stage IIIA	A128-09	True
S13722.58cfa82de4b0c9d6adf6a5ee	58cfa82de4b0c9d6adf6a5ee	6979f0583ba67718dda7c5ddb907abd8.filtered.	WGS	6979f0583ba67718dda7c5ddb907abd8	6979f0583ba67718dda7c5ddb907abd8.bam	77.7	2.03	0.08	58cfa82de4b0c9d6adf6a5ee	6979f0583ba67718dda7c5ddb907abd8.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A0J2-01A	D2F2560C-EC80-4FEA-9474-C47A2E85EA95	Primary Tumor	Illumina HiSeq	46cbf954-a4fb-4060-818c-a60666ae41d3	Breast	41.0	4F5E142F-D936-469D-ABAA-37BAF6F045AF	207F8A42-5B05-4876-B0AE-EBFAEEA27844	TCGA-AO-A0J2-01A-11D-A19H-09	GRCh37-lite	TCGA-AO-A0J2	TCGA-BRCA		s6459	Washington University School of Medicine	MSKCC		NO	T1c	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IA	A19H-09	True
S13722.58cfa82de4b0c9d6adf6a742	58cfa82de4b0c9d6adf6a742	G14580.TCGA-64-1678-01A-01D-1040-01.2.filtered.	WGS	G14580.TCGA-64-1678-01A-01D-1040-01.2	G14580.TCGA-64-1678-01A-01D-1040-01.2.bam	482.23	1.9	0.15	58cfa82de4b0c9d6adf6a742	G14580.TCGA-64-1678-01A-01D-1040-01.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-1678-01A	F77CF4D3-9829-4FD3-95A1-B29AED9E94B8	Primary Tumor	Illumina HiSeq	3abe422b-51c0-4fb1-932d-f9e07cdb2150	Lung	70.0	0A2D9FAD-C5DF-46C1-BF96-529C7C92DFBA	53BB7112-3E38-45FE-A9C4-1B0871BABF4A	TCGA-64-1678-01A-01D-1040-01	HG19_Broad_variant	TCGA-64-1678	TCGA-LUAD		s11207	Broad Institute of MIT and Harvard	Fox Chase	United States	NO	T2b	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIA	1040-01	False
S13722.58cfa82de4b0c9d6adf6a74a	58cfa82de4b0c9d6adf6a74a	G13227.TCGA-43-3394-01A-01D-1553-08.1.filtered.	WGS	G13227.TCGA-43-3394-01A-01D-1553-08.1	G13227.TCGA-43-3394-01A-01D-1553-08.1.bam	532.37	1.9	0.05	58cfa82de4b0c9d6adf6a74a	G13227.TCGA-43-3394-01A-01D-1553-08.1.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-43-3394-01A	CE8612AB-3149-4A6A-B424-29C0C21C9B8B	Primary Tumor	Illumina HiSeq	bc49e74a-6128-4677-93fa-776314b3caef	Lung	52.0	D8F165AF-1DF5-4876-ABF8-7596E52A3BC3	EFE4D5DD-FFFB-41DF-AB86-BE06CC16646F	TCGA-43-3394-01A-01D-1553-08	HG19_Broad_variant	TCGA-43-3394	TCGA-LUSC		s10073	Broad Institute of MIT and Harvard	Christiana Healthcare	United States	NO	T2a	N0	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IB	1553-08	False
S13722.58cfa82de4b0c9d6adf6a759	58cfa82de4b0c9d6adf6a759	G13230.TCGA-60-2713-01A-01D-1522-08.3.filtered.	WGS	G13230.TCGA-60-2713-01A-01D-1522-08.3	G13230.TCGA-60-2713-01A-01D-1522-08.3.bam	661.3	1.9	0.05	58cfa82de4b0c9d6adf6a759	G13230.TCGA-60-2713-01A-01D-1522-08.3.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-60-2713-01A	E58E8850-154F-4695-BEE0-005C76410327	Primary Tumor	Illumina HiSeq	34149172-2cd5-402b-a1c6-c4fd3919f717	Lung	64.0	88A9B60F-89DD-4C2B-B13B-5EF5E10B94AB	79EB7BBA-F0D8-462C-ADD7-20A2FB7843E1	TCGA-60-2713-01A-01D-1522-08	HG19_Broad_variant	TCGA-60-2713	TCGA-LUSC		s10074	Broad Institute of MIT and Harvard	Roswell Park	United States	NO	T2	N0	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IB	1522-08	True
S13722.58cfa82de4b0c9d6adf6a778	58cfa82de4b0c9d6adf6a778	G14849.TCGA-44-2659-01A-01D-1931-08.5.filtered.	WGS	G14849.TCGA-44-2659-01A-01D-1931-08.5	G14849.TCGA-44-2659-01A-01D-1931-08.5.bam	82.96	1.9	0.15	58cfa82de4b0c9d6adf6a778	G14849.TCGA-44-2659-01A-01D-1931-08.5.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-2659-01A	BF15F7AD-9D92-473B-91D1-F24AA373AB97	Primary Tumor	Illumina HiSeq	bcdd7201-d7f2-45f5-bbaf-e0ca63b987c4	Lung	65.0	42208BA8-F465-4D62-9ED9-5DBFAA525913	2BDE43E2-FD4E-413E-ADC7-C50BCA75D358	TCGA-44-2659-01A-01D-1931-08	HG19_Broad_variant	TCGA-44-2659	TCGA-LUAD		s10626	Broad Institute of MIT and Harvard	Christiana Healthcare	United States	NO	T1	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIB	1931-08	True
S13722.58cfa82de4b0c9d6adf6a77a	58cfa82de4b0c9d6adf6a77a	G12520.TCGA-60-2711-01A-01D-0963-08.1.filtered.	WGS	G12520.TCGA-60-2711-01A-01D-0963-08.1	G12520.TCGA-60-2711-01A-01D-0963-08.1.bam	620.3	1.9	0.15	58cfa82de4b0c9d6adf6a77a	G12520.TCGA-60-2711-01A-01D-0963-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-60-2711-01A	1F11DE87-A5FE-49FD-80C1-E279B2BC69DE	Primary Tumor	Illumina HiSeq	53773d17-2e17-4544-845d-b784120af48d	Lung	64.0	8A3A376A-A4DB-4D4F-85CE-A894A2AA60BB	D54CA81C-1BCC-41EA-B17A-9F7249EBE9C1	TCGA-60-2711-01A-01D-0963-08	HG19_Broad_variant	TCGA-60-2711	TCGA-LUSC		s10496	Broad Institute of MIT and Harvard	Roswell Park	United States	NO	T2	N0	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IB	0963-08	False
S13722.58cfa82ee4b0c9d6adf6a7cf	58cfa82ee4b0c9d6adf6a7cf	G25249.TCGA-CR-7391-01A-11D-2334-08.1.filtered.	WGS	G25249.TCGA-CR-7391-01A-11D-2334-08.1	G25249.TCGA-CR-7391-01A-11D-2334-08.1.bam	85.7		0.05	58cfa82ee4b0c9d6adf6a7cf	G25249.TCGA-CR-7391-01A-11D-2334-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-7391-01A	832316EE-08AB-412B-9E4D-8A57FF84BC11	Primary Tumor	Illumina HiSeq	ef4db578-e4b8-4047-b761-df26ecf7a41e	Head and Neck	36.0	54B7DB2E-F0DD-469D-81BB-4E2A86EBEA9D	C121DE15-78F7-4698-91BF-FD0485C466C2	TCGA-CR-7391-01A-11D-2334-08	HG19_Broad_variant	TCGA-CR-7391	TCGA-HNSC		s15862	Broad Institute of MIT and Harvard	Vanderbilt University	United States	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	2334-08	False
S13722.58cfa82ee4b0c9d6adf6a7d6	58cfa82ee4b0c9d6adf6a7d6	G23064.TCGA_CR_6472_01A_11D_2268_08.1.filtered.	WGS	G23064.TCGA_CR_6472_01A_11D_2268_08.1	G23064.TCGA_CR_6472_01A_11D_2268_08.1.bam	118.0	1.9	0.15	58cfa82ee4b0c9d6adf6a7d6	G23064.TCGA_CR_6472_01A_11D_2268_08.1.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-6472-01A	0956BC67-DD55-4C54-A56A-F22F2856662A	Primary Tumor	Illumina HiSeq	8bf4b442-c0d0-4794-b87d-990df38dfce7	Head and Neck	59.0	76095F05-CD2B-4973-800A-10FE58EE1609	5193A482-6ED9-4504-BD7C-C8B9E4103577	TCGA-CR-6472-01A-11D-2268-08	HG19_Broad_variant	TCGA-CR-6472	TCGA-HNSC		s15603	Broad Institute of MIT and Harvard	Vanderbilt University	United States	NO			Head and Neck Squamous Cell Carcinoma		2268-08	True
S13722.58cfa82ee4b0c9d6adf6a89a	58cfa82ee4b0c9d6adf6a89a	G35154.TCGA-HT-8104-01A-11D-A461-08.2.filtered.	WGS	G35154.TCGA-HT-8104-01A-11D-A461-08.2	G35154.TCGA-HT-8104-01A-11D-A461-08.2.bam	129.6		0.08	58cfa82ee4b0c9d6adf6a89a	G35154.TCGA-HT-8104-01A-11D-A461-08.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-8104-01A	5DE6FD84-ED02-4C27-9947-DB57F05FAF6D	Primary Tumor	Illumina HiSeq	85f4a2b5-246f-41da-9777-57d2ceaf1b70	Brain	51.0	13845BA9-5FC0-408A-8CA9-AC32511765B7	3139DEFD-0311-4F2A-9AD4-A9903F481832	TCGA-HT-8104-01A-11D-A461-08	HG19_Broad_variant	TCGA-HT-8104	TCGA-LGG		s8334	Broad Institute of MIT and Harvard	Case Western - St Joes	United States	NO			Astrocytoma		A461-08	True
S13722.58cfa82ee4b0c9d6adf6a8e2	58cfa82ee4b0c9d6adf6a8e2	G35154.TCGA-DU-5870-01A-11D-A461-08.3.filtered.	WGS	G35154.TCGA-DU-5870-01A-11D-A461-08.3	G35154.TCGA-DU-5870-01A-11D-A461-08.3.bam	55.6	1.9	0.08	58cfa82ee4b0c9d6adf6a8e2	G35154.TCGA-DU-5870-01A-11D-A461-08.3.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5870-01A	EB42625E-FBBB-4BEE-BBE9-315B3CA2138A	Primary Tumor	Illumina HiSeq	781639a0-ea42-4e90-8e48-2dd0de69143f	Brain	34.0	25E75875-4A84-4C29-9030-0E0922BD6567	8EFA4E9E-F222-4CCB-BF34-32443183BD7F	TCGA-DU-5870-01A-11D-A461-08	HG19_Broad_variant	TCGA-DU-5870	TCGA-LGG		s8318	Broad Institute of MIT and Harvard	Henry Ford Hospital	United States	NO			Oligodendroglioma		A461-08	True
S13722.58cfa82ee4b0c9d6adf6a90a	58cfa82ee4b0c9d6adf6a90a	G32457.TCGA-FD-A3N6-01A-11D-A21A-08.1.filtered.	WGS	G32457.TCGA-FD-A3N6-01A-11D-A21A-08.1	G32457.TCGA-FD-A3N6-01A-11D-A21A-08.1.bam	47.84		0.08	58cfa82ee4b0c9d6adf6a90a	G32457.TCGA-FD-A3N6-01A-11D-A21A-08.1.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3N6-01A	8C1DD7F7-B74A-4FA2-B6A7-86F0348D2567	Primary Tumor	Illumina HiSeq	d881868c-a616-4a4c-bbb7-4fbda95e1323	Bladder	43.0	6CD6D1F4-D8E4-47F9-812F-EB7FEC925F8D	D4615CA0-B5C7-4A5C-8593-BD50034A78AE	TCGA-FD-A3N6-01A-11D-A21A-08	HG19_Broad_variant	TCGA-FD-A3N6	TCGA-BLCA		s2849	Broad Institute of MIT and Harvard	BLN - University Of Chicago	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A21A-08	True
S13722.58cfa82ee4b0c9d6adf6a911	58cfa82ee4b0c9d6adf6a911	G16921.TCGA-BP-4977-01A-01D-2048-08.1.filtered.	WGS	G16921.TCGA-BP-4977-01A-01D-2048-08.1	G16921.TCGA-BP-4977-01A-01D-2048-08.1.bam	26.1	1.9	0.16	58cfa82ee4b0c9d6adf6a911	G16921.TCGA-BP-4977-01A-01D-2048-08.1.bam	Alive	MALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-4977-01A	CC353686-E2B6-46A1-8095-48E2BC44B11F	Primary Tumor	Illumina HiSeq	eb47b3fe-95b7-490e-99d4-9e326b44d448	Kidney	57.0	35C747C0-38BB-4D2E-A428-8E24106ADFAB	1E046AB9-FA4C-4C15-8D78-ED0048C80EBF	TCGA-BP-4977-01A-01D-2048-08	HG19_Broad_variant	TCGA-BP-4977	TCGA-KIRC		s8831	Broad Institute of MIT and Harvard	MSKCC		NO	T1b	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2048-08	False
S13722.58cfa82ee4b0c9d6adf6a9c4	58cfa82ee4b0c9d6adf6a9c4	G23076.TCGA_CV_5443_01A_01D_2268_08.1.filtered.	WGS	G23076.TCGA_CV_5443_01A_01D_2268_08.1	G23076.TCGA_CV_5443_01A_01D_2268_08.1.bam	385.0	1.9	0.15	58cfa82ee4b0c9d6adf6a9c4	G23076.TCGA_CV_5443_01A_01D_2268_08.1.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5443-01A	180036A2-3B56-405E-A1FE-D5932517B6C7	Primary Tumor	Illumina HiSeq	9e76f187-2863-42f5-9540-da82b815d6c0	Head and Neck	63.0	746322C7-FE75-4B9F-9309-93E9CFA4CB5A	D4B80307-ABBD-48BB-B52C-6DCD409699A2	TCGA-CV-5443-01A-01D-2268-08	HG19_Broad_variant	TCGA-CV-5443	TCGA-HNSC		s15742	Broad Institute of MIT and Harvard	MD Anderson Cancer Center		NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	2268-08	True
S13722.58cfa82ee4b0c9d6adf6a9d5	58cfa82ee4b0c9d6adf6a9d5	G25788.TCGA-55-7281-01A-11D-2036-08.1.filtered.	WGS	G25788.TCGA-55-7281-01A-11D-2036-08.1	G25788.TCGA-55-7281-01A-11D-2036-08.1.bam	196.7		0.05	58cfa82ee4b0c9d6adf6a9d5	G25788.TCGA-55-7281-01A-11D-2036-08.1.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-55-7281-01A	659668E8-F0D9-4FF2-BBC8-9246F2EF49AB	Primary Tumor	Illumina HiSeq	19c6ac35-62fd-4db0-8641-22abc19d0b52	Lung	70.0	AFEC3B25-C3F7-4E48-8FB0-6FB4DD581081	D5443922-FEA5-4FF0-BD6E-8CE04E1951D8	TCGA-55-7281-01A-11D-2036-08	HG19_Broad_variant	TCGA-55-7281	TCGA-LUAD		s11213	Broad Institute of MIT and Harvard	International Genomics Consortium	United States	NO	T1b	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	2036-08	True
S13722.58cfa82ee4b0c9d6adf6aa04	58cfa82ee4b0c9d6adf6aa04	G25250.TCGA-CR-6470-01A-11D-2334-08.1.filtered.	WGS	G25250.TCGA-CR-6470-01A-11D-2334-08.1	G25250.TCGA-CR-6470-01A-11D-2334-08.1.bam	137.7	1.9	0.05	58cfa82ee4b0c9d6adf6aa04	G25250.TCGA-CR-6470-01A-11D-2334-08.1.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-6470-01A	CD032DDB-55F2-4C77-8DCF-E4E630F7DE6F	Primary Tumor	Illumina HiSeq	1a71c849-3daa-48f9-b309-4c340a01def2	Head and Neck	38.0	AFB7EA63-2959-4E53-95EA-7A032DCB5A8B	02C6A893-49C5-49D1-8EB1-195021E70D52	TCGA-CR-6470-01A-11D-2334-08	HG19_Broad_variant	TCGA-CR-6470	TCGA-HNSC		s16019	Broad Institute of MIT and Harvard	Vanderbilt University	United States	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2334-08	False
S13722.58cfa82ee4b0c9d6adf6aa06	58cfa82ee4b0c9d6adf6aa06	G23074.TCGA_CN_4741_01A_01D_2268_08.1.filtered.	WGS	G23074.TCGA_CN_4741_01A_01D_2268_08.1	G23074.TCGA_CN_4741_01A_01D_2268_08.1.bam	215.7	1.9	0.14	58cfa82ee4b0c9d6adf6aa06	G23074.TCGA_CN_4741_01A_01D_2268_08.1.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4741-01A	277B02E9-DED5-4980-845D-AF53690000AC	Primary Tumor	Illumina HiSeq	b508fa53-d86f-4e56-9703-6cdb7095ed0b	Head and Neck	75.0	03C9108A-5139-4BAC-9641-C7DBBEDEF420	F652367A-D6C9-4A0A-AADE-1AB988BE3BE6	TCGA-CN-4741-01A-01D-2268-08	HG19_Broad_variant	TCGA-CN-4741	TCGA-HNSC		s15745	Broad Institute of MIT and Harvard	University of Pittsburgh		NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	2268-08	True
S13722.58cfa82ee4b0c9d6adf6aa44	58cfa82ee4b0c9d6adf6aa44	G25251.TCGA-CR-7404-01A-11D-2334-08.1.filtered.	WGS	G25251.TCGA-CR-7404-01A-11D-2334-08.1	G25251.TCGA-CR-7404-01A-11D-2334-08.1.bam	181.7		0.05	58cfa82ee4b0c9d6adf6aa44	G25251.TCGA-CR-7404-01A-11D-2334-08.1.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-7404-01A	D189A6C6-210F-4957-B500-457D5CE3F867	Primary Tumor	Illumina HiSeq	f8742c2f-2e32-467e-9347-f0dd0959da6b	Head and Neck	53.0	A39131B9-E7C7-4385-A1B9-D8A0A0950337	83ECA7B5-45BB-44C0-8AFE-36F8988D0078	TCGA-CR-7404-01A-11D-2334-08	HG19_Broad_variant	TCGA-CR-7404	TCGA-HNSC		s15602	Broad Institute of MIT and Harvard	Vanderbilt University	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		2334-08	False
S13722.58cfa82ee4b0c9d6adf6aa50	58cfa82ee4b0c9d6adf6aa50	G23069.TCGA_CR_6480_01A_11D_2268_08.2.filtered.	WGS	G23069.TCGA_CR_6480_01A_11D_2268_08.2	G23069.TCGA_CR_6480_01A_11D_2268_08.2.bam	158.7	1.9	0.15	58cfa82ee4b0c9d6adf6aa50	G23069.TCGA_CR_6480_01A_11D_2268_08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-6480-01A	BA9D4568-71A8-41FC-A2BE-0BF784E36D6A	Primary Tumor	Illumina HiSeq	cf0a07e0-8d0a-4c16-8d48-7efb9bf38f8a	Head and Neck	53.0	0C6B4631-381E-4B73-AC9E-62BBC1849FF4	EF673D3D-2031-4036-BA25-4BC7EF04075B	TCGA-CR-6480-01A-11D-2268-08	HG19_Broad_variant	TCGA-CR-6480	TCGA-HNSC		s16166	Broad Institute of MIT and Harvard	Vanderbilt University	United States	NO			Head and Neck Squamous Cell Carcinoma		2268-08	True
S13722.58cfa82ee4b0c9d6adf6ab16	58cfa82ee4b0c9d6adf6ab16	G25783.TCGA-55-6986-01A-11D-1945-08.2.filtered.	WGS	G25783.TCGA-55-6986-01A-11D-1945-08.2	G25783.TCGA-55-6986-01A-11D-1945-08.2.bam	62.0		0.05	58cfa82ee4b0c9d6adf6ab16	G25783.TCGA-55-6986-01A-11D-1945-08.2.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-55-6986-01A	028E99E9-5B9A-4954-BB6E-6D4709A3CEA8	Primary Tumor	Illumina HiSeq	ee88a53a-b82b-4bd8-b13b-da8f5da9e39c	Lung	74.0	9622C370-68D0-48DA-A7E0-5EB4765B6F27	5A7F3C88-EF02-4E97-8009-5622245B6A09	TCGA-55-6986-01A-11D-1945-08	HG19_Broad_variant	TCGA-55-6986	TCGA-LUAD		s11106	Broad Institute of MIT and Harvard	International Genomics Consortium	United States	NO	T2	N0	Lung Bronchioloalveolar Carcinoma Nonmucinous	Stage IB	1945-08	True
S13722.58cfa82ee4b0c9d6adf6ab9c	58cfa82ee4b0c9d6adf6ab9c	G25777.TCGA-67-6215-01A-11D-1753-08.1.filtered.	WGS	G25777.TCGA-67-6215-01A-11D-1753-08.1	G25777.TCGA-67-6215-01A-11D-1753-08.1.bam	292.4	1.9	0.05	58cfa82ee4b0c9d6adf6ab9c	G25777.TCGA-67-6215-01A-11D-1753-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-67-6215-01A	DBD5B0DE-94C9-45DD-AFB3-6820A7ECACA2	Primary Tumor	Illumina HiSeq	70835707-2b01-4434-88b9-57b2c434b88e	Lung	52.0	3BA5F6B9-6458-44E2-A0AA-B5C7E5FCD632	68C2A355-862C-4657-B296-5776ED8447B0	TCGA-67-6215-01A-11D-1753-08	HG19_Broad_variant	TCGA-67-6215	TCGA-LUAD		s10633	Broad Institute of MIT and Harvard	St Joseph's Medical Center (MD)	United States	NO	T2a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1753-08	True
S13722.58cfa82ee4b0c9d6adf6ac27	58cfa82ee4b0c9d6adf6ac27	G37566.TCGA-HC-7737-01A-11D-2114-08.3.filtered.	WGS	G37566.TCGA-HC-7737-01A-11D-2114-08.3	G37566.TCGA-HC-7737-01A-11D-2114-08.3.bam	205.3		0.05	58cfa82ee4b0c9d6adf6ac27	G37566.TCGA-HC-7737-01A-11D-2114-08.3.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN		Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7737-01A	73F875CB-BCFC-43BA-AB97-4E94CAF836D4	Primary Tumor	Illumina HiSeq	855b7ac8-18b6-4ec4-9471-8d12a802bf46	Prostate	55.0	47B6E89A-EA86-475A-9F1D-02001069C895	DCF98ACC-736B-4AF6-BDCA-A320A413165A	TCGA-HC-7737-01A-11D-2114-08	HG19_Broad_variant	TCGA-HC-7737	TCGA-PRAD		s3407	Broad Institute of MIT and Harvard	International Genomics Consortium	United States	NO	T2c	N1	Prostate Adenocarcinoma Acinar Type		2114-08	False
S13722.58cfa82ee4b0c9d6adf6ac9a	58cfa82ee4b0c9d6adf6ac9a	G41960.TCGA-91-6847-01A-11D-1945-08.1.filtered.	WGS	G41960.TCGA-91-6847-01A-11D-1945-08.1	G41960.TCGA-91-6847-01A-11D-1945-08.1.bam	528.7	1.9	0.05	58cfa82ee4b0c9d6adf6ac9a	G41960.TCGA-91-6847-01A-11D-1945-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6847-01A	97831D28-AB41-4C18-BFC2-C4C6BC757D13	Primary Tumor	Illumina HiSeq	7d8d3882-a579-44c1-b63d-eabff64671d1	Lung	62.0	96A05D4B-3731-4B98-B38F-A6B33CD6ED96	020FAB36-C7DE-4933-B2BF-DC7B019A1326	TCGA-91-6847-01A-11D-1945-08	HG19_Broad_variant	TCGA-91-6847	TCGA-LUAD		s10635	Broad Institute of MIT and Harvard	ABS - IUPUI	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1945-08	True
S13722.58cfa82ee4b0c9d6adf6ac88	58cfa82ee4b0c9d6adf6ac88	G47088.TCGA-34-5240-01A-01D-1441-08.1.filtered.	WGS	G47088.TCGA-34-5240-01A-01D-1441-08.1	G47088.TCGA-34-5240-01A-01D-1441-08.1.bam	715.7	1.9	0.05	58cfa82ee4b0c9d6adf6ac88	G47088.TCGA-34-5240-01A-01D-1441-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-34-5240-01A	E7D1B042-5B1C-4C29-B501-A5EF4810ECD2	Primary Tumor	Illumina HiSeq	8c136698-e283-46dc-83d9-44916f08fe6b	Lung	73.0	49395D22-CD07-4AB7-BDF3-CFA56687BA43	4C3840DF-9824-40DB-879E-6D24ADC8C155	TCGA-34-5240-01A-01D-1441-08	HG19_Broad_variant	TCGA-34-5240	TCGA-LUSC		s10361	Broad Institute of MIT and Harvard	University of Pittsburgh	United States	NO	T2	N1	Lung Basaloid Squamous Cell Carcinoma	Stage IIB	1441-08	False
S13722.58cfa82ee4b0c9d6adf6acac	58cfa82ee4b0c9d6adf6acac	G37566.TCGA-HC-7740-01A-11D-2114-08.2.filtered.	WGS	G37566.TCGA-HC-7740-01A-11D-2114-08.2	G37566.TCGA-HC-7740-01A-11D-2114-08.2.bam	31.3		0.05	58cfa82ee4b0c9d6adf6acac	G37566.TCGA-HC-7740-01A-11D-2114-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7740-01A	91E249A6-B0B0-487E-9FAD-0E9F5798DCAE	Primary Tumor	Illumina HiSeq	dd2df8bb-8035-4f08-b3d4-d9ee910fd0ea	Prostate	59.0	54D1CF0E-5D54-486C-A863-733B5EDC5986	7303F9FE-88BB-48BA-B9B4-EBF9E4770C1C	TCGA-HC-7740-01A-11D-2114-08	HG19_Broad_variant	TCGA-HC-7740	TCGA-PRAD		s3762	Broad Institute of MIT and Harvard	International Genomics Consortium	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2114-08	False
S13722.58cfa82ee4b0c9d6adf6ad0e	58cfa82ee4b0c9d6adf6ad0e	G37568.TCGA-DK-A1AE-01A-11D-A13W-08.2.filtered.	WGS	G37568.TCGA-DK-A1AE-01A-11D-A13W-08.2	G37568.TCGA-DK-A1AE-01A-11D-A13W-08.2.bam	76.27	1.91	0.08	58cfa82ee4b0c9d6adf6ad0e	G37568.TCGA-DK-A1AE-01A-11D-A13W-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AE-01A	493A4FF2-37A5-4B79-928D-83DBFE534556	Primary Tumor	Illumina HiSeq	2722f260-d3b4-4088-860d-7a5070921255	Bladder	84.0	67865453-D515-4D63-84E8-CFB2686A211D	ABD2D959-D5ED-4EB3-9759-67EB1AA23325	TCGA-DK-A1AE-01A-11D-A13W-08	HG19_Broad_variant	TCGA-DK-A1AE	TCGA-BLCA		s2688	Broad Institute of MIT and Harvard	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13W-08	True
S13722.58cfa82ee4b0c9d6adf6ad66	58cfa82ee4b0c9d6adf6ad66	G35154.TCGA-HT-A5R7-01A-11D-A461-08.2.filtered.	WGS	G35154.TCGA-HT-A5R7-01A-11D-A461-08.2	G35154.TCGA-HT-A5R7-01A-11D-A461-08.2.bam	17.75		0.08	58cfa82ee4b0c9d6adf6ad66	G35154.TCGA-HT-A5R7-01A-11D-A461-08.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-A5R7-01A	7E41BABA-7EF6-4030-B595-D95CD96336B5	Primary Tumor	Illumina HiSeq	c239bee2-d22d-4390-be44-ed4be0395f57	Brain	33.0	7BA53D9A-FE20-487A-B4BB-84451E207755	C71F8C39-653F-42F2-AD3E-439CF86A0738	TCGA-HT-A5R7-01A-11D-A461-08	HG19_Broad_variant	TCGA-HT-A5R7	TCGA-LGG		s8119	Broad Institute of MIT and Harvard	Case Western - St Joes	United States	NO			Astrocytoma		A461-08	True
S13722.58cfa82ee4b0c9d6adf6af6a	58cfa82ee4b0c9d6adf6af6a	G41960.TCGA-55-6972-01A-11D-1945-08.1.filtered.	WGS	G41960.TCGA-55-6972-01A-11D-1945-08.1	G41960.TCGA-55-6972-01A-11D-1945-08.1.bam	520.7		0.05	58cfa82ee4b0c9d6adf6af6a	G41960.TCGA-55-6972-01A-11D-1945-08.1.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-55-6972-01A	C4D1E105-28B7-48DF-ABEF-FBE09782FDB2	Primary Tumor	Illumina HiSeq	30f0b521-90e2-41a2-9dcc-97b6702a46fc	Lung	72.0	38C83B40-FBA4-48D4-AD6E-93768CB6139F	46693A2B-5105-4770-A9E1-031DFEDEB694	TCGA-55-6972-01A-11D-1945-08	HG19_Broad_variant	TCGA-55-6972	TCGA-LUAD		s11113	Broad Institute of MIT and Harvard	International Genomics Consortium	United States	NO	T2	N0	Lung Papillary Adenocarcinoma	Stage IB	1945-08	True
S13722.58cfa82fe4b0c9d6adf6b8a5	58cfa82fe4b0c9d6adf6b8a5	TCGA-A6-2683-01A-01D-1554-10_wgs_Illumina.filtered.	WGS	TCGA-A6-2683-01A-01D-1554-10_wgs_Illumina	TCGA-A6-2683-01A-01D-1554-10_wgs_Illumina.bam	467.29	1.9	0.05	58cfa82fe4b0c9d6adf6b8a5	TCGA-A6-2683-01A-01D-1554-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2683-01A	FAFD4576-0709-49E1-926F-AD1EE09907EC	Primary Tumor	Illumina HiSeq	9e91b702-c4fb-4c6e-9060-987e5ff14421	Colorectal	57.0	C24759F8-566B-42DA-A26D-BB0BF51EE15F	FC453F67-6623-4E8C-B519-0BD79E4D4651	TCGA-A6-2683-01A-01D-1554-10	GRCh37-lite	TCGA-A6-2683	TCGA-COAD		s13015	Baylor College of Medicine	Christiana Healthcare		NO	T4	N0	Colon Adenocarcinoma	Stage IV	1554-10	False
S13722.58cfa830e4b0c9d6adf6ba4a	58cfa830e4b0c9d6adf6ba4a	TCGA-A6-3807-01A-01D-1459-10_wgs_Illumina.filtered.	WGS	TCGA-A6-3807-01A-01D-1459-10_wgs_Illumina	TCGA-A6-3807-01A-01D-1459-10_wgs_Illumina.bam	380.0	1.9	0.05	58cfa830e4b0c9d6adf6ba4a	TCGA-A6-3807-01A-01D-1459-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-3807-01A	5116E3B4-2BAC-40F5-8046-B9C1783FAAA5	Primary Tumor	Illumina HiSeq	b5897ed2-6c9b-4c6e-b131-41b62e60ecb9	Colorectal	53.0	1EB2A255-6EDD-4ADB-B52D-99DCEC590C5D	F38B5D2E-5CAB-45C7-BB0A-38B2EFC5C156	TCGA-A6-3807-01A-01D-1459-10	GRCh37-lite	TCGA-A6-3807	TCGA-COAD		s13652	Baylor College of Medicine	Christiana Healthcare		NO	T3	N2	Colon Adenocarcinoma	Stage IIIC	1459-10	False
S13722.58cfa83ce4b0c9d6adf730b4	58cfa83ce4b0c9d6adf730b4	fae749c6bcfc193aa1b9126628a2cf23.filtered.	WGS	fae749c6bcfc193aa1b9126628a2cf23	fae749c6bcfc193aa1b9126628a2cf23.bam	116.59	1.95	0.07	58cfa83ce4b0c9d6adf730b4	fae749c6bcfc193aa1b9126628a2cf23.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0IJ-01A	2C86C3EA-D926-4D39-A5AE-39ECE4774287	Primary Tumor	Illumina HiSeq	b665cc0b-5952-419e-87a4-d97d3298f607	Breast	42.0	9EF8142A-8627-4DCF-8C87-15B1BC2BFEA2	B7FAC67C-EB7A-485C-A9B3-3E36388D02B1	TCGA-B6-A0IJ-01A-11D-A128-09	GRCh37-lite	TCGA-B6-A0IJ	TCGA-BRCA		s6907	Washington University School of Medicine	Duke	United States	NO	T3	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIB	A128-09	True
S13722.58cfa82ee4b0c9d6adf6ac7e	58cfa82ee4b0c9d6adf6ac7e	G47088.TCGA-85-8052-01A-11D-2244-08.3.filtered.	WGS	G47088.TCGA-85-8052-01A-11D-2244-08.3	G47088.TCGA-85-8052-01A-11D-2244-08.3.bam	56.03		0.05	58cfa82ee4b0c9d6adf6ac7e	G47088.TCGA-85-8052-01A-11D-2244-08.3.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-85-8052-01A	395BABB3-3F5D-4E71-A675-AF4443F23028	Primary Tumor	Illumina HiSeq	541bd2eb-5c99-4a8c-a9d3-c05c470d15f8	Lung	53.0	9248B38E-EC7B-4C7C-BCB0-E942CE3C4847	43AA4123-0FE2-4071-8A81-CBDD0410B917	TCGA-85-8052-01A-11D-2244-08	HG19_Broad_variant	TCGA-85-8052	TCGA-LUSC		s10498	Broad Institute of MIT and Harvard	Asterand	Russia	NO	T3	N0	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IIB	2244-08	False
S13722.58cfa82ee4b0c9d6adf6ac7a	58cfa82ee4b0c9d6adf6ac7a	G39020.TCGA-IN-7806-01A-11D-2053-08.3.filtered.	WGS	G39020.TCGA-IN-7806-01A-11D-2053-08.3	G39020.TCGA-IN-7806-01A-11D-2053-08.3.bam	341.7		0.05	58cfa82ee4b0c9d6adf6ac7a	G39020.TCGA-IN-7806-01A-11D-2053-08.3.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-IN-7806-01A	87C217D4-66F4-46CA-8244-7856CE658FD3	Primary Tumor	Illumina HiSeq	65b3a7db-195a-47e8-804b-a1d4a5df79aa	Stomach	50.0	9B864C79-BF5C-4430-86E8-D8479ED90D25	576A1741-8C65-40DA-9F0F-B2CA805D70F3	TCGA-IN-7806-01A-11D-2053-08	HG19_Broad_variant	TCGA-IN-7806	TCGA-STAD		s15297	Broad Institute of MIT and Harvard	University of Pittsburgh	United States	NO	T3	N1	Stomach  Adenocarcinoma  Diffuse Type	Stage IIB	2053-08	False
S13722.58cfa82ee4b0c9d6adf6acec	58cfa82ee4b0c9d6adf6acec	G49537.TCGA-DE-A3KN-01A-11D-A20C-08.2.filtered.	WGS	G49537.TCGA-DE-A3KN-01A-11D-A20C-08.2	G49537.TCGA-DE-A3KN-01A-11D-A20C-08.2.bam	47.57		0.08	58cfa82ee4b0c9d6adf6acec	G49537.TCGA-DE-A3KN-01A-11D-A20C-08.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DE-A3KN-01A	085FFCDC-8600-42E2-852A-506465F716A2	Primary Tumor	Illumina HiSeq	62705306-2ad4-4287-ac8d-ca27cf525430	Thyroid	49.0	620B21C9-AC06-4154-A941-2532C775C6D8	07A7C634-BD9A-4FC2-B9FE-87B060EC3D1F	TCGA-DE-A3KN-01A-11D-A20C-08	HG19_Broad_variant	TCGA-DE-A3KN	TCGA-THCA		s11984	Broad Institute of MIT and Harvard	University of North Carolina	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A20C-08	False
S13722.58cfa82ee4b0c9d6adf6acef	58cfa82ee4b0c9d6adf6acef	G49537.TCGA-DJ-A4UT-01A-11D-A257-08.1.filtered.	WGS	G49537.TCGA-DJ-A4UT-01A-11D-A257-08.1	G49537.TCGA-DJ-A4UT-01A-11D-A257-08.1.bam	37.91		0.08	58cfa82ee4b0c9d6adf6acef	G49537.TCGA-DJ-A4UT-01A-11D-A257-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A4UT-01A	ACB80B76-2394-4250-8687-60E40E16E83B	Primary Tumor	Illumina HiSeq	3f6de736-5ec7-4e27-85a6-a39f216ce0bf	Thyroid	32.0	4D6855A8-076D-4F95-B6CE-2B250CE3087D	64A17D5B-8F40-4CCF-8F2F-E68C5FE6B1FF	TCGA-DJ-A4UT-01A-11D-A257-08	HG19_Broad_variant	TCGA-DJ-A4UT	TCGA-THCA		s11980	Broad Institute of MIT and Harvard	Memorial Sloan Kettering	United States	NO	T1a	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A257-08	False
S13722.58cfa82ee4b0c9d6adf6ad00	58cfa82ee4b0c9d6adf6ad00	G49537.TCGA-E8-A418-01A-11D-A23M-08.1.filtered.	WGS	G49537.TCGA-E8-A418-01A-11D-A23M-08.1	G49537.TCGA-E8-A418-01A-11D-A23M-08.1.bam	30.97		0.08	58cfa82ee4b0c9d6adf6ad00	G49537.TCGA-E8-A418-01A-11D-A23M-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-E8-A418-01A	EBBD54AD-7B97-4081-AD11-7F7F3CE74EEF	Primary Tumor	Illumina HiSeq	dcbb2120-b24f-4bc5-a07f-706d58345c05	Thyroid	75.0	979CBB75-28D9-4D33-8083-077C25BDDFD6	63EA274B-D42B-4787-9C54-8EE95EA376EC	TCGA-E8-A418-01A-11D-A23M-08	HG19_Broad_variant	TCGA-E8-A418	TCGA-THCA		s12088	Broad Institute of MIT and Harvard	Asterand	Russia	NO	T4a	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A23M-08	False
S13722.58cfa82ee4b0c9d6adf6ad02	58cfa82ee4b0c9d6adf6ad02	G49537.TCGA-E8-A416-01A-11D-A23M-08.2.filtered.	WGS	G49537.TCGA-E8-A416-01A-11D-A23M-08.2	G49537.TCGA-E8-A416-01A-11D-A23M-08.2.bam	16.01		0.08	58cfa82ee4b0c9d6adf6ad02	G49537.TCGA-E8-A416-01A-11D-A23M-08.2.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-E8-A416-01A	86B82345-6F4D-44FD-A9DB-6F107DE62F53	Primary Tumor	Illumina HiSeq	d49de1af-8dd9-4fdb-8a60-87bd8894395b	Thyroid	51.0	AF7B5868-2C11-4C74-8033-E914C987ECE6	C8381701-31CB-465A-BDF2-1B8132BE7A14	TCGA-E8-A416-01A-11D-A23M-08	HG19_Broad_variant	TCGA-E8-A416	TCGA-THCA		s12623	Broad Institute of MIT and Harvard	Asterand	Vietnam	NO	T1b	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A23M-08	False
S13722.58cfa82ee4b0c9d6adf6ad1c	58cfa82ee4b0c9d6adf6ad1c	G49537.TCGA-BJ-A45K-01A-11D-A23U-08.3.filtered.	WGS	G49537.TCGA-BJ-A45K-01A-11D-A23U-08.3	G49537.TCGA-BJ-A45K-01A-11D-A23U-08.3.bam	27.47		0.08	58cfa82ee4b0c9d6adf6ad1c	G49537.TCGA-BJ-A45K-01A-11D-A23U-08.3.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A45K-01A	8CFB88F6-7B37-4F1E-882B-3A368B604167	Primary Tumor	Illumina HiSeq	9a38b46c-3b59-40ad-9d22-d0d153c211a1	Thyroid	33.0	29B4816D-4CFB-45F0-BCD2-6B948245F3A4	77EBE6D2-6537-49D3-849D-FE93E2CF52AF	TCGA-BJ-A45K-01A-11D-A23U-08	HG19_Broad_variant	TCGA-BJ-A45K	TCGA-THCA		s12615	Broad Institute of MIT and Harvard	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A23U-08	False
S13722.58cfa82ee4b0c9d6adf6ad12	58cfa82ee4b0c9d6adf6ad12	G49537.TCGA-DE-A2OL-01A-11D-A18F-08.2.filtered.	WGS	G49537.TCGA-DE-A2OL-01A-11D-A18F-08.2	G49537.TCGA-DE-A2OL-01A-11D-A18F-08.2.bam	71.37		0.08	58cfa82ee4b0c9d6adf6ad12	G49537.TCGA-DE-A2OL-01A-11D-A18F-08.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DE-A2OL-01A	77BB90F0-E923-4E28-BB88-4D6B420E0B5C	Primary Tumor	Illumina HiSeq	60e1b538-0f36-45ea-892a-a8b64734f42b	Thyroid	44.0	6CBA95AD-2702-4F50-8B1E-BECDAF014B83	FC812906-D3B6-4210-A842-96F095280CBF	TCGA-DE-A2OL-01A-11D-A18F-08	HG19_Broad_variant	TCGA-DE-A2OL	TCGA-THCA		s12350	Broad Institute of MIT and Harvard	University of North Carolina	United States	NO	T2	NX	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A18F-08	False
S13722.58cfa82ee4b0c9d6adf6ad18	58cfa82ee4b0c9d6adf6ad18	G49537.TCGA-EM-A2OV-01A-11D-A202-08.1.filtered.	WGS	G49537.TCGA-EM-A2OV-01A-11D-A202-08.1	G49537.TCGA-EM-A2OV-01A-11D-A202-08.1.bam	24.95		0.08	58cfa82ee4b0c9d6adf6ad18	G49537.TCGA-EM-A2OV-01A-11D-A202-08.1.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-EM-A2OV-01A	55E03FFC-F006-4EC8-8E5D-A738FF091F8A	Primary Tumor	Illumina HiSeq	6c8370c6-102f-4bde-84ce-bf930800ac6a	Thyroid	64.0	1183BCB5-50A7-4CC0-A94C-732636B7EE7D	2DFE70FD-2650-49C0-B6EB-67DF585D063B	TCGA-EM-A2OV-01A-11D-A202-08	HG19_Broad_variant	TCGA-EM-A2OV	TCGA-THCA		s12347	Broad Institute of MIT and Harvard	University Health Network	Canada	NO	T2	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage II	A202-08	True
S13722.58cfa82ee4b0c9d6adf6ad1f	58cfa82ee4b0c9d6adf6ad1f	G39020.TCGA-BR-8486-01A-31D-2394-08.2.filtered.	WGS	G39020.TCGA-BR-8486-01A-31D-2394-08.2	G39020.TCGA-BR-8486-01A-31D-2394-08.2.bam	280.0		0.05	58cfa82ee4b0c9d6adf6ad1f	G39020.TCGA-BR-8486-01A-31D-2394-08.2.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-8486-01A	B8A1C8C7-3945-4D84-8F58-3A1A1EB10730	Primary Tumor	Illumina HiSeq	09ea179f-e2fc-479c-9b04-7c3ae8034874	Stomach	90.0	65FA5F32-8747-41B7-8287-061587DC22DE	6A7CDAF6-211E-4EB8-A70E-1153D69C45E4	TCGA-BR-8486-01A-31D-2394-08	HG19_Broad_variant	TCGA-BR-8486	TCGA-STAD		s14678	Broad Institute of MIT and Harvard	Asterand	Russia	NO	T1b	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IA	2394-08	True
S13722.58cfa82ee4b0c9d6adf6adac	58cfa82ee4b0c9d6adf6adac	G39020.TCGA-CD-8529-01A-11D-2340-08.2.filtered.	WGS	G39020.TCGA-CD-8529-01A-11D-2340-08.2	G39020.TCGA-CD-8529-01A-11D-2340-08.2.bam	200.7		0.05	58cfa82ee4b0c9d6adf6adac	G39020.TCGA-CD-8529-01A-11D-2340-08.2.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-8529-01A	5B7E557A-6AEE-4077-B3CD-C96179E643AE	Primary Tumor	Illumina HiSeq	65281f4c-9277-4d03-8566-75feb73c114d	Stomach	65.0	EB18C784-32F7-4570-A661-E4DF8F55378C	931B24DA-5D6D-4C2D-8DE9-EF32D6EB8565	TCGA-CD-8529-01A-11D-2340-08	HG19_Broad_variant	TCGA-CD-8529	TCGA-STAD		s14958	Broad Institute of MIT and Harvard	ILSbio	Vietnam	NO	T4	N0	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage IV	2340-08	False
S13722.58cfa82ee4b0c9d6adf6add6	58cfa82ee4b0c9d6adf6add6	G39020.TCGA-BR-8690-01A-11D-2394-08.4.filtered.	WGS	G39020.TCGA-BR-8690-01A-11D-2394-08.4	G39020.TCGA-BR-8690-01A-11D-2394-08.4.bam	390.0		0.05	58cfa82ee4b0c9d6adf6add6	G39020.TCGA-BR-8690-01A-11D-2394-08.4.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-8690-01A	337819D2-5281-4B41-9583-A476924BC837	Primary Tumor	Illumina HiSeq	4a0c62bb-6857-41e2-8933-37b5cb32f6b7	Stomach	54.0	0F7EBFFA-D119-45D6-8AF1-2048ECA173E7	EDC8839F-FA6B-41E0-AD49-F688073730BD	TCGA-BR-8690-01A-11D-2394-08	HG19_Broad_variant	TCGA-BR-8690	TCGA-STAD		s14390	Broad Institute of MIT and Harvard	Asterand	Ukraine	NO	T3	N3a	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIB	2394-08	True
S13722.58cfa82ee4b0c9d6adf6ae16	58cfa82ee4b0c9d6adf6ae16	G49837.TCGA-94-7943-01A-11D-A320-08.2.filtered.	WGS	G49837.TCGA-94-7943-01A-11D-A320-08.2	G49837.TCGA-94-7943-01A-11D-A320-08.2.bam	203.0		0.08	58cfa82ee4b0c9d6adf6ae16	G49837.TCGA-94-7943-01A-11D-A320-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Squamous Cell Carcinoma	Aligned reads	TCGA-94-7943-01A	AECF85CC-058C-46F3-9CDC-3573AC3B8438	Primary Tumor	Illumina HiSeq	f0eef218-f0af-4e9d-8f67-cdfc840480bc	Lung	80.0	E447DA47-227D-4956-9F46-AD1F81B73EBA	7731EF7F-25BD-42F5-9A20-BE249306A711	TCGA-94-7943-01A-11D-A320-08	HG19_Broad_variant	TCGA-94-7943	TCGA-LUSC		s10509	Broad Institute of MIT and Harvard	Washington University - Emory	United States	NO	T1b	NX	Lung Squamous Cell Carcinoma- Not Otherwise Specified (NOS)	Stage IA	A320-08	True
S13722.58cfa82ee4b0c9d6adf6aeaa	58cfa82ee4b0c9d6adf6aeaa	G49537.TCGA-ET-A4KN-01A-11D-A257-08.1.filtered.	WGS	G49537.TCGA-ET-A4KN-01A-11D-A257-08.1	G49537.TCGA-ET-A4KN-01A-11D-A257-08.1.bam	32.52		0.07	58cfa82ee4b0c9d6adf6aeaa	G49537.TCGA-ET-A4KN-01A-11D-A257-08.1.bam	Alive	FEMALE	WHITE		Thyroid Carcinoma	Aligned reads	TCGA-ET-A4KN-01A	7629F864-A009-4AA9-BF7E-2D99E00D294E	Primary Tumor	Illumina HiSeq	82a795da-f726-45af-a15f-a778695d466a	Thyroid	51.0	E01D507C-8E8E-45C6-B4EF-193177A382C4	178D0486-CB0D-4979-8BDF-BB3FE99149BD	TCGA-ET-A4KN-01A-11D-A257-08	HG19_Broad_variant	TCGA-ET-A4KN	TCGA-THCA		s12619	Broad Institute of MIT and Harvard	Johns Hopkins	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage III	A257-08	False
S13722.58cfa82ee4b0c9d6adf6aea0	58cfa82ee4b0c9d6adf6aea0	G49537.TCGA-FY-A2QD-01A-11D-A19J-08.1.filtered.	WGS	G49537.TCGA-FY-A2QD-01A-11D-A19J-08.1	G49537.TCGA-FY-A2QD-01A-11D-A19J-08.1.bam	37.07		0.08	58cfa82ee4b0c9d6adf6aea0	G49537.TCGA-FY-A2QD-01A-11D-A19J-08.1.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A2QD-01A	B0CB6ED7-3D9F-4D5E-8DF5-EDCC921C43B4	Primary Tumor	Illumina HiSeq	102342da-d9ce-4eb4-8c20-dda6ce072830	Thyroid	61.0	08D3CB3B-9A80-4034-B06D-B37DD38C8B9B	E7335A24-E5FC-4558-9EBA-511C5A802320	TCGA-FY-A2QD-01A-11D-A19J-08	HG19_Broad_variant	TCGA-FY-A2QD	TCGA-THCA		s12226	Broad Institute of MIT and Harvard	International Genomics Consortium	United States	NO	T1	N0	Thyroid Papillary Carcinoma - Classical/usual		A19J-08	False
S13722.58cfa82ee4b0c9d6adf6aedb	58cfa82ee4b0c9d6adf6aedb	G49537.TCGA-DJ-A2Q1-01A-22D-A19J-08.1.filtered.	WGS	G49537.TCGA-DJ-A2Q1-01A-22D-A19J-08.1	G49537.TCGA-DJ-A2Q1-01A-22D-A19J-08.1.bam	27.76		0.09	58cfa82ee4b0c9d6adf6aedb	G49537.TCGA-DJ-A2Q1-01A-22D-A19J-08.1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A2Q1-01A	E35B2928-8784-45D0-A71A-A2DF161542FA	Primary Tumor	Illumina HiSeq	0cac59ec-55cb-4769-ba6d-92c08a076186	Thyroid	44.0	D1361CB2-6758-4A8C-AE97-8AD5192572FC	007AAB66-2F07-459D-8952-3041D6EA24A8	TCGA-DJ-A2Q1-01A-22D-A19J-08	HG19_Broad_variant	TCGA-DJ-A2Q1	TCGA-THCA		s11981	Broad Institute of MIT and Harvard	Memorial Sloan Kettering	United States	NO	T1b	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A19J-08	False
S13722.58cfa82ee4b0c9d6adf6af4e	58cfa82ee4b0c9d6adf6af4e	G49537.TCGA-EL-A4K6-01A-12D-A257-08.2.filtered.	WGS	G49537.TCGA-EL-A4K6-01A-12D-A257-08.2	G49537.TCGA-EL-A4K6-01A-12D-A257-08.2.bam	55.8		0.08	58cfa82ee4b0c9d6adf6af4e	G49537.TCGA-EL-A4K6-01A-12D-A257-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-EL-A4K6-01A	4FC8E011-4433-4537-B03F-457A3A70240F	Primary Tumor	Illumina HiSeq	3fa6f792-4048-42a5-990b-a50e3e20fa7a	Thyroid	75.0	BB98FF62-4CD8-46D6-9A85-8439265BE40B	66EB4833-1B87-4FD9-A53D-26DC7AD6DE29	TCGA-EL-A4K6-01A-12D-A257-08	HG19_Broad_variant	TCGA-EL-A4K6	TCGA-THCA		s12498	Broad Institute of MIT and Harvard	MD Anderson	United States	NO	T4	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage IV	A257-08	False
S13722.58cfa82ee4b0c9d6adf6afc7	58cfa82ee4b0c9d6adf6afc7	G49537.TCGA-DJ-A13L-01A-11D-A21Z-08.1.filtered.	WGS	G49537.TCGA-DJ-A13L-01A-11D-A21Z-08.1	G49537.TCGA-DJ-A13L-01A-11D-A21Z-08.1.bam	32.87		0.08	58cfa82ee4b0c9d6adf6afc7	G49537.TCGA-DJ-A13L-01A-11D-A21Z-08.1.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13L-01A	C7A2F394-3E3F-4C90-9F1E-F2BE3E5B0D6B	Primary Tumor	Illumina HiSeq	56cad7af-d64e-4a7f-9d2e-206cbb921c3f	Thyroid	85.0	AB13FB1A-8B7F-4D84-84A9-C4F7EE59CAF8	1924D200-6929-4EEF-8A7F-317F8FBAB915	TCGA-DJ-A13L-01A-11D-A21Z-08	HG19_Broad_variant	TCGA-DJ-A13L	TCGA-THCA		s12501	Broad Institute of MIT and Harvard	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage I	A21Z-08	True
S13722.58cfa82fe4b0c9d6adf6b8ca	58cfa82fe4b0c9d6adf6b8ca	TCGA-A4-A4ZT-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-A4-A4ZT-01A-11D-A26P-10_wgs_Illumina	TCGA-A4-A4ZT-01A-11D-A26P-10_wgs_Illumina.bam	55.16		0.09	58cfa82fe4b0c9d6adf6b8ca	TCGA-A4-A4ZT-01A-11D-A26P-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-A4-A4ZT-01A	8B3C068D-5090-4030-8E7E-39DA005DEE79	Primary Tumor	Illumina HiSeq	90b348f5-ec38-4672-a60b-2bf4add19464	Kidney	71.0	460188E7-2A1E-4C3F-9C96-48C59A3FA9A0	483BB781-0179-42E1-BF9C-487B240769B8	TCGA-A4-A4ZT-01A-11D-A26P-10	GRCh37-lite	TCGA-A4-A4ZT	TCGA-KIRP		s11635	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1b	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A26P-10	True
S13722.58cfa82fe4b0c9d6adf6b92e	58cfa82fe4b0c9d6adf6b92e	TCGA-A4-A57E-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-A4-A57E-01A-11D-A26P-10_wgs_Illumina	TCGA-A4-A57E-01A-11D-A26P-10_wgs_Illumina.bam	37.08		0.08	58cfa82fe4b0c9d6adf6b92e	TCGA-A4-A57E-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-A4-A57E-01A	D80F601B-1064-4FF0-9C51-7F6AFB22D1F5	Primary Tumor	Illumina HiSeq	8e29468f-f3dd-48a6-9c1a-3bd0083bae2d	Kidney	59.0	341EA198-C8A2-4675-8077-2C450E9925E1	2DEB8F9A-9E0A-46D1-BCB5-902DB3B5C8AC	TCGA-A4-A57E-01A-11D-A26P-10	GRCh37-lite	TCGA-A4-A57E	TCGA-KIRP		s11637	Baylor College of Medicine	International Genomics Consortium	United States	NO	T2a	N0	Kidney Papillary Renal Cell Carcinoma	Stage IV	A26P-10	True
S13722.58cfa830e4b0c9d6adf6bc36	58cfa830e4b0c9d6adf6bc36	TCGA-AL-3467-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-AL-3467-01A-02D-1402-10_wgs_Illumina	TCGA-AL-3467-01A-02D-1402-10_wgs_Illumina.bam	305.07	1.9	0.05	58cfa830e4b0c9d6adf6bc36	TCGA-AL-3467-01A-02D-1402-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-AL-3467-01A	4D02010E-9E69-40D3-9BF0-3D4510AA0614	Primary Tumor	Illumina HiSeq	23233f91-10b3-48ca-9864-1ed41832b031	Kidney	54.0	70E32971-74E6-4C92-8424-D10541D39360	74C4C45F-818F-43A6-82A0-8E3E4EFDA26B	TCGA-AL-3467-01A-02D-1402-10	GRCh37-lite	TCGA-AL-3467	TCGA-KIRP		s11580	Baylor College of Medicine	Fox Chase		NO	T1b	NX	Kidney Papillary Renal Cell Carcinoma		1402-10	False
S13722.58cfa82fe4b0c9d6adf6b8e1	58cfa82fe4b0c9d6adf6b8e1	TCGA-A6-A56B-01A-31D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-A6-A56B-01A-31D-A28G-10_wgs_Illumina	TCGA-A6-A56B-01A-31D-A28G-10_wgs_Illumina.bam	38.26		0.08	58cfa82fe4b0c9d6adf6b8e1	TCGA-A6-A56B-01A-31D-A28G-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-A56B-01A	74A0264D-1D31-430D-9A88-E7334C8AA96C	Primary Tumor	Illumina HiSeq	319d9aec-3e76-4b48-b4a8-9ffcb0f3acc4	Colorectal	57.0	4425892C-8C35-4F6C-B531-1EC510AD19D2	D3D65DB3-36F9-41C7-8E5E-1683CE94DFCB	TCGA-A6-A56B-01A-31D-A28G-10	GRCh37-lite	TCGA-A6-A56B	TCGA-COAD		s13353	Baylor College of Medicine	Christiana Healthcare	United States	NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	A28G-10	True
S13722.58cfa82fe4b0c9d6adf6ba25	58cfa82fe4b0c9d6adf6ba25	TCGA-A3-3363-01A-01D-2094-10_wgs_Illumina.filtered.	WGS	TCGA-A3-3363-01A-01D-2094-10_wgs_Illumina	TCGA-A3-3363-01A-01D-2094-10_wgs_Illumina.bam	864.57	1.9	0.14	58cfa82fe4b0c9d6adf6ba25	TCGA-A3-3363-01A-01D-2094-10_wgs_Illumina.bam	Alive	MALE	ASIAN		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-A3-3363-01A	659294B9-DED9-498A-BC00-C1D4D456AA4A	Primary Tumor	Illumina HiSeq	cbce285a-a226-46dc-9f92-dfe98700c750	Kidney	50.0	605E86AC-58F6-47D4-8BDE-15EB23C857CC	0F53E757-1823-409F-A0EA-249270728E15	TCGA-A3-3363-01A-01D-2094-10	GRCh37-lite	TCGA-A3-3363	TCGA-KIRC		s9301	Baylor College of Medicine	International Genomics Consortium		NO	T2	N0	Kidney Clear Cell Renal Carcinoma	Stage II	2094-10	False
S13722.58cfa830e4b0c9d6adf6bc4c	58cfa830e4b0c9d6adf6bc4c	TCGA-AL-3473-01A-01D-1253-10_wgs_Illumina.filtered.	WGS	TCGA-AL-3473-01A-01D-1253-10_wgs_Illumina	TCGA-AL-3473-01A-01D-1253-10_wgs_Illumina.bam	543.0	1.9	0.14	58cfa830e4b0c9d6adf6bc4c	TCGA-AL-3473-01A-01D-1253-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-AL-3473-01A	A7BF785F-0539-4899-AC21-47D1FC347EE8	Primary Tumor	Illumina HiSeq	7f8267f9-4d48-48c6-aebb-a596aaf7755c	Kidney	55.0	DE88A41B-8A32-40D6-9C0B-1FE2303D8AD2	14DD86C1-DFB3-4124-A453-4D64223BC048	TCGA-AL-3473-01A-01D-1253-10	GRCh37-lite	TCGA-AL-3473	TCGA-KIRP		s11638	Baylor College of Medicine	Fox Chase		NO	T2	N0	Kidney Papillary Renal Cell Carcinoma	Stage II	1253-10	False
S13722.58cfa830e4b0c9d6adf6bc4a	58cfa830e4b0c9d6adf6bc4a	TCGA-AL-3468-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-AL-3468-01A-02D-1402-10_wgs_Illumina	TCGA-AL-3468-01A-02D-1402-10_wgs_Illumina.bam	171.07	1.9	0.05	58cfa830e4b0c9d6adf6bc4a	TCGA-AL-3468-01A-02D-1402-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-AL-3468-01A	2272C592-B9B6-4483-9F7F-6E185699B900	Primary Tumor	Illumina HiSeq	2cdb23d3-23d0-4aef-9ab9-0f01c712eafa	Kidney	74.0	2E825CE0-8121-4D0F-B876-905A1DF66D46	19D6CF34-1CD7-4242-A4D1-5D3E11F428AA	TCGA-AL-3468-01A-02D-1402-10	GRCh37-lite	TCGA-AL-3468	TCGA-KIRP		s11578	Baylor College of Medicine	Fox Chase	United States	NO	T2	NX	Kidney Papillary Renal Cell Carcinoma	Stage II	1402-10	False
S13722.58cfa830e4b0c9d6adf6be71	58cfa830e4b0c9d6adf6be71	TCGA-BP-4326-01A-01D-2097-10_wgs_Illumina.filtered.	WGS	TCGA-BP-4326-01A-01D-2097-10_wgs_Illumina	TCGA-BP-4326-01A-01D-2097-10_wgs_Illumina.bam	109.0	1.9	0.14	58cfa830e4b0c9d6adf6be71	TCGA-BP-4326-01A-01D-2097-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-4326-01A	7664C241-B369-4D76-9CD1-7F2BDC1D267F	Primary Tumor	Illumina HiSeq	8d64ee9c-1973-46e9-8ad7-1d9c3a96a47c	Kidney	53.0	068BFE4D-341C-49F7-B7A9-5D070DE00AB3	54842328-9432-4820-8976-7964BF9BF147	TCGA-BP-4326-01A-01D-2097-10	GRCh37-lite	TCGA-BP-4326	TCGA-KIRC		s9163	Baylor College of Medicine	MSKCC		NO	T1b	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2097-10	False
S13722.58cfa830e4b0c9d6adf6bca2	58cfa830e4b0c9d6adf6bca2	TCGA-AZ-4315-01A-01W-1461-10_wgs_Illumina.filtered.	WGS	TCGA-AZ-4315-01A-01W-1461-10_wgs_Illumina	TCGA-AZ-4315-01A-01W-1461-10_wgs_Illumina.bam	171.0		0.5	58cfa830e4b0c9d6adf6bca2	TCGA-AZ-4315-01A-01W-1461-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4315-01A	DE287A25-981D-49F8-81AF-FE0300E4CD31	Primary Tumor	Illumina HiSeq	707a2d43-0ea1-4012-8f29-4202690c6608	Colorectal	61.0	BA9E5603-BB1D-4AA8-93E4-40043164F143	A9D1B074-7F36-4A04-B270-A2061249FF20	TCGA-AZ-4315-01A-01W-1461-10	GRCh37-lite	TCGA-AZ-4315	TCGA-COAD		s13211	Baylor College of Medicine	University of Pittsburgh		NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1461-10	False
S13722.58cfa830e4b0c9d6adf6bcb3	58cfa830e4b0c9d6adf6bcb3	TCGA-B0-5695-01A-11D-2103-10_wgs_Illumina.filtered.	WGS	TCGA-B0-5695-01A-11D-2103-10_wgs_Illumina	TCGA-B0-5695-01A-11D-2103-10_wgs_Illumina.bam	239.4	1.9	0.15	58cfa830e4b0c9d6adf6bcb3	TCGA-B0-5695-01A-11D-2103-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-B0-5695-01A	FB9BAFA5-7133-4955-8156-4EB6763DC8E1	Primary Tumor	Illumina HiSeq	a8ffeac5-01c4-4dac-92b8-413f4009f4fa	Kidney	61.0	86E4862C-7405-40B5-B73F-BE0C6C52EA6D	B6365BDB-E6D5-4615-95B3-DB12A0C2F3D9	TCGA-B0-5695-01A-11D-2103-10	GRCh37-lite	TCGA-B0-5695	TCGA-KIRC		s8833	Baylor College of Medicine	University of Pittsburgh		NO	T1b	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2103-10	False
S13722.58cfa830e4b0c9d6adf6becd	58cfa830e4b0c9d6adf6becd	TCGA-AL-A5DJ-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-AL-A5DJ-01A-11D-A26P-10_wgs_Illumina	TCGA-AL-A5DJ-01A-11D-A26P-10_wgs_Illumina.bam	26.68		0.07	58cfa830e4b0c9d6adf6becd	TCGA-AL-A5DJ-01A-11D-A26P-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-AL-A5DJ-01A	B06CDF61-61C9-4035-A55D-1EF21DC21069	Primary Tumor	Illumina HiSeq	0fd919c5-b847-49f4-b928-4dd15a94c3a0	Kidney	54.0	BD6B7CBE-57B6-45B9-96F6-4D39B8303407	B4F515CE-5BEE-4E40-A66A-01F41E92181E	TCGA-AL-A5DJ-01A-11D-A26P-10	GRCh37-lite	TCGA-AL-A5DJ	TCGA-KIRP		s11579	Baylor College of Medicine	Fox Chase	United States	NO	T3a	NX	Kidney Papillary Renal Cell Carcinoma	Stage III	A26P-10	True
S13722.58cfa830e4b0c9d6adf6bed5	58cfa830e4b0c9d6adf6bed5	TCGA-BP-4756-01A-01D-2097-10_wgs_Illumina.filtered.	WGS	TCGA-BP-4756-01A-01D-2097-10_wgs_Illumina	TCGA-BP-4756-01A-01D-2097-10_wgs_Illumina.bam	133.0	1.9	0.14	58cfa830e4b0c9d6adf6bed5	TCGA-BP-4756-01A-01D-2097-10_wgs_Illumina.bam	Alive	FEMALE	ASIAN		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-4756-01A	9ECDDE9C-2179-4830-BD10-C4FA40F26066	Primary Tumor	Illumina HiSeq	21f5c572-343f-4923-af48-99ee2a4ccbdf	Kidney	62.0	98D425BE-4D70-4260-8C4F-B0EB89E0E4A6	DB4592FB-13C2-4D61-9DC3-A5D43DEF8D4B	TCGA-BP-4756-01A-01D-2097-10	GRCh37-lite	TCGA-BP-4756	TCGA-KIRC		s9164	Baylor College of Medicine	MSKCC		NO	T1b	N0	Kidney Clear Cell Renal Carcinoma	Stage I	2097-10	False
S13722.58cfa830e4b0c9d6adf6bf19	58cfa830e4b0c9d6adf6bf19	TCGA-AY-A54L-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-AY-A54L-01A-11D-A28G-10_wgs_Illumina	TCGA-AY-A54L-01A-11D-A28G-10_wgs_Illumina.bam	62.42		0.07	58cfa830e4b0c9d6adf6bf19	TCGA-AY-A54L-01A-11D-A28G-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Colon Adenocarcinoma	Aligned reads	TCGA-AY-A54L-01A	D8E9EA52-FF28-4626-BAA3-71350FD53DDF	Primary Tumor	Illumina HiSeq	709d8bea-f505-4558-b12a-7bd4322e75ea	Colorectal	74.0	52EFBEB4-7B23-4C49-92F9-931A3EB99055	080ECC31-756A-4A1B-A51E-D632AC8219F7	TCGA-AY-A54L-01A-11D-A28G-10	GRCh37-lite	TCGA-AY-A54L	TCGA-COAD		s13542	Baylor College of Medicine	UNC	United States	NO	T2	N0	Colon Adenocarcinoma	Stage I	A28G-10	True
S13722.58cfa830e4b0c9d6adf6c000	58cfa830e4b0c9d6adf6c000	TCGA-B3-4104-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-B3-4104-01A-02D-1402-10_wgs_Illumina	TCGA-B3-4104-01A-02D-1402-10_wgs_Illumina.bam	198.07	1.9	0.05	58cfa830e4b0c9d6adf6c000	TCGA-B3-4104-01A-02D-1402-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B3-4104-01A	E15A108E-0B32-426F-926A-3FB1AF0A82D3	Primary Tumor	Illumina HiSeq	bf671eff-6fe3-4498-b767-06041f20c7e5	Kidney	75.0	BB0EFB98-DB70-499D-BC72-56AF138C419C	8E0F02B3-2BC5-4E1B-BA7E-809CB7FDB58C	TCGA-B3-4104-01A-02D-1402-10	GRCh37-lite	TCGA-B3-4104	TCGA-KIRP		s11642	Baylor College of Medicine	Christiana Healthcare		NO	T2	NX	Kidney Papillary Renal Cell Carcinoma	Stage II	1402-10	False
S13722.58cfa830e4b0c9d6adf6c005	58cfa830e4b0c9d6adf6c005	TCGA-B3-4103-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-B3-4103-01A-02D-1402-10_wgs_Illumina	TCGA-B3-4103-01A-02D-1402-10_wgs_Illumina.bam	216.07	1.9	0.05	58cfa830e4b0c9d6adf6c005	TCGA-B3-4103-01A-02D-1402-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B3-4103-01A	1A726069-0B44-42AD-9A20-0EE90B31796B	Primary Tumor	Illumina HiSeq	e00b0cfe-8b23-4f21-998f-957efbc26955	Kidney	56.0	3829FA12-FDD5-4829-8F00-BDFBB057F23E	1DA96C26-20A5-435A-8CA3-9F698B8652A2	TCGA-B3-4103-01A-02D-1402-10	GRCh37-lite	TCGA-B3-4103	TCGA-KIRP		s11853	Baylor College of Medicine	Christiana Healthcare		NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	1402-10	False
S13722.58cfa830e4b0c9d6adf6c00e	58cfa830e4b0c9d6adf6c00e	TCGA-B3-3926-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-B3-3926-01A-02D-1402-10_wgs_Illumina	TCGA-B3-3926-01A-02D-1402-10_wgs_Illumina.bam	191.07	1.9	0.05	58cfa830e4b0c9d6adf6c00e	TCGA-B3-3926-01A-02D-1402-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B3-3926-01A	2666AB3E-F2B9-4B3D-BFCE-AAC2A4BAFE62	Primary Tumor	Illumina HiSeq	7825c6ac-6e33-4e1d-82cc-35cf60c16253	Kidney	59.0	3BB75DF9-E710-4F3D-B1B1-A4D459EB376F	72293A70-9DC8-4E4A-ACDC-C74587A90420	TCGA-B3-3926-01A-02D-1402-10	GRCh37-lite	TCGA-B3-3926	TCGA-KIRP		s11582	Baylor College of Medicine	Christiana Healthcare		NO	T1	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	1402-10	False
S13722.58cfa830e4b0c9d6adf6c14d	58cfa830e4b0c9d6adf6c14d	TCGA-BA-5556-01A-01D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-BA-5556-01A-01D-A32X-10_wgs_Illumina	TCGA-BA-5556-01A-01D-A32X-10_wgs_Illumina.bam	116.7	1.9	0.08	58cfa830e4b0c9d6adf6c14d	TCGA-BA-5556-01A-01D-A32X-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5556-01A	70741B73-9683-42BD-87FC-6A021A70103B	Primary Tumor	Illumina HiSeq	e855f092-899d-469a-981c-5094b07c31ac	Head and Neck	58.0	C00EEDDB-6AE2-48BA-8677-C174E579A724	8294A969-59A1-4D3B-895B-F07E96BF9F7A	TCGA-BA-5556-01A-01D-A32X-10	GRCh37-lite	TCGA-BA-5556	TCGA-HNSC		s16319	Baylor College of Medicine	UNC		NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	A32X-10	True
S13722.58cfa830e4b0c9d6adf6c048	58cfa830e4b0c9d6adf6c048	TCGA-B3-3925-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-B3-3925-01A-02D-1402-10_wgs_Illumina	TCGA-B3-3925-01A-02D-1402-10_wgs_Illumina.bam	241.07	1.9	0.05	58cfa830e4b0c9d6adf6c048	TCGA-B3-3925-01A-02D-1402-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B3-3925-01A	75A53BFF-BF0F-4AD8-9B8E-14A27914D4F2	Primary Tumor	Illumina HiSeq	9130f58c-9250-4f4f-a60d-028366b76852	Kidney	52.0	16223531-33C3-4D2C-8715-FA9899CEE168	42F88B95-FA12-47C7-93F1-CF72F207291C	TCGA-B3-3925-01A-02D-1402-10	GRCh37-lite	TCGA-B3-3925	TCGA-KIRP		s11770	Baylor College of Medicine	Christiana Healthcare		NO	T3a	NX	Kidney Papillary Renal Cell Carcinoma	Stage III	1402-10	False
S13722.58cfa830e4b0c9d6adf6c156	58cfa830e4b0c9d6adf6c156	TCGA-B9-4117-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-B9-4117-01A-02D-1402-10_wgs_Illumina	TCGA-B9-4117-01A-02D-1402-10_wgs_Illumina.bam	155.07	1.9	0.05	58cfa830e4b0c9d6adf6c156	TCGA-B9-4117-01A-02D-1402-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B9-4117-01A	71B35CD8-ECEE-4599-BB24-B1EF78118423	Primary Tumor	Illumina HiSeq	4d9a1f84-a989-4caa-84d2-36d42c950675	Kidney	48.0	F3871637-192D-4324-9C59-CECFFF436356	6BA5F81A-B7A0-4C18-A112-2E11094EEC85	TCGA-B9-4117-01A-02D-1402-10	GRCh37-lite	TCGA-B9-4117	TCGA-KIRP		s11776	Baylor College of Medicine	UNC		NO	T2	NX	Kidney Papillary Renal Cell Carcinoma		1402-10	False
S13722.58cfa830e4b0c9d6adf6c15e	58cfa830e4b0c9d6adf6c15e	TCGA-BA-6869-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-BA-6869-01A-11D-A32X-10_wgs_Illumina	TCGA-BA-6869-01A-11D-A32X-10_wgs_Illumina.bam	379.7	1.9	0.07	58cfa830e4b0c9d6adf6c15e	TCGA-BA-6869-01A-11D-A32X-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-6869-01A	FAFD6F5B-1D76-4537-BD1C-E0BD7B4E2166	Primary Tumor	Illumina HiSeq	e35c380b-a1ee-47e3-b382-139ed8640d98	Head and Neck	62.0	F4ED2C84-39F8-4AB3-8762-A9920ACC2432	3E604A1C-B95F-44FF-9723-E2FAC845DA3B	TCGA-BA-6869-01A-11D-A32X-10	GRCh37-lite	TCGA-BA-6869	TCGA-HNSC		s15615	Baylor College of Medicine	UNC	United States	NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	A32X-10	True
S13722.58cfa830e4b0c9d6adf6c198	58cfa830e4b0c9d6adf6c198	TCGA-B9-4116-01A-02D-1402-10_wgs_Illumina.filtered.	WGS	TCGA-B9-4116-01A-02D-1402-10_wgs_Illumina	TCGA-B9-4116-01A-02D-1402-10_wgs_Illumina.bam	149.07	1.8	0.05	58cfa830e4b0c9d6adf6c198	TCGA-B9-4116-01A-02D-1402-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B9-4116-01A	4EDD92E1-5DA5-49A3-80E4-FA456AA425B8	Primary Tumor	Illumina HiSeq	23059106-498b-44b7-a1a9-72b42dcd751c	Kidney	75.0	DAC245C0-39A0-40D3-8FE1-E33F97B95D27	E6801359-D1D7-4871-B2FB-180674A2E469	TCGA-B9-4116-01A-02D-1402-10	GRCh37-lite	TCGA-B9-4116	TCGA-KIRP		s11772	Baylor College of Medicine	UNC		NO	T2a	NX	Kidney Papillary Renal Cell Carcinoma		1402-10	False
S13722.58cfa830e4b0c9d6adf6bc5e	58cfa830e4b0c9d6adf6bc5e	TCGA-AL-3472-01A-01D-1253-10_wgs_Illumina.filtered.	WGS	TCGA-AL-3472-01A-01D-1253-10_wgs_Illumina	TCGA-AL-3472-01A-01D-1253-10_wgs_Illumina.bam	543.0	1.9	0.13	58cfa830e4b0c9d6adf6bc5e	TCGA-AL-3472-01A-01D-1253-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-AL-3472-01A	42D044AE-1416-477D-AC80-779C49BC8D35	Primary Tumor	Illumina HiSeq	8f19974d-a670-4221-82fc-60d3918c19e0	Kidney	57.0	7EEA5C2A-F1A2-432E-88A2-E96B809E15D9	63D0C49D-918D-41FB-808A-1F8001981917	TCGA-AL-3472-01A-01D-1253-10	GRCh37-lite	TCGA-AL-3472	TCGA-KIRP		s11852	Baylor College of Medicine	Fox Chase		NO	T2	N0	Kidney Papillary Renal Cell Carcinoma		1253-10	False
S13722.58cfa830e4b0c9d6adf6c1c8	58cfa830e4b0c9d6adf6c1c8	TCGA-BC-A217-01A-11D-A152-10_wgs_Illumina.filtered.	WGS	TCGA-BC-A217-01A-11D-A152-10_wgs_Illumina	TCGA-BC-A217-01A-11D-A152-10_wgs_Illumina.bam	102.31	1.74	0.09	58cfa830e4b0c9d6adf6c1c8	TCGA-BC-A217-01A-11D-A152-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Liver Hepatocellular Carcinoma	Aligned reads	TCGA-BC-A217-01A	6DCFC418-AB28-4365-95EA-C1AE254F2341	Primary Tumor	Illumina HiSeq	a8b86f30-113b-4e02-98d3-b1dae29380d3	Liver	75.0	C827A8B9-359C-4A6F-B950-839B3FB0C097	2BFF30D5-BE79-4686-8164-7A7D9619D3C0	TCGA-BC-A217-01A-11D-A152-10	GRCh37-lite	TCGA-BC-A217	TCGA-LIHC		s17057	Baylor College of Medicine	UNC	United States	NO	T2	NX	Hepatocellular Carcinoma	Stage II	A152-10	True
S13722.58cfa830e4b0c9d6adf6c178	58cfa830e4b0c9d6adf6c178	TCGA-B9-4115-01A-01D-1554-10_wgs_Illumina.filtered.	WGS	TCGA-B9-4115-01A-01D-1554-10_wgs_Illumina	TCGA-B9-4115-01A-01D-1554-10_wgs_Illumina.bam	374.67	1.9	0.05	58cfa830e4b0c9d6adf6c178	TCGA-B9-4115-01A-01D-1554-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B9-4115-01A	A121406A-30B2-4717-AE96-EDCB17D911E2	Primary Tumor	Illumina HiSeq	4971043f-212e-4a2c-a9db-7e10c9203ce1	Kidney	53.0	31769C98-8882-44E9-B61B-417903B3E4F5	0ED63D84-D3FE-4289-9255-35F4A03B703B	TCGA-B9-4115-01A-01D-1554-10	GRCh37-lite	TCGA-B9-4115	TCGA-KIRP		s11858	Baylor College of Medicine	UNC		NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	1554-10	False
S13722.58cfa830e4b0c9d6adf6c1d6	58cfa830e4b0c9d6adf6c1d6	TCGA-BC-A216-01A-11D-A152-10_wgs_Illumina.filtered.	WGS	TCGA-BC-A216-01A-11D-A152-10_wgs_Illumina	TCGA-BC-A216-01A-11D-A152-10_wgs_Illumina.bam	85.26	1.85	0.09	58cfa830e4b0c9d6adf6c1d6	TCGA-BC-A216-01A-11D-A152-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Liver Hepatocellular Carcinoma	Aligned reads	TCGA-BC-A216-01A	4BBDBE77-F3CB-4B64-9826-72DEBB734784	Primary Tumor	Illumina HiSeq	b808f3c9-f5be-4c4d-af62-4389365badbb	Liver	62.0	F8B5247F-5276-4189-9041-2D914482D539	C1D9ED06-7498-4C6C-A0DE-DBF28E868109	TCGA-BC-A216-01A-11D-A152-10	GRCh37-lite	TCGA-BC-A216	TCGA-LIHC		s16672	Baylor College of Medicine	UNC	United States	NO	T3	NX	Hepatocellular Carcinoma	Stage IIIA	A152-10	True
S13722.58cfa830e4b0c9d6adf6c2a2	58cfa830e4b0c9d6adf6c2a2	TCGA-BP-4807-01A-01D-2098-10_wgs_Illumina.filtered.	WGS	TCGA-BP-4807-01A-01D-2098-10_wgs_Illumina	TCGA-BP-4807-01A-01D-2098-10_wgs_Illumina.bam	91.4	1.9	0.16	58cfa830e4b0c9d6adf6c2a2	TCGA-BP-4807-01A-01D-2098-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-BP-4807-01A	33CF0893-0411-4758-AA90-602BFEDF0850	Primary Tumor	Illumina HiSeq	929b4e29-102f-48e2-a919-ff967127437e	Kidney	42.0	26307437-2F30-4647-81AC-F6BAE5BE6113	A54AAC0E-4108-49CF-BF50-687031C7CDA6	TCGA-BP-4807-01A-01D-2098-10	GRCh37-lite	TCGA-BP-4807	TCGA-KIRC		s9447	Baylor College of Medicine	MSKCC		NO	T1a	NX	Kidney Clear Cell Renal Carcinoma	Stage I	2098-10	True
S13722.58cfa830e4b0c9d6adf6c23e	58cfa830e4b0c9d6adf6c23e	TCGA-BW-A5NQ-01A-11D-A27I-10_wgs_Illumina.filtered.	WGS	TCGA-BW-A5NQ-01A-11D-A27I-10_wgs_Illumina	TCGA-BW-A5NQ-01A-11D-A27I-10_wgs_Illumina.bam	66.53		0.07	58cfa830e4b0c9d6adf6c23e	TCGA-BW-A5NQ-01A-11D-A27I-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-BW-A5NQ-01A	C7F1B389-AEC7-4993-8AFB-B7A56064F8FC	Primary Tumor	Illumina HiSeq	4bbd34a1-0024-44aa-9e51-9ac4c51c7f1d	Liver	63.0	C8FFE03A-62C3-4B47-9DEA-CB3377F59ABB	E30C64D5-E796-4CFC-8DC8-6E62BF97822F	TCGA-BW-A5NQ-01A-11D-A27I-10	GRCh37-lite	TCGA-BW-A5NQ	TCGA-LIHC		s16848	Baylor College of Medicine	St Joseph's Medical Center (MD)	United States	NO	T1	NX	Hepatocellular Carcinoma	Stage I	A27I-10	True
S13722.58cfa830e4b0c9d6adf6c28c	58cfa830e4b0c9d6adf6c28c	TCGA-AD-A5EJ-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-AD-A5EJ-01A-11D-A28G-10_wgs_Illumina	TCGA-AD-A5EJ-01A-11D-A28G-10_wgs_Illumina.bam	40.09		0.07	58cfa830e4b0c9d6adf6c28c	TCGA-AD-A5EJ-01A-11D-A28G-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AD-A5EJ-01A	613AA3E8-A70B-45A9-9C08-0C2346C8BF00	Primary Tumor	Illumina HiSeq	ce0bf9ea-efa0-4c54-8970-a703051d667e	Colorectal	74.0	F675116A-BFEC-47AE-AC24-9B61DD3CC6C1	711C8A16-3CF8-42D8-B29E-FD1E9EF1C82B	TCGA-AD-A5EJ-01A-11D-A28G-10	GRCh37-lite	TCGA-AD-A5EJ	TCGA-COAD		s13538	Baylor College of Medicine	International Genomics Consortium	United States	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	A28G-10	True
S13722.58cfa831e4b0c9d6adf6c3e3	58cfa831e4b0c9d6adf6c3e3	TCGA-CC-5260-01A-01D-A12Z-10_wgs_Illumina.filtered.	WGS	TCGA-CC-5260-01A-01D-A12Z-10_wgs_Illumina	TCGA-CC-5260-01A-01D-A12Z-10_wgs_Illumina.bam	91.26	1.95	0.08	58cfa831e4b0c9d6adf6c3e3	TCGA-CC-5260-01A-01D-A12Z-10_wgs_Illumina.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-CC-5260-01A	CA8AFB2C-BE3D-41E8-8DBC-19FE7AB6154B	Primary Tumor	Illumina HiSeq	94aaf939-2195-4c49-b867-778f3670e7ff	Liver	61.0	7F347680-CD4D-4289-8F8F-3B0541381A42	3BACC189-01B8-46CC-A442-F393C0F428C6	TCGA-CC-5260-01A-01D-A12Z-10	GRCh37-lite	TCGA-CC-5260	TCGA-LIHC		s16581	Baylor College of Medicine	ILSbio		NO	T4	N0	Hepatocellular Carcinoma	Stage IIIC	A12Z-10	True
S13722.58cfa831e4b0c9d6adf6c3b6	58cfa831e4b0c9d6adf6c3b6	TCGA-CC-5262-01A-01D-A21X-10_wgs_Illumina.filtered.	WGS	TCGA-CC-5262-01A-01D-A21X-10_wgs_Illumina	TCGA-CC-5262-01A-01D-A21X-10_wgs_Illumina.bam	73.73	1.92	0.07	58cfa831e4b0c9d6adf6c3b6	TCGA-CC-5262-01A-01D-A21X-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-CC-5262-01A	1B428ADA-EB3F-40C2-B4BF-1BBF6B61729D	Primary Tumor	Illumina HiSeq	c98a5543-b4b7-42ad-807e-73cdbbf77345	Liver	67.0	DC595EED-D459-40FD-8417-6A1C56759EC8	47E5FF56-9534-4FCF-A593-33027E877F93	TCGA-CC-5262-01A-01D-A21X-10	GRCh37-lite	TCGA-CC-5262	TCGA-LIHC		s16851	Baylor College of Medicine	ILSbio		NO	T4	N0	Hepatocellular Carcinoma	Stage IIIC	A21X-10	False
S13722.58cfa831e4b0c9d6adf6c3a6	58cfa831e4b0c9d6adf6c3a6	TCGA-CC-A1HT-01A-11D-A12Z-10_wgs_Illumina.filtered.	WGS	TCGA-CC-A1HT-01A-11D-A12Z-10_wgs_Illumina	TCGA-CC-A1HT-01A-11D-A12Z-10_wgs_Illumina.bam	75.65	1.95	0.08	58cfa831e4b0c9d6adf6c3a6	TCGA-CC-A1HT-01A-11D-A12Z-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-CC-A1HT-01A	670C1CBC-4494-45F1-BB8B-18DB82D4F7E0	Primary Tumor	Illumina HiSeq	f7c13bc4-5edc-4964-8267-e7956bf2fdd0	Liver	50.0	96F911ED-2064-4745-AD07-6C47B0A0C7CD	6B25A78F-20DC-4CCC-B4C0-F9885D16725D	TCGA-CC-A1HT-01A-11D-A12Z-10	GRCh37-lite	TCGA-CC-A1HT	TCGA-LIHC		s16850	Baylor College of Medicine	ILSbio	Vietnam	NO	T3	N0	Hepatocellular Carcinoma	Stage IIIA	A12Z-10	True
S13722.58cfa831e4b0c9d6adf6c3be	58cfa831e4b0c9d6adf6c3be	TCGA-CC-5261-01A-01D-A12Z-10_wgs_Illumina.filtered.	WGS	TCGA-CC-5261-01A-01D-A12Z-10_wgs_Illumina	TCGA-CC-5261-01A-01D-A12Z-10_wgs_Illumina.bam	125.45	1.93	0.08	58cfa831e4b0c9d6adf6c3be	TCGA-CC-5261-01A-01D-A12Z-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-CC-5261-01A	1AD7F17E-B3B8-40E9-AAB8-5A17E0AEC408	Primary Tumor	Illumina HiSeq	43047cdb-fea6-4e20-9248-30ae5624c5a7	Liver	44.0	538998F3-5230-4963-8B67-D34DE695E97D	A2F143D6-BA07-4FF0-960D-B29C3C716665	TCGA-CC-5261-01A-01D-A12Z-10	GRCh37-lite	TCGA-CC-5261	TCGA-LIHC		s16582	Baylor College of Medicine	ILSbio		NO	T2	N0	Hepatocellular Carcinoma	Stage II	A12Z-10	True
S13722.58cfa831e4b0c9d6adf6c422	58cfa831e4b0c9d6adf6c422	TCGA-BW-A5NP-01A-11D-A27I-10_wgs_Illumina.filtered.	WGS	TCGA-BW-A5NP-01A-11D-A27I-10_wgs_Illumina	TCGA-BW-A5NP-01A-11D-A27I-10_wgs_Illumina.bam	62.92		0.08	58cfa831e4b0c9d6adf6c422	TCGA-BW-A5NP-01A-11D-A27I-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-BW-A5NP-01A	56A82A56-0241-4D3D-9DE2-696B0C36DF91	Primary Tumor	Illumina HiSeq	ce91806d-fb1a-452a-ad2e-51c7bdfbeb15	Liver	26.0	C13884B6-EAEF-4E1C-8FA7-5FE76548D32F	1C00925B-7328-4DB0-B930-04AAB2D80719	TCGA-BW-A5NP-01A-11D-A27I-10	GRCh37-lite	TCGA-BW-A5NP	TCGA-LIHC		s16972	Baylor College of Medicine	St Joseph's Medical Center (MD)	United States	NO	T2	N0	Hepatocellular Carcinoma	Stage IV	A27I-10	True
S13722.58cfa831e4b0c9d6adf6c418	58cfa831e4b0c9d6adf6c418	TCGA-CJ-4878-01A-01D-2098-10_wgs_Illumina.filtered.	WGS	TCGA-CJ-4878-01A-01D-2098-10_wgs_Illumina	TCGA-CJ-4878-01A-01D-2098-10_wgs_Illumina.bam	215.7	1.9	0.15	58cfa831e4b0c9d6adf6c418	TCGA-CJ-4878-01A-01D-2098-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-4878-01A	7CA06DBE-F073-4AEE-86FF-A545FAD5EA93	Primary Tumor	Illumina HiSeq	cb7f204c-4503-4691-b1c7-fe363b44f4de	Kidney	71.0	24814EED-FDDB-475A-822E-EFFF92202954	DE4C3F91-D164-47DF-9971-FEBA840D247C	TCGA-CJ-4878-01A-01D-2098-10	GRCh37-lite	TCGA-CJ-4878	TCGA-KIRC		s9567	Baylor College of Medicine	MD Anderson Cancer Center		NO	T3a	NX	Kidney Clear Cell Renal Carcinoma	Stage III	2098-10	True
S13722.58cfa831e4b0c9d6adf6c43a	58cfa831e4b0c9d6adf6c43a	TCGA-CJ-4870-01A-01D-2098-10_wgs_Illumina.filtered.	WGS	TCGA-CJ-4870-01A-01D-2098-10_wgs_Illumina	TCGA-CJ-4870-01A-01D-2098-10_wgs_Illumina.bam	85.7	1.9	0.15	58cfa831e4b0c9d6adf6c43a	TCGA-CJ-4870-01A-01D-2098-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CJ-4870-01A	78048432-2DE1-498C-9CF1-9C5BD43DAA39	Primary Tumor	Illumina HiSeq	22d3d6f1-5686-493f-b205-6ecc2602d2b8	Kidney	58.0	F7D03CD3-2D55-400A-BB29-F86CCAE475EC	267A9862-17BD-4056-BA4A-1F373736FFBB	TCGA-CJ-4870-01A-01D-2098-10	GRCh37-lite	TCGA-CJ-4870	TCGA-KIRC		s9566	Baylor College of Medicine	MD Anderson Cancer Center		NO	T3a	NX	Kidney Clear Cell Renal Carcinoma	Stage III	2098-10	True
S13722.58cfa830e4b0c9d6adf6c1ae	58cfa830e4b0c9d6adf6c1ae	TCGA-B9-4617-01A-01D-1253-10_wgs_Illumina.filtered.	WGS	TCGA-B9-4617-01A-01D-1253-10_wgs_Illumina	TCGA-B9-4617-01A-01D-1253-10_wgs_Illumina.bam	45.94	1.9	0.15	58cfa830e4b0c9d6adf6c1ae	TCGA-B9-4617-01A-01D-1253-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-B9-4617-01A	A6E960AF-3CA5-42FB-B546-451C2583282D	Primary Tumor	Illumina HiSeq	dbbf365c-a7c9-4093-8ffb-acf0b6eabf20	Kidney	41.0	605B6DD3-552B-403C-98D9-C8B441B37A90	BEF23192-57CD-4301-B7A7-5E82CA62482D	TCGA-B9-4617-01A-01D-1253-10	GRCh37-lite	TCGA-B9-4617	TCGA-KIRP		s11586	Baylor College of Medicine	UNC		NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma		1253-10	False
S13722.58cfa831e4b0c9d6adf6c450	58cfa831e4b0c9d6adf6c450	TCGA-BW-A5NO-01A-11D-A27I-10_wgs_Illumina.filtered.	WGS	TCGA-BW-A5NO-01A-11D-A27I-10_wgs_Illumina	TCGA-BW-A5NO-01A-11D-A27I-10_wgs_Illumina.bam	61.1		0.08	58cfa831e4b0c9d6adf6c450	TCGA-BW-A5NO-01A-11D-A27I-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-BW-A5NO-01A	EE63C44B-91F4-4004-8DEA-192EAB527036	Primary Tumor	Illumina HiSeq	b36db6ae-5ff9-4608-9db1-8dd5dc62fd82	Liver	50.0	3CBD785D-CAD5-4299-8FE8-695CA8DB726D	81A8B064-E735-455F-B2DB-AF7AE11DAAC4	TCGA-BW-A5NO-01A-11D-A27I-10	GRCh37-lite	TCGA-BW-A5NO	TCGA-LIHC		s16580	Baylor College of Medicine	St Joseph's Medical Center (MD)	United States	NO	T3a	NX	Hepatocellular Carcinoma	Stage IIIA	A27I-10	True
S13722.58cfa831e4b0c9d6adf6c630	58cfa831e4b0c9d6adf6c630	TCGA-CN-4737-01A-01D-2266-10_Illumina.filtered.	WGS	TCGA-CN-4737-01A-01D-2266-10_Illumina	TCGA-CN-4737-01A-01D-2266-10_Illumina.bam	142.0	1.9	0.05	58cfa831e4b0c9d6adf6c630	TCGA-CN-4737-01A-01D-2266-10_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4737-01A	1F744ADA-6DE1-446D-B62C-76A7FC8B40AF	Primary Tumor	Illumina HiSeq	cd1138ab-45a7-4da9-a78d-142e2e75f255	Head and Neck	19.0	BA5D40F5-56A2-438B-92B8-6EB7DB6D6AFA	878A7FE7-20FF-4651-9587-B4D6FD42E929	TCGA-CN-4737-01A-01D-2266-10	GRCh37-lite	TCGA-CN-4737	TCGA-HNSC		s16030	Baylor College of Medicine	University of Pittsburgh		NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	2266-10	True
S13722.58cfa831e4b0c9d6adf6c470	58cfa831e4b0c9d6adf6c470	TCGA-CA-6718-01A-11D-1835-10_wgs_Illumina.filtered.	WGS	TCGA-CA-6718-01A-11D-1835-10_wgs_Illumina	TCGA-CA-6718-01A-11D-1835-10_wgs_Illumina.bam	376.7	1.9	0.05	58cfa831e4b0c9d6adf6c470	TCGA-CA-6718-01A-11D-1835-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CA-6718-01A	DF5AB6CC-6F68-4B6B-95E2-954C6B57BA9C	Primary Tumor	Illumina HiSeq	3f12f1a7-45cc-4500-b7e1-8ac12465fbfe	Colorectal	46.0	F235AFBB-DC2A-41DD-B373-77C0AACEFB37	0980E7FD-051D-45E9-9CA6-2BAF073DA4E8	TCGA-CA-6718-01A-11D-1835-10	GRCh37-lite	TCGA-CA-6718	TCGA-COAD		s13037	Baylor College of Medicine	ILSbio	Vietnam	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1835-10	False
S13722.58cfa831e4b0c9d6adf6c66a	58cfa831e4b0c9d6adf6c66a	TCGA-CR-7382-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CR-7382-01A-11D-A32X-10_wgs_Illumina	TCGA-CR-7382-01A-11D-A32X-10_wgs_Illumina.bam	170.7		0.08	58cfa831e4b0c9d6adf6c66a	TCGA-CR-7382-01A-11D-A32X-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-7382-01A	F030E410-2585-461E-AD23-9FDF026AC06C	Primary Tumor	Illumina HiSeq	ab5f1c0e-d07d-49b4-9fc2-b74f3c4928a6	Head and Neck	49.0	A8D8886B-B422-4C66-B0B4-4C9F0546B1B3	B86E88E7-0D5F-4B32-A35F-DC97251AB990	TCGA-CR-7382-01A-11D-A32X-10	GRCh37-lite	TCGA-CR-7382	TCGA-HNSC		s16328	Baylor College of Medicine	Vanderbilt University	United States	NO	T2	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	A32X-10	True
S13722.58cfa831e4b0c9d6adf6c7ba	58cfa831e4b0c9d6adf6c7ba	TCGA-CN-6011-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CN-6011-01A-11D-A32X-10_wgs_Illumina	TCGA-CN-6011-01A-11D-A32X-10_wgs_Illumina.bam	193.0	1.9	0.08	58cfa831e4b0c9d6adf6c7ba	TCGA-CN-6011-01A-11D-A32X-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6011-01A	E7D49212-E9CB-4CD7-923A-BDFC82A4A150	Primary Tumor	Illumina HiSeq	33680362-5ef1-477f-9dbc-64dc2ed0d5a8	Head and Neck	57.0	AFBF3020-1715-4E74-8224-05E316796999	21205681-A0C7-48D0-81D4-0B7EF31158CF	TCGA-CN-6011-01A-11D-A32X-10	GRCh37-lite	TCGA-CN-6011	TCGA-HNSC		s15500	Baylor College of Medicine	University of Pittsburgh		NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	A32X-10	True
S13722.58cfa830e4b0c9d6adf6c2c4	58cfa830e4b0c9d6adf6c2c4	TCGA-AD-A5EK-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-AD-A5EK-01A-11D-A28G-10_wgs_Illumina	TCGA-AD-A5EK-01A-11D-A28G-10_wgs_Illumina.bam	58.87		0.08	58cfa830e4b0c9d6adf6c2c4	TCGA-AD-A5EK-01A-11D-A28G-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AD-A5EK-01A	E8EC26BD-C88D-42B9-AC8A-AB121B8140F8	Primary Tumor	Illumina HiSeq	e84aec8b-4304-43e0-96c7-d605fc64dd11	Colorectal	51.0	C48314EE-C778-4B82-8E5A-4923DF4C8413	D0A0D845-32E2-4590-B909-29BD27B92900	TCGA-AD-A5EK-01A-11D-A28G-10	GRCh37-lite	TCGA-AD-A5EK	TCGA-COAD		s13537	Baylor College of Medicine	International Genomics Consortium	United States	NO	T2	N0	Colon Adenocarcinoma	Stage I	A28G-10	True
S13722.58cfa831e4b0c9d6adf6c6c6	58cfa831e4b0c9d6adf6c6c6	TCGA-CV-5432-01A-02D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CV-5432-01A-02D-A32X-10_wgs_Illumina	TCGA-CV-5432-01A-02D-A32X-10_wgs_Illumina.bam	341.0	1.9	0.08	58cfa831e4b0c9d6adf6c6c6	TCGA-CV-5432-01A-02D-A32X-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5432-01A	D89B1FD6-BEF4-4803-8ED3-3B442BE600B6	Primary Tumor	Illumina HiSeq	6d564719-34a3-4b79-bf57-a5c8f73d7436	Head and Neck	68.0	B4A36114-80D3-4F28-B85A-077DC31EB485	9988EB07-01F6-4F83-8699-BB63E0525F08	TCGA-CV-5432-01A-02D-A32X-10	GRCh37-lite	TCGA-CV-5432	TCGA-HNSC		s16196	Baylor College of Medicine	MD Anderson Cancer Center		NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	A32X-10	True
S13722.58cfa831e4b0c9d6adf6c6b0	58cfa831e4b0c9d6adf6c6b0	TCGA-CR-6491-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CR-6491-01A-11D-A32X-10_wgs_Illumina	TCGA-CR-6491-01A-11D-A32X-10_wgs_Illumina.bam	78.7	1.9	0.08	58cfa831e4b0c9d6adf6c6b0	TCGA-CR-6491-01A-11D-A32X-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-6491-01A	5FCE954C-11B9-41F4-9471-4B5BDC0EFA7F	Primary Tumor	Illumina HiSeq	85a87fce-1144-4d78-8495-597c211a5312	Head and Neck	60.0	E23D2F8B-ACA4-43C2-876E-F8C6E1CA2D93	A315B798-F037-48D5-91ED-E733E3BBD6EE	TCGA-CR-6491-01A-11D-A32X-10	GRCh37-lite	TCGA-CR-6491	TCGA-HNSC		s15504	Baylor College of Medicine	Vanderbilt University	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	A32X-10	True
S13722.58cfa831e4b0c9d6adf6c8a8	58cfa831e4b0c9d6adf6c8a8	TCGA-CZ-5453-01A-01D-2102-10_wgs_Illumina.filtered.	WGS	TCGA-CZ-5453-01A-01D-2102-10_wgs_Illumina	TCGA-CZ-5453-01A-01D-2102-10_wgs_Illumina.bam	156.4	1.9	0.15	58cfa831e4b0c9d6adf6c8a8	TCGA-CZ-5453-01A-01D-2102-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CZ-5453-01A	577847B9-F9B6-4954-868F-3D5AB2B4F694	Primary Tumor	Illumina HiSeq	28e40615-1ae0-420f-b7c0-ca99eaa91361	Kidney	67.0	5C1B955D-9D60-4975-A1E6-C4D531E79190	64446AEC-C125-4C81-B9CC-62482CB1AAED	TCGA-CZ-5453-01A-01D-2102-10	GRCh37-lite	TCGA-CZ-5453	TCGA-KIRC		s9307	Baylor College of Medicine	Harvard		NO	T2	NX	Kidney Clear Cell Renal Carcinoma	Stage II	2102-10	False
S13722.58cfa831e4b0c9d6adf6c89a	58cfa831e4b0c9d6adf6c89a	TCGA-DD-A1EH-01A-11D-A12Z-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A1EH-01A-11D-A12Z-10_wgs_Illumina	TCGA-DD-A1EH-01A-11D-A12Z-10_wgs_Illumina.bam	38.71	1.93	0.08	58cfa831e4b0c9d6adf6c89a	TCGA-DD-A1EH-01A-11D-A12Z-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A1EH-01A	CAB5B264-ABAB-4BDB-816E-9D2C0AC30629	Primary Tumor	Illumina HiSeq	6126a7f9-c6d2-4361-9420-37af4bfafb5f	Liver	23.0	44C98B82-ADCB-4597-A9DB-83E7D2A0E2F9	B9F03936-1DE5-4330-8B0F-6D0AB533876E	TCGA-DD-A1EH-01A-11D-A12Z-10	GRCh37-lite	TCGA-DD-A1EH	TCGA-LIHC		s16776	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T3	N0	Hepatocellular Carcinoma	Stage III	A12Z-10	True
S13722.58cfa831e4b0c9d6adf6c8e1	58cfa831e4b0c9d6adf6c8e1	TCGA-CW-5585-01A-01D-2103-10_wgs_Illumina.filtered.	WGS	TCGA-CW-5585-01A-01D-2103-10_wgs_Illumina	TCGA-CW-5585-01A-01D-2103-10_wgs_Illumina.bam	288.4	1.88	0.15	58cfa831e4b0c9d6adf6c8e1	TCGA-CW-5585-01A-01D-2103-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Clear Cell Carcinoma	Aligned reads	TCGA-CW-5585-01A	0487FC41-386C-4D76-9084-DAF959BF5E98	Primary Tumor	Illumina HiSeq	ff078c8b-f861-46f7-ac62-eb5ff21a805c	Kidney	51.0	B5040DA2-0D96-422A-9760-98A95C136FE8	3FEAC02A-C99F-4DD9-9EFF-E4F5E87F7DC5	TCGA-CW-5585-01A-01D-2103-10	GRCh37-lite	TCGA-CW-5585	TCGA-KIRC		s9306	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T3b	N0	Kidney Clear Cell Renal Carcinoma	Stage IV	2103-10	False
S13722.58cfa831e4b0c9d6adf6c8e4	58cfa831e4b0c9d6adf6c8e4	TCGA-CX-7086-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CX-7086-01A-11D-A32X-10_wgs_Illumina	TCGA-CX-7086-01A-11D-A32X-10_wgs_Illumina.bam	464.7		0.08	58cfa831e4b0c9d6adf6c8e4	TCGA-CX-7086-01A-11D-A32X-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CX-7086-01A	AD6C9D09-2C03-4786-A72D-DD2AA5F603D4	Primary Tumor	Illumina HiSeq	2c64cb1b-6ae4-4191-9b2c-e5c13e267e83	Head and Neck	53.0	B293A736-9A82-4AD9-BF7E-9E2CEA09DDBC	E52FFA79-557A-4024-81F3-F3826C227EC5	TCGA-CX-7086-01A-11D-A32X-10	GRCh37-lite	TCGA-CX-7086	TCGA-HNSC		s16343	Baylor College of Medicine	Medical College of Georgia	United States	NO	T3	N1	Head and Neck Squamous Cell Carcinoma	Stage III	A32X-10	True
S13722.58cfa831e4b0c9d6adf6c8fe	58cfa831e4b0c9d6adf6c8fe	TCGA-CN-6994-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CN-6994-01A-11D-A32X-10_wgs_Illumina	TCGA-CN-6994-01A-11D-A32X-10_wgs_Illumina.bam	267.7		0.07	58cfa831e4b0c9d6adf6c8fe	TCGA-CN-6994-01A-11D-A32X-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6994-01A	6909302D-358A-46CD-8052-EEDB09C83C83	Primary Tumor	Illumina HiSeq	165171a0-a11e-4c82-b718-897ca9741478	Head and Neck	67.0	1A5AF8E2-61B4-4A04-B4B6-EA41FC34C89A	190EB791-383D-4E27-870D-E470630843E7	TCGA-CN-6994-01A-11D-A32X-10	GRCh37-lite	TCGA-CN-6994	TCGA-HNSC		s16325	Baylor College of Medicine	University of Pittsburgh	United States	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	A32X-10	True
S13722.58cfa831e4b0c9d6adf6c8b8	58cfa831e4b0c9d6adf6c8b8	TCGA-DD-A4NG-01A-11D-A27I-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A4NG-01A-11D-A27I-10_wgs_Illumina	TCGA-DD-A4NG-01A-11D-A27I-10_wgs_Illumina.bam	15.95		0.07	58cfa831e4b0c9d6adf6c8b8	TCGA-DD-A4NG-01A-11D-A27I-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A4NG-01A	89791F8F-DC06-4A04-B166-AFBFD6CF53DE	Primary Tumor	Illumina HiSeq	ef6dfbd5-d562-4452-9843-9c3db280717c	Liver	77.0	38507EDD-DFB4-4931-9895-2C0482BD4555	03C88506-D72E-4A44-A34E-A7F0564F1799	TCGA-DD-A4NG-01A-11D-A27I-10	GRCh37-lite	TCGA-DD-A4NG	TCGA-LIHC		s16856	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T3a	NX	Hepatocellular Carcinoma	Stage IIIA	A27I-10	True
S13722.58cfa831e4b0c9d6adf6c934	58cfa831e4b0c9d6adf6c934	TCGA-DD-A4ND-01A-11D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A4ND-01A-11D-A25V-10_wgs_Illumina	TCGA-DD-A4ND-01A-11D-A25V-10_wgs_Illumina.bam	24.52		0.07	58cfa831e4b0c9d6adf6c934	TCGA-DD-A4ND-01A-11D-A25V-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A4ND-01A	C0BF9278-9CBB-4361-B4D8-AB172B67E276	Primary Tumor	Illumina HiSeq	7b8d29e8-a5ac-4b38-9ac0-77398a23286f	Liver	56.0	4282039E-396B-44D8-B4EC-AC14C46DDEF6	D9C5493E-F969-4C04-A646-9A3134011021	TCGA-DD-A4ND-01A-11D-A25V-10	GRCh37-lite	TCGA-DD-A4ND	TCGA-LIHC		s16857	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T1	N0	Hepatocellular Carcinoma	Stage I	A25V-10	True
S13722.58cfa831e4b0c9d6adf6c954	58cfa831e4b0c9d6adf6c954	TCGA-DQ-5629-01A-01D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-DQ-5629-01A-01D-A32X-10_wgs_Illumina	TCGA-DQ-5629-01A-01D-A32X-10_wgs_Illumina.bam	233.7	1.9	0.08	58cfa831e4b0c9d6adf6c954	TCGA-DQ-5629-01A-01D-A32X-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-5629-01A	E95E9E7D-A1ED-46EB-9CF8-1D355BF0577F	Primary Tumor	Illumina HiSeq	3fb0505f-e847-4658-93f1-0af7d8617e66	Head and Neck	64.0	57EA3EED-F8E2-4310-90C0-50D89F818A12	2AFB198A-D4AA-4544-BDCE-85695E185869	TCGA-DQ-5629-01A-01D-A32X-10	GRCh37-lite	TCGA-DQ-5629	TCGA-HNSC		s16345	Baylor College of Medicine	University of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		A32X-10	True
S13722.58cfa831e4b0c9d6adf6c9a4	58cfa831e4b0c9d6adf6c9a4	TCGA-DD-A1ED-01A-11D-A152-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A1ED-01A-11D-A152-10_wgs_Illumina	TCGA-DD-A1ED-01A-11D-A152-10_wgs_Illumina.bam	38.22	1.7	0.08	58cfa831e4b0c9d6adf6c9a4	TCGA-DD-A1ED-01A-11D-A152-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A1ED-01A	0FF6364A-E6F4-47CA-A7E7-14705BF0A8DF	Primary Tumor	Illumina HiSeq	baa8f20c-66ac-448e-9ca3-b1302905fa30	Liver	68.0	1CF84C3E-E7E2-43A6-B9AF-E0042312F02F	4C3EDA94-56F4-46D3-8C88-50D476E773F6	TCGA-DD-A1ED-01A-11D-A152-10	GRCh37-lite	TCGA-DD-A1ED	TCGA-LIHC		s16977	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T1	N0	Hepatocellular Carcinoma	Stage I	A152-10	True
S13722.58cfa831e4b0c9d6adf6c9bf	58cfa831e4b0c9d6adf6c9bf	TCGA-DD-A1EJ-01A-11D-A152-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A1EJ-01A-11D-A152-10_wgs_Illumina	TCGA-DD-A1EJ-01A-11D-A152-10_wgs_Illumina.bam	51.74	1.45	0.08	58cfa831e4b0c9d6adf6c9bf	TCGA-DD-A1EJ-01A-11D-A152-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A1EJ-01A	52292FFC-0902-4D97-B461-20723987A177	Primary Tumor	Illumina HiSeq	65b1f0b7-fec9-4ee4-8634-583e00af7202	Liver	71.0	2D549BB0-9E98-40C7-8B33-545C481DD105	9C681CD9-25FB-42AC-AA6B-BB962882FA22	TCGA-DD-A1EJ-01A-11D-A152-10	GRCh37-lite	TCGA-DD-A1EJ	TCGA-LIHC		s16586	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T1	N1	Hepatocellular Carcinoma	Stage IIIC	A152-10	True
S13722.58cfa831e4b0c9d6adf6c9f6	58cfa831e4b0c9d6adf6c9f6	TCGA-DD-A4NB-01A-12D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A4NB-01A-12D-A25V-10_wgs_Illumina	TCGA-DD-A4NB-01A-12D-A25V-10_wgs_Illumina.bam	9.12		0.07	58cfa831e4b0c9d6adf6c9f6	TCGA-DD-A4NB-01A-12D-A25V-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A4NB-01A	1983FADE-44F1-41E0-8983-F2CE8D649655	Primary Tumor	Illumina HiSeq	a3509f59-4d19-4a9b-afd1-dc57f8f871dd	Liver	25.0	0A79C3EE-9DD0-4FF7-B079-C9A0AEB08E1F	5D58B984-E0B8-4237-A576-0E9D4079599E	TCGA-DD-A4NB-01A-12D-A25V-10	GRCh37-lite	TCGA-DD-A4NB	TCGA-LIHC		s16855	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T1	N0	Fibrolamellar Carcinoma	Stage I	A25V-10	True
S13722.58cfa831e4b0c9d6adf6ca23	58cfa831e4b0c9d6adf6ca23	TCGA-DD-A1EI-01A-11D-A12Z-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A1EI-01A-11D-A12Z-10_wgs_Illumina	TCGA-DD-A1EI-01A-11D-A12Z-10_wgs_Illumina.bam	51.84	1.86	0.08	58cfa831e4b0c9d6adf6ca23	TCGA-DD-A1EI-01A-11D-A12Z-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A1EI-01A	3ACF7438-FD65-442C-8A30-68B6714537F3	Primary Tumor	Illumina HiSeq	3578b4d9-a65f-4096-bb30-1b3509f8a918	Liver	46.0	65FB618A-9296-47AD-BBA9-A93FC3F88E68	C016D025-3C92-41C5-B846-493B1FCCE79E	TCGA-DD-A1EI-01A-11D-A12Z-10	GRCh37-lite	TCGA-DD-A1EI	TCGA-LIHC		s16975	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T1	N0	Hepatocellular Carcinoma	Stage I	A12Z-10	True
S13722.58cfa831e4b0c9d6adf6ca58	58cfa831e4b0c9d6adf6ca58	TCGA-DD-A4NA-01A-11D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-DD-A4NA-01A-11D-A25V-10_wgs_Illumina	TCGA-DD-A4NA-01A-11D-A25V-10_wgs_Illumina.bam	38.33		0.08	58cfa831e4b0c9d6adf6ca58	TCGA-DD-A4NA-01A-11D-A25V-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-DD-A4NA-01A	BEE9D6C8-948F-4B76-97CA-B985064249EF	Primary Tumor	Illumina HiSeq	9011fbab-0082-4675-98d0-33225253f93c	Liver	67.0	1E7C53F1-DFB6-4A50-BD83-F8062B1306F2	5EAD73FE-1C34-48ED-B20D-89FC3C82DBD6	TCGA-DD-A4NA-01A-11D-A25V-10	GRCh37-lite	TCGA-DD-A4NA	TCGA-LIHC		s17059	Baylor College of Medicine	Mayo Clinic - Rochester	United States	NO	T2	N1	Hepatocellular Carcinoma	Stage IIIC	A25V-10	True
S13722.58cfa831e4b0c9d6adf6ca63	58cfa831e4b0c9d6adf6ca63	TCGA-CN-6989-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-CN-6989-01A-11D-A32X-10_wgs_Illumina	TCGA-CN-6989-01A-11D-A32X-10_wgs_Illumina.bam	182.7		0.08	58cfa831e4b0c9d6adf6ca63	TCGA-CN-6989-01A-11D-A32X-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6989-01A	F33AA93F-B32D-4C4F-9A71-1E5AB69C6899	Primary Tumor	Illumina HiSeq	190e57a0-694b-46ca-a944-0bf0e9d732c2	Head and Neck	64.0	7AC8FB22-0A09-4B16-AF8C-B5C2E90A968A	08227616-02A5-46E8-9DB1-F2D1D691AB23	TCGA-CN-6989-01A-11D-A32X-10	GRCh37-lite	TCGA-CN-6989	TCGA-HNSC		s16177	Baylor College of Medicine	University of Pittsburgh	United States	NO	T3	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	A32X-10	True
S13722.58cfa831e4b0c9d6adf6cc3c	58cfa831e4b0c9d6adf6cc3c	TCGA-EP-A2KB-01A-11D-A183-10_wgs_Illumina.filtered.	WGS	TCGA-EP-A2KB-01A-11D-A183-10_wgs_Illumina	TCGA-EP-A2KB-01A-11D-A183-10_wgs_Illumina.bam	51.77		0.08	58cfa831e4b0c9d6adf6cc3c	TCGA-EP-A2KB-01A-11D-A183-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-EP-A2KB-01A	18C08546-BED3-4ED9-B223-479AFE633C8E	Primary Tumor	Illumina HiSeq	41e9afd1-d090-475a-ba8a-48976ddc9d52	Liver	46.0	E2895132-DA4F-4DB5-B417-510E99FCE776	305A5074-5384-45A0-985D-289B178D09F6	TCGA-EP-A2KB-01A-11D-A183-10	GRCh37-lite	TCGA-EP-A2KB	TCGA-LIHC		s16781	Baylor College of Medicine	Christiana Healthcare	United States	NO	T1	NX	Hepatocellular Carcinoma	Stage I	A183-10	True
S13722.58cfa831e4b0c9d6adf6cbe9	58cfa831e4b0c9d6adf6cbe9	TCGA-ED-A459-01A-11D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-ED-A459-01A-11D-A25V-10_wgs_Illumina	TCGA-ED-A459-01A-11D-A25V-10_wgs_Illumina.bam	19.74		0.08	58cfa831e4b0c9d6adf6cbe9	TCGA-ED-A459-01A-11D-A25V-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-ED-A459-01A	56403463-1727-4C23-A709-DE5F168C4073	Primary Tumor	Illumina HiSeq	eefae457-c645-4b48-b599-b479b7be4414	Liver	47.0	97FA4D8B-1C05-41A6-97C4-0B27DC70EB4C	7FC7B316-F3D3-4E71-9417-423FE334E6BC	TCGA-ED-A459-01A-11D-A25V-10	GRCh37-lite	TCGA-ED-A459	TCGA-LIHC		s16980	Baylor College of Medicine	Asterand	Vietnam	NO	T2	N0	Hepatocellular Carcinoma	Stage II	A25V-10	True
S13722.58cfa831e4b0c9d6adf6cc38	58cfa831e4b0c9d6adf6cc38	TCGA-EP-A26S-01A-11D-A16V-10_wgs_Illumina.filtered.	WGS	TCGA-EP-A26S-01A-11D-A16V-10_wgs_Illumina	TCGA-EP-A26S-01A-11D-A16V-10_wgs_Illumina.bam	64.0		0.07	58cfa831e4b0c9d6adf6cc38	TCGA-EP-A26S-01A-11D-A16V-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-EP-A26S-01A	B7D6621C-8BCE-4A01-8588-9D7761D9372B	Primary Tumor	Illumina HiSeq	e3122147-a994-4b8f-aa05-ddb36413802a	Liver	70.0	A0B2FF38-E6BF-4F27-98AB-5CF924B0E236	463BF060-8BA6-4A73-8173-172025F7B527	TCGA-EP-A26S-01A-11D-A16V-10	GRCh37-lite	TCGA-EP-A26S	TCGA-LIHC		s16982	Baylor College of Medicine	Christiana Healthcare	United States	NO	T1	N0	Hepatocellular Carcinoma	Stage I	A16V-10	True
S13722.58cfa831e4b0c9d6adf6cb2c	58cfa831e4b0c9d6adf6cb2c	TCGA-ED-A4XI-01A-11D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-ED-A4XI-01A-11D-A25V-10_wgs_Illumina	TCGA-ED-A4XI-01A-11D-A25V-10_wgs_Illumina.bam	23.36		0.08	58cfa831e4b0c9d6adf6cb2c	TCGA-ED-A4XI-01A-11D-A25V-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-ED-A4XI-01A	C52ABAC9-07DA-4B3D-BF8A-2161CACF9682	Primary Tumor	Illumina HiSeq	a2c23e6e-f1ad-454f-999a-c07f31a63536	Liver	58.0	25EB5AFD-E7A6-4F3C-82B4-A3DE1F8F9BE1	670F971F-A525-4EF8-91BA-610CFBAEB914	TCGA-ED-A4XI-01A-11D-A25V-10	GRCh37-lite	TCGA-ED-A4XI	TCGA-LIHC		s16589	Baylor College of Medicine	Asterand	Vietnam	NO	T2	N0	Hepatocellular Carcinoma	Stage II	A25V-10	True
S13722.58cfa831e4b0c9d6adf6cc1c	58cfa831e4b0c9d6adf6cc1c	TCGA-EP-A2KA-01A-11D-A183-10_wgs_Illumina.filtered.	WGS	TCGA-EP-A2KA-01A-11D-A183-10_wgs_Illumina	TCGA-EP-A2KA-01A-11D-A183-10_wgs_Illumina.bam	69.11		0.07	58cfa831e4b0c9d6adf6cc1c	TCGA-EP-A2KA-01A-11D-A183-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-EP-A2KA-01A	440375D7-CDCD-418A-8992-0A8CA42D290D	Primary Tumor	Illumina HiSeq	e0364f92-b574-4946-8ba1-2504614f0845	Liver	52.0	E6E1BF11-DA29-4052-85A1-584401F0FA3D	484A41C8-FCAF-488D-97DC-BFE6A4B88A95	TCGA-EP-A2KA-01A-11D-A183-10	GRCh37-lite	TCGA-EP-A2KA	TCGA-LIHC		s16983	Baylor College of Medicine	Christiana Healthcare	United States	NO	T3a	NX	Hepatocellular Carcinoma	Stage IIIA	A183-10	True
S13722.58cfa832e4b0c9d6adf6ce68	58cfa832e4b0c9d6adf6ce68	TCGA-G3-A25V-01A-11D-A16V-10_wgs_Illumina.filtered.	WGS	TCGA-G3-A25V-01A-11D-A16V-10_wgs_Illumina	TCGA-G3-A25V-01A-11D-A16V-10_wgs_Illumina.bam	62.02	1.79	0.08	58cfa832e4b0c9d6adf6ce68	TCGA-G3-A25V-01A-11D-A16V-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-G3-A25V-01A	F435EC00-0DB8-46B4-96BF-890A9D931DF3	Primary Tumor	Illumina HiSeq	ddbeb5de-c37a-4565-8b8d-8965c09eb657	Liver	68.0	634AB666-0845-4B62-A2A1-ABD408D8B829	4624FD20-E2AD-4826-B606-A694B04E1076	TCGA-G3-A25V-01A-11D-A16V-10	GRCh37-lite	TCGA-G3-A25V	TCGA-LIHC		s16688	Baylor College of Medicine	Alberta Health Services	Canada	NO	T1	N0	Hepatocellular Carcinoma	Stage I	A16V-10	True
S13722.58cfa832e4b0c9d6adf6ce70	58cfa832e4b0c9d6adf6ce70	TCGA-FV-A496-01A-11D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-FV-A496-01A-11D-A25V-10_wgs_Illumina	TCGA-FV-A496-01A-11D-A25V-10_wgs_Illumina.bam	36.61		0.07	58cfa832e4b0c9d6adf6ce70	TCGA-FV-A496-01A-11D-A25V-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-FV-A496-01A	8AFA3140-DCBD-44C0-AB13-4ADA6A0444D4	Primary Tumor	Illumina HiSeq	62727522-1644-478e-a555-06a870b68bab	Liver	84.0	FD1E3B28-C143-4EF6-A699-3A61CB20A5ED	6E6AD1A2-F1EB-44D1-9852-F5752AFCF5EB	TCGA-FV-A496-01A-11D-A25V-10	GRCh37-lite	TCGA-FV-A496	TCGA-LIHC		s16787	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1	NX	Hepatocellular Carcinoma	Stage I	A25V-10	True
S13722.58cfa832e4b0c9d6adf6ce7e	58cfa832e4b0c9d6adf6ce7e	TCGA-FV-A495-01A-11D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-FV-A495-01A-11D-A25V-10_wgs_Illumina	TCGA-FV-A495-01A-11D-A25V-10_wgs_Illumina.bam	17.43		0.08	58cfa832e4b0c9d6adf6ce7e	TCGA-FV-A495-01A-11D-A25V-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-FV-A495-01A	BD48FA5E-0152-46F0-A4FA-8CF723FF2DCD	Primary Tumor	Illumina HiSeq	bd95350e-cf5e-48c9-929a-3e397b36cd21	Liver	51.0	B7FC877D-6055-4A28-BBDF-50CE7236B7BF	84FE77B4-F6CC-49BF-A6B9-1621EC9394F8	TCGA-FV-A495-01A-11D-A25V-10	GRCh37-lite	TCGA-FV-A495	TCGA-LIHC		s16591	Baylor College of Medicine	International Genomics Consortium	United States	NO	T2	NX	Hepatocellular Carcinoma	Stage II	A25V-10	True
S13722.58cfa832e4b0c9d6adf6ce6c	58cfa832e4b0c9d6adf6ce6c	TCGA-G3-A3CK-01A-11D-A20W-10_wgs_Illumina.filtered.	WGS	TCGA-G3-A3CK-01A-11D-A20W-10_wgs_Illumina	TCGA-G3-A3CK-01A-11D-A20W-10_wgs_Illumina.bam	43.11		0.08	58cfa832e4b0c9d6adf6ce6c	TCGA-G3-A3CK-01A-11D-A20W-10_wgs_Illumina.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-G3-A3CK-01A	39EB1DB0-2722-4AF4-8254-D0E10256C64D	Primary Tumor	Illumina HiSeq	210fd1fb-0012-410b-bfc8-bf53607bfe12	Liver	61.0	2F38C711-639F-4611-9076-DC99A1DB8239	1127B561-EA40-4D5E-95DF-DAA0A5EBC1E4	TCGA-G3-A3CK-01A-11D-A20W-10	GRCh37-lite	TCGA-G3-A3CK	TCGA-LIHC		s16988	Baylor College of Medicine	Alberta Health Services	Canada	NO	T1	N0	Hepatocellular Carcinoma	Stage I	A20W-10	False
S13722.58cfa832e4b0c9d6adf6ce6f	58cfa832e4b0c9d6adf6ce6f	TCGA-GL-A4EM-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-GL-A4EM-01A-11D-A25F-10_wgs_Illumina	TCGA-GL-A4EM-01A-11D-A25F-10_wgs_Illumina.bam	11.47		0.08	58cfa832e4b0c9d6adf6ce6f	TCGA-GL-A4EM-01A-11D-A25F-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-GL-A4EM-01A	2C084454-18E9-4837-9BBA-7E91A73A48E0	Primary Tumor	Illumina HiSeq	39550a3d-400e-427e-871c-7749ae5dc2f3	Kidney	61.0	353CDF9B-F87E-45ED-8263-B1720FAE4EEA	7815397B-AA39-4B79-BCAA-6859A3F115F8	TCGA-GL-A4EM-01A-11D-A25F-10	GRCh37-lite	TCGA-GL-A4EM	TCGA-KIRP		s11777	Baylor College of Medicine	ABS - IUPUI	United States	NO	T1b	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A25F-10	True
S13722.58cfa832e4b0c9d6adf6ce87	58cfa832e4b0c9d6adf6ce87	TCGA-FV-A3R3-01A-11D-A22F-10_wgs_Illumina.filtered.	WGS	TCGA-FV-A3R3-01A-11D-A22F-10_wgs_Illumina	TCGA-FV-A3R3-01A-11D-A22F-10_wgs_Illumina.bam	16.97		0.08	58cfa832e4b0c9d6adf6ce87	TCGA-FV-A3R3-01A-11D-A22F-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-FV-A3R3-01A	3DD7C93D-8194-44EE-8014-10DD81EF6441	Primary Tumor	Illumina HiSeq	0f95ee88-7930-46cd-a565-bf3d91f5f505	Liver	38.0	8ABDA02F-AEDF-4599-9407-E253207D5D4C	C285C2FA-24B4-47A1-874D-86E74B002B05	TCGA-FV-A3R3-01A-11D-A22F-10	GRCh37-lite	TCGA-FV-A3R3	TCGA-LIHC		s16685	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1	NX	Hepatocellular Carcinoma	Stage I	A22F-10	True
S13722.58cfa831e4b0c9d6adf6cc59	58cfa831e4b0c9d6adf6cc59	TCGA-EP-A3RK-01A-11D-A22F-10_wgs_Illumina.filtered.	WGS	TCGA-EP-A3RK-01A-11D-A22F-10_wgs_Illumina	TCGA-EP-A3RK-01A-11D-A22F-10_wgs_Illumina.bam	46.15		0.08	58cfa831e4b0c9d6adf6cc59	TCGA-EP-A3RK-01A-11D-A22F-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-EP-A3RK-01A	F15279DD-5D12-460B-9BD1-B4F95681CA65	Primary Tumor	Illumina HiSeq	3b2093f5-b5ba-4e57-b4a1-47a180f9bb81	Liver	73.0	253DA6EE-8786-4A20-A0DC-58816A8A9C39	0D259AC2-03D1-4814-9B0B-D05E3A6029B7	TCGA-EP-A3RK-01A-11D-A22F-10	GRCh37-lite	TCGA-EP-A3RK	TCGA-LIHC		s16682	Baylor College of Medicine	Christiana Healthcare	United States	NO	T3a	NX	Hepatocellular Carcinoma	Stage IIIA	A22F-10	True
S13722.58cfa832e4b0c9d6adf6ce7c	58cfa832e4b0c9d6adf6ce7c	TCGA-G3-A5SL-01A-11D-A27I-10_wgs_Illumina.filtered.	WGS	TCGA-G3-A5SL-01A-11D-A27I-10_wgs_Illumina	TCGA-G3-A5SL-01A-11D-A27I-10_wgs_Illumina.bam	50.54		0.07	58cfa832e4b0c9d6adf6ce7c	TCGA-G3-A5SL-01A-11D-A27I-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-G3-A5SL-01A	9A56D8A8-DADD-442E-BC09-732CD619AEF7	Primary Tumor	Illumina HiSeq	f55def89-845d-40d8-a532-eb471f2c04d3	Liver	70.0	5AF5519D-73EE-481B-A47C-06F54DBD372F	70422E6D-CB1F-4284-8BE9-1D4517FFAD60	TCGA-G3-A5SL-01A-11D-A27I-10	GRCh37-lite	TCGA-G3-A5SL	TCGA-LIHC		s17064	Baylor College of Medicine	Alberta Health Services	Canada	NO	T2	NX	Hepatocellular Carcinoma	Stage II	A27I-10	True
S13722.58cfa832e4b0c9d6adf6ce62	58cfa832e4b0c9d6adf6ce62	TCGA-FV-A2QQ-01A-11D-A22F-10_wgs_Illumina.filtered.	WGS	TCGA-FV-A2QQ-01A-11D-A22F-10_wgs_Illumina	TCGA-FV-A2QQ-01A-11D-A22F-10_wgs_Illumina.bam	36.18		0.08	58cfa832e4b0c9d6adf6ce62	TCGA-FV-A2QQ-01A-11D-A22F-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-FV-A2QQ-01A	D680DF09-368E-42B5-B540-45C41ED31042	Primary Tumor	Illumina HiSeq	5e2beb4b-957f-4d8e-956f-798a63355329	Liver	80.0	A0096AF4-ABD3-4F6E-A6AC-2CF2E57C7BD9	4904D56F-0FE7-4482-8F6D-9E54D261F399	TCGA-FV-A2QQ-01A-11D-A22F-10	GRCh37-lite	TCGA-FV-A2QQ	TCGA-LIHC		s16861	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1	N1	Hepatocellular Carcinoma	Stage IVA	A22F-10	True
S13722.58cfa832e4b0c9d6adf6cf76	58cfa832e4b0c9d6adf6cf76	TCGA-FV-A23B-01A-11D-A16V-10_wgs_Illumina.filtered.	WGS	TCGA-FV-A23B-01A-11D-A16V-10_wgs_Illumina	TCGA-FV-A23B-01A-11D-A16V-10_wgs_Illumina.bam	76.29	1.85	0.08	58cfa832e4b0c9d6adf6cf76	TCGA-FV-A23B-01A-11D-A16V-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-FV-A23B-01A	C95ED407-BCC2-44AA-BC59-BF7549F2D665	Primary Tumor	Illumina HiSeq	1727600d-b6d6-4ab4-9eb1-03b214f5be2c	Liver	70.0	D056433D-C3E2-467A-8151-DDF2A6D8683A	63ADC09C-E1B1-40DD-9C35-2F8276B656FC	TCGA-FV-A23B-01A-11D-A16V-10	GRCh37-lite	TCGA-FV-A23B	TCGA-LIHC		s16786	Baylor College of Medicine	International Genomics Consortium	United States	NO	T2	N0	Hepatocellular Carcinoma	Stage II	A16V-10	True
S13722.58cfa832e4b0c9d6adf6d112	58cfa832e4b0c9d6adf6d112	TCGA-FV-A3I0-01A-11D-A22F-10_wgs_Illumina.filtered.	WGS	TCGA-FV-A3I0-01A-11D-A22F-10_wgs_Illumina	TCGA-FV-A3I0-01A-11D-A22F-10_wgs_Illumina.bam	32.65		0.07	58cfa832e4b0c9d6adf6d112	TCGA-FV-A3I0-01A-11D-A22F-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-FV-A3I0-01A	A8C2AA08-9156-4845-AD77-5E060858C757	Primary Tumor	Illumina HiSeq	63861662-f89c-47c7-80f6-165f38ed4253	Liver	76.0	810D65B3-59D9-4815-AA41-0C21A0D17AC2	5DF489BC-6178-49E4-8A42-506F70300DFF	TCGA-FV-A3I0-01A-11D-A22F-10	GRCh37-lite	TCGA-FV-A3I0	TCGA-LIHC		s16593	Baylor College of Medicine	International Genomics Consortium	United States	NO	T2	NX	Hepatocholangiocarcinoma (Mixed)	Stage II	A22F-10	True
S13722.58cfa832e4b0c9d6adf6d0d8	58cfa832e4b0c9d6adf6d0d8	TCGA-G3-A25S-01A-11D-A16V-10_wgs_Illumina.filtered.	WGS	TCGA-G3-A25S-01A-11D-A16V-10_wgs_Illumina	TCGA-G3-A25S-01A-11D-A16V-10_wgs_Illumina.bam	82.14	1.93	0.08	58cfa832e4b0c9d6adf6d0d8	TCGA-G3-A25S-01A-11D-A16V-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-G3-A25S-01A	B865DEC4-F051-4FBE-9405-F832FF2010D7	Primary Tumor	Illumina HiSeq	95c222bc-3817-42a2-b237-911c68ec0cf0	Liver	64.0	D12BE3F6-68BC-4583-9478-FC01A0EB9387	C05ADC19-2E01-4712-A35A-69EEE4D40998	TCGA-G3-A25S-01A-11D-A16V-10	GRCh37-lite	TCGA-G3-A25S	TCGA-LIHC		s16686	Baylor College of Medicine	Alberta Health Services	Canada	NO	T1	N0	Hepatocellular Carcinoma	Stage I	A16V-10	True
S13722.58cfa832e4b0c9d6adf6cfd2	58cfa832e4b0c9d6adf6cfd2	TCGA-GL-A59R-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-GL-A59R-01A-11D-A26P-10_wgs_Illumina	TCGA-GL-A59R-01A-11D-A26P-10_wgs_Illumina.bam	21.08		0.08	58cfa832e4b0c9d6adf6cfd2	TCGA-GL-A59R-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-GL-A59R-01A	78412F82-CC55-43D5-96CA-1D02CF957725	Primary Tumor	Illumina HiSeq	78730e13-6aeb-4c56-8ac4-4a73dcd37bbd	Kidney	79.0	6F084D86-6CE0-431A-87D7-0E543392EA15	C504D5A9-29B0-4B7E-AC7B-5E543449A0F4	TCGA-GL-A59R-01A-11D-A26P-10	GRCh37-lite	TCGA-GL-A59R	TCGA-KIRP		s11647	Baylor College of Medicine	ABS - IUPUI	United States	NO	T3c	N0	Kidney Papillary Renal Cell Carcinoma	Stage III	A26P-10	True
S13722.58cfa832e4b0c9d6adf6d0a2	58cfa832e4b0c9d6adf6d0a2	TCGA-IA-A40X-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-IA-A40X-01A-11D-A25F-10_wgs_Illumina	TCGA-IA-A40X-01A-11D-A25F-10_wgs_Illumina.bam	35.98		0.08	58cfa832e4b0c9d6adf6d0a2	TCGA-IA-A40X-01A-11D-A25F-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-IA-A40X-01A	0C151271-2CF9-43F4-9E9B-FE927DE43131	Primary Tumor	Illumina HiSeq	0d27ff83-40ce-4ea3-8368-b9f9f3b4fe26	Kidney	49.0	863393ED-42BB-4232-93F4-2B5759D9822C	E1217EBE-1826-41A9-B6C4-702100A66F5E	TCGA-IA-A40X-01A-11D-A25F-10	GRCh37-lite	TCGA-IA-A40X	TCGA-KIRP		s11862	Baylor College of Medicine	Cleveland Clinic	United States	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A25F-10	True
S13722.58cfa832e4b0c9d6adf6d11e	58cfa832e4b0c9d6adf6d11e	TCGA-FV-A4ZQ-01A-11D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-FV-A4ZQ-01A-11D-A25V-10_wgs_Illumina	TCGA-FV-A4ZQ-01A-11D-A25V-10_wgs_Illumina.bam	41.34		0.08	58cfa832e4b0c9d6adf6d11e	TCGA-FV-A4ZQ-01A-11D-A25V-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-FV-A4ZQ-01A	65E430E1-0C9A-4045-83A9-653B7CFF811D	Primary Tumor	Illumina HiSeq	34884ff9-c16b-4800-9b84-dd3ec001b261	Liver	52.0	56DAAD30-A336-4311-9FEB-26CF3E48C734	D02597F8-3AC7-4165-A65F-0E134E5D215B	TCGA-FV-A4ZQ-01A-11D-A25V-10	GRCh37-lite	TCGA-FV-A4ZQ	TCGA-LIHC		s16592	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1	NX	Hepatocellular Carcinoma	Stage I	A25V-10	True
S13722.58cfa832e4b0c9d6adf6d168	58cfa832e4b0c9d6adf6d168	TCGA-KL-8328-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8328-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8328-01A-11D-2310-10_wgs_Illumina.bam	110.3		0.05	58cfa832e4b0c9d6adf6d168	TCGA-KL-8328-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8328-01A	452135F2-6DE6-4593-A091-DDF6344EE431	Primary Tumor	Illumina HiSeq	c5c55965-aec9-4c64-9d09-4dbba956669c	Kidney	60.0	BBCD6B07-862B-4DA1-8880-9D98B643898C	2CCD028D-E7E0-4F77-A512-F658A31819A4	TCGA-KL-8328-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8328	TCGA-KICH		s16518	Baylor College of Medicine	MSKCC	United States	NO	T2b	N0	Kidney Chromophobe	Stage II	2310-10	True
S13722.58cfa832e4b0c9d6adf6d164	58cfa832e4b0c9d6adf6d164	TCGA-KL-8327-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8327-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8327-01A-11D-2310-10_wgs_Illumina.bam	112.3		0.05	58cfa832e4b0c9d6adf6d164	TCGA-KL-8327-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8327-01A	02979422-5149-4750-AD5F-483E0BEC6AC5	Primary Tumor	Illumina HiSeq	791eea87-33dd-4932-9e4e-d31487fc9a39	Kidney	46.0	F35E66EC-7AA5-477C-ABF7-07C35C90F7DE	D72A7338-C144-4C62-A70E-2177A3B4B77E	TCGA-KL-8327-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8327	TCGA-KICH		s16521	Baylor College of Medicine	MSKCC	United States	NO	T1b	N0	Kidney Chromophobe	Stage I	2310-10	True
S13722.58cfa832e4b0c9d6adf6d130	58cfa832e4b0c9d6adf6d130	TCGA-FV-A3I1-01A-11D-A22F-10_wgs_Illumina.filtered.	WGS	TCGA-FV-A3I1-01A-11D-A22F-10_wgs_Illumina	TCGA-FV-A3I1-01A-11D-A22F-10_wgs_Illumina.bam	39.14		0.08	58cfa832e4b0c9d6adf6d130	TCGA-FV-A3I1-01A-11D-A22F-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-FV-A3I1-01A	BFD20D71-18A5-4F01-8D56-84378AD92359	Primary Tumor	Illumina HiSeq	137dd060-0c76-4ad8-b447-bcf55d593f0c	Liver	81.0	A744BE68-D008-4847-A11D-89918A419A5F	992D9566-B1DA-421A-BF36-D23382B115FA	TCGA-FV-A3I1-01A-11D-A22F-10	GRCh37-lite	TCGA-FV-A3I1	TCGA-LIHC		s16986	Baylor College of Medicine	International Genomics Consortium	United States	NO	T2	N0	Hepatocellular Carcinoma	Stage II	A22F-10	True
S13722.58cfa832e4b0c9d6adf6d062	58cfa832e4b0c9d6adf6d062	TCGA-G3-A25T-01A-11D-A16V-10_wgs_Illumina.filtered.	WGS	TCGA-G3-A25T-01A-11D-A16V-10_wgs_Illumina	TCGA-G3-A25T-01A-11D-A16V-10_wgs_Illumina.bam	80.84	2.02	0.08	58cfa832e4b0c9d6adf6d062	TCGA-G3-A25T-01A-11D-A16V-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-G3-A25T-01A	F6E5979D-D6A9-4408-BD1B-1B37D1064E83	Primary Tumor	Illumina HiSeq	97875fbb-c05a-4e3b-89e6-28f20a7eb82f	Liver	45.0	D42D6E07-8E0E-4345-B1B9-1B8B4574D042	41840DC1-5EA2-4F01-A0D4-8B65ADD641C8	TCGA-G3-A25T-01A-11D-A16V-10	GRCh37-lite	TCGA-G3-A25T	TCGA-LIHC		s16690	Baylor College of Medicine	Alberta Health Services	Canada	NO	T3	N0	Hepatocellular Carcinoma	Stage IIIA	A16V-10	True
S13722.58cfa832e4b0c9d6adf6d291	58cfa832e4b0c9d6adf6d291	TCGA-KL-8340-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8340-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8340-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d291	TCGA-KL-8340-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8340-01A	3129E869-BB2F-423A-BD20-D0DAAE33B11A	Primary Tumor	Illumina HiSeq	24326cad-efd9-4017-90e3-2ae8ac037b99	Kidney	34.0	07C3C6E6-D297-4D80-9C28-974FA470A132	D113CE88-04AB-4675-B363-92F80C28DE34	TCGA-KL-8340-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8340	TCGA-KICH		s16477	Baylor College of Medicine	MSKCC	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True
S13722.58cfa832e4b0c9d6adf6d29a	58cfa832e4b0c9d6adf6d29a	TCGA-KL-8343-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8343-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8343-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d29a	TCGA-KL-8343-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KL-8343-01A	B4A0BF74-1381-4C17-B97D-206810D9E59A	Primary Tumor	Illumina HiSeq	a7a4a6a6-4a0b-4611-9bd4-1d86b0ddf49c	Kidney	72.0	FFE4DFE1-B2FE-448E-8664-8299484FC809	34739BD6-B3BE-441D-8CDB-E4233BF14080	TCGA-KL-8343-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8343	TCGA-KICH		s16394	Baylor College of Medicine	MSKCC	United States	NO	T3	N0	Kidney Chromophobe	Stage III	2310-10	True
S13722.58cfa832e4b0c9d6adf6d296	58cfa832e4b0c9d6adf6d296	TCGA-KM-8439-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KM-8439-01A-11D-2310-10_wgs_Illumina	TCGA-KM-8439-01A-11D-2310-10_wgs_Illumina.bam	96.3		0.05	58cfa832e4b0c9d6adf6d296	TCGA-KM-8439-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KM-8439-01A	739DEED4-D1DC-458F-BD0F-1E24D2BFD305	Primary Tumor	Illumina HiSeq	1da1e41d-ec72-4c5f-9c1f-50f9606970e1	Kidney	30.0	A59051E9-5155-4073-A4D6-C9A8C54AD118	9D3B0B87-5FC5-4D09-9C63-4D5FC4BC46D0	TCGA-KM-8439-01A-11D-2310-10	GRCh37-lite	TCGA-KM-8439	TCGA-KICH		s16484	Baylor College of Medicine	NCI Urologic Oncology Branch	United States	NO	T1b	NX	Kidney Chromophobe	Stage I	2310-10	True
S13722.58cfa832e4b0c9d6adf6d2a0	58cfa832e4b0c9d6adf6d2a0	TCGA-KM-8477-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KM-8477-01A-11D-2310-10_wgs_Illumina	TCGA-KM-8477-01A-11D-2310-10_wgs_Illumina.bam	26.3		0.05	58cfa832e4b0c9d6adf6d2a0	TCGA-KM-8477-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KM-8477-01A	9680B5FF-1882-434F-9981-E8AC33764B93	Primary Tumor	Illumina HiSeq	af92bfa8-a70f-4436-b545-46899487c859	Kidney	56.0	50DA0237-8E9D-4C08-AE44-F32103E8F095	4ECBFD89-393F-4126-AA1C-951A2C23EF89	TCGA-KM-8477-01A-11D-2310-10	GRCh37-lite	TCGA-KM-8477	TCGA-KICH		s16397	Baylor College of Medicine	NCI Urologic Oncology Branch	United States	NO	T1a	NX	Kidney Chromophobe	Stage I	2310-10	True
S13722.58cfa832e4b0c9d6adf6d246	58cfa832e4b0c9d6adf6d246	TCGA-IA-A40Y-01A-11D-A25F-10_wgs_Illumina.filtered.	WGS	TCGA-IA-A40Y-01A-11D-A25F-10_wgs_Illumina	TCGA-IA-A40Y-01A-11D-A25F-10_wgs_Illumina.bam	22.07		0.08	58cfa832e4b0c9d6adf6d246	TCGA-IA-A40Y-01A-11D-A25F-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-IA-A40Y-01A	1DB41963-A520-47F0-828C-ED5C626507B1	Primary Tumor	Illumina HiSeq	2157f13c-f876-4b2f-91eb-f3ada3c0b2e7	Kidney	60.0	05ACDAC8-480B-43B6-82F5-B0DDC4A1C36F	AD9455E9-7147-489E-9B1F-3540C457C260	TCGA-IA-A40Y-01A-11D-A25F-10	GRCh37-lite	TCGA-IA-A40Y	TCGA-KIRP		s11863	Baylor College of Medicine	Cleveland Clinic	United States	NO	T3a	N1	Kidney Papillary Renal Cell Carcinoma	Stage III	A25F-10	True
S13722.58cfa832e4b0c9d6adf6d29d	58cfa832e4b0c9d6adf6d29d	TCGA-KM-8438-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KM-8438-01A-11D-2310-10_wgs_Illumina	TCGA-KM-8438-01A-11D-2310-10_wgs_Illumina.bam	40.3		0.05	58cfa832e4b0c9d6adf6d29d	TCGA-KM-8438-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KM-8438-01A	23656226-2D99-4548-959F-5C2EED803E33	Primary Tumor	Illumina HiSeq	171af111-4e87-4e89-af1b-ee3fbed93db6	Kidney	45.0	3CBDEE56-19F7-4A7A-850E-A7664E67C919	148536CE-EE2A-4952-A19D-10D6F44146B9	TCGA-KM-8438-01A-11D-2310-10	GRCh37-lite	TCGA-KM-8438	TCGA-KICH		s16399	Baylor College of Medicine	NCI Urologic Oncology Branch	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True
S13722.58cfa832e4b0c9d6adf6d2b8	58cfa832e4b0c9d6adf6d2b8	TCGA-KL-8331-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8331-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8331-01A-11D-2310-10_wgs_Illumina.bam	125.3		0.05	58cfa832e4b0c9d6adf6d2b8	TCGA-KL-8331-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8331-01A	8AC7F218-BD7B-4DDA-8879-2CEC49748E42	Primary Tumor	Illumina HiSeq	30f11cbf-417b-4a4a-b440-1c22bfc3b225	Kidney	48.0	EEA84BEB-0F41-4120-A350-6F31EC8712BB	7087A2B6-7FC4-45B0-8C48-248864F03DEB	TCGA-KL-8331-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8331	TCGA-KICH		s16421	Baylor College of Medicine	MSKCC	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True
S13722.58cfa832e4b0c9d6adf6d2d4	58cfa832e4b0c9d6adf6d2d4	TCGA-KL-8346-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8346-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8346-01A-11D-2310-10_wgs_Illumina.bam	69.8		0.05	58cfa832e4b0c9d6adf6d2d4	TCGA-KL-8346-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8346-01A	A122D361-835E-4CF2-850F-AF7864AA112C	Primary Tumor	Illumina HiSeq	bed80d0d-f127-4c4f-9a1f-2c032aa9b498	Kidney	62.0	ABCF54FE-D93E-4C3B-ACD0-757CDD6A3D3B	BD2EC47B-A120-4B3B-B10D-AEE09805AB33	TCGA-KL-8346-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8346	TCGA-KICH		s16429	Baylor College of Medicine	MSKCC	United States	NO	T2b	N0	Kidney Chromophobe	Stage II	2310-10	True
S13722.58cfa832e4b0c9d6adf6d2c4	58cfa832e4b0c9d6adf6d2c4	TCGA-KL-8337-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8337-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8337-01A-11D-2310-10_wgs_Illumina.bam	168.3		0.05	58cfa832e4b0c9d6adf6d2c4	TCGA-KL-8337-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN		Kidney Chromophobe	Aligned reads	TCGA-KL-8337-01A	5F633C79-FCF8-47DA-B349-ADA3FB794819	Primary Tumor	Illumina HiSeq	283efb4c-4edf-48c2-975a-9578517c0270	Kidney	26.0	988D64CE-EE26-4837-8161-86C4831BE203	A3FD2EE0-3DD0-4992-9A9F-75E487B43441	TCGA-KL-8337-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8337	TCGA-KICH		s16390	Baylor College of Medicine	MSKCC	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True
S13722.58cfa832e4b0c9d6adf6d2b6	58cfa832e4b0c9d6adf6d2b6	TCGA-KL-8332-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8332-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8332-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d2b6	TCGA-KL-8332-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8332-01A	3EC3BCB3-492C-4942-BE02-76A67F57E38F	Primary Tumor	Illumina HiSeq	b51b4316-5d7e-4f98-96f9-01d644b87e6d	Kidney	55.0	CD734D15-92C6-4B43-A5D3-EC823F6B9DC2	C6D6F49E-6E95-4E41-8388-71F6FE017D80	TCGA-KL-8332-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8332	TCGA-KICH		s16520	Baylor College of Medicine	MSKCC	United States	NO	T1b	N0	Kidney Chromophobe	Stage I	2310-10	True
S13722.58cfa832e4b0c9d6adf6d2d0	58cfa832e4b0c9d6adf6d2d0	TCGA-KL-8333-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8333-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8333-01A-11D-2310-10_wgs_Illumina.bam	46.3		0.05	58cfa832e4b0c9d6adf6d2d0	TCGA-KL-8333-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8333-01A	02EC7A3A-2812-4A65-93CD-07BF655CC91B	Primary Tumor	Illumina HiSeq	824e5509-79ee-455a-8650-3c757cdf6fbf	Kidney	69.0	77186D62-B354-49A4-8A2A-12F5F6B938F6	C56505CB-E150-408D-9DF6-3AF4E608C376	TCGA-KL-8333-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8333	TCGA-KICH		s16434	Baylor College of Medicine	MSKCC	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True
S13722.58cfa832e4b0c9d6adf6d2da	58cfa832e4b0c9d6adf6d2da	TCGA-KL-8334-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8334-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8334-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d2da	TCGA-KL-8334-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8334-01A	9AABCBD7-A26A-49B1-ABF1-02C0DC3ADCF2	Primary Tumor	Illumina HiSeq	8f7d6dce-86ff-4bee-b2df-12b2ff95f653	Kidney	37.0	E9938C51-8FC6-4ED0-9201-E51C0E943D1F	94434272-4CBD-4B4D-BD98-44F18526DD69	TCGA-KL-8334-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8334	TCGA-KICH		s16485	Baylor College of Medicine	MSKCC	United States	NO	T3a	N0	Kidney Chromophobe	Stage III	2310-10	True
S13722.58cfa832e4b0c9d6adf6d2e0	58cfa832e4b0c9d6adf6d2e0	TCGA-KL-8330-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8330-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8330-01A-11D-2310-10_wgs_Illumina.bam	210.3		0.05	58cfa832e4b0c9d6adf6d2e0	TCGA-KL-8330-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KL-8330-01A	0F3C4F8F-0766-46B0-81B4-18CA4F6EA20A	Primary Tumor	Illumina HiSeq	ee57fec3-c6dc-4fef-9340-d24a48421fe8	Kidney	44.0	81431ED0-D762-4131-895B-852B2F78786D	09537DCE-C797-4B60-962A-D4C3CD6AB00A	TCGA-KL-8330-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8330	TCGA-KICH		s16522	Baylor College of Medicine	MSKCC	United States	NO	T2b	N0	Kidney Chromophobe	Stage II	2310-10	True
S13722.58cfa832e4b0c9d6adf6d2f9	58cfa832e4b0c9d6adf6d2f9	TCGA-KN-8426-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8426-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8426-01A-11D-2310-10_wgs_Illumina.bam	110.3		0.05	58cfa832e4b0c9d6adf6d2f9	TCGA-KN-8426-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KN-8426-01A	B08DFBA8-6AFB-4217-9259-72BE6F1F3363	Primary Tumor	Illumina HiSeq	d5461fca-308e-41be-a207-bdb698350564	Kidney	50.0	8A7FAD85-8756-4411-BE2B-A87159B843A5	A3DEAFCB-B54F-4B7E-89AC-C92C16FB919F	TCGA-KN-8426-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8426	TCGA-KICH		s16473	Baylor College of Medicine	Harvard	United States	NO	T3a	NX	Kidney Chromophobe	Stage IV	2310-10	True
S13722.58cfa832e4b0c9d6adf6d2e6	58cfa832e4b0c9d6adf6d2e6	TCGA-KM-8476-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KM-8476-01A-11D-2310-10_wgs_Illumina	TCGA-KM-8476-01A-11D-2310-10_wgs_Illumina.bam	50.3		0.05	58cfa832e4b0c9d6adf6d2e6	TCGA-KM-8476-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KM-8476-01A	4E4FAF51-2CBF-4910-A093-186660E4A19B	Primary Tumor	Illumina HiSeq	bcb52a60-30eb-4af3-8ec1-512d6157e6be	Kidney	47.0	450DFCB0-F059-4427-9A72-EA51DC48956E	5BEBC389-DE0D-45B8-9D2F-6476988C358A	TCGA-KM-8476-01A-11D-2310-10	GRCh37-lite	TCGA-KM-8476	TCGA-KICH		s16391	Baylor College of Medicine	NCI Urologic Oncology Branch	United States	NO	T1	NX	Kidney Chromophobe	Stage I	2310-10	True
S13722.58cfa832e4b0c9d6adf6d2e2	58cfa832e4b0c9d6adf6d2e2	TCGA-KL-8344-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8344-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8344-01A-11D-2310-10_wgs_Illumina.bam	156.3		0.05	58cfa832e4b0c9d6adf6d2e2	TCGA-KL-8344-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8344-01A	A5AF1391-89D3-4F41-930E-7E8272AFEC98	Primary Tumor	Illumina HiSeq	85c6bd93-8e9d-43f8-ad70-a8d080e1c284	Kidney	51.0	4CEA843F-80AE-4284-B70F-8989717EEE7C	3ACE181A-23BD-424E-A87E-E0C01A2A2CB8	TCGA-KL-8344-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8344	TCGA-KICH		s16474	Baylor College of Medicine	MSKCC	United States	NO	T3a	N0	Kidney Chromophobe	Stage III	2310-10	True
S13722.58cfa832e4b0c9d6adf6d2fa	58cfa832e4b0c9d6adf6d2fa	TCGA-KM-8443-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KM-8443-01A-11D-2310-10_wgs_Illumina	TCGA-KM-8443-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d2fa	TCGA-KM-8443-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KM-8443-01A	2F1C4DB6-88A7-4A5D-A5FE-94D85F569440	Primary Tumor	Illumina HiSeq	eecb2ae5-92c3-432e-be0c-d7463b8efbb1	Kidney	57.0	F606FE9C-7D9F-4615-AB16-0BB4C796ADEA	C00DE7A0-0B09-4E07-988C-EF2A7F8E932A	TCGA-KM-8443-01A-11D-2310-10	GRCh37-lite	TCGA-KM-8443	TCGA-KICH		s16528	Baylor College of Medicine	NCI Urologic Oncology Branch	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True
S13722.58cfa832e4b0c9d6adf6d2fe	58cfa832e4b0c9d6adf6d2fe	TCGA-KM-8441-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KM-8441-01A-11D-2310-10_wgs_Illumina	TCGA-KM-8441-01A-11D-2310-10_wgs_Illumina.bam	28.3		0.05	58cfa832e4b0c9d6adf6d2fe	TCGA-KM-8441-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KM-8441-01A	F31BA8EC-A3DD-4DD8-8D15-F6C5975EBE44	Primary Tumor	Illumina HiSeq	a15ce5fc-4e2f-4fe0-b799-1be690aa31b9	Kidney	61.0	566A0F2C-743C-4F18-B14E-1667A8666008	97C1A300-978D-4DF1-9E97-CE2F92B9EFF1	TCGA-KM-8441-01A-11D-2310-10	GRCh37-lite	TCGA-KM-8441	TCGA-KICH		s16570	Baylor College of Medicine	NCI Urologic Oncology Branch	United States	NO	T1b	NX	Kidney Chromophobe	Stage I	2310-10	True
S13722.58cfa832e4b0c9d6adf6d320	58cfa832e4b0c9d6adf6d320	TCGA-KN-8425-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8425-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8425-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d320	TCGA-KN-8425-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KN-8425-01A	CC316FAF-DCB1-4DEA-B8B0-A17D000FF40F	Primary Tumor	Illumina HiSeq	60135711-8234-4e49-8d15-e9a5a0726f68	Kidney	53.0	84ED1792-CEC8-4F98-9988-74B3F5F6F516	81BB13FC-F082-4C0B-8066-1729F11EF617	TCGA-KN-8425-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8425	TCGA-KICH		s16527	Baylor College of Medicine	Harvard	United States	NO	T1b	N0	Kidney Chromophobe	Stage I	2310-10	True
S13722.58cfa832e4b0c9d6adf6d332	58cfa832e4b0c9d6adf6d332	TCGA-KN-8432-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8432-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8432-01A-11D-2310-10_wgs_Illumina.bam	205.3		0.05	58cfa832e4b0c9d6adf6d332	TCGA-KN-8432-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KN-8432-01A	AF1111AF-9384-4E37-9B16-227D38007EBD	Primary Tumor	Illumina HiSeq	be9bfce6-c244-4dcb-b5df-36fab219e0f6	Kidney	86.0	F27E987E-DA76-40C2-B7B8-5DEE724D7EB7	85ED2434-DA94-4333-90CA-6CA4691CBDD3	TCGA-KN-8432-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8432	TCGA-KICH		s16406	Baylor College of Medicine	Harvard	United States	NO	T2b	NX	Kidney Chromophobe	Stage II	2310-10	True
S13722.58cfa832e4b0c9d6adf6d338	58cfa832e4b0c9d6adf6d338	TCGA-KN-8427-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8427-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8427-01A-11D-2310-10_wgs_Illumina.bam	198.3		0.05	58cfa832e4b0c9d6adf6d338	TCGA-KN-8427-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KN-8427-01A	955D428C-8FE8-456B-B86D-65EA6C2A1B18	Primary Tumor	Illumina HiSeq	1ab3dc9e-2973-4b02-bf13-e2f1f27c0f05	Kidney	54.0	8719FECD-7AB5-4468-A978-5C6BF1D4A1D7	07E0E938-F61F-477A-92A2-5B7E74B78943	TCGA-KN-8427-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8427	TCGA-KICH		s16442	Baylor College of Medicine	Harvard	United States	NO	T4	N1	Kidney Chromophobe	Stage IV	2310-10	True
S13722.58cfa832e4b0c9d6adf6d32e	58cfa832e4b0c9d6adf6d32e	TCGA-KN-8421-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8421-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8421-01A-11D-2310-10_wgs_Illumina.bam	112.3		0.05	58cfa832e4b0c9d6adf6d32e	TCGA-KN-8421-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KN-8421-01A	2FC175D1-9D95-44FD-A53E-820F6F404551	Primary Tumor	Illumina HiSeq	2b4a72cf-171d-4cea-ac2a-528687128d7c	Kidney	47.0	D4694662-8330-4F19-A25D-9A12751C1B57	BA686386-8113-4885-B20F-6AD09A295604	TCGA-KN-8421-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8421	TCGA-KICH		s16476	Baylor College of Medicine	Harvard	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True
S13722.58cfa832e4b0c9d6adf6d334	58cfa832e4b0c9d6adf6d334	TCGA-KM-8639-01A-11D-2397-10_wgs_Illumina.filtered.	WGS	TCGA-KM-8639-01A-11D-2397-10_wgs_Illumina	TCGA-KM-8639-01A-11D-2397-10_wgs_Illumina.bam	157.0		0.05	58cfa832e4b0c9d6adf6d334	TCGA-KM-8639-01A-11D-2397-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KM-8639-01A	2EA84E23-6A0A-4C5D-9C70-D5355A85DF35	Primary Tumor	Illumina HiSeq	f1dafc21-d5b0-48e6-ab3e-2fffa2d599e4	Kidney	67.0	E1D3EE37-402B-4727-8E27-B797D42F46BA	0B811C6A-8F05-44BD-AC33-FB720D189E71	TCGA-KM-8639-01A-11D-2397-10	GRCh37-lite	TCGA-KM-8639	TCGA-KICH		s16572	Baylor College of Medicine	NCI Urologic Oncology Branch	United States	NO	T1a	NX	Kidney Chromophobe	Stage I	2397-10	False
S13722.58cfa832e4b0c9d6adf6d354	58cfa832e4b0c9d6adf6d354	TCGA-KO-8409-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KO-8409-01A-11D-2310-10_wgs_Illumina	TCGA-KO-8409-01A-11D-2310-10_wgs_Illumina.bam	151.2		0.05	58cfa832e4b0c9d6adf6d354	TCGA-KO-8409-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KO-8409-01A	08A96DEC-E658-493A-9308-83F7ACE3B3B6	Primary Tumor	Illumina HiSeq	a6a7348b-80db-4f3a-b7eb-77e0575ab072	Kidney	69.0	56B3AC6B-BD6E-4960-8610-292CF154A705	8DF1EEB4-DFC9-4A0A-8F93-98460C3AB489	TCGA-KO-8409-01A-11D-2310-10	GRCh37-lite	TCGA-KO-8409	TCGA-KICH		s16445	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T2b	N0	Kidney Chromophobe	Stage II	2310-10	True
S13722.58cfa832e4b0c9d6adf6d17e	58cfa832e4b0c9d6adf6d17e	TCGA-HD-7753-01A-11D-A32X-10_wgs_Illumina.filtered.	WGS	TCGA-HD-7753-01A-11D-A32X-10_wgs_Illumina	TCGA-HD-7753-01A-11D-A32X-10_wgs_Illumina.bam	103.73		0.07	58cfa832e4b0c9d6adf6d17e	TCGA-HD-7753-01A-11D-A32X-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-HD-7753-01A	E8AC39E6-377A-412C-B18D-F6C4FC654EC6	Primary Tumor	Illumina HiSeq	393b4af8-b44d-4c3f-b5ca-f7032b687a16	Head and Neck	62.0	E723F1BB-73A3-4D65-BD25-DE76138515E9	54E78DE0-D357-4125-A904-AB35E461572B	TCGA-HD-7753-01A-11D-A32X-10	GRCh37-lite	TCGA-HD-7753	TCGA-HNSC		s15534	Baylor College of Medicine	International Genomics Consortium	United States	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	A32X-10	True
S13722.58cfa832e4b0c9d6adf6d3ad	58cfa832e4b0c9d6adf6d3ad	TCGA-NH-A50V-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-NH-A50V-01A-11D-A28G-10_wgs_Illumina	TCGA-NH-A50V-01A-11D-A28G-10_wgs_Illumina.bam	33.86		0.08	58cfa832e4b0c9d6adf6d3ad	TCGA-NH-A50V-01A-11D-A28G-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-NH-A50V-01A	D3B7ADA6-5395-4212-A921-8E97C92B605D	Primary Tumor	Illumina HiSeq	80f9989d-1696-49b8-a893-f045bc8615ea	Colorectal	69.0	A7A71B11-5E34-49A4-8D54-BE27D9C8DAF0	55345803-83D4-4FDB-B0EE-328753801DA1	TCGA-NH-A50V-01A-11D-A28G-10	GRCh37-lite	TCGA-NH-A50V	TCGA-COAD		s13043	Baylor College of Medicine	Candler	United States	NO	T3	N2a	Colon Adenocarcinoma	Stage IIIB	A28G-10	True
S13722.58cfa832e4b0c9d6adf6d43a	58cfa832e4b0c9d6adf6d43a	TCGA-QG-A5YV-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-QG-A5YV-01A-11D-A28G-10_wgs_Illumina	TCGA-QG-A5YV-01A-11D-A28G-10_wgs_Illumina.bam	62.92		0.07	58cfa832e4b0c9d6adf6d43a	TCGA-QG-A5YV-01A-11D-A28G-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-QG-A5YV-01A	C83D38FC-E011-4F75-A100-96513611F3E9	Primary Tumor	Illumina HiSeq	fc951188-ba57-4cd7-a209-28726710bb92	Colorectal	64.0	69EF3E70-5D7A-4E30-ABDE-0F9F76EA3141	E3EF5CAD-4D6E-4F04-BABB-A908EE02644B	TCGA-QG-A5YV-01A-11D-A28G-10	GRCh37-lite	TCGA-QG-A5YV	TCGA-COAD		s13220	Baylor College of Medicine	BLN - Baylor	United States	NO	T4b	N1a	Colon Adenocarcinoma	Stage IIIC	A28G-10	True
S13722.58cfa832e4b0c9d6adf6d448	58cfa832e4b0c9d6adf6d448	TCGA-QG-A5YW-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-QG-A5YW-01A-11D-A28G-10_wgs_Illumina	TCGA-QG-A5YW-01A-11D-A28G-10_wgs_Illumina.bam	63.92		0.08	58cfa832e4b0c9d6adf6d448	TCGA-QG-A5YW-01A-11D-A28G-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-QG-A5YW-01A	9F45A227-1FD5-478C-A194-4A5C61B68CC3	Primary Tumor	Illumina HiSeq	32a205bb-36f6-42a4-8bc1-42318eeccd0f	Colorectal	55.0	D8DCE266-1073-4BF2-A714-748E7E942635	4CFB0AEE-6661-478A-8694-9D8BA15E46B7	TCGA-QG-A5YW-01A-11D-A28G-10	GRCh37-lite	TCGA-QG-A5YW	TCGA-COAD		s12894	Baylor College of Medicine	BLN - Baylor	United States	NO	T3	N2b	Colon Mucinous Adenocarcinoma	Stage IIIC	A28G-10	True
S13722.58cfa832e4b0c9d6adf6d437	58cfa832e4b0c9d6adf6d437	TCGA-QG-A5Z1-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-QG-A5Z1-01A-11D-A28G-10_wgs_Illumina	TCGA-QG-A5Z1-01A-11D-A28G-10_wgs_Illumina.bam	39.63		0.08	58cfa832e4b0c9d6adf6d437	TCGA-QG-A5Z1-01A-11D-A28G-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-QG-A5Z1-01A	9C45EAEC-D854-4F51-80A3-2D80D6B4AEBC	Primary Tumor	Illumina HiSeq	cc89a29c-287c-4a64-87c1-40ea6c90f58a	Colorectal	71.0	95601410-9608-4DDA-BA3F-462BE0E8C35F	D3AFF5D3-23C0-43AE-9C01-8DDD776B530B	TCGA-QG-A5Z1-01A-11D-A28G-10	GRCh37-lite	TCGA-QG-A5Z1	TCGA-COAD		s13041	Baylor College of Medicine	BLN - Baylor	United States	NO	T3	N1b	Colon Adenocarcinoma	Stage IIIB	A28G-10	True
S13722.58cfa832e4b0c9d6adf6d51c	58cfa832e4b0c9d6adf6d51c	TCGA-KO-8405-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KO-8405-01A-11D-2310-10_wgs_Illumina	TCGA-KO-8405-01A-11D-2310-10_wgs_Illumina.bam	91.2		0.05	58cfa832e4b0c9d6adf6d51c	TCGA-KO-8405-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KO-8405-01A	D52C3CB6-921E-4F26-B49C-E6E4F11F9C06	Primary Tumor	Illumina HiSeq	f0e77d93-bf81-460d-b8ea-9f6189208a33	Kidney	29.0	415C8373-535F-4CDD-883B-C7BD7CEB426E	6400C324-2C94-477D-ACB9-669D4EA46F1E	TCGA-KO-8405-01A-11D-2310-10	GRCh37-lite	TCGA-KO-8405	TCGA-KICH		s16535	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T3a	N0	Kidney Chromophobe	Stage III	2310-10	True
S13722.58cfa832e4b0c9d6adf6d4fc	58cfa832e4b0c9d6adf6d4fc	TCGA-KN-8437-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8437-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8437-01A-11D-2310-10_wgs_Illumina.bam	88.3		0.05	58cfa832e4b0c9d6adf6d4fc	TCGA-KN-8437-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KN-8437-01A	F1C1502E-1BD6-425A-B651-454363809668	Primary Tumor	Illumina HiSeq	b4d37e4e-5f70-4f9f-8577-67d22eef75a4	Kidney	42.0	05CC0766-7ED0-458E-B1D7-732B632C05A4	345A06D6-FA5C-4674-A847-88A6B537CF3C	TCGA-KN-8437-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8437	TCGA-KICH		s16410	Baylor College of Medicine	Harvard	United States	NO	T1a	NX	Kidney Chromophobe	Stage I	2310-10	True
S13722.58cfa832e4b0c9d6adf6d48a	58cfa832e4b0c9d6adf6d48a	TCGA-NH-A50T-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-NH-A50T-01A-11D-A28G-10_wgs_Illumina	TCGA-NH-A50T-01A-11D-A28G-10_wgs_Illumina.bam	43.71		0.08	58cfa832e4b0c9d6adf6d48a	TCGA-NH-A50T-01A-11D-A28G-10_wgs_Illumina.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-NH-A50T-01A	490EABCA-4575-4BD6-9604-6B6E23D069CE	Primary Tumor	Illumina HiSeq	2893d404-6a2e-482b-86f7-eb3ae051faf4	Colorectal	68.0	9F5AD422-C94D-4914-B6F0-071596ECB589	8A929C55-35A6-4645-BB70-4B85D281B139	TCGA-NH-A50T-01A-11D-A28G-10	GRCh37-lite	TCGA-NH-A50T	TCGA-COAD		s13547	Baylor College of Medicine	Candler	United States	NO	T3	N0	Colon Adenocarcinoma	Stage IIA	A28G-10	True
S13722.58cfa832e4b0c9d6adf6d523	58cfa832e4b0c9d6adf6d523	TCGA-KN-8419-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KN-8419-01A-11D-2310-10_wgs_Illumina	TCGA-KN-8419-01A-11D-2310-10_wgs_Illumina.bam	17.3		0.05	58cfa832e4b0c9d6adf6d523	TCGA-KN-8419-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KN-8419-01A	DC04B82C-E1E8-4917-BA19-C2FEA4A1B69A	Primary Tumor	Illumina HiSeq	14e44071-dc94-49f8-a105-4012aa8e1767	Kidney	43.0	65256F5D-63A8-49D3-9D76-A3D7E3DDC0E6	A592E80A-3B1A-46AA-BE30-BCD87D6BCA6F	TCGA-KN-8419-01A-11D-2310-10	GRCh37-lite	TCGA-KN-8419	TCGA-KICH		s16533	Baylor College of Medicine	Harvard	United States	NO	T2	N0	Kidney Chromophobe	Stage II	2310-10	True
S13722.58cfa832e4b0c9d6adf6d59a	58cfa832e4b0c9d6adf6d59a	TCGA-MH-A55W-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-MH-A55W-01A-11D-A26P-10_wgs_Illumina	TCGA-MH-A55W-01A-11D-A26P-10_wgs_Illumina.bam	41.46		0.07	58cfa832e4b0c9d6adf6d59a	TCGA-MH-A55W-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-MH-A55W-01A	2030E10B-A4C2-460F-9E29-90C8A76EA05E	Primary Tumor	Illumina HiSeq	02bc7316-2306-488a-9d16-c7a439636912	Kidney	50.0	7846E991-0D5F-4E97-ABE1-945C3BE9C9F9	2425A532-F562-423A-88F5-228642F53875	TCGA-MH-A55W-01A-11D-A26P-10	GRCh37-lite	TCGA-MH-A55W	TCGA-KIRP		s11593	Baylor College of Medicine	BLN - Baylor	United States	NO	T1b	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A26P-10	True
S13722.58cfa832e4b0c9d6adf6d59c	58cfa832e4b0c9d6adf6d59c	TCGA-MH-A562-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-MH-A562-01A-11D-A26P-10_wgs_Illumina	TCGA-MH-A562-01A-11D-A26P-10_wgs_Illumina.bam	34.1		0.08	58cfa832e4b0c9d6adf6d59c	TCGA-MH-A562-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-MH-A562-01A	45BDCFD6-1E3F-4BE8-B843-AE949E8E43EB	Primary Tumor	Illumina HiSeq	6eae65c7-1a89-44c9-a3c5-b7af6d633f1b	Kidney	57.0	4306E07D-6FC1-4C69-ACB8-00A1DC78CAD8	DDDEA2E4-B8C3-4157-9D92-6DE472E8375A	TCGA-MH-A562-01A-11D-A26P-10	GRCh37-lite	TCGA-MH-A562	TCGA-KIRP		s11782	Baylor College of Medicine	BLN - Baylor	United States	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A26P-10	True
S13722.58cfa832e4b0c9d6adf6d470	58cfa832e4b0c9d6adf6d470	TCGA-QG-A5Z2-01A-11D-A28G-10_wgs_Illumina.filtered.	WGS	TCGA-QG-A5Z2-01A-11D-A28G-10_wgs_Illumina	TCGA-QG-A5Z2-01A-11D-A28G-10_wgs_Illumina.bam	58.77		0.07	58cfa832e4b0c9d6adf6d470	TCGA-QG-A5Z2-01A-11D-A28G-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-QG-A5Z2-01A	84959E50-17F5-4F2B-8E0C-5EBB139D2C3A	Primary Tumor	Illumina HiSeq	2113677f-10e1-4987-bde0-35d29025de2e	Colorectal	61.0	3D753B5B-8E33-4307-9321-E4AD4821F3BF	31E63F89-A6A9-40FB-823D-F41587BD73D8	TCGA-QG-A5Z2-01A-11D-A28G-10	GRCh37-lite	TCGA-QG-A5Z2	TCGA-COAD		s13042	Baylor College of Medicine	BLN - Baylor	United States	NO	T2	N0	Colon Adenocarcinoma	Stage I	A28G-10	True
S13722.58cfa832e4b0c9d6adf6d5a2	58cfa832e4b0c9d6adf6d5a2	TCGA-MH-A560-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-MH-A560-01A-11D-A26P-10_wgs_Illumina	TCGA-MH-A560-01A-11D-A26P-10_wgs_Illumina.bam	8.04		0.07	58cfa832e4b0c9d6adf6d5a2	TCGA-MH-A560-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-MH-A560-01A	A40BEABE-496E-4324-A1D1-5A7D8B002AAB	Primary Tumor	Illumina HiSeq	b1efdb03-f6ae-443f-85cc-d545d7710c21	Kidney	62.0	2697D1DE-3D7E-4BD6-9EDE-7516BD10A701	CF5DEB22-F7EB-409D-A0E4-882716199C39	TCGA-MH-A560-01A-11D-A26P-10	GRCh37-lite	TCGA-MH-A560	TCGA-KIRP		s11594	Baylor College of Medicine	BLN - Baylor	United States	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A26P-10	True
S13722.58cfa832e4b0c9d6adf6d58e	58cfa832e4b0c9d6adf6d58e	TCGA-MR-A520-01A-11D-A25V-10_wgs_Illumina.filtered.	WGS	TCGA-MR-A520-01A-11D-A25V-10_wgs_Illumina	TCGA-MR-A520-01A-11D-A25V-10_wgs_Illumina.bam	24.04		0.08	58cfa832e4b0c9d6adf6d58e	TCGA-MR-A520-01A-11D-A25V-10_wgs_Illumina.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Liver Hepatocellular Carcinoma	Aligned reads	TCGA-MR-A520-01A	25E893AD-A0FD-45AE-9AA9-9BCD7C2EC8E5	Primary Tumor	Illumina HiSeq	aa52c229-8251-4890-a772-fac2f7c1b7ca	Liver	58.0	D7F0E432-C20B-4B2B-8D73-2A235F339BE7	352FBBB4-88A5-4354-B1FA-3A01DA3FBFA7	TCGA-MR-A520-01A-11D-A25V-10	GRCh37-lite	TCGA-MR-A520	TCGA-LIHC		s16790	Baylor College of Medicine	University of Minnesota	United States	NO	T1	NX	Hepatocellular Carcinoma	Stage I	A25V-10	True
S13722.58cfa832e4b0c9d6adf6d5b8	58cfa832e4b0c9d6adf6d5b8	TCGA-KO-8410-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KO-8410-01A-11D-2310-10_wgs_Illumina	TCGA-KO-8410-01A-11D-2310-10_wgs_Illumina.bam	71.2		0.05	58cfa832e4b0c9d6adf6d5b8	TCGA-KO-8410-01A-11D-2310-10_wgs_Illumina.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Kidney Chromophobe	Aligned reads	TCGA-KO-8410-01A	B5F6A0E3-F9AC-475F-9A34-B8B8834F1779	Primary Tumor	Illumina HiSeq	ccebf6d6-dff4-4e8b-b33c-391cf464f5ab	Kidney	74.0	3751E3F9-C61F-4D5A-8054-B08590539820	798BD17B-69B7-40D7-92FF-7C2389EDCCCF	TCGA-KO-8410-01A-11D-2310-10	GRCh37-lite	TCGA-KO-8410	TCGA-KICH		s16409	Baylor College of Medicine	MD Anderson Cancer Center	United States	NO	T1b	N0	Kidney Chromophobe	Stage I	2310-10	True
S13722.58cfa832e4b0c9d6adf6d5af	58cfa832e4b0c9d6adf6d5af	TCGA-MH-A561-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-MH-A561-01A-11D-A26P-10_wgs_Illumina	TCGA-MH-A561-01A-11D-A26P-10_wgs_Illumina.bam	42.2		0.08	58cfa832e4b0c9d6adf6d5af	TCGA-MH-A561-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-MH-A561-01A	E6E6A773-B155-45A9-989F-75C12CE1702A	Primary Tumor	Illumina HiSeq	49516926-9793-4b88-bfa8-c631918a9b7a	Kidney	66.0	9E93686E-D150-404A-BD88-1DD4D2999ED3	2E8AD1CD-D5D5-4BB4-8BBD-E9BEF45088DA	TCGA-MH-A561-01A-11D-A26P-10	GRCh37-lite	TCGA-MH-A561	TCGA-KIRP		s11592	Baylor College of Medicine	BLN - Baylor	United States	NO	T1a	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A26P-10	True
S13722.58cfa832e4b0c9d6adf6d2aa	58cfa832e4b0c9d6adf6d2aa	TCGA-KL-8326-01A-11D-2310-10_wgs_Illumina.filtered.	WGS	TCGA-KL-8326-01A-11D-2310-10_wgs_Illumina	TCGA-KL-8326-01A-11D-2310-10_wgs_Illumina.bam	71.3		0.05	58cfa832e4b0c9d6adf6d2aa	TCGA-KL-8326-01A-11D-2310-10_wgs_Illumina.bam	Alive	MALE	WHITE		Kidney Chromophobe	Aligned reads	TCGA-KL-8326-01A	03F3DD32-E1D1-485B-A968-3F55798F4D46	Primary Tumor	Illumina HiSeq	b96eaa8e-2627-4ac2-a3fb-1140269babf6	Kidney	69.0	59703768-8BE1-47A7-8C7D-D794C0936019	4729FE4B-C1AC-489B-A67E-91E5C5E3FF8C	TCGA-KL-8326-01A-11D-2310-10	GRCh37-lite	TCGA-KL-8326	TCGA-KICH		s16519	Baylor College of Medicine	MSKCC	United States	NO	T3a	N0	Kidney Chromophobe	Stage III	2310-10	True
S13722.58cfa832e4b0c9d6adf6d5ad	58cfa832e4b0c9d6adf6d5ad	TCGA-MH-A55Z-01A-11D-A26P-10_wgs_Illumina.filtered.	WGS	TCGA-MH-A55Z-01A-11D-A26P-10_wgs_Illumina	TCGA-MH-A55Z-01A-11D-A26P-10_wgs_Illumina.bam	53.89		0.07	58cfa832e4b0c9d6adf6d5ad	TCGA-MH-A55Z-01A-11D-A26P-10_wgs_Illumina.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Kidney Renal Papillary Cell Carcinoma	Aligned reads	TCGA-MH-A55Z-01A	F0F7E57F-1E9D-4F24-A685-A0811AACBBED	Primary Tumor	Illumina HiSeq	44cc1ed1-021d-4a1e-9a42-c6cb01ad7781	Kidney	65.0	1FC5BF90-235F-411C-AC1D-AEDC4DF1746F	B19EC4CD-2876-4A2B-BCB9-B3C8DB54FC15	TCGA-MH-A55Z-01A-11D-A26P-10	GRCh37-lite	TCGA-MH-A55Z	TCGA-KIRP		s11866	Baylor College of Medicine	BLN - Baylor	United States	NO	T1b	NX	Kidney Papillary Renal Cell Carcinoma	Stage I	A26P-10	True
S13722.58cfa82ee4b0c9d6adf6ade1	58cfa82ee4b0c9d6adf6ade1	G39020.TCGA-BR-8682-01A-11D-2394-08.3.filtered.	WGS	G39020.TCGA-BR-8682-01A-11D-2394-08.3	G39020.TCGA-BR-8682-01A-11D-2394-08.3.bam	231.0		0.05	58cfa82ee4b0c9d6adf6ade1	G39020.TCGA-BR-8682-01A-11D-2394-08.3.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-8682-01A	D5EFCDE2-21E6-4071-9AA4-3C5688A45B3F	Primary Tumor	Illumina HiSeq	36f56254-f585-4353-89b4-00cb5cfa20eb	Stomach	52.0	4E6BBC3C-BB9E-46C0-8B22-60F9725DB516	EA2055D1-7B8B-4AAF-9A70-8802F4DEEF9B	TCGA-BR-8682-01A-11D-2394-08	HG19_Broad_variant	TCGA-BR-8682	TCGA-STAD		s15038	Broad Institute of MIT and Harvard	Asterand	Vietnam	NO	T4a	N0	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage IIB	2394-08	True
S13722.58cfa82fe4b0c9d6adf6b657	58cfa82fe4b0c9d6adf6b657	TCGA-64-5778-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-64-5778-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_3_rg.sorted	TCGA-64-5778-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_3_rg.sorted.bam	702.7	1.9	0.15	58cfa82fe4b0c9d6adf6b657	TCGA-64-5778-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5778-01A	8FDBD88F-19AE-4AB8-BCD7-6BFA1BBDE742	Primary Tumor	Illumina HiSeq	bd5570f2-ed45-408a-a615-0a6808c31d84	Lung	60.0	92514FD2-A178-42E8-8929-0910558E7F87	BC8FFDB4-AB99-44B7-95B0-7BC2F8110B76	TCGA-64-5778-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5778	TCGA-LUAD		s10796	Harvard Medical School	Fox Chase	United States	NO	T2	N0	Lung Bronchioloalveolar Carcinoma Nonmucinous	Stage IB	1623-02	True
S13722.58cfa82fe4b0c9d6adf6b6b7	58cfa82fe4b0c9d6adf6b6b7	TCGA-64-5781-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-64-5781-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_7_rg.sorted	TCGA-64-5781-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_7_rg.sorted.bam	555.7	1.9	0.15	58cfa82fe4b0c9d6adf6b6b7	TCGA-64-5781-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5781-01A	41C4C704-825E-49F5-9D54-DBD7D30725E0	Primary Tumor	Illumina HiSeq	901f4776-2659-4626-abec-5a9323e6f75e	Lung	55.0	B32F509D-91E5-4601-B8B3-4B0A5212C22B	69DEF564-A4D8-4820-9ED6-F17AF2CAB0A7	TCGA-64-5781-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5781	TCGA-LUAD		s11352	Harvard Medical School	Fox Chase	United States	NO	T2	N0	Lung Adenocarcinoma Mixed Subtype	Stage IB	1623-02	True
S13722.58cfa82fe4b0c9d6adf6b852	58cfa82fe4b0c9d6adf6b852	TCGA-A5-A0R9-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_5_rg.sorted.filtered.	WGS	TCGA-A5-A0R9-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_5_rg.sorted	TCGA-A5-A0R9-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_5_rg.sorted.bam	112.95	1.93	0.17	58cfa82fe4b0c9d6adf6b852	TCGA-A5-A0R9-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0R9-01A	284174FD-1320-4617-9E99-75BD75DF9BF3	Primary Tumor	Illumina HiSeq	4139f46d-ae94-47a2-a3ae-0b96262c6a89	Uterus	51.0	986AC6AC-087F-412B-BB0C-9BE10D104989	6BBEF031-7106-4D36-86A9-F8A2333448BB	TCGA-A5-A0R9-01A-11D-A101-02	HG19_Broad_variant	TCGA-A5-A0R9	TCGA-UCEC		s4419	Harvard Medical School	Cedars Sinai		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa82fe4b0c9d6adf6b86e	58cfa82fe4b0c9d6adf6b86e	TCGA-A6-2671-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2671-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2671-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	243.0	1.9	0.15	58cfa82fe4b0c9d6adf6b86e	TCGA-A6-2671-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2671-01A	565E2726-4942-4726-89D3-C5E3797F7204	Primary Tumor	Illumina HiSeq	866dc7b9-86cd-4842-ad2f-1d5e7c714ccb	Colorectal	85.0	81505915-6C01-4299-AE89-964DC20D93CB	82E23BAF-DA11-4175-BEE0-81C0C0137D72	TCGA-A6-2671-01A-01D-1405-02	HG18	TCGA-A6-2671	TCGA-COAD		s13649	Harvard Medical School	Christiana Healthcare		NO	T3	N2	Colon Adenocarcinoma	Stage IV	1405-02	True
S13722.58cfa82fe4b0c9d6adf6b938	58cfa82fe4b0c9d6adf6b938	TCGA-64-5779-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-64-5779-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_5_rg.sorted	TCGA-64-5779-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_5_rg.sorted.bam	439.7	1.9	0.15	58cfa82fe4b0c9d6adf6b938	TCGA-64-5779-01A-01D-1623_110824_SN208_0222_BB0164ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5779-01A	1C58D9B8-17A2-4FC6-9898-FE6F47BD2C2A	Primary Tumor	Illumina HiSeq	40156a89-cb76-4ae2-b73d-ec06c1cbd7bb	Lung	61.0	4131DA8F-3C6C-43E1-A7EB-81CB8988F524	AE15BEF8-478B-432E-B429-643A75BD2EB8	TCGA-64-5779-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5779	TCGA-LUAD		s11463	Harvard Medical School	Fox Chase	United States	NO	T2	N2	Lung Acinar Adenocarcinoma	Stage IIIA	1623-02	True
S13722.58cfa830e4b0c9d6adf6baaa	58cfa830e4b0c9d6adf6baaa	TCGA-A5-A0GD-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0GD-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_3_rg.sorted	TCGA-A5-A0GD-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_3_rg.sorted.bam	96.48	1.95	0.14	58cfa830e4b0c9d6adf6baaa	TCGA-A5-A0GD-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GD-01A	1486A031-B74D-4976-8B0B-4569E6978F49	Primary Tumor	Illumina HiSeq	98b5ea92-9e57-4d1f-937d-8bb0dd2a3cf2	Uterus	75.0	F449F50A-7664-4DDC-87AA-6A061EE7190C	069406A8-56D7-4E93-8570-7880A99D6C2D	TCGA-A5-A0GD-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GD	TCGA-UCEC		s4771	Harvard Medical School	Cedars Sinai		NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa830e4b0c9d6adf6be10	58cfa830e4b0c9d6adf6be10	TCGA-BH-A0HX-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BH-A0HX-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_7_rg.sorted	TCGA-BH-A0HX-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_7_rg.sorted.bam	19.84	1.95	0.16	58cfa830e4b0c9d6adf6be10	TCGA-BH-A0HX-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0HX-01A	3B01D064-8C00-4972-9F07-407EAC8E7534	Primary Tumor	Illumina HiSeq	06f7db86-540c-401d-bbd9-0b88698c5f36	Breast	54.0	989C2DF5-5183-4DAA-A8DA-FC9AB18A437C	11821020-0E93-4479-85F8-306976DE6722	TCGA-BH-A0HX-01A-21D-A060-02	HG19_Broad_variant	TCGA-BH-A0HX	TCGA-BRCA		s6126	Harvard Medical School	University of Pittsburgh		NO	T2	N1a	Infiltrating Ductal Carcinoma	Stage IIB	A060-02	True
S13722.58cfa830e4b0c9d6adf6be3a	58cfa830e4b0c9d6adf6be3a	TCGA-BJ-A18Z-01A-21D-A13U_120712_SN1222_0125_BD13TPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A18Z-01A-21D-A13U_120712_SN1222_0125_BD13TPACXX_s_1_rg.sorted	TCGA-BJ-A18Z-01A-21D-A13U_120712_SN1222_0125_BD13TPACXX_s_1_rg.sorted.bam	45.3	1.98	0.17	58cfa830e4b0c9d6adf6be3a	TCGA-BJ-A18Z-01A-21D-A13U_120712_SN1222_0125_BD13TPACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A18Z-01A	0D497FAF-2C1C-4173-A5FE-770CCA73323C	Primary Tumor	Illumina HiSeq	a740c90f-9cbc-4ff1-8cad-c78d4dbb92cf	Thyroid	58.0	19DEE039-9C98-4D4A-8BAF-EEA1B6DDA8EB	815C53C3-8ADD-4612-B93C-3ED4BFA530AA	TCGA-BJ-A18Z-01A-21D-A13U-02	HG19_Broad_variant	TCGA-BJ-A18Z	TCGA-THCA		s12354	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A13U-02	True
S13722.58cfa830e4b0c9d6adf6be3c	58cfa830e4b0c9d6adf6be3c	TCGA-BJ-A18Y-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BJ-A18Y-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_1_rg.sorted	TCGA-BJ-A18Y-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_1_rg.sorted.bam	77.56	2.0	0.18	58cfa830e4b0c9d6adf6be3c	TCGA-BJ-A18Y-01A-11D-A13U_120706_SN1222_0122_AC0WPYACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A18Y-01A	ACB3B9DB-16E9-40F5-87A9-9DF9D4CEEE54	Primary Tumor	Illumina HiSeq	0074a697-0800-4872-9a48-48945f46d18d	Thyroid	29.0	5D1D84D0-9A03-4381-9CF1-E460B3617AAA	56D2A069-7969-40F1-A237-E4FE7E62C84C	TCGA-BJ-A18Y-01A-11D-A13U-02	HG19_Broad_variant	TCGA-BJ-A18Y	TCGA-THCA		s12351	Harvard Medical School	University of Pittsburgh	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A13U-02	True
S13722.58cfa830e4b0c9d6adf6bdc0	58cfa830e4b0c9d6adf6bdc0	TCGA-BG-A186-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A186-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_1_rg.sorted	TCGA-BG-A186-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_1_rg.sorted.bam	79.77	1.93	0.17	58cfa830e4b0c9d6adf6bdc0	TCGA-BG-A186-01A-11D-A12F_120413_SN1120_0132_AD0T6RACXX_s_1_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A186-01A	FE4DB898-3A9F-4DFF-ADCB-7B8C30137350	Primary Tumor	Illumina HiSeq	f65268ef-b937-4d49-922e-a5e3ebc0eab8	Uterus	61.0	B1645A83-57B7-4357-B977-63A5B6AEE39E	ECF410AD-B160-4F00-A165-38529FAE974B	TCGA-BG-A186-01A-11D-A12F-02	HG19_Broad_variant	TCGA-BG-A186	TCGA-UCEC		s4792	Harvard Medical School	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A12F-02	True
S13722.58cfa830e4b0c9d6adf6be8d	58cfa830e4b0c9d6adf6be8d	TCGA-BK-A0CB-01A-32D-A101_120330_SN208_0280_AD0UKLACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BK-A0CB-01A-32D-A101_120330_SN208_0280_AD0UKLACXX_s_1_rg.sorted	TCGA-BK-A0CB-01A-32D-A101_120330_SN208_0280_AD0UKLACXX_s_1_rg.sorted.bam	79.7	1.9	0.16	58cfa830e4b0c9d6adf6be8d	TCGA-BK-A0CB-01A-32D-A101_120330_SN208_0280_AD0UKLACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BK-A0CB-01A	59E9029A-8DDD-4447-B35A-72BC39F82A30	Primary Tumor	Illumina HiSeq	2c466122-c49e-4866-b9d4-faf31dde999c	Uterus	60.0	7678C70D-A298-4472-89A0-427AF1E93D28	F186159C-DCE6-467C-AAAF-BB08FBAE6827	TCGA-BK-A0CB-01A-32D-A101-02	HG19_Broad_variant	TCGA-BK-A0CB	TCGA-UCEC		s5006	Harvard Medical School	Christiana Healthcare		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6bee6	58cfa830e4b0c9d6adf6bee6	TCGA-AX-A0IU-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_2_rg.sorted.filtered.	WGS	TCGA-AX-A0IU-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_2_rg.sorted	TCGA-AX-A0IU-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_2_rg.sorted.bam	117.75	2.28	0.16	58cfa830e4b0c9d6adf6bee6	TCGA-AX-A0IU-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_2_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A0IU-01A	7E64EA6C-A3DB-48EB-91BE-131361510A92	Primary Tumor	Illumina HiSeq	927c6e80-e2e3-4198-98a4-77a79159fb8a	Uterus	79.0	DC4B3695-CE62-48D5-9F1D-7DD70D049C97	24746F36-88BC-44B0-955A-55A2CC98E17C	TCGA-AX-A0IU-01A-11D-A101-02	HG19_Broad_variant	TCGA-AX-A0IU	TCGA-UCEC		s4999	Harvard Medical School	Gynecologic Oncology Group		NO			Serous endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6bf83	58cfa830e4b0c9d6adf6bf83	TCGA-BR-6453-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BR-6453-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_4_rg.sorted	TCGA-BR-6453-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_4_rg.sorted.bam	93.7	1.9	0.15	58cfa830e4b0c9d6adf6bf83	TCGA-BR-6453-01A-11D-1798_130115_SN1222_0169_BD1K2PACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6453-01A	AE633E83-303F-4A90-AC3B-34458FD9BEEF	Primary Tumor	Illumina HiSeq	e92977c9-6880-4f84-842a-9152e558d0b1	Stomach	54.0	A8F3B148-5929-4025-81A1-6595D49F2279	EE3446DC-7278-47AF-8F65-F63A1D423644	TCGA-BR-6453-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6453	TCGA-STAD		s15305	Harvard Medical School	Asterand	Russia	NO	T2	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	True
S13722.58cfa830e4b0c9d6adf6bf30	58cfa830e4b0c9d6adf6bf30	TCGA-BR-4191-01A-02D-1128_120805_SN1222_0143_BD172BACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-4191-01A-02D-1128_120805_SN1222_0143_BD172BACXX_s_3_rg.sorted	TCGA-BR-4191-01A-02D-1128_120805_SN1222_0143_BD172BACXX_s_3_rg.sorted.bam	266.9	1.9	0.15	58cfa830e4b0c9d6adf6bf30	TCGA-BR-4191-01A-02D-1128_120805_SN1222_0143_BD172BACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4191-01A	74F859CF-6DF5-4E96-AE6B-CFAAB691D5FD	Primary Tumor	Illumina HiSeq	d71fa3ea-a7fb-40af-a7b9-64ceca39e135	Stomach	72.0	E5A1A598-5896-46F9-8DCA-BA19AC138D14	125C563B-A1CE-4FFC-8D8D-19C7CA2E1049	TCGA-BR-4191-01A-02D-1128-02	HG19_Broad_variant	TCGA-BR-4191	TCGA-STAD		s14608	Harvard Medical School	Asterand	Russia	NO	TX	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1128-02	True
S13722.58cfa830e4b0c9d6adf6bfa4	58cfa830e4b0c9d6adf6bfa4	TCGA-BR-6457-01A-21D-1798_130116_SN208_0448_AC1J58ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-6457-01A-21D-1798_130116_SN208_0448_AC1J58ACXX_s_3_rg.sorted	TCGA-BR-6457-01A-21D-1798_130116_SN208_0448_AC1J58ACXX_s_3_rg.sorted.bam	77.4	1.9	0.15	58cfa830e4b0c9d6adf6bfa4	TCGA-BR-6457-01A-21D-1798_130116_SN208_0448_AC1J58ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6457-01A	05CE16D4-A999-491A-91AD-9449A57228FF	Primary Tumor	Illumina HiSeq	695f7145-7735-48f7-98e8-99b86bb936f4	Stomach	69.0	BADB9AE0-9C44-41D4-848B-EE03B6FCA503	85EEEBBE-BDBB-4FE7-8CCD-401E818EEB29	TCGA-BR-6457-01A-21D-1798-02	HG19_Broad_variant	TCGA-BR-6457	TCGA-STAD		s14618	Harvard Medical School	Asterand	Ukraine	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	True
S13722.58cfa830e4b0c9d6adf6bfc0	58cfa830e4b0c9d6adf6bfc0	TCGA-B5-A0JS-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_4_rg.sorted.filtered.	WGS	TCGA-B5-A0JS-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_4_rg.sorted	TCGA-B5-A0JS-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_4_rg.sorted.bam	61.49	1.87	0.17	58cfa830e4b0c9d6adf6bfc0	TCGA-B5-A0JS-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JS-01A	0DA7BBD4-ED8D-474B-B494-CB93C5FA811E	Primary Tumor	Illumina HiSeq	06607d3e-b9f0-4332-aee8-7001d26e7d12	Uterus	54.0	D0B88B1C-150D-4ABC-9F9E-8C51CB208EFA	D2DD7ED4-03F6-463E-94BD-6CF98D80E8FD	TCGA-B5-A0JS-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0JS	TCGA-UCEC		s5208	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6c022	58cfa830e4b0c9d6adf6c022	TCGA-BJ-A0ZE-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZE-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_4_rg.sorted	TCGA-BJ-A0ZE-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_4_rg.sorted.bam	36.9	2.03	0.15	58cfa830e4b0c9d6adf6c022	TCGA-BJ-A0ZE-01A-11D-A10R_120617_SN1222_0117_BD1414ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZE-01A	AB8C9101-ADEB-4C43-A8BB-B089EBD711F6	Primary Tumor	Illumina HiSeq	b215d9c2-6a64-45cf-8e4b-0e2b87207119	Thyroid	63.0	695C5627-F442-4A86-9702-EF35DEFD8C8C	ED0B1C86-A516-422F-92C4-7C535E709989	TCGA-BJ-A0ZE-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZE	TCGA-THCA		s12231	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A10R-02	True
S13722.58cfa830e4b0c9d6adf6c12f	58cfa830e4b0c9d6adf6c12f	TCGA-BG-A0MU-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A0MU-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_1_rg.sorted	TCGA-BG-A0MU-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_1_rg.sorted.bam	74.26	2.08	0.16	58cfa830e4b0c9d6adf6c12f	TCGA-BG-A0MU-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MU-01A	A7329910-B1C7-4A18-B28E-8FAD79121339	Primary Tumor	Illumina HiSeq	c676fa46-db3a-402d-804d-9717141fdae6	Uterus	78.0	F0AF3F30-3D64-4BD8-9A8F-7FF7AB9BB7B0	0BB10C9F-C337-4E2E-A661-9CE12C8BEB35	TCGA-BG-A0MU-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0MU	TCGA-UCEC		s5393	Harvard Medical School	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6c164	58cfa830e4b0c9d6adf6c164	TCGA-BA-5151-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BA-5151-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_3_rg.sorted	TCGA-BA-5151-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_3_rg.sorted.bam	227.7	1.9	0.15	58cfa830e4b0c9d6adf6c164	TCGA-BA-5151-01A-01D-1431_120423_SN590_0154_AC0JBHACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5151-01A	A55FB87D-F606-48A5-82F5-09EACBACF41B	Primary Tumor	Illumina HiSeq	d1067ce4-863a-49f4-9061-d2e677695382	Head and Neck	72.0	63384A6A-9686-44EE-8C8F-22923968C9DE	5B29B8E2-23E6-4E6E-815C-B8D0EF534B14	TCGA-BA-5151-01A-01D-1431-02	HG19_Broad_variant	TCGA-BA-5151	TCGA-HNSC		s15488	Harvard Medical School	UNC		NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True
S13722.58cfa831e4b0c9d6adf6c36c	58cfa831e4b0c9d6adf6c36c	TCGA-CD-5803-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CD-5803-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_8_rg.sorted	TCGA-CD-5803-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_8_rg.sorted.bam	193.3	1.9	0.14	58cfa831e4b0c9d6adf6c36c	TCGA-CD-5803-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_8_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5803-01A	33901C6F-9180-4A19-866C-F4AC6BEC76DA	Primary Tumor	Illumina HiSeq	1002025d-03b9-46ab-988a-576f59957cac	Stomach	78.0	EB71264D-C896-4910-BF46-D6F129B83941	EABD49CE-0F0C-443D-9BF4-0ADD2C2532B2	TCGA-CD-5803-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5803	TCGA-STAD		s15118	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1598-02	True
S13722.58cfa830e4b0c9d6adf6c2ca	58cfa830e4b0c9d6adf6c2ca	TCGA-BG-A0RY-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A0RY-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_7_rg.sorted	TCGA-BG-A0RY-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_7_rg.sorted.bam	73.32	1.95	0.16	58cfa830e4b0c9d6adf6c2ca	TCGA-BG-A0RY-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0RY-01A	F299AD43-BB16-46CE-9617-48CC6C6F29E7	Primary Tumor	Illumina HiSeq	5464e1b6-9efc-49a0-bd5b-4fcd152a7718	Uterus	68.0	260692E1-9B2C-4F8B-952D-1B95C042E659	8DB9ED84-C708-4075-B93D-CC58E84E6D99	TCGA-BG-A0RY-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0RY	TCGA-UCEC		s4258	Harvard Medical School	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa831e4b0c9d6adf6c4d2	58cfa831e4b0c9d6adf6c4d2	TCGA-CF-A3MG-01A-11D-A210_120914_SN590_0180_BC19KDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CF-A3MG-01A-11D-A210_120914_SN590_0180_BC19KDACXX_s_7_rg.sorted	TCGA-CF-A3MG-01A-11D-A210_120914_SN590_0180_BC19KDACXX_s_7_rg.sorted.bam	66.73		0.14	58cfa831e4b0c9d6adf6c4d2	TCGA-CF-A3MG-01A-11D-A210_120914_SN590_0180_BC19KDACXX_s_7_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A3MG-01A	39EFA06A-FFE5-40B3-8F8A-A2D7071BC9E3	Primary Tumor	Illumina HiSeq	695ed631-423c-4381-ae8f-4a70fd6266b9	Bladder	48.0	1ACF91C8-4971-4893-AC27-64EA4A4C3023	99993BCD-8555-407A-A918-3F51D57BA720	TCGA-CF-A3MG-01A-11D-A210-26	HG19_Broad_variant	TCGA-CF-A3MG	TCGA-BLCA		s3095	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	True
S13722.58cfa831e4b0c9d6adf6c560	58cfa831e4b0c9d6adf6c560	TCGA-CH-5767-01A-11D-1784_130329_SN590_0221_BD1WHDACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CH-5767-01A-11D-1784_130329_SN590_0221_BD1WHDACXX_s_6_rg.sorted	TCGA-CH-5767-01A-11D-1784_130329_SN590_0221_BD1WHDACXX_s_6_rg.sorted.bam	200.4	1.9	0.16	58cfa831e4b0c9d6adf6c560	TCGA-CH-5767-01A-11D-1784_130329_SN590_0221_BD1WHDACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5767-01A	8DC53431-44AB-485E-B4E6-C3D06509506D	Primary Tumor	Illumina HiSeq	4ec6dbff-5194-4938-949c-d5ae0ec6a882	Prostate	66.0	A87E6352-C469-484D-87FC-FABDBA237D01	02D28407-4AE4-4DA6-ABB5-6D6A4BB3D8D3	TCGA-CH-5767-01A-11D-1784-02	HG19_Broad_variant	TCGA-CH-5767	TCGA-PRAD		s4129	Harvard Medical School	Indivumed	Germany	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True
S13722.58cfa831e4b0c9d6adf6c4b4	58cfa831e4b0c9d6adf6c4b4	TCGA-CE-A13K-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CE-A13K-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_1_rg.sorted	TCGA-CE-A13K-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_1_rg.sorted.bam	88.59	2.02	0.17	58cfa831e4b0c9d6adf6c4b4	TCGA-CE-A13K-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-CE-A13K-01A	A1227FFA-2733-4A43-BA82-834755453870	Primary Tumor	Illumina HiSeq	7f979498-38e3-4b28-b84a-c3eede43fa06	Thyroid	30.0	DAF2A444-AB89-48D4-9DA7-888AC3099AB7	7CEF35A1-E530-47C9-9A86-3EA2C970FCD3	TCGA-CE-A13K-01A-11D-A10R-02	HG19_Broad_variant	TCGA-CE-A13K	TCGA-THCA		s12632	Harvard Medical School	ILSbio	Vietnam	NO	T3	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	True
S13722.58cfa831e4b0c9d6adf6c604	58cfa831e4b0c9d6adf6c604	TCGA-CQ-5330-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CQ-5330-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_4_rg.sorted	TCGA-CQ-5330-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_4_rg.sorted.bam	258.0	1.9	0.14	58cfa831e4b0c9d6adf6c604	TCGA-CQ-5330-01A-01D-1681_120425_SN1222_0100_BD0T1VACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-5330-01A	9FFA79FA-D2D8-48E1-8FD6-4B020ECF357C	Primary Tumor	Illumina HiSeq	a37f15ec-e0df-4bcd-8275-88312d0a1566	Head and Neck	69.0	A70301B0-F66D-49B7-B420-C1F56B90002D	AB6DC814-ECE0-497C-BC58-5FECE5D3DCE6	TCGA-CQ-5330-01A-01D-1681-02	HG19_Broad_variant	TCGA-CQ-5330	TCGA-HNSC		s15640	Harvard Medical School	University Health Network, Toronto	Canada	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True
S13722.58cfa831e4b0c9d6adf6c68a	58cfa831e4b0c9d6adf6c68a	TCGA-CU-A0YR-01A-12D-A10R_120926_SN590_0182_BD1EAGACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CU-A0YR-01A-12D-A10R_120926_SN590_0182_BD1EAGACXX_s_7_rg.sorted	TCGA-CU-A0YR-01A-12D-A10R_120926_SN590_0182_BD1EAGACXX_s_7_rg.sorted.bam	36.74	1.82	0.16	58cfa831e4b0c9d6adf6c68a	TCGA-CU-A0YR-01A-12D-A10R_120926_SN590_0182_BD1EAGACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A0YR-01A	811B3950-36E7-485F-BC48-ACA1EEE2DDEF	Primary Tumor	Illumina HiSeq	197d19a7-07c1-4cd3-b41d-a8233c9d8a42	Bladder	83.0	B362FCFA-4E31-4321-9E17-11A8BAE839C3	0CB51232-CFEA-4F4F-A26A-173B1094A64B	TCGA-CU-A0YR-01A-12D-A10R-02	HG19_Broad_variant	TCGA-CU-A0YR	TCGA-BLCA		s3096	Harvard Medical School	UNC	United States	NO	T2	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A10R-02	True
S13722.58cfa831e4b0c9d6adf6c6c3	58cfa831e4b0c9d6adf6c6c3	TCGA-CU-A3QU-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CU-A3QU-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_1_rg.sorted	TCGA-CU-A3QU-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_1_rg.sorted.bam	73.31		0.15	58cfa831e4b0c9d6adf6c6c3	TCGA-CU-A3QU-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A3QU-01A	AE6D853B-A7F0-4465-B7BF-5A45006AB3B3	Primary Tumor	Illumina HiSeq	c4c9ea17-be51-4e92-8cdc-0d5880def11c	Bladder	58.0	75448068-DED8-42F0-BB99-6D1C4B3FFA4E	98A4CFCF-34FE-433A-A598-4191742DC977	TCGA-CU-A3QU-01A-11D-A233-26	HG19_Broad_variant	TCGA-CU-A3QU	TCGA-BLCA		s3278	MD Anderson - Institute for Applied Cancer Science	UNC	United States	NO	T2b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	True
S13722.58cfa831e4b0c9d6adf6c662	58cfa831e4b0c9d6adf6c662	TCGA-CM-4750-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4750-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4750-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	450.02	1.9	0.14	58cfa831e4b0c9d6adf6c662	TCGA-CM-4750-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4750-01A	C777A777-373A-4773-9566-6C373261F00A	Primary Tumor	Illumina HiSeq	eae74e76-b630-469d-9ad7-549fbfe64297	Colorectal	34.0	463D4B1E-2068-45DD-9631-FB9C7268FE6C	EE814BA4-311A-4ABC-B7A6-F32C68C50F2A	TCGA-CM-4750-01A-01D-1405-02	HG18	TCGA-CM-4750	TCGA-COAD		s12891	Harvard Medical School	MSKCC	United States	NO	T1	N1b	Colon Adenocarcinoma	Stage IIIA	1405-02	True
S13722.58cfa831e4b0c9d6adf6c794	58cfa831e4b0c9d6adf6c794	TCGA-CN-6017-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CN-6017-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_2_rg.sorted	TCGA-CN-6017-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_2_rg.sorted.bam	69.0	1.9	0.15	58cfa831e4b0c9d6adf6c794	TCGA-CN-6017-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6017-01A	23C4E2EB-142B-4FCC-A974-9A248AEC3F37	Primary Tumor	Illumina HiSeq	e0dae8a5-f74f-4e25-98c2-238e28c54863	Head and Neck	55.0	6C07CD48-2269-4D42-9879-309EA4CD3A74	48A22F9A-2A18-4FCA-8271-44B3F7C3A628	TCGA-CN-6017-01A-11D-1681-02	HG19_Broad_variant	TCGA-CN-6017	TCGA-HNSC		s16181	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True
S13722.58cfa831e4b0c9d6adf6c7ac	58cfa831e4b0c9d6adf6c7ac	TCGA-D6-6827-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-D6-6827-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_4_rg.sorted	TCGA-D6-6827-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_4_rg.sorted.bam	262.7	1.9	0.14	58cfa831e4b0c9d6adf6c7ac	TCGA-D6-6827-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6827-01A	3C5BC678-41E9-46B3-9686-5CD95659AB71	Primary Tumor	Illumina HiSeq	849f41d7-0557-40ce-bca0-8a54c496fef2	Head and Neck	55.0	C53D6135-C614-45F4-8F41-49B20ED4A549	E2CDC496-8A62-4501-98C0-2AF2CCF48988	TCGA-D6-6827-01A-11D-1911-02	HG19_Broad_variant	TCGA-D6-6827	TCGA-HNSC		s16057	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	1911-02	True
S13722.58cfa831e4b0c9d6adf6c876	58cfa831e4b0c9d6adf6c876	TCGA-D6-6826-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D6-6826-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_3_rg.sorted	TCGA-D6-6826-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_3_rg.sorted.bam	275.7	1.9	0.14	58cfa831e4b0c9d6adf6c876	TCGA-D6-6826-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6826-01A	31243867-8E9F-46E9-A213-B83544EB8028	Primary Tumor	Illumina HiSeq	377f848a-3e59-4eee-bd9d-87fdc1a898bb	Head and Neck	64.0	1737989D-8463-4761-B111-53E4FD396375	07759CEA-B923-4D20-96DB-7952D50314C7	TCGA-D6-6826-01A-11D-1911-02	HG19_Broad_variant	TCGA-D6-6826	TCGA-HNSC		s15912	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1911-02	True
S13722.58cfa831e4b0c9d6adf6c7bc	58cfa831e4b0c9d6adf6c7bc	TCGA-CN-6019-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CN-6019-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_4_rg.sorted	TCGA-CN-6019-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_4_rg.sorted.bam	172.0	1.9	0.15	58cfa831e4b0c9d6adf6c7bc	TCGA-CN-6019-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6019-01A	EE3061EC-273C-4BEF-A325-35E9C469BF01	Primary Tumor	Illumina HiSeq	e7b9cb7d-0a1a-4461-ab89-108d02821762	Head and Neck	61.0	AC349695-2219-4A67-ADD5-A94FF85794E1	2C509E96-12D7-4DBB-A02F-DCDCC6F76952	TCGA-CN-6019-01A-11D-1681-02	HG19_Broad_variant	TCGA-CN-6019	TCGA-HNSC		s16178	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True
S13722.58cfa831e4b0c9d6adf6c866	58cfa831e4b0c9d6adf6c866	TCGA-D6-6823-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D6-6823-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_1_rg.sorted	TCGA-D6-6823-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_1_rg.sorted.bam	384.7	1.9	0.14	58cfa831e4b0c9d6adf6c866	TCGA-D6-6823-01A-11D-1911_120518_SN1120_0143_BC0VN6ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-D6-6823-01A	FBDAB01C-191C-4AEF-9451-CA3AFEC55FA1	Primary Tumor	Illumina HiSeq	250e5855-f3af-4c16-9efe-918be02bf754	Head and Neck	50.0	2DA83450-04C2-44D0-AB8A-9CC876242D5A	FE15C318-C3B1-4541-A0DA-4E41D7E99FBB	TCGA-D6-6823-01A-11D-1911-02	HG19_Broad_variant	TCGA-D6-6823	TCGA-HNSC		s15531	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1911-02	True
S13722.58cfa831e4b0c9d6adf6c8da	58cfa831e4b0c9d6adf6c8da	TCGA-D1-A168-01A-31D-A12F_120413_SN1120_0133_BC0J8UACXX_s_6_rg.sorted.filtered.	WGS	TCGA-D1-A168-01A-31D-A12F_120413_SN1120_0133_BC0J8UACXX_s_6_rg.sorted	TCGA-D1-A168-01A-31D-A12F_120413_SN1120_0133_BC0J8UACXX_s_6_rg.sorted.bam	60.13	1.98	0.15	58cfa831e4b0c9d6adf6c8da	TCGA-D1-A168-01A-31D-A12F_120413_SN1120_0133_BC0J8UACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A168-01A	41893E97-7E90-4B03-B738-260F288ADE4C	Primary Tumor	Illumina HiSeq	f7d0c63d-0a01-4ff3-b721-3c10692581ca	Uterus	67.0	B44C673E-9560-4B59-9FF3-34CE230CAD1C	4593D11C-3A35-4269-80EC-D282497CF71C	TCGA-D1-A168-01A-31D-A12F-02	HG19_Broad_variant	TCGA-D1-A168	TCGA-UCEC		s4438	Harvard Medical School	Mayo Clinic		NO			Endometrioid endometrial adenocarcinoma		A12F-02	True
S13722.58cfa831e4b0c9d6adf6c958	58cfa831e4b0c9d6adf6c958	TCGA-DK-A3IK-01A-32D-A21C_120914_SN590_0179_AD13PPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DK-A3IK-01A-32D-A21C_120914_SN590_0179_AD13PPACXX_s_3_rg.sorted	TCGA-DK-A3IK-01A-32D-A21C_120914_SN590_0179_AD13PPACXX_s_3_rg.sorted.bam	35.88		0.16	58cfa831e4b0c9d6adf6c958	TCGA-DK-A3IK-01A-32D-A21C_120914_SN590_0179_AD13PPACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IK-01A	3F0A0748-9ACC-4D0B-BA18-7C08BD183F86	Primary Tumor	Illumina HiSeq	6c286798-955c-487f-b541-72f253866ada	Bladder	87.0	4FF20C48-29EE-4101-B409-C4573E38CF92	B13B80DE-1722-44D3-888D-EEE8677F205C	TCGA-DK-A3IK-01A-32D-A21C-26	HG19_Broad_variant	TCGA-DK-A3IK	TCGA-BLCA		s2887	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A21C-26	True
S13722.58cfa831e4b0c9d6adf6c949	58cfa831e4b0c9d6adf6c949	TCGA-DJ-A13O-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DJ-A13O-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_5_rg.sorted	TCGA-DJ-A13O-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_5_rg.sorted.bam	21.24	1.93	0.16	58cfa831e4b0c9d6adf6c949	TCGA-DJ-A13O-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13O-01A	77D5B246-33BA-4A96-9D73-06ACA797653E	Primary Tumor	Illumina HiSeq	ae4a78d9-4c9a-40f7-9612-17d11799ea67	Thyroid	56.0	457B11C0-3C36-4907-8C76-60E3861EBABB	EC713290-9998-489B-9D1E-CC9D33CF5428	TCGA-DJ-A13O-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13O	TCGA-THCA		s12241	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	True
S13722.58cfa831e4b0c9d6adf6c9b0	58cfa831e4b0c9d6adf6c9b0	TCGA-DJ-A13M-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DJ-A13M-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_6_rg.sorted	TCGA-DJ-A13M-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_6_rg.sorted.bam	24.89	1.93	0.14	58cfa831e4b0c9d6adf6c9b0	TCGA-DJ-A13M-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13M-01A	BA9DEC81-FFC0-453A-9621-94BEBA45FAB1	Primary Tumor	Illumina HiSeq	6d7b5f3b-5fba-469e-a651-31a4569d7877	Thyroid	28.0	28913C64-8637-4537-AF8C-7315097A5AD1	8C708D3B-B312-4C27-898B-A0FE87110474	TCGA-DJ-A13M-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13M	TCGA-THCA		s12369	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A10R-02	True
S13722.58cfa831e4b0c9d6adf6c9e7	58cfa831e4b0c9d6adf6c9e7	TCGA-DJ-A1QQ-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_4_rg.sorted.filtered.	WGS	TCGA-DJ-A1QQ-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_4_rg.sorted	TCGA-DJ-A1QQ-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_4_rg.sorted.bam	48.48	1.91	0.16	58cfa831e4b0c9d6adf6c9e7	TCGA-DJ-A1QQ-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_4_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QQ-01A	99EF2FEC-5A3C-4E42-8F78-7EAF9877E26D	Primary Tumor	Illumina HiSeq	091bb28f-4fe0-41e6-b7c5-b952dc370506	Thyroid	43.0	64D1F58A-986F-4D4B-962E-DA59A48C988B	DDE34A05-A208-4F86-9803-0FB1EB858947	TCGA-DJ-A1QQ-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QQ	TCGA-THCA		s12639	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	True
S13722.58cfa831e4b0c9d6adf6c9ce	58cfa831e4b0c9d6adf6c9ce	TCGA-DK-A3WY-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A3WY-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_7_rg.sorted	TCGA-DK-A3WY-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_7_rg.sorted.bam	13.9		0.15	58cfa831e4b0c9d6adf6c9ce	TCGA-DK-A3WY-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3WY-01A	9BB5D187-033E-4E86-A76E-E1A6D20488F7	Primary Tumor	Illumina HiSeq	ae1b3911-b342-4886-b75a-3e9be21dae41	Bladder	67.0	33D579B3-198D-46CA-B2CF-574A0673E26F	ABA3AF01-2CBD-4450-9CCB-698DF8982E91	TCGA-DK-A3WY-01A-11D-A233-26	HG19_Broad_variant	TCGA-DK-A3WY	TCGA-BLCA		s2895	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	True
S13722.58cfa831e4b0c9d6adf6ca25	58cfa831e4b0c9d6adf6ca25	TCGA-DE-A0Y2-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DE-A0Y2-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_3_rg.sorted	TCGA-DE-A0Y2-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_3_rg.sorted.bam	63.0	2.03	0.14	58cfa831e4b0c9d6adf6ca25	TCGA-DE-A0Y2-01A-11D-A10R_120617_SN1222_0116_AC0WMMACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DE-A0Y2-01A	6AD260AD-769A-4F3C-BD07-927ADF6B2338	Primary Tumor	Illumina HiSeq	eaf940db-08d0-4dc4-b390-0576523fb2f5	Thyroid	30.0	EB4FEEBB-293E-43E3-A2ED-344B17D180B3	E86091EB-6DCC-479B-BAFD-3DABA65787EC	TCGA-DE-A0Y2-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DE-A0Y2	TCGA-THCA		s12514	Harvard Medical School	University of North Carolina	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	True
S13722.58cfa831e4b0c9d6adf6ca5e	58cfa831e4b0c9d6adf6ca5e	TCGA-DJ-A1QG-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DJ-A1QG-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_1_rg.sorted	TCGA-DJ-A1QG-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_1_rg.sorted.bam	73.27	1.98	0.17	58cfa831e4b0c9d6adf6ca5e	TCGA-DJ-A1QG-01A-11D-A14U_120629_SN1222_0121_BD143UACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QG-01A	CB29E795-7618-4882-A7E0-69D39787B80C	Primary Tumor	Illumina HiSeq	cd7d52cc-20ac-4fa7-a821-231d15f926fc	Thyroid	62.0	D0A669AF-1A0A-451D-9D6F-9EEE15F7264C	EF88FE61-36C4-43CF-BD57-D15F7E264DF0	TCGA-DJ-A1QG-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QG	TCGA-THCA		s12240	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A14U-02	True
S13722.58cfa831e4b0c9d6adf6cb30	58cfa831e4b0c9d6adf6cb30	TCGA-EA-A3HQ-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EA-A3HQ-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_3_rg.sorted	TCGA-EA-A3HQ-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_3_rg.sorted.bam	14.36		0.15	58cfa831e4b0c9d6adf6cb30	TCGA-EA-A3HQ-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3HQ-01A	6BF00B63-89F8-420C-8D36-F680FB0908B1	Primary Tumor	Illumina HiSeq	33c80031-f923-4aa0-adfa-9e229f413f83	Cervix	60.0	E4B391D9-2F3E-474C-AFA0-FDF4FD11FDF9	0032959A-5D7B-4D74-927E-25F79EF25D49	TCGA-EA-A3HQ-01A-11D-A20X-26	HG19_Broad_variant	TCGA-EA-A3HQ	TCGA-CESC		s1180	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T2a	N0	Cervical Squamous Cell Carcinoma		A20X-26	True
S13722.58cfa831e4b0c9d6adf6ca60	58cfa831e4b0c9d6adf6ca60	TCGA-CN-6013-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CN-6013-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_1_rg.sorted	TCGA-CN-6013-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_1_rg.sorted.bam	354.0	1.9	0.15	58cfa831e4b0c9d6adf6ca60	TCGA-CN-6013-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6013-01A	714496C5-D221-4397-9C5A-CD2D22603E6F	Primary Tumor	Illumina HiSeq	2ca5ef3f-76f6-4db9-85e7-d32249cd642f	Head and Neck	56.0	D018CD44-6B01-44F2-9181-81153225AAB8	2DE7DBC6-2A3E-4E67-BB96-552E27137618	TCGA-CN-6013-01A-11D-1681-02	HG19_Broad_variant	TCGA-CN-6013	TCGA-HNSC		s15629	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True
S13722.58cfa831e4b0c9d6adf6cdb1	58cfa831e4b0c9d6adf6cdb1	TCGA-FG-6692-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FG-6692-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_6_rg.sorted	TCGA-FG-6692-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_6_rg.sorted.bam	270.7	1.9	0.15	58cfa831e4b0c9d6adf6cdb1	TCGA-FG-6692-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6692-01A	5F10CD91-1E03-4016-B35A-8629A1A8FCC9	Primary Tumor	Illumina HiSeq	66eb8fac-6ead-47b2-be40-effbb245f499	Brain	63.0	FDDB3709-5F1C-40C8-A39A-48329DFE9C97	5BB5BFCC-DB34-474C-95E6-3A84C3A7DBAA	TCGA-FG-6692-01A-11D-1891-02	HG19_Broad_variant	TCGA-FG-6692	TCGA-LGG		s8367	Harvard Medical School	Case Western	United States	NO			Oligodendroglioma		1891-02	True
S13722.58cfa831e4b0c9d6adf6cd9e	58cfa831e4b0c9d6adf6cd9e	TCGA-FE-A238-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FE-A238-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_5_rg.sorted	TCGA-FE-A238-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_5_rg.sorted.bam	71.81	1.88	0.16	58cfa831e4b0c9d6adf6cd9e	TCGA-FE-A238-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A238-01A	DFFC4F7A-C67A-4AC5-A338-717DFFDE686D	Primary Tumor	Illumina HiSeq	004a2d8a-2dac-4e95-b287-dde59c5f0561	Thyroid	36.0	D68C3B99-CB82-48BD-A1F8-BEE0A9A9E8C3	BA986EBD-8E2D-4BAF-AC16-FCEB1286F590	TCGA-FE-A238-01A-11D-A16N-02	HG19_Broad_variant	TCGA-FE-A238	TCGA-THCA		s12004	Harvard Medical School	Ohio State University	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True
S13722.58cfa831e4b0c9d6adf6cdc4	58cfa831e4b0c9d6adf6cdc4	TCGA-FG-6690-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FG-6690-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_7_rg.sorted	TCGA-FG-6690-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_7_rg.sorted.bam	113.7	1.9	0.16	58cfa831e4b0c9d6adf6cdc4	TCGA-FG-6690-01A-11D-1891_130919_SN590_0238_AC29TRACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-6690-01A	AD202887-88B3-4E0F-A4C3-7E135D4CB258	Primary Tumor	Illumina HiSeq	e33fa79f-3d33-4f0b-81d9-705ab9c8a19c	Brain	70.0	F6C7B8C5-02DF-4B89-B527-F647762A98B7	BA96EFD0-90DE-4458-89DE-8B16639760B8	TCGA-FG-6690-01A-11D-1891-02	HG19_Broad_variant	TCGA-FG-6690	TCGA-LGG		s8146	Harvard Medical School	Case Western	United States	NO			Oligodendroglioma		1891-02	True
S13722.58cfa831e4b0c9d6adf6cdb4	58cfa831e4b0c9d6adf6cdb4	TCGA-FE-A231-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FE-A231-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_1_rg.sorted	TCGA-FE-A231-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_1_rg.sorted.bam	101.76	2.16	0.16	58cfa831e4b0c9d6adf6cdb4	TCGA-FE-A231-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A231-01A	7044DEE0-FD6C-4E75-B731-DC60A386A1AB	Primary Tumor	Illumina HiSeq	2983a837-7d6a-4e9d-a68a-a3aa674fbb8b	Thyroid	70.0	96C298EB-0699-42AE-B2EA-63A192353D69	056B3922-279A-4869-A933-0C53C1137450	TCGA-FE-A231-01A-11D-A14U-02	HG19_Broad_variant	TCGA-FE-A231	TCGA-THCA		s12256	Harvard Medical School	Ohio State University	United States	NO	T3	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A14U-02	True
S13722.58cfa832e4b0c9d6adf6cf3c	58cfa832e4b0c9d6adf6cf3c	TCGA-G9-6373-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_1_rg.sorted.filtered.	WGS	TCGA-G9-6373-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_1_rg.sorted	TCGA-G9-6373-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_1_rg.sorted.bam	59.4	2.0	0.15	58cfa832e4b0c9d6adf6cf3c	TCGA-G9-6373-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6373-01A	C3A509C6-35A6-4D17-A9FD-0AA8884B33A0	Primary Tumor	Illumina HiSeq	b8d1f15f-e927-4a6e-8154-620ccb08e6f5	Prostate	68.0	18365C1F-9BC0-4865-B40D-DEF3EE73331C	A0563516-591D-4FC2-AF37-8BA62A071C58	TCGA-G9-6373-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6373	TCGA-PRAD		s3976	Harvard Medical School	Roswell Park	United States	NO	T3a		Prostate Adenocarcinoma Acinar Type		1784-02	True
S13722.58cfa832e4b0c9d6adf6cee6	58cfa832e4b0c9d6adf6cee6	TCGA-FI-A2D0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FI-A2D0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_3_rg.sorted	TCGA-FI-A2D0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_3_rg.sorted.bam	65.38		0.17	58cfa832e4b0c9d6adf6cee6	TCGA-FI-A2D0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-FI-A2D0-01A	1B35D083-F7C9-47D2-9A9E-718788F9E39A	Primary Tumor	Illumina HiSeq	5d8357bd-6f87-41b8-af0f-a2bdcb483e07	Uterus	55.0	A2D2A29A-5ABC-48C3-AC17-76B8B9EE1717	9406B9B9-CC2D-470D-BFB6-2118C0B84982	TCGA-FI-A2D0-01A-11D-A17E-02	HG19_Broad_variant	TCGA-FI-A2D0	TCGA-UCEC		s5399	Harvard Medical School	Washington University	United States	NO			Endometrioid endometrial adenocarcinoma		A17E-02	True
S13722.58cfa832e4b0c9d6adf6cf4e	58cfa832e4b0c9d6adf6cf4e	TCGA-G9-6356-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-G9-6356-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_1_rg.sorted	TCGA-G9-6356-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_1_rg.sorted.bam	144.4	1.9	0.15	58cfa832e4b0c9d6adf6cf4e	TCGA-G9-6356-01A-11D-1784_130215_SN590_0211_AC1UJWACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6356-01A	1D7FFBE7-6139-412B-8739-8082A63A2B33	Primary Tumor	Illumina HiSeq	4c78b0a9-d4e9-4656-95bf-0306c7bb406e	Prostate	60.0	C6E0F83F-ABA3-4705-ABAC-C81C885B53BA	E43C07B2-F48D-4780-9766-15CC08CE6FE2	TCGA-G9-6356-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6356	TCGA-PRAD		s4146	Harvard Medical School	Roswell Park	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True
S13722.58cfa832e4b0c9d6adf6cf6c	58cfa832e4b0c9d6adf6cf6c	TCGA-G9-6496-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G9-6496-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_3_rg.sorted	TCGA-G9-6496-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_3_rg.sorted.bam	223.4	1.9	0.14	58cfa832e4b0c9d6adf6cf6c	TCGA-G9-6496-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6496-01A	CE2B7E17-424E-4954-8A68-19D7F98D2E7E	Primary Tumor	Illumina HiSeq	9bf9f3ef-b79e-4a93-8df6-ab2b9a3f24aa	Prostate	61.0	ECE85143-957D-4AD1-BFCC-B71307EFB911	10BB38BE-9E75-4793-89B5-7BB19D7AA4F8	TCGA-G9-6496-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6496	TCGA-PRAD		s3619	Harvard Medical School	Roswell Park	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True
S13722.58cfa832e4b0c9d6adf6cfc9	58cfa832e4b0c9d6adf6cfc9	TCGA-FU-A3HZ-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_4_rg.sorted.filtered.	WGS	TCGA-FU-A3HZ-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_4_rg.sorted	TCGA-FU-A3HZ-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_4_rg.sorted.bam	19.8		0.16	58cfa832e4b0c9d6adf6cfc9	TCGA-FU-A3HZ-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3HZ-01A	6FF12A54-10DA-4941-BFEA-7B66E19B4BE9	Primary Tumor	Illumina HiSeq	40af9367-bd77-4c64-98d6-d2e2c6e5c11a	Cervix	64.0	6408A1F5-F5F7-40C8-A2EE-CB8038C15C95	230B8BFA-EBC7-4058-AA0C-78CA7DD01386	TCGA-FU-A3HZ-01A-11D-A20X-26	HG19_Broad_variant	TCGA-FU-A3HZ	TCGA-CESC		s1202	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2a2	N0	Cervical Squamous Cell Carcinoma		A20X-26	True
S13722.58cfa832e4b0c9d6adf6d02e	58cfa832e4b0c9d6adf6d02e	TCGA-G9-6367-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G9-6367-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_3_rg.sorted	TCGA-G9-6367-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_3_rg.sorted.bam	59.4	1.9	0.14	58cfa832e4b0c9d6adf6d02e	TCGA-G9-6367-01A-11D-1784_130215_SN590_0212_BC1NP2ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6367-01A	9F751C9D-AD41-4F02-B7F8-12423857D418	Primary Tumor	Illumina HiSeq	d4203e0e-c16e-4638-a239-378ffed98124	Prostate	60.0	5BC98578-E4C7-4BE8-89DF-F26AA5D545A9	9667EB66-775F-4C37-9309-FF73E55D553B	TCGA-G9-6367-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6367	TCGA-PRAD		s3612	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True
S13722.58cfa832e4b0c9d6adf6d0c9	58cfa832e4b0c9d6adf6d0c9	TCGA-IG-A3YB-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IG-A3YB-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_3_rg.sorted	TCGA-IG-A3YB-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_3_rg.sorted.bam	34.41		0.15	58cfa832e4b0c9d6adf6d0c9	TCGA-IG-A3YB-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A3YB-01A	A1A233EA-5DDA-4EEB-BD92-6667E8B3EF57	Primary Tumor	Illumina HiSeq	6b51ea9f-5ca3-4973-bc0f-8df5ae95abbd	Esophagus	61.0	F936DE42-1441-4C4C-882A-DC67D332C125	335AAD40-B278-4EEC-BEE6-FC4F77C63370	TCGA-IG-A3YB-01A-11D-A248-26	HG19_Broad_variant	TCGA-IG-A3YB	TCGA-ESCA		s1911	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T3	N1		Stage IIIA	A248-26	True
S13722.58cfa832e4b0c9d6adf6cfe8	58cfa832e4b0c9d6adf6cfe8	TCGA-GV-A3JX-01A-11D-A210_120912_SN1222_0148_AC188PACXX_s_1_rg.sorted.filtered.	WGS	TCGA-GV-A3JX-01A-11D-A210_120912_SN1222_0148_AC188PACXX_s_1_rg.sorted	TCGA-GV-A3JX-01A-11D-A210_120912_SN1222_0148_AC188PACXX_s_1_rg.sorted.bam	67.04		0.15	58cfa832e4b0c9d6adf6cfe8	TCGA-GV-A3JX-01A-11D-A210_120912_SN1222_0148_AC188PACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3JX-01A	D9DCBB57-F6C2-4465-8A60-AFE876E113CA	Primary Tumor	Illumina HiSeq	317cc3f0-7a98-402b-bb1f-81a0437fbaf8	Bladder	59.0	CE32612D-F504-4164-AE50-04C4AC2999FB	A8636E11-C752-46F4-A6A8-42D5B7DCBD02	TCGA-GV-A3JX-01A-11D-A210-26	HG19_Broad_variant	TCGA-GV-A3JX	TCGA-BLCA		s2736	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	True
S13722.58cfa832e4b0c9d6adf6d0e2	58cfa832e4b0c9d6adf6d0e2	TCGA-IG-A3YC-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-IG-A3YC-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_5_rg.sorted	TCGA-IG-A3YC-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_5_rg.sorted.bam	24.61		0.15	58cfa832e4b0c9d6adf6d0e2	TCGA-IG-A3YC-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A3YC-01A	6A05288E-D051-40A5-9F4E-864AB806A5DC	Primary Tumor	Illumina HiSeq	a1261941-39f5-47ec-a6a4-ab07b298fb93	Esophagus	62.0	C754C363-924A-404A-9D60-4CA2A3930D2A	44EE541C-5657-43A9-9D56-6D88319E4617	TCGA-IG-A3YC-01A-11D-A248-26	HG19_Broad_variant	TCGA-IG-A3YC	TCGA-ESCA		s1622	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T3	N1		Stage IIIA	A248-26	True
S13722.58cfa832e4b0c9d6adf6d126	58cfa832e4b0c9d6adf6d126	TCGA-FY-A3ON-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FY-A3ON-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_1_rg.sorted	TCGA-FY-A3ON-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_1_rg.sorted.bam	44.16		0.14	58cfa832e4b0c9d6adf6d126	TCGA-FY-A3ON-01A-11D-A221_120610_SN1120_0152_BD13TDACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A3ON-01A	4D1AEC67-C345-4721-8EE8-356B0DFF009B	Primary Tumor	Illumina HiSeq	276539e6-e471-4dc2-96e7-0c80fb486af1	Thyroid	20.0	1392A49C-87BC-45E7-B7D2-ACD53E921467	68FEC551-495D-47E6-BF85-FBD422FC68D6	TCGA-FY-A3ON-01A-11D-A221-26	HG19_Broad_variant	TCGA-FY-A3ON	TCGA-THCA		s12121	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	True
S13722.58cfa832e4b0c9d6adf6d1a8	58cfa832e4b0c9d6adf6d1a8	TCGA-HT-7472-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_7_rg.sorted.filtered.	WGS	TCGA-HT-7472-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_7_rg.sorted	TCGA-HT-7472-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_7_rg.sorted.bam	62.7		0.17	58cfa832e4b0c9d6adf6d1a8	TCGA-HT-7472-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7472-01A	482D4078-7576-48CF-BF7C-29014935FD47	Primary Tumor	Illumina HiSeq	518f9b23-97da-447f-90e5-a03c5ae09642	Brain	38.0	F05081A2-2465-4EA4-9EC3-319810FE2D45	A68374D7-4782-4FF5-B921-35D45468A4D1	TCGA-HT-7472-01A-11D-2022-02	HG19_Broad_variant	TCGA-HT-7472	TCGA-LGG		s8574	Harvard Medical School	Case Western - St Joes	United States	NO			Oligodendroglioma		2022-02	True
S13722.58cfa832e4b0c9d6adf6d196	58cfa832e4b0c9d6adf6d196	TCGA-K4-A3WV-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_6_rg.sorted.filtered.	WGS	TCGA-K4-A3WV-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_6_rg.sorted	TCGA-K4-A3WV-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_6_rg.sorted.bam	33.77		0.15	58cfa832e4b0c9d6adf6d196	TCGA-K4-A3WV-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-K4-A3WV-01A	D53EADE8-A845-4252-AECE-92F3573486A7	Primary Tumor	Illumina HiSeq	ca7a6b06-a6fa-4314-80ef-725b81781598	Bladder	77.0	3ADFA409-A9F8-4EDB-AAF7-C5285AE5F895	9A7CA3A1-631F-41BA-A490-04D470C4AF8E	TCGA-K4-A3WV-01A-11D-A23Q-26	HG19_Broad_variant	TCGA-K4-A3WV	TCGA-BLCA		s2937	MD Anderson - Institute for Applied Cancer Science	ABS - Lahey Clinic	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A23Q-26	True
S13722.58cfa832e4b0c9d6adf6d2a6	58cfa832e4b0c9d6adf6d2a6	TCGA-IR-A3LL-01A-11D-A20X_140117_SN590_0245_AC371LACXX_s_4_rg.sorted.filtered.	WGS	TCGA-IR-A3LL-01A-11D-A20X_140117_SN590_0245_AC371LACXX_s_4_rg.sorted	TCGA-IR-A3LL-01A-11D-A20X_140117_SN590_0245_AC371LACXX_s_4_rg.sorted.bam	66.26		0.15	58cfa832e4b0c9d6adf6d2a6	TCGA-IR-A3LL-01A-11D-A20X_140117_SN590_0245_AC371LACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LL-01A	7C4AB1CA-4BDD-4EF7-9A42-F6C0C7136D26	Primary Tumor	Illumina HiSeq	817ccf3b-ceaa-45cf-a938-67e531a9f57a	Cervix	60.0	A0FB972A-CE8F-441F-8707-C3CC1081DEE0	5457562E-E184-4D13-B11C-49728B689275	TCGA-IR-A3LL-01A-11D-A20X-26	HG19_Broad_variant	TCGA-IR-A3LL	TCGA-CESC		s1378	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b1	N0	Cervical Squamous Cell Carcinoma		A20X-26	True
S13722.58cfa832e4b0c9d6adf6d362	58cfa832e4b0c9d6adf6d362	TCGA-L5-A4OH-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-L5-A4OH-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_5_rg.sorted	TCGA-L5-A4OH-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_5_rg.sorted.bam	43.66		0.17	58cfa832e4b0c9d6adf6d362	TCGA-L5-A4OH-01A-11D-A267_131001_SN1222_0222_BC2CN2ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OH-01A	3FA7FC16-49DA-4BF6-90C4-74DF5CF68B65	Primary Tumor	Illumina HiSeq	ba83865e-0ba3-48ab-841f-de07856ee9bc	Esophagus	71.0	4029F7BA-1D2D-49B8-A37B-4D4A5D0ACB79	C886B6DD-1595-49DD-B4DA-B69AA9C813E4	TCGA-L5-A4OH-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OH	TCGA-ESCA		s1747	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N0		Stage I	A267-26	True
S13722.58cfa832e4b0c9d6adf6d388	58cfa832e4b0c9d6adf6d388	TCGA-L5-A4OP-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A4OP-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_1_rg.sorted	TCGA-L5-A4OP-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_1_rg.sorted.bam	41.04		0.17	58cfa832e4b0c9d6adf6d388	TCGA-L5-A4OP-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OP-01A	97031483-1185-41D6-9722-0A03B63CAA19	Primary Tumor	Illumina HiSeq	940f64ee-414a-4190-9fc9-c697ad112dfe	Esophagus	67.0	BA02D5B4-9CA9-4455-81D4-E5F2C8C0DF74	5D8E8DA5-04FF-4548-96EC-AE1E80C57CD1	TCGA-L5-A4OP-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OP	TCGA-ESCA		s1923	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N0		Stage IA	A267-26	True
S13722.58cfa832e4b0c9d6adf6d386	58cfa832e4b0c9d6adf6d386	TCGA-LN-A4A3-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_5_rg.sorted.filtered.	WGS	TCGA-LN-A4A3-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_5_rg.sorted	TCGA-LN-A4A3-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_5_rg.sorted.bam	20.45		0.16	58cfa832e4b0c9d6adf6d386	TCGA-LN-A4A3-01A-11D-A267_131001_SN1120_0280_BD2FDEACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A4A3-01A	3C0BB5E2-AD33-4D91-A31E-2A18F1C94D2D	Primary Tumor	Illumina HiSeq	e04a9b3d-9bc4-4857-9030-288efed94e80	Esophagus	61.0	3C85B0AB-C83E-4371-9F53-6A71D3763F3F	5402975D-7AE7-46FC-847A-4EE7DEBCD553	TCGA-LN-A4A3-01A-11D-A267-26	HG19_Broad_variant	TCGA-LN-A4A3	TCGA-ESCA		s1770	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N1		Stage III	A267-26	True
S13722.58cfa832e4b0c9d6adf6d418	58cfa832e4b0c9d6adf6d418	TCGA-V4-A9F2-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-V4-A9F2-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_2_rg.sorted	TCGA-V4-A9F2-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_2_rg.sorted.bam	38.01		0.16	58cfa832e4b0c9d6adf6d418	TCGA-V4-A9F2-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F2-01A	411DDF79-FE92-44AD-8D10-EEB703F11BE7	Primary Tumor	Illumina HiSeq	c4fcd1a4-5246-4a6b-b5b0-45b8b838edf2	Eye	78.0	2F2FF6C7-9568-47E4-AB09-6050F84BBF5C	87781EA6-C3E9-476A-B5D2-E58FC557FC7A	TCGA-V4-A9F2-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F2	TCGA-UVM		s207	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3b	N0		Stage IIIA	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d4aa	58cfa832e4b0c9d6adf6d4aa	TCGA-V4-A9ET-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_5_rg.sorted.filtered.	WGS	TCGA-V4-A9ET-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_5_rg.sorted	TCGA-V4-A9ET-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_5_rg.sorted.bam	57.02		0.17	58cfa832e4b0c9d6adf6d4aa	TCGA-V4-A9ET-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9ET-01A	5383FB57-69C2-4B34-AF7F-C67208EFB2B5	Primary Tumor	Illumina HiSeq	98f43560-a2c1-4edb-a936-9c84114cf0c2	Eye	57.0	C16B2576-AB56-4BEB-B621-22EA9FC4E898	D544884F-7E0D-4029-B778-55E14B5C2C38	TCGA-V4-A9ET-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9ET	TCGA-UVM		s244	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4b	N0		Stage IIIB	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d426	58cfa832e4b0c9d6adf6d426	TCGA-V4-A9F0-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_4_rg.sorted.filtered.	WGS	TCGA-V4-A9F0-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_4_rg.sorted	TCGA-V4-A9F0-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_4_rg.sorted.bam	54.63		0.15	58cfa832e4b0c9d6adf6d426	TCGA-V4-A9F0-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F0-01A	92FCA97D-6123-46A7-9C34-7A6F877FE612	Primary Tumor	Illumina HiSeq	96f55937-5d74-4e04-8ab5-f928a9a23da4	Eye	59.0	62859C7E-4B8D-4122-9365-B1595E944C42	C752F975-1E44-4EDF-87BA-4823698AC3F5	TCGA-V4-A9F0-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F0	TCGA-UVM		s227	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4b	N0		Stage IIIB	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d4a6	58cfa832e4b0c9d6adf6d4a6	TCGA-V4-A9EW-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_8_rg.sorted.filtered.	WGS	TCGA-V4-A9EW-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_8_rg.sorted	TCGA-V4-A9EW-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_8_rg.sorted.bam	43.67		0.16	58cfa832e4b0c9d6adf6d4a6	TCGA-V4-A9EW-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EW-01A	6BE5176C-4980-4663-ADFF-D04F05737DA0	Primary Tumor	Illumina HiSeq	3dd4d560-67ce-426b-9eeb-63fec58eaf05	Eye	44.0	685D5387-B35F-40EE-8F14-491CE212F0DE	6B52C651-649F-41C5-B0DD-197F77F2AA10	TCGA-V4-A9EW-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EW	TCGA-UVM		s216	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d4ca	58cfa832e4b0c9d6adf6d4ca	TCGA-V4-A9F5-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-V4-A9F5-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_1_rg.sorted	TCGA-V4-A9F5-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_1_rg.sorted.bam	57.62		0.17	58cfa832e4b0c9d6adf6d4ca	TCGA-V4-A9F5-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F5-01A	BBF07E1F-8C17-4C2E-89ED-38332D82E455	Primary Tumor	Illumina HiSeq	11ec05e6-4b9a-4abf-8b47-45f259c5eaf3	Eye	85.0	16FCA21C-963E-4D77-8B5A-3C178DAC6168	38812469-1716-4B6F-8DBE-822654AC13F6	TCGA-V4-A9F5-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F5	TCGA-UVM		s245	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4e	N0		Stage IV	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d54e	58cfa832e4b0c9d6adf6d54e	TCGA-L5-A4OS-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-L5-A4OS-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_3_rg.sorted	TCGA-L5-A4OS-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_3_rg.sorted.bam	26.15		0.16	58cfa832e4b0c9d6adf6d54e	TCGA-L5-A4OS-01A-11D-A28P_140122_SN1222_0236_BD2CT4ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OS-01A	D5AC647F-0C6D-40D7-87A8-FAA1CC968C82	Primary Tumor	Illumina HiSeq	5c0f7af4-2359-4784-8db9-a4acac6fbb09	Esophagus	86.0	8734680B-CA7B-49F4-A539-0182B45454F3	C3CAE2EF-E23F-4D72-8B4F-E9F9AF08340D	TCGA-L5-A4OS-01A-11D-A28P-26	HG19_Broad_variant	TCGA-L5-A4OS	TCGA-ESCA		s1849	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T2	N1		Stage IIB	A28P-26	True
S13722.58cfa832e4b0c9d6adf6d528	58cfa832e4b0c9d6adf6d528	TCGA-L5-A4OJ-01A-11D-A267_131018_SN590_0241_BC30HBACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A4OJ-01A-11D-A267_131018_SN590_0241_BC30HBACXX_s_1_rg.sorted	TCGA-L5-A4OJ-01A-11D-A267_131018_SN590_0241_BC30HBACXX_s_1_rg.sorted.bam	44.72		0.17	58cfa832e4b0c9d6adf6d528	TCGA-L5-A4OJ-01A-11D-A267_131018_SN590_0241_BC30HBACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OJ-01A	CB419344-6148-43D4-B549-570BD09B3E05	Primary Tumor	Illumina HiSeq	b8117191-ea00-451f-85ca-53357a42b44f	Esophagus	70.0	4F03824A-79D6-40E8-A9E0-4079B1209F38	74221A72-4B40-4943-877D-7979EB4BD268	TCGA-L5-A4OJ-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OJ	TCGA-ESCA		s1651	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T1	N0		Stage I	A267-26	True
S13722.58cfa832e4b0c9d6adf6d5a8	58cfa832e4b0c9d6adf6d5a8	TCGA-LN-A49S-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-LN-A49S-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_5_rg.sorted	TCGA-LN-A49S-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_5_rg.sorted.bam	29.69		0.17	58cfa832e4b0c9d6adf6d5a8	TCGA-LN-A49S-01A-11D-A248_121207_SN1222_0162_BD1MA7ACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49S-01A	E9F82800-647A-4D61-BD1F-2C17C4CCAFBA	Primary Tumor	Illumina HiSeq	f173addf-1b74-441d-b167-5eb17cdfe1c3	Esophagus	59.0	A83FF623-8AF0-44A9-8468-95457A017E5A	151B9A13-9D3D-4AF2-A779-24F62A13975B	TCGA-LN-A49S-01A-11D-A248-26	HG19_Broad_variant	TCGA-LN-A49S	TCGA-ESCA		s1680	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0		Stage IIA	A248-26	True
S13722.58cfa832e4b0c9d6adf6d4fa	58cfa832e4b0c9d6adf6d4fa	TCGA-L5-A4OE-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A4OE-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_1_rg.sorted	TCGA-L5-A4OE-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_1_rg.sorted.bam	43.86		0.16	58cfa832e4b0c9d6adf6d4fa	TCGA-L5-A4OE-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OE-01A	0A466142-C513-4257-85D4-4BD7CFD0EF29	Primary Tumor	Illumina HiSeq	49822c02-a9e7-4e7e-bd12-f1756b639beb	Esophagus	81.0	BD8CADB2-1382-4BF5-A68F-C5A71837FE95	C5F599A9-1398-4E49-9CC7-77129658E143	TCGA-L5-A4OE-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OE	TCGA-ESCA		s1838	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T3	N2		Stage IIIB	A267-26	True
S13722.58cfa831e4b0c9d6adf6c485	58cfa831e4b0c9d6adf6c485	TCGA-CM-4752-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4752-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4752-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	846.02	1.9	0.15	58cfa831e4b0c9d6adf6c485	TCGA-CM-4752-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4752-01A	7EA546CE-F48A-4D9C-96B4-A0124C692870	Primary Tumor	Illumina HiSeq	ad469933-d84b-4305-85e2-a7d919298b71	Colorectal	58.0	5703F0D8-DB96-40CE-8009-51D2EC188ABF	43756C1F-6ED2-468B-B0AD-D44A447C7709	TCGA-CM-4752-01A-01D-1405-02	HG18	TCGA-CM-4752	TCGA-COAD		s13219	Harvard Medical School	MSKCC		NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	True
S13722.58cfa82de4b0c9d6adf6a534	58cfa82de4b0c9d6adf6a534	49320cdd49b83c21082251cf7413af62.filtered.	WGS	49320cdd49b83c21082251cf7413af62	49320cdd49b83c21082251cf7413af62.bam			0.08	58cfa82de4b0c9d6adf6a534	49320cdd49b83c21082251cf7413af62.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A051-01A	B045F24B-F822-4DF9-9FFA-47308EDCEC8C	Primary Tumor	Illumina HiSeq	16685246-b33b-4810-9cef-2ec37924f621	Uterus	69.0	417CFF62-B034-4197-9CFD-E640D55F3094	BCF858FD-CC3B-4FDE-AB10-EB96216F4366	TCGA-AP-A051-01A-21D-A013-09	GRCh37-lite	TCGA-AP-A051	TCGA-UCEC		s5190	Washington University School of Medicine	MSKCC		NO			Endometrioid endometrial adenocarcinoma		A013-09	True
S13722.58cfa82de4b0c9d6adf6a577	58cfa82de4b0c9d6adf6a577	4d55b306c9f948c74d83dd41705f0440.filtered.	WGS	4d55b306c9f948c74d83dd41705f0440	4d55b306c9f948c74d83dd41705f0440.bam	91.17	1.76	0.08	58cfa82de4b0c9d6adf6a577	4d55b306c9f948c74d83dd41705f0440.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A1MQ-01A	EB59CF69-1997-41B9-BF69-69AD7DA292A1	Primary Tumor	Illumina HiSeq	6eef85cb-d9eb-495a-b69a-6944cbd18483	Cervix	35.0	F5FC27D9-4949-43E9-B358-78CB69D87A3C	A67F4531-99EF-43DF-82F5-F6ABC4B11826	TCGA-C5-A1MQ-01A-11D-A200-09	GRCh37-lite	TCGA-C5-A1MQ	TCGA-CESC		s1163	Washington University School of Medicine	Medical College of Wisconsin	United States	NO	T2b	N0	Cervical Squamous Cell Carcinoma		A200-09	True
S13722.58cfa82de4b0c9d6adf6a666	58cfa82de4b0c9d6adf6a666	804182419c4c4708dc5058194c29d6d2.filtered.	WGS	804182419c4c4708dc5058194c29d6d2	804182419c4c4708dc5058194c29d6d2.bam	22.3		0.08	58cfa82de4b0c9d6adf6a666	804182419c4c4708dc5058194c29d6d2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Sarcoma	Aligned reads	TCGA-DX-A3LT-01A	E7A72F7E-77B1-4D95-8F37-39A6CFFC35DC	Primary Tumor	Illumina HiSeq	3daa0a7d-91d3-4cad-a48a-5a08bdd32529	Mesenchymal	62.0	32F8354A-7D2F-467B-AFED-E7F91369615F	A2F02FF7-8433-4CB5-9324-34F13EDEACA1	TCGA-DX-A3LT-01A-12D-A21Q-09	GRCh37-lite	TCGA-DX-A3LT	TCGA-SARC		s2490	Washington University School of Medicine	Memorial Sloan Kettering	United States	NO					A21Q-09	True
S13722.58cfa82fe4b0c9d6adf6b8e0	58cfa82fe4b0c9d6adf6b8e0	TCGA-A7-A0CE-01A-11D-A12L-09_IlluminaGA-DNASeq_whole_1.filtered.	WGS	TCGA-A7-A0CE-01A-11D-A12L-09_IlluminaGA-DNASeq_whole_1	TCGA-A7-A0CE-01A-11D-A12L-09_IlluminaGA-DNASeq_whole_1.bam	40.39	1.89	0.07	58cfa82fe4b0c9d6adf6b8e0	TCGA-A7-A0CE-01A-11D-A12L-09_IlluminaGA-DNASeq_whole_1.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A7-A0CE-01A	9D95A65B-E41D-4F93-92D4-99DCE29FF40D	Primary Tumor	Illumina HiSeq	d744c7c6-690c-4f5e-968e-532936b3696a	Breast	57.0	9DC315CE-3B76-4754-B103-2C2580CDE4AB	7B08E810-F3C9-4155-AC11-F45A3A4F8B41	TCGA-A7-A0CE-01A-11D-A12L-09	GRCh37-lite	TCGA-A7-A0CE	TCGA-BRCA		s5490	Washington University School of Medicine	Christiana Healthcare		NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A12L-09	False
S13722.58cfa82fe4b0c9d6adf6b948	58cfa82fe4b0c9d6adf6b948	TCGA-A2-A04T-01A-21D-A128-09_IlluminaGA-DNASeq_whole.filtered.	WGS	TCGA-A2-A04T-01A-21D-A128-09_IlluminaGA-DNASeq_whole	TCGA-A2-A04T-01A-21D-A128-09_IlluminaGA-DNASeq_whole.bam	91.2	1.92	0.08	58cfa82fe4b0c9d6adf6b948	TCGA-A2-A04T-01A-21D-A128-09_IlluminaGA-DNASeq_whole.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A04T-01A	B58AD350-5140-4FA8-BC2C-24BCA8395F3A	Primary Tumor	Illumina HiSeq	6dd42df3-896f-418a-9f13-468ac66d69bc	Breast	62.0	6DD4870F-1EC2-484B-8703-6397D8E67DAA	B752B444-F033-4BE4-9D24-E5E80B4181AF	TCGA-A2-A04T-01A-21D-A128-09	GRCh37-lite	TCGA-A2-A04T	TCGA-BRCA		s5637	Washington University School of Medicine	Walter Reed		NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A128-09	True
S13722.58cfa830e4b0c9d6adf6bc2c	58cfa830e4b0c9d6adf6bc2c	TCGA-AO-A0J4-01A-11D-A128-09_IlluminaGA-DNASeq_whole.filtered.	WGS	TCGA-AO-A0J4-01A-11D-A128-09_IlluminaGA-DNASeq_whole	TCGA-AO-A0J4-01A-11D-A128-09_IlluminaGA-DNASeq_whole.bam	78.64	1.86	0.08	58cfa830e4b0c9d6adf6bc2c	TCGA-AO-A0J4-01A-11D-A128-09_IlluminaGA-DNASeq_whole.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A0J4-01A	A9B7D7FE-BE31-4F71-AFEE-C1BFDF511888	Primary Tumor	Illumina HiSeq	b518df9f-2eae-4c82-92e3-3eb196cdd3a5	Breast	41.0	CF11642A-EB96-4B37-B914-371C71F8E0CA	110B5F05-DED7-45EC-B0F6-A941C92D77DD	TCGA-AO-A0J4-01A-11D-A128-09	GRCh37-lite	TCGA-AO-A0J4	TCGA-BRCA		s5960	Washington University School of Medicine	MSKCC		NO	T1c	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IA	A128-09	True
S13722.58cfa830e4b0c9d6adf6bbae	58cfa830e4b0c9d6adf6bbae	TCGA-A2-A0D2-01A-21D-A128-09_IlluminaGA-DNASeq_whole.filtered.	WGS	TCGA-A2-A0D2-01A-21D-A128-09_IlluminaGA-DNASeq_whole	TCGA-A2-A0D2-01A-21D-A128-09_IlluminaGA-DNASeq_whole.bam	61.59	1.89	0.08	58cfa830e4b0c9d6adf6bbae	TCGA-A2-A0D2-01A-21D-A128-09_IlluminaGA-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-A2-A0D2-01A	99E32C59-AA73-43FA-88C9-399DDADB2C72	Primary Tumor	Illumina HiSeq	221d4b81-a70e-4647-8a9a-ce4866538392	Breast	45.0	72439E36-3C17-4A90-B3E1-8F6CCFD3DCD4	51A5A15A-1551-469F-A5B0-09581EC47975	TCGA-A2-A0D2-01A-21D-A128-09	GRCh37-lite	TCGA-A2-A0D2	TCGA-BRCA		s5488	Washington University School of Medicine	Walter Reed		NO	T2	N0 (i+)	Infiltrating Ductal Carcinoma	Stage IIA	A128-09	True
S13722.58cfa830e4b0c9d6adf6bdc6	58cfa830e4b0c9d6adf6bdc6	TCGA-BH-A0B3-01A-11D-A128-09_IlluminaGA-DNASeq_whole.filtered.	WGS	TCGA-BH-A0B3-01A-11D-A128-09_IlluminaGA-DNASeq_whole	TCGA-BH-A0B3-01A-11D-A128-09_IlluminaGA-DNASeq_whole.bam	52.29	1.9	0.08	58cfa830e4b0c9d6adf6bdc6	TCGA-BH-A0B3-01A-11D-A128-09_IlluminaGA-DNASeq_whole.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0B3-01A	18EB4DFC-556F-4BF3-A411-4780209ED1E0	Primary Tumor	Illumina HiSeq	82535082-739b-4a9b-8609-4724bbdd27ee	Breast	53.0	FC1F0AD4-8412-4143-8EBF-FA6592F396E9	43F7A2E0-FEC9-4E43-872D-18C6C946FA17	TCGA-BH-A0B3-01A-11D-A128-09	GRCh37-lite	TCGA-BH-A0B3	TCGA-BRCA		s6464	Washington University School of Medicine	University of Pittsburgh		NO	T2	N1a	Infiltrating Ductal Carcinoma	Stage IIB	A128-09	True
S13722.58cfa830e4b0c9d6adf6bdd8	58cfa830e4b0c9d6adf6bdd8	TCGA-BH-A0E0-01A-11D-A128-09_IlluminaGA-DNASeq_whole.filtered.	WGS	TCGA-BH-A0E0-01A-11D-A128-09_IlluminaGA-DNASeq_whole	TCGA-BH-A0E0-01A-11D-A128-09_IlluminaGA-DNASeq_whole.bam	55.87	1.93	0.08	58cfa830e4b0c9d6adf6bdd8	TCGA-BH-A0E0-01A-11D-A128-09_IlluminaGA-DNASeq_whole.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0E0-01A	20E8106B-1290-4735-ABE4-7621E08E3DC8	Primary Tumor	Illumina HiSeq	fc737335-21e7-4997-b267-04d3f91043f5	Breast	38.0	662CC11C-DA31-4E31-8E77-46011B38EA96	E8392F20-C9E3-4649-B64F-5B266C393A76	TCGA-BH-A0E0-01A-11D-A128-09	GRCh37-lite	TCGA-BH-A0E0	TCGA-BRCA		s5804	Washington University School of Medicine	University of Pittsburgh		NO	T3	N3a	Infiltrating Ductal Carcinoma	Stage IIIC	A128-09	True
S13722.58cfa830e4b0c9d6adf6c1ea	58cfa830e4b0c9d6adf6c1ea	TCGA-AO-A0J6-01A-11D-A128-09_IlluminaGA-DNASeq_whole.filtered.	WGS	TCGA-AO-A0J6-01A-11D-A128-09_IlluminaGA-DNASeq_whole	TCGA-AO-A0J6-01A-11D-A128-09_IlluminaGA-DNASeq_whole.bam	73.05	2.0	0.08	58cfa830e4b0c9d6adf6c1ea	TCGA-AO-A0J6-01A-11D-A128-09_IlluminaGA-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-AO-A0J6-01A	E9F4F373-37A5-48AD-A1A0-B0D47820111A	Primary Tumor	Illumina HiSeq	71b1d18c-e0ab-473a-b4ee-55ebb68cfda8	Breast	61.0	0C12EA89-EEB4-4865-91EB-10CF75884C21	F69E5057-EDA6-4391-BA9A-AEDBF6B572DA	TCGA-AO-A0J6-01A-11D-A128-09	GRCh37-lite	TCGA-AO-A0J6	TCGA-BRCA		s5798	Washington University School of Medicine	MSKCC		NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A128-09	True
S13722.58cfa83ce4b0c9d6adf72f0f	58cfa83ce4b0c9d6adf72f0f	d70abbce939febed4d88a2f3041db471.filtered.	WGS	d70abbce939febed4d88a2f3041db471	d70abbce939febed4d88a2f3041db471.bam	97.91	1.93	0.08	58cfa83ce4b0c9d6adf72f0f	d70abbce939febed4d88a2f3041db471.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A1NU-01A	E56491AF-718F-4CA1-B3CD-0E5B3154697B	Primary Tumor	Illumina HiSeq	55250c6d-b9fb-4613-8463-59123f4e2065	Uterus	74.0	7901F084-C220-4865-A034-DA0144D63A28	FD504153-3CF6-44B9-99D5-21961EBAC188	TCGA-D1-A1NU-01A-11D-A34H-09	GRCh37-lite	TCGA-D1-A1NU	TCGA-UCEC		s4399	Washington University School of Medicine	Mayo Clinic	United States	NO			Serous endometrial adenocarcinoma		A34H-09	True
S13722.58cfa82fe4b0c9d6adf6b64a	58cfa82fe4b0c9d6adf6b64a	TCGA-73-4662-01A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_5_rg.sorted.filtered.	WGS	TCGA-73-4662-01A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_5_rg.sorted	TCGA-73-4662-01A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_5_rg.sorted.bam	337.2	1.9	0.15	58cfa82fe4b0c9d6adf6b64a	TCGA-73-4662-01A-01D-1203_110629_SN208_0211_AB0BP8ABXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4662-01A	294FF941-AEA1-4588-9A0E-E9F5393E2BB6	Primary Tumor	Illumina HiSeq	bb68d6e1-efca-4ccb-bbd6-45c4da207bb7	Lung	65.0	C7D727B6-47C6-4339-B9DD-5BAF41527BD4	DCC0A32E-EF17-4AA8-8321-A03137A61D72	TCGA-73-4662-01A-01D-1203-02	HG19_Broad_variant	TCGA-73-4662	TCGA-LUAD		s10663	Harvard Medical School	Roswell Park	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1203-02	True
S13722.58cfa82fe4b0c9d6adf6b66c	58cfa82fe4b0c9d6adf6b66c	TCGA-50-5946-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-50-5946-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_3_rg.sorted	TCGA-50-5946-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_3_rg.sorted.bam	242.4	1.9	0.14	58cfa82fe4b0c9d6adf6b66c	TCGA-50-5946-01A-11D-1751_111111_SN208_0254_B0160ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-50-5946-01A	C95957A7-1A1A-4C8D-BB61-7C99B500F224	Primary Tumor	Illumina HiSeq	b7f024ff-9569-4d31-b652-ffc2ceaa2789	Lung	62.0	AD9A794F-52DD-4572-BF29-CD3D11BA6C24	F9F38A15-2964-4AE0-90AA-E5F3F7461AB3	TCGA-50-5946-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5946	TCGA-LUAD		s10790	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Lung Adenocarcinoma Mixed Subtype	Stage IA	1751-02	True
S13722.58cfa82fe4b0c9d6adf6b6ba	58cfa82fe4b0c9d6adf6b6ba	TCGA-44-6778-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-44-6778-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_5_rg.sorted	TCGA-44-6778-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_5_rg.sorted.bam	227.7	1.9	0.15	58cfa82fe4b0c9d6adf6b6ba	TCGA-44-6778-01A-11D-1853_120312_SN1120_0120_AD0PYGACXX_s_5_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN		Lung Adenocarcinoma	Aligned reads	TCGA-44-6778-01A	5D5CC436-6E57-4D23-A164-7F5153C2E666	Primary Tumor	Illumina HiSeq	8d0de456-4a8c-48ad-bfc5-fa6e66ba6e0d	Lung	59.0	15321297-7110-4E79-8D6F-94C95BC83C94	737A7A30-1F60-4D88-B94D-B5FCD996FED2	TCGA-44-6778-01A-11D-1853-02	HG19_Broad_variant	TCGA-44-6778	TCGA-LUAD		s11126	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	True
S13722.58cfa82fe4b0c9d6adf6b6aa	58cfa82fe4b0c9d6adf6b6aa	TCGA-44-6774-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-6774-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_7_rg.sorted	TCGA-44-6774-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_7_rg.sorted.bam	62.7	1.9	0.17	58cfa82fe4b0c9d6adf6b6aa	TCGA-44-6774-01A-21D-1853_111204_SN208_0256_C0562ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6774-01A	33C71EAD-4C2A-476D-85EF-885DBBFC2CBD	Primary Tumor	Illumina HiSeq	5ff8e7e5-3b91-49af-b384-9d870bd9e425	Lung	56.0	79CF84B5-84FF-42E5-B438-697B35D272FC	6B977266-994D-4440-BC09-59FD8737F2D0	TCGA-44-6774-01A-21D-1853-02	HG19_Broad_variant	TCGA-44-6774	TCGA-LUAD		s10996	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	True
S13722.58cfa82fe4b0c9d6adf6b790	58cfa82fe4b0c9d6adf6b790	TCGA-44-6146-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_3_rg.sorted.filtered.	WGS	TCGA-44-6146-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_3_rg.sorted	TCGA-44-6146-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_3_rg.sorted.bam	72.0	1.9	0.16	58cfa82fe4b0c9d6adf6b790	TCGA-44-6146-01A-11D-1751_110927_SN208_0243_BC00TKACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6146-01A	0C0B610E-FE4C-406D-A5ED-5CC3B11DABF5	Primary Tumor	Illumina HiSeq	99148000-be38-4da1-aeaa-4b0271725662	Lung	64.0	AD66185F-983D-4416-B705-25D3D4D8B5A5	2D5C6425-E3F4-4389-9DDF-FDE694B4227E	TCGA-44-6146-01A-11D-1751-02	HG19_Broad_variant	TCGA-44-6146	TCGA-LUAD		s11337	Harvard Medical School	Christiana Healthcare	United States	NO	T3	N0	Lung Mucinous Adenocarcinoma	Stage IIB	1751-02	True
S13722.58cfa82fe4b0c9d6adf6b7b6	58cfa82fe4b0c9d6adf6b7b6	TCGA-44-3918-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_6_rg.sorted.filtered.	WGS	TCGA-44-3918-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_6_rg.sorted	TCGA-44-3918-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_6_rg.sorted.bam	467.53	1.9	0.16	58cfa82fe4b0c9d6adf6b7b6	TCGA-44-3918-01A-01D-1103_110729_SN208_0215_BD0CLPABXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-3918-01A	6E3B6B72-142D-4B8D-A462-28A205796E41	Primary Tumor	Illumina HiSeq	96ae9138-6a97-4b93-9d28-35ec09a8d772	Lung	60.0	2FF8BAFD-2AC5-4BFD-8C60-81519CD44166	81D8D7E2-65FA-4E92-B064-0D7D41C54E7F	TCGA-44-3918-01A-01D-1103-02	HG19_Broad_variant	TCGA-44-3918	TCGA-LUAD		s11122	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1103-02	True
S13722.58cfa82fe4b0c9d6adf6b868	58cfa82fe4b0c9d6adf6b868	TCGA-A5-A0R7-01A-31D-A101_120403_SN1222_0093_AC0L7VACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0R7-01A-31D-A101_120403_SN1222_0093_AC0L7VACXX_s_3_rg.sorted	TCGA-A5-A0R7-01A-31D-A101_120403_SN1222_0093_AC0L7VACXX_s_3_rg.sorted.bam	88.28	1.87	0.17	58cfa82fe4b0c9d6adf6b868	TCGA-A5-A0R7-01A-31D-A101_120403_SN1222_0093_AC0L7VACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0R7-01A	02B25675-094D-4098-96DA-51D121380FEC	Primary Tumor	Illumina HiSeq	daa92f08-7339-46a6-8a74-e6756c170ed5	Uterus	55.0	550C6341-260A-4156-B00C-0AE9031D647F	4C9B54D0-A58E-44CF-8937-913A34F0788C	TCGA-A5-A0R7-01A-31D-A101-02	HG19_Broad_variant	TCGA-A5-A0R7	TCGA-UCEC		s4777	Harvard Medical School	Cedars Sinai		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa82fe4b0c9d6adf6b8fe	58cfa82fe4b0c9d6adf6b8fe	TCGA-49-6744-01A-11D-1853_111218_SN208_0258_C054RACXX_s_5_rg.sorted.filtered.	WGS	TCGA-49-6744-01A-11D-1853_111218_SN208_0258_C054RACXX_s_5_rg.sorted	TCGA-49-6744-01A-11D-1853_111218_SN208_0258_C054RACXX_s_5_rg.sorted.bam	62.7	1.9	0.15	58cfa82fe4b0c9d6adf6b8fe	TCGA-49-6744-01A-11D-1853_111218_SN208_0258_C054RACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-49-6744-01A	15340DD3-84AE-49FB-989A-EB212F3E73DA	Primary Tumor	Illumina HiSeq	8290093a-0193-41fa-8e87-71960e0e640e	Lung	64.0	A9D69D7E-298C-4AB6-B64F-1EDC58832CCD	7455D0A5-45DB-461F-9026-5A0FE3D55A6A	TCGA-49-6744-01A-11D-1853-02	HG19_Broad_variant	TCGA-49-6744	TCGA-LUAD		s10656	Harvard Medical School	Johns Hopkins	United States	NO	T2a	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIA	1853-02	True
S13722.58cfa82fe4b0c9d6adf6b8b3	58cfa82fe4b0c9d6adf6b8b3	TCGA-50-5051-01A-21D-1853_120322_SN208_0277_AD0PL1ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-50-5051-01A-21D-1853_120322_SN208_0277_AD0PL1ACXX_s_7_rg.sorted	TCGA-50-5051-01A-21D-1853_120322_SN208_0277_AD0PL1ACXX_s_7_rg.sorted.bam	416.7	1.9	0.15	58cfa82fe4b0c9d6adf6b8b3	TCGA-50-5051-01A-21D-1853_120322_SN208_0277_AD0PL1ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-50-5051-01A	E1C55BAC-BB41-4964-ADD5-ECD6BA04B58D	Primary Tumor	Illumina HiSeq	fd2a1c20-3ed6-4057-8fb5-4027ce0eec74	Lung	42.0	180EB213-0DDC-4F10-AB0E-B3AF92CDE3C3	80170E98-4886-4A34-BC88-F2B2F84743B2	TCGA-50-5051-01A-21D-1853-02	HG19_Broad_variant	TCGA-50-5051	TCGA-LUAD		s10789	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	True
S13722.58cfa830e4b0c9d6adf6bc90	58cfa830e4b0c9d6adf6bc90	TCGA-AZ-4308-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4308-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4308-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	414.02	1.9	0.15	58cfa830e4b0c9d6adf6bc90	TCGA-AZ-4308-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4308-01A	3D8FD9B2-9AA2-4C81-8843-535AE66D6140	Primary Tumor	Illumina HiSeq	562ea734-bcd1-499a-8054-f710f2de3e41	Colorectal	47.0	6F0E65B2-7CA0-4F10-8952-B64900009001	1C7E82B6-A8EB-4593-B329-5299BC05140E	TCGA-AZ-4308-01A-01D-1405-02	HG18	TCGA-AZ-4308	TCGA-COAD		s13540	Harvard Medical School	University of Pittsburgh		NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	1405-02	True
S13722.58cfa830e4b0c9d6adf6bd8c	58cfa830e4b0c9d6adf6bd8c	TCGA-BG-A0M0-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BG-A0M0-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_6_rg.sorted	TCGA-BG-A0M0-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_6_rg.sorted.bam	94.25	2.11	0.15	58cfa830e4b0c9d6adf6bd8c	TCGA-BG-A0M0-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M0-01A	8BF0B156-6EB4-45E8-9CBB-0979EFBEA898	Primary Tumor	Illumina HiSeq	bedca351-a4f7-4fbd-af8e-d49f3d9b2c37	Uterus	66.0	E3F599DB-19CF-4086-8E5D-D3527119120F	78D21C64-205B-4C9C-A862-8A70348D2602	TCGA-BG-A0M0-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0M0	TCGA-UCEC		s5216	Harvard Medical School	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6bded	58cfa830e4b0c9d6adf6bded	TCGA-BH-A0DK-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BH-A0DK-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_5_rg.sorted	TCGA-BH-A0DK-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_5_rg.sorted.bam	43.73	2.05	0.16	58cfa830e4b0c9d6adf6bded	TCGA-BH-A0DK-01A-21D-A060_130807_SN590_0236_BC291KACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0DK-01A	F2BBFA9D-9A9D-4F46-9FDE-378E4C44E2AD	Primary Tumor	Illumina HiSeq	71acb20b-f186-44d4-a92e-a2751f845fe3	Breast	49.0	1ACAE6E0-3100-4DE8-A436-E15CDBE1322B	92245807-8B1B-4E96-8567-6CFE5E70ADE4	TCGA-BH-A0DK-01A-21D-A060-02	HG19_Broad_variant	TCGA-BH-A0DK	TCGA-BRCA		s5493	Harvard Medical School	University of Pittsburgh		NO	T2	N0 (i-)	Infiltrating Ductal Carcinoma	Stage IIA	A060-02	True
S13722.58cfa830e4b0c9d6adf6bd9b	58cfa830e4b0c9d6adf6bd9b	TCGA-BG-A0M3-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-BG-A0M3-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_8_rg.sorted	TCGA-BG-A0M3-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_8_rg.sorted.bam	101.93	1.88	0.15	58cfa830e4b0c9d6adf6bd9b	TCGA-BG-A0M3-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M3-01A	8BDD4E0E-5BEC-43F2-B9FA-D6E94A72FE05	Primary Tumor	Illumina HiSeq	d3fa774f-c50e-499c-ad6e-1a5f67dd2be3	Uterus	74.0	1802CD6B-4D4A-45FA-B839-7450071E41EE	04E49830-378E-4EB2-B77C-70D6955627F7	TCGA-BG-A0M3-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0M3	TCGA-UCEC		s5394	Harvard Medical School	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6be7e	58cfa830e4b0c9d6adf6be7e	TCGA-BJ-A192-01A-31D-A13U_120706_SN1120_0170_BD1422ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-BJ-A192-01A-31D-A13U_120706_SN1120_0170_BD1422ACXX_s_4_rg.sorted	TCGA-BJ-A192-01A-31D-A13U_120706_SN1120_0170_BD1422ACXX_s_4_rg.sorted.bam	32.81	2.02	0.17	58cfa830e4b0c9d6adf6be7e	TCGA-BJ-A192-01A-31D-A13U_120706_SN1120_0170_BD1422ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE		Thyroid Carcinoma	Aligned reads	TCGA-BJ-A192-01A	B55375C3-9EF2-4D2F-9C29-224E746931C4	Primary Tumor	Illumina HiSeq	9218178e-761c-40ac-b3ca-044bf37f8686	Thyroid	54.0	582C3030-1F23-4535-9C8B-6B594E656AF4	6D770754-E14D-4E47-AE33-BE0FC9B40CE9	TCGA-BJ-A192-01A-31D-A13U-02	HG19_Broad_variant	TCGA-BJ-A192	TCGA-THCA		s12235	Harvard Medical School	University of Pittsburgh	United States	NO	T3	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A13U-02	True
S13722.58cfa830e4b0c9d6adf6bec9	58cfa830e4b0c9d6adf6bec9	TCGA-AP-A0LP-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-AP-A0LP-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_4_rg.sorted	TCGA-AP-A0LP-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_4_rg.sorted.bam	109.58	1.91	0.16	58cfa830e4b0c9d6adf6bec9	TCGA-AP-A0LP-01A-12D-A101_120330_SN208_0279_BC0L73ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LP-01A	EFAE3940-D3CC-4988-BDB4-FA05D977AFF5	Primary Tumor	Illumina HiSeq	369f32c0-ebb9-490e-baa4-0735e0efa092	Uterus	76.0	D67450C1-8848-4B28-9C16-83AA7132E8C8	C7A70C11-A05E-473D-929E-59A260FFBD97	TCGA-AP-A0LP-01A-12D-A101-02	HG19_Broad_variant	TCGA-AP-A0LP	TCGA-UCEC		s5202	Harvard Medical School	MSKCC		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6bf21	58cfa830e4b0c9d6adf6bf21	TCGA-BR-4279-01A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4279-01A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_1_rg.sorted	TCGA-BR-4279-01A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_1_rg.sorted.bam	7.9	1.9	0.16	58cfa830e4b0c9d6adf6bf21	TCGA-BR-4279-01A-01D-1128_121127_SN208_0441_BC1F8CACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4279-01A	117EB38B-0C62-4336-A866-FA5BD013256A	Primary Tumor	Illumina HiSeq	0fa8a7d6-6636-4135-82f6-21c9df279b16	Stomach	43.0	84AD647D-76B8-4EDA-8603-40220089BE34	01DC88B7-45FC-464C-A613-9793CD0C068B	TCGA-BR-4279-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4279	TCGA-STAD		s14814	Harvard Medical School	Asterand	Russia	NO	T2a	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage II	1128-02	True
S13722.58cfa830e4b0c9d6adf6bf9f	58cfa830e4b0c9d6adf6bf9f	TCGA-BR-6458-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-6458-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_5_rg.sorted	TCGA-BR-6458-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_5_rg.sorted.bam	306.4	1.9	0.15	58cfa830e4b0c9d6adf6bf9f	TCGA-BR-6458-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6458-01A	E516880B-C4E5-43CD-A358-BE0DB88564D7	Primary Tumor	Illumina HiSeq	545acf44-8e16-46b9-b35a-c860c08b416b	Stomach	57.0	A30B45F5-C6E4-4975-A912-8313D93DFD27	2DD3E59B-4DBB-49B4-9DC4-A949FE48AA17	TCGA-BR-6458-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6458	TCGA-STAD		s14613	Harvard Medical School	Asterand	Ukraine	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	True
S13722.58cfa830e4b0c9d6adf6bfe8	58cfa830e4b0c9d6adf6bfe8	TCGA-BR-6565-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6565-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_7_rg.sorted	TCGA-BR-6565-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_7_rg.sorted.bam	338.7	1.9	0.14	58cfa830e4b0c9d6adf6bfe8	TCGA-BR-6565-01A-11D-1798_130116_SN208_0448_AC1J58ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6565-01A	DAECEA36-B379-46CE-8AE9-A38D22556CE2	Primary Tumor	Illumina HiSeq	8cfafa49-f561-4e59-98c5-b9a816534417	Stomach	67.0	1D7AAE07-2453-4DC3-A26D-D67161172648	E5F188AD-28C2-4AD0-89DD-C13493CE4B03	TCGA-BR-6565-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6565	TCGA-STAD		s14881	Harvard Medical School	Asterand	Russia	NO	T4a	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIB	1798-02	True
S13722.58cfa830e4b0c9d6adf6c01c	58cfa830e4b0c9d6adf6c01c	TCGA-B5-A0K7-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_8_rg.sorted.filtered.	WGS	TCGA-B5-A0K7-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_8_rg.sorted	TCGA-B5-A0K7-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_8_rg.sorted.bam	106.4	2.0	0.15	58cfa830e4b0c9d6adf6c01c	TCGA-B5-A0K7-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K7-01A	2F0640BC-598C-4714-9E9B-7E0F2CA4567F	Primary Tumor	Illumina HiSeq	b1ac8e27-775c-4d91-8a4d-9d096cde589d	Uterus	64.0	51E8577D-6849-422E-8F37-2EA8C400BBE5	ED30E619-1EBE-4CCE-B7FD-93B552953B65	TCGA-B5-A0K7-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0K7	TCGA-UCEC		s5390	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6c050	58cfa830e4b0c9d6adf6c050	TCGA-B5-A0K6-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-B5-A0K6-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_5_rg.sorted	TCGA-B5-A0K6-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_5_rg.sorted.bam	110.74	2.06	0.14	58cfa830e4b0c9d6adf6c050	TCGA-B5-A0K6-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K6-01A	5CBA9441-6812-49C0-A0F6-7928ED4E5B81	Primary Tumor	Illumina HiSeq	06cd1c7f-2531-4a07-bf4f-c086f7a954a0	Uterus	58.0	69BF0D3A-B7AE-4EE1-B7D1-18A32FCFA67C	A4364F57-81A8-4B96-BA31-1D8B1CC78C5D	TCGA-B5-A0K6-01A-11D-A043-02	HG19_Broad_variant	TCGA-B5-A0K6	TCGA-UCEC		s4247	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa830e4b0c9d6adf6c1fc	58cfa830e4b0c9d6adf6c1fc	TCGA-BG-A0M2-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A0M2-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_7_rg.sorted	TCGA-BG-A0M2-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_7_rg.sorted.bam	63.57	1.97	0.15	58cfa830e4b0c9d6adf6c1fc	TCGA-BG-A0M2-01A-11D-A101_120330_SN208_0279_BC0L73ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M2-01A	9731E0B3-C62D-43CB-8AE7-8F973D69AB19	Primary Tumor	Illumina HiSeq	9dcd7360-a8dc-49cb-bf13-8fb36c436e30	Uterus	62.0	2AF18345-2A71-4574-AC8E-83DDEED3AD57	E59EB8B5-DA68-44B3-BB18-8C42F583B2BA	TCGA-BG-A0M2-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0M2	TCGA-UCEC		s4604	Harvard Medical School	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6c23c	58cfa830e4b0c9d6adf6c23c	TCGA-BT-A2LB-01A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BT-A2LB-01A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_6_rg.sorted	TCGA-BT-A2LB-01A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_6_rg.sorted.bam	51.24		0.18	58cfa830e4b0c9d6adf6c23c	TCGA-BT-A2LB-01A-11D-A18D_120904_SN1120_0186_BC1911ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A2LB-01A	D17A5AB1-3789-4652-AFF5-D8F4F2291F9C	Primary Tumor	Illumina HiSeq	de67212f-594e-409c-bd19-3d40f013b89a	Bladder	73.0	7C6178A6-6D4C-4DEF-B4AC-A064AB4A6C8A	FAD087E0-3752-4144-960B-659B59312C92	TCGA-BT-A2LB-01A-11D-A18D-02	HG19_Broad_variant	TCGA-BT-A2LB	TCGA-BLCA		s3087	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A18D-02	True
S13722.58cfa830e4b0c9d6adf6c260	58cfa830e4b0c9d6adf6c260	TCGA-C5-A3HL-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-C5-A3HL-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_7_rg.sorted	TCGA-C5-A3HL-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_7_rg.sorted.bam	48.29		0.14	58cfa830e4b0c9d6adf6c260	TCGA-C5-A3HL-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A3HL-01A	09329A53-D58D-4480-95D8-32043E40DE6E	Primary Tumor	Illumina HiSeq	84c6e022-f737-4fae-a2c7-812ef4f00adf	Cervix	76.0	2A3CC87B-B120-49EC-93E6-8BDDBAE5C97C	04FC6219-3EAC-4BB8-82CA-CD0AA6B0ACE3	TCGA-C5-A3HL-01A-11D-A20X-26	HG19_Broad_variant	TCGA-C5-A3HL	TCGA-CESC		s1516	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO	T1b2	N0	Cervical Squamous Cell Carcinoma		A20X-26	True
S13722.58cfa830e4b0c9d6adf6c29e	58cfa830e4b0c9d6adf6c29e	TCGA-BR-4366-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4366-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_1_rg.sorted	TCGA-BR-4366-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_1_rg.sorted.bam	194.2	1.9	0.15	58cfa830e4b0c9d6adf6c29e	TCGA-BR-4366-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4366-01A	525A6978-2D7B-4F3A-AC68-13FE8CBBBDCC	Primary Tumor	Illumina HiSeq	c4b9424f-d0da-48ae-8723-69cbccfdefc6	Stomach	87.0	8C2D2CCE-E071-42E8-89B2-77C56B4F3472	5AF4101A-F7F6-4014-BC9C-02446DA9CBDC	TCGA-BR-4366-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4366	TCGA-STAD		s15235	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1154-02	True
S13722.58cfa830e4b0c9d6adf6c272	58cfa830e4b0c9d6adf6c272	TCGA-BJ-A0ZA-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZA-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_5_rg.sorted	TCGA-BJ-A0ZA-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_5_rg.sorted.bam	34.66	1.95	0.15	58cfa830e4b0c9d6adf6c272	TCGA-BJ-A0ZA-01A-11D-A10R_120616_SN1120_0154_BD142VACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZA-01A	4C513413-263E-4C7B-B997-7B688C47B698	Primary Tumor	Illumina HiSeq	787aed3e-08d4-4fa8-93e1-c04216a9875f	Thyroid	67.0	A61A9EC7-B893-44A5-AB6F-A390C168BE88	F3A353BB-07C3-49D1-BED2-2F8F5A328E1C	TCGA-BJ-A0ZA-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZA	TCGA-THCA		s12744	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A10R-02	True
S13722.58cfa830e4b0c9d6adf6c2da	58cfa830e4b0c9d6adf6c2da	TCGA-BR-4370-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_1_rg.sorted.filtered.	WGS	TCGA-BR-4370-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_1_rg.sorted	TCGA-BR-4370-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_1_rg.sorted.bam	179.2	1.9	0.15	58cfa830e4b0c9d6adf6c2da	TCGA-BR-4370-01A-01D-1154_130815_VM001_0003_VMR0003CXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4370-01A	A2A71CB0-9DBD-45CC-8867-DA84500515E7	Primary Tumor	Illumina HiSeq	a1feb789-c851-4608-a5c1-382bb432c4c7	Stomach	74.0	CFB7901B-E4E1-42FE-802D-DCD34F8C4912	B27FAC46-97C3-4262-B8CB-6E15AA75483A	TCGA-BR-4370-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4370	TCGA-STAD		s14883	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1154-02	True
S13722.58cfa830e4b0c9d6adf6c2ec	58cfa830e4b0c9d6adf6c2ec	TCGA-BR-6566-01A-11D-1798_130116_SN208_0449_BD1RNWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BR-6566-01A-11D-1798_130116_SN208_0449_BD1RNWACXX_s_2_rg.sorted	TCGA-BR-6566-01A-11D-1798_130116_SN208_0449_BD1RNWACXX_s_2_rg.sorted.bam	118.7	1.9	0.15	58cfa830e4b0c9d6adf6c2ec	TCGA-BR-6566-01A-11D-1798_130116_SN208_0449_BD1RNWACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6566-01A	43F0421C-6578-4D77-9314-EF0305C7EFBD	Primary Tumor	Illumina HiSeq	ae711b74-3be9-4959-addd-03427c07f35b	Stomach	64.0	EEB8703E-5F0A-429D-9A5C-7C5227EB7A01	7BAAEED3-AA68-4825-84F1-0516B543C762	TCGA-BR-6566-01A-11D-1798-02	HG19_Broad_variant	TCGA-BR-6566	TCGA-STAD		s14884	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1798-02	True
S13722.58cfa831e4b0c9d6adf6c384	58cfa831e4b0c9d6adf6c384	TCGA-CD-5801-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CD-5801-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_6_rg.sorted	TCGA-CD-5801-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_6_rg.sorted.bam	374.0	2.0	0.17	58cfa831e4b0c9d6adf6c384	TCGA-CD-5801-01A-11D-1598_121025_SN590_0187_BC191FACXX_s_6_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5801-01A	DF822EA3-E0E6-4AD3-A228-E20E3A737DAC	Primary Tumor	Illumina HiSeq	5196b0dd-1d41-47f4-84a8-999f211443f4	Stomach	69.0	9D0DF8D7-8D59-4983-9BBF-C6C106BDEFEC	F32CB4AA-D842-427A-8B7E-371764308512	TCGA-CD-5801-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5801	TCGA-STAD		s15317	Harvard Medical School	ILSbio	Vietnam	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1598-02	True
S13722.58cfa831e4b0c9d6adf6c498	58cfa831e4b0c9d6adf6c498	TCGA-CN-4722-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-4722-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_7_rg.sorted	TCGA-CN-4722-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_7_rg.sorted.bam	52.7	1.9	0.16	58cfa831e4b0c9d6adf6c498	TCGA-CN-4722-01A-01D-1431_120423_SN590_0153_BC0KJ3ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4722-01A	B64BFCA1-033C-4501-A900-103AC105C084	Primary Tumor	Illumina HiSeq	3723e20c-1e27-4158-8bc5-1768c49ee5e5	Head and Neck	61.0	6E767FC9-0F5A-49EC-999A-CDA2DAEBA6FF	0CA196A7-5A71-4E70-8FA6-9506E1883032	TCGA-CN-4722-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4722	TCGA-HNSC		s15758	Harvard Medical School	University of Pittsburgh		NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1431-02	True
S13722.58cfa831e4b0c9d6adf6c424	58cfa831e4b0c9d6adf6c424	TCGA-CN-4725-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CN-4725-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_3_rg.sorted	TCGA-CN-4725-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_3_rg.sorted.bam	52.7	1.9	0.17	58cfa831e4b0c9d6adf6c424	TCGA-CN-4725-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4725-01A	3BE2ACE5-1C2A-49E9-8DA9-CEED6119530B	Primary Tumor	Illumina HiSeq	7ddc2537-f164-4a40-befe-6e0a3deed186	Head and Neck	60.0	DD42AB2F-E936-4ACE-93D8-60375E03F2FE	C8B71532-685F-47AC-B019-B898A8D1670D	TCGA-CN-4725-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4725	TCGA-HNSC		s15755	Harvard Medical School	University of Pittsburgh		NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1431-02	True
S13722.58cfa831e4b0c9d6adf6c4a4	58cfa831e4b0c9d6adf6c4a4	TCGA-CF-A1HR-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CF-A1HR-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_3_rg.sorted	TCGA-CF-A1HR-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_3_rg.sorted.bam	37.6	2.0	0.16	58cfa831e4b0c9d6adf6c4a4	TCGA-CF-A1HR-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A1HR-01A	39EA19E1-4959-4F1B-9934-54BDAF766842	Primary Tumor	Illumina HiSeq	65dee943-f41b-4f59-a5bb-2477053d1079	Bladder	62.0	6E77AB45-9C53-4A74-9581-043005C3E685	B048E28D-38FC-4E37-9C54-9C56526AD0E3	TCGA-CF-A1HR-01A-11D-A13U-02	HG19_Broad_variant	TCGA-CF-A1HR	TCGA-BLCA		s2872	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	True
S13722.58cfa831e4b0c9d6adf6c514	58cfa831e4b0c9d6adf6c514	TCGA-CN-4735-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CN-4735-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_2_rg.sorted	TCGA-CN-4735-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_2_rg.sorted.bam	52.7	1.9	0.13	58cfa831e4b0c9d6adf6c514	TCGA-CN-4735-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4735-01A	FE844945-3EA9-449E-993C-DF392FABCFD0	Primary Tumor	Illumina HiSeq	b8913a67-9dd4-41f9-8888-c998df0a0a23	Head and Neck	52.0	FBB300FA-8793-42DA-A68E-4570AE2E5186	F759672A-62CA-49DC-BC4F-643E8A885787	TCGA-CN-4735-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4735	TCGA-HNSC		s16032	Harvard Medical School	University of Pittsburgh		NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True
S13722.58cfa831e4b0c9d6adf6c57e	58cfa831e4b0c9d6adf6c57e	TCGA-CN-4729-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CN-4729-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_3_rg.sorted	TCGA-CN-4729-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_3_rg.sorted.bam	99.7	1.9	0.15	58cfa831e4b0c9d6adf6c57e	TCGA-CN-4729-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4729-01A	2FC960BD-01B0-422D-AD33-34520FA3DF0E	Primary Tumor	Illumina HiSeq	8b48a937-18eb-4e54-95d1-680ce9284b60	Head and Neck	73.0	1DA8FE25-AEE2-45FD-A1F3-3239A42E54B2	A49670C2-95A6-4DEB-BFC5-59B0FF37389E	TCGA-CN-4729-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4729	TCGA-HNSC		s15620	Harvard Medical School	University of Pittsburgh		NO	T2	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1431-02	True
S13722.58cfa830e4b0c9d6adf6c102	58cfa830e4b0c9d6adf6c102	TCGA-B5-A0K9-01A-21D-A101_120330_SN208_0279_BC0L73ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-B5-A0K9-01A-21D-A101_120330_SN208_0279_BC0L73ACXX_s_1_rg.sorted	TCGA-B5-A0K9-01A-21D-A101_120330_SN208_0279_BC0L73ACXX_s_1_rg.sorted.bam	97.15	2.16	0.13	58cfa830e4b0c9d6adf6c102	TCGA-B5-A0K9-01A-21D-A101_120330_SN208_0279_BC0L73ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0K9-01A	4485CC98-5D58-4EB4-8325-7D1A617B6461	Primary Tumor	Illumina HiSeq	71c016d1-ab89-4d8f-acb9-92767959d603	Uterus	88.0	52A96216-708F-43F2-A923-130A1C35922D	30D94271-91F3-4CF5-83C0-4708662115D0	TCGA-B5-A0K9-01A-21D-A101-02	HG19_Broad_variant	TCGA-B5-A0K9	TCGA-UCEC		s5210	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa831e4b0c9d6adf6c68f	58cfa831e4b0c9d6adf6c68f	TCGA-CU-A3YL-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CU-A3YL-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_3_rg.sorted	TCGA-CU-A3YL-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_3_rg.sorted.bam	42.41		0.15	58cfa831e4b0c9d6adf6c68f	TCGA-CU-A3YL-01A-11D-A233_120829_SN1120_0183_AC18U8ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A3YL-01A	087A7F70-2FA8-4A16-B130-4DF10A70C662	Primary Tumor	Illumina HiSeq	8753d7f5-4d92-4781-8d19-d44710fa4f45	Bladder	67.0	F66AD788-E2D8-4688-820F-49A609701533	CAD008C4-3B53-4E9D-8730-9807E4753DDD	TCGA-CU-A3YL-01A-11D-A233-26	HG19_Broad_variant	TCGA-CU-A3YL	TCGA-BLCA		s3274	MD Anderson - Institute for Applied Cancer Science	UNC	United States	NO	T4a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	True
S13722.58cfa831e4b0c9d6adf6c810	58cfa831e4b0c9d6adf6c810	TCGA-D1-A2G0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D1-A2G0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_5_rg.sorted	TCGA-D1-A2G0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_5_rg.sorted.bam	59.69		0.17	58cfa831e4b0c9d6adf6c810	TCGA-D1-A2G0-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A2G0-01A	6F661F0D-F08B-486E-8BD7-4306E1593EB9	Primary Tumor	Illumina HiSeq	675cc0ce-f2e1-4e4c-a337-4bc31fcb46c5	Uterus	70.0	134CD317-CBEB-4633-B540-B639454615F7	DF417E78-8258-40C2-8305-2FE14DCC8035	TCGA-D1-A2G0-01A-11D-A17E-02	HG19_Broad_variant	TCGA-D1-A2G0	TCGA-UCEC		s4803	Harvard Medical School	Mayo Clinic	United States	NO			Mixed serous and endometrioid		A17E-02	True
S13722.58cfa831e4b0c9d6adf6c77e	58cfa831e4b0c9d6adf6c77e	TCGA-CS-5396-01A-02D-1465_130906_SN1440_0166_BC2A68ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CS-5396-01A-02D-1465_130906_SN1440_0166_BC2A68ACXX_s_4_rg.sorted	TCGA-CS-5396-01A-02D-1465_130906_SN1440_0166_BC2A68ACXX_s_4_rg.sorted.bam	152.7	1.9	0.15	58cfa831e4b0c9d6adf6c77e	TCGA-CS-5396-01A-02D-1465_130906_SN1440_0166_BC2A68ACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-CS-5396-01A	B6C2C9BD-625B-4A98-830C-49C344F6CB5F	Primary Tumor	Illumina HiSeq	3d26b7bb-4cc9-4d9b-8c42-6fbd2ea9b590	Brain	53.0	CE1ED4B3-AF89-4BBD-B9A6-EEFA007E4368	F2F5E5EE-B807-4CAF-99B3-68270C1F305E	TCGA-CS-5396-01A-02D-1465-02	HG19_Broad_variant	TCGA-CS-5396	TCGA-LGG		s8342	Harvard Medical School	Thomas Jefferson University	United States	NO			Oligodendroglioma		1465-02	True
S13722.58cfa831e4b0c9d6adf6c8d6	58cfa831e4b0c9d6adf6c8d6	TCGA-D1-A16B-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D1-A16B-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_1_rg.sorted	TCGA-D1-A16B-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_1_rg.sorted.bam	93.6	1.92	0.15	58cfa831e4b0c9d6adf6c8d6	TCGA-D1-A16B-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16B-01A	BCA1057A-1E96-404D-8A37-5A8DC1944EE7	Primary Tumor	Illumina HiSeq	fee88e21-5479-4b67-8933-80c22e6fa222	Uterus	64.0	6A59FF6E-7CC6-4D46-8983-7D9E6A48CC19	D581BCAA-4EA7-4364-840B-E2D24F1916E4	TCGA-D1-A16B-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A16B	TCGA-UCEC		s5017	Harvard Medical School	Mayo Clinic		NO			Endometrioid endometrial adenocarcinoma		A12F-02	True
S13722.58cfa831e4b0c9d6adf6c8ba	58cfa831e4b0c9d6adf6c8ba	TCGA-DK-A3IM-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-DK-A3IM-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_7_rg.sorted	TCGA-DK-A3IM-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_7_rg.sorted.bam	26.41		0.15	58cfa831e4b0c9d6adf6c8ba	TCGA-DK-A3IM-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3IM-01A	41B59716-116F-4942-8B63-409870A87E26	Primary Tumor	Illumina HiSeq	27ca0d22-3ef8-4c3c-814a-94dfb76c3289	Bladder	76.0	7A37AE7C-6B46-410D-AE2B-12FD868C25B3	CDAC6FE7-FB06-4F9A-86D0-DF0DF26FD558	TCGA-DK-A3IM-01A-11D-A210-26	HG19_Broad_variant	TCGA-DK-A3IM	TCGA-BLCA		s2882	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A210-26	True
S13722.58cfa831e4b0c9d6adf6c8ce	58cfa831e4b0c9d6adf6c8ce	TCGA-D1-A16Q-01A-12D-A12F_120511_SN208_0299_BD12J9ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-D1-A16Q-01A-12D-A12F_120511_SN208_0299_BD12J9ACXX_s_5_rg.sorted	TCGA-D1-A16Q-01A-12D-A12F_120511_SN208_0299_BD12J9ACXX_s_5_rg.sorted.bam	74.24	1.92	0.14	58cfa831e4b0c9d6adf6c8ce	TCGA-D1-A16Q-01A-12D-A12F_120511_SN208_0299_BD12J9ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16Q-01A	7F4F3AED-69AF-421E-817B-B258DCC0BAC5	Primary Tumor	Illumina HiSeq	c23e5f4d-d7be-44b1-a19e-c949819d58c9	Uterus	54.0	BFE3DA05-506E-4837-AC72-A285FE079C58	23DF790A-0AB3-4EFB-AD9D-62AF1B79D941	TCGA-D1-A16Q-01A-12D-A12F-02	HG19_Broad_variant	TCGA-D1-A16Q	TCGA-UCEC		s5024	Harvard Medical School	Mayo Clinic		NO			Endometrioid endometrial adenocarcinoma		A12F-02	True
S13722.58cfa831e4b0c9d6adf6c9da	58cfa831e4b0c9d6adf6c9da	TCGA-DJ-A13T-01A-11D-A10R_120629_SN1120_0167_AC0WMBACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DJ-A13T-01A-11D-A10R_120629_SN1120_0167_AC0WMBACXX_s_1_rg.sorted	TCGA-DJ-A13T-01A-11D-A10R_120629_SN1120_0167_AC0WMBACXX_s_1_rg.sorted.bam	48.83	2.0	0.16	58cfa831e4b0c9d6adf6c9da	TCGA-DJ-A13T-01A-11D-A10R_120629_SN1120_0167_AC0WMBACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Thyroid Carcinoma	Aligned reads	TCGA-DJ-A13T-01A	0B170ED4-D919-466B-B765-47878B865AED	Primary Tumor	Illumina HiSeq	f42aa2a6-4acd-4650-aea7-c83fbddf27d2	Thyroid	37.0	6883BA87-9184-40D7-840B-603B15D73F7A	76DCBA6C-0992-44BB-9492-3023A2430CC4	TCGA-DJ-A13T-01A-11D-A10R-02	HG19_Broad_variant	TCGA-DJ-A13T	TCGA-THCA		s12513	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	True
S13722.58cfa831e4b0c9d6adf6c9e6	58cfa831e4b0c9d6adf6c9e6	TCGA-DK-A3X1-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DK-A3X1-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_1_rg.sorted	TCGA-DK-A3X1-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_1_rg.sorted.bam	47.57		0.16	58cfa831e4b0c9d6adf6c9e6	TCGA-DK-A3X1-01A-12D-A233_120829_SN1120_0184_BD1DRAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A3X1-01A	6BDDAFDE-7004-49B6-80CF-8081CD4B7D44	Primary Tumor	Illumina HiSeq	4c8de054-fd6d-4ebd-8a6e-b5061ef5913b	Bladder	78.0	3D440A83-214E-432F-89D2-B523BFE7C6EF	4A8B5117-AF70-40AB-9698-B736EF20F3DE	TCGA-DK-A3X1-01A-12D-A233-26	HG19_Broad_variant	TCGA-DK-A3X1	TCGA-BLCA		s3286	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	True
S13722.58cfa831e4b0c9d6adf6c96a	58cfa831e4b0c9d6adf6c96a	TCGA-DJ-A1QI-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DJ-A1QI-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_5_rg.sorted	TCGA-DJ-A1QI-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_5_rg.sorted.bam	97.61	1.98	0.17	58cfa831e4b0c9d6adf6c96a	TCGA-DJ-A1QI-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QI-01A	3B1E2BD6-3D32-40F7-9B32-0DF32DFCBC72	Primary Tumor	Illumina HiSeq	e0052e53-2d8c-45ba-8d2c-db4eab61a141	Thyroid	63.0	C58506A1-8C6B-4CE8-99E0-F2D1234F95F5	3C049586-BD3C-490D-93DB-E344BD6A1AE8	TCGA-DJ-A1QI-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QI	TCGA-THCA		s12641	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage II	A14U-02	True
S13722.58cfa831e4b0c9d6adf6ca54	58cfa831e4b0c9d6adf6ca54	TCGA-DB-5280-01A-01D-1465_130906_SN1440_0166_BC2A68ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DB-5280-01A-01D-1465_130906_SN1440_0166_BC2A68ACXX_s_5_rg.sorted	TCGA-DB-5280-01A-01D-1465_130906_SN1440_0166_BC2A68ACXX_s_5_rg.sorted.bam	325.7	1.9	0.15	58cfa831e4b0c9d6adf6ca54	TCGA-DB-5280-01A-01D-1465_130906_SN1440_0166_BC2A68ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DB-5280-01A	4797C600-F024-42FE-B287-D919B24DCB79	Primary Tumor	Illumina HiSeq	47363648-94bb-4221-a905-4832396ef90e	Brain	43.0	D9B929FD-335C-46B1-B60D-B846C372AA6A	677B8F71-325E-49F9-B3D7-B6ADB6831ED5	TCGA-DB-5280-01A-01D-1465-02	HG19_Broad_variant	TCGA-DB-5280	TCGA-LGG		s8130	Harvard Medical School	Mayo Clinic - Rochester	United States	NO			Oligoastrocytoma		1465-02	True
S13722.58cfa831e4b0c9d6adf6caaa	58cfa831e4b0c9d6adf6caaa	TCGA-D1-A16D-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-D1-A16D-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_3_rg.sorted	TCGA-D1-A16D-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_3_rg.sorted.bam	64.8	1.88	0.16	58cfa831e4b0c9d6adf6caaa	TCGA-D1-A16D-01A-11D-A12F_120511_SN208_0299_BD12J9ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-D1-A16D-01A	5693302A-4548-4C0B-8725-0CB7C67BC4F8	Primary Tumor	Illumina HiSeq	c72febd1-cbf3-4ba1-9e3e-35d65e99aa5e	Uterus	49.0	007BDFD3-81B6-42C3-A4A6-C4DDAF1BE0AE	DCA0D1DE-E9A0-45CF-B709-A492D513C1C4	TCGA-D1-A16D-01A-11D-A12F-02	HG19_Broad_variant	TCGA-D1-A16D	TCGA-UCEC		s4613	Harvard Medical School	Mayo Clinic		NO			Endometrioid endometrial adenocarcinoma		A12F-02	True
S13722.58cfa831e4b0c9d6adf6c9dc	58cfa831e4b0c9d6adf6c9dc	TCGA-DU-6392-01A-11D-1703_130906_SN1440_0166_BC2A68ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DU-6392-01A-11D-1703_130906_SN1440_0166_BC2A68ACXX_s_6_rg.sorted	TCGA-DU-6392-01A-11D-1703_130906_SN1440_0166_BC2A68ACXX_s_6_rg.sorted.bam	16.0	2.0	0.13	58cfa831e4b0c9d6adf6c9dc	TCGA-DU-6392-01A-11D-1703_130906_SN1440_0166_BC2A68ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-6392-01A	FCD9E1C4-BDDB-4856-844C-03DF48FBA499	Primary Tumor	Illumina HiSeq	8f4eff17-77e1-4e7d-9fc7-83ae4db50b3a	Brain	35.0	14780BB2-67A9-4ACA-BCE4-12793FB1808E	E7B36F2D-9AB1-4A46-B669-65367B841752	TCGA-DU-6392-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-6392	TCGA-LGG		s8561	Harvard Medical School	Henry Ford Hospital	United States	NO			Astrocytoma		1703-02	True
S13722.58cfa831e4b0c9d6adf6caf8	58cfa831e4b0c9d6adf6caf8	TCGA-EA-A3HR-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EA-A3HR-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_1_rg.sorted	TCGA-EA-A3HR-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_1_rg.sorted.bam	47.83		0.16	58cfa831e4b0c9d6adf6caf8	TCGA-EA-A3HR-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3HR-01A	638035F6-2909-4A44-980F-468AC5D74E18	Primary Tumor	Illumina HiSeq	a2c5a51a-5933-4597-b207-2c761c54f7c2	Cervix	57.0	1FBFA952-F272-4531-9F9D-1B8BD1DD0845	2B1D8BBD-0F37-40D4-AF38-C78C4BB556BB	TCGA-EA-A3HR-01A-11D-A20X-26	HG19_Broad_variant	TCGA-EA-A3HR	TCGA-CESC		s1179	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T2a	N0	Cervical Squamous Cell Carcinoma		A20X-26	True
S13722.58cfa831e4b0c9d6adf6cb28	58cfa831e4b0c9d6adf6cb28	TCGA-E7-A3Y1-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-E7-A3Y1-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_7_rg.sorted	TCGA-E7-A3Y1-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_7_rg.sorted.bam	43.56		0.17	58cfa831e4b0c9d6adf6cb28	TCGA-E7-A3Y1-01A-11D-A233_120829_SN1120_0184_BD1DRAACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-E7-A3Y1-01A	F7C891EB-3B09-4E01-BB8A-53D570518CBE	Primary Tumor	Illumina HiSeq	aaeb4857-84bb-4a72-9e0d-81280de1ca61	Bladder	57.0	FABE5B98-4586-445D-9513-598BB7FD1909	46542747-5AF3-4F7E-AE97-7E0689976D0A	TCGA-E7-A3Y1-01A-11D-A233-26	HG19_Broad_variant	TCGA-E7-A3Y1	TCGA-BLCA		s3109	MD Anderson - Institute for Applied Cancer Science	Asterand	Ukraine	NO		N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A233-26	True
S13722.58cfa831e4b0c9d6adf6cc63	58cfa831e4b0c9d6adf6cc63	TCGA-EA-A3HU-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EA-A3HU-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_3_rg.sorted	TCGA-EA-A3HU-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_3_rg.sorted.bam	40.2		0.16	58cfa831e4b0c9d6adf6cc63	TCGA-EA-A3HU-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3HU-01A	9912432E-74BC-4846-93B4-FA2BF8070BD1	Primary Tumor	Illumina HiSeq	4f5312e3-89a9-41d7-a296-8b90e22cb408	Cervix	43.0	05409DA8-60DC-4073-91F0-F91832F3A607	B66F8B97-9149-4C12-A66E-4BC7D1352269	TCGA-EA-A3HU-01A-11D-A20X-26	HG19_Broad_variant	TCGA-EA-A3HU	TCGA-CESC		s1520	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T2a2	N0	Cervical Squamous Cell Carcinoma		A20X-26	True
S13722.58cfa831e4b0c9d6adf6cc9c	58cfa831e4b0c9d6adf6cc9c	TCGA-FD-A3SM-01A-11D-A233_120830_SN208_0423_AC190AACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FD-A3SM-01A-11D-A233_120830_SN208_0423_AC190AACXX_s_5_rg.sorted	TCGA-FD-A3SM-01A-11D-A233_120830_SN208_0423_AC190AACXX_s_5_rg.sorted.bam	22.6		0.16	58cfa831e4b0c9d6adf6cc9c	TCGA-FD-A3SM-01A-11D-A233_120830_SN208_0423_AC190AACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SM-01A	474582F2-8DEC-4FBC-803F-4FD9BA2E0957	Primary Tumor	Illumina HiSeq	bacf3136-6605-4a66-a869-8d91e4003a0d	Bladder	70.0	5F7DE481-C011-43A8-844B-F47569499F0D	AF7DFCCA-999E-4EA2-A14B-1E923C2ECE38	TCGA-FD-A3SM-01A-11D-A233-26	HG19_Broad_variant	TCGA-FD-A3SM	TCGA-BLCA		s3299	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T3a	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A233-26	True
S13722.58cfa831e4b0c9d6adf6cd3c	58cfa831e4b0c9d6adf6cd3c	TCGA-ET-A25M-01A-11D-A16N_120718_SN590_0170_BD141RACXX_s_6_rg.sorted.filtered.	WGS	TCGA-ET-A25M-01A-11D-A16N_120718_SN590_0170_BD141RACXX_s_6_rg.sorted	TCGA-ET-A25M-01A-11D-A16N_120718_SN590_0170_BD141RACXX_s_6_rg.sorted.bam	54.33	1.96	0.17	58cfa831e4b0c9d6adf6cd3c	TCGA-ET-A25M-01A-11D-A16N_120718_SN590_0170_BD141RACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25M-01A	8023D4C9-B56D-417A-9A52-D45B59C756ED	Primary Tumor	Illumina HiSeq	893b646b-2fc5-4163-905e-37bfeb036280	Thyroid	33.0	0C601625-ED21-47E5-BC3D-A0057D6A148F	7DE80DCB-BBFD-4D87-AD80-EE29258EFFD1	TCGA-ET-A25M-01A-11D-A16N-02	HG19_Broad_variant	TCGA-ET-A25M	TCGA-THCA		s12002	Harvard Medical School	Johns Hopkins	United States	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True
S13722.58cfa831e4b0c9d6adf6cdc0	58cfa831e4b0c9d6adf6cdc0	TCGA-FI-A2CY-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FI-A2CY-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_1_rg.sorted	TCGA-FI-A2CY-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_1_rg.sorted.bam	72.14		0.16	58cfa831e4b0c9d6adf6cdc0	TCGA-FI-A2CY-01A-11D-A17E_120511_SN1120_0140_AD12J0ACXX_s_1_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-FI-A2CY-01A	B9AB4AB9-BA9C-4A01-9F61-55C82B924936	Primary Tumor	Illumina HiSeq	d1004865-f030-4d10-90a0-3d6d105408a0	Uterus	60.0	047B688C-AA29-4A63-B555-9275AF4B0CEE	4BCC9DA0-4F58-4BB8-B660-D8591AD1CE18	TCGA-FI-A2CY-01A-11D-A17E-02	HG19_Broad_variant	TCGA-FI-A2CY	TCGA-UCEC		s5398	Harvard Medical School	Washington University	United States	NO			Mixed serous and endometrioid		A17E-02	True
S13722.58cfa831e4b0c9d6adf6cdab	58cfa831e4b0c9d6adf6cdab	TCGA-FE-A234-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FE-A234-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_2_rg.sorted	TCGA-FE-A234-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_2_rg.sorted.bam	101.34	2.14	0.18	58cfa831e4b0c9d6adf6cdab	TCGA-FE-A234-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A234-01A	E4C85BDD-7B7C-414F-9503-647D9B825915	Primary Tumor	Illumina HiSeq	f1eeb2ea-cc97-40b1-ac5b-fa027012fff2	Thyroid	26.0	8765B072-83E1-40B2-B1C9-15F38D799FC3	D4A41A96-02D5-455E-BB12-7225EBEA15A5	TCGA-FE-A234-01A-11D-A14U-02	HG19_Broad_variant	TCGA-FE-A234	TCGA-THCA		s12388	Harvard Medical School	Ohio State University	United States	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	True
S13722.58cfa832e4b0c9d6adf6cf3d	58cfa832e4b0c9d6adf6cf3d	TCGA-G9-6378-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_3_rg.sorted.filtered.	WGS	TCGA-G9-6378-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_3_rg.sorted	TCGA-G9-6378-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_3_rg.sorted.bam	245.4	1.9	0.13	58cfa832e4b0c9d6adf6cf3d	TCGA-G9-6378-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_3_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6378-01A	12F225D0-CBFF-44EB-9183-BACC7F33B090	Primary Tumor	Illumina HiSeq	cc75d8b4-ea9f-4b89-9c12-d370ba7a227f	Prostate	54.0	940BBB5C-7280-41ED-9332-47C2072AE072	CA3B6408-29B5-4DB1-A56D-7B47F966177D	TCGA-G9-6378-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6378	TCGA-PRAD		s3801	Harvard Medical School	Roswell Park	United States	NO	T2c		Prostate Adenocarcinoma Acinar Type		1784-02	True
S13722.58cfa832e4b0c9d6adf6cfb6	58cfa832e4b0c9d6adf6cfb6	TCGA-G9-6342-01A-11D-1957_130222_SN1222_0174_BC1RNEACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G9-6342-01A-11D-1957_130222_SN1222_0174_BC1RNEACXX_s_7_rg.sorted	TCGA-G9-6342-01A-11D-1957_130222_SN1222_0174_BC1RNEACXX_s_7_rg.sorted.bam	201.7	1.9	0.14	58cfa832e4b0c9d6adf6cfb6	TCGA-G9-6342-01A-11D-1957_130222_SN1222_0174_BC1RNEACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6342-01A	00E41E6A-9FE7-44F9-978B-7B05B179506A	Primary Tumor	Illumina HiSeq	2e8198a3-6874-4ea2-9d85-405122d87da4	Prostate	61.0	2C85548B-D1FD-4FC8-9908-60205A42E080	0C765D21-A6AE-4FE8-9B80-7DEBA8459E76	TCGA-G9-6342-01A-11D-1957-02	HG19_Broad_variant	TCGA-G9-6342	TCGA-PRAD		s3797	Harvard Medical School	Roswell Park	United States	NO	T3a		Prostate Adenocarcinoma Acinar Type		1957-02	True
S13722.58cfa832e4b0c9d6adf6cfea	58cfa832e4b0c9d6adf6cfea	TCGA-G9-6494-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_1_rg.sorted.filtered.	WGS	TCGA-G9-6494-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_1_rg.sorted	TCGA-G9-6494-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_1_rg.sorted.bam	129.4	1.9	0.13	58cfa832e4b0c9d6adf6cfea	TCGA-G9-6494-01A-11D-1784_130131_SN1120_0234_AD1PVUACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6494-01A	0C459149-0DFE-4206-B50B-DB79180EBB57	Primary Tumor	Illumina HiSeq	d55338b0-a49a-4c6e-ba7d-757df0a55dfe	Prostate	66.0	45DB5303-BBAB-4F8C-A2A2-9A9A9BFA2FD1	5BCBE988-68F6-48D0-8F2A-B34369A5FBB9	TCGA-G9-6494-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6494	TCGA-PRAD		s3620	Harvard Medical School	Roswell Park	United States	NO	T4	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True
S13722.58cfa832e4b0c9d6adf6d11f	58cfa832e4b0c9d6adf6d11f	TCGA-IR-A3LK-01A-12D-A20X_140417_SN590_0248_AC3EUFACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IR-A3LK-01A-12D-A20X_140417_SN590_0248_AC3EUFACXX_s_3_rg.sorted	TCGA-IR-A3LK-01A-12D-A20X_140417_SN590_0248_AC3EUFACXX_s_3_rg.sorted.bam	71.39		0.16	58cfa832e4b0c9d6adf6d11f	TCGA-IR-A3LK-01A-12D-A20X_140417_SN590_0248_AC3EUFACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LK-01A	B79558C5-1DB2-4B1E-A7B8-EFBD19AA855E	Primary Tumor	Illumina HiSeq	1c6981be-5fe3-4898-ba63-e0cd0eecc5e5	Cervix	69.0	DCA9FF1F-DD32-43DD-8FD4-446D014F5DB8	9E7C0BE8-042F-4B5F-BFE9-E993081589AD	TCGA-IR-A3LK-01A-12D-A20X-26	HG19_Broad_variant	TCGA-IR-A3LK	TCGA-CESC		s1376	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b2	N0	Cervical Squamous Cell Carcinoma		A20X-26	True
S13722.58cfa832e4b0c9d6adf6d190	58cfa832e4b0c9d6adf6d190	TCGA-IR-A3LH-01A-21D-A20X_140117_SN590_0246_BC37BDACXX_s_8_rg.sorted.filtered.	WGS	TCGA-IR-A3LH-01A-21D-A20X_140117_SN590_0246_BC37BDACXX_s_8_rg.sorted	TCGA-IR-A3LH-01A-21D-A20X_140117_SN590_0246_BC37BDACXX_s_8_rg.sorted.bam	62.48		0.15	58cfa832e4b0c9d6adf6d190	TCGA-IR-A3LH-01A-21D-A20X_140117_SN590_0246_BC37BDACXX_s_8_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LH-01A	F24ED9C0-92BB-4003-86D2-42AB26617A05	Primary Tumor	Illumina HiSeq	159f94e1-d4e4-45d7-9220-90578144802f	Cervix	49.0	D95E5389-DD55-4D55-AB01-6A770C66502F	7BDB76AA-01BA-48A8-A58A-29B118B8118A	TCGA-IR-A3LH-01A-21D-A20X-26	HG19_Broad_variant	TCGA-IR-A3LH	TCGA-CESC		s1535	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T2a1	N0	Cervical Squamous Cell Carcinoma		A20X-26	True
S13722.58cfa832e4b0c9d6adf6d19c	58cfa832e4b0c9d6adf6d19c	TCGA-HG-A2PA-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_4_rg.sorted.filtered.	WGS	TCGA-HG-A2PA-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_4_rg.sorted	TCGA-HG-A2PA-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_4_rg.sorted.bam	61.98		0.15	58cfa832e4b0c9d6adf6d19c	TCGA-HG-A2PA-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-HG-A2PA-01A	E2FF7CFD-A101-45B9-895F-26F403E7BDFB	Primary Tumor	Illumina HiSeq	2c605f98-0c77-45ff-bcea-2fcf6094ca2d	Cervix	38.0	235DBD13-5052-4E19-9C1C-A72A1A9A79CE	ECE06317-01F9-4EF2-ACE0-E9B18C7F4DE1	TCGA-HG-A2PA-01A-11D-A20X-26	HG19_Broad_variant	TCGA-HG-A2PA	TCGA-CESC		s1534	MD Anderson - Institute for Applied Cancer Science	Roswell Park	United States	NO	T1b2	N0	Cervical Squamous Cell Carcinoma		A20X-26	True
S13722.58cfa832e4b0c9d6adf6d19a	58cfa832e4b0c9d6adf6d19a	TCGA-IR-A3LC-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IR-A3LC-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_3_rg.sorted	TCGA-IR-A3LC-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_3_rg.sorted.bam	81.15		0.15	58cfa832e4b0c9d6adf6d19a	TCGA-IR-A3LC-01A-11D-A20X_140117_SN590_0246_BC37BDACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LC-01A	58BDCACE-0047-456E-A225-68953EDAFE5E	Primary Tumor	Illumina HiSeq	8b84ea0a-0512-427e-8456-2facdcd978b9	Cervix	40.0	AC6D15A0-67CF-42AA-97DC-BA50D0E9F409	47A900B4-52E8-448E-B092-EEE4E394A309	TCGA-IR-A3LC-01A-11D-A20X-26	HG19_Broad_variant	TCGA-IR-A3LC	TCGA-CESC		s1375	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b1	N0	Cervical Squamous Cell Carcinoma		A20X-26	True
S13722.58cfa832e4b0c9d6adf6d1f4	58cfa832e4b0c9d6adf6d1f4	TCGA-IG-A51D-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-IG-A51D-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_3_rg.sorted	TCGA-IG-A51D-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_3_rg.sorted.bam	23.75		0.16	58cfa832e4b0c9d6adf6d1f4	TCGA-IG-A51D-01A-11D-A267_131001_SN1120_0279_AC2DKPACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A51D-01A	F8DBAB24-B9F4-4B8A-BFEA-57856CCF6364	Primary Tumor	Illumina HiSeq	c422f0b8-8f83-4d33-b800-bab29faa7b7b	Esophagus	63.0	3889C9FE-3777-4B3D-9CF1-12135D4D7F7D	02AA44BC-DD51-4A76-B94E-FF273011E904	TCGA-IG-A51D-01A-11D-A267-26	HG19_Broad_variant	TCGA-IG-A51D	TCGA-ESCA		s1825	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T1	N1		Stage IIB	A267-26	True
S13722.58cfa832e4b0c9d6adf6d222	58cfa832e4b0c9d6adf6d222	TCGA-IR-A3LI-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_5_rg.sorted.filtered.	WGS	TCGA-IR-A3LI-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_5_rg.sorted	TCGA-IR-A3LI-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_5_rg.sorted.bam	19.9		0.16	58cfa832e4b0c9d6adf6d222	TCGA-IR-A3LI-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LI-01A	75BC22D8-738D-45F8-B6C0-C664F5FEF47C	Primary Tumor	Illumina HiSeq	3a9d3f81-919f-44e3-a9cc-813b4dcaf027	Cervix	48.0	EBFA4682-49C9-4AC1-8147-E3860D852D28	689630AD-8262-403B-9983-B4BAE99B8A45	TCGA-IR-A3LI-01A-11D-A20X-26	HG19_Broad_variant	TCGA-IR-A3LI	TCGA-CESC		s1210	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T2b	N1	Endocervical Type of Adenocarcinoma		A20X-26	True
S13722.58cfa832e4b0c9d6adf6d20e	58cfa832e4b0c9d6adf6d20e	TCGA-HT-7468-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HT-7468-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_5_rg.sorted	TCGA-HT-7468-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_5_rg.sorted.bam	188.0		0.13	58cfa832e4b0c9d6adf6d20e	TCGA-HT-7468-01A-11D-2022_130911_SN1222_0218_BC2A1NACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7468-01A	E6C55BA6-4C8A-4EA4-8DDE-74D01915DB02	Primary Tumor	Illumina HiSeq	e1855a2f-1904-41ee-ba33-a27e1c202d99	Brain	30.0	D2775F99-CC96-4C72-94FF-E3BA985DC151	143CEFE3-F477-4CDE-AEA6-CE0610835570	TCGA-HT-7468-01A-11D-2022-02	HG19_Broad_variant	TCGA-HT-7468	TCGA-LGG		s8759	Harvard Medical School	Case Western - St Joes	United States	NO			Oligodendroglioma		2022-02	True
S13722.58cfa832e4b0c9d6adf6d322	58cfa832e4b0c9d6adf6d322	TCGA-L5-A43C-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A43C-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_1_rg.sorted	TCGA-L5-A43C-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_1_rg.sorted.bam	21.33		0.16	58cfa832e4b0c9d6adf6d322	TCGA-L5-A43C-01A-11D-A248_121207_SN1222_0161_AC1HJ0ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A43C-01A	A935DAEB-1EFD-4113-A614-A5E4D446C72B	Primary Tumor	Illumina HiSeq	f5b917a1-f719-4ee6-b994-c4bc7dbbc159	Esophagus	81.0	2DD3A5ED-42EF-4CA1-AC40-B2F486F0395A	74016C2E-EEC8-4FE9-A297-A4E64D797DEE	TCGA-L5-A43C-01A-11D-A248-26	HG19_Broad_variant	TCGA-L5-A43C	TCGA-ESCA		s1646	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO					A248-26	True
S13722.58cfa832e4b0c9d6adf6d3ea	58cfa832e4b0c9d6adf6d3ea	TCGA-V4-A9EO-01A-12D-A40D_140808_SN590_0253_AC499NACXX_s_3_rg.sorted.filtered.	WGS	TCGA-V4-A9EO-01A-12D-A40D_140808_SN590_0253_AC499NACXX_s_3_rg.sorted	TCGA-V4-A9EO-01A-12D-A40D_140808_SN590_0253_AC499NACXX_s_3_rg.sorted.bam	16.22		0.17	58cfa832e4b0c9d6adf6d3ea	TCGA-V4-A9EO-01A-12D-A40D_140808_SN590_0253_AC499NACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EO-01A	BCB87378-9F43-45E4-BDF2-F6DFA6AC5B8C	Primary Tumor	Illumina HiSeq	e433357d-cafe-49f8-b481-e9b804bd4a06	Eye	74.0	C46DB8A8-DAF3-4E99-9307-E6C6CD8F79D5	B0A67E95-2ED2-43EB-9490-5F94BB8E21F4	TCGA-V4-A9EO-01A-12D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EO	TCGA-UVM		s240	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d1fa	58cfa832e4b0c9d6adf6d1fa	TCGA-GV-A3JW-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-GV-A3JW-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_7_rg.sorted	TCGA-GV-A3JW-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_7_rg.sorted.bam	45.77		0.15	58cfa832e4b0c9d6adf6d1fa	TCGA-GV-A3JW-01A-11D-A210_120912_SN1222_0149_BD1CW3ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3JW-01A	3D644EAF-82FC-4BC7-93B7-3E600E8C6511	Primary Tumor	Illumina HiSeq	586abfdd-f50a-4834-8143-3bda5638ea60	Bladder	74.0	B02C03B6-24AA-42D3-9310-741DE1EF0D30	D7EFF32B-E9EB-4891-93D7-4C3D10BE21EA	TCGA-GV-A3JW-01A-11D-A210-26	HG19_Broad_variant	TCGA-GV-A3JW	TCGA-BLCA		s2737	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO	T2	NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	True
S13722.58cfa832e4b0c9d6adf6d4be	58cfa832e4b0c9d6adf6d4be	TCGA-V4-A9F7-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-V4-A9F7-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_2_rg.sorted	TCGA-V4-A9F7-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_2_rg.sorted.bam	49.86		0.16	58cfa832e4b0c9d6adf6d4be	TCGA-V4-A9F7-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F7-01A	64422CC5-5E5B-4EF9-A9E2-214CEBF8DFBC	Primary Tumor	Illumina HiSeq	8388df36-e4c1-4450-bc87-acc118ce705e	Eye	78.0	44AD0268-6B48-4264-A1DD-58C2302224D7	07397855-A0D5-4287-A21B-5AB83A4E0DE0	TCGA-V4-A9F7-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F7	TCGA-UVM		s257	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0		Stage IIB	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d498	58cfa832e4b0c9d6adf6d498	TCGA-V4-A9EF-01A-21D-A40D_140725_SN590_0251_AC41YJACXX_s_4_rg.sorted.filtered.	WGS	TCGA-V4-A9EF-01A-21D-A40D_140725_SN590_0251_AC41YJACXX_s_4_rg.sorted	TCGA-V4-A9EF-01A-21D-A40D_140725_SN590_0251_AC41YJACXX_s_4_rg.sorted.bam	37.33		0.17	58cfa832e4b0c9d6adf6d498	TCGA-V4-A9EF-01A-21D-A40D_140725_SN590_0251_AC41YJACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EF-01A	A18D3BA3-E2F4-4144-9C25-2019CAD193F4	Primary Tumor	Illumina HiSeq	bf602ec4-fef9-41b6-9f28-a773493f4507	Eye	56.0	0966DF5C-5838-4E92-ADA6-304241CCAEF1	0CE78DDD-32D4-43DB-B7A4-FE7C3AD9563D	TCGA-V4-A9EF-01A-21D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EF	TCGA-UVM		s215	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4b	N0		Stage IIIB	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d56c	58cfa832e4b0c9d6adf6d56c	TCGA-V4-A9EY-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_2_rg.sorted.filtered.	WGS	TCGA-V4-A9EY-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_2_rg.sorted	TCGA-V4-A9EY-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_2_rg.sorted.bam	24.77		0.16	58cfa832e4b0c9d6adf6d56c	TCGA-V4-A9EY-01A-11D-A40D_140714_SN1440_0192_AC3RUUACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EY-01A	15D19CCC-52B8-41F6-B1C1-2CC55691AED5	Primary Tumor	Illumina HiSeq	27c8b2d4-9133-49cb-a86b-84553dcf1c8e	Eye	66.0	E8C4DEFB-7781-4B3D-B209-7D444A1A1BB5	FDFEA8DC-451B-4493-B7ED-DBF97D7C1D78	TCGA-V4-A9EY-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EY	TCGA-UVM		s218	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d4a2	58cfa832e4b0c9d6adf6d4a2	TCGA-V4-A9F8-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-V4-A9F8-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_3_rg.sorted	TCGA-V4-A9F8-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_3_rg.sorted.bam	54.24		0.17	58cfa832e4b0c9d6adf6d4a2	TCGA-V4-A9F8-01A-11D-A40D_140716_SN208_0519_BC5946ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F8-01A	64BD88BD-1D5A-4569-9F46-F668D448C336	Primary Tumor	Illumina HiSeq	05bff1f2-adb9-4252-892d-c86207753ca1	Eye	68.0	6B903079-A499-4AE3-B399-59276DCB9C70	5FABEAFA-9ADE-43AA-B4EB-979826FAE9BF	TCGA-V4-A9F8-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F8	TCGA-UVM		s252	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True
S13722.58cfa82fe4b0c9d6adf6b5da	58cfa82fe4b0c9d6adf6b5da	TCGA-35-4123-01A-01D-1103_110913_SN208_0238_BC008YACXX_s_6_rg.sorted.filtered.	WGS	TCGA-35-4123-01A-01D-1103_110913_SN208_0238_BC008YACXX_s_6_rg.sorted	TCGA-35-4123-01A-01D-1103_110913_SN208_0238_BC008YACXX_s_6_rg.sorted.bam	766.93	1.9	0.16	58cfa82fe4b0c9d6adf6b5da	TCGA-35-4123-01A-01D-1103_110913_SN208_0238_BC008YACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-35-4123-01A	6CF49CF0-DE4C-4C90-8358-EAE19C6206B0	Primary Tumor	Illumina HiSeq	c620a587-dd69-4a1c-81c9-5ae742181fbc	Lung	38.0	3AF63E86-157B-408C-9527-58A45107DDD2	D1765CB9-4A13-425F-8B2D-E632B656058B	TCGA-35-4123-01A-01D-1103-02	HG19_Broad_variant	TCGA-35-4123	TCGA-LUAD		s11335	Harvard Medical School	Cureline	Russia	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1103-02	True
S13722.58cfa82fe4b0c9d6adf6b5e4	58cfa82fe4b0c9d6adf6b5e4	TCGA-44-2661-01A-01D-1103_110913_SN208_0238_BC008YACXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-2661-01A-01D-1103_110913_SN208_0238_BC008YACXX_s_7_rg.sorted	TCGA-44-2661-01A-01D-1103_110913_SN208_0238_BC008YACXX_s_7_rg.sorted.bam	735.66	1.9	0.15	58cfa82fe4b0c9d6adf6b5e4	TCGA-44-2661-01A-01D-1103_110913_SN208_0238_BC008YACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-2661-01A	F3501466-CF32-4866-B5FB-E94DD32341BC	Primary Tumor	Illumina HiSeq	fbe0b7e0-45f4-4c61-9965-be52ae790251	Lung	69.0	48DD9724-8848-48C3-8628-7E78A24E3F2C	5F5307B5-02FF-4262-BB72-A215897B2EA7	TCGA-44-2661-01A-01D-1103-02	HG19_Broad_variant	TCGA-44-2661	TCGA-LUAD		s10650	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1103-02	True
S13722.58cfa82fe4b0c9d6adf6b617	58cfa82fe4b0c9d6adf6b617	TCGA-35-4122-01A-01D-1103_110804_SN208_0217_BC03EKABXX_s_3_rg.sorted.filtered.	WGS	TCGA-35-4122-01A-01D-1103_110804_SN208_0217_BC03EKABXX_s_3_rg.sorted	TCGA-35-4122-01A-01D-1103_110804_SN208_0217_BC03EKABXX_s_3_rg.sorted.bam	244.93	1.9	0.15	58cfa82fe4b0c9d6adf6b617	TCGA-35-4122-01A-01D-1103_110804_SN208_0217_BC03EKABXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-35-4122-01A	44ADF4CB-2829-4153-80FD-A8B7EE0E654A	Primary Tumor	Illumina HiSeq	3887aeb9-e6df-492e-ad08-f4037acba9aa	Lung	69.0	587F8383-3A48-49AF-8AC4-D86E6009C96B	DD8A0F54-0311-49FB-B270-ABF1AE9B56A5	TCGA-35-4122-01A-01D-1103-02	HG19_Broad_variant	TCGA-35-4122	TCGA-LUAD		s11445	Harvard Medical School	Cureline	Russia	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1103-02	True
S13722.58cfa82fe4b0c9d6adf6b77c	58cfa82fe4b0c9d6adf6b77c	TCGA-44-5645-01A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_5_rg.sorted.filtered.	WGS	TCGA-44-5645-01A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_5_rg.sorted	TCGA-44-5645-01A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_5_rg.sorted.bam	466.6	1.9	0.16	58cfa82fe4b0c9d6adf6b77c	TCGA-44-5645-01A-01D-1623_110804_SN208_0216_AD0CLLABXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-5645-01A	DDEACCCF-0953-4952-8A4E-C2617F2E7BCC	Primary Tumor	Illumina HiSeq	e1f13e42-abbc-4a28-91d2-65b2a95b0018	Lung	61.0	37A8D3A5-BAA0-427C-AB43-48AE4B93633B	A35054A5-9324-47AD-841E-E2ADCD97126D	TCGA-44-5645-01A-01D-1623-02	HG19_Broad_variant	TCGA-44-5645	TCGA-LUAD		s10993	Harvard Medical School	Christiana Healthcare	United States	NO	T1	NX	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1623-02	True
S13722.58cfa82fe4b0c9d6adf6b7d4	58cfa82fe4b0c9d6adf6b7d4	TCGA-44-3919-01A-02D-1103_110804_SN208_0217_BC03EKABXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-3919-01A-02D-1103_110804_SN208_0217_BC03EKABXX_s_7_rg.sorted	TCGA-44-3919-01A-02D-1103_110804_SN208_0217_BC03EKABXX_s_7_rg.sorted.bam	427.33	1.9	0.15	58cfa82fe4b0c9d6adf6b7d4	TCGA-44-3919-01A-02D-1103_110804_SN208_0217_BC03EKABXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-3919-01A	66ED89F6-8BA2-49D0-AF0F-4B6EBF2381BF	Primary Tumor	Illumina HiSeq	14d2cfc2-f4ac-4ab1-93d3-0e178305e26f	Lung	71.0	9DE8D353-3442-41D8-8BFE-A08C4975EACA	9C982400-B6C3-4D00-9981-BA06775FEF4F	TCGA-44-3919-01A-02D-1103-02	HG19_Broad_variant	TCGA-44-3919	TCGA-LUAD		s10994	Harvard Medical School	Christiana Healthcare	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1103-02	True
S13722.58cfa82fe4b0c9d6adf6b840	58cfa82fe4b0c9d6adf6b840	TCGA-A6-2679-01A-02D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2679-01A-02D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2679-01A-02D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	556.0	1.9	0.17	58cfa82fe4b0c9d6adf6b840	TCGA-A6-2679-01A-02D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2679-01A	0F74D992-00DA-4728-9564-086CA1B95921	Primary Tumor	Illumina HiSeq	6ba315a4-973a-47a1-b157-8f6ab62fdaef	Colorectal	73.0	1FCB9C83-18CB-42A4-8769-FDDB3541C95D	118D83B1-3464-40E3-8A77-270650CFED42	TCGA-A6-2679-01A-02D-1405-02	HG18	TCGA-A6-2679	TCGA-COAD		s13014	Harvard Medical School	Christiana Healthcare		NO	T3	N0	Colon Adenocarcinoma	Stage IIB	1405-02	True
S13722.58cfa82fe4b0c9d6adf6b842	58cfa82fe4b0c9d6adf6b842	TCGA-A6-2674-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2674-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2674-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	260.29	1.9	0.14	58cfa82fe4b0c9d6adf6b842	TCGA-A6-2674-01A-02D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2674-01A	57CDAA1C-4E94-4A28-AB3B-300C0457555F	Primary Tumor	Illumina HiSeq	92b3a16b-1a9e-47a3-9146-1a297c51c5a3	Colorectal	71.0	8ACA008C-F55A-420A-82C7-ACD2CCA77D85	9FDFC199-B878-4049-994E-B5CA384678FB	TCGA-A6-2674-01A-02D-1167-02	HG18	TCGA-A6-2674	TCGA-COAD		s13013	Harvard Medical School	Christiana Healthcare		NO	T3	N2	Colon Mucinous Adenocarcinoma	Stage IV	1167-02	True
S13722.58cfa82fe4b0c9d6adf6b8b8	58cfa82fe4b0c9d6adf6b8b8	TCGA-73-4675-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-73-4675-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole	TCGA-73-4675-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	482.2	1.9	0.16	58cfa82fe4b0c9d6adf6b8b8	TCGA-73-4675-01A-01D-1203-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-73-4675-01A	AE39E358-08D7-4367-AE68-82B469E791E4	Primary Tumor	Illumina HiSeq	14b3ad66-64c9-4b39-a34e-5cb29788735a	Lung	59.0	1F5FA8FD-1DE8-4456-8935-71B5A8B54BD2	356D01E0-DF80-40C6-BA06-8CD4EDFBD1EC	TCGA-73-4675-01A-01D-1203-02	GRCh37	TCGA-73-4675	TCGA-LUAD		s11013	Harvard Medical School	Roswell Park	United States	NO	T3	N1	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	True
S13722.58cfa82fe4b0c9d6adf6b898	58cfa82fe4b0c9d6adf6b898	TCGA-A6-2676-01A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_1.rg.sorted.filtered.	WGS	TCGA-A6-2676-01A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_1.rg.sorted	TCGA-A6-2676-01A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_1.rg.sorted.bam	296.29	1.9	0.17	58cfa82fe4b0c9d6adf6b898	TCGA-A6-2676-01A-01D-1167-02_101203_SN177_0125_B802RYABXX_s_1.rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2676-01A	89A6384E-1CEA-440B-9F17-D57CB0805174	Primary Tumor	Illumina HiSeq	c175a01b-eba5-4c4d-b786-fc9f54a2fa60	Colorectal	75.0	CBBD1187-E8F7-4E63-A8E2-3C19863E89F5	D02407DB-AECE-475A-AA3F-00653B1E7BEE	TCGA-A6-2676-01A-01D-1167-02	HG18_Broad_variant	TCGA-A6-2676	TCGA-COAD		s13022	Harvard Medical School	Christiana Healthcare		NO	T4	N0	Colon Adenocarcinoma	Stage IIB	1167-02	True
S13722.58cfa82fe4b0c9d6adf6b940	58cfa82fe4b0c9d6adf6b940	TCGA-A6-3808-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-3808-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-3808-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	236.0	1.9	0.14	58cfa82fe4b0c9d6adf6b940	TCGA-A6-3808-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-3808-01A	4F9775F2-B663-4DAF-AA9E-50915CAE9407	Primary Tumor	Illumina HiSeq	58504a37-4eb0-44ec-bb5d-83e955521de2	Colorectal	73.0	037BA047-2228-43DE-8DF8-32920A689ECA	2B2625B5-FBDD-41C3-9BB3-71566C5FBBA4	TCGA-A6-3808-01A-01D-1167-02	HG18	TCGA-A6-3808	TCGA-COAD		s13173	Harvard Medical School	Christiana Healthcare		NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	True
S13722.58cfa82fe4b0c9d6adf6b98e	58cfa82fe4b0c9d6adf6b98e	TCGA-50-5944-01A-11D-1751_111221_SN1120_0106_BD0M7HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-50-5944-01A-11D-1751_111221_SN1120_0106_BD0M7HACXX_s_1_rg.sorted	TCGA-50-5944-01A-11D-1751_111221_SN1120_0106_BD0M7HACXX_s_1_rg.sorted.bam	115.4	1.9	0.14	58cfa82fe4b0c9d6adf6b98e	TCGA-50-5944-01A-11D-1751_111221_SN1120_0106_BD0M7HACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-50-5944-01A	1C339545-C08A-4A77-B8E9-A7E49E53853F	Primary Tumor	Illumina HiSeq	c76f3861-5117-4ed7-9ca6-eecc10e949f3	Lung	69.0	BF8FDF82-62B4-4B5D-93E7-CE153576FE49	71CD46A8-30B0-4452-860D-3ED173C461A7	TCGA-50-5944-01A-11D-1751-02	HG19_Broad_variant	TCGA-50-5944	TCGA-LUAD		s11348	Harvard Medical School	University of Pittsburgh	United States	NO	T1	N0	Lung Acinar Adenocarcinoma	Stage IA	1751-02	True
S13722.58cfa830e4b0c9d6adf6bb0a	58cfa830e4b0c9d6adf6bb0a	TCGA-A5-A0R6-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_2_rg.sorted.filtered.	WGS	TCGA-A5-A0R6-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_2_rg.sorted	TCGA-A5-A0R6-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_2_rg.sorted.bam	55.64	2.08	0.15	58cfa830e4b0c9d6adf6bb0a	TCGA-A5-A0R6-01A-11D-A101_120403_SN1222_0093_AC0L7VACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0R6-01A	39609D3C-F5D3-4BC4-B356-1403C6DD1CB5	Primary Tumor	Illumina HiSeq	7485f99f-a7fe-456f-873d-eb1be9fa04b1	Uterus	64.0	836BD487-091B-4728-BCD7-8065E5B76465	FBE6A365-A19A-42F1-9198-63549F77CD9B	TCGA-A5-A0R6-01A-11D-A101-02	HG19_Broad_variant	TCGA-A5-A0R6	TCGA-UCEC		s4991	Harvard Medical School	Cedars Sinai		NO			Serous endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6bbfe	58cfa830e4b0c9d6adf6bbfe	TCGA-A6-2684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-2684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-2684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	463.6	1.9	0.15	58cfa830e4b0c9d6adf6bbfe	TCGA-A6-2684-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-2684-01A	49929108-023E-4D35-B26D-50AB4D3AE581	Primary Tumor	Illumina HiSeq	1d127721-dd08-4127-af3b-0dfd623ea7bf	Colorectal	75.0	73B6994E-C9BF-41A8-A455-17D7BE309A9F	5A35E547-72DB-4B4E-8459-1264D0845506	TCGA-A6-2684-01A-01D-1405-02	HG18	TCGA-A6-2684	TCGA-COAD		s13174	Harvard Medical School	Christiana Healthcare		NO	T2	N0	Colon Adenocarcinoma	Stage I	1405-02	True
S13722.58cfa830e4b0c9d6adf6bc26	58cfa830e4b0c9d6adf6bc26	TCGA-A6-3810-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-A6-3810-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole	TCGA-A6-3810-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	420.6	1.9	0.16	58cfa830e4b0c9d6adf6bc26	TCGA-A6-3810-01A-01D-1167-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-A6-3810-01A	B728E6E8-A0E4-496B-904C-6F07C12E901F	Primary Tumor	Illumina HiSeq	54687a8d-c693-4ae5-8451-4f4c80adca53	Colorectal	62.0	F2BD44D3-A53C-4A10-9AE1-A93E762F174C	AD4275F1-789D-471C-88DD-B6E76069D856	TCGA-A6-3810-01A-01D-1167-02	HG18	TCGA-A6-3810	TCGA-COAD		s13016	Harvard Medical School	Christiana Healthcare		NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1167-02	True
S13722.58cfa830e4b0c9d6adf6bcc4	58cfa830e4b0c9d6adf6bcc4	TCGA-AZ-4313-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4313-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4313-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	397.02	1.9	0.15	58cfa830e4b0c9d6adf6bcc4	TCGA-AZ-4313-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4313-01A	1FD75C4D-E74C-410C-A150-814722C6C1CC	Primary Tumor	Illumina HiSeq	b8e9093c-1570-45c6-8278-f686c276ee91	Colorectal	51.0	475F161C-2F7F-43A2-B187-DE6038752F39	F64D4985-D460-435C-8EC0-477D313A895A	TCGA-AZ-4313-01A-01D-1405-02	HG18	TCGA-AZ-4313	TCGA-COAD		s13212	Harvard Medical School	University of Pittsburgh		NO	T1	N0	Colon Adenocarcinoma	Stage I	1405-02	True
S13722.58cfa830e4b0c9d6adf6be18	58cfa830e4b0c9d6adf6be18	TCGA-AZ-4615-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-AZ-4615-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-AZ-4615-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	361.02	1.9	0.15	58cfa830e4b0c9d6adf6be18	TCGA-AZ-4615-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-AZ-4615-01A	BF69A4CE-EC7E-4752-A86D-DCC80E3C9A57	Primary Tumor	Illumina HiSeq	82dc215a-4234-4f8b-a4c0-50c8103dda6e	Colorectal	84.0	89811300-8202-4A82-8353-5B2B2B2ECFD4	90D11094-F492-4B05-81AB-E637AEC8F953	TCGA-AZ-4615-01A-01D-1405-02	HG18	TCGA-AZ-4615	TCGA-COAD		s13216	Harvard Medical School	University of Pittsburgh		NO	T3	N1	Colon Adenocarcinoma	Stage IIIB	1405-02	True
S13722.58cfa830e4b0c9d6adf6c02a	58cfa830e4b0c9d6adf6c02a	TCGA-AX-A0IW-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-AX-A0IW-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_3_rg.sorted	TCGA-AX-A0IW-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_3_rg.sorted.bam	112.67	1.79	0.14	58cfa830e4b0c9d6adf6c02a	TCGA-AX-A0IW-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AX-A0IW-01A	DB21FCCF-40CB-4235-A34D-336A03B8C8F4	Primary Tumor	Illumina HiSeq	26dfa889-ba7c-4cc0-8adc-59d5eb4e4026	Uterus	67.0	874A1C5C-229B-4BCE-B612-55EFF238D533	CFB35E8C-470B-4F9E-B7C1-63FCAA162F3C	TCGA-AX-A0IW-01A-11D-A043-02	HG19_Broad_variant	TCGA-AX-A0IW	TCGA-UCEC		s4422	Harvard Medical School	Gynecologic Oncology Group		NO			Serous endometrial adenocarcinoma		A043-02	True
S13722.58cfa831e4b0c9d6adf6c42c	58cfa831e4b0c9d6adf6c42c	TCGA-BT-A2LD-01A-12D-A210_120914_SN590_0180_BC19KDACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BT-A2LD-01A-12D-A210_120914_SN590_0180_BC19KDACXX_s_5_rg.sorted	TCGA-BT-A2LD-01A-12D-A210_120914_SN590_0180_BC19KDACXX_s_5_rg.sorted.bam	16.84		0.18	58cfa831e4b0c9d6adf6c42c	TCGA-BT-A2LD-01A-12D-A210_120914_SN590_0180_BC19KDACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A2LD-01A	9DD97821-7AFD-4982-8B1D-F14F845B79F7	Primary Tumor	Illumina HiSeq	205bfe9f-2bc9-4236-930c-a862874ad8e0	Bladder	78.0	AEB379D5-B157-4BCE-82C5-0CD0077DB01F	BF6A16B2-9DC9-4E9A-A810-2EBA7E9B56A1	TCGA-BT-A2LD-01A-12D-A210-26	HG19_Broad_variant	TCGA-BT-A2LD	TCGA-BLCA		s3089	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T3a	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A210-26	True
S13722.58cfa831e4b0c9d6adf6c4a6	58cfa831e4b0c9d6adf6c4a6	TCGA-BJ-A0ZJ-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A0ZJ-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_2_rg.sorted	TCGA-BJ-A0ZJ-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_2_rg.sorted.bam	59.26	1.9	0.16	58cfa831e4b0c9d6adf6c4a6	TCGA-BJ-A0ZJ-01A-11D-A10R_120616_SN1120_0153_AC0WMJACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A0ZJ-01A	8877B479-B62A-4794-B71E-418DE96DFF23	Primary Tumor	Illumina HiSeq	649e17cb-1adf-40a9-a837-4980acc1a108	Thyroid	36.0	C6D64D80-C8AA-494A-8C0E-8640BEEBDFC9	D54FCA2A-0B8E-4A33-8B52-3FBF0E47D799	TCGA-BJ-A0ZJ-01A-11D-A10R-02	HG19_Broad_variant	TCGA-BJ-A0ZJ	TCGA-THCA		s12629	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A10R-02	True
S13722.58cfa831e4b0c9d6adf6c46a	58cfa831e4b0c9d6adf6c46a	TCGA-CA-5256-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CA-5256-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CA-5256-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	806.02	1.9	0.13	58cfa831e4b0c9d6adf6c46a	TCGA-CA-5256-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	FEMALE	ASIAN		Colon Adenocarcinoma	Aligned reads	TCGA-CA-5256-01A	17633A60-E12B-4A7C-BD8A-C16341DDC606	Primary Tumor	Illumina HiSeq	21c81645-36f0-4e4a-8f23-b589998bcb76	Colorectal	54.0	D4D5DEB6-6CFB-4E25-9824-8F7DC8D5B451	A8F8AAD6-F8C5-4133-A651-454C047A19D0	TCGA-CA-5256-01A-01D-1405-02	HG18	TCGA-CA-5256	TCGA-COAD		s13544	Harvard Medical School	ILSbio		NO	T3	N0	Colon Adenocarcinoma	Stage IIA	1405-02	True
S13722.58cfa831e4b0c9d6adf6c524	58cfa831e4b0c9d6adf6c524	TCGA-CM-4744-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.filtered.	WGS	TCGA-CM-4744-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole	TCGA-CM-4744-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	471.0	1.9	0.14	58cfa831e4b0c9d6adf6c524	TCGA-CM-4744-01A-01D-1405-02_IlluminaHiSeq-DNASeq_whole.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Colon Adenocarcinoma	Aligned reads	TCGA-CM-4744-01A	CC15469C-7BAD-4E86-9DA3-AE0C72E9D380	Primary Tumor	Illumina HiSeq	e1403b52-6792-4d08-acad-95659ceeca82	Colorectal	69.0	A545FB9A-C386-4A80-9A25-660DC4F62904	6D073A6F-FB7B-4ED2-BD24-5233E019D64A	TCGA-CM-4744-01A-01D-1405-02	HG18	TCGA-CM-4744	TCGA-COAD		s13689	Harvard Medical School	MSKCC		NO	T2	N0	Colon Adenocarcinoma	Stage I	1405-02	True
S13722.58cfa831e4b0c9d6adf6cda9	58cfa831e4b0c9d6adf6cda9	TCGA-FG-7636-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FG-7636-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_3_rg.sorted	TCGA-FG-7636-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_3_rg.sorted.bam	103.7		0.15	58cfa831e4b0c9d6adf6cda9	TCGA-FG-7636-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FG-7636-01A	B342E980-8383-4F1B-BF57-4098C37A536C	Primary Tumor	Illumina HiSeq	336bd48f-3c20-4a2f-a2ef-38bb94e30e11	Brain	48.0	BF70C0A6-CA2D-4355-B5BA-738094382E28	CE49A704-BECD-4A35-978B-4E21572CC5B2	TCGA-FG-7636-01A-11D-2088-02	HG19_Broad_variant	TCGA-FG-7636	TCGA-LGG		s8573	Harvard Medical School	Case Western	United States	NO			Astrocytoma		2088-02	False
S13722.58cfa831e4b0c9d6adf6cd65	58cfa831e4b0c9d6adf6cd65	TCGA-FE-A232-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_5_rg.sorted.filtered.	WGS	TCGA-FE-A232-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_5_rg.sorted	TCGA-FE-A232-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_5_rg.sorted.bam	72.56	2.05	0.18	58cfa831e4b0c9d6adf6cd65	TCGA-FE-A232-01A-11D-A14U_120629_SN1222_0120_AC0WKWACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A232-01A	5EB0D577-223B-4409-89D1-5C5D196AFFC3	Primary Tumor	Illumina HiSeq	ca8aaa05-1546-46a2-aee9-1ad97cadf087	Thyroid	44.0	213BE6EE-1E61-4FA0-9B73-66B696086397	AD42DF5B-2665-4CA1-8049-943F684B6BFD	TCGA-FE-A232-01A-11D-A14U-02	HG19_Broad_variant	TCGA-FE-A232	TCGA-THCA		s12530	Harvard Medical School	Ohio State University	United States	NO	T3	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	True
S13722.58cfa832e4b0c9d6adf6ce2a	58cfa832e4b0c9d6adf6ce2a	TCGA-FN-7833-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_4_rg.sorted.filtered.	WGS	TCGA-FN-7833-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_4_rg.sorted	TCGA-FN-7833-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_4_rg.sorted.bam	141.7		0.14	58cfa832e4b0c9d6adf6ce2a	TCGA-FN-7833-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-FN-7833-01A	5B9D7565-A933-449D-8FFA-EC5F82DB2E77	Primary Tumor	Illumina HiSeq	91f0d100-c921-4319-9d82-98819189b525	Brain	25.0	CF2E4A0A-59C5-41DA-9F24-DE83EEB856E5	1C69F8E8-7D70-4BD1-8B42-7E93DC23DA7B	TCGA-FN-7833-01A-11D-2088-02	HG19_Broad_variant	TCGA-FN-7833	TCGA-LGG		s8366	Harvard Medical School	International Genomics Consortium	United States	NO			Oligoastrocytoma		2088-02	False
S13722.58cfa832e4b0c9d6adf6d2a8	58cfa832e4b0c9d6adf6d2a8	TCGA-HT-7604-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HT-7604-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_6_rg.sorted	TCGA-HT-7604-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_6_rg.sorted.bam	175.0		0.13	58cfa832e4b0c9d6adf6d2a8	TCGA-HT-7604-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_6_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7604-01A	019C5DE9-74FD-48B7-95A3-227532E16C5A	Primary Tumor	Illumina HiSeq	b3d0b563-b12d-4872-9a0c-f795ca13842f	Brain	50.0	9CA3488A-91F8-4EB2-8B03-24E8629757E1	31412731-7A51-4E73-BFC4-0098275D633B	TCGA-HT-7604-01A-11D-2088-02	HG19_Broad_variant	TCGA-HT-7604	TCGA-LGG		s8575	Harvard Medical School	Case Western - St Joes	United States	NO			Astrocytoma		2088-02	False
S13722.58cfa832e4b0c9d6adf6d234	58cfa832e4b0c9d6adf6d234	TCGA-JX-A3Q8-01A-11D-A245_140206_SN1222_0239_BC2RAKACXX_s_3_rg.sorted.filtered.	WGS	TCGA-JX-A3Q8-01A-11D-A245_140206_SN1222_0239_BC2RAKACXX_s_3_rg.sorted	TCGA-JX-A3Q8-01A-11D-A245_140206_SN1222_0239_BC2RAKACXX_s_3_rg.sorted.bam	63.47		0.14	58cfa832e4b0c9d6adf6d234	TCGA-JX-A3Q8-01A-11D-A245_140206_SN1222_0239_BC2RAKACXX_s_3_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-JX-A3Q8-01A	34629EB8-0C5E-4910-8E13-BF7D6A1E337F	Primary Tumor	Illumina HiSeq	e8f02d77-0077-4817-a34b-ab4ddd64bbd5	Cervix	40.0	28954012-3732-40B0-8EA7-F48CBEEF4105	52CB86FE-6EFF-4FF4-BC53-FD82E04854FB	TCGA-JX-A3Q8-01A-11D-A245-26	HG19_Broad_variant	TCGA-JX-A3Q8	TCGA-CESC		s1380	MD Anderson - Institute for Applied Cancer Science	Washington University	United States	NO	T1b1	N0	Endocervical Type of Adenocarcinoma		A245-26	True
S13722.58cfa832e4b0c9d6adf6d28b	58cfa832e4b0c9d6adf6d28b	TCGA-HT-7601-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_5_rg.sorted.filtered.	WGS	TCGA-HT-7601-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_5_rg.sorted	TCGA-HT-7601-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_5_rg.sorted.bam	56.0		0.15	58cfa832e4b0c9d6adf6d28b	TCGA-HT-7601-01A-11D-2088_130923_SN1222_0220_BC2DUUACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HT-7601-01A	E7FDF164-A85D-4FF5-9676-D2215CA35403	Primary Tumor	Illumina HiSeq	5faa261d-a169-4ab5-a52b-de3b50c46299	Brain	30.0	7F6B5679-49E1-498D-BD1F-A757CD7DB4CC	5F766AF5-08F5-4E10-AAED-4B582275CFC1	TCGA-HT-7601-01A-11D-2088-02	HG19_Broad_variant	TCGA-HT-7601	TCGA-LGG		s8153	Harvard Medical School	Case Western - St Joes	United States	NO			Astrocytoma		2088-02	False
S13722.58cfa832e4b0c9d6adf6d3f0	58cfa832e4b0c9d6adf6d3f0	TCGA-V4-A9ED-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_2_rg.sorted.filtered.	WGS	TCGA-V4-A9ED-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_2_rg.sorted	TCGA-V4-A9ED-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_2_rg.sorted.bam	53.75		0.17	58cfa832e4b0c9d6adf6d3f0	TCGA-V4-A9ED-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9ED-01A	367869F9-BBE7-4E57-A16F-F2B63F2DE697	Primary Tumor	Illumina HiSeq	db951476-e1a5-4731-8c40-dbe710922b60	Eye	45.0	F1A146CE-B2C6-4CD5-9153-F640D38ABAF1	8CDB01C8-C2D9-40DB-84EE-00B50B9EC314	TCGA-V4-A9ED-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9ED	TCGA-UVM		s220	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3b	N0		Stage IIIA	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d3d7	58cfa832e4b0c9d6adf6d3d7	TCGA-V4-A9EJ-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_7_rg.sorted.filtered.	WGS	TCGA-V4-A9EJ-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_7_rg.sorted	TCGA-V4-A9EJ-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_7_rg.sorted.bam	36.7		0.17	58cfa832e4b0c9d6adf6d3d7	TCGA-V4-A9EJ-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EJ-01A	D9CCBA9B-6BF0-44D9-8097-A97AB747F0BD	Primary Tumor	Illumina HiSeq	9a75e8fd-7cbd-4d0f-a91b-22e52e02c00d	Eye	38.0	6D2FBFD2-E1BF-483E-B0A0-A308F93871D4	42B46C86-61F4-4C2E-9EC3-0ED0113F3EC3	TCGA-V4-A9EJ-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EJ	TCGA-UVM		s206	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0		Stage IIB	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d400	58cfa832e4b0c9d6adf6d400	TCGA-V4-A9EK-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_8_rg.sorted.filtered.	WGS	TCGA-V4-A9EK-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_8_rg.sorted	TCGA-V4-A9EK-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_8_rg.sorted.bam	48.23		0.16	58cfa832e4b0c9d6adf6d400	TCGA-V4-A9EK-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_8_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EK-01A	4464418C-EC35-4826-B3D5-152AC2A27A04	Primary Tumor	Illumina HiSeq	9f84d9e1-572c-43b9-8fa8-695decf3b44e	Eye	37.0	9F324851-EAAE-41B8-BB0E-5D5CEB9E5B23	01AA5AFA-5877-45CA-98DB-9547B99B30C5	TCGA-V4-A9EK-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EK	TCGA-UVM		s234	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0		Stage IIB	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d47f	58cfa832e4b0c9d6adf6d47f	TCGA-V4-A9EC-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_1_rg.sorted.filtered.	WGS	TCGA-V4-A9EC-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_1_rg.sorted	TCGA-V4-A9EC-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_1_rg.sorted.bam	44.61		0.16	58cfa832e4b0c9d6adf6d47f	TCGA-V4-A9EC-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EC-01A	EEAB0529-31E6-4EDB-BD2C-A21F2A169381	Primary Tumor	Illumina HiSeq	b19262ce-546a-4f20-b2c6-542d12745c33	Eye	75.0	3234E814-AD34-48F0-AEBD-19E1A694ED8E	3ED594C4-5AF5-4461-838D-367758D3BA55	TCGA-V4-A9EC-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EC	TCGA-UVM		s232	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0		Stage IIB	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d4f4	58cfa832e4b0c9d6adf6d4f4	TCGA-V3-A9ZX-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_2_rg.sorted.filtered.	WGS	TCGA-V3-A9ZX-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_2_rg.sorted	TCGA-V3-A9ZX-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_2_rg.sorted.bam	47.71		0.15	58cfa832e4b0c9d6adf6d4f4	TCGA-V3-A9ZX-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V3-A9ZX-01A	5019E7F1-DB46-4A07-9E7B-B6E5D1481B84	Primary Tumor	Illumina HiSeq	ad32c24c-f4fa-4356-95a8-15d394368122	Eye	56.0	A2DFEBBB-9A38-4CC2-A3F3-857C2A70DCF4	314EE286-7E1A-4CF8-A39D-D12E23C6DAAB	TCGA-V3-A9ZX-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V3-A9ZX	TCGA-UVM		s195	MD Anderson - Institute for Applied Cancer Science	Cleveland Clinic Foundation	United States	NO	T2b	NX		Stage IIB	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d4f6	58cfa832e4b0c9d6adf6d4f6	TCGA-L5-A4OI-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-L5-A4OI-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_1_rg.sorted	TCGA-L5-A4OI-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_1_rg.sorted.bam	40.07		0.16	58cfa832e4b0c9d6adf6d4f6	TCGA-L5-A4OI-01A-11D-A267_131018_SN590_0240_AC2MW5ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE		Esophageal Carcinoma	Aligned reads	TCGA-L5-A4OI-01A	CB2AF13B-CBED-4657-8FD4-FED8DB375CBA	Primary Tumor	Illumina HiSeq	61f0c88a-c61d-400f-b8cf-b9cacd5fcada	Esophagus	79.0	1B1CBB34-DA71-4441-B1A1-C936E8F04C73	8D5A0D62-D9C1-46D1-9B81-685293B45E6B	TCGA-L5-A4OI-01A-11D-A267-26	HG19_Broad_variant	TCGA-L5-A4OI	TCGA-ESCA		s1924	MD Anderson - Institute for Applied Cancer Science	University of Michigan	United States	NO	T3	N3		Stage IIIC	A267-26	True
S13722.58cfa832e4b0c9d6adf6d401	58cfa832e4b0c9d6adf6d401	TCGA-V4-A9EH-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_5_rg.sorted.filtered.	WGS	TCGA-V4-A9EH-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_5_rg.sorted	TCGA-V4-A9EH-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_5_rg.sorted.bam	32.48		0.17	58cfa832e4b0c9d6adf6d401	TCGA-V4-A9EH-01A-11D-A40D_140725_SN590_0251_AC41YJACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EH-01A	5E54122F-1C4D-45CC-8842-CD1C1DF0EED8	Primary Tumor	Illumina HiSeq	f23ae536-eb5e-4d13-baf2-94a4eb03d083	Eye	53.0	A320EAC2-C0FB-44D0-9849-DD541C2428E1	AC2BA0CC-C007-44BF-8C99-4C88D55C022E	TCGA-V4-A9EH-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EH	TCGA-UVM		s222	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4c	N0		Stage IIIB	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d582	58cfa832e4b0c9d6adf6d582	TCGA-V4-A9EA-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_8_rg.sorted.filtered.	WGS	TCGA-V4-A9EA-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_8_rg.sorted	TCGA-V4-A9EA-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_8_rg.sorted.bam	33.08		0.17	58cfa832e4b0c9d6adf6d582	TCGA-V4-A9EA-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EA-01A	A9FE64A9-6D22-4E9F-96F3-F16AF7D298F8	Primary Tumor	Illumina HiSeq	35b1a08b-2b90-4f04-887c-7e95542f287e	Eye	66.0	1A18A8C2-C00F-42B2-B5C6-3AAB27BCE06D	10EEDA0C-C4C3-4F47-A3AF-599FDFCD62DF	TCGA-V4-A9EA-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EA	TCGA-UVM		s188	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d58a	58cfa832e4b0c9d6adf6d58a	TCGA-V4-A9E9-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_7_rg.sorted.filtered.	WGS	TCGA-V4-A9E9-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_7_rg.sorted	TCGA-V4-A9E9-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_7_rg.sorted.bam	31.06		0.16	58cfa832e4b0c9d6adf6d58a	TCGA-V4-A9E9-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9E9-01A	418152BD-7D33-4F0A-B890-2356B30D6F44	Primary Tumor	Illumina HiSeq	d8293c54-78cb-49a0-a69f-f36723632ddd	Eye	50.0	5CB8105A-6D8B-441B-A8F7-89308DD4FC92	3782E96A-456F-4747-B75B-A48597EDFD90	TCGA-V4-A9E9-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9E9	TCGA-UVM		s189	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d590	58cfa832e4b0c9d6adf6d590	TCGA-V3-A9ZY-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_3_rg.sorted.filtered.	WGS	TCGA-V3-A9ZY-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_3_rg.sorted	TCGA-V3-A9ZY-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_3_rg.sorted.bam	50.6		0.15	58cfa832e4b0c9d6adf6d590	TCGA-V3-A9ZY-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V3-A9ZY-01A	2112A42A-9B85-475A-A31B-4CE7751CDEB9	Primary Tumor	Illumina HiSeq	00a09c4d-5a88-4562-b9f3-e397798bdc18	Eye	54.0	E835BB77-E3EE-41B0-B8E0-D39E966F91A7	CD97490D-738A-48A2-B014-F9DB48DE45FA	TCGA-V3-A9ZY-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V3-A9ZY	TCGA-UVM		s192	MD Anderson - Institute for Applied Cancer Science	Cleveland Clinic Foundation	United States	NO	T3a	NX		Stage IIB	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d6a6	58cfa832e4b0c9d6adf6d6a6	TCGA-V4-A9E5-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_4_rg.sorted.filtered.	WGS	TCGA-V4-A9E5-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_4_rg.sorted	TCGA-V4-A9E5-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_4_rg.sorted.bam	30.36		0.16	58cfa832e4b0c9d6adf6d6a6	TCGA-V4-A9E5-01A-11D-A40D_140715_SN590_0249_AC3M6CACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9E5-01A	029CC59C-60DF-4411-A044-3A2EEEE7B110	Primary Tumor	Illumina HiSeq	6d4c51c2-0829-4ab2-9c4e-0a4653d8b744	Eye	51.0	9FD9F385-A009-44AE-836F-F18BAD96628F	CE4927D1-2A65-4BEF-98E5-EDD02A341820	TCGA-V4-A9E5-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9E5	TCGA-UVM		s190	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4b	N0		Stage IIIB	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d61a	58cfa832e4b0c9d6adf6d61a	TCGA-LN-A49X-01A-31D-A267_131018_SN590_0241_BC30HBACXX_s_3_rg.sorted.filtered.	WGS	TCGA-LN-A49X-01A-31D-A267_131018_SN590_0241_BC30HBACXX_s_3_rg.sorted	TCGA-LN-A49X-01A-31D-A267_131018_SN590_0241_BC30HBACXX_s_3_rg.sorted.bam	16.61		0.16	58cfa832e4b0c9d6adf6d61a	TCGA-LN-A49X-01A-31D-A267_131018_SN590_0241_BC30HBACXX_s_3_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-LN-A49X-01A	B05AEFC4-2D61-44B6-9451-E660D10D8A79	Primary Tumor	Illumina HiSeq	e3d2b395-b1fa-4edd-86a9-72ca75792159	Esophagus	44.0	F67F4ACC-E1DC-41F5-AF25-F4C03856B1AC	92F976C9-1D13-4347-ADDB-6C8F4C2E078F	TCGA-LN-A49X-01A-31D-A267-26	HG19_Broad_variant	TCGA-LN-A49X	TCGA-ESCA		s1683	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T3	N0		Stage IIA	A267-26	True
S13722.58cfa82fe4b0c9d6adf6b7fc	58cfa82fe4b0c9d6adf6b7fc	TCGA-38-6178-01A-11D-1751_120301_SN208_0270_AD0KLRACXX_s_3_rg.sorted.filtered.	WGS	TCGA-38-6178-01A-11D-1751_120301_SN208_0270_AD0KLRACXX_s_3_rg.sorted	TCGA-38-6178-01A-11D-1751_120301_SN208_0270_AD0KLRACXX_s_3_rg.sorted.bam	240.4	1.9	0.14	58cfa82fe4b0c9d6adf6b7fc	TCGA-38-6178-01A-11D-1751_120301_SN208_0270_AD0KLRACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-38-6178-01A	EDF80622-AEA2-4B50-BB69-691D6708AA83	Primary Tumor	Illumina HiSeq	f309d501-6d91-40ce-839c-bef9a434bae1	Lung	70.0	81FB5FA9-D901-4FAA-B909-376B8676D2BC	DE9A3263-6ACD-4BBB-9F91-D4E7FCBEFA04	TCGA-38-6178-01A-11D-1751-02	HG19_Broad_variant	TCGA-38-6178	TCGA-LUAD		s11119	Harvard Medical School	UNC	United States	NO	T2b	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1751-02	True
S13722.58cfa82fe4b0c9d6adf6b756	58cfa82fe4b0c9d6adf6b756	TCGA-91-6835-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_5_rg.sorted.filtered.	WGS	TCGA-91-6835-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_5_rg.sorted	TCGA-91-6835-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_5_rg.sorted.bam	328.7	1.9	0.14	58cfa82fe4b0c9d6adf6b756	TCGA-91-6835-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-91-6835-01A	2F09479F-87FC-4C34-8E2C-333E970A3681	Primary Tumor	Illumina HiSeq	8c5e1a0f-e9a8-4ce4-b066-97b2040c5327	Lung	81.0	EFD3F14F-F785-4AEC-9EFD-6DD8E9C41EBA	A4DC40A6-EE0F-4637-937F-406F5FC8579F	TCGA-91-6835-01A-11D-1853-02	HG19_Broad_variant	TCGA-91-6835	TCGA-LUAD		s10913	Harvard Medical School	ABS - IUPUI	United States	NO	T1	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1853-02	True
S13722.58cfa82fe4b0c9d6adf6b9e2	58cfa82fe4b0c9d6adf6b9e2	TCGA-64-5815-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_3_rg.sorted.filtered.	WGS	TCGA-64-5815-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_3_rg.sorted	TCGA-64-5815-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_3_rg.sorted.bam	132.7	1.9	0.14	58cfa82fe4b0c9d6adf6b9e2	TCGA-64-5815-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5815-01A	A65700C2-E58C-4FD4-AEB1-5686B8F4D212	Primary Tumor	Illumina HiSeq	d64bfa4e-ae37-494a-aabe-6787ac58054a	Lung	74.0	4420AAE3-3F44-4852-974D-74F155B99FE4	7DC45930-978E-42B5-8ECB-942F3C6DA727	TCGA-64-5815-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5815	TCGA-LUAD		s11460	Harvard Medical School	Fox Chase	United States	NO	T2	N1	Lung Adenocarcinoma Mixed Subtype	Stage IIB	1623-02	True
S13722.58cfa830e4b0c9d6adf6bd86	58cfa830e4b0c9d6adf6bd86	TCGA-BG-A0LX-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BG-A0LX-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_7_rg.sorted	TCGA-BG-A0LX-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_7_rg.sorted.bam	65.42	2.11	0.15	58cfa830e4b0c9d6adf6bd86	TCGA-BG-A0LX-01A-11D-A043_120214_SN590_0138_AC0E8HACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0LX-01A	AC1D3946-FE6C-4BD8-B02C-638799CB0F67	Primary Tumor	Illumina HiSeq	182220ca-d437-40a2-adeb-d4cb1ce2f284	Uterus	57.0	99CDF3A0-90DC-4992-B75A-11DD41928D43	B294F25A-93D9-49A6-8FD3-6D2B0BBEF27C	TCGA-BG-A0LX-01A-11D-A043-02	HG19_Broad_variant	TCGA-BG-A0LX	TCGA-UCEC		s5218	Harvard Medical School	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa830e4b0c9d6adf6bdd6	58cfa830e4b0c9d6adf6bdd6	TCGA-BG-A0MC-01A-21D-A043_120530_SN1222_0110_AC0VLAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A0MC-01A-21D-A043_120530_SN1222_0110_AC0VLAACXX_s_1_rg.sorted	TCGA-BG-A0MC-01A-21D-A043_120530_SN1222_0110_AC0VLAACXX_s_1_rg.sorted.bam	84.24	2.08	0.16	58cfa830e4b0c9d6adf6bdd6	TCGA-BG-A0MC-01A-21D-A043_120530_SN1222_0110_AC0VLAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MC-01A	884FD57D-BD8E-40E7-82F6-0BA1C71101A9	Primary Tumor	Illumina HiSeq	db9c9c51-2c42-4a56-a87d-9c01038c4e6f	Uterus	74.0	46B48BF8-346B-4F25-916E-26A3CDDFA00D	9376C8CD-BD9D-4576-BBE3-7D771914AFA3	TCGA-BG-A0MC-01A-21D-A043-02	HG19_Broad_variant	TCGA-BG-A0MC	TCGA-UCEC		s4601	Harvard Medical School	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa830e4b0c9d6adf6bec7	58cfa830e4b0c9d6adf6bec7	TCGA-AP-A0LJ-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-AP-A0LJ-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_7_rg.sorted	TCGA-AP-A0LJ-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_7_rg.sorted.bam	83.32	2.09	0.15	58cfa830e4b0c9d6adf6bec7	TCGA-AP-A0LJ-01A-11D-A043_120324_SN1120_0127_BC0L80ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LJ-01A	B4A520AE-F259-48C8-823E-C10B9B8A133A	Primary Tumor	Illumina HiSeq	c3705d55-9194-4d83-9162-41aae551e016	Uterus	42.0	BE3ED392-4D9F-4EAF-8A56-D251846DF4DA	2A88E054-E64F-4C5F-97F0-53F95D64FC04	TCGA-AP-A0LJ-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LJ	TCGA-UCEC		s4996	Harvard Medical School	MSKCC		NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa830e4b0c9d6adf6bef8	58cfa830e4b0c9d6adf6bef8	TCGA-BJ-A28W-01A-11D-A16N_120805_SN208_0421_AC11HPACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A28W-01A-11D-A16N_120805_SN208_0421_AC11HPACXX_s_2_rg.sorted	TCGA-BJ-A28W-01A-11D-A16N_120805_SN208_0421_AC11HPACXX_s_2_rg.sorted.bam	59.66	1.88	0.17	58cfa830e4b0c9d6adf6bef8	TCGA-BJ-A28W-01A-11D-A16N_120805_SN208_0421_AC11HPACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A28W-01A	A6D37F61-BECA-46EA-A59A-62257475AC77	Primary Tumor	Illumina HiSeq	32effbdc-7d3b-4ad8-9245-1a253cbe1ff3	Thyroid	32.0	32AEF736-82A4-4813-A272-86EF160E7D56	229AD821-4BB0-4046-B5E6-6193005D3C8A	TCGA-BJ-A28W-01A-11D-A16N-02	HG19_Broad_variant	TCGA-BJ-A28W	TCGA-THCA		s12507	Harvard Medical School	University of Pittsburgh	United States	NO	T2	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True
S13722.58cfa830e4b0c9d6adf6bf60	58cfa830e4b0c9d6adf6bf60	TCGA-BR-4357-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-4357-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_5_rg.sorted	TCGA-BR-4357-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_5_rg.sorted.bam	197.2	1.9	0.16	58cfa830e4b0c9d6adf6bf60	TCGA-BR-4357-01A-01D-1154_130815_VM001_0001_VMR0001CXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4357-01A	BEC83DFF-2BBA-4467-92AA-5DC3DB9E0EAF	Primary Tumor	Illumina HiSeq	4bc9f55b-1edb-49c9-be1a-1d00a108b99b	Stomach	58.0	81C87C27-47C7-4DC7-BF92-E0037433DF30	93F60FA6-0D34-441E-8F61-80306E10D046	TCGA-BR-4357-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4357	TCGA-STAD		s15301	Harvard Medical School	Asterand	Russia	NO	T3	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1154-02	True
S13722.58cfa830e4b0c9d6adf6bf14	58cfa830e4b0c9d6adf6bf14	TCGA-BR-4267-01A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-4267-01A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_3_rg.sorted	TCGA-BR-4267-01A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_3_rg.sorted.bam	265.9	1.9	0.13	58cfa830e4b0c9d6adf6bf14	TCGA-BR-4267-01A-01D-1128_120805_SN1120_0181_AD16WCACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4267-01A	0D0F0200-25B8-483B-B04A-82A7833B4D30	Primary Tumor	Illumina HiSeq	cd48e485-3a3f-4eec-92e7-f1c52c0866f1	Stomach	51.0	32D28ED3-2E33-4D83-8DE6-82E156B33211	F0DB5AF5-091F-4CDC-9917-BEFD658BF454	TCGA-BR-4267-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4267	TCGA-STAD		s15044	Harvard Medical School	Asterand		NO	T2a	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1128-02	True
S13722.58cfa830e4b0c9d6adf6c1fa	58cfa830e4b0c9d6adf6c1fa	TCGA-BA-5559-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_6_rg.sorted.filtered.	WGS	TCGA-BA-5559-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_6_rg.sorted	TCGA-BA-5559-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_6_rg.sorted.bam	476.7	1.9	0.16	58cfa830e4b0c9d6adf6c1fa	TCGA-BA-5559-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5559-01A	17B17D91-C3DF-4B89-9C10-4DB069AFF656	Primary Tumor	Illumina HiSeq	a6749339-8b87-4219-84dd-8045857cbe79	Head and Neck	71.0	FBEA64F9-B46B-4AF1-BFB2-1791D93977B6	61532C84-EDD9-492D-AF89-99086F87381E	TCGA-BA-5559-01A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5559	TCGA-HNSC		s16320	Harvard Medical School	UNC		NO	TX	NX	Head and Neck Squamous Cell Carcinoma		1509-02	True
S13722.58cfa830e4b0c9d6adf6c224	58cfa830e4b0c9d6adf6c224	TCGA-C5-A2LS-01A-22D-A232_140124_SN1120_0291_AC2PHAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-C5-A2LS-01A-22D-A232_140124_SN1120_0291_AC2PHAACXX_s_1_rg.sorted	TCGA-C5-A2LS-01A-22D-A232_140124_SN1120_0291_AC2PHAACXX_s_1_rg.sorted.bam	49.75		0.15	58cfa830e4b0c9d6adf6c224	TCGA-C5-A2LS-01A-22D-A232_140124_SN1120_0291_AC2PHAACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-C5-A2LS-01A	185E1520-92EE-4AF5-AF15-FBEEFB352C99	Primary Tumor	Illumina HiSeq	3c012d75-0d17-4b4d-834f-cd4767f6b023	Cervix	37.0	79248694-77E1-4FBE-8C94-64A308FC982D	DE7180EF-3E7E-43D5-8ACE-C7ED57992345	TCGA-C5-A2LS-01A-22D-A232-26	HG19_Broad_variant	TCGA-C5-A2LS	TCGA-CESC		s1356	MD Anderson - Institute for Applied Cancer Science	Medical College of Wisconsin	United States	NO	T1b2	N0	Endocervical Adenocarcinoma of the Usual Type		A232-26	True
S13722.58cfa82fe4b0c9d6adf6b99a	58cfa82fe4b0c9d6adf6b99a	TCGA-64-5774-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_1_rg.sorted.filtered.	WGS	TCGA-64-5774-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_1_rg.sorted	TCGA-64-5774-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_1_rg.sorted.bam	877.7	1.9	0.15	58cfa82fe4b0c9d6adf6b99a	TCGA-64-5774-01A-01D-1623_120228_SN1120_0117_BC0DKWACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-64-5774-01A	FD3FC273-C035-40EA-A459-FF4806F5D592	Primary Tumor	Illumina HiSeq	b5b4f9c8-7044-4c76-ae48-241c8c4dd953	Lung	60.0	252C5D60-7033-44C3-8AB5-4604670A80F4	83902D13-5FD4-4640-B20F-3A8110F6D5EC	TCGA-64-5774-01A-01D-1623-02	HG19_Broad_variant	TCGA-64-5774	TCGA-LUAD		s10910	Harvard Medical School	Fox Chase	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1623-02	True
S13722.58cfa830e4b0c9d6adf6c290	58cfa830e4b0c9d6adf6c290	TCGA-BR-4294-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BR-4294-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_2_rg.sorted	TCGA-BR-4294-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_2_rg.sorted.bam	42.9	1.9	0.14	58cfa830e4b0c9d6adf6c290	TCGA-BR-4294-01A-01D-1128_121204_SN590_0204_BC1H5VACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4294-01A	ACAB1362-C8A0-448B-8533-0CD84D97959C	Primary Tumor	Illumina HiSeq	23c036ca-ac6a-45dc-9100-558b2249f3bc	Stomach	65.0	CB5D3EDE-205D-43F6-A3E3-DB287FB1783B	97DB8928-FACC-4095-984F-07C52A759DB4	TCGA-BR-4294-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4294	TCGA-STAD		s15374	Harvard Medical School	Asterand	Russia	NO	T2a	NX	Stomach  Intestinal Adenocarcinoma  Tubular Type		1128-02	True
S13722.58cfa830e4b0c9d6adf6c2d0	58cfa830e4b0c9d6adf6c2d0	TCGA-CE-A27D-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CE-A27D-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_1_rg.sorted	TCGA-CE-A27D-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_1_rg.sorted.bam	52.72	1.93	0.17	58cfa830e4b0c9d6adf6c2d0	TCGA-CE-A27D-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_1_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-CE-A27D-01A	75A93F0E-CD41-43C6-A303-FF37E31395E9	Primary Tumor	Illumina HiSeq	c2d55126-05aa-44ef-97c3-ae2ac400c1b9	Thyroid	28.0	1807CEEE-28E1-4E8D-A1C4-6F6AD60EE310	CE991BB3-A63D-40C1-BFAF-3C4498D2C6EE	TCGA-CE-A27D-01A-11D-A16N-02	HG19_Broad_variant	TCGA-CE-A27D	TCGA-THCA		s12362	Harvard Medical School	ILSbio	Vietnam	NO	T2	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True
S13722.58cfa830e4b0c9d6adf6c2d6	58cfa830e4b0c9d6adf6c2d6	TCGA-BR-6707-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6707-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_7_rg.sorted	TCGA-BR-6707-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_7_rg.sorted.bam	333.7	1.9	0.15	58cfa830e4b0c9d6adf6c2d6	TCGA-BR-6707-01A-11D-1880_121220_SN1222_0163_AC1HA2ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6707-01A	DF3DF249-86C2-43D4-ABE1-796CD7DF653F	Primary Tumor	Illumina HiSeq	e2babdbd-1849-48ed-8726-1e3788be6064	Stomach	75.0	36F691AA-B737-4369-AD62-84F987F697A6	AA430360-2BE7-4C92-A10C-52588D8A6061	TCGA-BR-6707-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6707	TCGA-STAD		s14890	Harvard Medical School	Asterand	Ukraine	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1880-02	True
S13722.58cfa830e4b0c9d6adf6c2e4	58cfa830e4b0c9d6adf6c2e4	TCGA-BR-6802-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6802-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_7_rg.sorted	TCGA-BR-6802-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_7_rg.sorted.bam	487.7	1.9	0.14	58cfa830e4b0c9d6adf6c2e4	TCGA-BR-6802-01A-11D-1880_121220_SN1222_0164_BC1HJ3ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6802-01A	7C831A1D-3253-4AF4-A0FF-7FE9FF9AF1CE	Primary Tumor	Illumina HiSeq	73cec875-41a5-40bd-9d13-9e1ed4dd64d0	Stomach	65.0	E3BF04C2-961F-4511-AF63-5A0E8AE6377B	0B4F4B0B-EF5C-4717-875A-7B8C5342DBC4	TCGA-BR-6802-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6802	TCGA-STAD		s14885	Harvard Medical School	Asterand	Russia	NO	T3	N2	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1880-02	True
S13722.58cfa831e4b0c9d6adf6c37a	58cfa831e4b0c9d6adf6c37a	TCGA-CD-5813-01A-11D-1598_121026_SN1120_0198_BC188JACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CD-5813-01A-11D-1598_121026_SN1120_0198_BC188JACXX_s_5_rg.sorted	TCGA-CD-5813-01A-11D-1598_121026_SN1120_0198_BC188JACXX_s_5_rg.sorted.bam	46.0	1.9	0.17	58cfa831e4b0c9d6adf6c37a	TCGA-CD-5813-01A-11D-1598_121026_SN1120_0198_BC188JACXX_s_5_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-CD-5813-01A	152B9D8A-19FD-4665-B9E4-4FEDFB1608CD	Primary Tumor	Illumina HiSeq	ccc0d204-3529-43aa-b108-62d12f6465bd	Stomach	60.0	09E42E33-D2EC-406C-9A42-36D9D2EBD6C6	2118F0C5-3178-40EA-850D-C3F6F8752DD9	TCGA-CD-5813-01A-11D-1598-02	HG19_Broad_variant	TCGA-CD-5813	TCGA-STAD		s14408	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Stomach Intestinal Adenocarcinoma Mucinous Type	Stage II	1598-02	True
S13722.58cfa831e4b0c9d6adf6c52e	58cfa831e4b0c9d6adf6c52e	TCGA-CH-5769-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5769-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_5_rg.sorted	TCGA-CH-5769-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_5_rg.sorted.bam	75.7	1.9	0.15	58cfa831e4b0c9d6adf6c52e	TCGA-CH-5769-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5769-01A	A7B76662-8380-4F35-9307-99C0ACACB904	Primary Tumor	Illumina HiSeq	2fe51267-827f-4ffb-8aa8-42352e2352d5	Prostate	48.0	18606532-21D5-40BF-92CF-A42B027449A1	5488DCD8-EC8B-4E14-8F62-5F9931580B87	TCGA-CH-5769-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5769	TCGA-PRAD		s3424	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c534	58cfa831e4b0c9d6adf6c534	TCGA-CH-5766-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5766-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_1_rg.sorted	TCGA-CH-5766-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_1_rg.sorted.bam	273.7	1.9	0.15	58cfa831e4b0c9d6adf6c534	TCGA-CH-5766-01A-11D-1572_130104_SN208_0446_BD1KR5ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5766-01A	A5C77AB6-6E98-4A3D-81C8-F3D5FABD31D2	Primary Tumor	Illumina HiSeq	f778efd0-d2ed-48bc-ab57-e2bd12130169	Prostate	55.0	8477DA86-95BD-4B6D-A3E8-C16C9D61EA1F	ACAE8359-C2D0-4EB8-836B-D0BDF815F065	TCGA-CH-5766-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5766	TCGA-PRAD		s3421	Harvard Medical School	Indivumed	Germany	NO	T3a	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c4ac	58cfa831e4b0c9d6adf6c4ac	TCGA-CF-A3MH-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CF-A3MH-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_1_rg.sorted	TCGA-CF-A3MH-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_1_rg.sorted.bam	63.16		0.15	58cfa831e4b0c9d6adf6c4ac	TCGA-CF-A3MH-01A-11D-A210_120906_SN208_0425_AD1CU2ACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A3MH-01A	B8A8D2FC-421B-4393-8D5A-946CF72CB496	Primary Tumor	Illumina HiSeq	f82c1606-fe81-428d-9889-58cafa1f29e4	Bladder	75.0	8CF68BB1-5966-40CD-A038-E9E91E608766	463978F0-D37A-4035-9D1C-8C0E7B0F721C	TCGA-CF-A3MH-01A-11D-A210-26	HG19_Broad_variant	TCGA-CF-A3MH	TCGA-BLCA		s2874	MD Anderson - Institute for Applied Cancer Science	ILSbio	Vietnam	NO	T2	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	True
S13722.58cfa831e4b0c9d6adf6c540	58cfa831e4b0c9d6adf6c540	TCGA-CH-5764-01A-21D-1572_130104_SN208_0445_AC1JWAACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5764-01A-21D-1572_130104_SN208_0445_AC1JWAACXX_s_5_rg.sorted	TCGA-CH-5764-01A-21D-1572_130104_SN208_0445_AC1JWAACXX_s_5_rg.sorted.bam	157.7	1.9	0.17	58cfa831e4b0c9d6adf6c540	TCGA-CH-5764-01A-21D-1572_130104_SN208_0445_AC1JWAACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5764-01A	ED73F136-42E8-4100-B432-D10370D07E8B	Primary Tumor	Illumina HiSeq	036937fb-20a8-45df-a234-f7396aefb2d1	Prostate	66.0	48726D56-93A1-4730-A660-FCEEE0321084	F57D0D07-21B0-4901-9D81-C371C4673D4A	TCGA-CH-5764-01A-21D-1572-02	HG19_Broad_variant	TCGA-CH-5764	TCGA-PRAD		s3777	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c4b7	58cfa831e4b0c9d6adf6c4b7	TCGA-BR-4253-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-4253-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_7_rg.sorted	TCGA-BR-4253-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_7_rg.sorted.bam	201.9	1.9	0.14	58cfa831e4b0c9d6adf6c4b7	TCGA-BR-4253-01A-01D-1128_120816_SN590_0175_AD16M6ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4253-01A	411257A4-A148-4606-8C8B-F9F1240E40ED	Primary Tumor	Illumina HiSeq	90590609-4f3e-48b4-98e5-963c1c97f057	Stomach	80.0	C536B8DF-6FE3-425E-82E8-36299A6BA2B9	B7CE561B-B51B-4C85-822D-58DF663DE8EA	TCGA-BR-4253-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4253	TCGA-STAD		s15104	Harvard Medical School	Asterand	Russia	NO	T3	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIIA	1128-02	True
S13722.58cfa831e4b0c9d6adf6c552	58cfa831e4b0c9d6adf6c552	TCGA-CH-5762-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5762-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_1_rg.sorted	TCGA-CH-5762-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_1_rg.sorted.bam	211.7	1.9	0.15	58cfa831e4b0c9d6adf6c552	TCGA-CH-5762-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5762-01A	D4FFAFDC-EE83-43DF-AA3B-7326503C6438	Primary Tumor	Illumina HiSeq	70b297c6-c1f6-4651-93c3-17888cf0b118	Prostate	60.0	6D1A2D44-72F3-4333-8506-E53CDC4E5185	25189A34-4C05-4D77-9A3B-212A475F66B1	TCGA-CH-5762-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5762	TCGA-PRAD		s3594	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c542	58cfa831e4b0c9d6adf6c542	TCGA-CH-5754-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CH-5754-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_5_rg.sorted	TCGA-CH-5754-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_5_rg.sorted.bam	197.7	1.9	0.16	58cfa831e4b0c9d6adf6c542	TCGA-CH-5754-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5754-01A	0AAD0ABD-750A-400D-A34F-491DA996D46C	Primary Tumor	Illumina HiSeq	9b3dfe47-a8c3-4a73-8aa3-66af9d5001a2	Prostate	65.0	BE645D37-B3E1-4D09-91CB-6231E25ACEB8	2C0EF4A5-DC20-45E7-B8EE-7525D77128B6	TCGA-CH-5754-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5754	TCGA-PRAD		s3596	Harvard Medical School	Indivumed	Germany	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c556	58cfa831e4b0c9d6adf6c556	TCGA-CH-5752-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5752-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_1_rg.sorted	TCGA-CH-5752-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_1_rg.sorted.bam	191.7	1.9	0.16	58cfa831e4b0c9d6adf6c556	TCGA-CH-5752-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5752-01A	D8F56D75-51AB-4A86-A502-C86E1DCD1EFF	Primary Tumor	Illumina HiSeq	d1bae4e7-eb79-4ede-abb5-19a328e4ad0c	Prostate	66.0	94A01526-7771-4A05-A9CE-9694B73DF3A7	490FC467-7E7E-40A1-98D0-ABA46EC71F53	TCGA-CH-5752-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5752	TCGA-PRAD		s3427	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c562	58cfa831e4b0c9d6adf6c562	TCGA-CH-5761-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5761-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_7_rg.sorted	TCGA-CH-5761-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_7_rg.sorted.bam	197.7	1.9	0.15	58cfa831e4b0c9d6adf6c562	TCGA-CH-5761-01A-11D-1572_130103_SN1222_0166_BD1K7EACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5761-01A	854A481B-71A2-4F23-80AA-E91E9F4069B1	Primary Tumor	Illumina HiSeq	4d316299-7958-45e8-93ab-2150e05d3210	Prostate	61.0	332A54B1-2DF4-4BAA-84AC-2D95ABEF4064	F2F787DA-691C-4E73-A8B1-8D662781953E	TCGA-CH-5761-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5761	TCGA-PRAD		s3593	Harvard Medical School	Indivumed	Germany	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c56a	58cfa831e4b0c9d6adf6c56a	TCGA-CH-5765-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CH-5765-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_7_rg.sorted	TCGA-CH-5765-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_7_rg.sorted.bam	256.7	1.9	0.16	58cfa831e4b0c9d6adf6c56a	TCGA-CH-5765-01A-11D-1572_130104_SN208_0445_AC1JWAACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5765-01A	716EB429-D7AF-4D4F-BD8D-AFCFF1A323EE	Primary Tumor	Illumina HiSeq	265ff01e-199b-4908-acaa-62aa8986967a	Prostate	55.0	E2359111-B056-4676-A8B6-C5CEA259B478	B7EFFFED-73EC-4139-A359-41B239F2978D	TCGA-CH-5765-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5765	TCGA-PRAD		s3428	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c67c	58cfa831e4b0c9d6adf6c67c	TCGA-CN-4739-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CN-4739-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_8_rg.sorted	TCGA-CN-4739-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_8_rg.sorted.bam	187.7	1.9	0.14	58cfa831e4b0c9d6adf6c67c	TCGA-CN-4739-01A-02D-1509_120420_SN1120_0135_BD0T5FACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4739-01A	7E3B90C1-8772-4E12-8050-A156558BEB82	Primary Tumor	Illumina HiSeq	796943be-2aa7-419f-801f-22c78459cc72	Head and Neck	71.0	F450DBE6-4972-4C49-AF97-963BCD0D0DA0	3B0BED92-ED76-451D-B605-A79FAE296DDE	TCGA-CN-4739-01A-02D-1509-02	HG19_Broad_variant	TCGA-CN-4739	TCGA-HNSC		s15888	Harvard Medical School	University of Pittsburgh		NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	True
S13722.58cfa831e4b0c9d6adf6c6b6	58cfa831e4b0c9d6adf6c6b6	TCGA-CQ-7065-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CQ-7065-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_1_rg.sorted	TCGA-CQ-7065-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_1_rg.sorted.bam	15.93		0.13	58cfa831e4b0c9d6adf6c6b6	TCGA-CQ-7065-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_1_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-7065-01A	20ECE2CA-8601-4CCA-AEC5-0A5C0B92594D	Primary Tumor	Illumina HiSeq	a7ab0507-8b7a-45aa-9e07-21bfc50fddd0	Head and Neck	40.0	65B44EBF-F817-4B29-8FB6-01B07BC2E7D1	DFB72780-B485-403B-997C-6F6FD0EF0E75	TCGA-CQ-7065-01A-11D-2317-26	HG19_Broad_variant	TCGA-CQ-7065	TCGA-HNSC		s16040	MD Anderson - Institute for Applied Cancer Science	University Health Network, Toronto	Canada	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	True
S13722.58cfa831e4b0c9d6adf6c6f4	58cfa831e4b0c9d6adf6c6f4	TCGA-CV-5977-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CV-5977-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_3_rg.sorted	TCGA-CV-5977-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_3_rg.sorted.bam	307.0	1.9	0.15	58cfa831e4b0c9d6adf6c6f4	TCGA-CV-5977-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5977-01A	50239D1D-B3A4-4240-AB83-B24BA67B1299	Primary Tumor	Illumina HiSeq	ccdab134-2f40-4e7a-8b7c-ac1269321d3e	Head and Neck	66.0	84756AB5-9CB6-4DBD-848C-A85804F22AA1	140E6B2E-7EDD-417D-B720-58BEAB50AEA5	TCGA-CV-5977-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-5977	TCGA-HNSC		s15896	Harvard Medical School	MD Anderson Cancer Center		NO	T3	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True
S13722.58cfa831e4b0c9d6adf6c7da	58cfa831e4b0c9d6adf6c7da	TCGA-CV-7091-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CV-7091-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_8_rg.sorted	TCGA-CV-7091-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_8_rg.sorted.bam	289.73		0.15	58cfa831e4b0c9d6adf6c7da	TCGA-CV-7091-01A-11D-2317_120623_SN1222_0119_BC0WLLACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7091-01A	2A192049-6435-49AB-8444-DDEB2B9EE774	Primary Tumor	Illumina HiSeq	8a0170b3-9cda-4426-be4b-9e488f6244c2	Head and Neck	54.0	3AB78DC4-682E-4B5A-ADDA-223ACF0FBB6A	78998DCE-A468-416B-9F81-D64E43B52883	TCGA-CV-7091-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7091	TCGA-HNSC		s16342	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	2317-26	True
S13722.58cfa831e4b0c9d6adf6c828	58cfa831e4b0c9d6adf6c828	TCGA-CV-7238-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CV-7238-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_4_rg.sorted	TCGA-CV-7238-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_4_rg.sorted.bam	143.73		0.14	58cfa831e4b0c9d6adf6c828	TCGA-CV-7238-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-7238-01A	78FCC813-D0A8-44AA-B004-62810DCA9D12	Primary Tumor	Illumina HiSeq	3eb627a6-bbcf-4699-ad23-e52a26cd4453	Head and Neck	69.0	831808D5-1883-4F6F-B252-1BB397FBD62A	D051D2CB-F8DE-4E42-B9CF-E7CBE43861A0	TCGA-CV-7238-01A-11D-2317-26	HG19_Broad_variant	TCGA-CV-7238	TCGA-HNSC		s15520	MD Anderson - Institute for Applied Cancer Science	MD Anderson Cancer Center	United States	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	True
S13722.58cfa831e4b0c9d6adf6c86a	58cfa831e4b0c9d6adf6c86a	TCGA-CV-6003-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CV-6003-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_4_rg.sorted	TCGA-CV-6003-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_4_rg.sorted.bam	223.0	1.9	0.14	58cfa831e4b0c9d6adf6c86a	TCGA-CV-6003-01A-11D-1681_120427_SN1120_0137_BD0T3FACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-6003-01A	417B357E-C90E-4B63-AE7A-4B782038FFD3	Primary Tumor	Illumina HiSeq	b314312e-2a3f-45dd-a813-870344654395	Head and Neck	50.0	6892F7E3-630E-45B5-8C30-139161461A85	9DF426C5-E45E-428B-A63C-11D4C1BEB4B2	TCGA-CV-6003-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-6003	TCGA-HNSC		s16197	Harvard Medical School	MD Anderson Cancer Center		NO	T2	N1	Head and Neck Squamous Cell Carcinoma	Stage III	1681-02	True
S13722.58cfa831e4b0c9d6adf6c8c0	58cfa831e4b0c9d6adf6c8c0	TCGA-CV-5971-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_4_rg.sorted.filtered.	WGS	TCGA-CV-5971-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_4_rg.sorted	TCGA-CV-5971-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_4_rg.sorted.bam	22.0	1.9	0.16	58cfa831e4b0c9d6adf6c8c0	TCGA-CV-5971-01A-11D-1681_120427_SN1120_0136_AC0JEMACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CV-5971-01A	1465B7EC-8D2B-47DD-8387-977EED44CC86	Primary Tumor	Illumina HiSeq	03c22e39-15a9-4b8a-8db1-cf41d618b7fc	Head and Neck	60.0	82589B3F-BD41-4ABE-9469-7DD48447DDDC	5739D7DE-98D4-4591-B8B1-E0E9AA9B05DF	TCGA-CV-5971-01A-11D-1681-02	HG19_Broad_variant	TCGA-CV-5971	TCGA-HNSC		s16198	Harvard Medical School	MD Anderson Cancer Center		NO	T4a	N2a	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True
S13722.58cfa831e4b0c9d6adf6c898	58cfa831e4b0c9d6adf6c898	TCGA-DU-5854-01A-11D-1703_130806_SN1440_0159_BC29Y3ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DU-5854-01A-11D-1703_130806_SN1440_0159_BC29Y3ACXX_s_1_rg.sorted	TCGA-DU-5854-01A-11D-1703_130806_SN1440_0159_BC29Y3ACXX_s_1_rg.sorted.bam	66.3	1.9	0.16	58cfa831e4b0c9d6adf6c898	TCGA-DU-5854-01A-11D-1703_130806_SN1440_0159_BC29Y3ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5854-01A	B95AFB1A-A1DF-4D85-AD34-191928E28A77	Primary Tumor	Illumina HiSeq	f499956c-7655-4be7-8a53-44403d30ea04	Brain	57.0	D5BAA53A-958C-4163-A388-D3C957C891F9	4716DB1C-94F8-40AE-B89B-EA41E6A7E8CE	TCGA-DU-5854-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-5854	TCGA-LGG		s8562	Harvard Medical School	Henry Ford Hospital	United States	NO			Astrocytoma		1703-02	True
S13722.58cfa831e4b0c9d6adf6c90a	58cfa831e4b0c9d6adf6c90a	TCGA-DU-5849-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DU-5849-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_5_rg.sorted	TCGA-DU-5849-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_5_rg.sorted.bam	97.3	1.8	0.14	58cfa831e4b0c9d6adf6c90a	TCGA-DU-5849-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5849-01A	5AF8ADA5-86B5-4832-8A8E-E975ECCA5515	Primary Tumor	Illumina HiSeq	d4f0a4e9-de7c-498f-89e7-aad71fb01915	Brain	48.0	9E0E239F-CED4-4CF3-BF3C-5EC8224D760B	7732E26C-3B82-4D03-A331-82D8088CEB44	TCGA-DU-5849-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-5849	TCGA-LGG		s8349	Harvard Medical School	Henry Ford Hospital	United States	NO			Oligodendroglioma		1703-02	True
S13722.58cfa831e4b0c9d6adf6c945	58cfa831e4b0c9d6adf6c945	TCGA-D7-6818-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_1_rg.sorted.filtered.	WGS	TCGA-D7-6818-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_1_rg.sorted	TCGA-D7-6818-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_1_rg.sorted.bam	113.7	1.9	0.14	58cfa831e4b0c9d6adf6c945	TCGA-D7-6818-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-6818-01A	AA2934F9-8783-428E-88A6-1D04B93FA1FD	Primary Tumor	Illumina HiSeq	5a217dfc-ada8-4dec-8f7c-06be0123b9ef	Stomach	53.0	953E155F-D9E1-41C8-BA12-351A38195D22	21E75BA4-E4C1-4D8A-BFA2-E4698B4FB46B	TCGA-D7-6818-01A-11D-1880-02	HG19_Broad_variant	TCGA-D7-6818	TCGA-STAD		s15464	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T2	N3	Stomach  Adenocarcinoma  Diffuse Type	Stage IIIA	1880-02	True
S13722.58cfa831e4b0c9d6adf6cb22	58cfa831e4b0c9d6adf6cb22	TCGA-E5-A2PC-01A-11D-A204_120926_SN1222_0153_BD1D4MACXX_s_1_rg.sorted.filtered.	WGS	TCGA-E5-A2PC-01A-11D-A204_120926_SN1222_0153_BD1D4MACXX_s_1_rg.sorted	TCGA-E5-A2PC-01A-11D-A204_120926_SN1222_0153_BD1D4MACXX_s_1_rg.sorted.bam	63.68		0.16	58cfa831e4b0c9d6adf6cb22	TCGA-E5-A2PC-01A-11D-A204_120926_SN1222_0153_BD1D4MACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-E5-A2PC-01A	4107AE6F-502C-4BDC-BF14-E4B3711CBA38	Primary Tumor	Illumina HiSeq	496052c5-5ab2-4852-88e1-348116a86746	Bladder	61.0	2195B75E-157F-4547-9705-1E7E75666CA8	FABA82E6-FF3D-468C-91EC-A88794619697	TCGA-E5-A2PC-01A-11D-A204-02	HG19_Broad_variant	TCGA-E5-A2PC	TCGA-BLCA		s3289	Harvard Medical School	Roswell Park	United States	NO	T2b	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A204-02	True
S13722.58cfa831e4b0c9d6adf6cb9e	58cfa831e4b0c9d6adf6cb9e	TCGA-EJ-7328-01A-31D-2111_130502_SN590_0228_AD24A9ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EJ-7328-01A-31D-2111_130502_SN590_0228_AD24A9ACXX_s_2_rg.sorted	TCGA-EJ-7328-01A-31D-2111_130502_SN590_0228_AD24A9ACXX_s_2_rg.sorted.bam	282.3		0.16	58cfa831e4b0c9d6adf6cb9e	TCGA-EJ-7328-01A-31D-2111_130502_SN590_0228_AD24A9ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7328-01A	42B7D14F-09E5-4D91-BB98-5FE35907A6A9	Primary Tumor	Illumina HiSeq	09a1120f-21a6-48c2-a9e8-3b229a16fc7f	Prostate	70.0	4539A7C3-CCA2-4ED0-9310-92CD843AA1CD	C4D292D4-D001-4704-94C9-CC1674F6F16E	TCGA-EJ-7328-01A-31D-2111-02	HG19_Broad_variant	TCGA-EJ-7328	TCGA-PRAD		s3960	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa831e4b0c9d6adf6cba6	58cfa831e4b0c9d6adf6cba6	TCGA-EJ-7784-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EJ-7784-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_2_rg.sorted	TCGA-EJ-7784-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_2_rg.sorted.bam	456.3		0.15	58cfa831e4b0c9d6adf6cba6	TCGA-EJ-7784-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7784-01A	4BC71292-60BB-4B63-86C1-0FE021083804	Primary Tumor	Illumina HiSeq	a2c5ffab-f279-44fb-a025-079de410f1c4	Prostate	63.0	0D3EC78C-3DA8-443F-BAA6-93CAED5B065C	2B122D7B-B5CE-44CE-B1EA-7E39E42B2A63	TCGA-EJ-7784-01A-11D-2111-02	HG19_Broad_variant	TCGA-EJ-7784	TCGA-PRAD		s3958	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa831e4b0c9d6adf6cba5	58cfa831e4b0c9d6adf6cba5	TCGA-EJ-7331-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EJ-7331-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_4_rg.sorted	TCGA-EJ-7331-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_4_rg.sorted.bam	214.3		0.15	58cfa831e4b0c9d6adf6cba5	TCGA-EJ-7331-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7331-01A	B424B73A-2DFA-473F-AB56-AB382CD1CDEF	Primary Tumor	Illumina HiSeq	a85ad241-998c-4d85-a63b-903ddeb62201	Prostate	64.0	5AA2E382-C8DF-44E3-8802-994188B11D55	F2DA114D-161B-46CD-BAA7-46E63DBC5D5C	TCGA-EJ-7331-01A-11D-2111-02	HG19_Broad_variant	TCGA-EJ-7331	TCGA-PRAD		s4139	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa831e4b0c9d6adf6cbb5	58cfa831e4b0c9d6adf6cbb5	TCGA-EJ-5507-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5507-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_7_rg.sorted	TCGA-EJ-5507-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_7_rg.sorted.bam	347.7	1.9	0.15	58cfa831e4b0c9d6adf6cbb5	TCGA-EJ-5507-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5507-01A	607200F5-DF80-4F5D-90FB-FDC455A7415B	Primary Tumor	Illumina HiSeq	0dbb7308-269c-4ad8-97c7-e7475ae08189	Prostate	54.0	F93327F7-0290-4915-97BB-E31BAE2697DD	D2336094-05BD-4E89-84A3-91D641DC31D0	TCGA-EJ-5507-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5507	TCGA-PRAD		s3787	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cbc9	58cfa831e4b0c9d6adf6cbc9	TCGA-EJ-5514-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5514-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_7_rg.sorted	TCGA-EJ-5514-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_7_rg.sorted.bam	271.7	1.9	0.15	58cfa831e4b0c9d6adf6cbc9	TCGA-EJ-5514-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5514-01A	F82D53B1-3DF8-4249-A615-464C9F4E0A32	Primary Tumor	Illumina HiSeq	581bee6a-6abe-4b55-8dc4-63bb242df1cf	Prostate	66.0	29AD80A4-B429-495C-885E-A92CFE2E4501	6F8F8AAC-C0DE-46F6-A7CF-502893CC57CB	TCGA-EJ-5514-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5514	TCGA-PRAD		s3439	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cbf4	58cfa831e4b0c9d6adf6cbf4	TCGA-EJ-7782-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-EJ-7782-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_8_rg.sorted	TCGA-EJ-7782-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_8_rg.sorted.bam	344.3		0.16	58cfa831e4b0c9d6adf6cbf4	TCGA-EJ-7782-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_8_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7782-01A	1426B4BF-F4A5-477C-BBBB-E0E656549764	Primary Tumor	Illumina HiSeq	f92312ba-ec6b-477e-a08c-12c8af6d1775	Prostate	71.0	951C894E-9354-45AD-834A-FFC04441A3A9	47FB5E53-DD88-4B25-B6EF-C1ABE55FD5BA	TCGA-EJ-7782-01A-11D-2111-02	HG19_Broad_variant	TCGA-EJ-7782	TCGA-PRAD		s3794	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa831e4b0c9d6adf6cbf9	58cfa831e4b0c9d6adf6cbf9	TCGA-EJ-7785-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EJ-7785-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_4_rg.sorted	TCGA-EJ-7785-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_4_rg.sorted.bam	160.3		0.15	58cfa831e4b0c9d6adf6cbf9	TCGA-EJ-7785-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7785-01A	2DEF2A53-D2E8-46F0-8B07-F32DBF1833A4	Primary Tumor	Illumina HiSeq	dfbfaf44-ade6-4c48-88fb-a3898d878853	Prostate	54.0	63EBD9B1-F118-4315-8722-708F47A07063	196C6111-FF69-40F1-A7AA-973C5AC9106E	TCGA-EJ-7785-01A-11D-2111-02	HG19_Broad_variant	TCGA-EJ-7785	TCGA-PRAD		s3966	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa831e4b0c9d6adf6cc60	58cfa831e4b0c9d6adf6cc60	TCGA-EJ-5501-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5501-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_3_rg.sorted	TCGA-EJ-5501-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_3_rg.sorted.bam	153.7	1.9	0.16	58cfa831e4b0c9d6adf6cc60	TCGA-EJ-5501-01A-01D-1572_130223_SN590_0214_BC1UJ3ACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5501-01A	8DF0C1E8-966C-4F46-AD15-FAE9E745A32E	Primary Tumor	Illumina HiSeq	6e2cf9a5-b8c5-4f44-8800-c95ad84bc9a8	Prostate	55.0	A1E37A0A-67F5-4A19-A540-A45CB89C4203	759BD886-73F1-4DEF-A446-98DAAC2C5B88	TCGA-EJ-5501-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5501	TCGA-PRAD		s3790	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cc90	58cfa831e4b0c9d6adf6cc90	TCGA-EJ-5518-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5518-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_7_rg.sorted	TCGA-EJ-5518-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_7_rg.sorted.bam	131.7	1.9	0.15	58cfa831e4b0c9d6adf6cc90	TCGA-EJ-5518-01A-01D-1572_130131_SN1120_0235_BD1TAFACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5518-01A	2B35C119-CDC1-49E2-8229-CA5CDE9E63D0	Primary Tumor	Illumina HiSeq	02ae3fcb-c1fe-400a-8172-0c62a8d4639c	Prostate	66.0	F12FA61C-FF1B-48E2-BE19-1D52D50DC261	BD026793-2032-4D13-9A6A-A189583A537C	TCGA-EJ-5518-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5518	TCGA-PRAD		s3430	Harvard Medical School	University of Pittsburgh	United States	NO	T4	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6ccc0	58cfa831e4b0c9d6adf6ccc0	TCGA-EJ-5531-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5531-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_1_rg.sorted	TCGA-EJ-5531-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_1_rg.sorted.bam	81.7	1.9	0.15	58cfa831e4b0c9d6adf6ccc0	TCGA-EJ-5531-01A-01D-1572_130221_SN1120_0239_BD1V59ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5531-01A	ADF3C2F7-D5F9-41C3-BD8C-7F9F1F22FF73	Primary Tumor	Illumina HiSeq	0993d456-af78-4078-aa16-bd810177c278	Prostate	62.0	48F3A8B8-110C-49AB-BD85-CE33328C2CF6	90219925-E6E8-40BC-8DD0-BD76F942B48C	TCGA-EJ-5531-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5531	TCGA-PRAD		s3445	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6ccf0	58cfa831e4b0c9d6adf6ccf0	TCGA-EJ-5512-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5512-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_5_rg.sorted	TCGA-EJ-5512-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_5_rg.sorted.bam	100.7	1.9	0.13	58cfa831e4b0c9d6adf6ccf0	TCGA-EJ-5512-01A-01D-1572_130131_SN1120_0234_AD1PVUACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5512-01A	C28F931F-5AB2-4899-9FE9-54024F082D92	Primary Tumor	Illumina HiSeq	1df8e29c-5be8-4dbf-abb8-f0ded9419a14	Prostate	46.0	D0B41403-8458-45E1-946E-21054FBA65B8	D5F126D6-7AAF-425A-BBEA-E7587A25529D	TCGA-EJ-5512-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5512	TCGA-PRAD		s3954	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cd06	58cfa831e4b0c9d6adf6cd06	TCGA-EJ-5496-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5496-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_3_rg.sorted	TCGA-EJ-5496-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_3_rg.sorted.bam	253.7	1.9	0.14	58cfa831e4b0c9d6adf6cd06	TCGA-EJ-5496-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5496-01A	6755C231-355F-4CC3-85F1-6306C7F5D44B	Primary Tumor	Illumina HiSeq	00039222-b24d-4c86-b6ac-ffc00b3b6ece	Prostate	59.0	D0873929-EAC8-42E2-AF6F-DF3CB9CE698C	0A4FA030-2417-4F6F-8B86-5036FCA48F1E	TCGA-EJ-5496-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5496	TCGA-PRAD		s3598	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cd2c	58cfa831e4b0c9d6adf6cd2c	TCGA-EJ-5495-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5495-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_1_rg.sorted	TCGA-EJ-5495-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_1_rg.sorted.bam	176.7	1.9	0.15	58cfa831e4b0c9d6adf6cd2c	TCGA-EJ-5495-01A-01D-1572_130125_SN1120_0233_AD1K3HACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5495-01A	962DD3D5-8501-4658-8CB9-2424B476124C	Primary Tumor	Illumina HiSeq	a2c14576-771c-460f-a71b-e25651274ca1	Prostate	68.0	8E53414F-455E-4665-AE0E-9E7405262A96	5644F0E3-3A3B-411A-B28D-C93C3BBD8F86	TCGA-EJ-5495-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5495	TCGA-PRAD		s3597	Harvard Medical School	University of Pittsburgh	United States	NO	T3b	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cd23	58cfa831e4b0c9d6adf6cd23	TCGA-F1-6874-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_7_rg.sorted.filtered.	WGS	TCGA-F1-6874-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_7_rg.sorted	TCGA-F1-6874-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_7_rg.sorted.bam	373.7	1.9	0.14	58cfa831e4b0c9d6adf6cd23	TCGA-F1-6874-01A-11D-1880_121220_SN1120_0207_BC1JALACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-F1-6874-01A	106F3344-F699-4B2C-8F62-4AC6C948DDE4	Primary Tumor	Illumina HiSeq	734d68fe-de19-4aef-8031-8ba255233eba	Stomach	79.0	C28FEBB9-E845-462F-B6A0-CB565EE6A049	273DDC2E-8E77-4F81-85C2-B9A8583D9E1D	TCGA-F1-6874-01A-11D-1880-02	HG19_Broad_variant	TCGA-F1-6874	TCGA-STAD		s14773	Harvard Medical School	UNC	United States	NO	T2	N0	Stomach  Intestinal Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IB	1880-02	True
S13722.58cfa831e4b0c9d6adf6cd5c	58cfa831e4b0c9d6adf6cd5c	TCGA-EJ-5494-01A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5494-01A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_7_rg.sorted	TCGA-EJ-5494-01A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_7_rg.sorted.bam	107.7	1.9	0.15	58cfa831e4b0c9d6adf6cd5c	TCGA-EJ-5494-01A-01D-1572_130125_SN208_0451_BD1RB1ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5494-01A	E27C50E2-2A41-4F8C-9EF8-2BC51FB0C23E	Primary Tumor	Illumina HiSeq	01d186ab-6289-40da-9715-4f766da74b10	Prostate	50.0	37103479-02BD-45E8-95B3-7A4A78523999	9AA32D54-78ED-4DFC-ACA4-E1A88404F791	TCGA-EJ-5494-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5494	TCGA-PRAD		s4131	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cd8c	58cfa831e4b0c9d6adf6cd8c	TCGA-EJ-7781-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-EJ-7781-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_6_rg.sorted	TCGA-EJ-7781-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_6_rg.sorted.bam	168.3		0.16	58cfa831e4b0c9d6adf6cd8c	TCGA-EJ-7781-01A-11D-2111_130502_SN590_0228_AD24A9ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-7781-01A	33283111-9A2F-4D5E-92A5-3435846404F7	Primary Tumor	Illumina HiSeq	bf6c4719-7b88-4975-9591-8bd34c19e3cf	Prostate	65.0	B5504343-6915-4D15-A81E-641B03C77F24	193083B4-B2E1-486C-A4F5-F62818AEBBC2	TCGA-EJ-7781-01A-11D-2111-02	HG19_Broad_variant	TCGA-EJ-7781	TCGA-PRAD		s4141	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa832e4b0c9d6adf6ce14	58cfa832e4b0c9d6adf6ce14	TCGA-EJ-5511-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EJ-5511-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_7_rg.sorted	TCGA-EJ-5511-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_7_rg.sorted.bam	398.7	1.9	0.15	58cfa832e4b0c9d6adf6ce14	TCGA-EJ-5511-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_7_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5511-01A	F8A42FEB-FBC9-4A13-BAD5-1DCEFCA2A9BF	Primary Tumor	Illumina HiSeq	dfa7170d-3cc1-43b7-9d24-7be107cf2896	Prostate	55.0	1DA89009-5DBE-4D62-9406-36330F47B738	5D753860-8965-45E5-A919-C076B53334D4	TCGA-EJ-5511-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5511	TCGA-PRAD		s3600	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6cd6c	58cfa831e4b0c9d6adf6cd6c	TCGA-ET-A25R-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_4_rg.sorted.filtered.	WGS	TCGA-ET-A25R-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_4_rg.sorted	TCGA-ET-A25R-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_4_rg.sorted.bam	101.84	1.93	0.17	58cfa831e4b0c9d6adf6cd6c	TCGA-ET-A25R-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-ET-A25R-01A	097B9CF1-EC0C-487C-9ADE-2BDAB12EB4CA	Primary Tumor	Illumina HiSeq	442f6193-a979-40e4-89db-2e541d3ebdb7	Thyroid	51.0	C29162A3-F162-4D32-AB9A-421BE1FEB13C	77A80565-1BC9-4F0A-AFB3-23955FE283EB	TCGA-ET-A25R-01A-11D-A16N-02	HG19_Broad_variant	TCGA-ET-A25R	TCGA-THCA		s12003	Harvard Medical School	Johns Hopkins	United States	NO	T3	NX	Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features)	Stage III	A16N-02	True
S13722.58cfa832e4b0c9d6adf6ce46	58cfa832e4b0c9d6adf6ce46	TCGA-EJ-5504-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5504-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_1_rg.sorted	TCGA-EJ-5504-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_1_rg.sorted.bam	125.7	1.9	0.15	58cfa832e4b0c9d6adf6ce46	TCGA-EJ-5504-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5504-01A	E1C3D1BD-CF8F-4FA4-AC8E-BF9E54F7AAD4	Primary Tumor	Illumina HiSeq	ea018935-4ded-4def-a204-bda7035ba32c	Prostate	65.0	7D0C0A85-8459-43A3-AC22-F447BB042149	FB332EAD-214E-4D76-BD3C-0774D906F68B	TCGA-EJ-5504-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5504	TCGA-PRAD		s3953	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N1	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa832e4b0c9d6adf6ce0c	58cfa832e4b0c9d6adf6ce0c	TCGA-FD-A3B6-01A-21D-A210_120912_SN1120_0192_AC18ALACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FD-A3B6-01A-21D-A210_120912_SN1120_0192_AC18ALACXX_s_3_rg.sorted	TCGA-FD-A3B6-01A-21D-A210_120912_SN1120_0192_AC18ALACXX_s_3_rg.sorted.bam	61.5		0.16	58cfa832e4b0c9d6adf6ce0c	TCGA-FD-A3B6-01A-21D-A210_120912_SN1120_0192_AC18ALACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3B6-01A	36054200-3FA4-4541-A25C-47282E4EF88D	Primary Tumor	Illumina HiSeq	15aeae5e-1ef3-4574-a7af-025ac4d4be89	Bladder	75.0	D6818C85-5857-44B0-AD64-1EEB53B80606	D8D4A23A-F993-4A8F-9414-AD25149B4CB3	TCGA-FD-A3B6-01A-21D-A210-26	HG19_Broad_variant	TCGA-FD-A3B6	TCGA-BLCA		s3298	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A210-26	True
S13722.58cfa832e4b0c9d6adf6cfac	58cfa832e4b0c9d6adf6cfac	TCGA-GE-A2C6-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_5_rg.sorted.filtered.	WGS	TCGA-GE-A2C6-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_5_rg.sorted	TCGA-GE-A2C6-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_5_rg.sorted.bam	75.85	1.8	0.17	58cfa832e4b0c9d6adf6cfac	TCGA-GE-A2C6-01A-11D-A16N_120805_SN208_0422_BD16VPACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-GE-A2C6-01A	7DEEDEBA-F05B-453C-9DF1-EEB20B0EC72E	Primary Tumor	Illumina HiSeq	4920d08d-433e-4371-8daa-641819a1e53f	Thyroid	33.0	D717EECF-11DC-4E15-851A-9EA18332A48B	A5FA44A2-8101-4A0C-982C-57337853BACA	TCGA-GE-A2C6-01A-11D-A16N-02	HG19_Broad_variant	TCGA-GE-A2C6	TCGA-THCA		s12123	Harvard Medical School	ABS - IUPUI	United States	NO	T2	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A16N-02	True
S13722.58cfa832e4b0c9d6adf6cfe0	58cfa832e4b0c9d6adf6cfe0	TCGA-GC-A3WC-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-GC-A3WC-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_1_rg.sorted	TCGA-GC-A3WC-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_1_rg.sorted.bam	23.27		0.17	58cfa832e4b0c9d6adf6cfe0	TCGA-GC-A3WC-01A-31D-A233_120904_SN1120_0186_BC1911ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GC-A3WC-01A	DB52C68A-ED44-4EC4-9381-D75F9BCBC29A	Primary Tumor	Illumina HiSeq	5d982317-5753-41de-85ef-30ee85c56ba9	Bladder	80.0	24F9D01B-1210-4716-9466-8FE9F3612B8B	50E62704-6262-4426-BDAE-0490DC108B61	TCGA-GC-A3WC-01A-31D-A233-26	HG19_Broad_variant	TCGA-GC-A3WC	TCGA-BLCA		s3307	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	True
S13722.58cfa832e4b0c9d6adf6d082	58cfa832e4b0c9d6adf6d082	TCGA-HC-7210-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_8_rg.sorted.filtered.	WGS	TCGA-HC-7210-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_8_rg.sorted	TCGA-HC-7210-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_8_rg.sorted.bam	131.3		0.15	58cfa832e4b0c9d6adf6d082	TCGA-HC-7210-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7210-01A	6A5AF80E-07AD-4CD3-AAAB-5DB1090835D9	Primary Tumor	Illumina HiSeq	e6934494-d8e1-44c6-a343-30a6aa2e6cbc	Prostate	74.0	9069FC65-9BAE-49F3-9329-B78C8CC6CF1E	D414D851-0AF6-4C8F-8E40-CCA9FDF79488	TCGA-HC-7210-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7210	TCGA-PRAD		s3983	Harvard Medical School	International Genomics Consortium	United States	NO	T2a	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa832e4b0c9d6adf6d0f5	58cfa832e4b0c9d6adf6d0f5	TCGA-HC-7209-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-HC-7209-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_6_rg.sorted	TCGA-HC-7209-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_6_rg.sorted.bam	121.3		0.15	58cfa832e4b0c9d6adf6d0f5	TCGA-HC-7209-01A-11D-2111_130502_SN590_0229_BD2459ACXX_s_6_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-HC-7209-01A	582D1177-73B0-4A9C-8505-70D6B402BD01	Primary Tumor	Illumina HiSeq	d228a749-988a-4fcb-9f15-e334295216fb	Prostate	60.0	AA7850AC-FB78-433B-8D55-A24C05935DB5	3C59E423-E1A6-4C67-8A88-63A0817B856E	TCGA-HC-7209-01A-11D-2111-02	HG19_Broad_variant	TCGA-HC-7209	TCGA-PRAD		s3625	Harvard Medical School	International Genomics Consortium	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		2111-02	True
S13722.58cfa832e4b0c9d6adf6d134	58cfa832e4b0c9d6adf6d134	TCGA-G2-A3VY-01A-11D-A233_120913_SN208_0428_BC188KACXX_s_6_rg.sorted.filtered.	WGS	TCGA-G2-A3VY-01A-11D-A233_120913_SN208_0428_BC188KACXX_s_6_rg.sorted	TCGA-G2-A3VY-01A-11D-A233_120913_SN208_0428_BC188KACXX_s_6_rg.sorted.bam	27.44		0.15	58cfa832e4b0c9d6adf6d134	TCGA-G2-A3VY-01A-11D-A233_120913_SN208_0428_BC188KACXX_s_6_rg.sorted.bam	Alive	MALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A3VY-01A	CD50C69F-0F45-4C57-B61A-8C6B41AB4F7E	Primary Tumor	Illumina HiSeq	fc9767fe-ddfb-4540-b151-0a80300c0a1d	Bladder	66.0	5A66149F-8FB0-41BC-880C-56D5541E3D94	8263C8A3-7CE5-4487-B8A1-29CE9417D1E3	TCGA-G2-A3VY-01A-11D-A233-26	HG19_Broad_variant	TCGA-G2-A3VY	TCGA-BLCA		s2914	MD Anderson - Institute for Applied Cancer Science	MD Anderson	United States	NO			Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A233-26	True
S13722.58cfa832e4b0c9d6adf6d1bb	58cfa832e4b0c9d6adf6d1bb	TCGA-EJ-5509-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5509-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_3_rg.sorted	TCGA-EJ-5509-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_3_rg.sorted.bam	116.7	1.9	0.14	58cfa832e4b0c9d6adf6d1bb	TCGA-EJ-5509-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5509-01A	13CE70A8-785C-4B59-B073-41922CB201F9	Primary Tumor	Illumina HiSeq	6fd44a89-a20c-4ecc-bafe-54da9b58cd9d	Prostate	63.0	99A7115E-046B-488E-95D2-48C35BD29867	4F3831BE-6C1C-4786-B953-2612753C1E5C	TCGA-EJ-5509-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5509	TCGA-PRAD		s3440	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa832e4b0c9d6adf6d254	58cfa832e4b0c9d6adf6d254	TCGA-IR-A3LA-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_7_rg.sorted.filtered.	WGS	TCGA-IR-A3LA-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_7_rg.sorted	TCGA-IR-A3LA-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_7_rg.sorted.bam	56.17		0.15	58cfa832e4b0c9d6adf6d254	TCGA-IR-A3LA-01A-11D-A232_140124_SN1120_0291_AC2PHAACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-IR-A3LA-01A	7B8C04D7-824D-493D-8F2C-9ED87A907192	Primary Tumor	Illumina HiSeq	96c944ec-9e55-4b27-aa91-b936b4d7cff5	Cervix	60.0	7925EA80-8AAE-4D99-AFE2-74AD1AAE6D9D	B541AE4A-279F-49A1-9877-1F2226A51737	TCGA-IR-A3LA-01A-11D-A232-26	HG19_Broad_variant	TCGA-IR-A3LA	TCGA-CESC		s1377	MD Anderson - Institute for Applied Cancer Science	Memorial Sloan Kettering	United States	NO	T1b1	N0	Endometrioid Adenocarcinoma of Endocervix		A232-26	True
S13722.58cfa832e4b0c9d6adf6d114	58cfa832e4b0c9d6adf6d114	TCGA-G2-A2ES-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G2-A2ES-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_7_rg.sorted	TCGA-G2-A2ES-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_7_rg.sorted.bam	46.96		0.16	58cfa832e4b0c9d6adf6d114	TCGA-G2-A2ES-01A-11D-A17R_120921_SN208_0430_AC18CWACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-G2-A2ES-01A	72D8EAE8-9EFB-45B2-ACBD-82C6B5732E38	Primary Tumor	Illumina HiSeq	5922785f-2336-403c-9cb6-0843df3383b5	Bladder	85.0	C2288290-F17A-435C-90E7-5A4913F0C076	52FA3B0A-B5C7-4A74-A798-0DB359029147	TCGA-G2-A2ES-01A-11D-A17R-02	HG19_Broad_variant	TCGA-G2-A2ES	TCGA-BLCA		s2919	Harvard Medical School	MD Anderson	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A17R-02	True
S13722.58cfa832e4b0c9d6adf6d269	58cfa832e4b0c9d6adf6d269	TCGA-K4-A3WS-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_1_rg.sorted.filtered.	WGS	TCGA-K4-A3WS-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_1_rg.sorted	TCGA-K4-A3WS-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_1_rg.sorted.bam	18.56		0.16	58cfa832e4b0c9d6adf6d269	TCGA-K4-A3WS-01A-11D-A23Q_120927_SN208_0432_AC188LACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-K4-A3WS-01A	68ADACD1-A16E-4489-9E68-792A6BD8811C	Primary Tumor	Illumina HiSeq	891c215b-20ad-4eb3-9e53-87910b1d06f4	Bladder	66.0	54070AE0-0C10-4C10-B8BB-A7313B80A45F	F1840542-AEBE-4B4C-BA50-1686740847D4	TCGA-K4-A3WS-01A-11D-A23Q-26	HG19_Broad_variant	TCGA-K4-A3WS	TCGA-BLCA		s3131	MD Anderson - Institute for Applied Cancer Science	ABS - Lahey Clinic	United States	NO	T3a	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A23Q-26	True
S13722.58cfa82fe4b0c9d6adf6b6be	58cfa82fe4b0c9d6adf6b6be	TCGA-55-6543-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_8.rg.sorted.filtered.	WGS	TCGA-55-6543-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_8.rg.sorted	TCGA-55-6543-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_8.rg.sorted.bam	127.4	1.9	0.15	58cfa82fe4b0c9d6adf6b6be	TCGA-55-6543-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_8.rg.sorted.bam	Alive	FEMALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-55-6543-01A	E68219B0-A9C2-49DF-8F0D-DB5EA97FD2DC	Primary Tumor	Illumina HiSeq	0715b83e-fcd8-41e9-88ac-cfeb5fabd3de	Lung	60.0	8D9491E7-9B14-4988-8FA7-E6AF041120BD	1D88DA12-E71A-4F44-8D71-DA8957BDFCD4	TCGA-55-6543-01A-11D-1751-02	HG19_Broad_variant	TCGA-55-6543	TCGA-LUAD		s10791	Harvard Medical School	International Genomics Consortium	United States	NO	T1b	N0	Lung Bronchioloalveolar Carcinoma Mucinous	Stage IA	1751-02	True
S13722.58cfa82fe4b0c9d6adf6b6d2	58cfa82fe4b0c9d6adf6b6d2	TCGA-44-3396-01A-01D-1203_110804_SN208_0216_AD0CLLABXX_s_7_rg.sorted.filtered.	WGS	TCGA-44-3396-01A-01D-1203_110804_SN208_0216_AD0CLLABXX_s_7_rg.sorted	TCGA-44-3396-01A-01D-1203_110804_SN208_0216_AD0CLLABXX_s_7_rg.sorted.bam	472.3	1.9	0.15	58cfa82fe4b0c9d6adf6b6d2	TCGA-44-3396-01A-01D-1203_110804_SN208_0216_AD0CLLABXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-3396-01A	3BD6BADB-27FF-4D8D-B206-4D28DC264862	Primary Tumor	Illumina HiSeq	bf55243b-c7c6-46fc-9d54-e1916b0d7ea2	Lung	74.0	B560DF97-986B-4A88-A0F1-C38A30080EDB	ECCC6A5C-BB25-4591-996A-EE2A7507F771	TCGA-44-3396-01A-01D-1203-02	HG19_Broad_variant	TCGA-44-3396	TCGA-LUAD		s10653	Harvard Medical School	Christiana Healthcare	United States	NO	T2	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1203-02	True
S13722.58cfa82fe4b0c9d6adf6b728	58cfa82fe4b0c9d6adf6b728	TCGA-44-6147-01A-11D-1751_111207_SN590_0112_D09CDACXX_s_1_rg.sorted.filtered.	WGS	TCGA-44-6147-01A-11D-1751_111207_SN590_0112_D09CDACXX_s_1_rg.sorted	TCGA-44-6147-01A-11D-1751_111207_SN590_0112_D09CDACXX_s_1_rg.sorted.bam	219.0	1.9	0.17	58cfa82fe4b0c9d6adf6b728	TCGA-44-6147-01A-11D-1751_111207_SN590_0112_D09CDACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-44-6147-01A	889AEC8E-14BA-48D9-8FE1-F2416E82B333	Primary Tumor	Illumina HiSeq	a9e60432-a9de-4497-b94d-5ead787d2de3	Lung	67.0	43F5270A-F2F2-4DD9-83B5-486B805E35B8	E9CE62EF-711E-4252-AC93-97B69C39041A	TCGA-44-6147-01A-11D-1751-02	HG19_Broad_variant	TCGA-44-6147	TCGA-LUAD		s11447	Harvard Medical School	Christiana Healthcare	United States	NO	T1b	NX	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	True
S13722.58cfa82fe4b0c9d6adf6b70a	58cfa82fe4b0c9d6adf6b70a	TCGA-67-6216-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_1.rg.sorted.filtered.	WGS	TCGA-67-6216-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_1.rg.sorted	TCGA-67-6216-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_1.rg.sorted.bam	355.4	1.9	0.14	58cfa82fe4b0c9d6adf6b70a	TCGA-67-6216-01A-11D-1751_111115_SN590_0111_D09ATACXX_s_1.rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Lung Adenocarcinoma	Aligned reads	TCGA-67-6216-01A	CCECCE70-DD54-4C5B-BF9F-CA87D290CB00	Primary Tumor	Illumina HiSeq	ae4aaef1-8b47-476b-933a-ff69761aa0a9	Lung	57.0	4EAA4B4A-E9DB-4E65-97D6-7FA1A205DA95	1003F495-01FE-47ED-A717-B8769F0FA3A3	TCGA-67-6216-01A-11D-1751-02	HG19_Broad_variant	TCGA-67-6216	TCGA-LUAD		s11242	Harvard Medical School	St Joseph's Medical Center (MD)	United States	NO	T1a	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IA	1751-02	True
S13722.58cfa82fe4b0c9d6adf6b864	58cfa82fe4b0c9d6adf6b864	TCGA-A5-A0GU-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_5_rg.sorted.filtered.	WGS	TCGA-A5-A0GU-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_5_rg.sorted	TCGA-A5-A0GU-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_5_rg.sorted.bam	101.03	2.18	0.17	58cfa82fe4b0c9d6adf6b864	TCGA-A5-A0GU-01A-11D-A043_120209_SN1120_0114_BC0DFVACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0GU-01A	ADC22472-E31D-419F-AEAE-CB01B9423343	Primary Tumor	Illumina HiSeq	7666f932-cff3-4ea2-8650-8d4bdae72cac	Uterus	58.0	074D4466-E072-42CD-9A6C-A595DC9363E7	BB726D7A-6861-48AA-9BFD-5DF8DAAA1538	TCGA-A5-A0GU-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0GU	TCGA-UCEC		s4241	Harvard Medical School	Cedars Sinai		NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa830e4b0c9d6adf6bada	58cfa830e4b0c9d6adf6bada	TCGA-49-6745-01A-11D-1853_111218_SN208_0258_C054RACXX_s_7_rg.sorted.filtered.	WGS	TCGA-49-6745-01A-11D-1853_111218_SN208_0258_C054RACXX_s_7_rg.sorted	TCGA-49-6745-01A-11D-1853_111218_SN208_0258_C054RACXX_s_7_rg.sorted.bam	88.7	1.9	0.15	58cfa830e4b0c9d6adf6bada	TCGA-49-6745-01A-11D-1853_111218_SN208_0258_C054RACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-49-6745-01A	9C7875AD-AB71-4D48-B2E3-E4C7A46393E9	Primary Tumor	Illumina HiSeq	b4eee7d7-a56c-4927-929e-ac66abe41408	Lung	82.0	357F3EFE-E2C9-432A-A2B6-75A5FDBAE3BE	A88D69EF-BE3C-4341-AD6C-0F035685862F	TCGA-49-6745-01A-11D-1853-02	HG19_Broad_variant	TCGA-49-6745	TCGA-LUAD		s11451	Harvard Medical School	Johns Hopkins	United States	NO	T2a	N2	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IIIA	1853-02	True
S13722.58cfa82fe4b0c9d6adf6b9e8	58cfa82fe4b0c9d6adf6b9e8	TCGA-A5-A0G9-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-A5-A0G9-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_3_rg.sorted	TCGA-A5-A0G9-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_3_rg.sorted.bam	54.22	1.93	0.16	58cfa82fe4b0c9d6adf6b9e8	TCGA-A5-A0G9-01A-11D-A043_120318_SN590_0146_AC0KH7ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-A5-A0G9-01A	45D58088-D3F4-4EB0-B75C-BCB98C0981DC	Primary Tumor	Illumina HiSeq	daffebdf-d935-425e-8576-3401ef583860	Uterus	79.0	117A5B33-42C5-4A52-BABE-D9712F3E7472	0DE57B60-95AF-48E2-85CA-58135A314355	TCGA-A5-A0G9-01A-11D-A043-02	HG19_Broad_variant	TCGA-A5-A0G9	TCGA-UCEC		s4778	Harvard Medical School	Cedars Sinai		NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa830e4b0c9d6adf6bd9a	58cfa830e4b0c9d6adf6bd9a	TCGA-BG-A0M6-01A-31D-A101_120330_SN1120_0129_BD0UCLACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BG-A0M6-01A-31D-A101_120330_SN1120_0129_BD0UCLACXX_s_2_rg.sorted	TCGA-BG-A0M6-01A-31D-A101_120330_SN1120_0129_BD0UCLACXX_s_2_rg.sorted.bam	71.62	1.94	0.14	58cfa830e4b0c9d6adf6bd9a	TCGA-BG-A0M6-01A-31D-A101_120330_SN1120_0129_BD0UCLACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M6-01A	002724FA-7051-49FA-9C58-4BCB7EBA4AC6	Primary Tumor	Illumina HiSeq	0db41cb8-f118-4d04-a002-22df953a0dec	Uterus	73.0	66E4B080-E6EF-4531-9B69-1B27F15C5669	61C058D9-E5DC-4D74-B378-28B8F0A2BF78	TCGA-BG-A0M6-01A-31D-A101-02	HG19_Broad_variant	TCGA-BG-A0M6	TCGA-UCEC		s4249	Harvard Medical School	University of Pittsburgh		NO			Serous endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6bdb3	58cfa830e4b0c9d6adf6bdb3	TCGA-BG-A0MG-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BG-A0MG-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_5_rg.sorted	TCGA-BG-A0MG-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_5_rg.sorted.bam	57.94	1.87	0.14	58cfa830e4b0c9d6adf6bdb3	TCGA-BG-A0MG-01A-21D-A101_120330_SN1120_0129_BD0UCLACXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0MG-01A	9CDE90C8-2BE0-4328-A032-FF1DC19E66FD	Primary Tumor	Illumina HiSeq	30b3e5f5-4066-401d-9cf3-5ee64b9014ef	Uterus	73.0	96B6826D-8A4C-45F5-8CD3-B5988AA5FD0E	755BD772-9331-402B-832B-2933AAECFC71	TCGA-BG-A0MG-01A-21D-A101-02	HG19_Broad_variant	TCGA-BG-A0MG	TCGA-UCEC		s4248	Harvard Medical School	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6be68	58cfa830e4b0c9d6adf6be68	TCGA-BJ-A28Z-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BJ-A28Z-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_2_rg.sorted	TCGA-BJ-A28Z-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_2_rg.sorted.bam	46.06	1.81	0.15	58cfa830e4b0c9d6adf6be68	TCGA-BJ-A28Z-01A-11D-A16N_120718_SN590_0169_AC0WL7ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A28Z-01A	6BA76174-620E-4851-857A-D0ADBFD6F3E6	Primary Tumor	Illumina HiSeq	3d2be877-3825-44b4-99b1-b3c314e68c0c	Thyroid	46.0	D9689254-AFE2-4544-AF54-E02670BD5EBD	F353E9F5-A869-4BE1-ACC4-A832D77285D4	TCGA-BJ-A28Z-01A-11D-A16N-02	HG19_Broad_variant	TCGA-BJ-A28Z	TCGA-THCA		s12508	Harvard Medical School	University of Pittsburgh	United States	NO	T3	N1a	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A16N-02	True
S13722.58cfa830e4b0c9d6adf6be55	58cfa830e4b0c9d6adf6be55	TCGA-AP-A0LT-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-AP-A0LT-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_1_rg.sorted	TCGA-AP-A0LT-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_1_rg.sorted.bam	118.49	2.07	0.17	58cfa830e4b0c9d6adf6be55	TCGA-AP-A0LT-01A-11D-A043_120327_SN590_0149_AD0U12ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-AP-A0LT-01A	43714E9A-E9C4-4206-AF92-1D00D2A8AE35	Primary Tumor	Illumina HiSeq	42ca121f-f3b0-4b47-acb4-f1294f88eb39	Uterus	57.0	C94DD7A5-DD58-4702-A7D1-8199D3F8C9CC	B057AD28-5D99-48BC-B642-7E548914F1B1	TCGA-AP-A0LT-01A-11D-A043-02	HG19_Broad_variant	TCGA-AP-A0LT	TCGA-UCEC		s4242	Harvard Medical School	MSKCC		NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa830e4b0c9d6adf6be38	58cfa830e4b0c9d6adf6be38	TCGA-B5-A0JY-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_6_rg.sorted.filtered.	WGS	TCGA-B5-A0JY-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_6_rg.sorted	TCGA-B5-A0JY-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_6_rg.sorted.bam	80.24	1.95	0.16	58cfa830e4b0c9d6adf6be38	TCGA-B5-A0JY-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JY-01A	61935424-44D0-4211-81C1-C925E436EAC5	Primary Tumor	Illumina HiSeq	e463dbb2-091a-4183-98b6-a90c2e55ffae	Uterus	50.0	95F418CE-FCD9-4402-BC24-1520F45CB6B7	88CE0037-F3F9-4F45-BF14-36A58FF61A3D	TCGA-B5-A0JY-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0JY	TCGA-UCEC		s4784	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6bf3d	58cfa830e4b0c9d6adf6bf3d	TCGA-BR-4187-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-4187-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_5_rg.sorted	TCGA-BR-4187-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_5_rg.sorted.bam	138.9	1.9	0.15	58cfa830e4b0c9d6adf6bf3d	TCGA-BR-4187-01A-01D-1128_120805_SN1222_0142_AD16TGACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4187-01A	12071070-D06B-4C7B-A7B1-77C84963ABE6	Primary Tumor	Illumina HiSeq	1da3a244-39ae-4b4d-baed-e4d9b312f777	Stomach	56.0	144FB4ED-63BB-4908-B678-6026E09566A3	57CF858D-FF3F-4528-96DB-5A820C9B78DE	TCGA-BR-4187-01A-01D-1128-02	HG19_Broad_variant	TCGA-BR-4187	TCGA-STAD		s15046	Harvard Medical School	Asterand	Russia	NO	TX	NX	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1128-02	True
S13722.58cfa830e4b0c9d6adf6bf87	58cfa830e4b0c9d6adf6bf87	TCGA-BJ-A3PR-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BJ-A3PR-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_7_rg.sorted	TCGA-BJ-A3PR-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_7_rg.sorted.bam	45.84		0.15	58cfa830e4b0c9d6adf6bf87	TCGA-BJ-A3PR-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-BJ-A3PR-01A	FD036EC5-3FFB-40B1-8002-943BE0E2532E	Primary Tumor	Illumina HiSeq	c8c8646f-54e4-4440-bf91-d2cd90083c44	Thyroid	69.0	E058A8E1-ED00-48A5-A46B-77538D7B73F1	57FD6BDA-C7B4-4B74-B21A-B7FF5D1C87EE	TCGA-BJ-A3PR-01A-11D-A221-26	HG19_Broad_variant	TCGA-BJ-A3PR	TCGA-THCA		s12358	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T1a	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	True
S13722.58cfa830e4b0c9d6adf6bf7e	58cfa830e4b0c9d6adf6bf7e	TCGA-B5-A0JV-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_5_rg.sorted.filtered.	WGS	TCGA-B5-A0JV-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_5_rg.sorted	TCGA-B5-A0JV-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_5_rg.sorted.bam	90.33	1.92	0.15	58cfa830e4b0c9d6adf6bf7e	TCGA-B5-A0JV-01A-11D-A101_120330_SN208_0280_AD0UKLACXX_s_5_rg.sorted.bam	Alive	FEMALE	BLACK OR AFRICAN AMERICAN		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JV-01A	233E947A-D5E2-48E5-A8CE-5DA1ABB20681	Primary Tumor	Illumina HiSeq	2c99d5d5-1f92-452e-9370-59486a6d7bce	Uterus	63.0	42199E5A-9F4F-4445-9E6E-114D47BA67FA	7132C5C6-9DC5-42A8-863F-D82280266427	TCGA-B5-A0JV-01A-11D-A101-02	HG19_Broad_variant	TCGA-B5-A0JV	TCGA-UCEC		s4783	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6c1aa	58cfa830e4b0c9d6adf6c1aa	TCGA-BA-5555-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_2_rg.sorted.filtered.	WGS	TCGA-BA-5555-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_2_rg.sorted	TCGA-BA-5555-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_2_rg.sorted.bam	213.7	1.9	0.16	58cfa830e4b0c9d6adf6c1aa	TCGA-BA-5555-01A-01D-1509_120420_SN1120_0135_BD0T5FACXX_s_2_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-BA-5555-01A	8970F713-4A7A-4125-892C-6A34139371D8	Primary Tumor	Illumina HiSeq	cd7725ec-bc8e-4c93-aba5-19dbdeb78b0d	Head and Neck	54.0	2920CA1C-6035-4350-ADA4-C60D485DBFFF	4AB42DF9-A215-4965-A125-CC0C4122FF06	TCGA-BA-5555-01A-01D-1509-02	HG19_Broad_variant	TCGA-BA-5555	TCGA-HNSC		s15609	Harvard Medical School	UNC		NO	T3	N2c	Head and Neck Squamous Cell Carcinoma	Stage IVA	1509-02	True
S13722.58cfa830e4b0c9d6adf6c1f6	58cfa830e4b0c9d6adf6c1f6	TCGA-BG-A0M4-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_1_rg.sorted.filtered.	WGS	TCGA-BG-A0M4-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_1_rg.sorted	TCGA-BG-A0M4-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_1_rg.sorted.bam	66.56	2.03	0.15	58cfa830e4b0c9d6adf6c1f6	TCGA-BG-A0M4-01A-11D-A101_120330_SN1120_0129_BD0UCLACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-BG-A0M4-01A	73E5310D-BA8C-4CBC-AA4F-E06206F898F4	Primary Tumor	Illumina HiSeq	6f34976e-c9a0-4b3f-afb6-d476e4d9f22d	Uterus	60.0	E6E7E411-45CF-47A1-BCF0-7AE800A61A8D	238A1E43-B716-479B-82C8-0E62A30F9BE9	TCGA-BG-A0M4-01A-11D-A101-02	HG19_Broad_variant	TCGA-BG-A0M4	TCGA-UCEC		s4429	Harvard Medical School	University of Pittsburgh		NO			Endometrioid endometrial adenocarcinoma		A101-02	True
S13722.58cfa830e4b0c9d6adf6c2c6	58cfa830e4b0c9d6adf6c2c6	TCGA-CF-A1HS-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CF-A1HS-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_5_rg.sorted	TCGA-CF-A1HS-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_5_rg.sorted.bam	42.45	1.95	0.16	58cfa830e4b0c9d6adf6c2c6	TCGA-CF-A1HS-01A-11D-A13U_121011_SN590_0184_BC192GACXX_s_5_rg.sorted.bam	Alive	FEMALE	ASIAN	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CF-A1HS-01A	A73C0842-39C5-4C2C-AA6A-F31341A4F36E	Primary Tumor	Illumina HiSeq	ed90abf4-1d04-41ce-9de3-9dcf24c1e375	Bladder	75.0	0A01E5BA-5549-4027-9E84-1BBB163A8F07	B8F18CDA-053F-4E40-8978-7524A4C0B49A	TCGA-CF-A1HS-01A-11D-A13U-02	HG19_Broad_variant	TCGA-CF-A1HS	TCGA-BLCA		s2875	Harvard Medical School	ILSbio	Vietnam	NO	T3	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A13U-02	True
S13722.58cfa830e4b0c9d6adf6c29a	58cfa830e4b0c9d6adf6c29a	TCGA-B5-A0JR-01A-13D-A043_120403_SN1222_0094_BD0UKBACXX_s_6_rg.sorted.filtered.	WGS	TCGA-B5-A0JR-01A-13D-A043_120403_SN1222_0094_BD0UKBACXX_s_6_rg.sorted	TCGA-B5-A0JR-01A-13D-A043_120403_SN1222_0094_BD0UKBACXX_s_6_rg.sorted.bam	91.47	2.12	0.14	58cfa830e4b0c9d6adf6c29a	TCGA-B5-A0JR-01A-13D-A043_120403_SN1222_0094_BD0UKBACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE		Uterine Corpus Endometrial Carcinoma	Aligned reads	TCGA-B5-A0JR-01A	A766D113-BC3F-4448-A4E5-F391FB0C0E22	Primary Tumor	Illumina HiSeq	1e3ae5a0-6439-4dba-a151-f107d43c65cf	Uterus	73.0	07381A09-5CBD-4744-86EC-41A81E470204	E4F782AB-1668-4730-95D9-CB28E3CF61FD	TCGA-B5-A0JR-01A-13D-A043-02	HG19_Broad_variant	TCGA-B5-A0JR	TCGA-UCEC		s4786	Harvard Medical School	Duke	United States	NO			Endometrioid endometrial adenocarcinoma		A043-02	True
S13722.58cfa831e4b0c9d6adf6c401	58cfa831e4b0c9d6adf6c401	TCGA-CH-5791-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CH-5791-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_1_rg.sorted	TCGA-CH-5791-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_1_rg.sorted.bam	145.7	2.0	0.17	58cfa831e4b0c9d6adf6c401	TCGA-CH-5791-01A-11D-1572_130125_SN208_0451_BD1RB1ACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-CH-5791-01A	829BED0C-C40D-44FD-AEE8-6C7589DB60F9	Primary Tumor	Illumina HiSeq	e2778c71-6feb-40df-8b1e-8d8f0e889beb	Prostate	72.0	C14B5C15-994B-4739-870B-A50984D274A1	500F071A-6697-4880-BBD0-9054CCAE108A	TCGA-CH-5791-01A-11D-1572-02	HG19_Broad_variant	TCGA-CH-5791	TCGA-PRAD		s3417	Harvard Medical School	Indivumed	Germany	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa831e4b0c9d6adf6c4be	58cfa831e4b0c9d6adf6c4be	TCGA-BR-4367-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_3_rg.sorted.filtered.	WGS	TCGA-BR-4367-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_3_rg.sorted	TCGA-BR-4367-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_3_rg.sorted.bam	65.9	1.9	0.14	58cfa831e4b0c9d6adf6c4be	TCGA-BR-4367-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4367-01A	D139BD0C-2EEB-44EC-856B-E77CB03D294E	Primary Tumor	Illumina HiSeq	98785371-4af3-4d04-acc8-5c53c8076618	Stomach	78.0	1506E790-C21C-4419-B11B-14250C947FB5	174658D3-1933-47FD-A883-5F4AFA169778	TCGA-BR-4367-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4367	TCGA-STAD		s14611	Harvard Medical School	Asterand	Russia	NO	TX	N1	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)		1154-02	True
S13722.58cfa831e4b0c9d6adf6c47a	58cfa831e4b0c9d6adf6c47a	TCGA-BT-A3PK-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_3_rg.sorted.filtered.	WGS	TCGA-BT-A3PK-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_3_rg.sorted	TCGA-BT-A3PK-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_3_rg.sorted.bam	57.66		0.17	58cfa831e4b0c9d6adf6c47a	TCGA-BT-A3PK-01A-21D-A221_120906_SN208_0426_BC194HACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-BT-A3PK-01A	73041FCF-F3B6-4851-B34D-1D62A1FCF6FE	Primary Tumor	Illumina HiSeq	637e8bd5-61ee-4d45-8cc5-e3b89950d020	Bladder	80.0	F09E1EEB-BCD5-4DBA-92F0-7D4B34B81CE7	EE975BE9-76BF-4B5A-BF4C-155750C168CD	TCGA-BT-A3PK-01A-21D-A221-26	HG19_Broad_variant	TCGA-BT-A3PK	TCGA-BLCA		s2858	MD Anderson - Institute for Applied Cancer Science	University of Pittsburgh	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A221-26	True
S13722.58cfa831e4b0c9d6adf6c426	58cfa831e4b0c9d6adf6c426	TCGA-CN-4727-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-4727-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_7_rg.sorted	TCGA-CN-4727-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_7_rg.sorted.bam	81.7	1.9	0.14	58cfa831e4b0c9d6adf6c426	TCGA-CN-4727-01A-01D-1431_120504_SN590_0155_AC0KTHACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4727-01A	12D05E8F-8D13-47C1-B713-2250F6ABCEF9	Primary Tumor	Illumina HiSeq	f26c4909-b285-4ca0-ac40-fe65ad4a6a1a	Head and Neck	56.0	F102AEF0-94B8-4D26-8055-35B76DA9DD5F	E42C764C-98DB-4E55-A625-B1443E6C4B3A	TCGA-CN-4727-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4727	TCGA-HNSC		s15495	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True
S13722.58cfa831e4b0c9d6adf6c580	58cfa831e4b0c9d6adf6c580	TCGA-BR-4368-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_5_rg.sorted.filtered.	WGS	TCGA-BR-4368-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_5_rg.sorted	TCGA-BR-4368-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_5_rg.sorted.bam	215.2	1.9	0.15	58cfa831e4b0c9d6adf6c580	TCGA-BR-4368-01A-01D-1154_130815_VM001_0002_VMR0002CXX_s_5_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-4368-01A	449BF2BE-B20E-4AD0-9FFB-910D83114018	Primary Tumor	Illumina HiSeq	138fe28f-1055-4872-99b0-71ca92e3494a	Stomach	78.0	87239062-9EA0-4987-AD13-5A2DDED4FF82	1AED45C5-BB15-43D4-9C04-291B7C5B4428	TCGA-BR-4368-01A-01D-1154-02	HG19_Broad_variant	TCGA-BR-4368	TCGA-STAD		s14469	Harvard Medical School	Asterand	Russia	NO	T4	N2	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IV	1154-02	True
S13722.58cfa831e4b0c9d6adf6c54a	58cfa831e4b0c9d6adf6c54a	TCGA-CN-4730-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_5_rg.sorted.filtered.	WGS	TCGA-CN-4730-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_5_rg.sorted	TCGA-CN-4730-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_5_rg.sorted.bam	23.7	1.9	0.14	58cfa831e4b0c9d6adf6c54a	TCGA-CN-4730-01A-01D-1431_120513_SN590_0157_AD0PU3ACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4730-01A	35C1F2C6-771C-4533-82DF-F8E2EC7107D7	Primary Tumor	Illumina HiSeq	56942e06-fb67-4bf4-993e-16cb67f52239	Head and Neck	62.0	8270C53E-F2CF-4F57-A1AC-A8BA978CC1C8	094C2014-ABA2-4C11-B076-27EA61C7A48E	TCGA-CN-4730-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4730	TCGA-HNSC		s15496	Harvard Medical School	University of Pittsburgh		NO	T4a	N1	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True
S13722.58cfa831e4b0c9d6adf6c5f5	58cfa831e4b0c9d6adf6c5f5	TCGA-CN-5355-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CN-5355-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_7_rg.sorted	TCGA-CN-5355-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_7_rg.sorted.bam	322.7	1.9	0.16	58cfa831e4b0c9d6adf6c5f5	TCGA-CN-5355-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_7_rg.sorted.bam	Alive	MALE	BLACK OR AFRICAN AMERICAN	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5355-01A	45A10908-19E6-421A-8903-1440BFA57C9D	Primary Tumor	Illumina HiSeq	083daa5f-0e79-4402-94b2-48a892a5a4f1	Head and Neck	64.0	63535469-D402-4BA2-9AB5-986E6ED80F55	180BC055-9C10-4B84-80C4-3DF00742719D	TCGA-CN-5355-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5355	TCGA-HNSC		s15501	Harvard Medical School	University of Pittsburgh		NO	T4a	N0	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True
S13722.58cfa831e4b0c9d6adf6c634	58cfa831e4b0c9d6adf6c634	TCGA-CN-5361-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-CN-5361-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_2_rg.sorted	TCGA-CN-5361-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_2_rg.sorted.bam	225.7	1.9	0.15	58cfa831e4b0c9d6adf6c634	TCGA-CN-5361-01A-01D-1431_120418_SN1222_0098_BD0T68ACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5361-01A	044579EF-16A6-4F00-B951-EDC423D8A14F	Primary Tumor	Illumina HiSeq	490cddf8-816a-45f5-acbf-3fd898eb3479	Head and Neck	80.0	C807171A-4433-4246-A454-C5CF768DA8AA	A4E6D494-865F-4F60-B9C6-13C9C0CEA6AB	TCGA-CN-5361-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5361	TCGA-HNSC		s16184	Harvard Medical School	University of Pittsburgh		NO	T4a	N2a	Head and Neck Squamous Cell Carcinoma	Stage IVA	1431-02	True
S13722.58cfa831e4b0c9d6adf6c619	58cfa831e4b0c9d6adf6c619	TCGA-CN-5356-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_8_rg.sorted.filtered.	WGS	TCGA-CN-5356-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_8_rg.sorted	TCGA-CN-5356-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_8_rg.sorted.bam	301.7	1.9	0.15	58cfa831e4b0c9d6adf6c619	TCGA-CN-5356-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_8_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-5356-01A	E1FED7AA-2BCE-45AE-B0C6-7F50EF97E425	Primary Tumor	Illumina HiSeq	c8e59618-fd16-4e8e-abe2-e3d5d674390c	Head and Neck	56.0	BCB5DA85-78D6-4519-9740-378587B1BD37	199B42E1-301A-49AD-A364-BBF4FAD8B049	TCGA-CN-5356-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-5356	TCGA-HNSC		s15885	Harvard Medical School	University of Pittsburgh		NO	T3	N0	Head and Neck Squamous Cell Carcinoma	Stage III	1431-02	True
S13722.58cfa831e4b0c9d6adf6c642	58cfa831e4b0c9d6adf6c642	TCGA-CN-4734-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_1_rg.sorted.filtered.	WGS	TCGA-CN-4734-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_1_rg.sorted	TCGA-CN-4734-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_1_rg.sorted.bam	72.7	1.9	0.15	58cfa831e4b0c9d6adf6c642	TCGA-CN-4734-01A-01D-1431_120412_SN208_0283_AD0V1GACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-4734-01A	B80FDC9A-341D-4277-9664-8E8F770D9DDD	Primary Tumor	Illumina HiSeq	4b3be461-622d-492e-8465-1d0d1167701c	Head and Neck	70.0	20614787-1E55-40F0-88DE-080640EB8A03	EA9125C8-3F3B-47CE-AD79-802692B1FB4A	TCGA-CN-4734-01A-01D-1431-02	HG19_Broad_variant	TCGA-CN-4734	TCGA-HNSC		s15759	Harvard Medical School	University of Pittsburgh		NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	1431-02	True
S13722.58cfa831e4b0c9d6adf6c6c8	58cfa831e4b0c9d6adf6c6c8	TCGA-CU-A3KJ-01A-11D-A21C_120914_SN590_0179_AD13PPACXX_s_7_rg.sorted.filtered.	WGS	TCGA-CU-A3KJ-01A-11D-A21C_120914_SN590_0179_AD13PPACXX_s_7_rg.sorted	TCGA-CU-A3KJ-01A-11D-A21C_120914_SN590_0179_AD13PPACXX_s_7_rg.sorted.bam	49.18		0.15	58cfa831e4b0c9d6adf6c6c8	TCGA-CU-A3KJ-01A-11D-A21C_120914_SN590_0179_AD13PPACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-CU-A3KJ-01A	A75584BC-BEF7-48F6-B4B3-C1472A3AF768	Primary Tumor	Illumina HiSeq	6b7a9ee7-ee89-4473-9170-7372313595f7	Bladder	75.0	3D92F5A6-949A-4176-9309-4294CCA6FC25	25847D62-9932-4A04-9B00-378794D2CE72	TCGA-CU-A3KJ-01A-11D-A21C-26	HG19_Broad_variant	TCGA-CU-A3KJ	TCGA-BLCA		s3098	MD Anderson - Institute for Applied Cancer Science	UNC	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A21C-26	True
S13722.58cfa831e4b0c9d6adf6c772	58cfa831e4b0c9d6adf6c772	TCGA-CQ-7068-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_6_rg.sorted.filtered.	WGS	TCGA-CQ-7068-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_6_rg.sorted	TCGA-CQ-7068-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_6_rg.sorted.bam	637.73		0.15	58cfa831e4b0c9d6adf6c772	TCGA-CQ-7068-01A-11D-2317_120730_SN1222_0140_AC11GKACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-7068-01A	8EBE8C25-5EF9-42D4-9414-8313227B673F	Primary Tumor	Illumina HiSeq	77b40e7d-41a7-4e5d-a3e9-ce1e2d077c98	Head and Neck	80.0	1C86E4AF-03CE-477C-BE08-0CFA565861B7	F0B87929-92F5-4AB9-849F-00F970E56577	TCGA-CQ-7068-01A-11D-2317-26	HG19_Broad_variant	TCGA-CQ-7068	TCGA-HNSC		s15506	MD Anderson - Institute for Applied Cancer Science	University Health Network, Toronto	Canada	NO	T2	N0	Head and Neck Squamous Cell Carcinoma	Stage II	2317-26	True
S13722.58cfa831e4b0c9d6adf6c801	58cfa831e4b0c9d6adf6c801	TCGA-CN-6018-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_3_rg.sorted.filtered.	WGS	TCGA-CN-6018-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_3_rg.sorted	TCGA-CN-6018-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_3_rg.sorted.bam	96.0	1.9	0.14	58cfa831e4b0c9d6adf6c801	TCGA-CN-6018-01A-11D-1681_120425_SN1222_0099_AC0JCEACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CN-6018-01A	55838E1F-07E8-49CA-89D6-46216BABC6F7	Primary Tumor	Illumina HiSeq	ce9ca233-92c4-44b8-b97f-b56f1f73cb5a	Head and Neck	85.0	1A3E8C8B-9E99-499A-9BA7-4CDFC11B106D	7F0998E4-AF05-42C5-962C-5EA4D8993EB0	TCGA-CN-6018-01A-11D-1681-02	HG19_Broad_variant	TCGA-CN-6018	TCGA-HNSC		s15498	Harvard Medical School	University of Pittsburgh	United States	NO	T4a	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	1681-02	True
S13722.58cfa831e4b0c9d6adf6ca0d	58cfa831e4b0c9d6adf6ca0d	TCGA-DK-A1AD-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DK-A1AD-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_5_rg.sorted	TCGA-DK-A1AD-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_5_rg.sorted.bam	55.51	1.93	0.17	58cfa831e4b0c9d6adf6ca0d	TCGA-DK-A1AD-01A-11D-A13U_121025_SN590_0188_AC190CACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE		Bladder Urothelial Carcinoma	Aligned reads	TCGA-DK-A1AD-01A	88A521CE-A5E9-4C6F-83D4-EC36A62FEDB6	Primary Tumor	Illumina HiSeq	26694fc3-c6e4-45f9-82f0-57b6f4955b4b	Bladder	69.0	C79F4327-675D-4651-994D-E683096DF9C3	86DF29FD-B5F6-4316-BC89-DC9386D177C6	TCGA-DK-A1AD-01A-11D-A13U-02	HG19_Broad_variant	TCGA-DK-A1AD	TCGA-BLCA		s2711	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T3b	N2	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A13U-02	True
S13722.58cfa831e4b0c9d6adf6c94f	58cfa831e4b0c9d6adf6c94f	TCGA-D7-5578-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_2_rg.sorted.filtered.	WGS	TCGA-D7-5578-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_2_rg.sorted	TCGA-D7-5578-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_2_rg.sorted.bam	331.0	1.88	0.15	58cfa831e4b0c9d6adf6c94f	TCGA-D7-5578-01A-01D-1598_121023_SN208_0437_BD1H3FACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-D7-5578-01A	A3C1F9A2-9174-48CF-81DC-2AFCFDC4BA9C	Primary Tumor	Illumina HiSeq	306aee2b-5fac-4825-952b-d838746530a5	Stomach	80.0	E88D8673-C0BE-4549-8DAF-100187608F17	A00E8607-F965-421B-B0ED-57C09488F514	TCGA-D7-5578-01A-01D-1598-02	HG19_Broad_variant	TCGA-D7-5578	TCGA-STAD		s15401	Harvard Medical School	Greater Poland Cancer Center	Poland	NO	T3	N2	Stomach  Intestinal Adenocarcinoma  Tubular Type	Stage IIIA	1598-02	True
S13722.58cfa831e4b0c9d6adf6ca21	58cfa831e4b0c9d6adf6ca21	TCGA-DJ-A1QD-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-DJ-A1QD-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_6_rg.sorted	TCGA-DJ-A1QD-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_6_rg.sorted.bam	61.38	2.0	0.18	58cfa831e4b0c9d6adf6ca21	TCGA-DJ-A1QD-01A-11D-A14U_120717_SN1120_0175_AC1179ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-DJ-A1QD-01A	DA201150-748E-4B74-BB35-10C995E26079	Primary Tumor	Illumina HiSeq	df7bafb3-c992-479d-be29-dae220124025	Thyroid	20.0	A8307181-67CE-4A79-8D23-76CEEE1D2761	781162AA-AAFA-4C44-B9AF-727917E8C9F4	TCGA-DJ-A1QD-01A-11D-A14U-02	HG19_Broad_variant	TCGA-DJ-A1QD	TCGA-THCA		s12367	Harvard Medical School	Memorial Sloan Kettering	United States	NO	T2	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A14U-02	True
S13722.58cfa831e4b0c9d6adf6cb12	58cfa831e4b0c9d6adf6cb12	TCGA-EA-A3HS-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EA-A3HS-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_3_rg.sorted	TCGA-EA-A3HS-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_3_rg.sorted.bam	76.91		0.16	58cfa831e4b0c9d6adf6cb12	TCGA-EA-A3HS-01A-11D-A20X_140106_SN590_0243_AC371BACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EA-A3HS-01A	753EE373-FBCF-4349-B9B2-5A41936E27E9	Primary Tumor	Illumina HiSeq	684e83c6-0894-4bfd-a2ee-6b1877c74f82	Cervix	35.0	0835FA38-9870-472E-B9A0-2A2652807BC5	E87CC37B-FD44-4DD9-9D14-455B89C6D4C2	TCGA-EA-A3HS-01A-11D-A20X-26	HG19_Broad_variant	TCGA-EA-A3HS	TCGA-CESC		s1522	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T1b	N0	Cervical Squamous Cell Carcinoma		A20X-26	True
S13722.58cfa831e4b0c9d6adf6cbaf	58cfa831e4b0c9d6adf6cbaf	TCGA-EK-A3GN-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EK-A3GN-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_2_rg.sorted	TCGA-EK-A3GN-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_2_rg.sorted.bam	50.85		0.14	58cfa831e4b0c9d6adf6cbaf	TCGA-EK-A3GN-01A-11D-A20X_140417_SN590_0248_AC3EUFACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A3GN-01A	F727FCB9-E457-4643-9468-F739133B7E9C	Primary Tumor	Illumina HiSeq	b9e845ee-3e61-4ccf-b14e-f8a6b8481bd3	Cervix	47.0	EB5034E2-D4A7-48E0-9524-31DDD63C9D94	49F2E671-D283-4B5C-B8A3-490C0A383FC1	TCGA-EK-A3GN-01A-11D-A20X-26	HG19_Broad_variant	TCGA-EK-A3GN	TCGA-CESC		s1364	MD Anderson - Institute for Applied Cancer Science	Gynecologic Oncology Group	United States	NO	TX	NX	Cervical Squamous Cell Carcinoma		A20X-26	True
S13722.58cfa831e4b0c9d6adf6cbbe	58cfa831e4b0c9d6adf6cbbe	TCGA-EK-A3GM-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_4_rg.sorted.filtered.	WGS	TCGA-EK-A3GM-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_4_rg.sorted	TCGA-EK-A3GM-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_4_rg.sorted.bam	59.88		0.15	58cfa831e4b0c9d6adf6cbbe	TCGA-EK-A3GM-01A-11D-A20X_140131_SN590_0247_AC3FDBACXX_s_4_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A3GM-01A	CB780C10-8810-4384-B829-954AAB1C16C8	Primary Tumor	Illumina HiSeq	2ec77e09-5fb7-4247-9027-1db441eab2b8	Cervix	65.0	A4B92B76-FF87-475E-924B-840F652FC019	4981CFD4-2A8C-4CF8-8AC2-31BDF9DC02CD	TCGA-EK-A3GM-01A-11D-A20X-26	HG19_Broad_variant	TCGA-EK-A3GM	TCGA-CESC		s1186	MD Anderson - Institute for Applied Cancer Science	Gynecologic Oncology Group	United States	NO			Endocervical Type of Adenocarcinoma		A20X-26	True
S13722.58cfa831e4b0c9d6adf6cbb4	58cfa831e4b0c9d6adf6cbb4	TCGA-EK-A2RN-01A-12D-A20X_140117_SN590_0246_BC37BDACXX_s_2_rg.sorted.filtered.	WGS	TCGA-EK-A2RN-01A-12D-A20X_140117_SN590_0246_BC37BDACXX_s_2_rg.sorted	TCGA-EK-A2RN-01A-12D-A20X_140117_SN590_0246_BC37BDACXX_s_2_rg.sorted.bam	17.97		0.17	58cfa831e4b0c9d6adf6cbb4	TCGA-EK-A2RN-01A-12D-A20X_140117_SN590_0246_BC37BDACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-EK-A2RN-01A	B610D391-0C9D-4114-94D6-5E4AA4270122	Primary Tumor	Illumina HiSeq	def278f8-93eb-4373-a525-98b2cf12af7a	Cervix	45.0	24BACABF-8C6F-416A-B1F3-B0BAAA2F0AD9	3B5905A9-4B73-4946-A10B-D3E7ECAFFC7C	TCGA-EK-A2RN-01A-12D-A20X-26	HG19_Broad_variant	TCGA-EK-A2RN	TCGA-CESC		s1368	MD Anderson - Institute for Applied Cancer Science	Gynecologic Oncology Group	United States	NO	T2b	N1	Cervical Squamous Cell Carcinoma		A20X-26	True
S13722.58cfa831e4b0c9d6adf6cc2f	58cfa831e4b0c9d6adf6cc2f	TCGA-DU-7008-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_1_rg.sorted.filtered.	WGS	TCGA-DU-7008-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_1_rg.sorted	TCGA-DU-7008-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_1_rg.sorted.bam	111.0		0.15	58cfa831e4b0c9d6adf6cc2f	TCGA-DU-7008-01A-11D-2022_130910_SN208_0495_BD2FGNACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-7008-01A	427C40F6-D1BD-49F2-B303-A975793B937E	Primary Tumor	Illumina HiSeq	3a51e8e7-621e-4d62-bb3d-cb6700af6a43	Brain	41.0	7A0C3571-4265-4D36-AFBC-FA234970F94B	7602BA72-B5E0-49C7-940A-6E9EFBDB5C58	TCGA-DU-7008-01A-11D-2022-02	HG19_Broad_variant	TCGA-DU-7008	TCGA-LGG		s8566	Harvard Medical School	Henry Ford Hospital	United States	NO			Oligodendroglioma		2022-02	True
S13722.58cfa831e4b0c9d6adf6cc80	58cfa831e4b0c9d6adf6cc80	TCGA-EL-A3T6-01A-11D-A221_120523_SN1222_0108_AC0VL4ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-EL-A3T6-01A-11D-A221_120523_SN1222_0108_AC0VL4ACXX_s_7_rg.sorted	TCGA-EL-A3T6-01A-11D-A221_120523_SN1222_0108_AC0VL4ACXX_s_7_rg.sorted.bam	40.31		0.15	58cfa831e4b0c9d6adf6cc80	TCGA-EL-A3T6-01A-11D-A221_120523_SN1222_0108_AC0VL4ACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-EL-A3T6-01A	90507BAA-B716-4BCF-A18E-9D8AE97D809A	Primary Tumor	Illumina HiSeq	fb31d05f-8a2e-416d-92b9-fd333e80561f	Thyroid	34.0	61367375-8317-4CAE-86CF-2FD65AB8ABC8	C1FE07E8-83AC-47A7-B8E5-FA62DE03BB17	TCGA-EL-A3T6-01A-11D-A221-26	HG19_Broad_variant	TCGA-EL-A3T6	TCGA-THCA		s12518	MD Anderson - Institute for Applied Cancer Science	MD Anderson	United States	NO	T3	N0	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	True
S13722.58cfa832e4b0c9d6adf6cdfc	58cfa832e4b0c9d6adf6cdfc	TCGA-FD-A3SN-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_7_rg.sorted.filtered.	WGS	TCGA-FD-A3SN-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_7_rg.sorted	TCGA-FD-A3SN-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_7_rg.sorted.bam	33.16		0.15	58cfa832e4b0c9d6adf6cdfc	TCGA-FD-A3SN-01A-12D-A233_120830_SN208_0423_AC190AACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-FD-A3SN-01A	0FB043D3-D86B-4CD8-8C01-9E2B3E965BB0	Primary Tumor	Illumina HiSeq	2281a267-dad6-42d6-9df2-8d37a696c507	Bladder	79.0	127892ED-8A7A-41CB-8ABE-353E09E6D327	B0AD1373-0C51-41A3-9F8B-BDE28C67CFB8	TCGA-FD-A3SN-01A-12D-A233-26	HG19_Broad_variant	TCGA-FD-A3SN	TCGA-BLCA		s2719	MD Anderson - Institute for Applied Cancer Science	BLN - University Of Chicago	United States	NO	T3b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage III	A233-26	True
S13722.58cfa832e4b0c9d6adf6ce63	58cfa832e4b0c9d6adf6ce63	TCGA-GV-A3QH-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_5_rg.sorted.filtered.	WGS	TCGA-GV-A3QH-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_5_rg.sorted	TCGA-GV-A3QH-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_5_rg.sorted.bam	38.38		0.14	58cfa832e4b0c9d6adf6ce63	TCGA-GV-A3QH-01A-11D-A221_120830_SN590_0178_AD143RACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GV-A3QH-01A	33BC6A7C-9844-41E3-96B3-1E34BB3FEDD5	Primary Tumor	Illumina HiSeq	5672aee8-638c-45c6-af4f-0ccc5e2a1b45	Bladder	67.0	DEB7311F-E747-44EC-92C3-1E56CD5CACF2	B14D2F40-53F3-4A3A-8FA8-1BE7F102CA25	TCGA-GV-A3QH-01A-11D-A221-26	HG19_Broad_variant	TCGA-GV-A3QH	TCGA-BLCA		s3129	MD Anderson - Institute for Applied Cancer Science	BLN - Cleveland Clinic	United States	NO		NX	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A221-26	True
S13722.58cfa832e4b0c9d6adf6ce8b	58cfa832e4b0c9d6adf6ce8b	TCGA-FY-A3RA-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_6_rg.sorted.filtered.	WGS	TCGA-FY-A3RA-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_6_rg.sorted	TCGA-FY-A3RA-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_6_rg.sorted.bam	38.77		0.17	58cfa832e4b0c9d6adf6ce8b	TCGA-FY-A3RA-01A-11D-A221_120611_SN1222_0114_AC0WL3ACXX_s_6_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A3RA-01A	58FF4366-20A3-40A2-A87A-551E17CDB5D3	Primary Tumor	Illumina HiSeq	a7a005ec-f27f-4c17-8bb6-879c800bb0ae	Thyroid	21.0	E67E2BBE-8C3F-41B1-BE3C-C89555A10AEE	40CA310C-DB41-44D5-A76C-72938CF4AED0	TCGA-FY-A3RA-01A-11D-A221-26	HG19_Broad_variant	TCGA-FY-A3RA	TCGA-THCA		s12651	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	True
S13722.58cfa832e4b0c9d6adf6ce99	58cfa832e4b0c9d6adf6ce99	TCGA-FY-A3R8-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_3_rg.sorted.filtered.	WGS	TCGA-FY-A3R8-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_3_rg.sorted	TCGA-FY-A3R8-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_3_rg.sorted.bam	51.96		0.15	58cfa832e4b0c9d6adf6ce99	TCGA-FY-A3R8-01A-11D-A221_120524_SN1120_0144_AC0VNCACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A3R8-01A	C77976B6-35EA-4623-A92A-6D9440A978E6	Primary Tumor	Illumina HiSeq	7d0e9d6d-fb33-481e-93f7-84ae9641ce75	Thyroid	62.0	BAA64E5A-237E-44AC-8B22-2D86E710F7DB	3D9D0EC4-8C81-40D9-886F-8813570E732D	TCGA-FY-A3R8-01A-11D-A221-26	HG19_Broad_variant	TCGA-FY-A3R8	TCGA-THCA		s12392	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T3	NX	Thyroid Papillary Carcinoma - Classical/usual	Stage III	A221-26	True
S13722.58cfa832e4b0c9d6adf6cf22	58cfa832e4b0c9d6adf6cf22	TCGA-G9-6364-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G9-6364-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_7_rg.sorted	TCGA-G9-6364-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_7_rg.sorted.bam	79.4	1.9	0.13	58cfa832e4b0c9d6adf6cf22	TCGA-G9-6364-01A-21D-1784_130215_SN590_0211_AC1UJWACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6364-01A	F8D8B417-5945-42A5-850A-FBC04B4F0E61	Primary Tumor	Illumina HiSeq	01dfbaf5-2c53-4f89-97c0-f845932cfde5	Prostate	72.0	242C8BCB-F8D3-4D3A-ABB1-0AB5D74D3BCB	6E0AAA4D-9ACC-4E63-AC7E-5B478D6406B5	TCGA-G9-6364-01A-21D-1784-02	HG19_Broad_variant	TCGA-G9-6364	TCGA-PRAD		s4147	Harvard Medical School	Roswell Park	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1784-02	True
S13722.58cfa832e4b0c9d6adf6cf96	58cfa832e4b0c9d6adf6cf96	TCGA-G9-6351-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_2_rg.sorted.filtered.	WGS	TCGA-G9-6351-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_2_rg.sorted	TCGA-G9-6351-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_2_rg.sorted.bam	149.7	1.9	0.15	58cfa832e4b0c9d6adf6cf96	TCGA-G9-6351-01A-21D-1957_130405_SN590_0222_BD21LGACXX_s_2_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6351-01A	F59B9C65-46E8-4CC3-AA71-8844F6C2273C	Primary Tumor	Illumina HiSeq	ddf40c8c-cec5-4f4b-853a-1541566f51b5	Prostate	51.0	92436584-12D6-4CF2-9AB1-CDF98E4E8260	DE6145E0-8D30-4CA1-A169-0BDC7E5BC57A	TCGA-G9-6351-01A-21D-1957-02	HG19_Broad_variant	TCGA-G9-6351	TCGA-PRAD		s3618	Harvard Medical School	Roswell Park	United States	NO	T2c		Prostate Adenocarcinoma Acinar Type		1957-02	True
S13722.58cfa832e4b0c9d6adf6cf9f	58cfa832e4b0c9d6adf6cf9f	TCGA-H2-A3RH-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_2_rg.sorted.filtered.	WGS	TCGA-H2-A3RH-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_2_rg.sorted	TCGA-H2-A3RH-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_2_rg.sorted.bam	62.17		0.15	58cfa832e4b0c9d6adf6cf9f	TCGA-H2-A3RH-01A-11D-A221_120610_SN1120_0151_AC0WN0ACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-H2-A3RH-01A	0314B145-2F3A-4A90-A580-375B5F0A63A4	Primary Tumor	Illumina HiSeq	dddfb702-cb09-4a5f-b023-b31d89ec07a8	Thyroid	41.0	1A9E811D-1C60-409C-A7D2-1D58AFA473E9	8358E269-BD6E-4189-86AB-520C84405DAA	TCGA-H2-A3RH-01A-11D-A221-26	HG19_Broad_variant	TCGA-H2-A3RH	TCGA-THCA		s12532	MD Anderson - Institute for Applied Cancer Science	Christiana Healthcare	United States	NO	T1b	N0	Thyroid Papillary Carcinoma - Follicular (>= 99% follicular patterned)	Stage I	A221-26	True
S13722.58cfa832e4b0c9d6adf6cfbe	58cfa832e4b0c9d6adf6cfbe	TCGA-G9-6385-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_7_rg.sorted.filtered.	WGS	TCGA-G9-6385-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_7_rg.sorted	TCGA-G9-6385-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_7_rg.sorted.bam	249.4	1.9	0.14	58cfa832e4b0c9d6adf6cfbe	TCGA-G9-6385-01A-11D-1784_130301_SN590_0217_BC1UHMACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-G9-6385-01A	E82A04CF-E81E-43C6-9CD9-0E29FA0F00AE	Primary Tumor	Illumina HiSeq	53da3cf6-b29e-4b1f-9d51-c1f9648b6634	Prostate	66.0	CFE4B1FA-B658-49D3-87AD-6DF7D75A58DF	00D3CD80-E6C2-4408-8F10-3656BD371157	TCGA-G9-6385-01A-11D-1784-02	HG19_Broad_variant	TCGA-G9-6385	TCGA-PRAD		s3456	Harvard Medical School	Roswell Park	United States	NO	T2c		Prostate Adenocarcinoma Acinar Type		1784-02	True
S13722.58cfa832e4b0c9d6adf6d024	58cfa832e4b0c9d6adf6d024	TCGA-GC-A3BM-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_3_rg.sorted.filtered.	WGS	TCGA-GC-A3BM-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_3_rg.sorted	TCGA-GC-A3BM-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_3_rg.sorted.bam	51.48		0.15	58cfa832e4b0c9d6adf6d024	TCGA-GC-A3BM-01A-11D-A23Q_120926_SN1222_0153_BD1D4MACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GC-A3BM-01A	7840AEA9-40C4-473E-BE33-8FA0B9F332C9	Primary Tumor	Illumina HiSeq	1901f2a9-837a-482c-8073-472f3c4d9ba1	Bladder	70.0	5C631CE8-F96A-4C35-A459-556FC4AB21E1	5FE3FF9D-CCF4-4C76-820D-26FD5D1FCD15	TCGA-GC-A3BM-01A-11D-A23Q-26	HG19_Broad_variant	TCGA-GC-A3BM	TCGA-BLCA		s2924	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2b	N0	Muscle invasive urothelial carcinoma (pT2 or above)	Stage II	A23Q-26	True
S13722.58cfa832e4b0c9d6adf6d042	58cfa832e4b0c9d6adf6d042	TCGA-FU-A3EO-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FU-A3EO-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_1_rg.sorted	TCGA-FU-A3EO-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_1_rg.sorted.bam	43.71		0.16	58cfa832e4b0c9d6adf6d042	TCGA-FU-A3EO-01A-11D-A20X_140106_SN590_0244_BC384EACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	Aligned reads	TCGA-FU-A3EO-01A	B7F2958F-256E-4C30-9C61-11E76DDB36BA	Primary Tumor	Illumina HiSeq	31874bb0-fa47-43d4-8135-1be05e8163eb	Cervix	55.0	59F1684E-5631-4E1E-A1DC-91739F7C159C	50DBFC58-57DC-4878-8506-7B6B21899DF5	TCGA-FU-A3EO-01A-11D-A20X-26	HG19_Broad_variant	TCGA-FU-A3EO	TCGA-CESC		s1201	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2b	N0	Endocervical Type of Adenocarcinoma		A20X-26	True
S13722.58cfa832e4b0c9d6adf6d0dd	58cfa832e4b0c9d6adf6d0dd	TCGA-HW-7495-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_3_rg.sorted.filtered.	WGS	TCGA-HW-7495-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_3_rg.sorted	TCGA-HW-7495-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_3_rg.sorted.bam	107.0		0.15	58cfa832e4b0c9d6adf6d0dd	TCGA-HW-7495-01A-11D-2022_130913_SN1440_0168_BD2B0UACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-HW-7495-01A	49967A57-7C12-46BB-8D71-CEBBB17C9935	Primary Tumor	Illumina HiSeq	10d85d7f-6926-453a-bfef-d1b9d129d9d1	Brain	45.0	1CCC7965-99A5-420A-B5AB-F9853B50E3B1	07DDE76E-E126-4D66-BA85-059F076B7D04	TCGA-HW-7495-01A-11D-2022-02	HG19_Broad_variant	TCGA-HW-7495	TCGA-LGG		s8577	Harvard Medical School	MSKCC	United States	NO			Oligodendroglioma		2022-02	True
S13722.58cfa832e4b0c9d6adf6d026	58cfa832e4b0c9d6adf6d026	TCGA-GD-A3OQ-01A-32D-A221_120902_SN1222_0147_AC195DACXX_s_4_rg.sorted.filtered.	WGS	TCGA-GD-A3OQ-01A-32D-A221_120902_SN1222_0147_AC195DACXX_s_4_rg.sorted	TCGA-GD-A3OQ-01A-32D-A221_120902_SN1222_0147_AC195DACXX_s_4_rg.sorted.bam	40.42		0.15	58cfa832e4b0c9d6adf6d026	TCGA-GD-A3OQ-01A-32D-A221_120902_SN1222_0147_AC195DACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Bladder Urothelial Carcinoma	Aligned reads	TCGA-GD-A3OQ-01A	2E85C30C-C4C4-4096-9EEF-4EB2C7D991A3	Primary Tumor	Illumina HiSeq	a07d0456-032d-409c-af8d-c4d6349ef4db	Bladder	48.0	E3D22638-C0AE-48AA-A523-8C9A6CFBF063	F77305E9-430E-4E7D-97A6-C97FFDDC3B65	TCGA-GD-A3OQ-01A-32D-A221-26	HG19_Broad_variant	TCGA-GD-A3OQ	TCGA-BLCA		s2923	MD Anderson - Institute for Applied Cancer Science	ABS - IUPUI	United States	NO	T4a	N1	Muscle invasive urothelial carcinoma (pT2 or above)	Stage IV	A221-26	True
S13722.58cfa832e4b0c9d6adf6d132	58cfa832e4b0c9d6adf6d132	TCGA-FY-A3R6-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_1_rg.sorted.filtered.	WGS	TCGA-FY-A3R6-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_1_rg.sorted	TCGA-FY-A3R6-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_1_rg.sorted.bam	10.85		0.16	58cfa832e4b0c9d6adf6d132	TCGA-FY-A3R6-01A-11D-A221_120611_SN1222_0115_BD141KACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FY-A3R6-01A	905469D2-4C97-4293-A20C-1B1F0462A25D	Primary Tumor	Illumina HiSeq	bd320251-720a-4498-a699-419a2544fe75	Thyroid	57.0	65414BA0-8800-4626-9488-10D79274CF32	EFF7FEA8-DF07-4DAD-BD26-7384906844E9	TCGA-FY-A3R6-01A-11D-A221-26	HG19_Broad_variant	TCGA-FY-A3R6	TCGA-THCA		s12258	MD Anderson - Institute for Applied Cancer Science	International Genomics Consortium	United States	NO	T2	N1b	Thyroid Papillary Carcinoma - Classical/usual	Stage IVA	A221-26	True
S13722.58cfa832e4b0c9d6adf6d191	58cfa832e4b0c9d6adf6d191	TCGA-FE-A3PC-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_2_rg.sorted.filtered.	WGS	TCGA-FE-A3PC-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_2_rg.sorted	TCGA-FE-A3PC-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_2_rg.sorted.bam	48.5		0.15	58cfa832e4b0c9d6adf6d191	TCGA-FE-A3PC-01A-11D-A221_120524_SN1120_0145_BD12MWACXX_s_2_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Thyroid Carcinoma	Aligned reads	TCGA-FE-A3PC-01A	A86AC3B5-B5E9-4420-8DE0-A358FCAD85B6	Primary Tumor	Illumina HiSeq	7072b927-397f-4821-a834-0b1e21ec3434	Thyroid	37.0	7A5628FF-C5C2-4F25-809B-640415323477	8B0BF4B5-9846-473B-A2DB-8390B0DB90A7	TCGA-FE-A3PC-01A-11D-A221-26	HG19_Broad_variant	TCGA-FE-A3PC	TCGA-THCA		s12647	MD Anderson - Institute for Applied Cancer Science	Ohio State University	United States	NO	T3	N1	Thyroid Papillary Carcinoma - Classical/usual	Stage I	A221-26	True
S13722.58cfa832e4b0c9d6adf6d3e3	58cfa832e4b0c9d6adf6d3e3	TCGA-V4-A9EL-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_1_rg.sorted.filtered.	WGS	TCGA-V4-A9EL-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_1_rg.sorted	TCGA-V4-A9EL-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_1_rg.sorted.bam	36.66		0.17	58cfa832e4b0c9d6adf6d3e3	TCGA-V4-A9EL-01A-11D-A40D_140808_SN590_0253_AC499NACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9EL-01A	8DE236F1-C029-44DF-A2A9-319145488BAA	Primary Tumor	Illumina HiSeq	37f105ff-ac0b-4651-9c5f-008d937dc883	Eye	60.0	DB91E719-82B1-4E9A-AB28-AC67B726340B	50022AEA-CB52-4402-9FC2-C8A4EC1600FF	TCGA-V4-A9EL-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9EL	TCGA-UVM		s199	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d49c	58cfa832e4b0c9d6adf6d49c	TCGA-V4-A9F4-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_4_rg.sorted.filtered.	WGS	TCGA-V4-A9F4-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_4_rg.sorted	TCGA-V4-A9F4-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_4_rg.sorted.bam	55.04		0.16	58cfa832e4b0c9d6adf6d49c	TCGA-V4-A9F4-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_4_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F4-01A	4B9FD822-17AA-4A22-8E17-175A72931D5D	Primary Tumor	Illumina HiSeq	1f82d81a-7827-4bb8-89b2-fc4bd009cdde	Eye	41.0	AD550F5E-1469-4A09-9CDA-3F069B1AE258	1837571E-8D54-4BA2-A9FB-B7160BFD38BB	TCGA-V4-A9F4-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F4	TCGA-UVM		s236	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T4a	N0		Stage IIIA	A40D-26	True
S13722.58cfa832e4b0c9d6adf6d4e5	58cfa832e4b0c9d6adf6d4e5	TCGA-V4-A9F1-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_1_rg.sorted.filtered.	WGS	TCGA-V4-A9F1-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_1_rg.sorted	TCGA-V4-A9F1-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_1_rg.sorted.bam	51.84		0.17	58cfa832e4b0c9d6adf6d4e5	TCGA-V4-A9F1-01A-11D-A40D_140715_SN1440_0193_BC4K41ACXX_s_1_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Uveal Melanoma	Aligned reads	TCGA-V4-A9F1-01A	94F3D9B0-0EE4-4F6A-A8FF-CE7A4D8FAB76	Primary Tumor	Illumina HiSeq	83f97de6-ac60-4cc0-bcff-bdecfe40f951	Eye	46.0	6C6A3062-B453-434B-9168-7837CAABC4EF	706721D2-3759-4664-BFB7-8FF7273C2786	TCGA-V4-A9F1-01A-11D-A40D-26	HG19_Broad_variant	TCGA-V4-A9F1	TCGA-UVM		s226	MD Anderson - Institute for Applied Cancer Science	Institut Curie	France	NO	T3a	N0		Stage IIB	A40D-26	True
S13722.58cfa82de4b0c9d6adf6a5dc	58cfa82de4b0c9d6adf6a5dc	5c54cebf17d98a845d11ad5d5185f4a0.filtered.	WGS	5c54cebf17d98a845d11ad5d5185f4a0	5c54cebf17d98a845d11ad5d5185f4a0.bam	37.22	1.8	0.07	58cfa82de4b0c9d6adf6a5dc	5c54cebf17d98a845d11ad5d5185f4a0.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-B6-A0RU-01A	6956473B-92E5-4069-A26B-B48E280E76F2	Primary Tumor	Illumina HiSeq	2efc5248-9be4-4e98-a400-f2ee744ac29d	Breast	40.0	C94232F8-2E37-46D0-B12A-B8E920E659D9	97064332-1D4F-4571-93FF-354FFE6D7DF9	TCGA-B6-A0RU-01A-11D-A12L-09	GRCh37-lite	TCGA-B6-A0RU	TCGA-BRCA		s5950	Washington University School of Medicine	Duke	United States	NO	T1c	N0 (i-)	Other  specify	Stage IA	A12L-09	False
S13722.58cfa82ee4b0c9d6adf6aa51	58cfa82ee4b0c9d6adf6aa51	G35155.TCGA-CR-5243-01A-01D-1512-08.2.filtered.	WGS	G35155.TCGA-CR-5243-01A-01D-1512-08.2	G35155.TCGA-CR-5243-01A-01D-1512-08.2.bam	348.7	1.9	0.05	58cfa82ee4b0c9d6adf6aa51	G35155.TCGA-CR-5243-01A-01D-1512-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-5243-01A	E37F479F-CA05-45E4-AC6D-A974BED6E7F8	Primary Tumor	Illumina HiSeq	9b40a7ed-a315-4294-ade6-8b2194292f0b	Head and Neck	51.0	D89D46EA-9A7A-4FD8-B11E-9C9CA4780119	297E8B35-5B8B-4D5B-B812-86165F949A20	TCGA-CR-5243-01A-01D-1512-08	HG19_Broad_variant	TCGA-CR-5243	TCGA-HNSC		s15873	Broad Institute of MIT and Harvard	Vanderbilt University		NO	TX	NX	Head and Neck Squamous Cell Carcinoma		1512-08	False
S13722.58cfa82ee4b0c9d6adf6ab7e	58cfa82ee4b0c9d6adf6ab7e	G35155.TCGA-CQ-5323-01A-01D-1683-08.2.filtered.	WGS	G35155.TCGA-CQ-5323-01A-01D-1683-08.2	G35155.TCGA-CQ-5323-01A-01D-1683-08.2.bam	481.0	1.9	0.05	58cfa82ee4b0c9d6adf6ab7e	G35155.TCGA-CQ-5323-01A-01D-1683-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CQ-5323-01A	DEEFDD62-4D35-40C9-AD4C-0B593F35CFF7	Primary Tumor	Illumina HiSeq	a8f7b17a-acda-474e-be1c-c3a584542451	Head and Neck	82.0	3AC5396D-B92F-41D5-A3F0-603AA52AAFA3	892067EF-C465-46EA-8F91-10636DD0081B	TCGA-CQ-5323-01A-01D-1683-08	HG19_Broad_variant	TCGA-CQ-5323	TCGA-HNSC		s15874	Broad Institute of MIT and Harvard	University Health Network, Toronto	Canada	NO	T1	N0	Head and Neck Squamous Cell Carcinoma	Stage I	1683-08	False
S13722.58cfa82ee4b0c9d6adf6ab8d	58cfa82ee4b0c9d6adf6ab8d	G35155.TCGA-DQ-7591-01A-11D-2078-08.2.filtered.	WGS	G35155.TCGA-DQ-7591-01A-11D-2078-08.2	G35155.TCGA-DQ-7591-01A-11D-2078-08.2.bam	482.7		0.05	58cfa82ee4b0c9d6adf6ab8d	G35155.TCGA-DQ-7591-01A-11D-2078-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-DQ-7591-01A	3EF779CF-772E-445E-93C8-E1094EA8B878	Primary Tumor	Illumina HiSeq	17aee7fb-ed6f-46de-8dc7-ad13153b83a3	Head and Neck	62.0	FB144A86-0EB9-4754-BD74-8BA4BFFE7666	4068A2FC-452D-4B2C-88D8-72D30097527B	TCGA-DQ-7591-01A-11D-2078-08	HG19_Broad_variant	TCGA-DQ-7591	TCGA-HNSC		s15871	Broad Institute of MIT and Harvard	University of Michigan	United States	NO	TX	NX	Head and Neck Squamous Cell Carcinoma		2078-08	False
S13722.58cfa82ee4b0c9d6adf6abe9	58cfa82ee4b0c9d6adf6abe9	G35155.TCGA-CR-6481-01A-11D-1870-08.2.filtered.	WGS	G35155.TCGA-CR-6481-01A-11D-1870-08.2	G35155.TCGA-CR-6481-01A-11D-1870-08.2.bam	88.7	1.9	0.05	58cfa82ee4b0c9d6adf6abe9	G35155.TCGA-CR-6481-01A-11D-1870-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-6481-01A	9A76BD98-1D2B-4D0F-9772-883520FF6210	Primary Tumor	Illumina HiSeq	577ba651-2ad3-4e83-a94c-547efbe03ebe	Head and Neck	47.0	04652163-A674-446F-9E86-607DE19E4C34	5E7D2531-81C1-48BB-9C0A-1867D1F83F92	TCGA-CR-6481-01A-11D-1870-08	HG19_Broad_variant	TCGA-CR-6481	TCGA-HNSC		s15869	Broad Institute of MIT and Harvard	Vanderbilt University	United States	NO			Head and Neck Squamous Cell Carcinoma		1870-08	False
S13722.58cfa82ee4b0c9d6adf6ac6c	58cfa82ee4b0c9d6adf6ac6c	G35155.TCGA-HD-7754-01A-11D-2078-08.2.filtered.	WGS	G35155.TCGA-HD-7754-01A-11D-2078-08.2	G35155.TCGA-HD-7754-01A-11D-2078-08.2.bam	471.73		0.05	58cfa82ee4b0c9d6adf6ac6c	G35155.TCGA-HD-7754-01A-11D-2078-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-HD-7754-01A	10F53522-9AE7-47B9-80AA-B4B481561465	Primary Tumor	Illumina HiSeq	58f7e425-aa07-404f-afe5-6a47488d4296	Head and Neck	69.0	ADB496A1-07EB-45B9-8690-00184143300E	233ECDC4-0B42-4533-8908-64AC7D3AC33B	TCGA-HD-7754-01A-11D-2078-08	HG19_Broad_variant	TCGA-HD-7754	TCGA-HNSC		s16167	Broad Institute of MIT and Harvard	International Genomics Consortium	United States	NO	T2	N2b	Head and Neck Squamous Cell Carcinoma	Stage IVA	2078-08	False
S13722.58cfa82ee4b0c9d6adf6abf5	58cfa82ee4b0c9d6adf6abf5	G35155.TCGA-CR-7368-01A-11D-2129-08.2.filtered.	WGS	G35155.TCGA-CR-7368-01A-11D-2129-08.2	G35155.TCGA-CR-7368-01A-11D-2129-08.2.bam	250.7		0.05	58cfa82ee4b0c9d6adf6abf5	G35155.TCGA-CR-7368-01A-11D-2129-08.2.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Head and Neck Squamous Cell Carcinoma	Aligned reads	TCGA-CR-7368-01A	27C28C89-F4E7-4AEC-A806-C0DA7756E47F	Primary Tumor	Illumina HiSeq	71be6814-d02e-4639-9836-25de17a1ec0f	Head and Neck	54.0	0C4C4B41-05AC-48CE-B5C0-A639FFAFC411	4B194AB3-D213-4A7A-BE46-909B4F0C7291	TCGA-CR-7368-01A-11D-2129-08	HG19_Broad_variant	TCGA-CR-7368	TCGA-HNSC		s15875	Broad Institute of MIT and Harvard	Vanderbilt University	United States	NO	T4a	N1	Head and Neck Squamous Cell Carcinoma	Stage IVA	2129-08	False
S13722.58cfa82fe4b0c9d6adf6b668	58cfa82fe4b0c9d6adf6b668	TCGA-55-6642-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_1_rg.sorted.filtered.	WGS	TCGA-55-6642-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_1_rg.sorted	TCGA-55-6642-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_1_rg.sorted.bam	245.7	1.9	0.14	58cfa82fe4b0c9d6adf6b668	TCGA-55-6642-01A-11D-1853_120310_SN590_0144_AD0PNFACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE		Lung Adenocarcinoma	Aligned reads	TCGA-55-6642-01A	474B86D9-D897-467D-85D4-51DFA26EA107	Primary Tumor	Illumina HiSeq	9b12800d-6911-4d3f-a25e-4d1b686b63aa	Lung	63.0	08D8F333-08F9-4268-99B7-61F7B057F542	93AF51CC-26FF-4904-84BC-2DFFB317D86A	TCGA-55-6642-01A-11D-1853-02	HG19_Broad_variant	TCGA-55-6642	TCGA-LUAD		s11552	Harvard Medical School	International Genomics Consortium	United States	NO	T2	N0	Lung Adenocarcinoma- Not Otherwise Specified (NOS)	Stage IB	1853-02	True
S13722.58cfa830e4b0c9d6adf6be26	58cfa830e4b0c9d6adf6be26	TCGA-BH-A0WA-01A-11D-A128-09_IlluminaGA-DNASeq_whole.filtered.	WGS	TCGA-BH-A0WA-01A-11D-A128-09_IlluminaGA-DNASeq_whole	TCGA-BH-A0WA-01A-11D-A128-09_IlluminaGA-DNASeq_whole.bam	63.5	1.95	0.07	58cfa830e4b0c9d6adf6be26	TCGA-BH-A0WA-01A-11D-A128-09_IlluminaGA-DNASeq_whole.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Breast Invasive Carcinoma	Aligned reads	TCGA-BH-A0WA-01A	786E8DBE-442E-4551-87B3-B4C333B04DD4	Primary Tumor	Illumina HiSeq	1671f5e8-9bbd-41c1-803e-c518d5ba004f	Breast	82.0	8EF7AD6F-A6E4-405C-B20E-D547985BD9D6	EDDFBFB9-3AE8-449B-B870-46062A2571C1	TCGA-BH-A0WA-01A-11D-A128-09	GRCh37-lite	TCGA-BH-A0WA	TCGA-BRCA		s6631	Washington University School of Medicine	University of Pittsburgh		NO	T1c	N0 (i-)		Stage I	A128-09	True
S13722.58cfa830e4b0c9d6adf6c032	58cfa830e4b0c9d6adf6c032	TCGA-BR-6852-01A-11D-1880_130115_SN590_0207_AC1H8PACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6852-01A-11D-1880_130115_SN590_0207_AC1H8PACXX_s_7_rg.sorted	TCGA-BR-6852-01A-11D-1880_130115_SN590_0207_AC1H8PACXX_s_7_rg.sorted.bam	385.7	1.9	0.15	58cfa830e4b0c9d6adf6c032	TCGA-BR-6852-01A-11D-1880_130115_SN590_0207_AC1H8PACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6852-01A	44799C67-61CD-4F3E-BDBC-423E2E0FD2E8	Primary Tumor	Illumina HiSeq	bff2f642-516a-4072-95aa-f213a4555f79	Stomach	64.0	F230ED0B-8D08-4546-9762-923097B4BF02	20F8131D-3F7E-47C5-AE84-A3886A387514	TCGA-BR-6852-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6852	TCGA-STAD		s15387	Harvard Medical School	Asterand	Ukraine	NO	T3	N0	Stomach  Adenocarcinoma  Not Otherwise Specified (NOS)	Stage IIA	1880-02	True
S13722.58cfa830e4b0c9d6adf6c2f5	58cfa830e4b0c9d6adf6c2f5	TCGA-BR-6803-01A-11D-1880_130329_SN590_0221_BD1WHDACXX_s_7_rg.sorted.filtered.	WGS	TCGA-BR-6803-01A-11D-1880_130329_SN590_0221_BD1WHDACXX_s_7_rg.sorted	TCGA-BR-6803-01A-11D-1880_130329_SN590_0221_BD1WHDACXX_s_7_rg.sorted.bam	91.7	1.9	0.14	58cfa830e4b0c9d6adf6c2f5	TCGA-BR-6803-01A-11D-1880_130329_SN590_0221_BD1WHDACXX_s_7_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Stomach Adenocarcinoma	Aligned reads	TCGA-BR-6803-01A	2F90209B-7464-4D7E-83D1-67850C263DED	Primary Tumor	Illumina HiSeq	af361f62-8dd0-4336-9fa9-41cdc800b18e	Stomach	54.0	E56FE72A-760A-4A60-9013-EA611080BA3F	D2F16739-9EAA-465D-95BA-D13C3AEB9A40	TCGA-BR-6803-01A-11D-1880-02	HG19_Broad_variant	TCGA-BR-6803	TCGA-STAD		s15308	Harvard Medical School	Asterand	Russia	NO	T3	N0	Stomach  Adenocarcinoma  Diffuse Type	Stage IIA	1880-02	True
S13722.58cfa831e4b0c9d6adf6c95b	58cfa831e4b0c9d6adf6c95b	TCGA-DU-5847-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_3_rg.sorted.filtered.	WGS	TCGA-DU-5847-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_3_rg.sorted	TCGA-DU-5847-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_3_rg.sorted.bam	173.3	1.9	0.14	58cfa831e4b0c9d6adf6c95b	TCGA-DU-5847-01A-11D-1703_130806_SN1222_0209_AD2AW0ACXX_s_3_rg.sorted.bam	Alive	FEMALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DU-5847-01A	92A7C445-2217-400A-BDCD-DF41502416B6	Primary Tumor	Illumina HiSeq	a76674c6-34c4-4c06-b7e4-eb602b3bc5fa	Brain	34.0	C68FC12C-C538-4A89-9F6E-C0800A5A6B53	F83FB674-A46C-47DE-BAD8-36605068D2E2	TCGA-DU-5847-01A-11D-1703-02	HG19_Broad_variant	TCGA-DU-5847	TCGA-LGG		s8136	Harvard Medical School	Henry Ford Hospital	United States	NO			Astrocytoma		1703-02	True
S13722.58cfa831e4b0c9d6adf6ca3c	58cfa831e4b0c9d6adf6ca3c	TCGA-DH-5143-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_5_rg.sorted.filtered.	WGS	TCGA-DH-5143-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_5_rg.sorted	TCGA-DH-5143-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_5_rg.sorted.bam	48.0	1.9	0.16	58cfa831e4b0c9d6adf6ca3c	TCGA-DH-5143-01A-01D-1465_130808_SN208_0488_BC294YACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Brain Lower Grade Glioma	Aligned reads	TCGA-DH-5143-01A	DCD0856D-423A-40D7-8070-4C0988D61416	Primary Tumor	Illumina HiSeq	9e2bca97-d504-4863-b306-8f559a2cc8a1	Brain	30.0	570101B6-3670-4D1A-A94D-0DDC8DF42061	55952783-8C2C-4528-A544-B4C962AB634A	TCGA-DH-5143-01A-01D-1465-02	HG19_Broad_variant	TCGA-DH-5143	TCGA-LGG		s8753	Harvard Medical School	University of Florida	United States	NO			Oligoastrocytoma		1465-02	True
S13722.58cfa831e4b0c9d6adf6cc92	58cfa831e4b0c9d6adf6cc92	TCGA-EJ-5510-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_5_rg.sorted.filtered.	WGS	TCGA-EJ-5510-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_5_rg.sorted	TCGA-EJ-5510-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_5_rg.sorted.bam	52.7	1.9	0.15	58cfa831e4b0c9d6adf6cc92	TCGA-EJ-5510-01A-01D-1572_130308_SN590_0219_BC1UVPACXX_s_5_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5510-01A	4A3D9EFE-F24E-4135-8A70-E202651E7A81	Primary Tumor	Illumina HiSeq	95ce00b3-cfc9-4400-ab07-de043b39cccf	Prostate	48.0	3EAE6B68-D333-4B36-9E70-D2BED19C1DFA	495CB006-3042-4F8A-9AFA-9C10415DBB26	TCGA-EJ-5510-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5510	TCGA-PRAD		s3603	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa832e4b0c9d6adf6ceda	58cfa832e4b0c9d6adf6ceda	TCGA-EJ-5505-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_3_rg.sorted.filtered.	WGS	TCGA-EJ-5505-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_3_rg.sorted	TCGA-EJ-5505-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_3_rg.sorted.bam	164.7	1.9	0.14	58cfa832e4b0c9d6adf6ceda	TCGA-EJ-5505-01A-01D-1572_130315_SN590_0220_BD1WFMACXX_s_3_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5505-01A	1EA3B879-5451-49FB-B930-16E9B5627F18	Primary Tumor	Illumina HiSeq	156ad547-dfb8-48c9-88b9-6842c81fead1	Prostate	57.0	A31147E1-4A52-4233-BC27-B0DFA6708DC6	3AB7712C-40E4-4752-AC1D-0CB9D7345413	TCGA-EJ-5505-01A-01D-1572-02	HG19_Broad_variant	TCGA-EJ-5505	TCGA-PRAD		s3605	Harvard Medical School	University of Pittsburgh	United States	NO	T2c	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa832e4b0c9d6adf6cedd	58cfa832e4b0c9d6adf6cedd	TCGA-EJ-5508-01A-02D-1572_130308_SN590_0219_BC1UVPACXX_s_1_rg.sorted.filtered.	WGS	TCGA-EJ-5508-01A-02D-1572_130308_SN590_0219_BC1UVPACXX_s_1_rg.sorted	TCGA-EJ-5508-01A-02D-1572_130308_SN590_0219_BC1UVPACXX_s_1_rg.sorted.bam	256.7	1.9	0.15	58cfa832e4b0c9d6adf6cedd	TCGA-EJ-5508-01A-02D-1572_130308_SN590_0219_BC1UVPACXX_s_1_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Prostate Adenocarcinoma	Aligned reads	TCGA-EJ-5508-01A	BD18DD01-D894-4BDD-9CE2-E25705A52A57	Primary Tumor	Illumina HiSeq	69098ac9-e4d2-44cd-ae04-e179d90a749e	Prostate	65.0	E3969BF5-B0CC-49E3-B8CB-3D9E98F1676D	706963B3-03D9-4990-AE75-09F8781D79B7	TCGA-EJ-5508-01A-02D-1572-02	HG19_Broad_variant	TCGA-EJ-5508	TCGA-PRAD		s3784	Harvard Medical School	University of Pittsburgh	United States	NO	T3a	N0	Prostate Adenocarcinoma Acinar Type		1572-02	True
S13722.58cfa832e4b0c9d6adf6d0cc	58cfa832e4b0c9d6adf6d0cc	TCGA-IG-A3QL-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_7_rg.sorted.filtered.	WGS	TCGA-IG-A3QL-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_7_rg.sorted	TCGA-IG-A3QL-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_7_rg.sorted.bam	27.52		0.15	58cfa832e4b0c9d6adf6d0cc	TCGA-IG-A3QL-01A-11D-A248_121212_SN1120_0205_AC1F18ACXX_s_7_rg.sorted.bam	Alive	MALE	WHITE	NOT HISPANIC OR LATINO	Esophageal Carcinoma	Aligned reads	TCGA-IG-A3QL-01A	0AC08ECF-4D70-48A4-9DFD-F44032551CB9	Primary Tumor	Illumina HiSeq	da10bdbe-12f7-41ed-b836-1689589d7ba2	Esophagus	54.0	D571A2B3-892B-46C4-883C-FDED4980492F	A48A75A1-B82B-4F4A-A04F-DFF6B1E801F1	TCGA-IG-A3QL-01A-11D-A248-26	HG19_Broad_variant	TCGA-IG-A3QL	TCGA-ESCA		s1824	MD Anderson - Institute for Applied Cancer Science	Asterand	Russia	NO	T2	N0		Stage IIA	A248-26	True
